PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MA, YH; HENDERSON, HE; VENMURTHY, MR; ROEDERER, G; MONSALVE, MV; CLARKE, LA; NORMAND, T; JULIEN, P; GAGNE, C; LAMBERT, M; DAVIGNON, J; LUPIEN, PJ; BRUNZELL, J; HAYDEN, MR				MA, YH; HENDERSON, HE; VENMURTHY, MR; ROEDERER, G; MONSALVE, MV; CLARKE, LA; NORMAND, T; JULIEN, P; GAGNE, C; LAMBERT, M; DAVIGNON, J; LUPIEN, PJ; BRUNZELL, J; HAYDEN, MR			A MUTATION IN THE HUMAN LIPOPROTEIN-LIPASE GENE AS THE MOST COMMON CAUSE OF FAMILIAL CHYLOMICRONEMIA IN FRENCH-CANADIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MISSENSE MUTATION; DEFICIENCY; HETEROZYGOTE; BINDING; DNA; LPL	Background. Lipoprotein lipase hydrolyzes the triglyceride core of chylomicrons and very-low-density lipoproteins and has a crucial role in regulating plasma lipoprotein levels. Deficiencies of lipoprotein lipase activity lead to aberrations in lipoprotein levels. Worldwide, the frequency of lipoprotein lipase deficiency is highest among French Canadians. We sought to determine the molecular basis of the disorder in this population. Methods. The entire coding sequence of the lipoprotein lipase gene from one French Canadian patient was amplified by the polymerase chain reaction and sequenced. Exon 5 from 36 other French Canadian patients was amplified and analyzed by dot blot hybridization with allele-specific oligonucleotides. Results. Sequence analysis revealed a missense substitution of leucine (CTG) for proline (CCG) at residue 207 in exon 5. This mutation was found on 54 of the 74 mutant alleles (73 percent) in the patients. Studies of site-directed in vitro mutagenesis have confirmed that this mutation generates inactive lipoprotein lipase and is the cause of lipoprotein lipase deficiency. Conclusions. We have identified a missense mutation at residue 207 of the lipoprotein lipase gene that is the most common cause of lipoprotein lipase deficiency in French Canadians. This mutation can be easily detected by dot blot analysis, providing opportunity for definitive DNA diagnosis of the disorder and identification of heterozygous carriers.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1W5,BC,CANADA; UNIV LAVAL,DEPT BIOCHEM,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV LAVAL,LIPID RES CTR,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of British Columbia; Laval University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Laval University; University of Washington; University of Washington Seattle			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Clarke, Lorne/0000-0003-0512-7281	NIDDK NIH HHS [DK-02456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BRUNZELL JD, 1983, J LIPID RES, V24, P12; BRUNZELL JD, 1989, METABOLIC BASIS INHE, V1, P1165; CHARBONNEAU H, 1987, ATLAS HIST CANADA, V1, P118; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CUPP M, 1987, J BIOL CHEM, V262, P6383; DEBRAEKELEER M, IN PRESS HUM HERED; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P6786, DOI 10.1021/bi00442a036; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; EMI M, 1990, J BIOL CHEM, V265, P5910; EMI M, 1990, AM J HUM GENET, V47, P107; FISHER KL, 1987, NUCLEIC ACIDS RES, V15, P7657, DOI 10.1093/nar/15.18.7657; FUNKE H, 1987, NUCLEIC ACIDS RES, V15, P9102, DOI 10.1093/nar/15.21.9102; GAGNE C, 1989, CAN MED ASSOC J, V140, P405; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HATA A, 1990, AM J HUM GENET, V47, P721; HENDERSON HE, 1990, MOL BIOL MED, V7, P511; HENDERSON HE, 1991, J CLIN INVEST, V87, P2005, DOI 10.1172/JCI115229; LANGLOIS S, 1989, P NATL ACAD SCI USA, V86, P948, DOI 10.1073/pnas.86.3.948; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NIKKILA EA, 1983, METABOLIC BASIS INHE, P622; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; WANG XB, 1989, DNA-J MOLEC CELL BIO, V8, P753, DOI 10.1089/dna.1989.8.753; WILSON DE, 1990, J CLIN INVEST, V86, P735, DOI 10.1172/JCI114770; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	30	99	104	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1761	1766		10.1056/NEJM199106203242502	http://dx.doi.org/10.1056/NEJM199106203242502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	2038366	Bronze			2022-12-24	WOS:A1991FR68100002
J	COX, JD				COX, JD			RADIATION ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESIDENTIAL-ADDRESS; RADIOTHERAPY				COX, JD (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025, USA.							CHAPMAN JD, 1989, PREDICTION TUMOR TRE, P323; COX JD, 1987, INT J RADIAT ONCOL, V13, P1271, DOI 10.1016/0360-3016(87)90215-X; FUKS Z, 1989, International Journal of Radiation Oncology, Biology, Physics, V17, P121; HONG WK, 1989, P AM SOC CLIN CONOL, V8, pA650; Horiot J C, 1988, Front Radiat Ther Oncol, V22, P149; LEIBEL S A, 1990, International Journal of Radiation Oncology, Biology, Physics, V19, P139, DOI 10.1016/0360-3016(90)90681-9; LIEBERMAN HB, 1990, 1990 COL U COLL PHYS, P162; ORDER SE, 1990, INT J RADIAT ONCOL, V18, P981, DOI 10.1016/0360-3016(90)90431-I; ROTMAN M, 1990, INT J RADIAT ONCOL, V19, P513, DOI 10.1016/0360-3016(90)90475-Y; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; TURRISI AT, 1988, INT J RADIAT ONCOL, V15, P183, DOI 10.1016/0360-3016(88)90364-1; WILSON JF, 1988, CURE PRESERVATION FU, P102; 1991, JAMA-J AM MED ASSOC, V265, P391	13	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3165	3167						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041139				2022-12-24	WOS:A1991FQ77000039
J	BEDELL, SE; DEITZ, DC; LEEMAN, D; DELBANCO, TL				BEDELL, SE; DEITZ, DC; LEEMAN, D; DELBANCO, TL			INCIDENCE AND CHARACTERISTICS OF PREVENTABLE LATROGENIC CARDIAC ARRESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED VENTRICULAR FLUTTER; DIGITALIS THERAPY; MEDICAL INPATIENTS; INTENSIVE-CARE; DRUG REACTIONS; FIBRILLATION; POINTES; DEATHS; TOXICITY; ILLNESS	We studied the contribution of iatrogenic illness to cardiac arrest among patients hospitalized in 1981 in a university teaching hospital. During this 1-year period, 28 (14%) of 203 arrests in which resuscitation was attempted followed an iatrogenic complication. Seventeen (61%) of the 28 patients died. The demographic characteristics of patients with iatrogenic arrest did not differ strikingly from those of other patients who arrested. However, patients with iatrogenic arrest were less likely to be in cardiogenic shock or to have suffered an acute myocardial infarction prior to arrest. They were more likely to survive to discharge from the hospital and tobe taking digoxin or antiarrhythmic medication prior to arrest. Among the 28 cases of iatrogenic cardiac arrest, 18 (9% of all arrests) might have been prevented by stricter attention to the patient's history, findings on physical examination, and laboratory data. The most common causes of potentially preventable arrest were medication errors and toxic effects (44%) as well as suboptimal response by physicians to clinical signs and symptoms (28%), most frequently dyspnea and tachypnea. Rapid, appropriate response to abnormal drug levels, to electrocardiographic signs of adverse drug effects, and to signs and symptoms of congestive heart failure or toxic effects from digoxin might decrease the incidence of cardiac arrest among hospitalized patients.	HARVARD UNIV, SCH MED, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; CHARLES A DANA RES INST, BOSTON, MA USA; HARVARD THORNDIKE LAB, BOSTON, MA USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard University; Beth Israel Deaconess Medical Center								ARMITAGE P, 1971, STATISTICAL METHODS; BAZATT HC, 1920, HEART, V7, P353; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUCHANAN DS, 1978, GERIATRICS, V33, P47; BUCHANAN DS, 1978, GERIATRICS, V33, P59; BURCHELL HB, 1983, J AM COLL CARDIOL, V1, P506, DOI 10.1016/S0735-1097(83)80080-1; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; De Mey C, 1979, Acta Tuberc Pneumol Belg, V70, P183; DENES P, 1981, AM J CARDIOL, V48, P9, DOI 10.1016/0002-9149(81)90566-X; DONABEDIAN A, 1978, SCIENCE, V200, P856, DOI 10.1126/science.417400; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FRIEDMAN GD, 1971, J AMER MED ASSOC, V217, P567, DOI 10.1001/jama.217.5.567; FRIEDMAN M, 1982, POSTGRAD MED, V71, P123, DOI 10.1080/00325481.1982.11716096; INGELFINGER JA, 1976, NEW ENGL J MED, V294, P867, DOI 10.1056/NEJM197604152941603; KEREN A, 1981, CIRCULATION, V64, P1167, DOI 10.1161/01.CIR.64.6.1167; KOSSMANN CE, 1978, AM J CARDIOL, V42, P1054, DOI 10.1016/0002-9149(78)90695-1; KOSTER RW, 1976, AM J CARDIOL, V38, P519, DOI 10.1016/0002-9149(76)90471-9; LASAGNA L, 1976, NEW ENGL J MED, V294, P898, DOI 10.1056/NEJM197604152941609; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MCLAMB JT, 1967, SOUTHERN MED J, V60, P469, DOI 10.1097/00007611-196705000-00006; MOORMAN JR, 1985, SOUTHERN MED J, V78, P561, DOI 10.1097/00007611-198505000-00016; MYERS JD, 1981, NEW ENGL J MED, V304, P664, DOI 10.1056/NEJM198103123041109; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; RAVIN CE, 1976, AM J ROENTGENOL, V126, P423, DOI 10.2214/ajr.126.2.423; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; SHAPIRO W, 1978, AM J CARDIOL, V41, P852, DOI 10.1016/0002-9149(78)90724-5; SMITH WM, 1980, ANN INTERN MED, V93, P578, DOI 10.7326/0003-4819-93-4-578; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TRUNET P, 1980, JAMA-J AM MED ASSOC, V244, P2617, DOI 10.1001/jama.244.23.2617; VENULET J, 1975, INT J CLIN PHARM BI, V12, P387; WILLIAMSON JW, 1967, J AMER MED ASSOC, V201, P938, DOI 10.1001/jama.201.12.938	37	115	115	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2815	2820		10.1001/jama.265.21.2815	http://dx.doi.org/10.1001/jama.265.21.2815			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033737				2022-12-24	WOS:A1991FN85500029
J	BRENNAN, TA				BRENNAN, TA			TRANSMISSION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS IN THE HEALTH-CARE SETTING - TIME FOR ACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RIGHTS COMMISSION DECISIONS; AIDS LITIGATION PROJECT; UNITED-STATES; HOUSEHOLD CONTACTS; NATIONAL SURVEY; HIV INFECTION; RISK; PHYSICIANS; WORKERS; EMERGENCY				BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABRAHAM K, 1986, DISTRIBUTING RISK, P227; ALTMAN LK, 1991, NY TIMES        0207, P4; ALTMAN LK, 1991, NY TIMES        0223, P9; ALTMAN LK, 1991, NY TIMES        0118, pA3; ANNAS GJ, 1988, HASTINGS CTR REPORT, V18, P26; ARRAS JD, 1988, HASTINGS CENT REP S, V18, P10; BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BRENNAN TA, 1987, ANN INTERN MED, V107, P581, DOI 10.7326/0003-4819-107-4-581; BRENNAN TA, IN PRESS JUST DOCTOR; BRENNAN TA, 1988, DUKE LAW J, P243; Calabresi Guido, 1970, COSTS ACCIDENTS; CHELIUS JR, 1977, WORKPLACE SAFETY HLT; COOKE M, 1989, NEW ENGL J MED, V321, P1334, DOI 10.1056/NEJM198911093211911; CRISP R, 1990, AIDS MORAL ISSUE, P62; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; EDGAR H, 1990, AM J LAW MED, V16, P155; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; FIELD MA, 1990, AM J LAW MED, V16, P33; FOY C, 1990, BRIT MED J, V300, P1048, DOI 10.1136/bmj.300.6731.1048; FRIEDLAND G, 1988, JAMA-J AM MED ASSOC, V259, P2898; FRIEDLAND GH, 1986, NEW ENGL J MED, V314, P344, DOI 10.1056/NEJM198602063140604; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V263, P2413, DOI 10.1001/jama.263.18.2413; GOSTIN L, 1989, HASTINGS CENT REP, V19, P32, DOI 10.2307/3561948; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; GOSTIN LO, 1989, JAMA-J AM MED ASSOC, V261, P1621; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; HARDY AM, 1986, JAMA-J AM MED ASSOC, V255, P209, DOI 10.1001/jama.255.2.209; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JASON JM, 1986, JAMA-J AM MED ASSOC, V255, P212, DOI 10.1001/jama.255.2.212; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1990, J ACQ IMMUN DEF SYND, V3, P987; LEWIS CE, 1990, JAMA-J AM MED ASSOC, V264, P2764, DOI 10.1001/jama.264.21.2764; LIFSON AR, 1986, JAMA-J AM MED ASSOC, V256, P3231, DOI 10.1001/jama.256.23.3231; LO B, 1989, ANN INTERN MED, V110, P727; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MARSHALL PA, 1990, ARCH INTERN MED, V150, P1501, DOI 10.1001/archinte.150.7.1501; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; Peterson L M, 1989, Law Med Health Care, V17, P139; REED RR, 1987, JAMA-J AM MED ASSOC, V258, P3279, DOI 10.1001/jama.258.22.3279; RHAME FS, 1990, JAMA-J AM MED ASSOC, V264, P507, DOI 10.1001/jama.264.4.507; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; RIZZO JA, 1990, MED CARE, V28, P251, DOI 10.1097/00005650-199003000-00005; ROGERS DE, 1988, JAMA-J AM MED ASSOC, V259, P1368, DOI 10.1001/jama.259.9.1368; SADE RM, 1971, NEW ENGL J MED, V285, P1288, DOI 10.1056/NEJM197112022852304; SMITH TJ, 1990, TENN LAW REV, V57, P539; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; SWARTZ MS, 1988, J HEALTH POLIT POLIC, V13, P607, DOI 10.1215/03616878-13-4-607; Turkington Richard C, 1989, Villanova Law Rev, V34, P871; VOLBERDING P, 1989, JAMA-J AM MED ASSOC, V261, P747, DOI 10.1001/jama.261.5.747; WATERS RC, 1990, FLA STATE U LAW REV, V17, P441; WEIL PA, 1990, MED CARE, V28, P468, DOI 10.1097/00005650-199005000-00006; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1990, NEW ENGL J MED, V322, P1392; 1987, JAMA-J AM MED ASSOC, V258, P2097; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1987, MMWR S2, V36, pS1; 1991, NATIONS HLTH     JAN, pA1; 1990, AAMC WEEKLY REPORT; 1989, PROTECTION DISCRIMIN; 1991, MMWR, V40, P21	65	35	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1504	1509		10.1056/NEJM199105233242112	http://dx.doi.org/10.1056/NEJM199105233242112			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM460	2023611				2022-12-24	WOS:A1991FM46000012
J	PEARSON, JW				PEARSON, JW			ENDOCERVICAL BRUSH FOR PAPANICOLAU SMEARS - ADVERSE-EFFECTS OR CONTRAINDICATIONS TO USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											PEARSON, JW (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724, USA.							BOON ME, 1989, ACTA CYTOL, V33, P843; DOTTERS DJ, 1988, AM J OBSTET GYNECOL, V159, P814, DOI 10.1016/S0002-9378(88)80143-1; WEITZMAN GA, 1988, J REPROD MED, V33, P677	3	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2409	2409						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016841				2022-12-24	WOS:A1991FJ95500042
J	COOKE, MP; ABRAHAM, KM; FORBUSH, KA; PERLMUTTER, RM				COOKE, MP; ABRAHAM, KM; FORBUSH, KA; PERLMUTTER, RM			REGULATION OF T-CELL RECEPTOR SIGNALING BY A SRC FAMILY PROTEIN-TYROSINE KINASE (P59FYN)	CELL			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; CD4 RECEPTOR; ACTIVATION; EXPRESSION; COMPLEX; PHOSPHORYLATION; POLYPEPTIDE; GENE; IDENTIFICATION	Engagement of the clonotypic antigen receptor (TCR) on T lymphocytes provokes an activation response leading to cell proliferation and lymphokine secretion. To examine the molecular basis of T cell signaling, we generated transgenic animals in which a lymphocyte-specific nonreceptor protein-tyrosine kinase p59fyn(T) is 20-fold overexpressed in developing T lineage cells. Thymocytes from these mice, analyzed using both cellular and biochemical assays, were remarkably hyperstimulable. Moreover, the responsiveness of normal thymocytes to TCR-derived signals correlated well with the extent to which p59fyn was expressed in these cells. Overexpression of a catalytically inactive form of p59fyn substantially inhibited TCR-mediated activation in otherwise normal thymocytes. These effects are unique to p59fyn; overexpression of a closely related T cell-specific tyrosine kinase, p56lck, elicits dramatically different phenotypes. Our results suggest that p59fyn is a critically important component of the TCR signal transduction apparatus.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	COOKE, MP (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195, USA.				NCI NIH HHS [CA09537, CA45682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009537, R01CA045682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, IN PRESS P NATL ACAD; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JUNE CH, 1990, J IMMUNOL, V144, P1591; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mishell B.B., 1980, SELECTED METHODS CEL; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Sambrook J., 1989, MOL CLONING LAB MANU; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SCHWARTZ RH, 1990, SCIENCE, V248, P1342; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WILLIAMS AF, 1982, SCIENCE, V216, P696, DOI 10.1126/science.6177036; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	53	436	443	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					281	291		10.1016/0092-8674(91)90162-R	http://dx.doi.org/10.1016/0092-8674(91)90162-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015626				2022-12-24	WOS:A1991FH09200011
J	GJERTSON, DW; TERASAKI, PI; TAKEMOTO, S; MICKEY, MR				GJERTSON, DW; TERASAKI, PI; TAKEMOTO, S; MICKEY, MR			NATIONAL ALLOCATION OF CADAVERIC KIDNEYS BY HLA MATCHING - PROJECTED EFFECT ON OUTCOME AND COSTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL	Background. Although receiving a cadaveric kidney matched at the HLA-A, B, and DR loci enhances graft survival in cyclosporine-treated patients, the value of a national system of kidney allocation based on HLA matching, with the attendant increased likelihood of better matching, is still questioned. Some fear that the costs of a national system are unjustified when only a small fraction of donors would exactly match any of the 16,000 potential recipients anyway. We estimated the effect on graft survival of the use of HLA matching for all allocations of cadaveric kidneys in the United States. Methods. The graft-survival rates in five mutually exclusive groups of transplants with increasing numbers of HLA mismatches were estimated by partitioning the data for 22,190 first-time recipients of cadaveric kidneys. Overall graft survival was projected as a weighted average with use of the percentages of transplants in the hierarchical groups in recipient waiting pools of various sizes. We compared the benefits and costs of HLA matching in a national system with those of introducing cyclosporine, which was projected to enhance graft survival by 7 percentage points at 10 years. Results. Sharing kidneys nationally on the basis of hierarchical HLA matching was estimated to enhance graft survival by an additional 5 percentage points at 10 years. The anticipated five-year cost of national allocation of kidneys by HLA matching for 7000 recipients, including consideration of the costs of graft removal and dialysis after transplant rejection, would be $6.5 million less than the cost of using cyclosporine alone. Conclusions. The use of an HLA allocation system will not add to the cost of renal transplantation, but it will improve the long-term results to the same extent as cyclosporine. We propose the initiation of a national kidney-sharing system based on hierarchical levels of HLA matches.	UNIV CALIF LOS ANGELES,TISSUE TYPING LAB,950 VET AVE,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					PHS HHS [2375] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cook D J, 1987, Clin Transpl, P277; EVANS RW, 1988, TRANSPL P, V20, P49; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; Gjertson D W, 1989, Clin Transpl, P353; HELD PJ, 1990, 16TH ANN SCI M AM SO; MANNINEN DL, 1991, TRANSPLANT P, V23, P1312; McClelland J, 1989, Clin Transpl, P471; MICKEY MR, 1989, TRANSPLANTATION, V47, P401; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; Persijn G G, 1988, Clin Transpl, P237; PFAFF WW, 1989, TRANSPL P, V21, P1405; STARZL TE, 1987, JAMA-J AM MED ASSOC, V257, P3073, DOI 10.1001/jama.257.22.3073; Takemoto S, 1989, Clin Transpl, P463; TAKEMOTO S, 1991, TRANSPLANT P, V23, P1318; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033; TERASAKI P, 1989, TRANSPLANT P, V21, P615; 1990, NIH90583 PUBL	17	83	84	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1032	1036		10.1056/NEJM199104113241505	http://dx.doi.org/10.1056/NEJM199104113241505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	2005940	Bronze			2022-12-24	WOS:A1991FF77100005
J	VOS, JC; SASKER, M; STUNNENBERG, HG				VOS, JC; SASKER, M; STUNNENBERG, HG			PROMOTER MELTING BY A STAGE-SPECIFIC VACCINIA VIRUS TRANSCRIPTION FACTOR IS INDEPENDENT OF THE PRESENCE OF RNA-POLYMERASE	CELL			English	Article							ACCURATE TRANSCRIPTION; GENE-TRANSCRIPTION; INITIATION-FACTOR; SOLUBLE EXTRACT; DNA-REPLICATION; PURIFICATION; PROTEIN; INVITRO; REQUIREMENT; MECHANISM	Fractionation of an extract prepared from HeLa cells infected with vaccinia virus resulted in the separation of factors involved in vaccinia virus intermediate transcription. Two activities, VITF-A and VITF-B, in addition to the viral RNA polymerase are necessary and sufficient to direct intermediate transcription in vitro. VITF-B confers intermediate promoter specificity to an early-specific extract prepared from virus particles. A committed complex between VITF-B and the template can sequester VITF-A and RNA polymerase into a preinitiation complex. VITF-B is further able to melt the promoter at the start site of transcription. Open complex formation is stimulated by ATP. In contrast to prokaryotic and eukaryotic pol III transcription, promoter melting is independent of the presence of RNA polymerase.			VOS, JC (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; Vos, J. Chris/0000-0003-3737-9942				BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BIEKER JJ, 1986, J BIOL CHEM, V261, P9732; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chamberlin M.J., 1976, RNA POLYMERASE, P159; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRE A, 1984, J BIOL CHEM, V259, P2509; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HIRSCHMANN P, 1990, J VIROL, V64, P6063, DOI 10.1128/JVI.64.12.6063-6069.1990; HOODADHINGRA U, 1989, J VIROL, V63, P714, DOI 10.1128/JVI.63.2.714-729.1989; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROHRMANN G, 1985, J VIROL, V56, P349, DOI 10.1128/JVI.56.2.349-355.1985; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHMITT JFC, 1988, J VIROL, V62, P1889, DOI 10.1128/JVI.62.6.1889-1897.1988; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SCHWER B, 1988, EMBO J, V7, P1183, DOI 10.1002/j.1460-2075.1988.tb02929.x; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WRIGHT CF, 1989, J VIROL, V63, P4224, DOI 10.1128/JVI.63.10.4224-4233.1989; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	40	45	45	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					105	113		10.1016/0092-8674(91)90412-R	http://dx.doi.org/10.1016/0092-8674(91)90412-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013091	Bronze			2022-12-24	WOS:A1991FF77300013
J	BRADDOCK, M; THORBURN, AM; KINGSMAN, AJ; KINGSMAN, SM				BRADDOCK, M; THORBURN, AM; KINGSMAN, AJ; KINGSMAN, SM			BLOCKING OF TAT-DEPENDENT HIV-1 RNA MODIFICATION BY AN INHIBITOR OF RNA POLYMERASE-II PROCESSIVITY	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATION; UNWINDING ACTIVITY; MAMMALIAN-CELLS; EXPRESSION; ELONGATION; PROTEIN	HUMAN immunodeficiency virus gene expression is regulated transcriptionally and post-transcriptionally 1-4 by the virally encoded tat protein (Tat). Tat functions through an RNA target sequence located in the untranslated region at the 5' end of viral transcripts 5-8. In Xenopus oocytes, translation of RNA containing the target sequence is specifically activated by Tat. This activation only occurs if the RNA is injected into the nucleus, and might be due to a Tat-dependent, nucleus-specific chemical modification of the RNA which somehow facilitates translation 8. Here we demonstrate that Tat activation of its target RNA in the nucleus involves a Tat-dependent covalent modification. The modified RNA is competent for translation after reinjection into either the nucleus or the cytoplasm in the absence of Tat. Furthermore, we find that the nucleoside analogue 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, which inhibits processivity of RNA polymerase II (ref. 9), blocks this Tat-dependent modification.	DEPT BIOCHEM,VIRUS MOLEC BIOL GRP,S PARKS RD,OXFORD OX1 3QU,ENGLAND; BRITISH BIOTECHNOL LTD,OXFORD OX4 5LY,ENGLAND	University of Oxford								BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; KIMMELMAN M, 1989, CELL, V59, P687; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693	23	48	49	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					439	441		10.1038/350439a0	http://dx.doi.org/10.1038/350439a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011194				2022-12-24	WOS:A1991FF04200056
J	LINDBLAD, B; STERNBY, NH; BERGQVIST, D				LINDBLAD, B; STERNBY, NH; BERGQVIST, D			INCIDENCE OF VENOUS THROMBOEMBOLISM VERIFIED BY NECROPSY OVER 30 YEARS	BRITISH MEDICAL JOURNAL			English	Article							AUTOPSY	Objective-To determine the incidence of venous thromboembolism in all necropsy reports over 30 years. Design-Study of all necropsies in one hospital in 1987 and longitudinal analysis of results of necropsy in 1957, 1964, 1975, and 1987. Setting-Departments of general surgery, infectious diseases, internal medicine, oncology, and orthopaedics in a Swedish general hospital. Main outcome measure-Number of cases of venous thromboembolism. Results-About a third of all necropsies showed venous thromboembolism. In 1987, 260 of 347 necropsies showing venous thromboembolism found pulmonary embolism, of which 93 were classified as fatal, 90 as contributory, and 77 as incidental. Only 21 contributory or fatal postoperative pulmonary emboli were seen. In only 106 of 260 patients with pulmonary embolism did routine necropsy not show the source of embolism. Calf veins were not routinely examined. Deep venous thrombosis was seen in 239 patients in 1987. The incidence of venous thromboembolism in the four years studied was remarkably stable except in the department of orthopaedics, where the proportion fell from 60.7% in 1975 to 32.2% in 1987 (p < 0.05), although there were only a few patients. Conclusions-The overall incidence of venous thromboembolism has not changed over 30 years. During this period the proportion of the population aged over 65 has doubled, and this may have masked the beneficial effects of prophylaxis and early mobilisation. Prevalences corrected for age are needed.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN PATHOL,S-21401 MALMO,SWEDEN	Lund University	LINDBLAD, B (corresponding author), LUND UNIV,MALMO GEN HOSP,DEPT SURG,S-21401 MALMO,SWEDEN.							BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; Havig O, 1977, Acta Chir Scand Suppl, V478, P1; KAIJ K, 1959, LAKARTIDNINGEN, V56, P1437; RUBINSTEIN I, 1988, ARCH INTERN MED, V148, P1425, DOI 10.1001/archinte.148.6.1425	4	302	334	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					709	711		10.1136/bmj.302.6778.709	http://dx.doi.org/10.1136/bmj.302.6778.709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021744	Bronze, Green Published			2022-12-24	WOS:A1991FE33300029
J	TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A				TACHAKRA, SS; PAWSEY, S; BECKETT, M; POTTS, D; IDOWU, A			OUTCOME OF PATIENTS WITH CHEST PAIN DISCHARGED FROM AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article									W MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,ISLEWORTH TW7 6AF,ENGLAND	Imperial College London	TACHAKRA, SS (corresponding author), CENT MIDDLESEX HOSP,DEPT ACCID & EMERGENCY,LONDON NW10 7NS,ENGLAND.							COLQUHOUN MC, 1989, BMJ-BRIT MED J, V299, P433, DOI 10.1136/bmj.299.6696.433; Slosberg B, 1977, JACEP, V6, P445; TACHAKRA SS, 1987, BRIT J ACCIDENT EMER, V2, P8; WILCOX RG, 1981, BRIT MED J, V282, P431, DOI 10.1136/bmj.282.6262.431; 1985, LANCET, V2, P578	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					504	505		10.1136/bmj.302.6775.504	http://dx.doi.org/10.1136/bmj.302.6775.504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012846	Bronze, Green Published			2022-12-24	WOS:A1991FB05500019
J	MAKI, DG; KLEIN, BS; MCCORMICK, RD; ALVARADO, CJ; ZILZ, MA; STOLZ, SM; HASSEMER, CA; GOULD, J; LIEGEL, AR				MAKI, DG; KLEIN, BS; MCCORMICK, RD; ALVARADO, CJ; ZILZ, MA; STOLZ, SM; HASSEMER, CA; GOULD, J; LIEGEL, AR			NOSOCOMIAL PSEUDOMONAS-PICKETTII BACTEREMIAS TRACED TO NARCOTIC TAMPERING - A CASE FOR SELECTIVE DRUG SCREENING OF HEALTH-CARE PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAINING-PROGRAMS; INFECTION; OUTBREAK; DEATHS; ABUSE	Three patients in a university hospital developed nosocomial infusion-related Pseudomonas pickettii bacteremia. Investigation identified six additional patients who had received intravenous fluid contaminated by P pickettii but did not become ill. All nine patients had had surgery, and each of these patients but only nine of 19 operated-on control patients had received intravenous fentanyl citrate in the operating room; the mean dose given to the nine case patients was far greater than that given to control patients. Fentanyl in 20 (40%) of 50 predrawn 30-mL syringes was shown to be contaminated by P pickettii. Contamination was caused by theft of fentanyl from predrawn syringes and replacement by distilled water contaminated by P pickettii. Narcotic theft by health care personnel may cause patients to suffer pain needlessly and can also result in dire unanticipated consequences, such as nosocomial bacteremia. Whereas drug testing in the workplace is highly controversial, we believe that testing of health care personnel is indicated when drug abuse or theft is suspected.	UNIV WISCONSIN HOSP & CLIN,HOSP PHARM,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,DEPT MED,INFECT DIS SECT,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT PEDIAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	MAKI, DG (corresponding author), UNIV WISCONSIN HOSP & CLIN,DEPT INFECT CONTROL,H4-574,MADISON,WI 53792, USA.							ANDERSON HJ, 1986, MOD HEALTHCARE, V16, P46; AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BUEHLER JW, 1985, NEW ENGL J MED, V313, P211, DOI 10.1056/NEJM198507253130402; DURANT W, 1967, AM J HOSP PHARM, V24, P112; GARDNER S, 1984, PEDIATR INFECT DIS J, V3, P420, DOI 10.1097/00006454-198409000-00006; GILARDI GL, 1985, MANUAL CLIN MICROBIO, P350; Goerth C R, 1985, Occup Health Saf, V54, P55; HALL RJ, 1978, INTRO HIGH PERFORMAN, P1; ISTRE GR, 1985, NEW ENGL J MED, V313, P205, DOI 10.1056/NEJM198507253130401; Japp H., 1981, CLIN MICROBIOL NEWSL, V3, P124; KAHAN A, 1983, J INFECTION, V7, P256, DOI 10.1016/S0163-4453(83)97196-7; KING A, 1979, J GEN MICROBIOL, V114, P137, DOI 10.1099/00221287-114-1-137; LABARBERA M, 1984, J PSYCHOACTIVE DRUGS, V15, P293; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; LEWIS DC, 1986, NEW ENGL J MED, V315, P826, DOI 10.1056/NEJM198609253151309; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V256, P3003, DOI 10.1001/jama.256.21.3003; MAKI DG, 1982, NEW ENGL J MED, V307, P1562, DOI 10.1056/NEJM198212163072507; MAKI DG, 1987, JAMA-J AM MED ASSOC, V258, P2396, DOI 10.1001/jama.258.17.2396; MAKI DG, 1980, 11TH P INT C CHEM 19, P1089; Maki DG, 1982, CURRENT TOPICS CLIN, P309; MAKI DG, 1981, CRC HDB HOSPITAL ACQ, P371; MAKI DG, 1977, MICROBIOLOGIC HAZARD, P13; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MORGAN JP, 1984, J PSYCHOACTIVE DRUGS, V16, P305, DOI 10.1080/02791072.1984.10472301; PHILLIPS I, 1972, LANCET, V1, P1258; PICKETT MJ, 1980, J GEN MICROBIOL, V120, P439; RAKATANSKY H, 1987, NEW ENGL J MED, V316, P694; RILEY PS, 1975, J CLIN MICROBIOL, V1, P61, DOI 10.1128/JCM.1.1.61-64.1975; ROBERTS LA, 1990, MED J AUSTRALIA, V152, P652, DOI 10.5694/j.1326-5377.1990.tb125422.x; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P458, DOI 10.1016/S0278-2391(86)80011-8; SPIEGELMAN WG, 1981, ANESTHESIOLOGY, V60, P335; VERSCHRAEGEN G, 1985, J CLIN MICROBIOL, V21, P278, DOI 10.1128/JCM.21.2.278-279.1985; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; ZIPORYN T, 1986, JAMA-J AM MED ASSOC, V256, P3061, DOI 10.1001/jama.256.22.3061; 1987, REGULATORY DIGEST	37	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					981	986		10.1001/jama.265.8.981	http://dx.doi.org/10.1001/jama.265.8.981			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1992211				2022-12-24	WOS:A1991EY43200025
J	METCALFE, MA; BAUM, JD				METCALFE, MA; BAUM, JD			INCIDENCE OF INSULIN-DEPENDENT DIABETES IN CHILDREN AGED UNDER 15 YEARS IN THE BRITISH-ISLES DURING 1988	BRITISH MEDICAL JOURNAL			English	Article							INCREASING INCIDENCE; MELLITUS; EPIDEMIOLOGY; SCOTLAND	Objective-To ascertain the annual incidence rate of insulin dependent diabetes diagnosed in children under the age of 15 years in the British Isles during 1988, and to compare the results with an earlier study carried out in 1973-4. Design-Active monthly reporting of cases by consultant paediatricians, with additional input from diabetologists and all specialist diabetes nurses and health visitors. Setting-British Isles (England, Wales, Scotland, Northern Ireland, Republic of Ireland) with a total population at risk of 11 819 000 children. Patients-All children diagnosed under the age of 15 years with primary insulin dependent diabetes from 1 January to 31 December 1988 and resident in the British Isles at diagnosis. Main outcome measures-National incidence rate of insulin dependent diabetes; differences in incidence rates between regions and between three age groups: 4 and under, 5-9, and 10-14 year olds. Results-1600 children (837 boys and 763 girls) had a confirmed diagnosis of insulin dependent diabetes, giving a national incidence rate of 13.5/100 000/year (95% confidence interval 12.9 to 14.2/100 000/year). This was considerably higher than the incidence rate of 7.7/100 000/year in children under the age of 16 years reported in the British Diabetic Association's study of 1973-4. The age-sex adjusted rates varied between regions, ranging from 6.8/100 000/year (Republic of Ireland) to 19.8/100 000/year (Scotland). There were considerable differences in the numbers of cases diagnosed each month, with the 10-14 year age group showing the most seasonal variation. A quarter of the children (404/1600) were under 5 years old. Case ascertainment was estimated as 90%. Conclusions-Insulin dependent diabetes in the British Isles does not seem to occur uniformly over time or geographical area. Even allowing for differences in ascertainment between the 1973-4 and 1988 studies, there seems to have been an increase in the incidence rate of insulin dependent diabetes in children under the age of 15 years during the 15 year time period. If diabetes is becoming more common in this age group, possibly by developing earlier in susceptible children, this would be a matter of considerable public health concern.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND	Bristol Royal Hospital For Children; University of Bristol								[Anonymous], 1982, GEIGY SCI TABLES; ARMITAGE P, 1987, JSTATISTICAL METHODS; BARCLAY RPC, 1988, SCOT MED J, V33, P237, DOI 10.1177/003693308803300205; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BLOOM A, 1975, BRIT MED J, V3, P580, DOI 10.1136/bmj.3.5983.580; BURDEN AC, 1989, DIABETIC MED, V6, P334; DAHLQUIST G, 1985, DIABETOLOGIA, V28, P802, DOI 10.1007/BF00291068; FREEDMAN LS, 1979, J EPIDEMIOL COMMUNIT, V33, P233; Hall S M, 1988, Arch Dis Child, V63, P344; JONER G, 1989, DIABETOLOGIA, V32, P79, DOI 10.1007/BF00505178; JONES C, 1990, POPULATION TRENDS, V60, P31; LESLIE PJ, 1990, DIABETIC MED S2, V7, pA24; MATSUURA N, 1981, TOHOKU J EXP MED S, V141, P181; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; PATTERSON CC, 1988, DIABETIC MED, V5, P160, DOI 10.1111/j.1464-5491.1988.tb00964.x; PATTERSON CC, 1983, DIABETOLOGIA, V24, P238, DOI 10.1007/BF00282706; REUNANEN A, 1982, ACTA PAEDIATR SCAND, V71, P893, DOI 10.1111/j.1651-2227.1982.tb09545.x; REWERS M, 1987, DIABETES, V36, P106, DOI 10.2337/diabetes.36.1.106; SOLTESZ G, 1990, DIABETIC MED, V7, P111, DOI 10.1111/j.1464-5491.1990.tb01343.x; WILLIAMS DRR, 1989, DIABETIC MED, V6, P320, DOI 10.1111/j.1464-5491.1989.tb01172.x; 1989, 1988 POPULATION ESTI; 1986, ISLE MAN INTERIM CEN; 1987, CENSUS 86 SUMMARY PO; 1987, 1986 EC ADV OFF REP; 1990, KEY POPULATION VIT 5; 1989, 3RD BRIT PAED SURV U; 1990, 67TH REG GEN OFF; 1973, CENSUS POPULATION IR, V2; 1987, GUERNSEY CENSUS 1986; 1975, CENSUS POPULATION 19; 1987, BMJ, V295, P479; 1987, DIRECTORY NURSES SPE; 1973, CENSUS 1971 SUMMARY	34	78	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					443	447		10.1136/bmj.302.6774.443	http://dx.doi.org/10.1136/bmj.302.6774.443			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004172	Green Published, Bronze			2022-12-24	WOS:A1991EZ03300021
J	LECHNER, J; CARBON, J				LECHNER, J; CARBON, J			A 240-KD MULTISUBUNIT PROTEIN COMPLEX, CBF3, IS A MAJOR COMPONENT OF THE BUDDING YEAST CENTROMERE	CELL			English	Article							BASE-PAIR MUTATIONS; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; TRANSCRIPTION FACTOR; DNA; PURIFICATION; INVITRO; CHROMOSOMES; DIGESTION; HISTONES	A key protein component (CBF3) of the budding yeast (S. cerevisiae) centromere/kinetochore has been purified and characterized. CBF3 is a 240 kd multisubunit protein complex that binds specifically to the yeast wild-type centromere DNA (CEN), but not to nonfunctional CEN DNA containing a single base substitution in the critical CDEIII consensus sequence. When purified by affinity chromatography, CBF3 contains three protein components: CBF3A (110 kd), CBF3B (64 kd), and CBF3C (58 kd). Highly purified CBF3 requires the presence of a separate assembly factor or chaperone activity to bind to CEN DNA. Treatment with phosphatase inactivates CBF3, indicating that at least one of the CBF3 subunits must be phosphorylated for DNA binding to occur. A 56 bp region including the 26 bp CDEIII consensus is protected from DNAase I cleavage in the CBF3-CEN DNA complex.			LECHNER, J (corresponding author), UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106, USA.				NATIONAL CANCER INSTITUTE [R01CA011034] Funding Source: NIH RePORTER; NCI NIH HHS [CA-11034] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RE, 1989, J BIOL CHEM, V264, P10843; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brinkley B.R., 1989, MITOSIS MOL MECHANIS, P77; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARBON J, 1990, New Biologist, V2, P10; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1983, NATURE, V305, P23, DOI 10.1038/305023a0; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOTAREL G, 1989, MOL CELL BIOL, V9, P3342; CUMBERLEDGE S, 1987, GENETICS, V117, P203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; FUTCHER B, 1986, MOL CELL BIOL, V6, P2213, DOI 10.1128/MCB.6.6.2213; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; JIANG WD, 1989, MOL CELL BIOL, V9, P5585, DOI 10.1128/MCB.9.12.5585; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OW RA, 1987, J BIOL CHEM, V262, P3409; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PLUTA AF, 1990, TRENDS BIOCHEM SCI, V15, P181, DOI 10.1016/0968-0004(90)90158-8; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SINGER MF, 1982, INT REV CYTOL, V76, P67, DOI 10.1016/S0074-7696(08)61789-1; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3	44	277	288	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					717	725		10.1016/0092-8674(91)90501-O	http://dx.doi.org/10.1016/0092-8674(91)90501-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997204				2022-12-24	WOS:A1991EZ47800007
J	PECORA, R				PECORA, R			DNA - A MODEL-COMPOUND FOR SOLUTION STUDIES OF MACROMOLECULES	SCIENCE			English	Article							TRANSIENT ELECTRIC BIREFRINGENCE; DYNAMIC LIGHT-SCATTERING; ROTATIONAL DIFFUSION-COEFFICIENTS; SYMMETRIC TOP MACROMOLECULES; ELASTIC HINGE MODEL; RESTRICTION FRAGMENTS; WORMLIKE CHAINS; CIRCULAR-CYLINDERS; AQUEOUS-SOLUTIONS; STIFF CHAINS	Well-defined, monodisperse, homologous series of oligonucleotides and DNA restriction fragments may now be produced and used as models of rigid and semirigid rodlike molecules in solution. Information from optical experiments on these model systems aids in the formulation and testing of theories of macromolecular dynamics in both dilute and concentrated solution.			PECORA, R (corresponding author), STANFORD UNIV,CHEM,STANFORD,CA 94305, USA.							ALLISON SA, 1990, MACROMOLECULES, V23, P1110, DOI 10.1021/ma00206a033; ARAGON SR, 1987, MACROMOLECULES, V20, P370, DOI 10.1021/ma00168a025; ARGON SR, 1985, MACROMOLECULES, V18, P1868; Berne B., 1976, DYNAMIC LIGHT SCATTE; BLOOMFIELD VA, 1985, DYNAMIC LIGHT SCATTE; BOTT SE, 1984, THESIS STANFORD U ST; BRIAN AA, 1981, BIOPOLYMERS, V20, P1305, DOI 10.1002/bip.1981.360200615; DEGIORGIO V, 1990, PHYS REV LETT, V64, P1043, DOI 10.1103/PhysRevLett.64.1043; DELATORRE JG, 1984, BIOPOLYMERS, V23, P611, DOI 10.1002/bip.360230402; DIEKMANN S, 1982, BIOPHYS CHEM, V15, P263, DOI 10.1016/0301-4622(82)80009-4; Doi M., 1986, THEORY POLYM DYNAMIC; EIMER W, 1990, BIOCHEMISTRY-US, V29, P799, DOI 10.1021/bi00455a030; EIMER W, 1987, THESIS BIELEFELD U B; EIMER W, IN PRESS J CHEM PHYS; ELIAS JG, 1981, BIOPOLYMERS, V20, P2369, DOI 10.1002/bip.1981.360201107; ELIAS JG, 1981, MACROMOLECULES, V14, P410, DOI 10.1021/ma50003a034; FRIED MG, 1984, BIOPOLYMERS, V23, P2141, DOI 10.1002/bip.360231104; FULMER AW, 1981, BIOPOLYMERS, V20, P1147, DOI 10.1002/bip.1981.360200606; GOINGA HT, UNPUB; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HAGERMAN PJ, 1983, BIOPOLYMERS, V22, P811, DOI 10.1002/bip.360220303; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1481, DOI 10.1002/bip.1981.360200709; HARD T, 1986, BIOPOLYMERS, V25, P1519, DOI 10.1002/bip.360250810; HERVET H, 1978, J CHEM PHYS, V68, P2725, DOI 10.1063/1.436110; KITANO T, 1977, POLYM J, V2, P153; LEWIS RJ, 1985, MACROMOLECULES, V18, P1530, DOI 10.1021/ma00150a003; LEWIS RJ, 1985, MACROMOLECULES, V18, P944, DOI 10.1021/ma00147a022; LEWIS RJ, 1988, J CHEM PHYS, V89, P2490, DOI 10.1063/1.455043; LEWIS RJ, 1987, MACROMOLECULES, V20, P2579, DOI 10.1021/ma00176a044; LEWIS RJ, 1981, MACROMOLECULES, V19, P134; LEWIS RJ, 1985, THESIS STANFORD U ST; MANDELKERN M, 1981, J MOL BIOL, V152, P153, DOI 10.1016/0022-2836(81)90099-1; NICOLAI T, 1989, MACROMOLECULES, V22, P2348, DOI 10.1021/ma00195a059; NICOLAI T, 1989, MACROMOLECULES, V22, P438, DOI 10.1021/ma00191a080; PECORA R, 1968, J CHEM PHYS, V49, P1032, DOI 10.1063/1.1670188; PECORA R, 1964, J CHEM PHYS, V40, P1604, DOI 10.1063/1.1725368; PECORA R, 1968, J CHEM PHYS, V48, P4126, DOI 10.1063/1.1669748; Pecora R, 1985, BER BUNSEN PHYS CHEM, DOI DOI 10.1002/BBPC.19870910455; POST CB, 1982, BIOPOLYMERS, V21, P2139, DOI 10.1002/bip.360211105; POST CB, 1982, BIOPOLYMERS, V21, P2123, DOI 10.1002/bip.360211104; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Roitman D. B., 1987, ROTATIONAL DYNAMICS, P192; ROITMAN DB, 1984, J CHEM PHYS, V81, P6333, DOI 10.1063/1.447542; ROITMAN DB, 1984, J CHEM PHYS, V81, P6348, DOI 10.1063/1.447543; RONDELEZ F, 1980, LASER SCATTERING FLU; SCALETTAR BA, 1989, MACROMOLECULES, V22, P4550, DOI 10.1021/ma00202a030; Schmitz K. S., 1990, INTRO DYNAMIC LIGHT; SCHULZ SF, 1990, J CHEM PHYS, V92, P7087, DOI 10.1063/1.458249; SCHURR JM, 1986, ANNU REV PHYS CHEM, V37, P271; SEILS J, UNPUB; SORLIE SS, 1990, MACROMOLECULES, V23, P487, DOI 10.1021/ma00204a022; SORLIE SS, 1988, MACROMOLECULES, V21, P1437, DOI 10.1021/ma00183a039; STELLWAGEN NC, 1981, BIOPOLYMERS, V20, P399, DOI 10.1002/bip.1981.360200302; STRZELECKA TE, 1990, BIOPOLYMERS, V30, P57, DOI 10.1002/bip.360300108; STRZELECKA TE, 1987, J AM CHEM SOC, V109, P4513, DOI 10.1021/ja00249a014; SZWARC M, 1956, J AM CHEM SOC, V78, P2656, DOI 10.1021/ja01592a101; TIRADO MM, 1979, J CHEM PHYS, V71, P2581, DOI 10.1063/1.438613; TIRADO MM, 1980, J CHEM PHYS, V73, P1986, DOI 10.1063/1.440288; TIRADO MM, 1984, J CHEM PHYS, V81, P2047, DOI 10.1063/1.447827; VENABLE RM, 1988, BIOPOLYMERS, V27, P1001, DOI 10.1002/bip.360270609; VOORDOUW G, 1978, BIOPHYS CHEM, V8, P71; WANG L, IN PRESS MACROMOLECU; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887; WIDOM J, 1983, BIOPOLYMERS, V22, P1595, DOI 10.1002/bip.360220612; WIDOM J, 1983, BIOPOLYMERS, V22, P1621, DOI 10.1002/bip.360220613; WILLIAMSON JR, 1989, BIOCHEMISTRY-US, V28, P2819, DOI 10.1021/bi00433a012; YAMAKAWA H, 1976, J CHEM PHYS, V64, P5222, DOI 10.1063/1.432197; Yamakawa H., 1971, MODERN THEORY POLYM; YOSHIZAKI T, 1984, J CHEM PHYS, V81, P982, DOI 10.1063/1.447699; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	70	64	66	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					893	898		10.1126/science.2000490	http://dx.doi.org/10.1126/science.2000490			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000490				2022-12-24	WOS:A1991EY62900034
J	CLEMMER, CR; BEEBE, TP				CLEMMER, CR; BEEBE, TP			GRAPHITE - A MIMIC FOR DNA AND OTHER BIOMOLECULES IN SCANNING TUNNELING MICROSCOPE STUDIES	SCIENCE			English	Article							TUNNELLING MICROSCOPY; NUCLEIC-ACIDS	Highly ordered pyrolytic graphite (HOPG) is the substrate often used in scanning tunneling microscope (STM) studies of biomolecules such as DNA. All of the images presented in this article are of freshly cleaved HOPG surfaces upon which no deposition has occurred. These images illustrate features previously thought to be due to biological molecules, such as periodicity and meandering of "molecules" over steps. These features can no longer be used to distinguish real molecules from features of the native substrate. The feasibility of the continued use of HOPG as a substrate for biological STM studies is discussed.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,CTR BIOPOLYMERS INTERFACES,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCRR NIH HHS [S07RR07092] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007092] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBRECHT TR, 1988, APPL PHYS LETT, V52, P362, DOI 10.1063/1.99465; AMREIN M, 1989, SCIENCE, V243, P1708, DOI 10.1126/science.2928803; ARSCOTT PG, 1989, NATURE, V339, P484, DOI 10.1038/339484a0; BEEBE TP, 1989, SCIENCE, V243, P370, DOI 10.1126/science.2911747; Binnig G., 1984, TRENDS PHYSICS, P38; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; CHANG H, UNPUB; CLEMMER CR, UNPUB; CRICENTI A, IN PRESS J VAC SCI A; DEROSE JA, IN PRESS J VAC SCI A; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; HEBEN MJ, 1989, J MICROSC-OXFORD, V152, P651; KELLER D, 1989, P NATL ACAD SCI USA, V86, P5356, DOI 10.1073/pnas.86.14.5356; KUWABARA M, 1990, APPL PHYS LETT, V56, P2396, DOI 10.1063/1.102906; LEE G, 1989, SCIENCE, V244, P475, DOI 10.1126/science.2470146; LINDSAY SM, 1988, J VAC SCI TECHNOL A, V6, P543; Liu C.-P., UNPUB; LYDING JW, 1988, J MICROSC-OXFORD, V152, P371, DOI 10.1111/j.1365-2818.1988.tb01398.x; MARTI O, 1987, SURF SCI, V181, P230, DOI 10.1016/0039-6028(87)90163-4; MOORE AW, 1981, CHEM PHYS CARBON, V17, P233; SALEMINK HWM, 1987, SURF SCI, V181, P139, DOI 10.1016/0039-6028(87)90150-6; SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361; SOTO MR, 1990, SURF SCI, V225, P190, DOI 10.1016/0039-6028(90)90437-D; Thrower P.A., 1969, CHEM PHYS CARBON, V5, P217; THUNDAT T, IN PRESS J VAC SCI A; WILSON TE, IN PRESS J VAC SCI A; YOUNGQUIST MG, IN PRESS J VAC SCI A; ZEGLINSKI DM, IN PRESS REV SCI INS; IN PRESS J VAC SCI A	30	288	294	1	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					640	642		10.1126/science.1992517	http://dx.doi.org/10.1126/science.1992517			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1992517				2022-12-24	WOS:A1991EW39900036
J	HOFMEYR, GJ; WILKINS, T; REDMAN, CWG				HOFMEYR, GJ; WILKINS, T; REDMAN, CWG			C4 AND PLASMA-PROTEIN IN HYPERTENSION DURING PREGNANCY WITH AND WITHOUT PROTEINURIA	BRITISH MEDICAL JOURNAL			English	Article							PRE-ECLAMPSIA		JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV WITWATERSRAND,PARKTOWN 2193,SOUTH AFRICA	University of Oxford; University of Witwatersrand								BERGE LN, 1988, ACTA OBSTET GYN SCAN, V67, P499, DOI 10.3109/00016348809029860; BUYON JP, 1986, AM J MED, V81, P194, DOI 10.1016/0002-9343(86)90251-2; MASSOBRIO M, 1985, AM J OBSTET GYNECOL, V152, P578, DOI 10.1016/0002-9378(85)90631-3; REDMAN CWG, 1986, CLIN OBSTET GYNAECOL, V13, P469; ROSIC B, 1988, Clinical and Experimental Obstetrics and Gynecology, V15, P157	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					218	218		10.1136/bmj.302.6770.218	http://dx.doi.org/10.1136/bmj.302.6770.218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998764	Green Published, Bronze			2022-12-24	WOS:A1991EV22800028
J	LEE, J				LEE, J			EVERYDAY AIDS AND APPLIANCES - BREAST PROSTHESES	BRITISH MEDICAL JOURNAL			English	Editorial Material											LEE, J (corresponding author), BREASTCARE & MASTECTOMY ASSOC,LONDON WC1 8JG,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					43	44		10.1136/bmj.302.6767.43	http://dx.doi.org/10.1136/bmj.302.6767.43			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991190	Green Published, Bronze			2022-12-24	WOS:A1991ER37200027
J	ATKIN, SH; DASMAHAPATRA, A; JAKER, MA; CHOROST, MI; REDDY, S				ATKIN, SH; DASMAHAPATRA, A; JAKER, MA; CHOROST, MI; REDDY, S			FINGERSTICK GLUCOSE DETERMINATION IN SHOCK	ANNALS OF INTERNAL MEDICINE			English	Article						GLUCOSE; HYPOTENSION; REAGENT STRIPS, VENOUS; SHOCK; FINGERSTICK GLUCOSE TESTING	BLOOD-GLUCOSE; ACCURACY; SYSTEMS; INSULIN	Objective: To evaluate the accuracy of fingerstick glucose measurements in severely hypotensive patients. Design: Prospective, nonrandomized comparison study. Setting: Emergency department in a university hospital. Patients: Twenty-five severely hypotensive patients (systolic blood pressure less-than-or-equal-to 80 mm Hg) and 39 normotensive patients. Measurements: Simultaneous fingerstick reagent strip glucose, venous reagent strip glucose, and laboratory glucose values were compared. Data were analyzed using error-grid analysis. Results: In hypotensive patients, the mean fingerstick glucose values were significantly lower than the values obtained either by venous reagent strip or laboratory glucose measurements. Fingerstick glucose values in the hypotensive group were 67.5% of laboratory glucose values, and were significantly lower than the values obtained in the normotensive group (91.8%, P < 0.001). Only 36% of the hypotensive patients had fingerstick glucose values within the acceptable range of 20% of the laboratory glucose value. Thirty-two percent of hypotensive patients were incorrectly diagnosed as hypoglycemic (glucose < 3.89 mmol/L [70 mg/dL]); 2 of these patients were actually hyperglycemic (glucose > 11.10 mmol/L [200 mg/dL]). Venous reagent strip measurements accurately reflected laboratory glucose values in both hypotensive and normotensive patients. Conclusions: Fingerstick glucose testing does not accurately represent venous glucose levels in severely hypotensive patients. If fingerstick glucose testing is relied on for these patients, errors in clinical management may be made. Venous reagent strip glucose testing correlates well with laboratory glucose measurements and should be the preferred method for rapid assessment of glucose level in critically ill patients with severe hypotension.			ATKIN, SH (corresponding author), UNIV HOSP NEWARK, DEPT EMERGENCY, C384, 150 BERGEN ST, NEWARK, NJ 07103 USA.							[Anonymous], 1987, DIABETES CARE, V10, P95; BARR B, 1984, DIABETES CARE, V7, P261, DOI 10.2337/diacare.7.3.261; BORST GC, 1987, DIABETES CARE, V10, P256, DOI 10.2337/diacare.10.2.256; BROWNING RG, 1990, ANN EMERG MED, V19, P683, DOI 10.1016/S0196-0644(05)82479-5; CAREY LC, 1970, ANN SURG, V172, P342, DOI 10.1097/00000658-197009000-00004; CHERNOW B, 1982, CRIT CARE MED, V10, P463, DOI 10.1097/00003246-198207000-00012; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; CLOWES GHA, 1978, AM J SURG, V135, P577, DOI 10.1016/0002-9610(78)90040-5; COX DJ, 1985, DIABETES CARE, V8, P529, DOI 10.2337/diacare.8.6.529; COX DJ, 1989, DIABETES CARE, V12, P235, DOI 10.2337/diacare.12.3.235; GAZZANIGA AB, 1982, EMERGENCY CARE PRINC, P412; GODINE JE, 1986, AM J MED, V80, P803, DOI 10.1016/0002-9343(86)90619-4; HOLLOWAY R, 1983, ALA J MED SCI, V20, P383; KOSCHINSKY T, 1988, DIABETES CARE, V11, P619, DOI 10.2337/diacare.11.8.619; LIN HC, 1989, J PEDIATR-US, V115, P998, DOI 10.1016/S0022-3476(89)80757-7; MAISELS MJ, 1983, CRIT CARE MED, V11, P293, DOI 10.1097/00003246-198304000-00010; Moghni M R, 1970, J Egypt Med Assoc, V53, P803; PLUM F, 1980, DIAGNOSIS STUPOR COM, P345; POINTER JE, 1986, ANN EMERG MED, V15, P372, DOI 10.1016/S0196-0644(86)80588-1; RASAIAH B, 1985, CAN MED ASSOC J, V132, P1357; SHAPIRO B, 1981, DIABETES CARE, V4, P396, DOI 10.2337/diacare.4.3.396; SHERWOOD MJ, 1983, CLIN CHEM, V29, P438; VITEK V, 1979, CLIN CHIM ACTA, V95, P93, DOI 10.1016/0009-8981(79)90341-3; 1987, ACCU CHEK 2 BLOOD GL	24	116	119	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1020	1024		10.7326/0003-4819-114-12-1020	http://dx.doi.org/10.7326/0003-4819-114-12-1020			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029097				2022-12-24	WOS:A1991FQ55500005
J	ENG, FJ; WARNER, JR				ENG, FJ; WARNER, JR			STRUCTURAL BASIS FOR THE REGULATION OF SPLICING OF A YEAST MESSENGER-RNA	CELL			English	Article							RIBOSOMAL-PROTEIN GENE; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; BINDING PROTEINS; EXON SEQUENCES; DNA FRAGMENTS; SEX-LETHAL; EXPRESSION; LEVEL; ELEMENTS	In S. cerevisiae, ribosomal protein L32 regulates the splicing of the transcript of its own gene, RPL32. We have identified an RNA structure within the transcript that is responsible for this regulation. Initial deletions limited essential sequences to the 5' exon and the first few nucleotides of the intron. To take advantage of phylogenetic comparison of RNA structures, RPL32 was cloned from the closely related species, Kluyveromyces lactis. The splicing of its transcript is similarly regulated. Sequences conserved between the S. cerevisiae and K. lactis transcripts suggested a structure involving base pairing of a region encompassing the 5' splice site with another near the 5' end of the transcript. Analysis of numerous site-directed mutations supports this structure. We infer that stabilization of this structure by L32 inhibits splicing by precluding the interaction of U1 RNA with the 5' splice site.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	ENG, FJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461, USA.				NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM25532, 5T32GM07128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532, T32GM007128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOZZONI I, 1984, J MOL BIOL, V180, P987, DOI 10.1016/0022-2836(84)90267-5; CAFFARELLI E, 1987, EMBO J, V6, P3493, DOI 10.1002/j.1460-2075.1987.tb02674.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DABEVA MD, 1987, J BIOL CHEM, V262, P16055; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; DRAPER DE, 1989, TRENDS BIOCHEM SCI, V14, P335, DOI 10.1016/0968-0004(89)90167-9; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GUTELL RR, 1986, EMBO J, V5, P1111, DOI 10.1002/j.1460-2075.1986.tb04330.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; KIM CH, 1983, J MOL BIOL, V165, P79, DOI 10.1016/S0022-2836(83)80243-5; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KRETZNER L, 1990, P NATL ACAD SCI USA, V87, P851, DOI 10.1073/pnas.87.2.851; KRUSE C, 1985, P NATL ACAD SCI USA, V82, P7515, DOI 10.1073/pnas.82.22.7515; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P5027, DOI 10.1093/nar/13.14.5027; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; McKeown M, 1990, Genet Eng (N Y), V12, P139; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PEARSON NJ, 1982, CELL, V29, P347, DOI 10.1016/0092-8674(82)90151-9; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; POTASHKIN JA, 1990, MOL CELL BIOL, V10, P3524, DOI 10.1128/MCB.10.7.3524; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWIDA U, 1988, YEAST, V4, P209, DOI 10.1002/yea.320040306; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WITTEKIND M, 1990, MOL CELL BIOL, V10, P2049, DOI 10.1128/MCB.10.5.2049; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WRAY LV, 1987, MOL CELL BIOL, V7, P1111, DOI 10.1128/MCB.7.3.1111; WRNER JR, 1977, J CELL BIOL, V80, P767	54	145	149	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					797	804		10.1016/0092-8674(91)90387-E	http://dx.doi.org/10.1016/0092-8674(91)90387-E			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040015				2022-12-24	WOS:A1991FP51600010
J	MOZZARELLI, A; RIVETTI, C; ROSSI, GL; HENRY, ER; EATON, WA				MOZZARELLI, A; RIVETTI, C; ROSSI, GL; HENRY, ER; EATON, WA			CRYSTALS OF HEMOGLOBIN WITH THE T-QUARTERNARY STRUCTURE BIND OXYGEN NONCOOPERATIVELY WITH NO BOHR EFFECT	NATURE			English	Article							HUMAN-HEMOGLOBIN; SINGLE-CRYSTALS; STEREOCHEMISTRY; MECHANISMS; CONSTANTS; AFFINITY; ENZYME; STATE	THE relationship between the structure and function of haemoglobin has mainly been studied by comparing its X-ray crystal structures with its function in solutions 1-11. To make a direct comparison we have studied the functional properties of haemoglobin in single crystals, an approach that has been an important part of the investigation of several enzyme mechanisms 12, 13. Here we report on the oxygen binding by single crystals of human haemoglobin grown in solutions of polyethylene glycol. Unlike haemoglobin crystals formed in concentrated salt solution, which crack and become disordered on oxygenation 14-16, crystals grown in polyethylene glycol remain intact. X-ray studies have shown that the T (deoxy) quaternary structure of haemoglobin in this crystal at pH 7.0 is maintained at atmospheric oxygen pressure, and that the salt-bridges are not broken 17-19. We find striking differences between oxygen binding by haemoglobin in this crystal and by haemoglobin in solution. Not only is oxygenation of the crystal noncooperative, but the oxygen affinity is independent of pH in the range 6.0-8.5, and is much lower than that of the T state in solution. The lack of cooperativity without a change in quaternary structure is predicted by the two-state allosteric model of Monod, Wyman and Changeux 1, 5. The absence of a Bohr effect without breakage of salt-bridges is predicted by Perutz's stereochemical mechanism 2, 4, 9-11. In contrast to the X-ray result that oxygen binds only to the alpha-haems, our measurements show that the alpha-haems have only a slightly higher affinity than the beta-haems.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	MOZZARELLI, A (corresponding author), UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY.		Henry, Eric R/J-3414-2013; Mozzarelli, Andrea/C-3615-2014	Henry, Eric R/0000-0002-5648-8696; Mozzarelli, Andrea/0000-0003-3762-0062; Rivetti, Claudio/0000-0003-3775-6779				ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BALDWIN JM, 1975, PROG BIOPHYS MOL BIO, V29, P227; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; BRZOZOWSKI A, 1984, HEMOGLOBIN, P37; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; Eaton W A, 1981, Methods Enzymol, V76, P175; EDELSTEIN SJ, 1975, REV BIOCH, V44, P209; Gill S J, 1981, Methods Enzymol, V76, P427; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; Haurowitz F., 1938, Z PHYSIOL CHEMIE, V254, P266; IMAI K, 1975, J BIOL CHEM, V250, P2227; Imai K., 1982, ALLOSTERIC EFFECTS H; KILMARTIN JV, 1978, J MOL BIOL, V123, P71, DOI 10.1016/0022-2836(78)90377-7; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LIDDINGTON RC, 1986, THESIS U YORK; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; MAKINEN MW, 1974, NATURE, V247, P62, DOI 10.1038/247062a0; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5351; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1953, ACTA CRYSTALLOGR, V6, P859, DOI 10.1107/S0365110X53002507; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1964, NATURE, V203, P687, DOI 10.1038/203687a0; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; ROSSI GL, 1970, J MOL BIOL, V49, P85, DOI 10.1016/0022-2836(70)90377-3; SAWICKI CA, 1977, J BIOL CHEM, V252, P7138; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHULMAN RG, 1975, Q REV BIOPHYS, V8, P325, DOI 10.1017/S0033583500001840; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0	35	117	117	3	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					416	419		10.1038/351416a0	http://dx.doi.org/10.1038/351416a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034292				2022-12-24	WOS:A1991FN85600062
J	LAI, KN; LI, PKT; LUI, SF; AU, TC; TAM, JSL; TONG, KL; LAI, FM				LAI, KN; LI, PKT; LUI, SF; AU, TC; TAM, JSL; TONG, KL; LAI, FM			MEMBRANOUS NEPHROPATHY RELATED TO HEPATITIS-B VIRUS IN ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; SURFACE ANTIGENEMIA; NEPHROTIC SYNDROME; VIRAL-HEPATITIS; GLOMERULONEPHRITIS; INFECTION; ANTIBODY; CHILDREN; ASSOCIATION; INTERFERON	Background. The natural course of adult hepatitis B virus (HBV)-related membranous nephropathy in areas where HBV infection is endemic (characterized by vertical and horizontal transmission of HBV in early childhood) has not been fully defined. Methods. We evaluated the clinical features, pathological findings, serologic profiles, therapeutic responses, and prognoses of 21 patients with adult-onset HBV-related membranous nephropathy. The patients were followed for a mean of 60 months (range, 12 to 108). Only patients with evidence of glomerular capillary deposition of hepatis B e antigen (HBeAg) in a renal-biopsy specimen were included. Results. The clinical features and serologic studies suggested that the patients had acquired chronic HBV infection in early childhood; moreover, other causes of membranous nephropathy had been excluded. All were seropositive for hepatitis B surface antigen and had high titers of antibody to hepatitis B core antigen at first clinical presentation. HBeAg was detected in the serum of 17 patients (81 percent), yet only 3 had even slightly increased plasma alanine aminotransferase levels. The clinical response to therapy with interferon alfa was disappointing; only one of the five patients treated had a complete remission with seroconversion to antibody to HBeAg. Contrary to reports of studies in children, spontaneous remission of the nephrotic syndrome or proteinuria was uncommon in the adults with HBV-related membranous nephropathy whom we studied. Proteinuria and HBV antigenemia persisted in untreated patients. During the follow-up period, 29 percent of the patients had progressive renal failure and 10 percent required maintenance dialysis therapy. Conclusions. The course of HBV-related membranous nephropathy in adults in areas where HBV is endemic is not benign. Regardless of treatment, the disease has a slowly but relentlessly progressive clinical course in approximately one third of patients.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT PATHOL,SHA TIN,HONG KONG; PRINCESS MARGARET HOSP,MED UNIT,HONG KONG,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital			Li, Philip K. T./D-4051-2017					BRZOKO W, 1974, LANCET, V2, P476; COGAN MG, 1977, AM J GASTROENTEROL, V68, P386; COMBES B, 1971, LANCET, V2, P234; FURUSE A, 1982, NEPHRON, V31, P212, DOI 10.1159/000182649; GARCIA G, 1985, HEPATOLOGY, V5, P317, DOI 10.1002/hep.1840050228; GUERRA IL, 1987, AM J KIDNEY DIS, V10, P385, DOI 10.1016/S0272-6386(87)80107-5; HIROSE H, 1984, KIDNEY INT, V26, P338, DOI 10.1038/ki.1984.178; HSU HC, 1983, CLIN NEPHROL, V20, P121; ITO H, 1981, LAB INVEST, V44, P214; KLEINKNECHT C, 1979, J PEDIATR-US, V95, P946, DOI 10.1016/S0022-3476(79)80281-4; KNECHT GL, 1978, GASTROENTEROLOGY, V75, P1152; KNIESER MR, 1974, ARCH PATHOL, V97, P193; KOHLER PF, 1974, ANN INTERN MED, V81, P448, DOI 10.7326/0003-4819-81-4-448; LAI KN, 1989, AM J CLIN PATHOL, V92, P159, DOI 10.1093/ajcp/92.2.159; LAI KN, 1989, ANN TROP PAEDIATR, V9, P45, DOI 10.1080/02724936.1989.11748595; LAI KN, 1990, NEPHRON, V54, P12; LAI KN, 1987, Q J MED, V63, P323; LEVY M, 1982, ADV NEPHROL, V11, P341; LIN CY, 1990, NEPHRON, V55, P37, DOI 10.1159/000185916; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LOK ASF, 1988, LANCET, V2, P298; MCCOLLUM RW, 1981, J MED VIROL, V8, P1, DOI 10.1002/jmv.1890080102; MIZUSHIMA N, 1987, GASTROENTEROLOGY, V92, P524, DOI 10.1016/0016-5085(87)90152-1; NAGY J, 1979, CLIN NEPHROL, V12, P109; PIGNATELLI M, 1987, J HEPATOL, V4, P15, DOI 10.1016/S0168-8278(87)80004-1; SEGGIE J, 1984, NEPHRON, V38, P115, DOI 10.1159/000183291; Szmuness W, 1978, VIRAL HEPATITIS, P297; TAKEKOSHI Y, 1978, LANCET, V2, P1065; THOMAS HC, 1985, BRIT MED BULL, V41, P374, DOI 10.1093/oxfordjournals.bmb.a072079; WONG VCW, 1984, LANCET, V1, P921	30	193	206	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1457	1463		10.1056/NEJM199105233242103	http://dx.doi.org/10.1056/NEJM199105233242103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023605				2022-12-24	WOS:A1991FM46000003
J	MOORE, RD; HIDALGO, J; SUGLAND, BW; CHAISSON, RE				MOORE, RD; HIDALGO, J; SUGLAND, BW; CHAISSON, RE			ZIDOVUDINE AND THE NATURAL-HISTORY OF THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; SAN-FRANCISCO; DOUBLE-BLIND; AIDS; SURVIVAL; EXPERIENCE; EFFICACY; AZT	Background and Methods. We sought to describe the trends in survival from 1983 to 1989 among persons with the acquired immunodeficiency syndrome (AIDS) and to examine the relative effects on the natural history of AIDS of zidovudine use and demographic and clinical characteristics. This longitudinal, observational, population-based study used data from the Maryland Human Immunodeficiency Virus Information System, a data base that links information from the Maryland AIDS Registry with data on public and private health care claims, vital statistics, and hospital, long-term care, and ambulatory care records. Results. The median survival after diagnosis among persons with AIDS (n = 1028) was 140 days longer for those given their diagnoses between 1987 and 1989 than for those given their diagnoses between 1983 and 1985 (450 vs. 310 days). Among the 714 persons in whom AIDS was diagnosed after April 1987 (when zidovudine became available), two-year survival was greater among men than women (P < 0.03), among persons less than 45 years old than among older persons (P < 0.001), among non-Hispanic whites than among minorities (P < 0.001), and among persons whose category of human immunodeficiency virus transmission was homosexual contact than among those with heterosexual, transfusion-related, or less common modes of transmission (P < 0.02). In all the analyses the groups with the longer survival were more likely to have received zidovudine. The median survival among those who received zidovudine was 770 days, as compared with 190 days among those who never received the drug (P < 0.001). By proportional-hazards analysis, zidovudine therapy was the factor most strongly associated with improved survival. Conclusions. For Maryland residents with AIDS there has been an improvement in survival since 1987. Zidovudine therapy and perhaps other aspects of care associated with it have contributed substantially to the improved survival.	AIDS ADM,DEPT HLTH & MENTAL HYG,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV MARYLAND,SCH PHARM,CTR DRUG POLICY,BALTIMORE,MD 21201	Maryland Department of Health & Mental Hygiene; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027668] Funding Source: NIH RePORTER; NIAID NIH HHS [5U01AI27668] Funding Source: Medline; PHS HHS [223-89-3603] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; Hidalgo J, 1990, QRB Qual Rev Bull, V16, P355; HIDALGO J, 1990, EVAL PROGRAM PLANN, V13, P39, DOI 10.1016/0149-7189(90)90007-J; HIDALGO J, 1990, 118TH ANN M AM PUBL; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MOORE RD, IN PRESS ARCH INTERN; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; TSAI WY, 1987, BIOMETRIKA, V74, P883	15	299	300	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1412	1416		10.1056/NEJM199105163242006	http://dx.doi.org/10.1056/NEJM199105163242006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020297				2022-12-24	WOS:A1991FL12500006
J	BENFIELD, DG; FLAKSMAN, RJ; LIN, TH; KANTAK, AD; KOKOMOOR, FW; VOLLMAN, JH				BENFIELD, DG; FLAKSMAN, RJ; LIN, TH; KANTAK, AD; KOKOMOOR, FW; VOLLMAN, JH			TEACHING INTUBATION SKILLS USING NEWLY DECEASED INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This prospective study was designed to (1) test the hypothesis that the majority of families of newly dead infants in a tertiary neonatal intensive care unit would consent to their infants' being intubated for teaching purposes, (2) determine factors related to family consent, and (3) determine the effects of participation on resident physicians and respiratory therapists. Family consent for intubation was requested following 44 (80%) of the 55 deaths that occurred during the 10-month study period. Of these requests, 32 (73%) were granted. Proportionately more white than black families consented and consent was positively related to autopsy permission. Fifty-three (75%) of 71 trainees completed a mailed questionnaire after their first intubation experience. Although each respondent found the experience helpful, many reported mixed feelings categorized as doubt about participating, apprehension and discomfort, respect for the body, appreciation for the opportunity, a sense of achievement, and feelings of comfort knowing that consent had been obtained. These findings confirm our initial hypothesis and suggest that (1) newly dead infants can be a valuable resource for teaching intubation skills, and (2) others considering a similar approach need to be aware of and sensitive to trainees' feelings.	CHILDRENS HOSP MED CTR,NEONATOL INTENS CARE UNIT,AKRON,OH 44308; AKRON REG PERINATAL CTR,AKRON,OH; NORTHEASTERN OHIO UNIV,COLL MED,DEPT PEDIAT,ROOTSTOWN,OH 44272	Northeast Ohio Medical University (NEOMED)	BENFIELD, DG (corresponding author), CHILDRENS HOSP MED CTR,DEPT PEDIAT,DIV NEONATOL,281 LOCUST ST,AKRON,OH 44308, USA.							BRANDT AM, 1978, HASTINGS CTR REP, V8, P28; Crawford T, 1987, Physician Exec, V13, P25; FELDMAN DS, 1986, STATVIEW 512 PLUS PR; Fox Renee, 1979, ESSAYS MED SOCIOLOGY, P51; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; ORLOWSKI JP, 1989, NEW ENGL J MED, V320, P396; TOCHEN ML, 1979, J PEDIATR-US, V95, P1050, DOI 10.1016/S0022-3476(79)80309-1	8	48	48	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2360	2363		10.1001/jama.265.18.2360	http://dx.doi.org/10.1001/jama.265.18.2360			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016832				2022-12-24	WOS:A1991FJ95500030
J	DULCEY, CS; GEORGER, JH; KRAUTHAMER, V; STENGER, DA; FARE, TL; CALVERT, JM				DULCEY, CS; GEORGER, JH; KRAUTHAMER, V; STENGER, DA; FARE, TL; CALVERT, JM			DEEP UV PHOTOCHEMISTRY OF CHEMISORBED MONOLAYERS - PATTERNED COPLANAR MOLECULAR ASSEMBLIES	SCIENCE			English	Article							GOLD	Deep ultraviolet (UV) irradiation is shown to modify organosilane self-assembled monolayer (SAM) films by a photocleavage mechanism, which renders the surface amenable to further SAM modification. Patterned UV exposure creates alternating regions of intact SAM film and hydrophilic, reactive sites. The exposed regions can undergo a second chemisorption reaction to produce an assembly of SAMs in the same molecular plane with similar substrate attachment chemistry. The UV-patterned films are used as a template for selective buildup of fluorophores, metals, and biological cells.	USN,RES LAB,CTR BIOMOLEC SCI & ENGN,CODE 6090,WASHINGTON,DC 20375; GEOCENTERS INC,FT WASHINGTON,MD 20744; US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857	United States Department of Defense; United States Navy; Naval Research Laboratory; US Food & Drug Administration (FDA)								Benson S.W, 1976, THERMOCHEMICAL KINET; BIEDLER JL, 1973, CANCER RES, V33, P2643; DOUB DL, 1947, J AM CHEM SOC, V69, P2714; KALLURY KMR, 1988, ANAL CHEM, V60, P169, DOI 10.1021/ac00153a014; KLEINFELD D, 1988, J NEUROSCI, V8, P4098; LAIBINIS PE, 1989, SCIENCE, V245, P845, DOI 10.1126/science.245.4920.845; LAND DP, 1990, REV SCI INSTRUM, V61, P1674, DOI 10.1063/1.1141131; POLYMEROPOULOS EE, 1978, J CHEM PHYS, V69, P1836, DOI 10.1063/1.436844; ROBERTS G, 1990, LANGMUIR BLODGETT FI, pCH7; SCHNUR JM, Patent No. 7182123; SRINIVASAN R, 1989, CHEM REV, V89, P1303, DOI 10.1021/cr00096a003; STENGER DA, Patent No. 7598194; SWALEN JD, 1987, LANGMUIR, V3, P932, DOI 10.1021/la00078a011; WALSH R, 1981, ACCOUNTS CHEM RES, V14, P246, DOI 10.1021/ar00068a004; WASSERMAN SR, 1989, J MATER RES, V4, P886, DOI 10.1557/JMR.1989.0886; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; Zisman WA., 1964, ADV CHEM SER	17	489	538	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					551	554		10.1126/science.2020853	http://dx.doi.org/10.1126/science.2020853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020853				2022-12-24	WOS:A1991FJ12700042
J	HSIAO, K; MEINER, Z; KAHANA, E; CASS, C; KAHANA, I; AVRAHAMI, D; SCARLATO, G; ABRAMSKY, O; PRUSINER, SB; GABIZON, R				HSIAO, K; MEINER, Z; KAHANA, E; CASS, C; KAHANA, I; AVRAHAMI, D; SCARLATO, G; ABRAMSKY, O; PRUSINER, SB; GABIZON, R			MUTATION OF THE PRION PROTEIN IN LIBYAN JEWS WITH CREUTZFELDT-JAKOB DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; SCRAPIE INCUBATION-TIME; HUNTINGTONS-DISEASE; GENE; POLYMORPHISM; LINKAGE; ANTICIPATION; ISRAEL	Background. Creutzfeldt-Jakob disease is a transmissible neurodegenerative disorder that occurs more than 100 times more frequently among Libyan Jews than in the worldwide population. We examined 11 patients with the disease - 10 Libyan Jews from Israel and 1 Libyan Jews from Italy - to determine whether abnormalities of the prion protein could be detected in them. Abnormal forms of this host-encoded protein are the predominant if not sole components of the transmissible agent that causes the disease. Methods. The prion-protein open-reading frame in peripheral-leukocyte DNA from the Italian patient was amplified with the polymerase chain reaction and sequenced. Allele-specific oligonucleotide hybridization was used to assess a prion-protein codon 200 lysine mutation in the 10 Israeli patients and 37 control subjects. Results. The prion-protein sequence in DNA from the Italian patient revealed a single nucleotide change (G --> A) at the first position of codon 200 that resulted in a substitution of lysine for glutamate. This substitution was detected in all 10 Israeli patients, 8 of whom had a positive family history of Creutzfeldt-Jakob disease. One patient was homozygous for the lysine mutation, and her clinical course did not differ from that of the patients heterozygous for the mutation. The lysine mutation was not found in one Moroccan Jew from Israel with Creutzfeldt-Jakob disease. Conclusions. The codon 200 lysine mutation of the prion-protein gene is consistently present among Libyan Jews with Creutzfeldt-Jakob disease, strongly supporting a genetic pathogenesis of their illness. The similarity of the clinical courses of the patient homozygous for this mutation and the patients heterozygous for it argues that familial Creutzfeldt-Jakob disease is a true dominant disorder.	HADASSAH UNIV HOSP,DEPT NEUROL,EIN KAREM,IL-91120 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,ASHQELON,ISRAEL; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; BARZILAI GOVT HOSP,ASHQELON,ISRAEL; UNIV MILAN,OSPED MAGGIORE POLICLIN,IST CLIN NEUROL,I-20122 MILAN,ITALY	Hebrew University of Jerusalem; Ben Gurion University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ben Gurion University; Barzilai Medical Center; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Cass, Carol E/F-5861-2010	Kahana, Esther/0000-0002-3863-3271	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967, P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG-08967, AG-02132] Funding Source: Medline; NINDS NIH HHS [NS-14069] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALPERS M, 1970, AM J TROP MED HYG, V19, P133, DOI 10.4269/ajtmh.1970.19.133; ALTER M, 1974, SCIENCE, V186, P848; ALTER M, 1976, SCIENCE, V192, P428, DOI 10.1126/science.192.4238.428-b; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BOCKMAN JM, 1985, NEW ENGL J MED, V312, P73, DOI 10.1056/NEJM198501103120202; BOCKMAN JM, 1987, ANN NEUROL, V21, P589, DOI 10.1002/ana.410210611; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DICKINSON AG, 1969, GENET RES, V13, P213, DOI 10.1017/S0016672300002895; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; Gajdusek D C, 1972, J Clin Pathol Suppl (R Coll Pathol), V6, P78, DOI 10.1136/jcp.25.Suppl_6.78; GOLDBERG H, 1979, SLOW TRANSMISSIBLE D, V1, P195; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; HERZBERG L, 1974, SCIENCE, V186, P848, DOI 10.1126/science.186.4166.848; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO K, 1989, ANN NEUROL, V26, P137; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, IN PRESS NEUROLOGY; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; KAHANA E, 1974, SCIENCE, V183, P90, DOI 10.1126/science.183.4120.90; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1979, SLOW TRANSMISSIBLE D, V1, P143; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1989, LANCET, V1, P51; PARRY HB, 1983, SCRAPIE DIS SHEEP, P31; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; RADHAKRISHNAN K, 1988, NEUROEPIDEMIOLOGY, V7, P42, DOI 10.1159/000110134; RIDLEY RM, 1988, J MED GENET, V25, P589, DOI 10.1136/jmg.25.9.589; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WILESMITH JW, 1988, VET REC, V123, P638	40	237	239	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1091	1097		10.1056/NEJM199104183241604	http://dx.doi.org/10.1056/NEJM199104183241604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008182				2022-12-24	WOS:A1991FG91200004
J	RIVIERE, Y; BLANK, V; KOURILSKY, P; ISRAEL, A				RIVIERE, Y; BLANK, V; KOURILSKY, P; ISRAEL, A			PROCESSING OF THE PRECURSOR OF NF-KAPPA-B BY THE HIV-1 PROTEASE DURING ACUTE INFECTION	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR; BINDING; EXPRESSION	TRANSCRIPTION of the human immunodeficiency virus type-1 (HIV-1) genome is regulated in part by cellular factors and is stimulated by activation of latently infected T cells. T-cell activation also correlates with the induction of the factor NF-kappa-B which binds to two adjacent sites in the HIV-1 long terminal repeat 1. This factor consists of two DNA-binding subunits of relative molecular mass 50,000 (50K) associated with two 65K subunits. It is located in the nucleus in mature B cells, but is present in other cell types as an inactive cytoplasmic complex 2, 3. External stimuli, including those that activate T cells, result in nuclear translocation of active NF-kappa-B. The cloning of the complementary DNA for the 50K subunit 4,5 helped to identify an exclusively cytoplasmic 105K precursor (p105) (V.B., P.K. and A.I., manuscript submitted). The expression of active NF-kappa-B might therefore also be regulated by the extent of processing of p105. Because HIV-1 requires active NF-kappa-B for efficient transcription 1, we tested the effect of HIV-1 infection on the processing of the human 105K precursor. We show here that the HIV-1 protease can process p105 and increases levels of active nuclear NF-kappa-B complex.	INST PASTEUR,UNITE BIOL MOLEC GENE,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE VIROL & IMMUNOL CELLULAIRE,CNRS,URA 1157,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, GENE DEV, V3, P1689; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Hirel PH, 1990, ANTIVIR CHEM CHEMOTH, V1, P9, DOI 10.1177/095632029000100103; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; LAURENT AG, 1989, J VIROL, V63, P4074, DOI 10.1128/JVI.63.9.4074-4078.1989; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	13	165	167	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					625	626		10.1038/350625a0	http://dx.doi.org/10.1038/350625a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017258				2022-12-24	WOS:A1991FH11200064
J	SUBBIAH, S				SUBBIAH, S			LOW-RESOLUTION REAL-SPACE ENVELOPES - AN APPROACH TO THE ABINITIO MACROMOLECULAR PHASE PROBLEM	SCIENCE			English	Article							INFORMATION-THEORY; MAXIMUM-ENTROPY; CRYSTALLOGRAPHY; REFINEMENT; CRYSTAL; IMAGES	An ab initio approach to the phase problem in macromolecular x-ray crystallography is described. A random gas of hard-sphere point scatterers is allowed to condense under the constraint of the solvent fraction and the restraint of the observed Fourier amplitude data. Two applications to real macromolecular examples are discussed. This method produces an approximate outline of the bulk solvent regions and thus yields a low-resolution picture of the unit cell that can be extended to higher resolutions in special cases, such as through the use of molecular replacement or of noncrystallographic symmetry-based phase extension.			SUBBIAH, S (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM-41455] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041455, R37GM041455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1986, P NATL ACAD SCI USA, V83, P5489, DOI 10.1073/pnas.83.15.5489; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRICOGNE G, 1984, ACTA CRYSTALLOGR A, V40, P410, DOI 10.1107/S0108767384000866; BRICOGNE G, 1982, COMPUTATIONAL CRYSTA, P258; BRITTEN PL, 1982, ACTA CRYSTALLOGR A, V38, P12; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLLINS DM, 1982, NATURE, V298, P49, DOI 10.1038/298049a0; COXETER HSM, 1961, INTRO GEOMETRY, P404; FLAHERTY KM, UNPUB; HAUPTMAN HA, 1972, CRYSTAL STRUCTURE DE; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARLE J, 1986, SCIENCE, V232, P837, DOI 10.1126/science.232.4752.837; KARLE J, 1950, ACTA CRYSTALLOGR, V3, P181, DOI 10.1107/S0365110X50000446; KARLE J, 1989, ACTA CRYSTALLOGR A, V45, P765, DOI 10.1107/S0108767389007403; KARLE J, 1980, INT J QUANTUM CHEM, V7, P357; KEEN DA, 1990, NATURE, V344, P423, DOI 10.1038/344423a0; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KLUG A, 1958, ACTA CRYSTALLOGR, V11, P515, DOI 10.1107/S0365110X58001456; KLUG A, 1958, ACTA CRYSTALLOGR A, V40, P11; LIPSCOMB WN, 1949, ACTA CRYSTALLOGR, V2, P193, DOI 10.1107/S0365110X49000515; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MONDRAGON A, 1989, J MOL BIOL, V205, P189, DOI 10.1016/0022-2836(89)90375-6; NARAYAN R, 1982, ACTA CRYSTALLOGR A, V38, P122, DOI 10.1107/S0567739482000229; NAVAZA J, 1985, ACTA CRYSTALLOGR A, V41, P222; Patterson AL, 1934, PHYS REV, V46, P0372, DOI 10.1103/PhysRev.46.372; PIRO OE, 1983, ACTA CRYSTALLOGR A, V39, P61, DOI 10.1107/S0108767383000094; PODJARNY AD, 1987, ANNU REV BIOPHYS BIO, V16, P351; POST B, 1979, ACTA CRYSTALLOGR A, V35, P17, DOI 10.1107/S0567739479000048; PRINCE E, 1988, ACTA CRYSTALLOGR A, V44, P218; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SEMENOVSKAYA SV, 1985, ACTA CRYSTALLOGR A, V41, P268, DOI 10.1107/S0108767385000563; SHEN W, 1987, NATURE, V329, P232, DOI 10.1038/329232a0; SUBBIAH S, UNPUB; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; THAYER M, IN PRESS J MOL BIOL; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; WILKINS SW, 1983, ACTA CRYSTALLOGR A, V39, P47, DOI 10.1107/S0108767383000082; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813	39	35	38	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					128	133		10.1126/science.2011749	http://dx.doi.org/10.1126/science.2011749			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011749				2022-12-24	WOS:A1991FE95200051
J	ANDERSON, C				ANDERSON, C			POLAR PSYCHOLOGY - COPING WITH IT ALL	NATURE			English	Editorial Material																			0	3	3	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					290	290		10.1038/350290a0	http://dx.doi.org/10.1038/350290a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD838	2008210				2022-12-24	WOS:A1991FD83800048
J	SHULKIN, DJ				SHULKIN, DJ			PREVENTION AND MANAGEMENT OF HIV-CONTAMINATED NEEDLESTICKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SHULKIN, DJ (corresponding author), UNIV PENN,SCH MED,ROBERT WOOD JOHNSON FDN,PHILADELPHIA,PA 19104, USA.							HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; SACKS HS, 1990, J GEN INTERN MED, V5, P132, DOI 10.1007/BF02600514; 1990, MMWR, V39, P19; 1990, MMWR, V39, P1	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1262	1262		10.1001/jama.265.10.1262	http://dx.doi.org/10.1001/jama.265.10.1262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995972				2022-12-24	WOS:A1991FA51100019
J	FLORAS, JS; LEGAULT, L; MORALI, GA; HARA, K; BLENDIS, LM				FLORAS, JS; LEGAULT, L; MORALI, GA; HARA, K; BLENDIS, LM			INCREASED SYMPATHETIC OUTFLOW IN CIRRHOSIS AND ASCITES - DIRECT EVIDENCE FROM INTRANEURAL RECORDINGS	ANNALS OF INTERNAL MEDICINE			English	Article						ASCITES; LIVER CIRRHOSIS; SYMPATHETIC NERVOUS SYSTEM; NOREPINEPHRINE; EPINEPHRINE	NERVOUS-SYSTEM ACTIVITY; OUTPUT CARDIAC-FAILURE; BODY NEGATIVE-PRESSURE; PLASMA NOREPINEPHRINE; WATER-RETENTION; DECOMPENSATED CIRRHOSIS; ESSENTIAL-HYPERTENSION; HEPATORENAL-SYNDROME; NEPHROTIC SYNDROME; VOLUME EXPANSION	Objective: To determine if central sympathetic outflow is increased in patients with cirrhosis and ascites. Patients: Eleven patients with cirrhosis and ascites, 8 patients with cirrhosis but without ascites, and 7 age-matched and 8 young healthy volunteers. Methods: With subjects supine, direct microneurographic recordings of efferent post-ganglionic muscle sympathetic nerve activity were obtained from the peroneal nerve, and sympathetic burst frequency was compared with subjects' blood pressure, heart rate, sodium excretion, catecholamines, and plasma renin activity. All patients with cirrhosis were studied at least 5 days after withdrawal from all medications and after 7 days of a 20 mmol/d sodium, 1-L fluid-restricted diet. Age-matched volunteers were studied after 7 days of 20 mmol/d sodium intake and young healthy volunteers after 7 days of 150 mmol/d sodium intake. Results: Sympathetic nerve activity in ascitic patients (65 +/- 15 bursts/min; mean +/- SD) was markedly increased, whether compared with patients with cirrhosis but without ascites (34 +/- 16 bursts/min; p < 0.001), age-matched healthy volunteers on similar sodium intake (27 +/- 22 bursts/min; P < 0.001), or young healthy subjects (21 +/- 10 bursts/min; P < 0.001). The frequency of muscle sympathetic nerve discharge was directly related to plasma norepinephrine and epinephrine concentrations, plasma renin activity, and heart rate, all of which were increased in those patients with cirrhosis and ascites, and inversely related to 24-hour urinary sodium excretion, the fractional excretion of sodium, and subjects' pulse pressures. Sympathetic nerve activity fell from 78 to 6 bursts/min in one patient after liver transplantation. Conclusions: This study provides the first direct evidence that elevated plasma norepinephrine concentrations in patients with cirrhosis and ascites are due to increased central sympathetic outflow. Sympathetic nerve activity is not increased in patients with cirrhosis but without ascites. Because there were direct positive correlations of sympathetic nerve activity with plasma norepinephrine concentrations, plasma epinephrine concentrations, plasma renin activity, and heart rate, the increase in central sympathetic outflow in patients with cirrhosis and ascites appears generalized and not restricted to muscle nerves. The anti-natriuretic effects of parallel increases in renal and muscle sympathetic nerve activity could account for the inverse correlation between muscle sympathetic nerve activity and sodium excretion.			FLORAS, JS (corresponding author), UNIV TORONTO, TORONTO GEN HOSP, DIV CARDIOL, 12 EN-234, 200 ELIZABETH ST, TORONTO M5G 2C4, ONTARIO, CANADA.		Floras, John S./D-4042-2015					ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; ANDERSON EA, 1987, HYPERTENSION, V9, P114, DOI 10.1161/01.HYP.9.6_Pt_2.III114; ANGELLJAMES JE, 1971, J PHYSIOL-LONDON, V214, P65; BERNARDI M, 1983, HEPATOLOGY, V3, P56; BETTER OS, 1983, KIDNEY INT, V23, P303, DOI 10.1038/ki.1983.20; BICHET DG, 1982, NEW ENGL J MED, V307, P1552, DOI 10.1056/NEJM198212163072504; BLENDIS LM, 1987, HEPATOLOGY, V7, P143, DOI 10.1002/hep.1840070128; DIBONA GF, 1988, AM J PHYSIOL, V254, pR1017, DOI 10.1152/ajpregu.1988.254.6.R1017; DIBONA GF, 1989, MINER ELECTROL METAB, V15, P44; DIBONA GF, 1984, KIDNEY INT, V25, P841, DOI 10.1038/ki.1984.99; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; ESLER M, 1988, HYPERTENSION, V11, P3, DOI 10.1161/01.HYP.11.1.3; FLORAS JS, 1988, J CLIN INVEST, V81, P1265, DOI 10.1172/JCI113444; FLORAS JS, 1990, CIRCULATION, V81, P1860, DOI 10.1161/01.CIR.81.6.1860; HENRIKSEN JH, 1984, GUT, V25, P1034, DOI 10.1136/gut.25.10.1034; KOEPKE JP, 1987, AM J PHYSIOL, V252, pR1019, DOI 10.1152/ajpregu.1987.252.5.R1019; KOSTREVA DR, 1980, AM J PHYSIOL, V238, pR390, DOI 10.1152/ajpregu.1980.238.5.R390; KOWALSKI HJ, 1953, J CLIN INVEST, V32, P1025, DOI 10.1172/JCI102813; LAWTON W, 1986, FASEB J, V45, P522; LEIMBACH WN, 1986, CIRCULATION, V73, P913, DOI 10.1161/01.CIR.73.5.913; MAJEWSKI H, 1983, J AUTON PHARMACOL, V3, P47, DOI 10.1111/j.1474-8673.1983.tb00496.x; MORLIN C, 1983, ACTA PHYSIOL SCAND, V119, P117, DOI 10.1111/j.1748-1716.1983.tb07315.x; NEZU M, 1985, HYPERTENSION, V7, P187, DOI 10.1161/01.HYP.7.2.187; NICHOLLS KM, 1985, CIRC RES, V56, P457, DOI 10.1161/01.RES.56.3.457; OSBORN JL, 1983, CIRC RES, V53, P298, DOI 10.1161/01.RES.53.3.298; PERSSON PB, 1989, AM J PHYSIOL, V256, pF485, DOI 10.1152/ajprenal.1989.256.3.F485; RINGLARSEN H, 1982, HEPATOLOGY, V2, P304; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1065, DOI 10.1056/NEJM198810203191606; SKORECKI KL, 1988, AM J MED, V85, P375, DOI 10.1016/0002-9343(88)90590-6; SOLISHERRUZO JA, 1987, J HEPATOL, V5, P167, DOI 10.1016/S0168-8278(87)80569-X; SUNDLOF G, 1978, J PHYSIOL-LONDON, V278, P525, DOI 10.1113/jphysiol.1978.sp012322; SUNDLOF G, 1977, J PHYSIOL-LONDON, V272, P383, DOI 10.1113/jphysiol.1977.sp012050; SUNDLOF G, 1978, J PHYSIOL-LONDON, V274, P621, DOI 10.1113/jphysiol.1978.sp012170; TAGEJENSEN U, 1988, J HEPATOL, V6, P350, DOI 10.1016/S0168-8278(88)80053-9; THULUVATH PJ, 1989, Q J MED, V72, P737; UNIKOWSKY B, 1983, J CLIN INVEST, V72, P1594, DOI 10.1172/JCI111118; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; VICTOR RG, 1987, J APPL PHYSIOL, V63, P2558, DOI 10.1152/jappl.1987.63.6.2558; WEBB DJ, 1988, J HYPERTENS, V6, pS542, DOI 10.1097/00004872-198812040-00170; WEICKER H, 1984, CLIN CHIM ACTA, V141, P17, DOI 10.1016/0009-8981(84)90162-1; WESTFALL TC, 1985, ANNU REV PHARMACOL, V25, P621, DOI 10.1146/annurev.pharmtox.25.1.621; WILLETT I, 1985, J HEPATOL, V1, P639, DOI 10.1016/S0168-8278(85)80007-6; YAMADA Y, 1989, HYPERTENSION, V13, P870, DOI 10.1161/01.HYP.13.6.870; ZIMMERMAN BG, 1978, FED PROC, V37, P199	47	117	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					373	380		10.7326/0003-4819-114-5-373	http://dx.doi.org/10.7326/0003-4819-114-5-373			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992879				2022-12-24	WOS:A1991EZ17400005
J	GREENSON, JK; BELITSOS, PC; YARDLEY, JH; BARTLETT, JG				GREENSON, JK; BELITSOS, PC; YARDLEY, JH; BARTLETT, JG			AIDS ENTEROPATHY - OCCULT ENTERIC INFECTIONS AND DUODENAL MUCOSAL ALTERATIONS IN CHRONIC DIARRHEA	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA, CHRONIC; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM-AVIUM-INTRACELLULARE INFECTION; MICROSPORIDIA INFECTION	ACQUIRED IMMUNODEFICIENCY SYNDROME; INTESTINAL INFECTIONS; VIRUS HIV; T-CELLS; DISEASE	Objective: To investigate occult enteric infections and morphologic changes in the small intestine in patients with advanced human immunodeficiency virus (HIV) infection and chronic diarrhea of undefined cause. Design: Case-control study. Setting: Referral-based clinic and hospital in tertiary care center. Patients: Twenty-two patients with advanced HIV infection (19 with the acquired immunodeficiency syndrome [AIDS], 3 with AIDS-related complex) with chronic diarrhea, selected because of previously negative stool evaluations for bacterial or parasitic pathogens, were compared with 13 patients with advanced HIV infection (9 with AIDS, 4 with AIDS-related complex) without diarrhea by analysis of endoscopic biopsies using light and electron microscopy, viral culture, and morphometric studies. Both groups were convenience samples and had at least 7 months follow-up. Measurements and main Result: Eleven of twenty-two patients with HIV infection and chronic diarrhea but only 1 of 13 patients without diarrhea showed occult enteric pathogens (that is, undetected by routine studies) after extensive evaluation of duodenal and colorectal biopsies. Mycobacterium avium-intracellulare and microsporidia were the most common occult agents in study patients with diarrhea (5 each). Patients with diarrhea and occult enteric infections had greater weight loss (mean, 14.3 kg compared with 6.2 kg; P < 0.05) and shorter survival (1 of 11 compared with 8 of 11 still alive; P < 0.004) than those with diarrhea but no identified pathogens (defined as "AIDS enteropathy"). Duodenal morphometry showed decreased villus-to-crypt ratios because of villus atrophy and crypt elongation in HIV -infected patients both with and without diarrhea compared with normal controls (P < 0.001 for each). All three groups showed comparable frequencies of epithelial mitoses. Conclusions: Further endoscopic biopsy evaluation of patients with AIDS who had unexplained chronic diarrhea showed an occult infectious cause in half of the cases. However, altered villus and crypt architecture in advanced HIV infection was independent of the presence of diarrhea or enteric infection and therefore did not correlate with AIDS enteropathy. Subnormal epithelial proliferation in response to injury could be a factor, but the underlying cause of the architectural changes remains obscure. We suggest that T-cell dysfunction may play a role.	JOHNS HOPKINS UNIV HOSP, DIV INFECT DIS, BLALOCK 11, 600 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV HOSP, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040618] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 RO1DK4061802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONY MA, 1988, DIGEST DIS SCI, V33, P1141, DOI 10.1007/BF01535791; BARTELSMAN JFWM, 1989, SCAND J GASTROENTERO, V24, P112, DOI 10.3109/00365528909091381; BATMAN PA, 1989, J CLIN PATHOL, V42, P275, DOI 10.1136/jcp.42.3.275; COLEBUNDERS R, 1988, GUT, V29, P1687, DOI 10.1136/gut.29.12.1687; CONNOLLY GM, 1989, GUT, V30, P195, DOI 10.1136/gut.30.2.195; CUMMINS AG, 1990, GUT, V31, P317, DOI 10.1136/gut.31.3.317; DESPORTES I, 1985, J PROTOZOOL, V32, P250; ELLAKANY S, 1987, AM J CLIN PATHOL, V87, P356, DOI 10.1093/ajcp/87.3.356; FERREIRA RD, 1990, GASTROENTEROLOGY, V98, P1255, DOI 10.1016/0016-5085(90)90342-X; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; JARRY A, 1990, HISTOPATHOLOGY, V16, P133; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; MACDONALD TT, 1977, CELL TISSUE KINET, V10, P301, DOI 10.1111/j.1365-2184.1977.tb00298.x; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MATHIJS JM, 1988, LANCET, V1, P1111; NELSON JA, 1988, LANCET, V1, P259; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; RENE E, 1989, DIGEST DIS SCI, V34, P773, DOI 10.1007/BF01540353; RODGERS VD, 1986, GASTROENTEROLOGY, V90, P552, DOI 10.1016/0016-5085(86)91108-X; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; ULLRICH R, 1989, ANN INTERN MED, V111, P15, DOI 10.7326/0003-4819-111-1-15; 1989, LANCET, V2, P777; 1985, MMWR, V34, P373	26	158	158	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					366	372		10.7326/0003-4819-114-5-366	http://dx.doi.org/10.7326/0003-4819-114-5-366			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992878				2022-12-24	WOS:A1991EZ17400004
J	FU, LN; YE, RQ; BROWDER, LW; JOHNSTON, RN				FU, LN; YE, RQ; BROWDER, LW; JOHNSTON, RN			TRANSLATIONAL POTENTIATION OF MESSENGER-RNA WITH SECONDARY STRUCTURE IN XENOPUS	SCIENCE			English	Article							5' NONCODING REGION; C-MYC; UNWINDING ACTIVITY; MAMMALIAN-CELLS; OOCYTE MATURATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; POLIOVIRUS RNA; ANTISENSE RNA; POLY(A) RNAS	Differential translation of messenger RNA (mRNA) with stable secondary structure in the 5' untranslated leader may contribute to the dramatic changes in protein synthetic patterns that occur during oogenesis and early development. Plasmids that contained the bacterial gene chloramphenicol acetyltransferase and which encoded mRNA with (hpCAT) or without (CAT) a stable hairpin secondary structure in the 5' noncoding region were transcribed in vitro, and the resulting mRNAs were injected into Xenopus oocytes, eggs, and early embryos. During early oogenesis, hpCAT mRNA was translated at less than 3 percent of the efficiency of CAT mRNA. The relative translational potential of hpCAT reached 100 percent in the newly fertilized egg and returned to approximately 3 percent after the midblastula transition.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary			Johnston, Randal/B-9247-2009					ADAMSON ED, 1977, DEV BIOL, V57, P136, DOI 10.1016/0012-1606(77)90360-8; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CAPASSO O, 1987, EMBO J, V6, P1825, DOI 10.1002/j.1460-2075.1987.tb02437.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ETKIN LD, 1985, DEV BIOL, V108, P173, DOI 10.1016/0012-1606(85)90019-3; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; GALILI G, 1988, J BIOL CHEM, V263, P5764; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARSAKING ML, 1979, EUCARYOTIC GENE REGU, P239; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; KOZAK M, 1983, MICROBIOL REV, V47, P1; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LAZARUS P, 1988, ONCOGENE, V3, P517; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MCGREW LL, 1989, DEV BIOL, V134, P267, DOI 10.1016/0012-1606(89)90097-3; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1989, ONCOGENE, V4, P815; PATRICK TD, 1989, DEVELOPMENT, V106, P1; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1984, J MOL BIOL, V173, P227, DOI 10.1016/0022-2836(84)90191-8; ROLLER RJ, 1989, DEVELOPMENT, V106, P251; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WAGNER RW, 1990, P NATL ACAD SCI USA, V10, P5586; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	52	46	46	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					807	810		10.1126/science.1990443	http://dx.doi.org/10.1126/science.1990443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990443				2022-12-24	WOS:A1991EX57500049
J	WEINSTEIN, IB				WEINSTEIN, IB			MITOGENESIS IS ONLY ONE FACTOR IN CARCINOGENESIS	SCIENCE			English	Editorial Material							HUMAN CANCER; LECTURE		COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10032	Columbia University; Columbia University	WEINSTEIN, IB (corresponding author), COLUMBIA UNIV,DEPT MED,CTR COMPREHENS CANC,NEW YORK,NY 10032, USA.							ABELSON PH, 1990, SCIENCE, V249, P1357, DOI 10.1126/science.2402628; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AMES BN, 1979, SCIENCE, V204, P587, DOI 10.1126/science.373122; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7782, DOI 10.1073/pnas.87.19.7782; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7777, DOI 10.1073/pnas.87.19.7777; BLUM A, 1978, SCIENCE, V201, P1020, DOI 10.1126/science.684422; BOYD JA, 1990, GENETIC PHARM THER, V46, P469; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COLBURN NH, 1989, GENES SIGNAL TRANSDU; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HENDERSON BE, 1988, CANCER RES, V48, P246; HERRLICH P, 1986, ADV ENZYME REGUL, V25, P485, DOI 10.1016/0065-2571(86)90030-0; HOEL DG, 1988, CARCINOGENESIS, V9, P2045, DOI 10.1093/carcin/9.11.2045; HUFF J, IN PRESS MAXCYROSENA; IVANOVIC V, 1981, NATURE, V293, P404, DOI 10.1038/293404a0; MELNICK R, COMMUNICATION; RAO GN, 1987, FUND APPL TOXICOL, V9, P329, DOI 10.1016/0272-0590(87)90055-8; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1990, ADV 2ND MESSENGERS P; 1988, MONOGRAPHS EVALUA S7, V1	23	123	126	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					387	388		10.1126/science.1989073	http://dx.doi.org/10.1126/science.1989073			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989073				2022-12-24	WOS:A1991EU50400031
J	STRACHAN, DP				STRACHAN, DP			VENTILATORY FUNCTION AS A PREDICTOR OF FATAL STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; RISK-FACTORS; CHRONIC-BRONCHITIS; VITAL CAPACITY; LUNG-FUNCTION; MEN; MORTALITY; FRAMINGHAM; DEATH; BREATHLESSNESS	Objective - To investigate the relation between ventilatory function and subsequent mortality due to cerebrovascular disease. Design - Prospective longitudinal study. Subjects - A total of 18403 male civil servants aged 40-64 years at entry examination for the Whitehall study. Main outcome measures - Mortality from cerebrovascular disease (ICD8 430-438) after 18 years of follow up. Results - In all, 262 men with sinus rhythm at entry died due to stroke during the 18 years of follow up. Compared with men with a forced expiratory volume in one second of greater-than-or-equal-to 3.5 litres those with a value of < 3.0 litres were almost twice as likely to die of cerebrovascular disease (rate ratio adjusted for age and systolic blood pressure = 1.88, 95% confidence interval 1.32 to 2.69). This increased risk occurred within each tertile of systolic blood pressure. Nested case-control analyses were used to control precisely for confounding effects of age, height, and smoking (by matching) and employment grade and physiological risk factors (by modelling). The effect of forced expiratory volume in one second was independent of age, height, smoking habits, employment grade, blood pressure, weight, cholesterol concentration, glucose tolerance, electrocardiographic abnormalities, history of chest pain, and history of intermittent claudication. Conclusions - Measurements of ventilatory function may assist clinical decisions about whether to treat mild hypertension. Impaired ventilatory function and stroke may share common causes.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine								ABBOTT RD, 1987, JAMA-J AM MED ASSOC, V257, P949, DOI 10.1001/jama.257.7.949; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARRETTCONNOR E, 1988, AM J EPIDEMIOL, V128, P116, DOI 10.1093/oxfordjournals.aje.a114934; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P204; BROWN WS, 1989, HYPERTENSION S, V1, P51; COOK DG, 1988, EUR HEART J, V9, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062432; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DENNIS MS, 1987, BRIT J HOSP MED, V37, P194; DYKEN ML, 1984, STROKE, V15, P1105; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FRIEDMAN GD, 1976, NEW ENGL J MED, V294, P1071, DOI 10.1056/NEJM197605132942001; FUGLMEYER AR, 1983, SCAND J REHABIL MED, P118; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; HILLBOM ME, 1987, ACTA MED SCAND, P93; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KALES A, 1984, LANCET, V2, P1005; KANNEL WB, 1983, AM HEART J, V105, P311, DOI 10.1016/0002-8703(83)90532-X; KANNEL WB, 1974, CIRCULATION, V49, P1160, DOI 10.1161/01.CIR.49.6.1160; KANNEL WB, 1983, VASCULAR DISEASE CEN, P1; KELLYHAYES M, 1988, ARCH PHYS MED REHAB, V69, P415; KRYZANOWSKI M, 1986, INT J EPIDEMIOL, V15, P56; LANGE P, 1988, AM REV RESPIR DIS, V137, P1119, DOI 10.1164/ajrccm/137.5.1119; MARCUS EB, 1988, AM REV RESPIR DIS, V138, P1398, DOI 10.1164/ajrccm/138.6.1398; PERSSON C, 1986, AM J EPIDEMIOL, V124, P942, DOI 10.1093/oxfordjournals.aje.a114483; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; REID DD, 1974, LANCET, V1, P469; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; ROSE G, 1978, BRIT HEART J, V40, P636; SCHWARTZ J, 1989, American Review of Respiratory Disease, V139, pA28; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILLIAMS DRR, 1985, RECENT ADV COMMUNITY, V3, P117; ZHANG ZF, 1988, AM J PUBLIC HEALTH, V78, P975, DOI 10.2105/AJPH.78.8.975; 1988, EGRET EPIDEMIOLOGICA; 1985, SAS USERS GUIDE BASI	36	51	51	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	1991	302	6768					84	87		10.1136/bmj.302.6768.84	http://dx.doi.org/10.1136/bmj.302.6768.84			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995121	Bronze, Green Published			2022-12-24	WOS:A1991ER95100018
J	BRENNAN, TA; HEBERT, LE; LAIRD, NM; LAWTHERS, A; THORPE, KE; LEAPE, LL; LOCALIO, AR; LIPSITZ, SR; NEWHOUSE, JP; WEILER, PC; HIATT, HH				BRENNAN, TA; HEBERT, LE; LAIRD, NM; LAWTHERS, A; THORPE, KE; LEAPE, LL; LOCALIO, AR; LIPSITZ, SR; NEWHOUSE, JP; WEILER, PC; HIATT, HH			HOSPITAL CHARACTERISTICS ASSOCIATED WITH ADVERSE EVENTS AND SUBSTANDARD CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY DATA; DEATH RATES; QUALITY; ILLNESS; DISEASE; COST; SEVERITY	To explore the epidemiology of adverse events (AEs), which were defined as injuries due to medical treatment, and that subset of AEs caused by negligence, we studied interhospital variation in these outcomes in a sample of 31 000 medical records drawn from a random selection of 51 hospitals in New York in 1984. We found a substantial variation in both AE rates (0.2% to 7.9%; mean, 3.2%) and the percentage of AEs due to negligence (1% to 60%; mean, 24.9%) among hospitals. Univariate analyses of AEs revealed that primary teaching institutions had significantly higher rates (4.1%) and rural hospitals had significantly lower ones (1.0%). The percentage of AEs due to negligence was lower in primary teaching (10.7%) and for-profit (9.5%) hospitals and was significantly higher in hospitals with predominantly (> 80%) minority patients who had been discharged (37%). These findings were corroborated by multivariate analysis. Our results suggest that AEs and negligence are not randomly distributed and that certain types of hospitals have significantly higher rates of injuries due to substandard care. These observations may represent an important improvement on existing measures of quality because they take into account the fact that some hospitals' populations may be at risk of suffering a poor outcome.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,DIV GEN MED,BOSTON,MA 02115, USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022					ABRAMSON NS, 1980, JAMA-J AM MED ASSOC, V244, P582; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BIGBY J, 1986, AM J MED, V83, P1031; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1989, MED CARE, V29, P505; BURSTIN H R, 1991, Clinical Research, V39, p189A; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; DONABEDIAN A, 1985, INQUIRY-J HEALTH CAR, V22, P282; DUBOIS RW, 1987, AM J PUBLIC HEALTH, V77, P1162, DOI 10.2105/AJPH.77.9.1162; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FEIGENSON JS, 1978, JAMA-J AM MED ASSOC, V240, P1878; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOST TS, 1989, OHIO ST LJ, V50, P1; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1953, DOI 10.1001/jama.264.15.1953; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LAKSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931, DOI 10.1001/archinte.146.10.1931; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MASON WB, 1980, MED CARE, V18, P147, DOI 10.1097/00005650-198002000-00002; MOREHEAD MA, 1964, STUDY HOSPITAL CARE; PALMER RH, 1983, AMBULATORY HLTH CARE; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; SAFRAN C, 1989, MED CARE, V27, P204, DOI 10.1097/00005650-198902000-00010; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1985, 1984 NEW YORK STAT D; 1975, MED INSURANCE FEASIB	36	194	196	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3265	3269		10.1001/jama.265.24.3265	http://dx.doi.org/10.1001/jama.265.24.3265			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	2046108				2022-12-24	WOS:A1991FR83500032
J	FRANK, LG; GLICKMAN, SE; LICHT, P				FRANK, LG; GLICKMAN, SE; LICHT, P			FATAL SIBLING AGGRESSION, PRECOCIAL DEVELOPMENT, AND ANDROGENS IN NEONATAL SPOTTED HYENAS	SCIENCE			English	Article							CROCUTA-CROCUTA; SOCIAL-ORGANIZATION	Fatal neonatal sibling aggression is common in predatory birds but has not been previously reported in wild mammals. Spotted hyena females are strongly masculinized, both anatomically and behaviorally, apparently by high levels of androgens during ontogeny. Neonates display elevated androgen levels, precocial motor development, and fully erupted front teeth. Litters are usually twins, and siblings fight violently at birth, apparently leading to the death of one sibling in same-sex litters, whereas in mixed-sex litters both siblings usually survive.	UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	FRANK, LG (corresponding author), UNIV CALIF BERKELEY, DEPT PSYCHOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039917] Funding Source: NIH RePORTER; NIMH NIH HHS [MH39917] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BEKOFF M, 1981, AGGRESSIVE BEHAV, V7, P225, DOI 10.1002/1098-2337(1981)7:3<225::AID-AB2480070306>3.0.CO;2-I; FRANK LG, 1986, ANIM BEHAV, V34, P1510, DOI 10.1016/S0003-3472(86)80221-4; FRANK LG, 1990, J ZOOL, V221, P308, DOI 10.1111/j.1469-7998.1990.tb04001.x; FRANK LG, 1986, ANIM BEHAV, V34, P1500, DOI 10.1016/S0003-3472(86)80220-2; FRANK LG, UNPUB; Fraser D, 1990, J Reprod Fertil Suppl, V40, P355; GLICKMAN SE, 1987, P NATL ACAD SCI USA, V84, P3444, DOI 10.1073/pnas.84.10.3444; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; GOULD SJ, 1981, NAT HIST, V90, P16; HOFER H, 1989, 5TH INT THER C ROM; Kranendonk H.J., 1983, Zoologische Garten, V53, P339; KRUUK H, 1972, SPOTTED HYENA; LICHT P, 1982, BIOL REPROD, V27, P411, DOI 10.1095/biolreprod27.2.411; LINDEQUE M, 1982, J REPROD FERTIL, V65, P405; LINDEQUE M, 1986, J REPROD FERTIL, V78, P211; MACPHERSON AH, 1969, CAN WILDL REP SER, V8; MATTHEWS L. HARRISON, 1939, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V230, P1; MILLS MGL, 1990, KALAHARI HYAENAS, P138; MOCK DW, 1990, AM SCI, V78, P438; PARKER GA, 1989, AM NAT, V133, P846, DOI 10.1086/284956; Pournelle G. H., 1965, Journal of Mammalogy, V46, P503, DOI 10.2307/1377649; Rieger I., 1981, MAMMALIAN SPECIES, V150, P1; SMALE L, 1989, 5TH INT THER C ROM; TILSON RL, 1984, ANIM BEHAV, V32, P715, DOI 10.1016/S0003-3472(84)80147-5	24	134	139	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					702	704		10.1126/science.2024122	http://dx.doi.org/10.1126/science.2024122			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024122				2022-12-24	WOS:A1991FK18500047
J	ARANA, GW				ARANA, GW			DEXAMETHASONE SUPPRESSION TEST IN THE DIAGNOSIS OF DEPRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PSYCHIATRY; UTILITY				ARANA, GW (corresponding author), MED UNIV S CAROLINA,CHARLESTON,SC 29425, USA.							ARANA GW, 1985, ARCH GEN PSYCHIAT, V42, P1193; ARANA GW, 1988, AM J PSYCHIAT, V145, P707; CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15; GLASSMAN AH, 1987, AM J PSYCHIAT, V144, P1253	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2253	2254						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH877	2013959				2022-12-24	WOS:A1991FH87700042
J	KORENMAN, J; BAKER, B; WAGGONER, J; EVERHART, JE; DIBISCEGLIE, AM; HOOFNAGLE, JH				KORENMAN, J; BAKER, B; WAGGONER, J; EVERHART, JE; DIBISCEGLIE, AM; HOOFNAGLE, JH			LONG-TERM REMISSION OF CHRONIC HEPATITIS-B AFTER ALPHA-INTERFERON THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS-INFECTION; CONTROLLED TRIAL; E-ANTIGEN; HOMOSEXUAL MEN; HBSAG; ANTIBODY; FOLLOW	Objective: To evaluate whether remissions of chronic hepatitis B induced by alpha-interferon therapy are of long duration. Design: Cohort study. Setting: Clinical Center of the National Institutes of Health, a tertiary referral center. Patients: Sixty-four patients with chronic hepatitis B were treated with alpha-interferon between 1984 and 1986. Main Outcome Measures: Patients were followed with frequent examinations and determinations of serum liver biochemical tests and hepatitis B virus (HBV) markers including hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA using blot hybridization and polymerase chain reaction. Results: Among 64 patients with chronic hepatitis B who were treated with alpha-interferon, 23 (36%) responded to treatment with loss of HBeAg and improvement in serum aminotransferases. All 23 have been followed for 3 to 7 years (mean, 4.3 years). During follow-up, 3 of 23 patients relapsed, with reappearance of HBeAg and abnormal serum aminotransferases, all within 1 year of therapy. The remaining 20 patients continued to have no detectable HBeAg or HBV DNA (using blot hybridization) in serum and to be asymptomatic for liver disease, although 3 had minimal elevations in serum aminotransferases. Thirteen patients (65%) became negative for HBsAg between 0.2 and 6 years (mean, 3 years) after loss of HBeAg. Although no patient had HBV DNA that was detectable by blot hybridization, the 7 patients who remained HBsAg positive all had HBV DNA in serum detected by polymerase chain reaction, but only 2 of 13 HBsAg-negative patients had viral genome using this method. Testing sequential samples indicated that HBV DNA detected by polymerase chain reaction usually disappeared at or around the time that test results for HBsAg became negative. Conclusions: Remissions in chronic hepatitis B induced by alpha-interferon are of long duration and are followed, in most patients, by the loss of HBsAg and all evidence of residual virus replication.	NIDDKD, DIV DIGEST DIS & NUTR,BLDG 31,ROOM 9A23, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALEXANDER GJM, 1987, LANCET, V2, P66; BROOK MG, 1989, GUT, V30, P1116, DOI 10.1136/gut.30.8.1116; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARMAN WF, 1989, LANCET, V2, P588; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; DOOLEY JS, 1986, GASTROENTEROLOGY, V90, P150, DOI 10.1016/0016-5085(86)90087-9; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; Hoofnagle J. H., 1984, VIRAL HEPATITIS LIVE, P97; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989; KASSIANIDES C, 1988, VIRAL HEPATITIS LIVE, P840; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839, DOI 10.1016/0016-5085(87)90613-5; MOESTRUP T, 1986, BRIT MED J, V292, P854, DOI 10.1136/bmj.292.6524.854; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; SAMPLINER RE, 1979, AM J MED SCI, V277, P17, DOI 10.1097/00000441-197901000-00002; SARACCO G, 1989, HEPATOLOGY, V10, P336, DOI 10.1002/hep.1840100315; Ticehurst JR, 1989, DIAGNOSTIC PROCEDURE, P957	22	359	360	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					629	634		10.7326/0003-4819-114-8-629	http://dx.doi.org/10.7326/0003-4819-114-8-629			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003708				2022-12-24	WOS:A1991FG03100003
J	SHARP, KA; NICHOLLS, A; FINE, RF; HONIG, B				SHARP, KA; NICHOLLS, A; FINE, RF; HONIG, B			RECONCILING THE MAGNITUDE OF THE MICROSCOPIC AND MACROSCOPIC HYDROPHOBIC EFFECTS	SCIENCE			English	Article							FREE-ENERGY; SURFACE; DEPENDENCE; AREA	The magnitude of the hydrophobic effect, as measured from the surface area dependence of the solubilities of hydrocarbons in water, is generally thought to be about 25 calories per mole per square angstrom (cal mol-1 angstrom-2). However, the surface tension at a hydrocarbon-water interface, which is a "macroscopic" measure of the hydrophobic effect, is almost-equal-to 72 cal mol-1 angstrom-2. In an attempt to reconcile these values, alkane solubility data have been reevaluated to account for solute-solvent size differences, leading to a revised "microscopic" hydrophobic effect of 47 cal mol-1 angstrom-2. This value, when used in a simple geometric model for the curvature dependence of the hydrophobic effect, predicts a macroscopic alkane-water surface tension that is close to the macroscopic value.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168 ST, NEW YORK, NY 10032 USA; BIOSYM TECHNOL INC, SAN DIEGO, CA 92121 USA	Columbia University					NIGMS NIH HHS [GM41371, GM30518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030518, R01GM030518, R01GM041371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1907, PHYSICAL CHEM SURFAC; AVEYARD R, 1965, J COLLOID INTERF SCI, V20, P2255; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BENNAIM A, 1978, J PHYS CHEM-US, V82, P792, DOI 10.1021/j100496a008; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; BUFF FP, 1965, PHYS REV LETT, V15, P621, DOI 10.1103/PhysRevLett.15.621; CHOI DS, 1970, J CHEM PHYS, V53, P2608, DOI 10.1063/1.1674378; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; DEYOUNG LR, 1990, J PHYS CHEM-US, V94, P801, DOI 10.1021/j100365a054; DILL KA, 1990, SCIENCE, V250, P297, DOI 10.1126/science.2218535; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINE R, UNPUB; Flory PJ, 1941, J CHEM PHYS, V9, P660, DOI 10.1063/1.1750971; Harkins WD, 1921, J AM CHEM SOC, V43, P35, DOI 10.1021/ja01434a006; HERMANN RB, 1977, P NATL ACAD SCI USA, V74, P4144, DOI 10.1073/pnas.74.10.4144; HILDEBRAND JH, 1947, J CHEM PHYS, V15, P225, DOI 10.1063/1.1746484; Huggins ML, 1941, J CHEM PHYS, V9, P440, DOI 10.1063/1.1750930; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226; MANSOORI GA, 1971, J CHEM PHYS, V54, P1523, DOI 10.1063/1.1675048; MCAULIFFE C, 1966, J PHYS CHEM-US, V70, P1267, DOI 10.1021/j100876a049; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; NICHOLLS A, UNPUB; PIEROTTI RA, 1965, J PHYS CHEM-US, V69, P281, DOI 10.1021/j100885a043; POSTMA JPM, 1982, FARADAY SYMP CHEM S, P55, DOI 10.1039/fs9821700055; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; REYNOLDS JA, 1974, P NATL ACAD SCI USA, V71, P2925, DOI 10.1073/pnas.71.8.2925; TANFORD C, 1979, P NATL ACAD SCI USA, V76, P4175, DOI 10.1073/pnas.76.9.4175; TANFORD C, 1980, HYDROPHOBIC EFFECT; TOLMAN RC, 1949, J CHEM PHYS, V17, P333, DOI 10.1063/1.1747247	31	483	489	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1991	252	5002					106	109		10.1126/science.2011744	http://dx.doi.org/10.1126/science.2011744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011744				2022-12-24	WOS:A1991FE95200043
J	SLOANE, PD; MATHEW, LJ; SCARBOROUGH, M; DESAI, JR; KOCH, GG; TANGEN, C				SLOANE, PD; MATHEW, LJ; SCARBOROUGH, M; DESAI, JR; KOCH, GG; TANGEN, C			PHYSICAL AND PHARMACOLOGICAL RESTRAINT OF NURSING-HOME PATIENTS WITH DEMENTIA - IMPACT OF SPECIALIZED UNITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERMEDIATE-CARE FACILITY; ALZHEIMERS-DISEASE; MECHANICAL RESTRAINTS; DRUG-USE; RESIDENTS; AGITATION	This case-control study of 31 specialized dementia units and 32 traditional units in five states investigated use of physical and pharmacologic restraints among 625 patients with the diagnosis of dementia. Physical restraints were observed in use on 18.1% of dementia unit patients and on 51.6% of comparison unit patients who were out of bed during the day (adjusted odds ratio, 0.283; 95% confidence interval, 0.129 to 0.619). Pharmacologic restraints were routinely given to 45.3% of dementia unit patients and 43.4% of comparison unit patients (adjusted odds ratio, 0.950; 95% confidence interval, 0.611 to 1.477). We used multivariate logistic regression to identify residence in a nonspecialized nursing home unit, nonambulatory status, transfer dependency, mental status impairment, hip fracture history, and a high nursing staff-to-patient ratio, which we found to be independent predictors of physical restraint use. Physically abusive behavior, severe mental status impairment, and frequent family visitation were found to be significant predictors of pharmacologic restraint use, while advanced patient age, large nursing home size, and patient nonambulatory status were protective against such use. These results support the conclusion that physical and pharmacologic restraints constitute separate treatment modalities with different risk factors for use, and indicate that specialized dementia units are successful in reducing the use of physical but not pharmacologic restraints.	UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT BIOSTAT, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	SLOANE, PD (corresponding author), UNIV N CAROLINA, SCH MED, DEPT FAMILY MED, CAMPUS BOX 7595, CHAPEL HILL, NC 27599 USA.				NIA NIH HHS [1K08AG00341-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000341] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackermann J O, 1985, J Long Term Care Adm, V13, P90; APPELBAUM PS, 1984, AM J PSYCHIAT, V141, P202; BASEN MM, 1977, PUBLIC HEALTH REP, V92, P43; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; Calkins M P, 1989, Provider, V15, P7; COHENMANSFIELD J, 1986, J AM GERIATR SOC, V34, P722, DOI 10.1111/j.1532-5415.1986.tb04303.x; COVERT AB, 1977, J AM GERIATR SOC, V25, P85, DOI 10.1111/j.1532-5415.1977.tb00236.x; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; FOLMAR S, 1989, GERONTOLOGIST, V29, P650, DOI 10.1093/geront/29.5.650; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; Goldman L S, 1988, Clin Geriatr Med, V4, P589; Gwyther L P, 1986, Provider, V12, P20; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; KASHGARIAN M, 1980, AM J PUBLIC HEALTH, V70, P1217, DOI 10.2105/AJPH.70.11.1217-b; Kolcaba K, 1989, J Gerontol Nurs, V15, P29; LOFGREN RP, 1989, AM J PUBLIC HEALTH, V79, P735, DOI 10.2105/AJPH.79.6.735; MAAS M, 1988, NURS CLIN N AM, V23, P57; *MACE NL, 1990, DEMENTIA CARE PATIEN; MION LC, 1989, J AM GERIATR SOC, V37, P949, DOI 10.1111/j.1532-5415.1989.tb07280.x; OHTA RJ, 1988, GERONTOLOGIST, V28, P803, DOI 10.1093/geront/28.6.803; PRUCHNO RA, 1988, J GERONTOL, V43, pP164, DOI 10.1093/geronj/43.6.P164; RABINS PV, 1986, HOSP COMMUNITY PSYCH, V37, P120; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; ROBBINS LJ, 1987, J AM GERIATR SOC, V35, P290, DOI 10.1111/j.1532-5415.1987.tb04633.x; Rubenstein H S, 1983, Law Med Health Care, V11, P271; SHAH BV, 1984, SURVEY DATA ANAL SOF; SOBEL KG, 1983, DRUG INTEL CLIN PHAR, V17, P539; TERI L, 1989, J AM GERIATR SOC, V37, P109; Wagner L, 1987, Mod Healthc, V17, P40; Weiner A S, 1989, J Long Term Care Adm, V17, P14; WERNER P, 1989, J AM GERIATR SOC, V37, P1122, DOI 10.1111/j.1532-5415.1989.tb06675.x; WILLIAMS CC, 1989, GERONTOLOGIST, V29, P585, DOI 10.1093/geront/29.5.585; ZIMMER JG, 1984, AM J PUBLIC HEALTH, V74, P1118, DOI 10.2105/AJPH.74.10.1118; 1986, SUGI SUPPLEMENTAL LI; 1990, RESTRAINTS PACKET B; 1987, TABA323 C OFF TECHN; 1984, USE RESTRAINTS FEDER	40	82	82	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1278	1282		10.1001/jama.265.10.1278	http://dx.doi.org/10.1001/jama.265.10.1278			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995975				2022-12-24	WOS:A1991FA51100022
J	BLANC, P; WONG, H; BERNSTEIN, MS; BOUSHEY, HA				BLANC, P; WONG, H; BERNSTEIN, MS; BOUSHEY, HA			AN EXPERIMENTAL HUMAN-MODEL OF METAL FUME FEVER	ANNALS OF INTERNAL MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; BRONCHOALVEOLAR WASHINGS; FACTOR-ALPHA; ZINC; INTERLEUKIN-1; INFLAMMATION; MEDIATOR; CYTOKINE; LAVAGE; CELLS	Objective: To examine the pathogenesis of metal fume fever in humans by studying functional, cellular, and biochemical responses after exposure to zinc welding fume. Design: Clinical experimental study. Participants: We studied 14 welders recruited through public advertisements. Interventions: Participants welded galvanized steel. Measurements: We measured lung volumes, airflow, diffusing capacity for carbon monoxide, and airway reactivity at baseline as well as either 6 or 20 hours after welding. We carried out bronchoalveolar lavage either 8 hours (early follow-up, 5 participants) or 22 hours (late follow-up, 9 participants) after welding, assaying the fluid for total and differential cell counts and bronchoalveolar lavage supernatant concentrations of interleukin-1 and tumor necrosis factor (TNF). Main Results: Changes in pulmonary function and airway reactivity were minimal. Cumulative zinc exposure and polymorphonuclear leukocyte count in bronchoalveolar lavage fluid at late (r = 0.87; P < 0.01) and early (r = 0.93; P < 0.05)follow-up were positively correlated. Among the late follow-up group, the mean proportion of polymorphonuclear leukocytes was 37% (range, 19% to 63%), a statistically greater proportion than the 9% (range, 2% to 21%) seen among the early follow-up group (P < 0.05). We did not detect TNF or more than a trace amount of interleukin-1 in the bronchoalveolar lavage supernatant. Conclusions: Zinc oxide welding fume was associated with a marked dose-dependent increase in the number of polymorphonuclear leukocytes recovered in bronchoalveolar lavage fluid 22 hours after exposure but was not associated with a clinically significant change in pulmonary function or airway reactivity. Although we did not identify increases in either interleukin-1 or TNF levels in bronchoalveolar lavage fluid, cytokines or a cytokine-like mechanism may mediate the syndrome of metal fume fever.	UNIV CALIF SAN FRANCISCO, DIV OCCUPAT & ENVIRONM MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV PULM MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136] Funding Source: Medline; PHS HHS [K010H00079] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEECKMANS JM, 1963, ARCH ENVIRON HEALTH, V7, P346, DOI 10.1080/00039896.1963.10663544; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIBBY DC, 1989, J PHYSIOL-LONDON, V410, P367, DOI 10.1113/jphysiol.1989.sp017538; BROCKS A, 1977, BRIT MED J, V1, P1390, DOI 10.1136/bmj.1.6073.1390; CALLENDER G. R., 1937, Military Surgeon, V80, P67; CONNER MW, 1988, J TOXICOL ENV HEALTH, V25, P57, DOI 10.1080/15287398809531188; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; DRINKER PHILIP, 1927, JOUR INDUST HYG, V9, P98; GELB AF, 1973, AM REV RESPIR DIS, V107, P50; KUNKEL SL, 1990, PROG CLIN BIOL RES, V349, P433; LAM HF, 1985, TOXICOL APPL PHARM, V78, P29, DOI 10.1016/0041-008X(85)90301-1; LARSEN C, 1990, PROG CLIN BIOL RES, V349, P419; LECOURS R, 1986, THORAX, V41, P924, DOI 10.1136/thx.41.12.924; LEHMANN KB, 1910, ARCH HYG, V72, P358; LITOVITZ TL, 1989, AM J EMERG MED, V7, P495, DOI 10.1016/0735-6757(89)90252-0; MALO JL, 1990, EUR RESPIR J, V3, P111; MALO JL, 1987, CHEST, V92, P375, DOI 10.1378/chest.92.2.375; MARCHAT-AMORUSO B, 1990, American Review of Respiratory Disease, V141, pA423; MITCHELL MM, 1968, AM REV RESPIR DIS, V97, P571; MORI T, 1975, INT ARCH OCC ENV HEA, V36, P29, DOI 10.1007/BF01267849; MORIMOTO A, 1988, AM J PHYSIOL, V254, pR633, DOI 10.1152/ajpregu.1988.254.4.R633; MORIMOTO A, 1989, AM J PHYSIOL, V256, pR35, DOI 10.1152/ajpregu.1989.256.1.R35; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; MUELLER E J, 1985, Journal of Emergency Medicine, V2, P271, DOI 10.1016/0736-4679(85)90106-4; MURPHY JV, 1970, J AMER MED ASSOC, V212, P2119, DOI 10.1001/jama.212.12.2119; NELSON S, 1989, J INFECT DIS, V159, P189, DOI 10.1093/infdis/159.2.189; NETA R, 1988, ANN INTERN MED, V109, P1, DOI 10.7326/0003-4819-109-1-1; OLGILVIE CM, 1957, J CLIN INVEST, V36, P1; PERNIS B, 1960, CLIN LAVORO, V51, P579; RYAN L K, 1990, American Review of Respiratory Disease, V141, pA678; SCHMIDTKEHL L, 1928, ZENTRALBLATT GEWERBE, V5, P272; SCUDERI P, 1990, CELL IMMUNOL, V126, P391, DOI 10.1016/0008-8749(90)90330-T; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SILER TM, 1989, EXP LUNG RES, V15, P881, DOI 10.3109/01902148909069633; STURGIS CYRUS C., 1927, JOUR INDUST HYG, V9, P88; TANAKA Y, 1990, SCAND J IMMUNOL, V31, P547, DOI 10.1111/j.1365-3083.1990.tb02805.x; TAYLOR G, 1986, OCCUPATIONAL RESPIRA, P607; VACHERON F, 1990, J GEN VIROL, V71, P477, DOI 10.1099/0022-1317-71-2-477; VOLGELMEIER C, 1987, CHEST, V92, P946; WANKOWICZ Z, 1988, J LEUKOCYTE BIOL, V43, P349, DOI 10.1002/jlb.43.4.349; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365, DOI 10.1164/ajrccm/142.2.365; WINCHURCH RA, 1987, EUR J IMMUNOL, V17, P127, DOI 10.1002/eji.1830170121; 1990, AM REV RESPIR DIS, V141, pS165; 1975, OCCUPATIONAL EXPOSUR; 1988, CRITERIA RECOMMENDED; 1989, OSHA3112 US DEP LAB	48	69	72	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					930	936		10.7326/0003-4819-114-11-930	http://dx.doi.org/10.7326/0003-4819-114-11-930			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024859				2022-12-24	WOS:A1991FM97900003
J	BERAL, V; BULL, D; JAFFE, H; EVANS, B; GILL, N; TILLETT, H; SWERDLOW, AJ				BERAL, V; BULL, D; JAFFE, H; EVANS, B; GILL, N; TILLETT, H; SWERDLOW, AJ			IS RISK OF KAPOSIS-SARCOMA IN AIDS PATIENTS IN BRITAIN INCREASED IF SEXUAL PARTNERS CAME FROM UNITED-STATES OR AFRICA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the risk of Kaposi's sarcoma in patients with AIDS is increased by sexual contact with groups from abroad with a high incidence of Kaposi's sarcoma. Design-Analysis of data on patients with AIDS and Kaposi's sarcoma. Setting-United Kingdom. Patients-2830 patients with AIDS reported to the Communicable Disease Surveillance Centre and the Communicable Disease (Scotland) Unit up to March 1990, of whom 566 had Kaposi's sarcoma. Main outcome measures-Number of patients with Kaposi's sarcoma and possible source of HIV infection. Results-537 of 2291 men (23%) who acquired AIDS through sexual contact had Kaposi's sarcoma; the risk associated with heterosexual contact was 10% (14/135). None of the patients with Kaposi's sarcoma for whom information on source of infection was available had contracted AIDS through non-sexual means. Kaposi's sarcoma was more common among homosexual men whose likely source of infection included the United States (171/551, 31%) or Africa (9/134, 26%) than among those infected in the United Kingdom (119/625, 19%; p < 0.05). Conclusion-The data suggest that Kaposi's sarcoma is caused by a transmissible agent and that an important route of transmission is sexual contact.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; PUBL HLTH LAB SERV,CTR AIDS,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine	BERAL, V (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159				BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; 1989, J INFECTION, V18, P77	4	43	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					624	625		10.1136/bmj.302.6777.624	http://dx.doi.org/10.1136/bmj.302.6777.624			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC071	2012875	Bronze, Green Published			2022-12-24	WOS:A1991FC07100020
J	HOFMANN, JFX; GASSER, SM				HOFMANN, JFX; GASSER, SM			IDENTIFICATION AND PURIFICATION OF A PROTEIN THAT BINDS THE YEAST ARS CONSENSUS SEQUENCE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; SILENCER; ORIGIN; REQUIREMENTS; SEGREGATION; POLYMERASE; ELEMENTS; PLASMIDS; CLEAVAGE	We have identified a yeast protein that binds specifically to the ARS consensus sequence. By two-step chromatography we have purified the factor to apparent homogeneity as a single polypeptide of 67 kd. The purified ARS consensus-binding protein (ACBP) recognizes the ARS consensus of the four genomic ARS elements tested, binding preferentially to the T-rich single strand. Point mutations in the consensus significantly reduce the affinity of the single-strand binding. At the histone H4 ARS, ACBP recognizes both the perfect ARS consensus and a 9/11 match 3' of it. These two binding sites correlate with the boundaries of the minimal functional H4 ARS element. A similar configuration of binding sites is found at ARS1. We propose a model implicating this factor in an early step of the initiation of DNA replication.			HOFMANN, JFX (corresponding author), SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND.			Gasser, Susan/0000-0003-3610-9123				ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ALLIGER P, 1988, BIOCHIM BIOPHYS ACTA, V951, P396, DOI 10.1016/0167-4781(88)90112-1; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KEARSEY S, 1984, CELL, V37, P299, DOI 10.1016/0092-8674(84)90326-X; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIPLING D, 1990, MOL CELL BIOL, V10, P265, DOI 10.1128/MCB.10.1.265; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; Maniatis T., 1982, MOL CLONING; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; VAUGHN JP, 1990, NUCLEIC ACIDS RES, V18, P1965, DOI 10.1093/nar/18.8.1965; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801	36	77	79	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					951	960		10.1016/0092-8674(91)90319-T	http://dx.doi.org/10.1016/0092-8674(91)90319-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001590				2022-12-24	WOS:A1991FA94000012
J	LONGAKER, MT; GOLBUS, MS; FILLY, RA; ROSEN, MA; CHANG, SW; HARRISON, MR				LONGAKER, MT; GOLBUS, MS; FILLY, RA; ROSEN, MA; CHANG, SW; HARRISON, MR			MATERNAL OUTCOME AFTER OPEN FETAL SURGERY - A REVIEW OF THE 1ST 17 HUMAN CASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGENITAL DIAPHRAGMATIC-HERNIA; EXPERIMENTAL PULMONARY HYPOPLASIA; HYDRONEPHROSIS INUTERO; NATURAL-HISTORY; SACROCOCCYGEAL TERATOMA; HYDROCEPHALUS INUTERO; PRENATAL-DIAGNOSIS; RENAL DYSPLASIA; URINARY-TRACT; MANAGEMENT	A few fetal diseases may benefit from surgical treatment before birth, but hysterotomy and subsequent delivery by cesarean section pose a risk to the otherwise unaffected mother. To assess maternal risk of mortality, morbidity, and reproductive potential after fetal surgery, we reviewed our experience with 17 highly selected women who underwent fetal surgery. Fifteen of these procedures were performed for one of two congenital anomalies: severe bilateral hydronephrosis and congenital diaphragmatic hernia. There were no deaths or serious maternal injuries. In the 14 women who continued pregnancy after hysterotomy, uterine irritability and preterm labor were frequent complications, requiring early confinement in most cases. There has been no detectable effect on future fertility, as indicated by eight subsequent normal pregnancies. We conclude that hysterotomy for fetal surgery can be accomplished without unduly endangering the mother's life or her future reproductive potential. However, morbidity related to premature labor remains a serious problem, and our ability to control uterine contractions after hysterotomy remains the limiting factor in human fetal surgery.	UNIV CALIF SAN FRANCISCO, DEPT SURG,FETAL TREATMENT PROGRAM, 3RD & PARNASSUS AVE,ROOM 585 HSE, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Harrison, Michael/GYD-8608-2022					ADZICK NS, 1985, J PEDIATR SURG, V20, P673, DOI 10.1016/S0022-3468(85)80022-1; ADZICK NS, 1985, J PEDIATR SURG, V20, P315; ADZICK NS, 1984, J PEDIATR SURG, V19, P658, DOI 10.1016/S0022-3468(84)80349-8; ADZICK NS, 1986, J PEDIATR SURG, V21, P477, DOI 10.1016/S0022-3468(86)80215-9; ADZICK NS, 1985, J PEDIATR SURG, V20, P483; BOND SJ, 1989, OBSTET GYNECOL, V74, P25; CHINN DH, 1983, RADIOLOGY, V148, P119, DOI 10.1148/radiology.148.1.6856820; CROMBLEHOLME TM, 1988, J PEDIATR SURG, V23, P1114, DOI 10.1016/S0022-3468(88)80325-7; DUMESIC DA, 1982, NEW ENGL J MED, V307, P1128, DOI 10.1056/NEJM198210283071806; FLAKE AW, 1986, J PEDIATR SURG, V21, P563, DOI 10.1016/S0022-3468(86)80404-3; GLICK PL, 1984, J PEDIATR-US, V105, P97, DOI 10.1016/S0022-3476(84)80371-6; GLICK PL, 1983, J PEDIATR SURG, V18, P681, DOI 10.1016/S0022-3468(83)80003-7; GLICK PL, 1984, J PEDIATR SURG, V19, P870, DOI 10.1016/S0022-3468(84)80387-5; GLICK PL, 1984, J PEDIATR SURG, V19, P649, DOI 10.1016/S0022-3468(84)80348-6; GRANNUM PA, 1986, NEW ENGL J MED, V314, P1431, DOI 10.1056/NEJM198605293142207; HARRIGAN JT, 1981, NEW ENGL J MED, V304, P1527, DOI 10.1056/NEJM198106183042506; Harrison M.R., 1990, UNBORN PATIENT PRENA; HARRISON MR, 1990, J PEDIATR SURG, V25, P47, DOI 10.1016/S0022-3468(05)80163-0; HARRISON MR, 1982, J PEDIATR SURG, V17, P115, DOI 10.1016/S0022-3468(82)80193-0; HARRISON MR, 1981, J PEDIATR SURG, V16, P934, DOI 10.1016/S0022-3468(81)80849-4; HARRISON MR, 1980, SURGERY, V88, P174; HARRISON MR, 1980, SURGERY, V88, P260; HARRISON MR, 1982, J PEDIATR SURG, V17, P728, DOI 10.1016/S0022-3468(82)80437-5; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P774, DOI 10.1001/jama.246.7.774; HARRISON MR, 1987, J PEDIATR SURG, V22, P556, DOI 10.1016/S0022-3468(87)80221-X; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1982, NEW ENGL J MED, V306, P591, DOI 10.1056/NEJM198203113061006; HARRISON MR, 1982, NEW ENGL J MED, V307, P1651, DOI 10.1056/NEJM198212233072623; HARRISON MR, 1983, J PEDIATR SURG, V18, P247, DOI 10.1016/S0022-3468(83)80094-3; HARRISON MR, 1986, CLIN OBSTET GYNECOL, V29, P490, DOI 10.1097/00003081-198609000-00005; HARRISON MR, 1981, JAMA-J AM MED ASSOC, V246, P635, DOI 10.1001/jama.246.6.635; HOLZGREVE W, 1985, PRENATAL DIAG, V5, P245, DOI 10.1002/pd.1970050402; JEFFCOATE TNA, 1959, AM J OBSTET GYNECOL, V77, P475, DOI 10.1016/S0002-9378(16)36717-5; KUHLMANN R S, 1987, Fetal Therapy, V2, P95; LANGER JC, 1989, AM J OBSTET GYNECOL, V160, P1145, DOI 10.1016/0002-9378(89)90177-4; LONGAKER MT, 1989, J PEDIATR SURG, V24, P573, DOI 10.1016/S0022-3468(89)80509-3; NAKAYAMA DK, 1985, J PEDIATR SURG, V20, P118, DOI 10.1016/S0022-3468(85)80282-7; NAKAYAMA DK, 1983, J PEDIATR SURG, V18, P331, DOI 10.1016/S0022-3468(83)80177-8; NAKAYAMA DK, 1983, J PEDIATR SURG, V18, P347, DOI 10.1016/S0022-3468(83)80179-1; NAKAYAMA DK, 1984, J PEDIATR SURG, V19, P333, DOI 10.1016/S0022-3468(84)80248-1; NICOLAIDES K H, 1986, Fetal Therapy, V1, P185; NISULA BC, 1980, AM J OBSTET GYNECOL, V138, P77, DOI 10.1016/0002-9378(80)90014-9; RODECK CH, 1988, NEW ENGL J MED, V319, P1135, DOI 10.1056/NEJM198810273191706; RODECK CH, 1984, AM J OBSTET GYNECOL, V150, P769, DOI 10.1016/0002-9378(84)90683-5	44	115	120	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					737	741		10.1001/jama.265.6.737	http://dx.doi.org/10.1001/jama.265.6.737			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990189				2022-12-24	WOS:A1991EW47900025
J	YAMADA, T; PLACZEK, M; TANAKA, H; DODD, J; JESSELL, TM				YAMADA, T; PLACZEK, M; TANAKA, H; DODD, J; JESSELL, TM			CONTROL OF CELL PATTERN IN THE DEVELOPING NERVOUS-SYSTEM - POLARIZING ACTIVITY OF THE FLOOR PLATE AND NOTOCHORD	CELL			English	Article							CHICK LIMB BUD; NEURAL-TUBE; HOMEOBOX GENES; RETINOIC ACID; SPINAL-CORD; EMBRYO; MORPHOGENESIS; NEUROBLASTS; GUIDANCE	Individual classes of neural cells differentiate at distinct locations in the developing vertebrate nervous system. We provide evidence that the pattern of cell differentiation along the dorsoventral axis of the chick neural tube is regulated by signals derived from two ventral midline cell groups, the notochord and floor plate. Grafting an additional notochord or floor plate to ectopic positions, or deleting both cell groups, resulted in changes in the fate and position of neural cell types, defined by expression of specific antigens. These results suggest that the differentiation of neural cells is controlled, in part, by their position with respect to the notochord and floor plate.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10032 USA; GUNMA UNIV, SCH MED, DEPT PHARMACOL, MAEBASHI, GUNMA 371, JAPAN	Columbia University; Columbia University; Gunma University	YAMADA, T (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Placzek, Marysia/E-6172-2010	Placzek, Marysia/0000-0002-4106-9229				Ahlborn Friedrich, 1883, Z WISS ZOOL, V39, P191; ALTABA AR, 1989, NATURE, V341, P33; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; BOVOLENTA P, 1988, Society for Neuroscience Abstracts, V14, P271; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; DODD J, 1986, J EXP BIOL, V124, P225; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FONTAINEPERUS JC, 1989, DEVELOPMENT, V107, P413; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, IN PRESS COMMUNICATI; HATTA K, 1991, IN PRESS NATURE; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOMMA S, 1990, Society for Neuroscience Abstracts, V16, P836; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HORSTADIUS S, 1944, ACTA ZOOLOGICA, V25, P257; Hutchinson C, 1936, J COMP NEUROL, V63, P465, DOI 10.1002/cne.900630305; JACOBSON CO, 1964, ZOOL BIDR UPPS, V36, P73; JESSELL TM, 1989, CIBA F SYMP, V144, P255; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KITCHIN IC, 1949, J EXP ZOOL, V112, P393, DOI 10.1002/jez.1401120303; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; MADEN M, 1989, DEV BIOL, V135, P124, DOI 10.1016/0012-1606(89)90163-2; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MELTON DA, 1989, CIBA F SYMP, V144, P16; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; ROACH FC, 1945, J EXP ZOOL, V99, P53, DOI 10.1002/jez.1400990203; ROSENQUIST GLENN C., 1966, CARNEGIE INST WASH PUBL, V38, P71; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEDING G, 1962, ACTA ANAT, V49, P199; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; VANSTRAATEN HWM, 1987, NATO ASI, V5, P153; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WALLACE JA, 1985, J COMP NEUROL, V236, P443, DOI 10.1002/cne.902360403; WATTERSON RL, 1955, ANAT REC, V122, P539, DOI 10.1002/ar.1091220405; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WATTERSON RL, 1965, ORGANOGENESIS, P129; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAGINUMA H, 1990, DEVELOPMENT, V108, P705	54	647	659	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					635	647		10.1016/0092-8674(91)90247-V	http://dx.doi.org/10.1016/0092-8674(91)90247-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991324	hybrid			2022-12-24	WOS:A1991EX36100019
J	FISHER, LL; DOUGLAS, RG				FISHER, LL; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; CORTICOSTEROIDS; EHRLICHIOSIS		MERCK SHARP & DOHME INT,RAHWAY,NJ		FISHER, LL (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021, USA.							BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HIRSCH MS, 1990, J INFECT DIS, V161, P845, DOI 10.1093/infdis/161.5.845; MCDADE JE, 1990, J INFECT DIS, V161, P609, DOI 10.1093/infdis/161.4.609; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR, V39, P630; 1990, ANN INTERN MED, V113, P604; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	13	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3130	3132						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	2041125				2022-12-24	WOS:A1991FQ77000023
J	ROMANOWSKI, B; SUTHERLAND, R; FICK, GH; MOONEY, D; LOVE, EJ				ROMANOWSKI, B; SUTHERLAND, R; FICK, GH; MOONEY, D; LOVE, EJ			SEROLOGIC RESPONSE TO TREATMENT OF INFECTIOUS SYPHILIS	ANNALS OF INTERNAL MEDICINE			English	Article							SECONDARY SYPHILIS; TESTS	Objective: To evaluate the serologic response to treatment of patients with infectious syphilis. Design: Historical cohort study of all cases of infectious syphilis in Alberta from 1981 to 1987. Patients: A total of 1090 patients were entered; 857 with primary syphilis, 183 with secondary syphilis, and 50 with early latent disease. Two hundred and eight patients were excluded who either were pregnant, had negative serologic results before treatment, had clinical relapse, were treatment failures, or were lost to follow-up. Interventions: All 882 evaluable patients were treated with a recommended antibiotic regimen for infectious syphilis and returned for re-assessment including repeat serologic testing. Measurements and Main Results: Seventy-two percent (95% CI, 66% to 77%) and 56% (CI, 43% to 70%) of patients with initial episodes of primary or secondary syphilis had seroreverted according to rapid plasma reagin (RPR) test results by 36 months. A 2- and 3-tube decline was seen by 6 and 12 months in primary and secondary syphilis. Early latent syphilis resulted in only a 2-tube decrease at 12 months. Serologic response was not affected by sex, age, race, or sexual orientation. Patients with their first infection were more likely to experience RPR seroreversal than those with repeat infections. The RPR reversal rates also depended on the pretreatment titer and stage of disease. At 36 months, 24% (CI, 20% to 28%) of patients had nonreactive fluorescent treponemal antibody absorption tests (FTA-Abs), and 13% (CI, 11% to 15%) had nonreactive microhemoglutination tests for Treponema pallidum (MHA-TP). Conclusions: Adequate therapeutic response for syphilis must be based on illness episode and the pretreatment RPR titer. Treponemal tests can demonstrate seroreversion after 36 months, and a negative treponemal test does not rule out a past history of syphilis.	UNIV CALGARY, FAC MED DEPT COMMUNITY HLTH SERV, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary	ROMANOWSKI, B (corresponding author), ALBERTA HLTH, STD CONTROL, 4TH FLOOR, EXECUT BLDG, 10105 109TH ST, EDMONTON T5J 1M8, ALBERTA, CANADA.							ARMITAGE P, 1987, STATISTICAL METHODS, P424; BROWN ST, 1985, JAMA-J AM MED ASSOC, V253, P1296, DOI 10.1001/jama.253.9.1296; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P92, DOI 10.1097/00007435-197707000-00004; FIUMARA NJ, 1977, SEX TRANSM DIS, V4, P96, DOI 10.1097/00007435-197707000-00005; FIUMARA NJ, 1986, J AM ACAD DERMATOL, V15, P1059, DOI 10.1016/S0190-9622(86)80319-X; FIUMARA NJ, 1980, JAMA-J AM MED ASSOC, V243, P2500, DOI 10.1001/jama.243.24.2500; FIUMARA NJ, 1980, SEX TRANSM DIS, V7, P111, DOI 10.1097/00007435-198007000-00003; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; PERRYMAN MW, 1982, J CLIN MICROBIOL, V16, P286, DOI 10.1128/JCM.16.2.286-290.1982; PETERSEN CS, 1984, DAN MED BULL, V31, P70; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; WILLCOX RR, 1981, B WORLD HEALTH ORGAN, V59, P655; 1982, TECHNICAL REPORT SER, V674; 1951, J VENER DIS, V32, P355	14	177	186	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1005	1009		10.7326/0003-4819-114-12-1005	http://dx.doi.org/10.7326/0003-4819-114-12-1005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029095				2022-12-24	WOS:A1991FQ55500002
J	DILEO, AJ; ALLEGREZZA, AE				DILEO, AJ; ALLEGREZZA, AE			VALIDATABLE VIRUS REMOVAL FROM PROTEIN SOLUTIONS	NATURE			English	Article											DILEO, AJ (corresponding author), MILLIPORE CORP,80 ASHBY RD,BEDFORD,MA, USA.							BECHTEL MK, 1988, BIOMATER ARTIF CELL, V16, P123, DOI 10.3109/10731198809132562; DILEO AJ, MEMBRANE PROCESS SYS; DILEO AJ, UNPUB BIOTECHNOLOGY	3	7	8	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					420	421		10.1038/351420a0	http://dx.doi.org/10.1038/351420a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034293				2022-12-24	WOS:A1991FN85600065
J	SIXMA, TK; PRONK, SE; KALK, KH; WARTNA, ES; VANZANTEN, BAM; WITHOLT, B; HOL, WGJ				SIXMA, TK; PRONK, SE; KALK, KH; WARTNA, ES; VANZANTEN, BAM; WITHOLT, B; HOL, WGJ			CRYSTAL-STRUCTURE OF A CHOLERA TOXIN-RELATED HEAT-LABILE ENTEROTOXIN FROM ESCHERICHIA-COLI	NATURE			English	Article							AERUGINOSA EXOTOXIN-A; ADP-RIBOSYLTRANSFERASE ACTIVITY; AMINO-ACID-SEQUENCE; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; NUCLEOTIDE-SEQUENCE; B-SUBUNIT; DIPHTHERIA-TOXIN; 3-DIMENSIONAL STRUCTURE	Examination of the structure of Escherichia coli heat-labile enterotoxin in the AB5 complex at a resolution of 2.3 angstrom reveals that the doughnut-shaped B pentamer binds the enzymatic A subunit using a hairpin of the A2 fragment, through a highly charged central pore. Putative ganglioside G(M1-) binding sites on the B subunits are more than 20 angstrom removed from the membrane-crossing A1 subunit. This ADP-ribosylating (A1) fragment of the toxin has structural homology with the catalytic region of exotoxin A and hence also to diphtheria toxin.	STATE UNIV GRONINGEN, DEPT CHEM, BIOCHEM LAB, 9747 AG GRONINGEN, NETHERLANDS	University of Groningen	SIXMA, TK (corresponding author), STATE UNIV GRONINGEN, BIOSON RES INST, NIJENBORGH 16, 9747 AG GRONINGEN, NETHERLANDS.		Witholt, Bernard/A-7340-2012	Sixma, Titia K/0000-0001-6180-0632				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CLEMENS JD, 1986, LANCET, V2, P124; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DALLAS WS, 1980, NATURE, V288, P499, DOI 10.1038/288499a0; DERTZBAUGH MT, 1990, INFECT IMMUN, V58, P70, DOI 10.1128/IAI.58.1.70-79.1990; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5489; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FOSTER JW, 1985, CRC CR REV MICROBIOL, V11, P273; FUJINAGA M, 1989, J APPL CRYSTALLOGR, V22, P1, DOI 10.1107/S0021889888009550; GALLOWAY TS, 1987, BIOCHEM J, V244, P225, DOI 10.1042/bj2440225; GEARY SJ, 1982, INFECT IMMUN, V36, P215, DOI 10.1128/IAI.36.1.215-220.1982; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; GILL DM, 1980, J INFECT DIS, V141, P64, DOI 10.1093/infdis/141.1.64; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; GOINS B, 1988, BIOCHEMISTRY-US, V27, P2046, DOI 10.1021/bi00406a035; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HARFORD S, 1989, EUR J BIOCHEM, V183, P311, DOI 10.1111/j.1432-1033.1989.tb14930.x; HIRST TR, 1984, P NATL ACAD SCI-BIOL, V81, P7752, DOI 10.1073/pnas.81.24.7752; HOFSTRA H, 1984, J BIOL CHEM, V259, P5182; IIDA T, 1989, J BIOL CHEM, V264, P14065; JACOB CO, 1985, EMBO J, V4, P3339, DOI 10.1002/j.1460-2075.1985.tb04086.x; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LAI CY, 1983, BIOCHEM BIOPH RES CO, V116, P341, DOI 10.1016/0006-291X(83)90420-5; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LUDWIG DS, 1985, J BIOL CHEM, V260, P2528; LUKAC M, 1988, BIOCHEMISTRY-US, V27, P7629, DOI 10.1021/bi00420a009; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MOSS J, 1977, J BIOL CHEM, V252, P2455; MOSS J, 1981, J BIOL CHEM, V256, P2861; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; OKAMOTO K, 1988, J BACTERIOL, V170, P2208, DOI 10.1128/jb.170.5.2208-2211.1988; PETERSON JW, 1989, SCIENCE, V245, P857, DOI 10.1126/science.2549637; PICKETT CL, 1989, J BACTERIOL, V171, P4945, DOI 10.1128/jb.171.9.4945-4952.1989; PRONK SE, 1985, J BIOL CHEM, V260, P3580; RATTI G, 1983, NUCLEIC ACIDS RES, V11, P6589, DOI 10.1093/nar/11.19.6589; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SANCHEZ J, 1988, FEBS LETT, V241, P110, DOI 10.1016/0014-5793(88)81041-X; SANDKVIST M, 1987, J BACTERIOL, V169, P4570, DOI 10.1128/jb.169.10.4570-4576.1987; SCHODEL F, 1989, INFECT IMMUN, V57, P1347; SPICER EK, 1982, J BIOL CHEM, V257, P5716; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSUJI T, 1985, J BIOL CHEM, V260, P8552; TSUJI T, 1990, J BIOL CHEM, V265, P22520; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; YAMAMOTO T, 1987, J BACTERIOL, V169, P1352, DOI 10.1128/jb.169.3.1352-1357.1987	65	487	508	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1991	351	6325					371	377		10.1038/351371a0	http://dx.doi.org/10.1038/351371a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034287				2022-12-24	WOS:A1991FN85600047
J	LUPAS, A; VANDYKE, M; STOCK, J				LUPAS, A; VANDYKE, M; STOCK, J			PREDICTING COILED COILS FROM PROTEIN SEQUENCES	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; TRANSFER-RNA-SYNTHETASE; LEUCINE ZIPPER MOTIF; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; INTERMEDIATE FILAMENTS; MYOSIN ROD; EXPRESSION; SUBUNIT; GENE	The probability that a residue in a protein is part of a coiled-coil structure was assessed by comparison of its flanking sequences with sequences of known coiled-coil proteins. This method was used to delineate coiled-coil domains in otherwise globular proteins, such as the leucine zipper domains in transcriptional regulators, and to predict regions of discontinuity within coiled-coil structures, such as the hinge region in myosin. More than 200 proteins that probably have coiled-coil domains were identified in GenBank, including alpha- and beta-tubulins, flagellins, G protein beta-subunits, some bacterial transfer RNA synthetases, and members of the heat shock protein (Hsp70) family.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University					NIAID NIH HHS [AI20980] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYER PD, 1987, NUCLEIC ACIDS RES, V15, P2309, DOI 10.1093/nar/15.5.2309; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; FEDOROV OV, 1988, FEBS LETT, V241, P145, DOI 10.1016/0014-5793(88)81048-2; FREYMANN D, 1990, FASEB J, V4, pA2166; FREYMANN DM, 1984, NATURE, V311, P167, DOI 10.1038/311167a0; FU JH, 1989, MOL CELL BIOL, V9, P1120; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JASIN M, 1984, CELL, V36, P1089, DOI 10.1016/0092-8674(84)90059-X; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KUWAJIMA G, 1988, J BACTERIOL, V170, P3305, DOI 10.1128/jb.170.7.3305-3309.1988; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; YANEVA M, 1989, J BIOL CHEM, V264, P13407	31	3494	3593	6	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1162	1164		10.1126/science.252.5009.1162	http://dx.doi.org/10.1126/science.252.5009.1162			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031185				2022-12-24	WOS:A1991FN05600047
J	OBERLE, I; ROUSSEAU, F; HEITZ, D; KRETZ, C; DEVYS, D; HANAUER, A; BOUE, J; BERTHEAS, MF; MANDEL, JL				OBERLE, I; ROUSSEAU, F; HEITZ, D; KRETZ, C; DEVYS, D; HANAUER, A; BOUE, J; BERTHEAS, MF; MANDEL, JL			INSTABILITY OF A 550 BASE PAIR DNA SEGMENT AND ABNORMAL METHYLATION IN FRAGILE X-SYNDROME	SCIENCE			English	Article								The fragile X syndrome, a common cause of inherited mental retardation, is characterized by an unusual mode of inheritance. Phenotypic expression has been linked to abnormal cytosine methylation of a single CpG island, at or very near the fragile site. Probes adjacent to this island detected very localized DNA rearrangements that constituted the fragile X mutations, and whose target was a 550-base pair GC-rich fragment. Normal transmitting males had a 150- to 400-base pair insertion that was inherited by their daughters either unchanged, or with small differences in size. Fragile X-positive individuals in the next generation had much larger fragments that differed among siblings and showed a generally heterogeneous pattern indicating somatic mutation. The mutated allele appeared unmethylated in normal transmitting males, methylated only on the inactive X chromosome in their daughters, and totally methylated in most fragile X males. However, some males had a mosaic pattern. Expression of the fragile X syndrome thus appears to result from a two-step mutation as well as a highly localized methylation. Carriers of the fragile X mutation can easily be detected regardless of sex or phenotypic expression, and rare apparent false negatives may result from genetic heterogeneity or misdiagnosis.	FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, F-67085 STRASBOURG, FRANCE; INSERM, U73, F-75016 PARIS, FRANCE; HOP NORD ST PRIEST JAREZ, F-42277 St Priest En Jarez, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm)				Devys, Didier/0000-0001-9655-3512				BAKER E, 1985, AM J MED GENET, V22, P433; BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; CAMERINO G, 1983, NATURE, V306, P701, DOI 10.1038/306701a0; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JACKY PB, 1991, AM J MED GENET, V38, P400, DOI 10.1002/ajmg.1320380249; JENKINS EC, 1991, AM J MED GENET, V38, P447, DOI 10.1002/ajmg.1320380262; KENNERKNECHT I, 1991, AM J MED GENET, V38, P467, DOI 10.1002/ajmg.1320380266; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1991, AM J MED GENET, V38, P391, DOI 10.1002/ajmg.1320380247; LAIRD CD, 1987, GENETICS, V117, P587; MIGEON BR, 1986, P NATL ACAD SCI USA, V83, P2182, DOI 10.1073/pnas.83.7.2182; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; OBERLE I, 1986, HUM GENET, V72, P43, DOI 10.1007/BF00278816; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; RHOADS FA, 1982, AM J MED GENET, V12, P205, DOI 10.1002/ajmg.1320120211; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, UNPUB; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; SVED JA, 1990, AM J HUM GENET, V46, P443; TOMMERUP N, 1989, HUM GENET, V81, P377, DOI 10.1007/BF00283696; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOELCKEL MA, 1989, HUM GENET, V81, P353, DOI 10.1007/BF00283690; VOGEL F, 1990, HUM GENET, V86, P25; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WEBB T, 1989, FRAGILE X SYNDROME, P40; WENGER SL, 1987, AM J MED GENET, V26, P909, DOI 10.1002/ajmg.1320260419; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]	37	1317	1345	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1097	1102		10.1126/science.252.5009.1097	http://dx.doi.org/10.1126/science.252.5009.1097			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031184				2022-12-24	WOS:A1991FN05600035
J	BENDEFY, IM				BENDEFY, IM			HOME NEBULIZERS IN CHILDHOOD ASTHMA - SURVEY OF HOSPITAL SUPERVISED USE	BRITISH MEDICAL JOURNAL			English	Article							NEBULIZERS	Objective - To review the management of and outcome in asthmatic children using home nebulisers under hospital supervision. Design - Postal questionnaires sent to parents. Setting - Paediatric departments of a children's hospital and a district general hospital. Subjects - Parents of 93 asthmatic children who had been loaned home nebulisers for administration of bronchodilators with verbal instructions on their use. Main outcome measures - Drugs administered with nebuliser, side effects, frequency of hospital admission, and theoretical management of a severe attack. Results - 84 children took salbutamol and 37 received more than 10 mg a day during attacks; side effects were reported in 54 children. Parents of 16 children said that they would give another dose of bronchodilator rather than seek medical help if their child failed to respond to the first dose. Since being loaned nebulisers 65 children were admitted to hospital less frequently and 16 were not readmitted; over two thirds of parents thought that there had been a marked improvement in their child's asthma. Conclusions - Home nebulisers are valuable in childhood asthma. Excessive doses of bronchodilators may be given, however, and a weight related dose may be more appropriate. Parents should be given written as well as verbal instructions, especially regarding the management of severe attacks.	DEPT COMMUNITY CHILD HLTH,COMMUNITY HOUSE,MORDEN,SURREY,ENGLAND									FORFAR JO, 1984, TXB PAEDIATRICS, P554; LAROCHE CM, 1985, BRIT MED J, V290, P1611, DOI 10.1136/bmj.290.6482.1611; LENNEY W, 1978, LANCET, V1, P440; MILNER AD, 1981, ARCH DIS CHILD, V56, P84, DOI 10.1136/adc.56.2.84; MILNER AD, 1987, UPDATE          0215, P398; REISER J, 1986, ARCH DIS CHILD, V61, P88, DOI 10.1136/adc.61.1.88; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; 1982, BMJ, V285, P1251	9	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1180	1181		10.1136/bmj.302.6786.1180	http://dx.doi.org/10.1136/bmj.302.6786.1180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043813	Bronze, Green Published			2022-12-24	WOS:A1991FN04500020
J	GRIEM, P; WALLNY, HJ; FALK, K; ROTZSCHKE, O; ARNOLD, B; SCHONRICH, G; HAMMERLING, G; RAMMENSEE, HG				GRIEM, P; WALLNY, HJ; FALK, K; ROTZSCHKE, O; ARNOLD, B; SCHONRICH, G; HAMMERLING, G; RAMMENSEE, HG			UNEVEN TISSUE DISTRIBUTION OF MINOR HISTOCOMPATIBILITY PROTEINS VERSUS PEPTIDES IS CAUSED BY MHC EXPRESSION	CELL			English	Article							CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; INFLUENZA NUCLEOPROTEIN; CYTOTOXIC RESPONSE; VIRAL PEPTIDES; Y-ANTIGEN; H-Y; CELLS; COMPLEX; GRAFT	Naturally processed minor histocompatibility (H) peptides corresponding to H-4b, H-Y, and an unmapped BALB.B minor H gene were quantified in a relative way in 15 different tissues of male BALB.B mice. For one of these minor H antigens, we could also determine the relative content of the respective protein. For each minor H peptide, an individual tissue distribution was found. Tissues expressing little or no MHC (major histocompatibility complex), like brain, contained only small amounts of minor H peptides or none at all, although the same tissues contained minor H protein in substantial quantities. By contrast, K(b)-expressing brains from mice transgenic for K(b) under control of the glial acidic protein promoter contained both minor H peptide and protein in high amounts. Thus, the expression of minor H peptides in a given tissue is dependent on coexpression of the restricting MHC class I molecules.	DEUTSCH KLIN DIAGNOST,INST GENET,W-6200 WIESBADEN,GERMANY		GRIEM, P (corresponding author), MAX PLANCK INST BIOL,IMMUNGENET ABT,CORRENSSTR 42,W-7400 TUBINGEN,GERMANY.		Roetzschke, Olaf/GXH-0012-2022	Schonrich, Gunther/0000-0002-5346-5704				BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BEVAN MJ, 1975, NATURE, V256, P419, DOI 10.1038/256419a0; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; COUNCE S, 1956, ANN SURG, V144, P198, DOI 10.1097/00000658-195608000-00009; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FLAJNIK MF, 1985, EUR J IMMUNOL, V15, P540, DOI 10.1002/eji.1830150603; FORMAN J, 1984, J EXP MED, V159, P1724, DOI 10.1084/jem.159.6.1724; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GRAFF RJ, 1979, BIOL HDB, V3, P118; Klein J., 1986, NATURAL HIST MAJOR H; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; OHLEN C, 1990, J IMMUNOL, V145, P52; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STEINMULLER D, 1981, J IMMUNOL, V126, P1754; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANBLEEK GM, 1990, NATURE, V348, P213; VONBOEHMER H, 1979, J EXP MED, V150, P1134, DOI 10.1084/jem.150.5.1134; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WETTSTEIN PJ, 1989, HUMAN IMMUNOGENETICS, P339; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	32	73	75	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					633	640		10.1016/0092-8674(91)90095-G	http://dx.doi.org/10.1016/0092-8674(91)90095-G			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032287				2022-12-24	WOS:A1991FM03700013
J	LOGAN, GM; WEIMER, MK; ELLEFSON, M; PIERACH, CA; BLOOMER, JR				LOGAN, GM; WEIMER, MK; ELLEFSON, M; PIERACH, CA; BLOOMER, JR			BILE PORPHYRIN ANALYSIS IN THE EVALUATION OF VARIEGATE PORPHYRIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTOPORPHYRINOGEN OXIDASE; ENZYMATIC DEFECT; HEMOGLOBIN; FECES; HEME	Background. Variegate porphyria is a genetic disorder of porphyrin metabolism in which patients may have both neurologic dysfunction and photocutaneous lesions. Biochemical confirmation of the diagnosis can be difficult, particularly in patients without neurologic dysfunction at the time of testing. The demonstration of increased fecal excretion of porphyrin is frequently used for this purpose, but levels may be normal. Since elevated fecal porphyrin levels in variegate porphyria are presumably a consequence of increased biliary excretion, we evaluated whether analysis of porphyrins in bile distinguishes better between patients with variegate porphyria and controls. Methods. Bile samples were collected by duodenal aspiration from 10 patients with proved variegate porphyria who had no neurologic symptoms when they were studied and 17 control subjects. Bile and fecal porphyrin levels were measured fluorometrically. Results. The mean total porphyrin concentration in bile in the patients with variegate porphyria was significantly higher than that in the controls (67.8 vs. 0.71-mu-mol per liter; P < 0.00002). There was more than a ninefold difference between the highest level in any control subject and the lowest level in any patient with variegate porphyria. The mean fecal porphyrin level in the patients with variegate porphyria also differed significantly from that in the controls (0.79 vs. 0.14-mu-mol per gram of dry weight; P < 0.007), but four patients had levels within the control range. Conclusions. The concentration of porphyrin in bile is higher in patients with variegate porphyria than in controls, and the difference is greater than that for fecal porphyrin. Bile porphyrin measurements may be helpful in the evaluation of asymptomatic patients suspected of having variegate porphyria.	UNIV MINNESOTA,DEPT MED,DIV GASTROENTEROL HEPATOL & NUTR,BOX 36 UMHC,HARVARD ST & RIVER RD,MINNEAPOLIS,MN 55455; MINNEAPOLIS MED RES FDN INC,DEPT MED,MINNEAPOLIS,MN; ABBOTT NW HOSP,DEPT MED,MINNEAPOLIS,MN; ST PAUL RAMSEY MED CTR,GASTROENTEROL SECT,ST PAUL,MN 55101	University of Minnesota System; University of Minnesota Twin Cities; Minneapolis Medical Research Foundation; Saint Paul Ramsey Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034931, R01DK026466, R37DK026466] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34931, DK 26466] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZIZ MA, 1969, CLIN CHIM ACTA, V26, P525, DOI 10.1016/0009-8981(69)90083-7; BELCHER RV, 1969, CLIN CHIM ACTA, V25, P45, DOI 10.1016/0009-8981(69)90225-3; BEUKEVELD GJJ, 1987, CLIN CHEM, V33, P2164; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; COREY TJ, 1980, J AM ACAD DERMATOL, V2, P36, DOI 10.1016/S0190-9622(80)80290-8; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; DUANE WC, 1976, J LIPID RES, V17, P211; Eales L, 1966, S Afr Med J, V40, P380; EALES L, 1990, INT J BIOCHEM, V12, P837; ELDER GH, 1975, J CLIN PATHOL, V28, P601, DOI 10.1136/jcp.28.8.601; FORD RE, 1981, CLIN CHEM, V27, P397; FROMKE VL, 1978, AM J MED, V65, P80, DOI 10.1016/0002-9343(78)90696-4; GROSSER Y, 1973, S AFR MED J, V47, P2162; JENDRASSIK A, 1938, BIOCHEM Z, V296, P71; MORTON KO, 1988, GASTROENTEROLOGY, V94, P1488, DOI 10.1016/0016-5085(88)90690-7; MUSTAJOKI P, 1978, ANN INTERN MED, V89, P238, DOI 10.7326/0003-4819-89-2-238; MUSTAJOKI P, 1976, ACTA MED SCAND, V200, P171; POHFITZPATRICK MB, 1980, ARCH DERMATOL, V116, P543, DOI 10.1001/archderm.116.5.543; RIMINGTON C, 1968, CLIN SCI, V35, P211; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; SCHWARTZ S, 1985, GASTROENTEROLOGY, V89, P19, DOI 10.1016/0016-5085(85)90740-1; SIEPKER L, 1986, S AFR MED J, V70, P819; VILJOEN DJ, 1983, EUR J CLIN INVEST, V13, P283, DOI 10.1111/j.1365-2362.1983.tb00102.x; WATSON CJ, 1960, NEW ENGL J MED, V263, P1205, DOI 10.1056/NEJM196012152632401; 1989, SAS STAT GUIDE PERSO, P261	25	34	34	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1408	1411		10.1056/NEJM199105163242005	http://dx.doi.org/10.1056/NEJM199105163242005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020296				2022-12-24	WOS:A1991FL12500005
J	FERGUSON, BM; BREWER, BJ; REYNOLDS, AE; FANGMAN, WL				FERGUSON, BM; BREWER, BJ; REYNOLDS, AE; FANGMAN, WL			A YEAST ORIGIN OF REPLICATION IS ACTIVATED LATE IN S-PHASE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME-REPLICATION; DNA; SEQUENCES; GENES; ORGANIZATION; PLASMIDS; TIME	The mechanism that causes large regions of eukaryotic chromosomes to remain unreplicated until late in S phase is not understood. We have found that 67 kb of telomere-adjacent DNA at the right end of chromosome V in S. cerevisiae is replicated late in S phase. An ARS element in this region, ARS501, was shown by two-dimensional gel analysis to be an active origin of replication. Kinetic analyses indicate that the rate of replication fork movement within this late region is similar to that in early replicating regions. Therefore, the delayed replication of the region is a consequence of late origin activation. The results also support the idea that the pattern of interspersed early and late replication along the chromosomes of higher eukaryotes is a consequence of the temporal regulation of origin activation.	UNIV WASHINGTON,DEPT GENET SK-50,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Reynolds, Ann/B-7324-2013	Reynolds, Ann/0000-0002-2881-6955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926, R37GM018926] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18926] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BREWER BJ, 1988, CANCER CELL, V6, P229; CALDERON IL, 1983, CURR GENET, V7, P93, DOI 10.1007/BF00365632; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLEER R, 1987, MOL CELL BIOL, V7, P1180, DOI 10.1128/MCB.7.3.1180; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HAUSWIRTH WW, 1987, MITOCHONDRIA, P171; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HOLLINGSWORTH NM, 1988, THESIS U WASHINGTON; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACKSON DA, 1984, EMBO J, V3, P1837; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; MAINE GT, 1984, MOL CELL BIOL, V4, P86, DOI 10.1128/MCB.4.1.86; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MANIATIS T, 1908, MOL CLONING; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; SITNEY K, 1987, THESIS U CALIFORNIA; STINCHCOMB DT, 1982, J MOL BIOL, V158, P157, DOI 10.1016/0022-2836(82)90427-2; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; THRASHBINGHAM C, 1989, MOL CELL BIOL, V9, P809, DOI 10.1128/MCB.9.2.809; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257	38	184	188	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					507	515		10.1016/0092-8674(91)90468-E	http://dx.doi.org/10.1016/0092-8674(91)90468-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018976				2022-12-24	WOS:A1991FK18200017
J	HUGHES, PH; CONARD, SE; BALDWIN, DC; STORR, CL; SHEEHAN, DV				HUGHES, PH; CONARD, SE; BALDWIN, DC; STORR, CL; SHEEHAN, DV			RESIDENT PHYSICIAN SUBSTANCE USE IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STUDENTS	A national survey was conducted to determine patterns of drug use among 3000 American resident physicians. Sixty percent (1785) of the residents surveyed responded. This report evaluates the prevalence of drug use among the respondents, when they initiated drug use, and their reasons for current use. Substance use rates are compared with other studies of resident physicians and with a sample of their nonphysician age peers surveyed the same year. Heavy substance use patterns were not observed among resident physicians. They had significantly lower rates of use for most psychoactive substances than their peers in the general population but did report higher rates of past-month use of alcohol and benzodiazepines. A sizable minority began using benzodiazepines and prescription opiates during their residency years - the stage in physicians' training when they first receive prescribing privileges. Current users of benzodiazepines and opiates used these drugs primarily for self-treatment rather than recreation. These two substances are often associated with impairment at later stages in the physician's career.	JAMES A HALEY VET ADM MED CTR, TAMPA, FL 33612 USA; UNIV TEXAS, HLTH SCI CTR, DEPT FAMILY & COMMUNITY MED, DALLAS, TX 75235 USA; AMER MED ASSOC, DIV MED EDUC RES, CHICAGO, IL 60610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; University of Texas System; University of Texas Dallas; American Medical Association	HUGHES, PH (corresponding author), UNIV S FLORIDA, DEPT PSYCHIAT & BEHAV MED, CTR STUDY IMPAIRED PROFESS, 3515 E FLETCHER AVE, TAMPA, FL 33613 USA.		Sheehan, David V/L-6879-2013	Sheehan, David V/0000-0002-5118-7050	NIDA NIH HHS [1 R01 DA04877] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004877] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CLARK AW, 1988, J MED EDUC, V63, P44; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; CONARD S, 1989, AM J PSYCHIAT, V146, P382; CROWLEY AE, 1988, JAMA-J AM MED ASSOC, V260, P1049, DOI 10.1001/jama.1988.03410080019002; JOHNSTON L, 1989, ADM891638 DEP HLTH H; KORAN LM, 1988, WESTERN J MED, V148, P97; MADDUX JF, 1987, J MED EDUC, V62, P852; MCAULIFFE WE, 1984, J HEALTH SOC BEHAV, V25, P34, DOI 10.2307/2136703; REUBEN DB, 1990, JAMA-J AM MED ASSOC, V263, P958, DOI 10.1001/jama.263.7.958; SETHI BB, 1980, ACTA PSYCHIAT SCAND, V62, P447, DOI 10.1111/j.1600-0447.1980.tb00633.x; SINGH G, 1981, INDIAN J MED RES, V73, P594; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; 1985, RES MONOGRAPH, V57	13	89	90	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2069	2073		10.1001/jama.265.16.2069	http://dx.doi.org/10.1001/jama.265.16.2069			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013925				2022-12-24	WOS:A1991FG90700022
J	REDDY, P; HAHN, S				REDDY, P; HAHN, S			DOMINANT NEGATIVE MUTATIONS IN YEAST TFIID DEFINE A BIPARTITE DNA-BINDING REGION	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION-FACTOR; UPSTREAM ACTIVATION SITE; TATA-BOX; SACCHAROMYCES-CEREVISIAE; CYC1 GENE; HAP1 ACTIVATOR; S-CEREVISIAE; PROTEIN; SEQUENCES	Genetic analysis showed that the conserved C-terminal 180 amino acids of yeast TFIID contain all the essential functions for growth of yeast and response to acidic transcriptional activation signals. A genetic screen was used to identify functionally important residues within this C-terminal region. Five dominant TFIID mutations were isolated that had lost the ability to bind DNA. Four of these mutations were single amino acid substitutions in the most N-terminal of two 66-67 amino acid repeats in TFIID. Analogous mutations made in the most C-terminal repeat all failed to bind DNA and inhibited growth of cells, suggesting that the DNA-binding function of TFIID is partitioned between the two repeated regions. Overproduction of wild-type TFIID rescued the dominance of the TFIID mutants, suggesting that the mutant proteins are dominant because they compete with wild-type TFIID for binding to one or more essential transcription factors.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	REDDY, P (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.			Hahn, Steven/0000-0001-7240-2533				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAIO X, 1990, GENE, V88, P107; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NAWGA F, 1985, P NATL ACAD SCI USA, V82, P8557; OGDEN JE, 1986, MOL CELL BIOL, V6, P4335, DOI 10.1128/MCB.6.12.4335; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIKORSKI RS, 1989, GENETICS, V122, P19; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	45	120	121	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					349	357		10.1016/0092-8674(91)90168-X	http://dx.doi.org/10.1016/0092-8674(91)90168-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015629				2022-12-24	WOS:A1991FH09200017
J	ORMEROD, W				ORMEROD, W			SCIENCE AND SECRECY	NATURE			English	Editorial Material											ORMEROD, W (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							MOLLOY JO, 1971, J PROTOZOOL, V18, P157, DOI 10.1111/j.1550-7408.1971.tb03298.x	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					551	552		10.1038/350551a0	http://dx.doi.org/10.1038/350551a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017252				2022-12-24	WOS:A1991FH11200024
J	REGNIER, FE				REGNIER, FE			PERFUSION CHROMATOGRAPHY	NATURE			English	Article							LIQUID-CHROMATOGRAPHY; PROTEINS	Perfusion chromatography is a technique based on fluid dynamics for reducing stagnant mobile phase mass transfer in liquid chromatography. This is achieved by using supports with large pores that allow mobile phase to flow through particles.			REGNIER, FE (corresponding author), PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907, USA.							AFEYAN N, 1991, IN PRESS J CHROMATOG; AFEYAN N, 1989, 595661 US PAT APPL; AFEYAN NB, 1990, J CHROMATOGR, V519, P1, DOI 10.1016/0021-9673(90)85132-F; DONE JN, 1972, J CHROMATOGR SCI, V10, P606, DOI 10.1093/chromsci/10.10.606; Giddings J.C., 1965, DYNAMICS CHROMATOGRA; HORVATH C, 1976, J CHROMATOGR, V126, P401, DOI 10.1016/S0021-9673(01)84088-7; PEARSON JD, 1984, HIGH PERFORMANCE LIQ; REGNIER FE, 1987, CHROMATOGRAPHIA, V24, P241, DOI 10.1007/BF02688486; REGNIER FE, 1991, CHROMATOGRAPHY, pCH14; SNYDER LR, 1969, J CHROMATOGR SCI, V7, P352, DOI 10.1093/chromsci/7.6.352; THEVENON G, 1989, J CHROMATOGR, V476, P499, DOI 10.1016/S0021-9673(01)93894-4; TWEETEN KA, 1986, J CHROMATOGR, V359, P111, DOI 10.1016/0021-9673(86)80066-8; YANG Y, 1990, 469956 US PAT APPL	13	137	141	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					634	635		10.1038/350634a0	http://dx.doi.org/10.1038/350634a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017260				2022-12-24	WOS:A1991FH11200068
J	MADEN, A; SWINTON, M; GUNN, J				MADEN, A; SWINTON, M; GUNN, J			DRUG-DEPENDENCE IN PRISONERS	BRITISH MEDICAL JOURNAL			English	Article											MADEN, A (corresponding author), INST PSYCHIAT,DEPT FORENS PSYCHIAT,LONDON SE5 8AF,ENGLAND.							CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; Home Office, 1988, PUNISHMENT CUSTODY C; MADEN A, 1990, BRIT MED J, V301, P1133, DOI 10.1136/bmj.301.6761.1133; 1988, POLICY STATEMENT THR	4	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					880	880		10.1136/bmj.302.6781.880	http://dx.doi.org/10.1136/bmj.302.6781.880			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	2025727	Bronze, Green Published			2022-12-24	WOS:A1991FG42100022
J	GARCIA, JV; MILLER, AD				GARCIA, JV; MILLER, AD			SERINE PHOSPHORYLATION-INDEPENDENT DOWN-REGULATION OF CELL-SURFACE CD4 BY NEF	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HTLV-III; T-CELLS; PROTEIN; PATHOGENESIS; MODULATION; TYPE-1	A DECLINE in the T-cell population usually marks the onset of progressive immunological disease in individuals infected with the human immunodeficiency virus (HIV). Because CD4+ cells help to coordinate efficient immune responses, some of the defects in the immune function in advanced cases of AIDS may be explained by the disappearance of these cells. Therefore, an understanding of the mechanisms used by HIV to induce the reduction of CD4+ cells is important. Here we use a Moloney murine leukaemia virus-based retroviral vector in order to express the nef gene of HIV-1 in three lymphocytic cell lines expressing CD4. In all cases we find that cell-surface CD4 expression is inversely related to nef expression. However, nef does not alter steady-state levels of CD4 RNA or CD4 protein. Also, nef can downregulate a CD4 triple mutant (Ser --> Ala) that is neither phosphorylated nor down-regulated by phorbol esters, indicating that nef is acting by a different mechanism.			GARCIA, JV (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104, USA.			Miller, Dusty/0000-0002-3736-3660				ACRES RB, 1986, J BIOL CHEM, V261, P6210; AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GALLO RC, 1990, J ACQ IMMUN DEF SYND, V3, P380; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HASELTINE WA, 1990, RETROVIRUS BIOL HUMA; HOXIE JA, 1986, J IMMUNOL, V137, P1194; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PAVLAKIS G N, 1990, New Biologist, V2, P20; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; TEMIN HM, 1980, COLD SPRING HARB SYM, V44, P773, DOI 10.1101/SQB.1980.044.01.083; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980	18	704	717	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					508	511		10.1038/350508a0	http://dx.doi.org/10.1038/350508a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014052				2022-12-24	WOS:A1991FG14300054
J	GU, H; KITAMURA, D; RAJEWSKY, K				GU, H; KITAMURA, D; RAJEWSKY, K			B-CELL DEVELOPMENT REGULATED BY GENE REARRANGEMENT - ARREST OF MATURATION BY MEMBRANE-BOUND D-MU PROTEIN AND SELECTION OF DH ELEMENT READING FRAMES	CELL			English	Article							IMMUNOGLOBULIN HEAVY-CHAINS; PRE-B; LIGHT-CHAIN; TRANSGENIC MICE; STEM-CELLS; VH-GENE; SEGMENTS; REGION; LOCUS; MOUSE	In productively rearranged murine V(H)-D(H)-J(H) genes (encoding immunoglobulin heavy chain variable regions), the D(H) elements are preferentially used in one particular reading frame (RF1), although the recombination breakpoints at the D(H)-J(H) border vary. Despite this variability, the bias of RF usage is not due to cellular selection by antigen but is quantitatively established at the stage of D(H)-J(H) rearrangement: RF3 is counterselected on the basis of stop codons. RF2 allows the expression of a truncated-mu-chain (D-mu-protein) from most D(H)-J(H) joints. Using B cells in which the membrane exon of the mu-chain is disrupted by homologous recombination on one of the two homologous chromosomes, we obtain evidence that membrane-bound D-mu-signals arrest of differentiation, presumably by preventing V(H)-D(H)J(H) joining. In addition to RF3 and RF2 counterselection, promotion of D(H)-J(H) joining in areas of sequence homology further enforces RF1 usage.			GU, H (corresponding author), UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY.							ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CAMBIER JC, 1987, IMMUNOL REV, V95, P37, DOI 10.1111/j.1600-065X.1987.tb00499.x; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; EILAT D, 1988, J IMMUNOL, V141, P1745; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; KAARTINEN M, 1985, IMMUNOL TODAY, V6, P324, DOI 10.1016/0167-5699(85)90127-6; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; LANGMAN RE, 1987, MOL IMMUNOL, V24, P675, DOI 10.1016/0161-5890(87)90050-2; MARION TN, 1990, J IMMUNOL, V145, P2322; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER AM, 1990, SCIENCE, V250, P820; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RATHBUN G, 1989, IMMUNOGLOBULIN GENES; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUKADA S, 1990, J IMMUNOL, V144, P4053; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	35	213	215	2	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					47	54		10.1016/0092-8674(91)90406-O	http://dx.doi.org/10.1016/0092-8674(91)90406-O			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013094				2022-12-24	WOS:A1991FF77300007
J	CURRAN, WJ				CURRAN, WJ			SCIENTIFIC AND COMMERCIAL DEVELOPMENT OF HUMAN CELL-LINES - ISSUES OF PROPERTY, ETHICS, AND CONFLICT-OF-INTEREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		MOORE F, 1964, GIVE TAKE DEV TISSUE; Owens James Franklin, 1987, Med Trial Tech Q, V33, P335; PARKER PM, 1989, J LEGAL MED, V10, P357, DOI 10.1080/01947648909513576; WAGNER AB, 1987, COMPUT HIGH TECHNOL, V3, P231; 1987, NEW DEV BIOTECHNOLOG, V1	5	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					998	1000		10.1056/NEJM199104043241419	http://dx.doi.org/10.1056/NEJM199104043241419			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	FE376	2002828				2022-12-24	WOS:A1991FE37600031
J	MULLIN, GE				MULLIN, GE			FOOD ALLERGY AND IRRITABLE-BOWEL-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HYPERSENSITIVITY		NIAID,MUCOSAL IMMUN SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	MULLIN, GE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.		Mullin, Gerry/H-5294-2019	Mullin, Gerry/0000-0001-5317-6788				BENTLEY SJ, 1983, LANCET, V2, P295; JOHANSSON SGO, 1984, ANN ALLERGY, V53, P665; JONES AV, 1982, LANCET, V2, P115; PETITPIERRE M, 1985, ANN ALLERGY, V54, P538; ZWETCHKENBAUM JF, 1988, ANN ALLERGY, V60, P1	5	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1736	1736						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002578				2022-12-24	WOS:A1991FD65900033
J	DRAKE, JM; KLAFTER, J; LEVITZ, P				DRAKE, JM; KLAFTER, J; LEVITZ, P			CHEMICAL AND BIOLOGICAL MICROSTRUCTURES AS PROBED BY DYNAMIC PROCESSES	SCIENCE			English	Article							DIRECT ENERGY-TRANSFER; EXCITATION TRANSFER; RESTRICTED GEOMETRIES; SURFACE; FLUORESCENCE; RELAXATION; MORPHOLOGY; SYSTEMS	The dynamic process of electronic energy transfer is shown to be an important tool for probing the microstructure of molecular systems, particularly those in which donors and acceptors occupy specifically labeled sites of spatially confining host matrices. Special attention is given to analyzing the temporal behavior of the direct energy transfer reaction for systems in which the dipolar coupling is between a donor and randomly distributed acceptors. This dynamic process is dependent on two competing lengths when the donor and acceptor distribution is determined by the microstructure of the confining system: R(p), the dominant length characterizing the size of the confinement, and R0, which scales the strength of the dipolar coupling. When energy transfer processes are viewed in the context of these two competing lengths, a picture emerges of the microstructure of the confinement that is consistent with and corroborated by other structural probes.	CNRS, CRSOCI, F-45071 ORLEANS 2, FRANCE; TEL AVIV UNIV, SCH CHEM, IL-69978 TEL AVIV, ISRAEL	Centre National de la Recherche Scientifique (CNRS); Tel Aviv University	DRAKE, JM (corresponding author), EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA.							BAUMANN J, 1986, J CHEM PHYS, V85, P4087, DOI 10.1063/1.450880; BENNETT RG, 1964, J CHEM PHYS, V41, P3037, DOI 10.1063/1.1725670; BLUMEN A, 1981, NUOVO CIMENTO B, V63, P50, DOI 10.1007/BF02721411; BLUMEN A, 1986, J CHEM PHYS, V84, P1397, DOI 10.1063/1.450481; Blumen A., 1986, OPTICAL SPECTROSCOPY, P199; BUCHER H, 1967, MOL CRYST, V2, P199, DOI 10.1080/15421406708083417; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; CANTOR CR, 1971, P NATL ACAD SCI USA, V68, P2099, DOI 10.1073/pnas.68.9.2099; Drake J. M., 1986, MATER RES STAND, V73, P305; DRAKE JM, 1990, PHYS TODAY, V43, P46, DOI 10.1063/1.881244; EVEN U, 1984, PHYS REV LETT, V52, P2164, DOI 10.1103/PhysRevLett.52.2164; FERNANDEZ SM, 1976, NATURE, V264, P411, DOI 10.1038/264411a0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FORSTER T, 1949, Z NATURFORSCH A, V4, P321; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; INOKUTI M, 1965, J CHEM PHYS, V43, P1978, DOI 10.1063/1.1697063; KASATANI K, 1985, J PHYS CHEM-US, V89, P542, DOI 10.1021/j100249a035; KAUFFMANN HF, 1990, DYNAMICAL PROCESSES IN CONDENSED MOLECULAR SYSTEMS, P90; KLAFTER J, 1985, J LUMIN, V34, P77, DOI 10.1016/0022-2313(85)90096-1; KLAFTER J, 1984, J CHEM PHYS, V80, P875, DOI 10.1063/1.446743; KLAFTER J, 1986, P NATL ACAD SCI USA, V83, P848, DOI 10.1073/pnas.83.4.848; Klafter J, 1989, MOL DYNAMICS RESTRIC; KOPELMAN R, 1988, SCIENCE, V241, P1620, DOI 10.1126/science.241.4873.1620; LEVITZ P, 1987, PHYS REV LETT, V58, P686, DOI 10.1103/PhysRevLett.58.686; LEVITZ P, 1988, J CHEM PHYS, V89, P5224, DOI 10.1063/1.455613; LEVITZ P, 1988, CHEM PHYS LETT, V148, P557, DOI 10.1016/0009-2614(88)80330-0; LEVITZ P, UNPUB; Mandelbrot B. B., 1983, FRACTAL GEOMETRY NAT; MATAGA N, 1969, J PHYS CHEM-US, V73, P370, DOI 10.1021/j100722a016; OHMINE I, 1977, MACROMOLECULES, V10, P862, DOI 10.1021/ma60058a028; PEKCAN O, 1990, CHEM PHYS, V146, P283, DOI 10.1016/0301-0104(90)80049-4; PEKCAN O, 1988, PHYS REV LETT, V61, P641, DOI 10.1103/PhysRevLett.61.641; REHM D, 1971, CHEM PHYS LETT, V9, P387, DOI 10.1016/0009-2614(71)80249-X; Steinberg I. Z., 1983, TIME RESOLVED FLUORE, P411; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAMAI N, 1988, CHEM PHYS LETT, V147, P25, DOI 10.1016/0009-2614(88)80217-3; TAMAI N, 1987, J PHYS CHEM-US, V91, P3503, DOI 10.1021/j100297a010; ULLMAN EF, 1976, J BIOL CHEM, V251, P4172; YANG CL, 1985, J PHYS CHEM-US, V89, P3442, DOI 10.1021/j100262a003; YANG CL, 1989, MOL DYNAMICS RESTRIC, P371; Yen W. M., 1981, LASER SPECTROSCOPY S	42	105	109	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1574	1579		10.1126/science.2011737	http://dx.doi.org/10.1126/science.2011737			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011737				2022-12-24	WOS:A1991FD89000027
J	COOPER, E; COUTURIER, S; BALLIVET, M				COOPER, E; COUTURIER, S; BALLIVET, M			PENTAMERIC STRUCTURE AND SUBUNIT STOICHIOMETRY OF A NEURONAL NICOTINIC ACETYLCHOLINE-RECEPTOR	NATURE			English	Article							AFFINITY BINDING-SITE; FUNCTIONAL EXPRESSION; NONCOMPETITIVE BLOCKERS; H-3 CHLORPROMAZINE; XENOPUS OOCYTES; ALPHA-SUBUNIT; ION CHANNEL; CDNA; BRAIN; SEQUENCE	NEURONAL nicotinic acetylcholine receptors are members of a gene family of ligand-gated transmitter receptors that includes muscle nicotinic receptors, GABA(A) receptors and glycine receptors 1-4. Several lines of evidence indicate that neuronal nicotinic receptors can be made up of only two subunits, an alpha (alpha) subunit which binds ligand, and a non-alpha (n-alpha) or beta (beta) subunit 5-13. The stoichiometry of each subunit in the functional receptor has been difficult to assess, however. Estimates of the molecular weight of neuronal nicotinic receptor macromolecules suggest that these receptors contain at least four subunits but probably not more than five 5,12. We have examined the subunit stoichiometry of the chick neuronal alpha-4/n-alpha-1 receptor 7,9 by first using site-directed mutagenesis to create subunits that confer different single channel properties on the receptor. Co-injection with wild-type and mutant subunits led to the appearance of receptors with wild-type, mutant and hybrid conductances. From the number of hybrid conductances, we could deduce the number of each subunit in the functional receptor.	UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	COOPER, E (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1YG,QUEBEC,CANADA.							BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BERTRAND D, 1990, P NATL ACAD SCI USA, V87, P1993, DOI 10.1073/pnas.87.5.1993; BERTRAND D, IN PRESS ELECTROPHYS; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GREENINGLOH G, 1987, NATURE, V328, P215; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KUNDEL TA, 1985, P NATL ACAD SCI USA, V82, P488; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; PRESS WH, 1986, NUMERICAL RECIPES AR; RAFFERTY MA, 1980, SCIENCE, V208, P1454; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WHITING PJ, 1987, J NEUROSCI, V7, P4005; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	24	416	425	1	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					235	238		10.1038/350235a0	http://dx.doi.org/10.1038/350235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005979	Green Published			2022-12-24	WOS:A1991FC77900059
J	GREENBERGER, PA				GREENBERGER, PA			ALLERGY TO SULFA DRUGS WITH POSTCOITAL URTICARIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498				GREEN RL, 1985, JAMA-J AM MED ASSOC, V254, P531, DOI 10.1001/jama.254.4.531; SELL MB, 1985, AM J PSYCHIAT, V142, P271	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1458	1458						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999889				2022-12-24	WOS:A1991FB55000031
J	KHONG, TY; HEALY, DL; MCCLOUD, PI				KHONG, TY; HEALY, DL; MCCLOUD, PI			PREGNANCIES COMPLICATED BY ABNORMALLY ADHERENT PLACENTA AND SEX-RATIO AT BIRTH	BRITISH MEDICAL JOURNAL			English	Article									MONASH UNIV,MONASH MED CTR,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA; MONASH UNIV,DEPT MATH,CLAYTON,VIC 3168,AUSTRALIA	Monash University; Monash University								Fox H, 1972, OBSTET GYNECOL SURV, V27, P475; JAMES WH, 1987, HUM BIOL, V59, P721; KHONG TY, IN PRESS IMMUNOLOGIC; METTLER L, 1984, GYNECOL OBSTET INVES, V18, P281, DOI 10.1159/000299094; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					625	626		10.1136/bmj.302.6777.625	http://dx.doi.org/10.1136/bmj.302.6777.625			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012876	Green Published, Bronze			2022-12-24	WOS:A1991FC07100021
J	BLOT, WJ; DEVESA, SS; KNELLER, RW; FRAUMENI, JF				BLOT, WJ; DEVESA, SS; KNELLER, RW; FRAUMENI, JF			RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							UNITED-STATES; BARRETTS ESOPHAGUS; CANCER	Analyses of cancer incidence data from nine areas of the United States revealed steadily rising rates from 1976 to 1987 of adenocarcinomas of the esophagus and gastric cardia. The increases among men in this period ranged from 4% to 10% per year, and thus exceeded those of any other type of cancer. In contrast, there were relatively stable trends for squamous cell carcinoma of the esophagus and slight declines for adenocarcinoma of more distal portions of the stomach. Adenocarcinomas of the esophagus and gastric cardia disproportionately affected white men and rarely occurred among women. By the mid-1980s, among white men, adenocarcinomas accounted for about one third of all esophageal cancers, while cardia cancers accounted for about one half of all stomach cancers with specified subsites. The rising incidence rates and similar demographic patterns point to the need for investigation into the causes of these poorly understood cancers.			BLOT, WJ (corresponding author), NCI,BIOSTAT BRANCH,EPIDEMIOL & BIOSTAT PROGRAM,EPN,SUITE 431,BETHESDA,MD 20892, USA.							[Anonymous], 1976, INT CLASSIFICATION D; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; DYA NE, 1982, CANCER EPIDEMIOLOGY, P596; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LEVI F, 1990, INT J CANCER, V45, P852, DOI 10.1002/ijc.2910450511; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; MACDONALD WC, 1987, CANCER, V60, P1094, DOI 10.1002/1097-0142(19870901)60:5<1094::AID-CNCR2820600529>3.0.CO;2-4; MOELLER H, 1988, 6TH ANN ECP S INT S; POWELL J, 1990, BRIT J CANCER, V59, P440; RIES LAG, 1990, NIH902789 US DEP HLT; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; WANG HH, 1986, HUM PATHOL, V17, P482, DOI 10.1016/S0046-8177(86)80038-7; YANG PC, 1988, INT J EPIDEMIOL, V17, P293, DOI 10.1093/ije/17.2.293; YANG PC, 1988, CANCER, V61, P612, DOI 10.1002/1097-0142(19880201)61:3<612::AID-CNCR2820610332>3.0.CO;2-Q; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P1	16	1980	2036	1	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1287	1289		10.1001/jama.265.10.1287	http://dx.doi.org/10.1001/jama.265.10.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995976				2022-12-24	WOS:A1991FA51100024
J	WANEK, N; GARDINER, DM; MUNEOKA, K; BRYANT, SV				WANEK, N; GARDINER, DM; MUNEOKA, K; BRYANT, SV			CONVERSION BY RETINOIC ACID OF ANTERIOR CELLS INTO ZPA CELLS IN THE CHICK WING BUD	NATURE			English	Article							POLARIZING REGION; PATTERN-FORMATION; LIMB BUD; DIGITS	IN recent years there has been considerable interest in the role of retinoic acid (RA) in vertebrate-limb pattern formation. When RA is applied to the anterior of the chick wing bud, a mirror-image duplication of the limb pattern develops that is identical to the pattern resulting from grafts of posterior tissue (zone of polarizing activity, or ZPA) 1. It has been proposed that position along the anterior-posterior axis in the chick limb is specified by a gradient of a diffusible factor produced by the ZPA 2. The ZPA-mimicking action of RA has led to the hypothesis that exogenously applied RA acts by providing graded spatial information across the anterior-posterior limb axis 3,4. An alternative interpretation is that RA changes anterior cells into ZPA cells, which in turn provide the actual pattern-duplicating stimulus 3-5; there is already some preliminary evidence that this occurs 5. A hybrid interpretation has also been suggested whereby ZPA cells are formed in response to RA exposure and then begin to release retinoids that act as graded spatial cues 3. We have used a functional assay 6 to test anterior chick wing-bud cells for ZPA activity after exposure to RA. The results of our studies indicate that the action of RA is to change anterior cells into ZPA cells. Further, our results indicate that it is unlikely that RA-treated anterior cells then begin producing RA in such a way as to provide a graded positional signal.	UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA	University of California System; University of California Irvine				Muneoka, Ken/0000-0002-7520-6869				BRYANT SV, 1986, TRENDS GENET, V2, P153, DOI 10.1016/0168-9525(86)90210-6; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HONIG LS, 1981, NATURE, V291, P72, DOI 10.1038/291072a0; Javois L.C., 1984, PATTERN FORMATION PR, P557; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1982, NATURE, V295, P672, DOI 10.1038/295672a0; MEINHARDT H, 1989, DEVELOPMENT, V107, P169; SMITH JC, 1979, J EMBRYOL EXP MORPH, V52, P105; SMITH SM, 1989, DEVELOPMENT, V107, P121; STOCUM DL, 1984, J EXP ZOOL, V232, P207, DOI 10.1002/jez.1402320208; Summerbell D, 1983, Prog Clin Biol Res, V110 Pt A, P109; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0	19	219	228	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					81	83		10.1038/350081a0	http://dx.doi.org/10.1038/350081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002849				2022-12-24	WOS:A1991FA69300071
J	PARADIS, NA; MARTIN, GB; ROSENBERG, J; RIVERS, EP; GOETTING, MG; APPLETON, TJ; FEINGOLD, M; CRYER, PE; WORTSMAN, J; NOWAK, RM				PARADIS, NA; MARTIN, GB; ROSENBERG, J; RIVERS, EP; GOETTING, MG; APPLETON, TJ; FEINGOLD, M; CRYER, PE; WORTSMAN, J; NOWAK, RM			THE EFFECT OF STANDARD-DOSE AND HIGH-DOSE EPINEPHRINE ON CORONARY PERFUSION-PRESSURE DURING PROLONGED CARDIOPULMONARY-RESUSCITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLOSED-CHEST RESUSCITATION; AORTIC DIASTOLIC PRESSURE; RIGHT ATRIAL PRESSURES; CARDIAC-ARREST; BLOOD-FLOW; VENTRICULAR-FIBRILLATION; PLASMA-CATECHOLAMINES; MYOCARDIAL PERFUSION; HUMAN-BEINGS; DOGS	We studied the effect of standard and high doses of epinephrine on coronary perfusion pressure during cardiopulmonary resuscitation in 32 patients whose cardiac arrest was refractory to advanced cardiac life support. Simultaneous aortic and right atrial pressures were measured and plasma epinephrine levels were sampled. Patients remaining in cardiac arrest after multiple 1-mg doses of epinephrine received a high dose of 0.2 mg/kg. The increase in the coronary perfusion pressures was 3.7 +/- 5.0 mm Hg following a standard dose, not a statistically significant change. The increase after a high dose was 11.3 +/- 10.0 mm Hg; this was both statistically different than before administration and larger than after a standard dose. High-dose epinephrine was more likely to raise the coronary perfusion pressure above the previously demonstrated critical value of 15 mm Hg. The highest arterial plasma epinephrine level after a standard dose was 152 +/- 162 ng/mL, and after a high dose, 393 +/- 289 ng/mL. Because coronary perfusion pressure is a good predictor of outcome in cardiac arrest, the increase after high-dose epinephrine may improve rates of return of spontaneous circulation.	HENRY FORD HOSP,DEPT EMERGENCY MED,2799 W GRAND BLVD,DETROIT,MI 48202; HENRY FORD HOSP,DEPT PEDIAT,DETROIT,MI 48202; HENRY FORD HOSP,DIV BIOSTAT & RES EPIDEMIOL,DETROIT,MI 48202; WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63130; SO ILLINOIS UNIV,SCH MED,DEPT MED,SPRINGFIELD,IL 62708	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Washington University (WUSTL); Southern Illinois University System; Southern Illinois University								ABRAMSON NS, 1985, CRIT CARE MED, V13, P930, DOI 10.1097/00003246-198511000-00020; ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, CRIT CARE MED, V15, P682, DOI 10.1097/00003246-198707000-00011; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; CALLAHAM ML, 1990, ANN EMERG MED, V19, P479; CRILE GW, 1902, CLEVELAND MED J, V2, P35; CRILE GW, 1904, T S SURG GYNECOL ASS, V16, P362; DITCHEY RV, 1982, CIRCULATION, V66, P297, DOI 10.1161/01.CIR.66.2.297; EITEL DR, 1988, ANN EMERG MED, V17, P808, DOI 10.1016/S0196-0644(88)80560-2; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HAFT JI, 1974, PROG CARDIOVASC DIS, V17, P73, DOI 10.1016/0033-0620(74)90039-5; HOLMES HR, 1980, CRIT CARE MED, V8, P137, DOI 10.1097/00003246-198003000-00009; KERN KB, 1989, CRIT CARE MED, V17, P786, DOI 10.1097/00003246-198908000-00013; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; LEVINE RD, 1981, NEW YORK STATE J MED, V81, P1669; LITTLE RA, 1985, Q J MED, V54, P133; MARTIN GB, 1986, ANN EMERG MED, V15, P125, DOI 10.1016/S0196-0644(86)80005-1; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; NIEMANN JT, 1984, ANN EMERG MED, V13, P849, DOI 10.1016/S0196-0644(84)80458-8; OTTO CW, 1985, AM J EMERG MED, V3, P285, DOI 10.1016/0735-6757(85)90048-8; OTTO CW, 1981, CRIT CARE MED, V9, P321, DOI 10.1097/00003246-198104000-00008; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1989, CIRCULATION, V80, P361, DOI 10.1161/01.CIR.80.2.361; PARADIS NA, 1990, ANN EMERG MED, V19, P457; PEARSON JW, 1963, ANESTH ANALG, V42, P599; PEARSON JW, 1967, ANESTH ANALG, V46, P746; PIONKOWSKI RS, 1983, ANN EMERG MED, V12, P733, DOI 10.1016/S0196-0644(83)80245-5; QUINTON DN, 1987, LANCET, V1, P828; RALSTON SH, 1985, ANN EMERG MED, V14, P1044, DOI 10.1016/S0196-0644(85)80916-1; RALSTON SH, 1984, ANN EMERG MED, V13, P79, DOI 10.1016/S0196-0644(84)80566-1; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; REDDING JS, 1968, J AMER MED ASSOC, V203, P255; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; SHAH SD, 1985, J LAB CLIN MED, V106, P624; SWENSON RD, 1988, CIRCULATION, V78, P630, DOI 10.1161/01.CIR.78.3.630; WATERS LL, 1950, SCIENCE, V111, P634, DOI 10.1126/science.111.2893.634; WORTSMAN J, 1984, AM J MED, V77, P779, DOI 10.1016/0002-9343(84)90512-6; YAKAITIS RW, 1979, CRIT CARE MED, V7, P293, DOI 10.1097/00003246-197907000-00001; 1986, JAMA-J AM MED ASSOC, V255, P2841	44	115	121	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1139	1144		10.1001/jama.265.9.1139	http://dx.doi.org/10.1001/jama.265.9.1139			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996000				2022-12-24	WOS:A1991EZ47400031
J	SHULKIN, DJ				SHULKIN, DJ			RISKY BUSINESS - NEEDLESTICKS IN RESIDENCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SHULKIN, DJ (corresponding author), UNIV PENN, SCH MED, ROBERT WOOD JOHNSON FDN, PHILADELPHIA, PA 19104 USA.							AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; PORTEOUS MJL, 1990, BRIT MED J, V301, P167, DOI 10.1136/bmj.301.6744.167	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1181	1181		10.1001/jama.265.9.1181	http://dx.doi.org/10.1001/jama.265.9.1181			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996007				2022-12-24	WOS:A1991EZ47400040
J	KIRMAIER, C; GAUL, D; DEBEY, R; HOLTEN, D; SCHENCK, CC				KIRMAIER, C; GAUL, D; DEBEY, R; HOLTEN, D; SCHENCK, CC			CHARGE SEPARATION IN A REACTION CENTER INCORPORATING BACTERIOCHLOROPHYLL FOR PHOTOACTIVE BACTERIOPHEOPHYTIN	SCIENCE			English	Article							PHOTOSYNTHETIC REACTION CENTERS; BACTERIAL REACTION CENTERS; INITIAL ELECTRON-TRANSFER; NANOSECOND RECOMBINATION LUMINESCENCE; RHODOPSEUDOMONAS-SPHAEROIDES R-26; RHODOBACTER-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM; FEMTOSECOND SPECTROSCOPY; PURPLE BACTERIA; PRIMARY DONOR	Site-directed mutagenic replacement of M subunit Leu214 by His in the photosynthetic reaction center (RC) from Rhodobacter sphaeroides results in incorporation of a bacteriochlorophyll molecule (BChl) in place of the native bacteriopheophytin (BPh) electron acceptor. Evidence supporting this conclusion includes the ground-state absorption spectrum of the (M)L214H mutant, pigment and metal analyses, and time-resolved optical experiments. The genetically modified RC supports transmembrane charge separation from the photoexcited BChl dimer to the primary quinone through the new BChl molecule, but with a reduced quantum yield of 60 percent (compared to 100 percent in wild-type RCs). These results have important implications for the mechanism of charge separation in the RC, and rationalize the choice (bacterio)pheophytins as electron acceptors in a variety of photosynthetic systems.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523	Colorado State University	KIRMAIER, C (corresponding author), WASHINGTON UNIV,DEPT CHEM,ST LOUIS,MO 63130, USA.				NIGMS NIH HHS [GM18650, GM38214, GM00536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018650, R29GM038214, K04GM000536] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1986, P NATL ACAD SCI USA, V83, P8589, DOI 10.1073/pnas.83.22.8589; BIXON M, 1989, BIOCHIM BIOPHYS ACTA, V977, P273, DOI 10.1016/S0005-2728(89)80081-7; BIXON M, IN PRESS BIOCH BIOPH; BORISOV AY, 1980, FEBS LETT, V119, P121, DOI 10.1016/0014-5793(80)81012-X; BRESLOW E, 1967, J BIOL CHEM, V242, P4149; BRETON J, 1988, BIOCHEMISTRY-US, V27, P8276, DOI 10.1021/bi00421a043; BUDIL DE, 1987, ANNU REV PHYS CHEM, V38, P561, DOI 10.1146/annurev.pc.38.100187.003021; BYLINA EJ, 1988, P NATL ACAD SCI USA, V85, P7226, DOI 10.1073/pnas.85.19.7226; CALLAHAN PM, 1987, J AM CHEM SOC, V109, P7001, DOI 10.1021/ja00257a016; CHANG CH, 1986, FEBS LETT, V205, P82, DOI 10.1016/0014-5793(86)80870-5; CHIRINO A, UNPUB; COTTON TM, 1979, J AM CHEM SOC, V101, P7605, DOI 10.1021/ja00519a023; DEBEY R, UNPUB; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FAJER J, 1975, P NATL ACAD SCI USA, V72, P4956, DOI 10.1073/pnas.72.12.4956; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FRANZEN S, 1990, J PHYS CHEM-US, V94, P5135, DOI 10.1021/j100375a068; FRIESNER RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P99, DOI 10.1016/S0005-2728(89)80062-3; GOLDSTEIN RA, 1989, BIOCHIM BIOPHYS ACTA, V977, P78, DOI 10.1016/S0005-2728(89)80011-8; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOLZAPFEL W, 1990, P NATL ACAD SCI USA, V87, P5168, DOI 10.1073/pnas.87.13.5168; HOLZAPFEL W, 1989, CHEM PHYS LETT, V160, P1, DOI 10.1016/0009-2614(89)87543-8; HU YM, 1989, CHEM PHYS LETT, V160, P410, DOI 10.1016/0009-2614(89)87619-5; KIRMAIER C, 1988, FEBS LETT, V239, P211, DOI 10.1016/0014-5793(88)80919-0; KIRMAIER C, 1989, CHEM PHYS LETT, V159, P251, DOI 10.1016/0009-2614(89)87419-6; KIRMAIER C, 1987, PHOTOSYNTH RES, V13, P225, DOI 10.1007/BF00029401; KIRMAIER C, 1990, P NATL ACAD SCI USA, V87, P3552, DOI 10.1073/pnas.87.9.3552; KIRMAIER C, 1988, P NATL ACAD SCI USA, V85, P7562, DOI 10.1073/pnas.85.20.7562; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KOTOVA EA, 1981, FEBS LETT, V131, P51, DOI 10.1016/0014-5793(81)80885-X; LOCKHART DJ, 1990, J PHYS CHEM-US, V94, P6987, DOI 10.1021/j100381a015; LOCKHART DJ, 1988, J CHEM PHYS, V89, P1408, DOI 10.1063/1.455140; MARCUS RA, 1988, CHEM PHYS LETT, V146, P13, DOI 10.1016/0009-2614(88)85041-3; MARTIN JL, 1986, P NATL ACAD SCI USA, V83, P957, DOI 10.1073/pnas.83.4.957; MCDOWELL LM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P239, DOI 10.1016/0005-2728(90)90153-U; MCDOWELL LM, IN PRESS J PHYS CHEM; MCDOWELL LM, UNPUB; NAGARAJAN V, 1990, P NATL ACAD SCI USA, V87, P7888, DOI 10.1073/pnas.87.20.7888; PARSON WW, 1975, BIOCHIM BIOPHYS ACTA, V387, P265, DOI 10.1016/0005-2728(75)90109-7; SARAI A, 1980, BIOCHIM BIOPHYS ACTA, V589, P71, DOI 10.1016/0005-2728(80)90133-4; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P44, DOI 10.1016/0005-2728(82)90315-2; SCHERER POJ, 1989, CHEM PHYS, V131, P115, DOI 10.1016/0301-0104(89)87084-3; SEBRING ED, 1970, J BIOL CHEM, V245, P5395; SHUVALOV VA, 1981, P NATL ACAD SCI-BIOL, V78, P957, DOI 10.1073/pnas.78.2.957; SISTROM WR, 1977, J BACTERIOL, V131, P526, DOI 10.1128/JB.131.2.526-532.1977; STRALEY SC, 1973, BIOCHIM BIOPHYS ACTA, V305, P597, DOI 10.1016/0005-2728(73)90079-0; VANDERREST M, 1974, J BIOL CHEM, V249, P6446; WARSHEL A, 1988, J PHYS CHEM-US, V92, P2696, DOI 10.1021/j100320a057; WARSHEL A, 1989, SCIENCE, V246, P112, DOI 10.1126/science.2675313; WARSHEL A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251; WASIELEWSKI MR, 1986, FEBS LETT, V204, P386; WENDT RH, 1965, ANAL CHEM, V37, P920, DOI 10.1021/ac60226a003; WOODBURY N, IN PRESS P FELDAFING; WOODBURY NW, 1985, BIOCHEMISTRY-US, V24, P7516, DOI 10.1021/bi00347a002; WOODBURY NWT, 1984, BIOCHIM BIOPHYS ACTA, V767, P345, DOI 10.1016/0005-2728(84)90205-6; YEATES TO, 1988, P NATL ACAD SCI USA, V85, P7993, DOI 10.1073/pnas.85.21.7993	56	164	168	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					922	927		10.1126/science.2000491	http://dx.doi.org/10.1126/science.2000491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000491				2022-12-24	WOS:A1991EY62900039
J	JAMIESON, DJ; RAHE, B; PRINGLE, J; BEGGS, JD				JAMIESON, DJ; RAHE, B; PRINGLE, J; BEGGS, JD			A SUPPRESSOR OF A YEAST SPLICING MUTATION (PRP8-1) ENCODES A PUTATIVE ATP-DEPENDENT RNA HELICASE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE REGION; PROTEIN; TRANSFORMATION	FIVE small nuclear RNAs (snRNAs) are required for nuclear pre-messenger RNA splicing: U1, U2, U4, U5 and U6 1,2. The yeast U1 and U2 snRNAs base-pair to the 5' splice site and branch-point sequences of introns respectively 1. The role of the U5 and U4/U6 small nuclear ribonucleoprotein particles (snRNPs) is splicing is not clear, through a catalytic role for the U6 snRNA has be proposed 3. Less is known about yeast splicing factors, but the availability of genetic techniques in Saccharomyces cerevisiae has led to the identification of mutants deficient in nuclear pre-mRNA splicing (prp2-prp27)4,5. Several PRP genes have now been cloned and their protein products characterized. The PRP8 protein is a component of the U5 snRNP and associates with the U4/U6 snRNAs/snRNP to form a multi-snRNP particle believed to be important for spliceosome assembly 6. We have isolated extragenic suppressors of the prp8-1 mutation of S. cerevisiae and present here the preliminary characterization of one of these suppressors, spp81. The predicted amino-acid sequence of the SPP81 protein shows extensive similarity to a recently identified family of proteins thought to possess ATP-dependent RNA helicase activity. The possible role of this putative helicase in nuclear pre-mRNA splicing is discussed.	UNIV MICHIGAN,PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48103; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48103	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JAMIESON, DJ (corresponding author), UNIV EDINBURGH,INST CELL & MOLEC BIOL,KINGS BLDG,MAYFIELD RD,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.		, jbeggs/N-9551-2019; Beggs, Jean/H-4861-2011	Beggs, Jean/0000-0002-8179-6519				BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIRLING H, 1989, NATURE, V339, P56; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; JAMIESON DJ, IN PRESS MOL MICROBI; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; PEARSON NJ, 1982, MOL CELL BIOL, V2, P571, DOI 10.1128/MCB.2.5.571; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; Sherman F., 1982, METHODS YEAST GENETI; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; STRUHL K, 1980, J MOL BIOL, V136, P309, DOI 10.1016/0022-2836(80)90376-9; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206	30	100	101	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					715	717		10.1038/349715a0	http://dx.doi.org/10.1038/349715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996139	Green Published			2022-12-24	WOS:A1991EY62700054
J	ZWERDLING, RG; BROWN, J				ZWERDLING, RG; BROWN, J			PULMONARY-EMBOLISM IN CHILDREN - RISKS AND PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ZWERDLING, RG (corresponding author), UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA 01605, USA.							BERNSTEIN D, 1986, AM J DIS CHILD, V140, P667, DOI 10.1001/archpedi.1986.02140210065028; BUCK JR, 1981, J PEDIATR SURG, V16, P385, DOI 10.1016/S0022-3468(81)80700-2; BYARD RW, 1990, ARCH PATHOL LAB MED, V114, P142; GRACEY DR, 1982, MAYO CLIN PROC, V57, P742; RAMAN K, 1971, CHEST, V60, P555; 1986, JAMA-J AM MED ASSOC, V256, P744	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2888	2888						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033750				2022-12-24	WOS:A1991FN85500042
J	GOLDING, J; ROWLAND, A; GREENWOOD, R; LUNT, P				GOLDING, J; ROWLAND, A; GREENWOOD, R; LUNT, P			ALUMINUM SULFATE IN WATER IN NORTH CORNWALL AND OUTCOME OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether the excess aluminium sulphate accidentally added to the local water supply in north Cornwall in July 1988 had an adverse effect on the outcome of pregnancies. Design - Outcomes of all singleton pregnancies in the affected area at the time of the incident (n = 92) were compared with those in two control groups: pregnancies in this area completed before the incident (n = 68) and pregnancies in a neighbouring area (n = 193). Subjects - Mothers in the three groups, among whom there were 13 miscarriages, five terminations of pregnancy, and 336 live births. Main outcome measures - Fetal and perinatal loss, birth weight, gestation, obstetric complications, neonatal condition, and congenital defects. Results - Among 88 pregnancies in women exposed to excess aluminium sulphate there was no excess of perinatal deaths (n = 0), low birthweight (n = 3), preterm delivery (n = 4), or severe congenital malformations (n = 0). There was, however, an increased rate of talipes in exposed fetuses (four cases, one control; p = 0.01). Conclusions - Because of small numbers it is not possible to say that high doses of aluminium sulphate are safe in pregnancy, but there is no evidence from this study of major problems apparent at birth.	CORNWALL & ISLES SCILLY HLTH AUTHOR,TRURO TR1 1NR,ENGLAND		GOLDING, J (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND.		Lunt, Peter/AAF-8265-2020	Golding, Jean/0000-0003-2826-3307				Akar N, 1989, Paediatr Perinat Epidemiol, V3, P102; BERNUZZI V, 1989, TERATOLOGY, V40, P21, DOI 10.1002/tera.1420400104; GOLDING J, 1984, CHILD HLTH, V3, P31; LAPPE M, 1988, TRACE ELEMENTS HLTH; MARLOWE M, 1985, ARCH ENVIRON HEALTH, V40, P221, DOI 10.1080/00039896.1985.10545922; MATSUMOTO H, 1965, J NEUROPATH EXP NEUR, V24, P563, DOI 10.1097/00005072-196510000-00002; MORTON MS, 1976, BRIT J PREV SOC MED, V30, P36; OLIVER JMT, 1983, LANCET, V1, P181	8	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1175	1177		10.1136/bmj.302.6786.1175	http://dx.doi.org/10.1136/bmj.302.6786.1175			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043811	Green Published, Bronze			2022-12-24	WOS:A1991FN04500018
J	FRANK, D; KESHET, I; SHANI, M; LEVINE, A; RAZIN, A; CEDAR, H				FRANK, D; KESHET, I; SHANI, M; LEVINE, A; RAZIN, A; CEDAR, H			DEMETHYLATION OF CPG ISLANDS IN EMBRYONIC-CELLS	NATURE			English	Article							X-CHROMOSOME INACTIVATION; DENOVO METHYLATION; DNA METHYLATION; CHROMATIN STRUCTURE; TRANSGENIC MICE; 2 GENES; MOUSE; EXPRESSION; EMBRYOGENESIS; LINES	DNA in differentiated somatic cells has a fixed pattern of methylation, which is faithfully copied after replication. By contrast, the methylation patterns of many tissue-specific and some housekeeping genes are altered during normal development 1. This modification of DNA methylation in the embryo has also been observed in transgenic mice and in transfection experiments 2. Here we report the fate in mice of an in vitro-methylated adenine phosphoribosyltransferase transgene. The entire 5' CpG island region became demethylated, whereas the 3' end of the gene remained modified and was even methylated de novo at additional sites. Transfection experiments in vitro show that the demethylation is rapid, is specific for embryonic cell-types and affects a variety of different CpG island sequences. This suggests that gene sequences can be recognized in the early embryo and imprinted with the correct methylation pattern through a combination of demethylation and de novo methylation.	AGR RES ORG, VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	FRANK, D (corresponding author), HEBREW UNIV JERUSALEM, SCH MED, DEPT CELLULAR BIOCHEM, POB 1172, JERUSALEM, ISRAEL.		Levine, Alex/A-6867-2008					ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CEDAR H, 1982, COLD SPRING HARB SYM, V47, P605, DOI 10.1101/SQB.1983.047.01.071; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; CORDELL B, 1979, CELL, V18, P533, DOI 10.1016/0092-8674(79)90070-9; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; EINAT P, 1987, GENE DEV, V1, P1075, DOI 10.1101/gad.1.10.1075; GARTLER SM, 1975, EXP CELL RES, V91, P454, DOI 10.1016/0014-4827(75)90127-5; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KOLSTO AB, 1986, NUCLEIC ACIDS RES, V14, P9667; KRATZER PG, 1981, P NATL ACAD SCI-BIOL, V78, P3093, DOI 10.1073/pnas.78.5.3093; KRATZER PG, 1983, CELL, V33, P37, DOI 10.1016/0092-8674(83)90332-X; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LOWRY I, 1980, CELL, V22, P817; MONK M, 1987, DEVELOPMENT, V99, P371; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PONZETTOZIMMERMAN C, 1984, NUCLEIC ACIDS RES, V12, P2807, DOI 10.1093/nar/12.6.2807; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SHEMER R, 1990, J BIOL CHEM, V265, P1010; SHIMADA T, 1987, MOL CELL BIOL, V7, P2830, DOI 10.1128/MCB.7.8.2830; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; STEIN R, 1983, P NATL ACAD SCI-BIOL, V80, P2422, DOI 10.1073/pnas.80.9.2422	27	133	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					239	241		10.1038/351239a0	http://dx.doi.org/10.1038/351239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041571				2022-12-24	WOS:A1991FL99000059
J	MOORE, JM; PEATTIE, DA; FITZGIBBON, MJ; THOMSON, JA				MOORE, JM; PEATTIE, DA; FITZGIBBON, MJ; THOMSON, JA			SOLUTION STRUCTURE OF THE MAJOR BINDING-PROTEIN FOR THE IMMUNOSUPPRESSANT FK506	NATURE			English	Article							CIS-TRANS ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; FK506-BINDING PROTEIN; H-1-NMR SPECTRA; CYCLOSPORIN-A; CYCLOPHILIN; DISTINCT; PATHWAYS; CELL	THE major FK506 binding protein (FKBP, relative molecular mass approximately 11,800; M(r) 11.8K) and cyclophilin (M(r) approximately 17K) belong to a class of proteins termed immunophilins 1. Although unrelated at the amino-acid sequence level, they both possess peptidyl-prolyl cis-trans isomerase activities which are inhibited by immunosuppressants that block signal transduction pathways leading to T-lymphocyte activation. FK506 and rapamycin strongly inhibit the peptidyl-prolyl cis-trans isomerase activity of FKBP, whereas cyclosporin A inhibits that of cyclophilin 2-12. The significance of this enzyme activity and the role of the immunophilins in immunoregulation is unknown 1,13. To understand better the function of the immunophilins and their interaction with inhibitors, we are investigating the solution structures of FKBP and FKBP-inhibitor complexes by multidimensional NMR methods. Here we report the solution conformation of FKBP, as generated by NMR, distance geometry and molecular dynamics methods. The regular secondary structure of FKBP is composed mainly of beta-sheet (approximately 35%) with little helical structure (< 10%). The hydrophobic core of the molecule, containing the buried side chains of six of the protein's nine aromatic amino acids, is enclosed by a five-stranded antiparallel beta-sheet on one side, a loop and a short helix at residues 51-56 and 57-65, and an aperiodic loop at residues 81-95. Examination of the structure suggests a possible site of interaction with FK506.			MOORE, JM (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.			Moore, Jonathan/0000-0001-8633-3313				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; ECCLES C, 1989, 10TH M INT SOC MAGN; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; GUENTERT P, IN PRESS J MOL BIOL; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083; Wuthrich K., 1986, NMR PROTEINS NUCL AC	27	150	154	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					248	250		10.1038/351248a0	http://dx.doi.org/10.1038/351248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041572				2022-12-24	WOS:A1991FL99000062
J	EZZAT, S; STROM, C; MELMED, S				EZZAT, S; STROM, C; MELMED, S			COLON POLYPS IN ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Note							GROWTH		UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,DIV ENDOCRINOL & METAB,B-131, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041906, R01DK034824] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41906, DK 34824] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNNER JE, 1990, CLIN ENDOCRINOL, V32, P65, DOI 10.1111/j.1365-2265.1990.tb03751.x; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; EZZAT S, 1991, J CLIN ENDOCR METAB, V72, P245, DOI 10.1210/jcem-72-2-245; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KLEIN I, 1982, ANN INTERN MED, V97, P27, DOI 10.7326/0003-4819-97-1-27; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; MOON HD, 1950, CANCER RES, V10, P297; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1806, DOI 10.1210/endo-120-5-1806; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541	10	80	81	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					754	755		10.7326/0003-4819-114-9-754	http://dx.doi.org/10.7326/0003-4819-114-9-754			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012357				2022-12-24	WOS:A1991FJ11700008
J	SELBY, JV; NEWMAN, B; QUIROGA, J; CHRISTIAN, JC; AUSTIN, MA; FABSITZ, RR				SELBY, JV; NEWMAN, B; QUIROGA, J; CHRISTIAN, JC; AUSTIN, MA; FABSITZ, RR			CONCORDANCE FOR DYSLIPIDEMIC HYPERTENSION IN MALE TWINS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; RISK-FACTORS; INSULIN; PREVALENCE	Sixty cases of dyslipidemic hypertension were identified in the 1028 middle-aged, white, male twin participants in the first examination of the National Heart, Lung, and Blood Institute Twin Study (1969 to 1973). The prevalence of dyslipidemic hypertension was similar by zygosity but proband concordance was three times greater in monozygotic than dizygotic twins (0.44 [seven concordant and 18 discordant pairs] vs 0.14 [two concordant and 24 discordant pairs]), suggesting a genetic effect on the condition. Low high-density lipoprotein cholesterol level was the most common lipid abnormality in concordant pairs. Mortality from ischemic heart disease was significantly higher in individuals with dyslipidemic hypertension. Obesity and glucose intolerance were closely associated with the syndrome. Moreover, within the 18 discordant monozygotic twin pairs, the twins with dyslipidemic hypertension had gained significantly more weight as adults and were significantly heavier than their unaffected cotwins. Thus, although genetic factors may influence development of dyslipidemic hypertension, nongenetic, potentially modifiable aspects of obesity are also closely related to expression of this clinically important syndrome.	VET AFFAIRS MED CTR,DEPT MED,LONG BEACH,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,DEPT EPIDEMIOL,BERKELEY,CA 94720; INDIANA UNIV,SCH MED,DEPT MED GENET,INDIANAPOLIS,IN 46202; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; NHLBI,CLIN GENET & EPIDEMIOL BRANCH,BETHESDA,MD 20892	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Berkeley; Indiana University System; Indiana University-Purdue University Indianapolis; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM,DIV RES,NO CALIF REG,3451 PIEDMONT AVE,OAKLAND,CA 94611, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055026] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC55026] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; COX NJ, 1989, DIABETES, V38, P653, DOI 10.2337/diabetes.38.5.653; CRIQUI MH, 1986, CIRCULATION, V73, P40; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; FABSITZ RR, 1978, BEHAV GENET, V8, P15, DOI 10.1007/BF01067701; FEINLEIB M, 1970, ACTA GENET MED GEMEL, V19, P243, DOI 10.1017/S1120962300025592; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; HUNT SC, 1989, ARTERIOSCLEROSIS, V9, P335, DOI 10.1161/01.ATV.9.3.335; JABLON S, 1967, AM J HUM GENET, V19, P133; KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1; LEE ET, 1980, STATISTICAL METHODS; MACMAHON SW, 1985, ARTERIOSCLEROSIS, V5, P391, DOI 10.1161/01.ATV.5.4.391; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; NEUFELD HN, 1983, CIRCULATION, V67, P943, DOI 10.1161/01.CIR.67.5.943; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; NEWMAN B, 1990, AM J PUBLIC HEALTH, V80, P675, DOI 10.2105/AJPH.80.6.675; PERMUTT MA, 1990, DIABETES CARE, V13, P364, DOI 10.2337/diacare.13.3.364; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REED T, IN PRESS J CLIN EPID; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; SHIEH SM, 1987, ATHEROSCLEROSIS, V67, P49, DOI 10.1016/0021-9150(87)90264-4; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	25	87	88	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2079	2084		10.1001/jama.265.16.2079	http://dx.doi.org/10.1001/jama.265.16.2079			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013927				2022-12-24	WOS:A1991FG90700024
J	BURKHART, J				BURKHART, J			AMA-RPS INSTRUMENTAL IN ACHIEVING NEW MATERNITY LEAVE POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1756	1756						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002585				2022-12-24	WOS:A1991FD65900036
J	KERNAN, WN; HORWITZ, RI; BRASS, LM; VISCOLI, CM; TAYLOR, KJW				KERNAN, WN; HORWITZ, RI; BRASS, LM; VISCOLI, CM; TAYLOR, KJW			A PROGNOSTIC SYSTEM FOR TRANSIENT ISCHEMIA OR MINOR STROKE	ANNALS OF INTERNAL MEDICINE			English	Article							CEREBRAL INFARCTION; SURVIVAL; RECURRENCE; SCORE	Objective: To build a prognostic system for patients with carotid transient ischemic attack or minor stroke. Design: Inception cohort study with 2-year follow-up. Setting: Urban community teaching hospital. Patients: Eligible patients (n = 142), identified on a carotid ultrasound roster, had been hospitalized between 1984 and 1987 within 30 days of a first carotid transient ischemic attack or minor stroke. Measurements: Stroke or death within 2 years. Main Results: Three factors were associated with stroke or death: age of more than 65 years, diabetes, and hypertension. Based on regression coefficients, age of more than 65 years was assigned 3 points; diabetes, 3 points; and hypertension, 2 points. An initial prognostic system comprised risk groups 1 (0 points), 2 (1 to 5 points), and 3 (6 to 8 points). Outcome rates in the three groups were 2%, 31%, and 54% (P < 0.0001), respectively. In an independent test sample, the corresponding outcome rates for the initial system were 12%, 21%, and 31% (P = 0.04). A final prognostic system, including two additional predictors (coronary heart disease [1 point] and the distinction between stroke and transient ischemic attack for the baseline event [2 points]), comprised risk groups 1 (0 to 2 points), 2 (3 to 6 points), and 3 (7 to 11 points). Corresponding outcome rates were 3%, 27%, and 48% (P < 0.001) in the original cohort and 10%, 21%, and 59% (P < 0.001) in the test cohort. Conclusion: For selected patients with carotid transient ischemia or minor stroke, five clinical features can be combined to stratify effectively the risk for a subsequent stroke or death.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA	Yale University								ABUZEID HAH, 1978, ARCH NEUROL-CHICAGO, V35, P121, DOI 10.1001/archneur.1978.00500270003001; ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; BRITTON M, 1980, ACTA MED SCAND, V207, P37; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CHAMBERS BR, 1987, NEUROLOGY, V37, P221, DOI 10.1212/WNL.37.2.221; DAVID N J, 1960, J Chronic Dis, V11, P394, DOI 10.1016/0021-9681(60)90045-X; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FULLERTON KJ, 1988, Q J MED, V66, P147; GENT M, 1979, THROMB HAEMOSTASIS, V41, P123; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HOWARD G, 1989, J CLIN EPIDEMIOL, V42, P45, DOI 10.1016/0895-4356(89)90024-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLYHAYES M, 1988, ARCH PHYS MED REHAB, V69, P415; MARQUARDSEN J, 1969, NATURAL HIST ACUTE C; MARSHALL J, 1959, BMJ-BRIT MED J, V1, P1614, DOI 10.1136/bmj.1.5138.1614; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MIAH K, 1983, J CHRON DIS, V36, P279, DOI 10.1016/0021-9681(83)90063-2; MOORE DJ, 1985, J VASC SURG, V2, P654, DOI 10.1067/mva.1985.avs0020654; OLSSON T, 1990, DIABETOLOGIA, V33, P244, DOI 10.1007/BF00404803; RABKIN SW, 1978, ANN INTERN MED, V89, P15, DOI 10.7326/0003-4819-89-1-15; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACCO RL, 1989, STROKE, V20, P983, DOI 10.1161/01.STR.20.8.983; SILVER FL, 1984, STROKE, V15, P492, DOI 10.1161/01.STR.15.3.492; TAYLOR KJ, 1988, CLIN APPLICATIONS DO, V6, P120; WADE DT, 1985, Q J MED, V56, P601; WADE DT, 1984, AGE AGEING, V13, P76, DOI 10.1093/ageing/13.2.76; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1984, BMDP USERS GUIDE CON; 1988, SAS LANGUAGE GUIDE P	30	57	62	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					552	557		10.7326/0003-4819-114-7-552	http://dx.doi.org/10.7326/0003-4819-114-7-552			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001088				2022-12-24	WOS:A1991FD66100005
J	TALPAZ, M; KANTARJIAN, H; KURZROCK, R; TRUJILLO, JM; GUTTERMAN, JU				TALPAZ, M; KANTARJIAN, H; KURZROCK, R; TRUJILLO, JM; GUTTERMAN, JU			INTERFERON-ALPHA PRODUCES SUSTAINED CYTOGENETIC RESPONSES IN CHRONIC MYELOGENOUS LEUKEMIA - PHILADELPHIA CHROMOSOME-POSITIVE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; LEUKOCYTE INTERFERON; GRANULOCYTIC-LEUKEMIA; CULTURE REVEALS; REMISSION; THERAPY; CANCER	Objectives: To evaluate the frequency and the course of complete cytogenetic responses in interferon-alpha (IFN-alpha)-treated patients with chronic myelogenous leukemia. Design: Two prospective trials in consecutive patients. Setting: A major tertiary cancer center. Patients: Ninety-six consecutive patients with chronic myelogenous leukemia with disease duration of less than 1 year. Intervention: Patients received partially pure IFN-alpha intramuscularly, from 3 to 9 million U/d (51 patients) or recombinant IFN-alpha-2a (Roferon, Hoffmann-LaRoche, Inc., Nutley, New Jersey), 5 million U/m2 body surface area daily (45 patients). Measurements: Hematologic and cytogenetic tests were administered. Main Results: Seventy of the patients (73%) achieved hematologic remission (95% CI, 63% to 81%), and 18 (19%) had complete suppression of the Philadelphia chromosome on at least one cytogenetic test. A complete cytogenetic response was induced in 7 of 51 or 14% (CI, 6% to 26%) of the patients treated with the partially pure IFN-alpha and in 11 of 45 or 24% (CI, 13% to 40%) of the patients treated with recombinant IFN-alpha-2a. The difference in complete cytogenetic response between the two groups was 10.7% (CI, -5% to 26%; P > 0.2). Eleven patients had durable, ongoing, complete cytogenetic responses from 6 to more than 45 months (median, more than 30 months). Conclusion: This study was the first to show sustained, complete cytogenetic responses in a subset of patients with chronic myelogenous leukemia treated with single-agent therapy. The nature of this remission, that is, whether it depends on continuous therapy, requires further study.			TALPAZ, M (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT CLIN IMMUNOL & BIOL THERAPY, BOX 41, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.			Talpaz, Moshe/0000-0003-3361-3981				ARTHUR CK, 1988, BLOOD, V71, P1179; CHAMPLIN RE, 1985, BLOOD, V65, P1039; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; CUNNINGHAM I, 1979, BLOOD, V53, P375; DUBE ID, 1984, BLOOD, V63, P1172; ERNSTOFF MS, 1984, AM J MED, V76, P593, DOI 10.1016/0002-9343(84)90282-1; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P192, DOI 10.1200/JCO.1985.3.2.192; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1269, DOI 10.1056/NEJM198105213042105; KURZROCK R, 1987, BLOOD, V70, P943; LEE MS, 1988, BLOOD, V72, P893; MAEDA S, 1980, P NATL ACAD SCI-BIOL, V77, P7010, DOI 10.1073/pnas.77.12.7010; MCGLAVE PB, 1984, BLOOD, V63, P219; MORRA E, 1987, ASCO P, V6, P145; NIEDERLE N, 1987, SEMIN ONCOL, V14, P29; QUESADA JR, 1983, CANCER RES, V43, P940; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; SINGER JW, 1980, BLOOD, V56, P356; SOKAL JE, 1988, BLOOD, V72, P294; SPECK B, 1984, LANCET, V1, P665; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TALPAZ M, 1983, BLOOD, V62, P689; TRUJILLO JM, 1979, BLOOD, V53, P695; WILLIAMS CKO, 1981, ONCOLOGY, V38, P356, DOI 10.1159/000225587	26	425	428	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					532	538		10.7326/0003-4819-114-7-532	http://dx.doi.org/10.7326/0003-4819-114-7-532			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001086				2022-12-24	WOS:A1991FD66100002
J	SAAD, MF; LILLIOJA, S; NYOMBA, BL; CASTILLO, C; FERRARO, R; DEGREGORIO, M; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; HOWARD, BV; BOGARDUS, C				SAAD, MF; LILLIOJA, S; NYOMBA, BL; CASTILLO, C; FERRARO, R; DEGREGORIO, M; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; HOWARD, BV; BOGARDUS, C			RACIAL-DIFFERENCES IN THE RELATION BETWEEN BLOOD-PRESSURE AND INSULIN RESISTANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESSENTIAL-HYPERTENSION; LIPID-METABOLISM; PIMA-INDIANS; GLUCOSE; HYPERINSULINEMIA; CHILDREN; SODIUM; MASS	Background. Insulin resistance and the concomitant compensatory hyperinsulinemia have been implicated in the pathogenesis of hypertension. However, reports on the relation between insulin and blood pressure are inconsistent. This study was designed to investigate the possibility of racial differences in this relation. Methods. We studied 116 Pima Indians, 53 whites, and 42 blacks who were normotensive and did not have diabetes; the groups were comparable with respect to mean age (29, 30, and 31 years, respectively) and blood pressure (113/70, 111/68, and 113/68 mm Hg, respectively). Insulin resistance was determined by the euglycemic-hyperinsulinemic clamp technique during low-dose (40 mU per square meter of body-surface area per minute) and high-dose (400 mU per square meter per minute) insulin infusions. Results. The Pima Indians had higher fasting plasma insulin concentrations than the whites or blacks (176, 138, and 122 pmol per liter, respectively; P = 0.002) and lower rates of whole-body glucose disposal during both the low-dose (12.7, 17.1, and 19.5 mmol per minute; P < 0.001) and the high-dose (38.0, 43.1, and 45.7 mmol per minute; P < 0.001) insulin infusions. After adjustment for age, sex, body weight, and percentage of body fat, mean blood pressure (calculated as 1/3 systolic pressure + 2/3 diastolic pressure) was significantly correlated with the fasting plasma insulin concentration (r = 0.42) and the rate of glucose disposal during the low-dose (r = -0.41) and high-dose (r = -0.49) insulin infusions (P < 0.01 for each) in whites, but not in Pima Indians (r = -0.06, -0.02, and -0.04, respectively) or blacks (r = -0.10, -0.04, and 0.02, respectively. Conclusions. The relations between insulinemia, insulin resistance, and blood pressure differ among racial groups and may be mediated by mechanisms active in whites, but not in Pima Indians or blacks.	NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ; MEDLANTIC RES FDN,WASHINGTON,DC	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Lillioja, Stephen/A-8185-2012; Ravussin, Eric/N-1985-2017; Castillo, Carlos Fenandez-del/AAO-2602-2020; Steib, Lori/B-6628-2014	Ravussin, Eric/0000-0003-2129-547X; Steib, Lori/0000-0001-8274-318X; Lillioja, Stephen/0000-0001-5333-5240; Nyomba, B. L. Gregoire/0000-0001-9472-607X				ALBERTI KGM, 1989, DIABETES S2, V38, pA92; ANNEST JL, 1979, AM J EPIDEMIOL, V110, P492, DOI 10.1093/oxfordjournals.aje.a112830; [Anonymous], 1985, WHO TECH REP SER, V727, P1; AVIV A, 1989, HYPERTENSION, V14, P584, DOI 10.1161/01.HYP.14.6.584; BERNTORP K, 1985, Diabetes Research and Clinical Practice, V1, P307, DOI 10.1016/S0168-8227(86)80042-0; BONORA E, 1987, DIABETOLOGIA, V30, P719, DOI 10.1007/BF00296995; CAMBIEN F, 1987, ARTERIOSCLEROSIS, V7, P197, DOI 10.1161/01.ATV.7.2.197; CHANNICK BJ, 1969, ARCH INTERN MED, V123, P131, DOI 10.1001/archinte.123.2.131; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DONAHUE RP, 1987, AM J EPIDEMIOL, V125, P650, DOI 10.1093/oxfordjournals.aje.a114578; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Ferrannini E, 1989, J NEPHROL, V1, P3; FERRARI P, 1990, J HYPERTENS, V8, P491, DOI 10.1097/00004872-199006000-00001; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; HAFFNER SM, 1988, METABOLISM, V37, P338, DOI 10.1016/0026-0495(88)90133-3; LILLIOJA S, 1985, J CLIN INVEST, V75, P1106, DOI 10.1172/JCI111804; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LUCAS CP, 1985, HYPERTENSION, V7, P702, DOI 10.1161/01.HYP.7.5.702; MANICARDI V, 1986, J CLIN ENDOCR METAB, V62, P1302, DOI 10.1210/jcem-62-6-1302; MANOLIO TA, 1990, ARTERIOSCLEROSIS, V10, P430, DOI 10.1161/01.ATV.10.3.430; MARIGLIANO A, 1990, AM J HYPERTENS, V3, P521, DOI 10.1093/ajh/3.7.521; MBANYA JCN, 1988, LANCET, V1, P733; MOORE RD, 1983, BIOCHIM BIOPHYS ACTA, V737, P1, DOI 10.1016/0304-4157(83)90013-8; NAGULESPARAN M, 1982, DIABETES, V31, P952, DOI 10.2337/diacare.31.11.952; NOSADINI R, 1990, DIABETES S1, V39, pA87; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; PRATT JH, 1989, NEW ENGL J MED, V321, P1152, DOI 10.1056/NEJM198910263211703; REAVEN GM, 1987, LANCET, V2, P435; RESNICK LM, 1990, AM J HYPERTENS, V3, P373, DOI 10.1093/ajh/3.5.373; ROSE HG, 1987, HYPERTENSION, V9, P421; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SAAD MF, 1990, DIABETES, V39, P1430, DOI 10.2337/diabetes.39.11.1430; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; SINGER P, 1985, HYPERTENSION, V7, P182, DOI 10.1161/01.HYP.7.2.182; STOUT RW, 1975, CIRC RES, V36, P319, DOI 10.1161/01.RES.36.2.319; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; UUSITUPA M, 1987, DIABETES RES CLIN EX, V4, P19; VOORS AW, 1981, AM J EPIDEMIOL, V113, P347, DOI 10.1093/oxfordjournals.aje.a113103; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; WELBORN TA, 1966, LANCET, V1, P1336; 1978, WHO TECH REP SER, V628, P7; 1985, SAS USERS GUIDE STAT	43	416	428	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					733	739		10.1056/NEJM199103143241105	http://dx.doi.org/10.1056/NEJM199103143241105			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB556	1997839	Green Published			2022-12-24	WOS:A1991FB55600005
J	MOSS, AH; SIEGLER, M				MOSS, AH; SIEGLER, M			SHOULD ALCOHOLICS COMPETE EQUALLY FOR LIVER-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE TECHNOLOGY; ORGAN-TRANSPLANTATION; RESOURCE-ALLOCATION; RATIONING DECISIONS; MEDICAL-CARE; INEVITABILITY; CIRRHOSIS; NO	The circumstances of liver transplantation are unique among organ transplantation because of the dire, absolute scarcity of donor livers and the predominance of one disease-alcohol-related end-stage liver disease-as the principal cause of liver failure. We propose that patients who develop end-stage liver disease through no fault of their own should have higher priority for receiving a liver transplant than those whose end-stage liver disease results from failure to obtain treatment for alcoholism. We base our proposal on considerations of fairness and on whether public support for liver transplantation can be maintained if, as a result of a first-come, first-served approach, patients with alcohol-related end-stage liver disease receive more than half the available donor livers. We conclude that since not all can live, priorities must be established for the use of scarce health care resources.	UNIV CHICAGO, PRITZKER SCH MED, CTR CLIN MED ETH, CHICAGO, IL 60637 USA	University of Chicago	MOSS, AH (corresponding author), W VIRGINIA UNIV, HLTH SCI CTR N, CTR HLTH ETH & LAW, MORGANTOWN, WV 26506 USA.		Embrett, Mark G./H-4466-2014	Embrett, Mark G./0000-0002-3969-0219				ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P187, DOI 10.2105/AJPH.75.2.187; ARONSON MD, 1987, ALCOHOLISM GUIDE PRI, P9; ATTERBURY CE, 1986, J CLIN GASTROENTEROL, V8, P1, DOI 10.1097/00004836-198602000-00001; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P256; BERESFORD TP, 1990, PSYCHOSOMATICS, V31, P241, DOI 10.1016/S0033-3182(90)72160-3; BIGBY JA, 1987, ALCOHOLISM GUIDE PRI, P66; BLANK RH, 1988, RATIONING MED, P1; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; CALLAHAN D, 1988, HASTINGS CENT REP, V18, P14, DOI 10.2307/3562403; CAPER P, 1988, NEW ENGL J MED, V318, P1535, DOI 10.1056/NEJM198806093182310; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; ENGELHARDT HT, 1984, NEW ENGL J MED, V311, P66, DOI 10.1056/NEJM198407053110135; EVANS R W, 1983, Journal of the American Medical Association, V249, P2047, DOI 10.1001/jama.249.15.2047; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; FISHMAN R, 1986, ALCOHOL ALCOHOLISM, P27; FLAVIN DK, 1988, JAMA-J AM MED ASSOC, V259, P1546, DOI 10.1001/jama.259.10.1546; FOX RC, 1978, COURAGE FAIL, P226; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GALANTER M, 1990, AM J PSYCHIAT, V147, P64; GRANT BF, 1988, SEMIN LIVER DIS, V8, P12, DOI 10.1055/s-2008-1040525; JOHNSON B, 1989, J GEN INTERN MED, V4, P445, DOI 10.1007/BF02599698; KLERMAN GL, 1989, NEW ENGL J MED, V320, P394, DOI 10.1056/NEJM198902093200611; KNOWLES JH, 1977, SCIENCE, V198, P1103, DOI 10.1126/science.198.4322.1103; KUMAR S, 1990, HEPATOLOGY, V11, P159, DOI 10.1002/hep.1840110202; MENDELSON JH, 1985, DIAGNOSIS TREATMENT, P1; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; OLBRISCH ME, 1989, JAMA-J AM MED ASSOC, V261, P2958, DOI 10.1001/jama.1989.03420200048032; Outka Gene, 1974, J Relig Ethics, V2, P11; RAMSEY P, 1970, PATIENT PERSON, P242; SAXE L, 1983, EFFECTIVENESS COSTS, P3; SCHARSCHMIDT BF, 1984, HEPATOLOGY, V4, pS95, DOI 10.1002/hep.1840040723; SCHROEDER JS, 1987, JAMA-J AM MED ASSOC, V258, P3142, DOI 10.1001/jama.258.21.3142; STARZL TE, 1988, JAMA-J AM MED ASSOC, V260, P2542, DOI 10.1001/jama.260.17.2542; SURMAN OS, 1989, AM J PSYCHIAT, V146, P972; THORESON RW, 1987, TREATMENT PREVENTION, P157; THUROW LC, 1984, NEW ENGL J MED, V311, P1569, DOI 10.1056/NEJM198412133112410; WELCH HG, 1988, NEW ENGL J MED, V319, P171, DOI 10.1056/NEJM198807213190310; WINSLOW GR, 1982, TRIAGE JUSTICE, P39; 1990, ASSESSMENT LIVER TRA, V3, P25; 1987, MAKING DIFFICULT HLT, P73; 1990, 901656 US DEP HLTH H; 1986, ORGAN TRANSPLANTATIO, P9; 1990, FED REGISTER, V55, P3545	43	157	158	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1295	1298		10.1001/jama.265.10.1295	http://dx.doi.org/10.1001/jama.265.10.1295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995977				2022-12-24	WOS:A1991FA51100026
J	RAUB, W				RAUB, W			NEW DRUG AMELIORATES EFFECTS OF ASTHMA AND ALLERGIC RHINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, NEW ENGL J MED, V323, P1745; 1990, NEW ENGL J MED, V323, P1740	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-24	WOS:A1991EZ47400007
J	ANDERSEN, IB; SORENSEN, TIA; PRENER, A				ANDERSEN, IB; SORENSEN, TIA; PRENER, A			INCREASE IN INCIDENCE OF DISEASE DUE TO DIAGNOSTIC DRIFT - PRIMARY LIVER-CANCER IN DENMARK, 1943-85	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the extent to which changes in diagnostic methods and classification are responsible for the striking increase in incidence of primary liver cancer in Denmark since 1943. Design-Analysis of the time trends in sex specific, age standardised incidence of primary liver cancer and unspecified liver cancer (either secondary without known primary cancer or not specified as primary cancer) in the entire population from 1943 to 1985. By review of the 727 notifications from three periods of 5 years (1948-52, 1963-7, and 1978-82) the changes in histological diagnosis and classification were assessed. Setting-Denmark. Subjects-Notifications of liver cancer to the Danish cancer registry. Results-Concomitant with the increase in primary liver cancer, the incidence of the unspecified liver cancer declined. The proportion of histologically diagnosed primary liver cancer rose from 85% to 98%, whereas the proportion for unspecified liver cancer rose from 12% to 51%. When the proportion of primary versus unspecified liver cancer obtained by histological diagnosis was extrapolated to all cases, the annual incidence of primary liver cancer was 4.4 rather than 1.6 per 100 000 population in 1948-52 and 6.0 rather than 5.5 per 100 000 in 1978-82. Conclusion-The increase in the incidence of primary liver cancer may be much smaller than the numbers of registered cases indicate. This example emphasises the need to consider diagnostic drift in time trend studies of disease incidence.	HVIDOVRE UNIV HOSP,DEPT MED,DIV HEPATOL,DK-2650 COPENHAGEN,DENMARK; DANISH CANC SOC,DANISH CANC REGISTRY,COPENHAGEN,DENMARK	University of Copenhagen; Danish Cancer Society								[Anonymous], 1976, INT CLASSIFICATION D; BASSENDINE MF, 1987, BAILLIERE CLIN GASTR, V1, P1, DOI 10.1016/0950-3528(87)90031-5; FABER M, 1979, ENVIRON RES, V18, P37, DOI 10.1016/0013-9351(79)90135-X; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HARDELL L, 1984, BRIT J CANCER, V50, P389, DOI 10.1038/bjc.1984.188; JENSEN OM, 1980, CANCER MORBIDITY CAU; KEW MC, 1987, LANCET, V2, P1183; OLSEN JH, 1988, BRIT J CANCER, V58, P392, DOI 10.1038/bjc.1988.226; PRYTZ H, 1981, SCAND J GASTROENTERO, V16, P833; SARACCI R, 1980, J NATL CANCER I, V65, P241; Storm H H, 1986, Ugeskr Laeger, V148, P1110; STORM HH, 1989, CANCER INCIDENCE DEN; TUYNS AJ, 1975, J NATL CANCER I, V54, P61, DOI 10.1093/jnci/54.1.61; WATERHOUSE J, 1982, INT AGENCY RES CANCE, V42; 1957, MANUAL INT STATISTIC; 1986, STATISTICAL YB 1986, P171; 1983, LANCET, V1, P463	17	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					437	440		10.1136/bmj.302.6774.437	http://dx.doi.org/10.1136/bmj.302.6774.437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004170	Green Published, Bronze			2022-12-24	WOS:A1991EZ03300019
J	NELSON, DE				NELSON, DE			A NEW METHOD FOR CARBON ISOTOPIC ANALYSIS OF PROTEIN	SCIENCE			English	Article							ACCELERATOR MASS-SPECTROMETRY; BONE-COLLAGEN; RADIOCARBON; RATIOS; MARINE; C-13	The reaction of ninhydrin with amino acids can be used in carbon isotopic studies of protein. The reaction can be applied to extract as carbon dioxide only peptide-bonded carbon in proteinaceous material, thus avoiding most, if not all, contaminants. Test radiocarbon dates on ancient bone indicate that the method provides reliable ages, and stable carbon isotopic data suggest that our understanding of isotopic dietary reconstruction needs detailed examination. The technique should also be useful in biochemical tracing experiments and in global carbon budget studies, and the underlying principle may be applicable to other isotopes and molecules.	UNIV CALIF LAWRENCE LIVERMORE NATL LAB,CTR ACCELERATOR MASS SPECT,LIVERMORE,CA 94550	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System								BROWN TA, 1988, RADIOCARBON, V30, P171, DOI 10.1017/S0033822200044118; CHISHOLM BS, 1982, SCIENCE, V216, P1131, DOI 10.1126/science.216.4550.1131; DENIRO MJ, 1985, NATURE, V317, P806, DOI 10.1038/317806a0; GILLESPIE R, 1984, J ARCHAEOL SCI, V11, P165, DOI 10.1016/0305-4403(84)90051-7; HARE PE, 1983, CARNEGIE I WASHINGTO, V82, P410; Hedges R.E.M., 1980, P35; HOWE EE, 1951, AMINO ACIDS PROTEINS, P30; LEHNINGER AL, 1978, BIOCHEMISTRY-US, P85; LOGIN R, 1971, NATURE, V320, P241; LOVELL NC, 1986, ARCHAEOMETRY, V28, P51, DOI 10.1111/j.1475-4754.1986.tb00373.x; LOY TH, 1990, ANTIQUITY, V64, P110, DOI 10.1017/S0003598X00077346; Morlan R.E., 1990, CANADIAN J ARCHAEOLO, V14, P75; NELSON DE, 1986, RADIOCARBON, V28, P170, DOI 10.1017/S0033822200060082; NELSON DL, COMMUNICATION; NELSON DR, UNPUB; SCHOENINGER MJ, 1984, GEOCHIM COSMOCHIM AC, V48, P625, DOI 10.1016/0016-7037(84)90091-7; SOUTHON JR, IN PRESS NUCL INSTRU; STAFFORD TW, 1988, GEOCHIM COSMOCHIM AC, V52, P2257, DOI 10.1016/0016-7037(88)90128-7; STAFFORD TW, 1987, RADIOCARBON, V29, P24; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Van SLYKE DONALD D., 1941, JOUR BIOL CHEM, V141, P627; Van SLYKE DONALD D., 1941, JOUR BIOL CHEM, V141, P671; VANDERMERWE NJ, 1978, NATURE, V276, P815, DOI 10.1038/276815a0; VANKLINKEN GJ, 1990, RADIOCARBON, V32, P155, DOI 10.1017/S0033822200040157; VOGEL JS, 1987, RADIOCARBON, V29, P323; VOGEL JS, IN PRESS NUCL INSTRU; WILLIAMS PM, 1987, NATURE, V330, P246, DOI 10.1038/330246a0	27	54	54	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					552	554		10.1126/science.1990430	http://dx.doi.org/10.1126/science.1990430			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990430				2022-12-24	WOS:A1991EV45900048
J	BROEK, D; BARTLETT, R; CRAWFORD, K; NURSE, P				BROEK, D; BARTLETT, R; CRAWFORD, K; NURSE, P			INVOLVEMENT OF P34CDC2 IN ESTABLISHING THE DEPENDENCY OF S-PHASE ON MITOSIS	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; CELL-DIVISION CYCLE; FISSION YEAST; PROTEIN-KINASE; DNA-REPLICATION; TYROSINE PHOSPHORYLATION; CHROMOSOME CONDENSATION; COLORIMETRIC METHOD; MOLECULAR-CLONING; MITOTIC CONTROL	Mutants of cdc2+ can disrupt the dependency of S phase on completion of the previous mitosis. By changing the state of p34cdc2 it is possible to reprogramme a cell from entering mitosis to undergoing S phase. This leads to the proposal that the cell cycle can be considered a p34cdc2 cycle, and has implications for the evolution of life cycles.	UNIV OXFORD,IMPERIAL CANC RES FUND,DEPT BIOCHEM,MICROBIOL UNIT,OXFORD OX1 3QU,ENGLAND	University of Oxford								BARTLETT R, 1990, BIOESSAYS, V10, P457; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BEERMANN W, 1972, DEV STUDIES GIANT CH, P1; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BOSTOCK CJ, 1970, EXP CELL RES, V60, P16, DOI 10.1016/0014-4827(70)90484-2; BREWER EN, 1968, EXP CELL RES, V49, P79, DOI 10.1016/0014-4827(68)90521-1; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Crandall M, 1977, Adv Microb Physiol, V15, P307, DOI 10.1016/S0065-2911(08)60319-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; EGEL R, 1973, MOL GEN GENET, V122, P339, DOI 10.1007/BF00269434; Egel R., 1989, MOL BIOL FISSION YEA, P31; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GENDIMENICO GJ, 1988, ANAL BIOCHEM, V173, P45, DOI 10.1016/0003-2697(88)90156-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAGAN I, 1988, J CELL SCI, V91, P587; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KAI R, 1986, MOL CELL BIOL, V6, P2027, DOI 10.1128/MCB.6.6.2027; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KOHLI J, 1977, GENETICS, V87, P471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Mitchison J.M., 1971, BIOLOGY CELL CYCLE, P201; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORENO S, 1990, METHOD ENZYMOL, V194, P793; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBERTS J, 1988, CELL, V452, P397; ROMAN H, 1955, GENETICS, V40, P546; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAZER S, 1990, J CELL SCI, V97, P509; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SLUDER G, 1986, J EXP ZOOL, V238, P325, DOI 10.1002/jez.1402380307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	59	325	330	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					388	393		10.1038/349388a0	http://dx.doi.org/10.1038/349388a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992340				2022-12-24	WOS:A1991EV51400040
J	ADAMS, S				ADAMS, S			PRESCRIBING OF PSYCHOTROPIC-DRUGS TO CHILDREN AND ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article									SOUTHAMPTON ROTAT TRAINING SCHEME,ADOLESCENT UNIT,SOUTHAMPTON,ENGLAND									Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; RAPOPORT JL, 1983, DEV NEUROPSYCHIATRY, P385; SHAFFER D, 1968, ARCH DIS CHILD, V43, P665, DOI 10.1136/adc.43.232.665; STEINBERG D, 1985, CHILD ADOLESCENT PSY, P567; VARANKA TM, 1988, AM J PSYCHIAT, V145, P1557	5	26	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					217	217		10.1136/bmj.302.6770.217	http://dx.doi.org/10.1136/bmj.302.6770.217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV228	1998763	Green Published, Bronze			2022-12-24	WOS:A1991EV22800027
J	LIANG, TJ; HASEGAWA, K; RIMON, N; WANDS, JR; BENPORATH, E				LIANG, TJ; HASEGAWA, K; RIMON, N; WANDS, JR; BENPORATH, E			A HEPATITIS-B VIRUS MUTANT ASSOCIATED WITH AN EPIDEMIC OF FULMINANT-HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							E-ANTIGEN; PRECORE REGION; CORE ANTIGEN; NON-A; GENOME; LIVER; HBE; DNA; IDENTIFICATION; REPLICATION	Background. A nosocomial outbreak of fulminant hepatitis B occurred in five patients in Haifa, Israel. Previous investigations identified the suspected source as a carrier of hepatitis B surface antigen who was positive for antibodies to hepatitis B e antigen and had chronic liver disease. We examined the strain of hepatitis B virus (HBV) that caused this epidemic, in order to identify specific mutations in the precore or core region. Methods. The presence of HBV was identified by polymerase-chain-reaction amplification of viral DNA in serum from the source patient, the five patients with fulminant hepatitis B, and five controls with acute, self-limited hepatitis B. The amplified viral HBV DNA samples were then cloned and sequenced. Results. Sequence analysis of viral DNA established that the same HBV mutant with two mutations in the precore region was present in the source patient and the five patients with fulminant hepatic failure. This HBV mutant had significant sequence divergence from other known HBV subtypes in the X, precore, and core regions. Cloned HBV DNA derived from a hospitalized patient who had subclinical hepatitis B at the same time as the outbreak and from four other control subjects with acute, self-limited hepatitis B all contained the wild-type sequence in the precore region. Conclusions. In the outbreak we studied, a mutant hepatitis B viral strain was transmitted from a common source to five patients who subsequently died of fulminant hepatitis B infection. Naturally occurring viral mutations in the HBV genome may predispose the infected host to more severe liver injury.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114; TECHNION ISRAEL INST TECHNOL,RAMBAM MED CTR,FAC MED,VIROL LAB,HAIFA,ISRAEL	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	LIANG, TJ (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,149 13TH ST,7TH FL,BOSTON,MA 02114, USA.				NCI NIH HHS [CA-35711] Funding Source: Medline; NIAAA NIH HHS [AA-08169, AA-02666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035711, R01CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008169, R37AA002666, R01AA002666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BARKER LF, 1972, AM J MED SCI, V263, P27, DOI 10.1097/00000441-197201000-00005; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BLUM HE, 1990, IN PRESS VIRAL HEPAT; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; BRUNETTO MR, 1990, J HEPATOL, V10, P258, DOI 10.1016/0168-8278(90)90062-V; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1990, 1990 INT S VIR HEP L; CHANG C, 1987, J VIROL, V61, P3322, DOI 10.1128/JVI.61.10.3322-3325.1987; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DECOCK KM, 1986, ANN INTERN MED, V105, P546, DOI 10.7326/0003-4819-105-4-546; DELAPLANE D, 1983, PEDIATRICS, V72, P176; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GIRONES R, 1989, VIROLOGY, V170, P595, DOI 10.1016/0042-6822(89)90455-8; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; LIANG TJ, 1989, J CLIN INVEST, V84, P1367, DOI 10.1172/JCI114308; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MIYAZAKI K, 1990, 1990 M JAP ASS STUD; MONDELLI M, 1984, SEMIN LIVER DIS, V4, P47, DOI 10.1055/s-2008-1040645; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; SALFELD J, 1989, J VIROL, V63, P798, DOI 10.1128/JVI.63.2.798-808.1989; SARACCO G, 1988, ANN INTERN MED, V108, P380, DOI 10.7326/0003-4819-108-3-380; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOKITA M, 1990, 1990 M JAP ASS STUD; TONG SP, 1990, VIROLOGY, V176, P596, DOI 10.1016/0042-6822(90)90030-U; YOAKUM GH, 1983, SCIENCE, V222, P385, DOI 10.1126/science.6194563; 1984, MMWR, V33, P70; 1984, MMWR, V33, P76; 1979, MMWR, V28, P373	38	429	441	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1705	1709		10.1056/NEJM199106133242405	http://dx.doi.org/10.1056/NEJM199106133242405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034247				2022-12-24	WOS:A1991FQ15500005
J	OMATA, M; EHATA, T; YOKOSUKA, O; HOSODA, K; OHTO, M				OMATA, M; EHATA, T; YOKOSUKA, O; HOSODA, K; OHTO, M			MUTATIONS IN THE PRECORE REGION OF HEPATITIS-B VIRUS-DNA IN PATIENTS WITH FULMINANT AND SEVERE HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; POLYMERASE CHAIN-REACTION; CHRONIC LIVER-DISEASE; PRE-C REGION; E-ANTIGEN; SUBTYPE-ADR; ESCHERICHIA-COLI; CORE PROTEIN; SERUM; ANTIBODY	Background. The presence of the hepatitis B e antigen (HBeAg) in serum is known to be a marker of a high degree of viral infectivity. However, fulminant hepatitis may occur in persons who are negative for HBeAg. A single point mutation has been reported to produce a stop codon in the precore region of hepatitis B virus DNA and prevent the formation of the precore protein required to make HBeAg. To determine whether a precore-mutant virus is causally related to severe liver injury, we analyzed the entire precore region in viral strains isolated from patients with fatal cases and uncomplicated cases of hepatitis B. Methods. Serum was obtained from 9 patients with fatal hepatitis B(5 with fulminant and 4 with severe exacerbations of chronic hepatitis) and 10 patients with acute, self-limited hepatitis B. Serum samples from a sex partner implicated as the source of the virus in one case of fulminant hepatitis were also studied. The 87 nucleotides in the precore region of the hepatitis B virus were amplified by the polymerase chain reaction and then directly sequenced. Results. Of the nine patients with fatal hepatitis, seven had retrievable hepatitis B DNA. In all seven there was a point mutation from G to A at nucleotide 1896 of the precore region, converting tryptophan (TGG) to a stop codon (TAG). In contrast, this mutation was not found in the 10 patients with acute, self-limited hepatitis B. The hepatitis B DNA from the implicated source contained a sequence with the stop-codon mutation that was identical to the sequence in her partner, who had fulminant hepatitis. Conclusions. The presence of a mutant viral strain is associated with and may be involved in the pathogenesis of fulminant hepatitis B and severe exacerbations of chronic hepatitis.			OMATA, M (corresponding author), CHIBA UNIV,SCH MED,DEPT MED 1,1-8-1 INOHANA,CHIBA 280,JAPAN.							BICHKO V, 1985, FEBS LETT, V185, P208, DOI 10.1016/0014-5793(85)80771-7; BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151; CARMAN WF, 1989, LANCET, V2, P588; CHANG MH, 1987, J PEDIATR-US, V111, P34, DOI 10.1016/S0022-3476(87)80338-4; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; FAGAN EA, 1986, LANCET, V2, P538, DOI 10.1016/S0140-6736(86)90112-1; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; HADZIYANNIS SJ, 1983, HEPATOLOGY, V3, P656; HOOFNAGLE JH, 1983, GASTROENTEROLOGY, V84, P422; IMAZEKI F, 1985, HEPATOLOGY, V5, P783, DOI 10.1002/hep.1840050513; KATO N, 1990, J CLIN INVEST, V86, P1764, DOI 10.1172/JCI114903; KOBAYASHI M, 1984, GENE, V30, P227; KROGSGAARD K, 1986, J INFECT DIS, V153, P298, DOI 10.1093/infdis/153.2.298; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; MATSUYAMA Y, 1985, GASTROENTEROLOGY, V89, P1104, DOI 10.1016/0016-5085(85)90216-1; OKAMOTO H, 1988, J GEN VIROL, V69, P2575, DOI 10.1099/0022-1317-69-10-2575; OKAMOTO H, 1990, J VIROL, V64, P1298, DOI 10.1128/JVI.64.3.1298-1303.1990; OKAMOTO H, 1986, J GEN VIROL, V67, P2305, DOI 10.1099/0022-1317-67-11-2305; OKUDA K, 1987, HEPATOLOGY, V7, P974; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; ROOSSINCK MJ, 1986, MOL CELL BIOL, V6, P1393, DOI 10.1128/MCB.6.5.1393; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLICHT HJ, 1989, J VIROL, V63, P5399, DOI 10.1128/JVI.63.12.5399-5404.1989; SCHLICHT HJ, 1987, J VIROL, V61, P3701, DOI 10.1128/JVI.61.12.3701-3709.1987; SHIRAKI K, 1980, J PEDIATR-US, V97, P768, DOI 10.1016/S0022-3476(80)80261-7; TADA M, 1990, CANCER RES, V50, P1121; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TONG SP, 1990, VIROLOGY, V176, P596, DOI 10.1016/0042-6822(90)90030-U; TREPO CG, 1976, GUT, V17, P10, DOI 10.1136/gut.17.1.10; UY A, 1986, VIROLOGY, V155, P89, DOI 10.1016/0042-6822(86)90170-4; VALENZUELA P, 1980, ICN UCLA S MOL CELLU, V18, P57; VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383; VENTO S, 1985, HEPATOLOGY, V5, P192, DOI 10.1002/hep.1840050206; YOKOSUKA O, 1986, NEW ENGL J MED, V315, P1187, DOI 10.1056/NEJM198611063151903	40	482	494	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1991	324	24					1699	1704		10.1056/NEJM199106133242404	http://dx.doi.org/10.1056/NEJM199106133242404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ155	2034246				2022-12-24	WOS:A1991FQ15500004
J	ELLIOTT, T; CERUNDOLO, V; ELVIN, J; TOWNSEND, A				ELLIOTT, T; CERUNDOLO, V; ELVIN, J; TOWNSEND, A			PEPTIDE-INDUCED CONFORMATIONAL CHANGE OF THE CLASS-I HEAVY-CHAIN	NATURE			English	Article							TOXIC LYMPHOCYTES-T; INFLUENZA-A VIRUS; HLA-B ANTIGENS; SURFACE EXPRESSION; SYNTHETIC PEPTIDES; VIRAL PEPTIDES; NUCLEOPROTEIN; MOLECULES; BETA-2-MICROGLOBULIN; INVITRO	THERE is evidence that peptide ligands take part in the assembly of class I molecules 1-8. In particular, addition of peptides to extracts of the mutant cells RMA-S and .174/T2, in which stable assembly of class I does not occur 9-11, results in a conformational change in the class I heavy chain and stable association of the heavy chain with beta-2-microglobulin (beta-2m) (refs 1-3). Thus specific peptides may stabilize or induce a conformational change in the class I heavy chain that results in a rise in the binding affinity of the heavy chain for beta-2m (Fig. 1a). Here we show that peptides have two cooperative roles in class I assembly. Specific short peptides (9-10 amino acids) can induce folding of the heavy chain in the absence of beta-2m. Both short (nine amino acids) and longer sequences (15 amino acids) can stabilize performed low-affinity complexes of heavy chain and beta-2m. To alter the conformation of free heavy chains, the peptides must be exactly the correct size, and they are found to correspond to the sequences isolated from infected cells 12. This property may therefore be the basis for selection of epitopes presented in vivo.			ELLIOTT, T (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.			Cerundolo, Vincenzo/0000-0003-0040-3793; Townsend, Alain/0000-0002-3702-0107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, IN PRESS EUR J IMMUN; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; HUDDLESTON JA, 1982, NUCLEIC ACIDS RES, V10, P1029, DOI 10.1093/nar/10.3.1029; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; OZATO K, 1981, J IMMUNOL, V126, P317; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796	19	246	252	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					402	406		10.1038/351402a0	http://dx.doi.org/10.1038/351402a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034289				2022-12-24	WOS:A1991FN85600057
J	SOKOL, S; MELTON, DA				SOKOL, S; MELTON, DA			PREEXISTENT PATTERN IN XENOPUS ANIMAL POLE CELLS REVEALED BY INDUCTION WITH ACTIVIN	NATURE			English	Article							NEURAL INDUCTION; LAEVIS; MESODERM; EMBRYOS; AXIS; DIFFERENTIATION; GASTRULATION; HOMOLOG; SIGNALS; MARKER	ACTIVIN, a peptide growth factor related to tumour growth factor-beta, has been implicated in early inductive interactions in vertebrates 1-4 and can induce Xenopus blastula ectodermal explants to develop a rudimentary axial pattern with anteroposterior and dorsoventral polarity 4, 5. Here we demonstrate that prospective dorsal and ventral regions of the ectoderm respond differently to the same concentration of activin. Thus, activin does not seem to endow ectodermal cells with polarity but rather reveals a pre-existent pattern. Our results suggest that patterning of mesoderm is determined not only by a localized inducer, but also by the differential competence of cells in the responding tissue.			SOKOL, S (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Sokol, Sergei/0000-0002-3963-9202				ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; DALE L, 1987, DEVELOPMENT, V100, P279; DIXON JE, 1989, DEVELOPMENT, V106, P749; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NAKAMURA O, 1978, ORG MILESTONE HALF C, P179; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V163, P298, DOI 10.1007/BF00577017; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H., 1938, EMBRYONIC DEV INDUCT; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0	20	189	192	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					409	411		10.1038/351409a0	http://dx.doi.org/10.1038/351409a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034291				2022-12-24	WOS:A1991FN85600059
J	LAW, MR; FROST, CD; WALD, NJ				LAW, MR; FROST, CD; WALD, NJ			BY HOW MUCH DOES DIETARY SALT REDUCTION LOWER BLOOD-PRESSURE .1. ANALYSIS OF OBSERVATIONAL DATA AMONG POPULATIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SODIUM-INTAKE; 24-HOUR EXCRETION; RISK-FACTORS; HYPERTENSION; POTASSIUM; CULTURE; DISEASE; BELGIUM; CATIONS; MILTON	Objective-To estimate the quantitative relation between blood pressure and sodium intake. Design-Data were analysed from published reports of blood pressure and sodium intake for 24 different communities (47 000 people) throughout the world. Main outcome measure-Difference in blood pressure for a 100 mmol/24 h difference in sodium intake. Allowance was made for differences in blood pressure between economically developed and undeveloped communities to minimise overestimation of the association through confounding with other determinants of blood pressure. Results-Blood pressure was higher on average in the developed communities, but the association with sodium intake was similar in both types of community. A difference in sodium intake of 100 mmol/24 h was associated with an average difference in systolic blood pressure that ranged from 5 mm Hg at age 15-19 years to 10 mm Hg at age 60-69. The differences in diastolic blood pressure were about half as great. The standard deviation of blood pressure increased with sodium intake implying that the association of blood pressure with sodium intake in individuals was related to the initial blood pressure-the higher the blood pressure the greater the expected reduction in blood pressure for the same reduction in sodium intake. For example, at age 60-69 the estimated systolic blood pressure reduction in response to a 100 mmol/24 h reduction in sodium intake was on average 10 mm Hg but varied from 6 mm Hg for those on the fifth blood pressure centile to 15 mm Hg for those on the 95th centile. Conclusions-The association of blood pressure with sodium intake is substantially larger than is generally appreciated and increases with age and initial blood pressure.			LAW, MR (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					BAILEY K V, 1961, Trop Geogr Med, V13, P216; BAILEY KV, 1963, BRIT MED J, P775, DOI 10.1136/bmj.2.5360.775; BARNES R, 1965, Med J Aust, V1, P611; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; DAWBER THOMAS R., 1967, P255; ELLIOTT P, 1988, BRIT MED J, V297, P319; FODOR JG, 1980, EPIDEMIOLOGY ARTERIA, P353; FROMENT A, 1979, REV EPIDEMIOL SANTE, V27, P437; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GILLUM RF, 1979, HYPERTENSION, V1, P468, DOI 10.1161/01.HYP.1.5.468; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GRIM CE, 1980, J CHRON DIS, V33, P87, DOI 10.1016/0021-9681(80)90032-6; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; KESTELOOT H, 1980, EUR J CARDIOL, V11, P169; KESTELOOT H, 1987, HYPERTENSION, V9, P654, DOI 10.1161/01.HYP.9.6.654; KESTELOOT H, 1984, ANN CLIN RES, V16, P72; KOMACHI Y, 1971, JPN CIRCULATION J, V35, P189, DOI 10.1253/jcj.35.189; KURTZ TW, 1987, NEW ENGL J MED, V317, P1043, DOI 10.1056/NEJM198710223171702; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LEE MR, 1986, BMJ-BRIT MED J, V293, P266, DOI 10.1136/bmj.293.6541.266-b; LOWENSTEIN F, 1961, LANCET, V1, P389; LUFT FC, 1988, J CARDIOVASC PHARM, V12, pS49; MADDOCKS I., 1965, Papua and New Guinea Medical Journal, V8, P17; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MORSE WR, 1937, LANCET, V1, P966; MOSER M, 1959, AM J CARDIOL, V4, P727, DOI 10.1016/0002-9149(59)90122-5; OLIVER WJ, 1975, CIRCULATION, V52, P146, DOI 10.1161/01.CIR.52.1.146; PAGE LB, 1974, CIRCULATION, V49, P1132, DOI 10.1161/01.CIR.49.6.1132; PAGE LB, 1981, AM J CLIN NUTR, V34, P527, DOI 10.1093/ajcn/34.4.527; PRIOR IAM, 1968, NEW ENGL J MED, V279, P515, DOI 10.1056/NEJM196809052791004; SASAKI N, 1962, JPN HEART J, V3, P313; SCHNECKLOTH RE, 1962, AM HEART J, V63, P607, DOI 10.1016/0002-8703(62)90005-4; SIMMONS D, 1986, J EPIDEMIOL COMMUN H, V40, P188, DOI 10.1136/jech.40.2.188; SIMPSON FO, 1978, NEW ZEAL MED J, V87, P379; SIMPSON FO, 1982, NEW ZEAL MED J, V95, P873; STAESSEN J, 1981, J EPIDEMIOL COMMUN H, V35, P256, DOI 10.1136/jech.35.4.256; STAMLER J, 1976, JAMA-J AM MED ASSOC, V235, P2299, DOI 10.1001/jama.235.21.2299; TSENG WP, 1967, AM J EPIDEMIOL, V86, P513, DOI 10.1093/oxfordjournals.aje.a120762; TUOMILEHTO J, 1981, ACTA CARDIOL, V36, P83; 1989, J HUMAN HYPERTENSION, V3, P279	41	339	345	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1991	302	6780					811	815		10.1136/bmj.302.6780.811	http://dx.doi.org/10.1136/bmj.302.6780.811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025703	Bronze, Green Published			2022-12-24	WOS:A1991FF37700020
J	SPEAKMAN, JR; RACEY, PA				SPEAKMAN, JR; RACEY, PA			NO COST OF ECHOLOCATION FOR BATS IN FLIGHT	NATURE			English	Article							PTEROPUS-GOULDII; GAS-EXCHANGE; METABOLISM; PHYSIOLOGY	ECHOLOCATION has evolved in relatively few animal species 1. One constraint may be the high cost of producing pulses, the echoes of which can be detected over useful distances 2. The energy cost of echolocation in a small (6 g) insectivorous bat, when hanging at rest, was recently measured at 0.067 Joules per pulse 3, implying a mean cost for echolocation in flight of 9.5 x basal metabolic rate (range 7 to 12x). Because flight is very costly 4, whether the costs of echolocation and flying are additive is an important question. We measured the energy costs of flight in two species of small echolocating Microchiroptera using a novel combination of respirometry and doubly-labelled water 5. Flight energy expenditure (adjusted for body mass) was not significantly different between echolocating bats and non-echolocating bats and birds. The low cost of echolocation for flying vertebrates may have been a significant factor favouring its evolution in these groups.			SPEAKMAN, JR (corresponding author), UNIV ABERDEEN,DEPT ZOOL,ABERDEEN AB9 2TN,SCOTLAND.		Speakman, John R./A-9494-2008	Speakman, John R./0000-0002-2457-1823				BERNSTEIN MH, 1973, J EXP BIOL, V58, P401; BUTLER PJ, 1977, J EXP BIOL, V77, P7; CARPENTER RE, 1985, J EXP BIOL, V114, P619; CARPENTER RE, 1986, J EXP BIOL, V120, P79; COLLINS BG, 1978, PHYSL ZOOL, V52, P165; DAWKINS R, 1908, BIND WATCHMAKER; FLINT EN, 1984, AUK, V101, P288, DOI 10.1093/auk/101.2.288; GESSAMAN JA, 1980, COMP BIOCHEM PHYS A, V65, P273, DOI 10.1016/0300-9629(80)90030-4; GESSAMAN JA, 1988, CONDOR, V90, P662, DOI 10.2307/1368356; GESSAMAN JA, 1988, PHYSIOL ZOOL, V61, P507, DOI 10.1086/physzool.61.6.30156159; GOULD E, 1964, J EXP ZOOL, V156, P19, DOI 10.1002/jez.1401560103; HEALY S, 1990, EVOLUTION, V44, P339, DOI 10.1111/j.1558-5646.1990.tb05203.x; HUDSON DM, 1973, J EXP BIOL, V103, P121; LE FEBVRE EUGENE A., 1964, AUK, V81, P403; LIFSON N, 1966, J THEOR BIOL, V12, P46, DOI 10.1016/0022-5193(66)90185-8; MASMAN D, 1984, THESIS U GRONINGEN; NACTIGALL PE, 1988, ANIMAL SONAR PROCESS; PETTIGREW JD, 1986, SCIENCE, V231, P1304, DOI 10.1126/science.3945827; Racey PA, 1987, S ZOOL SOC LOND, V57, P107; ROTHE HJ, 1987, J COMP PHYSIOL B, V157, P99, DOI 10.1007/BF00702734; SPEAKMAN JR, 1988, PHYSIOL ZOOL, V61, P514, DOI 10.1086/physzool.61.6.30156160; SPEAKMAN JR, 1989, J COMP PHYSIOL A, V165, P679, DOI 10.1007/BF00610999; THOMAS SP, 1981, J EXP BIOL, V94, P231; THOMAS SP, 1975, J EXP BIOL, V63, P273; TORREBUENO JR, 1978, J EXP BIOL, V75, P223; TUCKER VA, 1972, AM J PHYSIOL, V222, P237, DOI 10.1152/ajplegacy.1972.222.2.237; TUCKER VA, 1968, J EXP BIOL, V48, P67; [No title captured]	28	175	178	3	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					421	423		10.1038/350421a0	http://dx.doi.org/10.1038/350421a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011191				2022-12-24	WOS:A1991FF04200049
J	MORROW, JD; MARGOLIES, GR; ROWLAND, J; ROBERTS, LJ				MORROW, JD; MARGOLIES, GR; ROWLAND, J; ROBERTS, LJ			EVIDENCE THAT HISTAMINE IS THE CAUSATIVE TOXIN OF SCOMBROID-FISH POISONING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN MAST-CELLS; PROSTAGLANDIN-D2; RELEASE; SYMPTOMS; INVIVO; ACID; RAT	Background. The highest morbidity world-wide from fish poisoning results from the ingestion of spoiled scombroid fish, such as tuna and mackerel, and its cause is not clear. Histamine could be responsible, because spoiled scombroid fish contain large quantities of histamine. Whether histamine is the causative toxin, however, has remained in question. To address this issue, we investigated whether histamine homeostasis is altered in poisoned people. Methods. The urinary excretion of histamine and its metabolite, N-methylhistamine, was measured in three persons who had scombroid-fish poisoning (scombrotoxism) after the ingestion of marlin. We measured 9-alpha, 11-beta-dihydroxy-15-oxo-2,3,18,19-tetranorprost-5-ene-1,20-dioic acid (PGD-M), the principal metabolite of prostaglandin D2, a mast-cell secretory product, to assess whether mast cells had been activated to release histamine. Results. The fish contained high levels of histamine (842 to 2503-mu-mol per 100 g of tissue). Symptoms of scombrotoxism - flushing and headache - began 10 to 30 minutes after the ingestion of fish. In urine samples collected one to four hours after fish ingestion, the levels of histamine and N-methylhistamine were 9 to 20 times and 15 to 20 times the normal mean, respectively. During the subsequent 24 hours, the levels fell to 4 to 15 times and 4 to 11 times the normal values. Levels of both were normal 14 days later. PGD-M excretion was not increased at any time. Two persons treated with diphenhydramine had prompt amelioration of symptoms. Conclusions. Scombroid-fish poisoning is associated with urinary excretion of histamine in quantities far exceeding those required to produce toxicity. The histamine is most likely derived from the spoiled fish. These results identify histamine as the toxin responsible for scombroid-fish poisoning.	VANDERBILT UNIV, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; NASHVILLE DAVIDSON CTY METROPOLITAN BOARD HLTH, DIV FOOD INSPECT, NASHVILLE, TN USA; VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NHLBI NIH HHS [HL-02499] Funding Source: Medline; NIGMS NIH HHS [GM-33040, GM-15431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033040, P50GM015431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARZUBIAGA C, IN PRESS J ALLERGY C; BAGNIS R, 1970, B WORLD HEALTH ORGAN, V42, P69; Bean N H, 1990, MMWR CDC Surveill Summ, V39, P15; BLAKESLEY ML, 1983, ANN EMERG MED, V12, P104, DOI 10.1016/S0196-0644(83)80386-2; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHURCH MK, 1989, INT ARCH ALLER A IMM, V88, P70, DOI 10.1159/000234752; DICKINSON G, 1982, ANN EMERG MED, V11, P487, DOI 10.1016/S0196-0644(82)80069-3; GRANERUS G, 1968, SCAND J CLIN LAB INV, VS 22, P49; HUGHES JM, 1976, NEW ENGL J MED, V295, P1117, DOI 10.1056/NEJM197611112952006; HUI JY, 1985, TOXICOL APPL PHARM, V81, P241, DOI 10.1016/0041-008X(85)90160-7; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; LERKE PA, 1978, WESTERN J MED, V129, P381; LEVISCHAFFER F, 1989, INT ARCH ALLER A IMM, V90, P352, DOI 10.1159/000235052; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LUKTON A., 1958, FOOD RES, V23, P611, DOI 10.1111/j.1365-2621.1958.tb17612.x; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MORROW JD, 1989, PROSTAGLANDINS, V38, P263, DOI 10.1016/0090-6980(89)90088-9; MORROW JD, IN PRESS ANAL BIOCH; MURPHY RC, 1982, METHOD ENZYMOL, V86, P547; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OTIL KJ, 1979, TOXICOL LETT, V3, P219; PRAKASH C, 1988, J CHEM SOC PERK T 1, P2821, DOI 10.1039/p19880002821; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; ROBERTS LJ, 1984, ANAL BIOCHEM, V136, P258, DOI 10.1016/0003-2697(84)90333-6; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; TAYLOR SL, 1986, CRC CR REV TOXICOL, V17, P91, DOI 10.3109/10408448609023767; TAYLOR SL, 1989, J TOXICOL-CLIN TOXIC, V27, P225, DOI 10.3109/15563658908994420; Weiss S, 1932, ARCH INTERN MED, V49, P360, DOI 10.1001/archinte.1932.00150100017002; WILLIAMS S, 1984, OFFICIAL METHODS ANA, P341; 1989, MMWR, V38, P140; 1982, FED REGISTER, V47, P40487	33	211	220	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					716	720		10.1056/NEJM199103143241102	http://dx.doi.org/10.1056/NEJM199103143241102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997836				2022-12-24	WOS:A1991FB55600002
J	BARGMANN, CI; HORVITZ, HR				BARGMANN, CI; HORVITZ, HR			CONTROL OF LARVAL DEVELOPMENT BY CHEMOSENSORY NEURONS IN CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							DAUER-INDUCING PHEROMONE; NERVOUS-SYSTEM; C-ELEGANS; CELL; MUTANTS; TEMPERATURE; GENETICS; FOOD	Larval development of the nematode Caenorhabditis elegans is controlled by the activities of four classes of chemosensory neurons. The choice between normal development and development into a specialized larval form called a dauer larva is regulated by competing environmental stimuli: food and a dauer pheromone. When the neuron classes ADF, ASG, ASI, and ASJ are killed, animals develop as dauer larvae regardless of environmental conditions. These neurons might sense food or dauer pheromone, or both, to initiate the specialized differentiation of many cell types that occurs during dauer formation. Entry into and exit from the dauer stage are primarily controlled by different chemosensory neurons. The analysis of mutants defective in dauer formation indicates that the chemosensory neurons are active in the absence of sensory inputs and that dauer pheromone inhibits the ability of these neurons to generate a signal necessary for normal development.			BARGMANN, CI (corresponding author), MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.			Bargmann, Cornelia/0000-0002-8484-0618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024663, R01GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARGMANN CI, UNPUB; BRENNER S, 1974, GENETICS, V77, P71; BROCKES JP, 1984, SCIENCE, V225, P1280, DOI 10.1126/science.6474177; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; Chappell L.H., 1982, P116; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Crisp D.J., 1974, pUnpaginated; GOLDEN JW, 1985, MOL GEN GENET, V198, P534, DOI 10.1007/BF00332953; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1984, J CHEM ECOL, V10, P1265, DOI 10.1007/BF00988553; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUBBELL WL, 1979, ANNU REV NEUROSCI, V2, P17, DOI 10.1146/annurev.ne.02.030179.000313; KIMURA K, 1990, J NEUROSCI, V10, P403; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; Maggenti A. R., 1981, GENERAL NEMATOLOGY; MELLON D, 1978, NATURE, V272, P246, DOI 10.1038/272246a0; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; TRUMAN JW, 1983, J COMP NEUROL, V216, P445, DOI 10.1002/cne.902160410; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Whitfield P.J., 1982, P34; ZALEWSKI AA, 1969, EXP NEUROL, V24, P285, DOI 10.1016/0014-4886(69)90022-3	38	326	349	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1243	1246		10.1126/science.2006412	http://dx.doi.org/10.1126/science.2006412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006412				2022-12-24	WOS:A1991FA69100045
J	ENGLISH, TL				ENGLISH, TL			SKEPTICAL OF SKEPTICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					964	964		10.1001/jama.265.8.964	http://dx.doi.org/10.1001/jama.265.8.964			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992204				2022-12-24	WOS:A1991EY43200007
J	MEISTER, M; WONG, ROL; BAYLOR, DA; SHATZ, CJ				MEISTER, M; WONG, ROL; BAYLOR, DA; SHATZ, CJ			SYNCHRONOUS BURSTS OF ACTION-POTENTIALS IN GANGLION-CELLS OF THE DEVELOPING MAMMALIAN RETINA	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; OCULAR DOMINANCE COLUMNS; CATS RETINOGENICULATE PATHWAY; RECEPTIVE-FIELD CHARACTERISTICS; PRENATAL DEVELOPMENT; FUNCTIONAL CONNECTIONS; VISUAL-CORTEX; RABBIT; TETRODOTOXIN; SEGREGATION	The development of orderly connections in the mammalian visual system depends on action potentials in the optic nerve fibers, even before the retina receives visual input. In particular, it has been suggested that correlated firing of retinal ganglion cells in the same eye directs the segregation of their synaptic terminals into eye-specific layers within the lateral geniculate nucleus. Such correlations in electrical activity were found by simultaneous recording of the extracellular action potentials of up to 100 ganglion cells in the isolated retina of the newborn ferret and the fetal cat. These neurons fired spikes in nearly synchronous bursts lasting a few seconds and separated by 1 to 2 minutes of silence. Individual bursts consisted of a wave of excitation, several hundred micrometers wide, sweeping across the retina at about 100 micrometers per second. These concerted firing patterns have the appropriate spatial and temporal properties to guide the refinement of connections between the retina and the lateral geniculate nucleus.			MEISTER, M (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT NEUROBIOL, STANFORD, CA 94305 USA.			Meister, Markus/0000-0003-2136-6506	NEI NIH HHS [EY 05750] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005750] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], [No title captured]; CUCCHIARO J, 1984, PROC R SOC SER B-BIO, V223, P141, DOI 10.1098/rspb.1984.0087; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GREINER JV, 1981, EXP EYE RES, V33, P315, DOI 10.1016/S0014-4835(81)80055-3; GUILLERY RW, 1972, J COMP NEUROL, V144, P117, DOI 10.1002/cne.901440106; HARRIS WA, 1981, ANNU REV PHYSIOL, V43, P689, DOI 10.1146/annurev.ph.43.030181.003353; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JEFFERY G, 1989, DEV BRAIN RES, V46, P187, DOI 10.1016/0165-3806(89)90282-4; KALIL RE, 1986, NATURE, V323, P156, DOI 10.1038/323156a0; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVICK WR, 1973, HDB SENSORY PHYSL, V7, P575; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MASLAND RH, 1977, J COMP NEUROL, V175, P275, DOI 10.1002/cne.901750303; MASLIM J, 1986, BRAIN RES, V373, P35, DOI 10.1016/0006-8993(86)90313-6; Miller K.D., 1990, CONNECTIONIST MODELI, P255; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; PAYNE B, 1988, CEREB CORTEX, V7, P309; Pine J., 1982, SOC NEUR ABST, V8, P670; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; RAPISARDI SC, 1975, EXP BRAIN RES, V22, P295; REGEHR WG, 1989, J NEUROSCI METH, V30, P91, DOI 10.1016/0165-0270(89)90055-1; SCHWARTZ EA, 1982, J PHYSIOL-LONDON, V323, P211, DOI 10.1113/jphysiol.1982.sp014069; SCHWARTZ EA, 1986, J PHYSIOL-LONDON, V376, P411, DOI 10.1113/jphysiol.1986.sp016160; SHATZ CJ, 1984, J NEUROSCI, V4, P1378; SHATZ CJ, 1983, J NEUROSCI, V3, P482; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1990, J NEUROBIOL, V21, P197, DOI 10.1002/neu.480210113; SPEAR PD, 1972, BRAIN RES, V45, P67, DOI 10.1016/0006-8993(72)90216-8; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; STRYKER MP, 1986, BIOL CHANGE OTOLARYN, P211; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WINFREE AT, 1990, ANN NY ACAD SCI, V591, P190	38	844	857	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	1991	252	5008					939	943		10.1126/science.2035024	http://dx.doi.org/10.1126/science.2035024			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035024				2022-12-24	WOS:A1991FM04000028
J	CHARNAS, LR; BERNARDINI, I; RADER, D; HOEG, JM; GAHL, WA				CHARNAS, LR; BERNARDINI, I; RADER, D; HOEG, JM; GAHL, WA			CLINICAL AND LABORATORY FINDINGS IN THE OCULOCEREBRORENAL SYNDROME OF LOWE, WITH SPECIAL REFERENCE TO GROWTH AND RENAL-FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM CREATININE CONCENTRATION; HIGH-DENSITY-LIPOPROTEIN; FANCONI SYNDROME; LENS EXAMINATION; CARNITINE; DISEASE; CYSTINOSIS; CHILDREN; PROGRESSION; DEFICIENCY	Background. The oculocerebrorenal syndrome of Lowe is an X-linked disorder whose clinical manifestations include congenital cataracts, mental retardation, and renal tubular dysfunction. We investigated growth, renal function, and serum chemistry values in patients with the oculocerebrorenal syndrome to determine the natural history of the disorder and its heterogeneity with respect to these characteristics. Methods. Twenty-three patients with the oculocerebrorenal syndrome, ranging in age from 4 months to 31 years, were examined. Height was compared with bone age. Renal function was assessed by measurements of proteinuria, urinary volume, and fractional excretions of potassium, phosphate, carnitine, and amino acids. Creatinine clearance was determined as a measure of glomerular function. Results. In the oculocerebrorenal syndrome, linear growth decreases after one year of age; bone age lies between chronologic age and height age. Renal dysfunction occurs in the first year of life, characterized by proteinuria (mean [+/- SD], 1.38 +/- 0.77 g of urinary protein per square meter of body-surface area per day; normal, less-than-or-equal-to 0.10), generalized aminoaciduria (mean, 686 +/- 505-mu-mol of urinary amino acid per kilogram of body weight per day; normal, 94 +/- 45), carnitine wasting (mean fractional excretion, 0.10 +/- 0.05; normal, 0.03 +/- 0.01), and phosphaturia progressing into the third decade. Urinary wasting of individual amino acids is milder than in cystinosis, and branched-chain amino acids are relatively spared. Reciprocal serum creatinine levels fall linearly with age, predicting renal failure in the fourth decade. Concentrations of the muscle enzymes creatine kinase, aspartate aminotransferase, and lactate dehydrogenase, as well as of total serum protein, serum alpha-2-globulin, and high-density lipoprotein cholesterol, are elevated. Conclusions. Renal glomerular deterioration is slowly progressive in the oculocerebrorenal syndrome. Renal tubular dysfunction begins early and persists; most patients require alkalinization therapy, and many benefit from supplemental potassium, phosphate, calcium, or carnitine. Serum enzyme elevations suggest muscle involvement in the oculocerebrorenal syndrome.	NICHHD,HUMAN GENET BRANCH,HUMAN BIOCHEM GENET SECT,BLDG 10,RM 9S242,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; NICHHD,HUMAN GENET BRANCH,NEUROGENET UNIT,BETHESDA,MD 20892; NHLBI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ABBASSI VALIOLLAH, 1968, AMER J DIS CHILD, V115, P145; ABITBOL C, 1990, J PEDIATR-US, V116, P243, DOI 10.1016/S0022-3476(05)82881-1; ADAMSON MD, 1989, SEMIN NEPHROL, V9, P147; ARBUS GS, 1981, PEDIATRICS, V67, P871; ATHREYA BH, 1983, ARTHRITIS RHEUM, V26, P728, DOI 10.1002/art.1780260605; ATTREE O, 1990, AM J HUM GENET SA244, V47; BANERJEE AK, 1982, IRISH J MED SCI, V15, P42; BERNARDINI I, 1985, J CLIN INVEST, V75, P1124, DOI 10.1172/JCI111806; BREMER HJ, 1981, DISTURBANCES AMINO A; CHARNAS L, 1988, NEUROPEDIATRICS, V19, P7, DOI 10.1055/s-2008-1052393; CHUTORIAN A, 1966, NEUROLOGY, V16, P115, DOI 10.1212/WNL.16.2_Part_1.115; CIBIS GW, 1986, OPHTHALMOLOGY, V93, P1041; DELLEMAN JW, 1977, J PEDIATR OPHTHALMOL, V14, P205; ELLIMAN D, 1983, J PEDIATR-US, V103, P1011, DOI 10.1016/S0022-3476(83)80759-8; FISHER DA, 1977, J CLIN ENDOCR METAB, V45, P191, DOI 10.1210/jcem-45-2-191; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1990, PEDIATR NEPHROL, V4, P129, DOI 10.1007/BF00858823; GAHL WA, 1988, ANN INTERN MED, V109, P557, DOI 10.7326/0003-4819-109-7-557; GAHL WA, 1988, J CLIN INVEST, V81, P549, DOI 10.1172/JCI113353; GAHL WA, 1989, METABOLIC BASIS INHE, V2, P2619; GARDNER RJM, 1976, J MED GENET, V13, P449, DOI 10.1136/jmg.13.6.449; GARZULY F, 1973, NEUROPADIATRIE, V4, P304, DOI 10.1055/s-0028-1091747; Gellis S S, 1972, Am J Dis Child, V124, P891; GINSBERG J, 1981, J PEDIAT OPHTH STRAB, V18, P16; GOBERNADO JM, 1984, ARCH NEUROL-CHICAGO, V41, P208, DOI 10.1001/archneur.1984.04050140106037; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GORMAN LS, 1985, CLIN CHEM PRINCIPLES, P354; Haldane JBS, 1935, J GENET, V31, P317, DOI 10.1007/BF02982403; HARPER GS, 1987, J BIOL CHEM, V262, P5637; HOEG JM, 1984, CLIN PHARMACOL THER, V36, P555, DOI 10.1038/clpt.1984.219; HOLTGREWE JL, 1986, J PEDIATR ORTHOPED, V6, P165, DOI 10.1097/01241398-198603000-00009; KIERAS FJ, 1984, BIOCHEM MED METAB B, V31, P201, DOI 10.1016/0006-2944(84)90024-3; KOHYAMA J, 1989, PEDIATR NEUROL, V5, P373, DOI 10.1016/0887-8994(89)90052-0; KORNFELD M, 1975, ARCH NEUROL-CHICAGO, V32, P103, DOI 10.1001/archneur.1975.00490440053008; LACHAUX A, 1986, ARCH FR PEDIATR, V43, P68; LEUMANN EP, 1978, HELV PAEDIATR ACTA, V33, P25; LOWE CU, 1952, AMA AM J DIS CHILD, V83, P164, DOI 10.1001/archpedi.1952.02040060030004; MATIN MA, 1980, J MENT DEFIC RES, V24, P1; MCGARRY JD, 1976, J LIPID RES, V17, P277; PAPADOPOULOS NM, 1989, CLIN CHEM, V35, P2231; REBOUCHE CJ, 1983, MAYO CLIN PROC, V58, P533; REIMOLD EW, 1981, AM J DIS CHILD, V135, P1039, DOI 10.1001/archpedi.1981.02130350039013; ROSE SR, 1989, J CLIN ENDOCR METAB, V68, P1086, DOI 10.1210/jcem-68-6-1086; ROSENBLATT D, 1974, J PEDIATR-US, V84, P924, DOI 10.1016/S0022-3476(74)80819-X; RUTHERFORD WE, 1977, KIDNEY INT, V11, P62, DOI 10.1038/ki.1977.8; SEPPALA R, 1990, LAB INVEST, V63, P197; SILVER DN, 1987, J CLIN INVEST, V79, P282, DOI 10.1172/JCI112795; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TRIPATHI RC, 1986, OPHTHALMOLOGY, V93, P1046; WADELIUS C, 1989, AM J HUM GENET, V44, P241; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WITZLEBEN CL, 1968, AM J MED, V44, P319, DOI 10.1016/0002-9343(68)90163-0; YAMASHINA I, 1983, MOL CELL BIOCHEM, V52, P107; YOSHIDA R, 1982, BIOCHEM BIOPH RES CO, V107, P1144; 1980, NIH81527 NAT HEART L	55	84	88	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1318	1325		10.1056/NEJM199105093241904	http://dx.doi.org/10.1056/NEJM199105093241904			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017228				2022-12-24	WOS:A1991FK18600004
J	HANDFORD, PA; MAYHEW, M; BARON, M; WINSHIP, PR; CAMPBELL, ID; BROWNLEE, GG				HANDFORD, PA; MAYHEW, M; BARON, M; WINSHIP, PR; CAMPBELL, ID; BROWNLEE, GG			KEY RESIDUES INVOLVED IN CALCIUM-BINDING MOTIFS IN EGF-LIKE DOMAINS	NATURE			English	Article							BETA-HYDROXYASPARTIC ACID; EPIDERMAL GROWTH-FACTOR; HUMAN FACTOR-IX; NUCLEOTIDE-SEQUENCE; PROTEIN; GENE; HOMOLOGY; REPEATS; SITE	MANY extracellular proteins with diverse functions contain domains similar to epidermal growth factor (EGF), a number of which have a consensus Asp/Asn, Asp/Asn, Asp*/Asn*, Tyr/Phe (where the asterisk denotes a beta-hydroxylated residue) 1. These include the coagulation factors IX and X, proteins with two EGF-like domains, the first of which contains the consensus residues 2. The first EGF-like domain of human factor IX contains a calcium-binding site, which is believed to be responsible for one of the high-affinity sites detected in this protein 3. Similar results have been obtained for bovine factor X 4. We have now used protein engineering and H-1-NMR techniques to investigate the importance of individual consensus residues for ligand binding. Measurement of a calcium-dependent Tyr 69 shift 3 in the isolated first EGF-like domain from human factor IX demonstrates that Asp 47, Asp 49, and Asp 64 are directly involved in this binding. Gln 50, whose importance has previously been overlooked, is also involved in this binding. Two mutations 5 in this domain, Asp 47 --> Glu, and Asp 64 --> Asn, present in patients with haemophilia B, reduce calcium binding to the domain > 4-fold and > 1,000-fold, respectively. Furthermore, the defective calcium binding of Asn 64 can be partially rescued by the compensatory mutation Gln 50 --> Glu. This latter mutation, when introduced singly more than doubles the affinity of the domain for calcium. This study thus defines residues involved in a new type of calcium-binding site and provides strong circumstantial evidence for calcium-binding motifs in many extracellular proteins, including the developmentally important proteins of Drosophila, notch, delta and crumbs 1,6-8.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3RE,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3RE,ENGLAND	University of Oxford; University of Oxford	HANDFORD, PA (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.							BARON M, 1990, THESIS U OXFORD; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; JAENICKE R, 1989, PROTEIN STRUCTURE PR, P208; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NISHIMURA H, 1989, THROMB HAEMOSTASIS, V62, P17; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VILLIERS CL, 1985, P NATL ACAD SCI USA, V82, P4477, DOI 10.1073/pnas.82.13.4477; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	22	274	277	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					164	167		10.1038/351164a0	http://dx.doi.org/10.1038/351164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030732				2022-12-24	WOS:A1991FL03500057
J	KENNEDY, A; SCHON, F				KENNEDY, A; SCHON, F			EPILEPSY - DISAPPEARING LESIONS APPEARING IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							CT LESIONS; COMPUTED-TOMOGRAPHY; CYSTICERCOSIS; SEIZURES; INDIA; SCAN	Objective-Investigation of spontaneously resolving lesions associated with epilepsy. Design-Observational study during one year. Setting-One neurology department. Patients-4 cases in patients (one of Indian parents, one African, one white English, and one Afro-Caribbean) resident in the United Kingdom, who presented with transient epilepsy. Main outcome measures-Findings on computed tomography and on screening for infections. Results-In all four cases a small mass lesion in one cerebral hemisphere was observed on computed tomography, which resolved after 9, 4, 3 and 1.5 months respectively without surgery. Conclusions-The number of cases seen in one year suggests that the lesions may be more common in the United Kingdom than previously recognised and that research into their cause is warranted.	ATKINSON MORLEYS HOSP,DEPT NEUROL,LONDON SW20 0NE,ENGLAND									AHUJA GK, 1989, J NEUROL NEUROSUR PS, V52, P915, DOI 10.1136/jnnp.52.7.915; BANSAL BC, 1989, J NEUROL NEUROSUR PS, V52, P1185, DOI 10.1136/jnnp.52.10.1185; CHANDY MJ, 1989, LANCET, V1, P390, DOI 10.1016/S0140-6736(89)91771-6; DEBEYL DZ, 1985, J NEUROL NEUROSUR PS, V48, P187, DOI 10.1136/jnnp.48.2.187; FEINSTEIN A, 1990, J NEUROL NEUROSUR PS, V53, P244, DOI 10.1136/jnnp.53.3.244; GOULATIA RK, 1987, EPILEPSIA, V28, P523, DOI 10.1111/j.1528-1157.1987.tb03682.x; MINGUETTI G, 1983, J NEUROL NEUROSUR PS, V46, P936, DOI 10.1136/jnnp.46.10.936; RAJSHEKHAR V, 1990, J NEUROL NEUROSUR PS, V53, P818, DOI 10.1136/jnnp.53.9.818-a; WADIA RS, 1987, J NEUROL NEUROSUR PS, V50, P1298, DOI 10.1136/jnnp.50.10.1298	9	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					933	935		10.1136/bmj.302.6782.933	http://dx.doi.org/10.1136/bmj.302.6782.933			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032034	Bronze, Green Published			2022-12-24	WOS:A1991FH48700016
J	MALIM, MH; CULLEN, BR				MALIM, MH; CULLEN, BR			HIV-1 STRUCTURAL GENE-EXPRESSION REQUIRES THE BINDING OF MULTIPLE REV MONOMERS TO THE VIRAL RRE - IMPLICATIONS FOR HIV-1 LATENCY	CELL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ESCHERICHIA-COLI; TRANS-ACTIVATOR; MESSENGER-RNA; PROTEIN; SEQUENCE; INVITRO; PURIFICATION; RECOGNITION; POLYMERASE	Expression of the structural proteins of HIV-1 requires the direct interaction of the viral Rev trans-activator with its cis-acting RNA target sequence, the Rev response element or RRE. Here, we demonstrate that this specific RNA-binding event is, as expected, mediated by the conserved arginine-rich motif of Rev. However, we also show that amino acid residues located proximal to this basic domain that are critical for in vivo Rev function are dispensable for sequence-specific binding to the RRE. Instead, these sequences are required for the multimerization of Rev on the viral RRE target sequence. The observation that Rev function requires the sequential binding of multiple Rev molecules to the RRE provides a biochemical explanation for the observed threshold effect for Rev function in vivo and suggests a molecular model for the high incidence of latent infection by HIV-1.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Duke University	MALIM, MH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.			Malim, Michael/0000-0002-7699-2064				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GENDELMAN HE, 1986, J VIROL, V58, P67, DOI 10.1128/JVI.58.1.67-74.1986; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; JONES K A, 1989, New Biologist, V1, P127; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NALIN CM, 1990, P NATL ACAD SCI USA, V87, P7593, DOI 10.1073/pnas.87.19.7593; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TILEY LS, 1990, P NATL ACAD SCI USA, V87, P7497, DOI 10.1073/pnas.87.19.7497; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	37	356	363	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					241	248		10.1016/0092-8674(91)90158-U	http://dx.doi.org/10.1016/0092-8674(91)90158-U			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015625				2022-12-24	WOS:A1991FH09200007
J	NOVELLO, AC				NOVELLO, AC			WOMEN AND HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1805	1805						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005724				2022-12-24	WOS:A1991FE86200005
J	LAWLOR, DA; DICKEL, CD; HAUSWIRTH, WW; PARHAM, P				LAWLOR, DA; DICKEL, CD; HAUSWIRTH, WW; PARHAM, P			ANCIENT HLA GENES FROM 7,500-YEAR-OLD ARCHAEOLOGICAL REMAINS	NATURE			English	Article							MOLECULAR ANALYSIS; CHAIN-REACTION; DNA-SEQUENCES; MUMMY DNA; ALLELES; CLONING; NUMBER; EVOLUTION; FAMILY; BRAIN	IN the past decade there has been increasing interest in cloning DNA from ancient and preserved tissues 1-6. Most studies, however, have focused on mitochondrial or chloroplast genes, present at hundreds to thousands of copies per cell compared with one or two for each nuclear gene 7-9. With a probe containing Alu repeat sequences, Paabo isolated a 3.4-kilobase DNA fragment from a 2,400-year-old Egyptian mummy 10 which was subsequently shown to contain an intron of the nuclear gene HLA-DQA (ref. 11). Here we report a more targeted approach to the characterization of nuclear genes from archaeological specimens. The Windover pond of central Florida has provided skeletal and soft tissue remains from 165 humans, radiocarbon-dated to be 6,990-8,130 years old 12-14. Using DNA obtained from one individual we have characterized segments from six nuclear genes: that for beta-2-microglobulin and five members of the class I HLA heavy chain gene family. Distinctive patterns of nucleotide substitution in the cloned heavy chain gene segments permit tentative assignment of the HLA-A,B type of the ancient individual.	STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV FLORIDA,COLL MED,DEPT IMMUNOL & MED MICROBIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT OPHTHALMOL,GAINESVILLE,FL 32610	Stanford University; Stanford University; State University System of Florida; University of Florida; State University System of Florida; University of Florida								BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; CHIEWSILP P, 1986, HLA ASIA OCEANIA 198, P40; DELPOZZO G, 1989, NATURE, V339, P431; Doran G.H., 1988, WET SITE ARCHAEOLOGY, P263, DOI 10.1201/9781351077750-17; Doran G.H., 1988, FLORIDA ANTHR, V41, P365; DORAN GH, 1986, NATURE, V323, P803, DOI 10.1038/323803a0; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; HAGELBERG E, 1989, NATURE, V342, P485, DOI 10.1038/342485a0; HANSEN T, IN PRESS TISSUE ANTI; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; KATO K, 1989, J IMMUNOL, V143, P3371; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAMPPA GK, 1980, PLANTA, V148, P437, DOI [10.1007/BF00552656, 10.1007/BF02395311]; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; MICHAELS GS, 1982, DEV BIOL, V94, P246, DOI 10.1016/0012-1606(82)90088-4; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PAABO S, 1985, NATURE, V314, P644, DOI 10.1038/314644a0; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAABO S, 1988, NUCLEIC ACIDS RES, V16, P9775, DOI 10.1093/nar/16.20.9775; PARHAM P, 1989, J IMMUNOL, V142, P3937; POHLA H, 1989, IMMUNOGENETICS, V29, P297, DOI 10.1007/BF00352839; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; THOMAS WK, 1990, J MOL EVOL, V31, P101, DOI 10.1007/BF02109479; ZEMMOUR J, 1990, J IMMUNOL, V144, P3619	30	94	98	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					785	788		10.1038/349785a0	http://dx.doi.org/10.1038/349785a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000147				2022-12-24	WOS:A1991EZ66600054
J	CREUZET, F; MCDERMOTT, A; GEBHARD, R; VANDERHOEF, K; SPIJKERASSINK, MB; HERZFELD, J; LUGTENBURG, J; LEVITT, MH; GRIFFIN, RG				CREUZET, F; MCDERMOTT, A; GEBHARD, R; VANDERHOEF, K; SPIJKERASSINK, MB; HERZFELD, J; LUGTENBURG, J; LEVITT, MH; GRIFFIN, RG			DETERMINATION OF MEMBRANE-PROTEIN STRUCTURE BY ROTATIONAL RESONANCE NMR - BACTERIORHODOPSIN	SCIENCE			English	Article							MAGIC-ANGLE; POLYCRYSTALLINE SOLIDS; SPIN DIFFUSION; SPECTRA	Rotationally resonant magnetization exchange, a new nuclear magnetic resonance (NMR) technique for measuring internuclear distances between like spins in solids, was used to determine the distance between the C-8 and C-18 carbons of retinal in two model compounds and in the membrane protein bacteriorhodopsin. Magnetization transfer between inequivalent spins with an isotropic shift separation, delta, is driven by magic angle spinning at a speed omega-r that matches the rotational resonance condition delta = n-omega-r, where n is a small integer. The distances measured in this way for both the 6-s-cis- and 6-s-trans-retinoic acid model compounds agreed well with crystallographically known distances. In bacteriorhodopsin the exchange trajectory between C-8 and C-18 was in good agreement with the internuclear distance for a 6-s-trans configuration [4.2 angstroms (angstrom)] and inconsistent with that for a 6-s-cis configuration (3.1 angstrom). The results illustrate that rotational resonance can be used for structural studies in membrane proteins and in other situations where diffraction and solution NMR techniques yield limited information.	MIT,FRANCIS BITTER NATL MAGNET LAB,CAMBRIDGE,MA 02139; LEIDEN STATE UNIV,GORLAEUS LABS,2300 RA LEIDEN,NETHERLANDS; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Leiden University; Leiden University - Excl LUMC; Brandeis University; Massachusetts Institute of Technology (MIT)			Levitt, Malcolm/B-3746-2010	Levitt, Malcolm/0000-0001-9878-1180; McDermott, Ann/0000-0002-9249-1649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036920, R01GM023403, R37GM023403, R01GM036810] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23403, GM-36920, GM-36810] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW ER, 1963, PHYS LETT, V4, P99, DOI 10.1016/0031-9163(63)90123-9; ANDREW ER, 1966, PHYS LETT, V21, P505, DOI 10.1016/0031-9163(66)91274-1; ANDREW ER, 1958, NATURE, V182, P1659, DOI 10.1038/1821659a0; COLUMBO MG, 1988, CHEM PHYS LETT, V146, P189; CREUZET F, UNPUB; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P799, DOI 10.1111/j.1751-1097.1988.tb02895.x; GAN ZH, 1990, MOL PHYS, V67, P1419; GRIFFIN RG, 1988, PHYSICS NMR SPECTROS, P203; HARBISON G S, 1985, Journal of the American Chemical Society, V107, P4809, DOI 10.1021/ja00303a001; HARBISON GS, 1985, BIOCHEMISTRY-US, V24, P6955, DOI 10.1021/bi00345a031; HERZFELD J, 1980, J CHEM PHYS, V73, P6021, DOI 10.1063/1.440136; HONIG B, 1971, P NATL ACAD SCI USA, V68, P1289, DOI 10.1073/pnas.68.6.1289; HONIG B, 1976, BIOCHEMISTRY-US, V15, P4593, DOI 10.1021/bi00666a008; KUBO A, 1988, J CHEM SOC FARAD T 1, V84, P3713, DOI 10.1039/f19888403713; LEVITT MH, 1990, J CHEM PHYS, V92, P6347, DOI 10.1063/1.458314; LOWE IJ, 1959, PHYS REV LETT, V2, P285, DOI 10.1103/PhysRevLett.2.285; MAAS WEJR, 1988, CHEM PHYS LETT, V149, P170, DOI 10.1016/0009-2614(88)87216-6; Mathies R. A., 1987, BIOL APPLICATIONS RA, P59; MCDERMOTT AE, 1990, BIOCHEMISTRY-US, V29, P5767, DOI 10.1021/bi00476a018; MEHRING M, 1983, PRINCIPLES HIGH RESO, P250; PINES A, 1973, J CHEM PHYS, V59, P569, DOI 10.1063/1.1680061; RALEIGH DP, 1989, J AM CHEM SOC, V111, P4502, DOI 10.1021/ja00194a057; RALEIGH DP, 1988, CHEM PHYS LETT, V146, P71, DOI 10.1016/0009-2614(88)85051-6; REDFIELD AG, 1971, COLD SPRING HARB SYM, V36, P405, DOI 10.1101/SQB.1972.036.01.052; RODMANGILSON HS, 1988, J AM CHEM SOC, V110, P1943; SCHAEFER J, 1976, J AM CHEM SOC, V98, P1031, DOI 10.1021/ja00420a036; STAM CH, 1972, ACTA CRYSTALL B-STRU, VB 28, P2936, DOI 10.1107/S0567740872007253; STAM CH, 1963, ACTA CRYSTALLOGR, V16, P62, DOI 10.1107/S0365110X63000104; WOLFF EK, 1977, J CHEM PHYS, V67, P2387, DOI 10.1063/1.435081; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	31	185	187	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					783	786		10.1126/science.1990439	http://dx.doi.org/10.1126/science.1990439			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990439				2022-12-24	WOS:A1991EX57500040
J	MOSIER, DE; GULIZIA, RJ; BAIRD, SM; WILSON, DB; SPECTOR, DH; SPECTOR, SA				MOSIER, DE; GULIZIA, RJ; BAIRD, SM; WILSON, DB; SPECTOR, DH; SPECTOR, SA			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION OF HUMAN-PBL-SCID MICE	SCIENCE			English	Article							HUMAN CYTOMEGALO-VIRUS; HU MOUSE; SEQUENCES; CLONES; PROBES	Severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood leukocytes (hu-PBL-SCID mice) have inducible human immune function and may be useful as a small animal model for acquired immunodeficiency syndrome (AIDS) research. Hu-PBL-SCID mice infected with human immunodeficiency virus-1 (HIV-1) contained virus that was recoverable by culture from the peritoneal cavity, spleen, peripheral blood, and lymph nodes for up to 16 weeks after infection; viral sequences were also detected by in situ hybridization and by amplification with the polymerase chain reaction (PCR). Mice could be infected with multiple strains of HIV-1, including LAV-1/Bru, IIIB, MN, SF2, and SF13. HIV-1 infection affected the concentration of human immunoglobulin and the number of CD4+ T cells in the mice. These results support the use of the hu-PBL-SCID mouse for studies of the pathogenesis and treatment of AIDS.	VET ADM MED CTR, LA JOLLA, CA 92161 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, LA JOLLA, CA 92093 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	MOSIER, DE (corresponding author), MED BIOL INST, DIV IMMUNOL, LA JOLLA, CA 92037 USA.			Spector, Deborah/0000-0002-7605-6348	NIAID NIH HHS [AI-27703, AI-29182] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI029182, R01AI027703, R01AI029182] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, UNPUB; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SPECTOR SA, 1989, CLIN CHEM, V35, P1581; SPECTOR SA, 1985, CLIN CHEM, V31, P1514	15	252	264	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 15	1991	251	4995					791	794		10.1126/science.1990441	http://dx.doi.org/10.1126/science.1990441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990441				2022-12-24	WOS:A1991EX57500043
J	SCHUCHAT, A; BROOME, CV; HIGHTOWER, A; COSTA, SJ; PARKIN, W				SCHUCHAT, A; BROOME, CV; HIGHTOWER, A; COSTA, SJ; PARKIN, W			USE OF SURVEILLANCE FOR INVASIVE PNEUMOCOCCAL DISEASE TO ESTIMATE THE SIZE OF THE IMMUNOSUPPRESSED HIV-INFECTED POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; PERSISTENT GENERALIZED LYMPHADENOPATHY; INTRAVENOUS DRUG-USERS; AIDS-RELATED COMPLEX; BACTERIAL PNEUMONIA; ANTIBODY-RESPONSES; BACTEREMIA; VACCINE	We used population-based surveillance in New Jersey in 1986 to quantify the risk of invasive pneumococcal disease in persons with the acquired immunodeficiency syndrome (AIDS) and in those who went on to develop AIDS. Using pneumococcal surveillance, we also devised a method to estimate the size of the immunosuppressed population infected with the human immunodeficiency virus (HIV), the so-called pre-AIDS population. From rates of pneumococcal disease that occurred in areas with a low incidence of AIDS, we calculated the number of patients expected to contract pneumococcal disease in areas with a high incidence of AIDS. There were 59 more cases of pneumococcal disease observed than expected; 14 of these patients had AIDS by the time of pneumococcal infection. We attributed the remaining 45 cases to the increased risk of pneumococcal infection in pre-AIDS. The pre-AIDS pneumococcal cases and the attack rate of pneumococcal disease in pre-AIDS were used to estimate the size of the 1986 pre-AIDS New Jersey population as 8823 pre-AIDS cases (95% confidence interval, 7377 to 10 714) or 0.37% of the adult New Jersey population. Surveillance for marker diseases may provide a simple, independent method of estimating the pre-AIDS population.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,STAT SERV,ATLANTA,GA 30333; NEW JERSEY STATE DEPT HLTH,DIV AIDS PREVENT & CONTROL,DATA ANAL UNIT,TRENTON,NJ; NEW JERSEY STATE DEPT HLTH,DIV EPIDEMIOL & DIS CONTROL,TRENTON,NJ	Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services; New Jersey Department of Health & Senior Services	SCHUCHAT, A (corresponding author), CTR DIS CONTROL,MENINGITIS & SPECIAL PATHOGENS BRANCH,BLDG 1,ROOM 4415,ATLANTA,GA 30333, USA.							AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; [Anonymous], MMWR MORB MORTAL WKL; [Anonymous], MMWR MORB MORTAL WKL; ARMITAGE P, 1987, STATISTICAL METHODS, P118; BALLET JJ, 1987, CLIN EXP IMMUNOL, V68, P479; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; JANOFF EN, 1988, J INFECT DIS, V158, P983, DOI 10.1093/infdis/158.5.983; KLEIN RS, 1989, J INFECT DIS, V160, P826, DOI 10.1093/infdis/160.5.826; OCHS HD, 1988, J CLIN IMMUNOL, V8, P57, DOI 10.1007/BF00915157; PARKIN JM, 1989, AIDS, V3, P37, DOI 10.1097/00002030-198903010-00008; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; RAGNI MV, 1987, J LAB CLIN MED, V109, P545; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; STONEBURNER R, 1988, 4 INT C AIDS STODKH; WHIMBEY E, 1986, ANN INTERN MED, V104, P511, DOI 10.7326/0003-4819-104-4-511; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1988, SAS STAT USERS GUIDE, P690; 1988, MMWR, V37, P593	20	69	69	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3275	3279		10.1001/jama.265.24.3275	http://dx.doi.org/10.1001/jama.265.24.3275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046109				2022-12-24	WOS:A1991FR83500034
J	BAYER, R				BAYER, R			PUBLIC-HEALTH POLICY AND THE AIDS EPIDEMIC - AN END TO HIV EXCEPTIONALISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BAYER, R (corresponding author), COLUMBIA UNIV,NEW YORK,NY 10027, USA.							ABRAHAM L, 1988, AM MED NEWS     0708, P4; ALBAEK E, IN PRESS PASSIONS PO; [Anonymous], 1988, REPORT PRESIDENTIAL, P130; Bayer R., 1991, PRIVATE ACTS SOCIAL; FRANKENBERG G, IN PRESS PASSIONS PO; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; HENRIKSSON B, IN PRESS PASSION POL; JONES L, 1990, HIV INFECTION LABELE, P3; KRAUTHAMMER C, 1990, TIME            0625, P80; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1989, 43RD AMA P HOUS DEL, P76; 1989, REPORT HOUSE DELEGAT, P23; 1990, MMWR, V39, P861; 1988, FED REGISTER, V53, P3554; 1990, MMWR, V39, P110; 1988, C LOCAL HLTH OFFICES; 1990, HAS FEDERAL RES AIDS; 1988, CONFRONTING AIDS UPD, P82; 1990, 1989 INT AIDS REP, P3	19	174	175	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1500	1504		10.1056/NEJM199105233242111	http://dx.doi.org/10.1056/NEJM199105233242111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM460	2023610				2022-12-24	WOS:A1991FM46000011
J	PERROT, V; RICHERD, S; VALERO, M				PERROT, V; RICHERD, S; VALERO, M			TRANSITION FROM HAPLOIDY TO DIPLOIDY	NATURE			English	Article							DOMINANCE	AS a direct consequence of sex, organisms undergo a haploid and a diploid stage during their life cycle. Although the relative duration of haploid and diploid phases varies greatly among taxa, the diploid phase is more conspicuous in all higher organisms. Therefore it is widely believed that diploidy offers more evolutionary possibilities 1-3 and is thus nearly always selected for. We have now performed computer simulations to investigate one possible advantage of diploidy, that is, protection against the expression of deleterious mutations. Instead of comparing isolated haploid and diploid populations, we considered interbreeding haploids and diploids. Diploids invaded the population only when the dominance degree of a single deleterious mutation was smaller than about 1/2, and the condition allowing diploidy to invade depended on how harmful the mutation was.	UNIV SCI & TECHNOL LILLE FLANDRES ARTOIS, GENET & EVOLUT POPULAT VEGETALES LAB, CNRS, URA 1185, F-59655 VILLENEUVE DASCQ, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	PERROT, V (corresponding author), UNIV BASEL, INST ZOOL, RHEINSPRUNG 9, CH-4051 BASEL, SWITZERLAND.		Valero, Myriam/C-7550-2011; Valero, Myriam/M-6052-2019	Valero, Myriam/0000-0002-9000-1423; Valero, Myriam/0000-0002-9000-1423				BERNSTEIN H, 1981, AM NAT, V117, P537, DOI 10.1086/283734; CHARLESWORTH B, 1979, NATURE, V278, P848, DOI 10.1038/278848a0; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; Fisher RA, 1928, AM NAT, V62, P115, DOI 10.1086/280193; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; KACSER H, 1981, GENETICS, V97, P639; KIMURA M, 1961, JAPAN J GENET      S, V36, P179; KONDRASHOV AS, 1991, NATURE, V351, P314, DOI 10.1038/351314a0; LEWIS J, 1979, J THEOR BIOL, V78, P425, DOI 10.1016/0022-5193(79)90341-2; Maynard Smith J., 1978, EVOLUTION SEX; PAQUIN C, 1983, NATURE, V302, P495, DOI 10.1038/302495a0; Stebbins G.L., 1950, VARIATION EVOLUTION, DOI 10.7312/steb94536; Wright S, 1934, AM NAT, V68, P24, DOI 10.1086/280521	14	109	110	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1991	351	6324					315	317		10.1038/351315a0	http://dx.doi.org/10.1038/351315a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034274				2022-12-24	WOS:A1991FM97600060
J	DU, XP; PLOW, EF; FRELINGER, AL; OTOOLE, TE; LOFTUS, JC; GINSBERG, MH				DU, XP; PLOW, EF; FRELINGER, AL; OTOOLE, TE; LOFTUS, JC; GINSBERG, MH			LIGANDS ACTIVATE INTEGRIN ALPHA-IIB-BETA-3 (PLATELET GPIIB-IIIA)	CELL			English	Article							ARG-GLY-ASP; FUNCTION-ASSOCIATED ANTIGEN-1; IIB-GLYCOPROTEIN-IIIA; AMINO-ACID SEQUENCES; CELL-BINDING DOMAIN; SYNTHETIC PEPTIDES; GLANZMANNS THROMBASTHENIA; FIBRONECTIN RECEPTOR; RECOGNITION SIGNAL; ADHESIVE PROTEINS	Integrin alpha-IIb-beta-3 (platelet GPIIb-IIIa) binds fibrinogen via recognition sequences such as Arg-Gly-Asp (RGD). Fibrinogen binding requires agonist activation of platelets, whereas the binding of short synthetic RGD peptides does not. We now find that RGD peptide binding leads to changes in alpha-IIb-beta-3 that are associated with acquisition of high affinity fibrinogen-binding function (activation) and subsequent platelet aggregation. The structural specificities for peptide activation and for inhibition of ligand binding are similar, indicating that both are consequences of occupancy of the same site(s) on alpha-IIb-beta-3. Thus, the RGD sequence is a trigger of high affinity ligand binding to alpha-IIb-beta-3, and certain RGD-mimetics are partial agonists as well as competitive antagonists of integrin function.			DU, XP (corresponding author), Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.		O'Toole, Timothy/I-4172-2013	Frelinger, Andrew/0000-0002-6871-7441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039150, P01HL016411, R01HL028235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28235, HL-39150, HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COHEN I, 1989, BLOOD, V73, P1880; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1980, BLOOD, V55, P169; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1980, BLOOD, V55, P661; GINSBERG MH, 1983, METHODS HEMATOLOGY, P158; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAM SCT, 1987, J BIOL CHEM, V262, P947; LASH JW, 1987, DEV BIOL, V123, P411, DOI 10.1016/0012-1606(87)90399-X; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MARGUERIE GA, 1982, J BIOL CHEM, V257, P1872; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEERSCHKE EI, 1981, BLOOD, V57, P663; PHILLIPS DR, 1988, BLOOD, V71, P831; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1990, IN PRESS J BIOL CHEM; STEINER B, 1989, J BIOL CHEM, V264, P13102; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODS VL, 1986, J BIOL CHEM, V261, P5242; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; ZAMARRON C, 1990, THROMB HAEMOSTASIS, V64, P41	66	472	479	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					409	416		10.1016/0092-8674(91)90458-B	http://dx.doi.org/10.1016/0092-8674(91)90458-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018974				2022-12-24	WOS:A1991FK18200007
J	MITTNACHT, S; WEINBERG, RA				MITTNACHT, S; WEINBERG, RA			G1/S PHOSPHORYLATION OF THE RETINOBLASTOMA PROTEIN IS ASSOCIATED WITH AN ALTERED AFFINITY FOR THE NUCLEAR COMPARTMENT	CELL			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; CELL-CYCLE; ENCODED PROTEIN; RB GENE; PRODUCT; EXPRESSION; CHROMOSOME-13	Hyperphosphorylation of the retinoblastoma protein (pRB) is assumed to be a regulatory event leading to the inactivation of its growth-repressing functions. We demonstrate a functional alteration linked to the phosphorylation status of the protein. The un- or under-phosphorylated species are tightly associated with the nuclear structure. The association is resistant to digestion with nucleases, and release requires elevated salt concentrations. In contrast, the hyperphosphorylated species are eluted under hypotonic buffer conditions. The conversion from low salt-resistant to low salt-extractable pRB occurs with transition through the G1/S boundary of the cell cycle and thus parallels the reported onset of pRB phosphorylation. The ability to form a tight nuclear association is impaired in several naturally occuring pRB mutants, all of which show alterations within the binding region for viral oncoproteins. We suggest that the tight nuclear interaction is essential for the growth-regulating functions of pRB and may be preempted by viral oncoproteins.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	MITTNACHT, S (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [CA39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COMMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRANKE WW, 1984, CELL, V36, P813, DOI 10.1016/0092-8674(84)90031-X; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; GRAND RJA, 1989, ONCOGENE, V4, P1291; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUBERMAN JA, 1987, CELL, V48, P7, DOI 10.1016/0092-8674(87)90347-3; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REISSMANN PT, 1989, ONCOGENE, V4, P839; RYGAARD K, 1990, CANCER RES, V50, P5312; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARLEY JM, 1989, ONCOGENE, V4, P725; VAUGHN JP, 1990, NUCLEIC ACIDS RES, V18, P1965, DOI 10.1093/nar/18.8.1965; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1988, ONCOGENE, V3, P471	71	325	328	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					381	393		10.1016/0092-8674(91)90456-9	http://dx.doi.org/10.1016/0092-8674(91)90456-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018973				2022-12-24	WOS:A1991FK18200005
J	OKANO, Y; EISENSMITH, RC; GUTTLER, F; LICHTERKONECKI, U; KONECKI, DS; TREFZ, FK; DASOVICH, M; WANG, T; HENRIKSEN, K; LOU, H; WOO, SLC				OKANO, Y; EISENSMITH, RC; GUTTLER, F; LICHTERKONECKI, U; KONECKI, DS; TREFZ, FK; DASOVICH, M; WANG, T; HENRIKSEN, K; LOU, H; WOO, SLC			MOLECULAR-BASIS OF PHENOTYPIC HETEROGENEITY IN PHENYLKETONURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; PRENATAL-DIAGNOSIS; LINKAGE DISEQUILIBRIUM; MAMMALIAN-CELLS; DNA; GENE; MUTATION; LOCUS; HYPERPHENYLALANINEMIA; SUBSTITUTION	Background. Phenylketonuria is a metabolic disorder that results from a deficiency of the hepatic enzyme phenylalanine hydroxylase. Its clinical phenotype varies widely, and to date more than 10 mutations in the phenylalanine hydroxylase gene have been identified in persons with the disorder. We attempted to relate the clinical phenotype of patients to their genotype. Methods. We studied 258 patients with phenylketonuria from Denmark and Germany for the presence of eight mutations previously found in patients from these countries. The in vitro activity of the enzymes associated with these mutations was determined by expression analysis in heterologous mammalian cells. The level of activity was then used to predict the in vivo level of phenylalanine hydroxylase activity in patients with various combinations of mutant phenylalanine hydroxylase alleles. Results. The eight mutations involved 64 percent of all mutant phenylalanine hydroxylase alleles in the patients. Expression analysis showed that these mutant enzymes produced from 0 to 50 percent of normal enzyme activity. The predicted level of phenylalanine hydroxylase activity correlated strongly with the pretreatment serum level of phenylalanine (r = 0.91, P < 0.001 in the Danish patients and r = 0.74, P < 0.001 in the German patients), phenylalanine tolerance in the Danish patients (r = 0.84, P < 0.001), and the serum phenylalanine level measured after standardized oral protein loading in the German patients (r = 0.84, P < 0.001). Conclusions. Our results strongly support the hypothesis that there is a molecular basis for phenotypic heterogeneity in phenylketonuria. The establishment of genotype will therefore aid in the prediction of biochemical and clinical phenotypes in patients with this disease.	BAYLOR UNIV, HOWARD HUGHES MED INST, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; BAYLOR UNIV, INST MOLEC GENET, HOUSTON, TX 77030 USA; JOHN F KENNEDY INST, GLOSTRUP, DENMARK; UNIV HEIDELBERG, KINDERKLIN, W-6900 HEIDELBERG, GERMANY	Baylor College of Medicine; Baylor University; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor University; Ruprecht Karls University Heidelberg					NICHD NIH HHS [HD-17711] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017711, R01HD017711] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABADIE V, 1989, GENOMICS, V5, P936, DOI 10.1016/0888-7543(89)90137-7; BARTHOLOME K, 1975, PEDIATR RES, V9, P899, DOI 10.1203/00006450-197509120-00006; BLASKOVICS ME, 1974, ARCH DIS CHILD, V49, P835, DOI 10.1136/adc.49.11.835; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DILELLA AG, 1987, METHOD ENZYMOL, V152, P447; DILELLA AG, 1988, LANCET, V1, P497; DILELLA AG, 1987, NATURE, V327, P333, DOI 10.1038/327333a0; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; DWORNICZAK B, 1989, HUM GENET, V84, P95, DOI 10.1007/BF00210683; GUTTLER F, 1987, J PEDIATR-US, V110, P68, DOI 10.1016/S0022-3476(87)80290-1; GUTTLER F, 1980, ACTA PAEDIATR SCAND, P1; JERVIS GA, 1947, J BIOL CHEM, V169, P651; JOHN SWM, 1990, AM J HUM GENET, V46, P970; JOHN SWM, 1989, AM J HUM GENET, V45, P905; KANG ES, 1970, PEDIATRICS, V45, P83; KAUFMAN S, 1975, PEDIATR RES, V9, P632, DOI 10.1203/00006450-197508000-00004; Kaufman S., 1976, ADV NEUROCHEM, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEDLEY FD, 1986, NEW ENGL J MED, V314, P1276, DOI 10.1056/NEJM198605153142002; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; LEDLEY FD, 1985, SCIENCE, V228, P77, DOI 10.1126/science.3856322; LICHTERKONECKI U, 1988, HUM GENET, V78, P347, DOI 10.1007/BF00291733; LICHTERKONECKI U, 1988, BIOCHEMISTRY-US, V27, P2881, DOI 10.1021/bi00408a032; LIDSKY AS, 1985, LANCET, V1, P549; LIDSKY AS, 1985, AM J HUM GENET, V37, P619; LYONNET S, 1989, AM J HUM GENET, V44, P511; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MCCAMAN MW, 1962, J LAB CLIN MED, V59, P885; MOORE S, 1958, ANAL CHEM, V30, P1185, DOI 10.1021/ac60139a005; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; OKANO Y, 1991, GENOMICS, V9, P96, DOI 10.1016/0888-7543(91)90225-4; OKANO Y, 1990, AM J HUM GENET, V46, P919; OKANO Y, 1990, AM J HUM GENET, V46, P18; OKANO Y, IN PRESS EUR J PEDIA; THOMPSON GN, 1990, J CLIN INVEST, V86, P317, DOI 10.1172/JCI114701; TREFZ FK, 1981, J INHERIT METAB DIS, V4, P101, DOI 10.1007/BF02263611; TREFZ FK, 1979, CLIN CHIM ACTA, V99, P211, DOI 10.1016/0009-8981(79)90264-X; WOO SLC, 1988, AM J HUM GENET, V43, P781; WOO SLC, 1983, NATURE, V306, P151, DOI 10.1038/306151a0; [No title captured]; 1990, SOMAT CELL MOLEC GEN, V16, P885	41	223	226	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1232	1238		10.1056/NEJM199105023241802	http://dx.doi.org/10.1056/NEJM199105023241802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	2014036				2022-12-24	WOS:A1991FJ82300002
J	RAMACHANDRAN, VS; GREGORY, RL				RAMACHANDRAN, VS; GREGORY, RL			PERCEPTUAL FILLING IN OF ARTIFICIALLY INDUCED SCOTOMAS IN HUMAN VISION	NATURE			English	Article							APPARENT MOTION; VISUAL AREAS; COLOR; CONTOURS; FORM	PATIENTS with scotomas or blind-spots in their visual field 1-5 resulting from damage to the visual pathways often report that the pattern from the rest of the visual field 'fills in' to occupy the scotoma. Here we describe a novel technique for generating an artificial perceptual scotoma which enabled us to study the spatial and temporal characteristics of this filling-in process. A homogeneous grey square subtending 1.5-degrees was displayed against a background of twinkling two-dimensional noise of equal mean luminance (Fig. 1). On steady eccentric fixation for 10 s the square vanished and was filled in by the twinkling noise from the surround. Using this display we found that 'filling in' is an active visual process that probably involves creating an actual neural representation of the surround rather than merely ignoring the absence of information from the scotoma; filling in can occur separately for colour and texture, suggesting separate mechanisms; the filling-in process does not completely suppress information from the scotoma, even after an image has faded completely from consciousness it can nevertheless contribute to motion perception; and the process can be strongly influenced by illusory contours.	UNIV BRISTOL,DEPT PSYCHOL,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol	RAMACHANDRAN, VS (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL 0109,LA JOLLA,CA 92092, USA.							ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; BENDER MB, 1946, ARCH NEURO PSYCHIATR, V55, P627, DOI 10.1001/archneurpsyc.1946.02300170075008; Brewster D., 1832, LETT NATURAL MAGIC; CRANE HD, 1983, SCIENCE, P1078; FINKEL LH, 1989, J NEUROSCI, V9, P3188; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Kaniza G., 1979, ORG VISION; KRAUSKOPF J, 1961, AM J PSYCHOL, V80, P632; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; POGGIO T, 1985, NATURE, V138, P645; POPPEL E, 1986, NATURE, V320, P523, DOI 10.1038/320523a0; RAMACHANDRAN VS, 1990, PERCEPTION, V19, P273; RAMACHANDRAN VS, 1990, AI AND THE EYE, P21; RAMACHANDRAN VS, 1986, PERCEPT PSYCHOPHYS, V39, P361, DOI 10.3758/BF03203005; RAMACHANDRAN VS, 1985, PERCEPTION, V14, P127, DOI 10.1068/p140127; RAMACHANDRAN VS, 1987, NATURE, V328, P645, DOI 10.1038/328645a0; RAMACHANDRAN VS, IN PRESS ARTFUL BRAI; RAMACHANDRAN VS, 1987, 11TH EUR C VIS PERC; RAMACHANDRAN VS, SOC NEUR ABSTR, V15, P624; Rock I., 1983, LOGIC PERCEPTION; SERGENT J, 1988, BRAIN, V3, P347; Shepard R. N., 1981, PERCEPTUAL ORG, P279; Teuber H.L., 1966, BRAIN CONSCIOUS EXPE, P182; TROXLER D, 1804, OPHTHALMOLOGISCHE 2, V1, P1; VANESSEN DC, 1979, ANNU REV NEUROSCI, V2, P227, DOI 10.1146/annurev.ne.02.030179.001303; VONDERHEYDT RE, 1978, SCIENCE, V224, P1260; WEISZCRANTZ IL, 1961, CURRENTPROBLEMS ANIM, P30; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	31	330	335	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					699	702		10.1038/350699a0	http://dx.doi.org/10.1038/350699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ130	2023631				2022-12-24	WOS:A1991FJ13000058
J	ROSENFELD, MA; SIEGFRIED, W; YOSHIMURA, K; YONEYAMA, K; FUKAYAMA, M; STIER, LE; PAAKKO, PK; GILARDI, P; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; JALLAT, S; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				ROSENFELD, MA; SIEGFRIED, W; YOSHIMURA, K; YONEYAMA, K; FUKAYAMA, M; STIER, LE; PAAKKO, PK; GILARDI, P; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; JALLAT, S; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			ADENOVIRUS-MEDIATED TRANSFER OF A RECOMBINANT ALPHA-L-ANTITRYPSIN GENE TO THE LUNG EPITHELIUM INVIVO	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; INSITU HYBRIDIZATION; DNA; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; EXPRESSION; CELLS; INDIVIDUALS; TYPE-5; ASSAY	The respiratory epithelium is a potential site for somatic gene therapy for the common hereditary disorders alpha-1-antitrypsin (alpha-1AT) deficiency and cystic fibrosis. A replication-deficient adenoviral vector (Ad-alpha-1AT) containing an adenovirus major late promoter and a recombinant human alpha-1AT gene was used to infect epithelial cells of the cotton rat respiratory tract in vitro and in vivo. Freshly isolated tracheobronchial epithelial cells infected with Ad-alpha-1AT contained human alpha-1AT messenger RNA transcripts and synthesized and secreted human alpha-1AT. After in vivo intratracheal administration of Ad-alpha-1AT to these rats, human alpha-1AT messenger RNA was observed in the respiratory epithelium, human alpha-1AT was synthesized and secreted by lung tissue, and human alpha-1AT was detected in the epithelial lining fluid for at least 1 week.	NHLBI,PULM BRANCH,BETHESDA,MD 20892; INST GUSTAVE ROUSSY,CNRS,UA 1301,F-94805 VILLEJUIF,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Transgene SA								BALLAY A, 1985, EMBO J, V4, P3861, DOI 10.1002/j.1460-2075.1985.tb04158.x; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; CHANOCK RM, 1966, JAMA-J AM MED ASSOC, V195, P151; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Evans MJ, 1989, LUNG CELL BIOL, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILARDI P, 1990, FEBS LETT, V267, P60, DOI 10.1016/0014-5793(90)80287-S; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAJAHMAD Y, 1986, J VIROL, V57, P267, DOI 10.1128/JVI.57.1.267-274.1986; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ MS, 1990, VIROLOGY, P01679; HUBBARD RC, 1990, LUNG, V168, P565, DOI 10.1007/BF02718179; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; MASSARO GD, 1989, LUNG CELL BIOL, P81; MICHALSKI JP, 1985, J IMMUNOL METHODS, V83, P101, DOI 10.1016/0022-1759(85)90063-8; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; Strauss SE, 1984, ADENOVIRUSES, P451; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	40	696	1198	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					431	434		10.1126/science.2017680	http://dx.doi.org/10.1126/science.2017680			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017680				2022-12-24	WOS:A1991FH10300040
J	BURCHFIELD, DJ; LUCAS, VW; ABRAMS, RM; MILLER, RL; DEVANE, CL				BURCHFIELD, DJ; LUCAS, VW; ABRAMS, RM; MILLER, RL; DEVANE, CL			DISPOSITION AND PHARMACODYNAMICS OF METHAMPHETAMINE IN PREGNANT SHEEP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-FLOW; AMPHETAMINE; HEMORRHAGE; COCAINE; HYPERTENSION; PERFORMANCE; ABUSE	To determine the placental transfer of methamphetamine, its subsequent fetal disposition, and its hemodynamic effects, we administered methamphetamine intravenously to 15 pregnant ewes 3 days after placement of maternal and fetal vascular catheters. Methamphetamine crossed the placenta within 30 seconds of its administration. Although the ewes had higher peak concentrations, the fetuses' longer elimination half-life ultimately led to higher fetal than maternal methamphetamine concentrations. The ratio of fetal tissue to plasma drug concentration 2 hours after administration was highest in the lung, followed by the placenta, kidney, intestine, liver, brain, and heart. Methamphetamine caused a 54% to 63% rise in maternal blood pressure, a 20% to 37% increase in fetal blood pressure, and a drop in fetal oxyhemoglobin saturation and arterial pH. We conclude that methamphetamine, in doses at or below what is commonly abused, has effects that could be detrimental to the health of the mother and her fetus.	UNIV FLORIDA, DEPT OBSTET & GYNECOL, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, DEPT PHARM PRACTICE, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, DEPT PSYCHIAT, GAINESVILLE, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	BURCHFIELD, DJ (corresponding author), UNIV FLORIDA, J HILLIS MILLER HLTH CTR, DEPT PEDIAT, DIV NEONATOL, BOX J-296, GAINESVILLE, FL 32610 USA.		DeVane, Lindsay/B-6645-2012		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005170] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 05170] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abrams R M, 1985, Alcohol Drug Res, V6, P361; ANGGARD E, 1970, EUR J CLIN PHARMACOL, V3, P3, DOI 10.1007/BF00560284; BECKETT AH, 1965, J PHARM PHARMACOL, VS 17, pS109, DOI 10.1111/j.2042-7158.1965.tb07757.x; BOST RO, 1989, J ANAL TOXICOL, V13, P300, DOI 10.1093/jat/13.5.300; BRINKMAN CR, 1984, MATERNAL FETAL MED P, P679; BROWNE JCM, 1953, J OBSTET GYN BRIT EM, V60, P141; BURCHFIELD DJ, 1987, PEDIATR RES, V21, pA256, DOI 10.1203/00006450-198704010-00532; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; CHYNN KY, 1975, JAMA-J AM MED ASSOC, V233, P55; FARRELL BM, 1983, J CHROMATOGR, V272, P111, DOI 10.1016/S0378-4347(00)86108-3; GARRIOTT J C, 1973, Journal of Forensic Sciences, V18, P434; GOODMAN SJ, 1970, J AMER MED ASSOC, V212, P480, DOI 10.1001/jama.1970.03170160068021; HALL JN, 1988, TRENDS PATTERNS METH; KANE FJ, 1969, J AMER MED ASSOC, V210, P556, DOI 10.1001/jama.1969.03160290108032; Lees M M, 1967, J Obstet Gynaecol Br Commonw, V74, P319; LITTLE BB, 1988, OBSTET GYNECOL, V72, P541; MAYER SE, 1980, PHARMACOL BASIS THER, P56; METCALFE J, 1974, Progress in Cardiovascular Diseases, V16, P363, DOI 10.1016/0033-0620(74)90028-0; NAEYE RL, 1979, AM J OBSTET GYNECOL, V133, P8, DOI 10.1016/0002-9378(79)90402-2; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; PASTERNAK JF, 1983, NEUROLOGY, V33, P559; PIPKIN FB, 1985, PHYSL DEV FETUS NEWB, P699; REYNOLDS ML, 1979, EARLY HUM DEV, V3, P163, DOI 10.1016/0378-3782(79)90005-7; RUBLER S, 1977, AM J CARDIOL, V40, P534, DOI 10.1016/0002-9149(77)90068-6; SZETO HH, 1982, ANNU REV PHARMACOL, V22, P221, DOI 10.1146/annurev.pa.22.040182.001253; TALLEDO OD, 1968, AM J OBSTET GYNECOL, V100, P218, DOI 10.1016/S0002-9378(15)33724-8; WEINER N, 1980, PHARMACOL BASIS THER, P138; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957; ZUSPAN FP, 1964, AM J OBSTET GYNECOL, V90, P88; 1990, NIDA CAPSULES, P1	30	61	63	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1968	1973		10.1001/jama.265.15.1968	http://dx.doi.org/10.1001/jama.265.15.1968			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008026				2022-12-24	WOS:A1991FF76800022
J	HATTA, K; KIMMEL, CB; HO, RK; WALKER, C				HATTA, K; KIMMEL, CB; HO, RK; WALKER, C			THE CYCLOPS MUTATION BLOCKS SPECIFICATION OF THE FLOOR PLATE OF THE ZEBRAFISH CENTRAL-NERVOUS-SYSTEM	NATURE			English	Article							EMBRYO; CELLS	THE floor plate is a set of epithelial cells present in the ventral midline of the neural tube in vertebrates 1 that seems to have an important role in the developmental patterning 2 of central nervous system fibre pathways 3,4, and arrangements of specific neurons 5. The floor plate arises from dorsal ectodermal cells closely associated with the mesoderm that forms notochord 6, and it may depend on interactions from the notochord for its specification. To learn the nature of these interactions we have analysed mutations in zebrafish (Brachydanio rerio). We report here that in wild-type embryos the floor plate develops as a simply organized single cell row, but that its development fails in embryos bearing the newly discovered zygotic lethal 'cyclops' mutation, cyc-1(b16). Mosaic analysis establishes that cyc-1 blocks floor plate development autonomously and reveals the presence of homeogenetic induction between floor plate cells.			HATTA, K (corresponding author), UNIV OREGON, INST NEUROSCI, EUGENE, OR 97403 USA.							Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; Adelmann HB, 1936, Q REV BIOL, V11, P161, DOI 10.1086/394504; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HATTA K, 1990, Society for Neuroscience Abstracts, V16, P310; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; Holtfreter J, 1934, ARCH EXP ZELLFORSCH, V15, P281; JACOBSON AG, 1981, MORPHOGENESIS PATTER, P233; JESSELL TM, 1989, CIBA F SYMP, V144, P255; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1988, TRENDS GENET, V4, P68, DOI 10.1016/0168-9525(88)90043-1; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KUWADA J Y, 1990, Society for Neuroscience Abstracts, V16, P309; KUWADA JY, 1990, J NEUROSCI, V10, P1299; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; METCALFE WK, 1990, DEVELOPMENT, V110, P491; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; STREISINGER G, 1986, GENETICS, V112, P311; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WALKER C, 1983, GENETICS, V103, P125; WARGA RM, 1990, DEVELOPMENT, V108, P569; YAMADA T, IN PRESS CELL	27	389	401	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1991	350	6316					339	341		10.1038/350339a0	http://dx.doi.org/10.1038/350339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008211				2022-12-24	WOS:A1991FD83800092
J	BOYES, J; BIRD, A				BOYES, J; BIRD, A			DNA METHYLATION INHIBITS TRANSCRIPTION INDIRECTLY VIA A METHYL-CPG BINDING-PROTEIN	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; GLOBIN GENE-EXPRESSION; INVITRO METHYLATION; ADENOVIRUS TYPE-2; MAMMALIAN NUCLEI; KINASE GENE; 5' REGION; PROMOTER; SEQUENCE; DEMETHYLATION	We have studied the mechanism by which DNA methylation inhibits transcription both in cell-free nuclear extracts and in the living cell. Repression of transcription in vitro for four different promoters was shown to be an indirect effect. The mediator of repression had properties indistinguishable from those of a methyl-CpG binding protein (MeCP-1) that has been previously identified. Use of differentially methylated promoters and methylated competitors in transient transfection assays suggested that indirect repression via MeCP-1 also occurs in the living cell. This was supported by the fact that MeCP-1-deficient cells showed much reduced repression of methylated genes.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Boyes, Joan/0000-0002-8705-9827; Bird, Adrian/0000-0002-8600-0372				ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; BUSSLINGER M, 1983, GLOBIN GENE EXPRESSI, P193; COTTEN M, 1989, MOL CELL BIOL, V9, P4479, DOI 10.1128/MCB.9.10.4479; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1988, J VIROL, V62, P3941, DOI 10.1128/JVI.62.11.3941-3946.1988; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIMURA FK, 1981, CELL, V23, P809, DOI 10.1016/0092-8674(81)90445-1; GILMAN M, 1987, CURRENT PROTOCOLS MO; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; HOELLER M, 1988, Genes and Development, V2, P1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LANGNER KD, 1984, P NATL ACAD SCI-BIOL, V81, P2950, DOI 10.1073/pnas.81.10.2950; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; SOLAGE A, 1978, BIOCHEMISTRY-US, V17, P2934, DOI 10.1021/bi00607a036; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VARDIMON L, 1982, P NATL ACAD SCI-BIOL, V79, P1073, DOI 10.1073/pnas.79.4.1073; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	40	617	632	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1123	1134		10.1016/0092-8674(91)90267-3	http://dx.doi.org/10.1016/0092-8674(91)90267-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004419				2022-12-24	WOS:A1991FD55800010
J	TSAO, J; CHAPMAN, MS; AGBANDJE, M; KELLER, W; SMITH, K; WU, H; LUO, M; SMITH, TJ; ROSSMANN, MG; COMPANS, RW; PARRISH, CR				TSAO, J; CHAPMAN, MS; AGBANDJE, M; KELLER, W; SMITH, K; WU, H; LUO, M; SMITH, TJ; ROSSMANN, MG; COMPANS, RW; PARRISH, CR			THE 3-DIMENSIONAL STRUCTURE OF CANINE PARVOVIRUS AND ITS FUNCTIONAL IMPLICATIONS	SCIENCE			English	Article							RECEPTOR ATTACHMENT SITE; TOBACCO NECROSIS VIRUS; BEAN MOSAIC-VIRUS; GENOME ORGANIZATION; NUCLEOTIDE-SEQUENCE; 2.9-A RESOLUTION; 3.0-A RESOLUTION; PROTEIN GENE; MINUTE VIRUS; RNA	The three-dimensional atomic structure of a single-stranded DNA virus has been determined. Infectious virions of canine parvovirus contain 60 protein subunits that are predominantly VP-2. The central structural motif of VP-2 has the same topology (an eight-stranded anti-parallel beta-barrel) as has been found in many other icosahedral viruses but represents only about one-third of the capsid protein. There is a 22 angstrom (angstrom) long protrusion on the threefold axes, a 15 angstrom deep canyon circulating about each of the five cylindrical structures at the fivefold axes, and a 15 angstrom deep depression at the twofold axes. By analogy with rhinoviruses, the canyon may be the site of receptor attachment. Residues related to the antigenic properties of the virus are found on the threefold protrusions. Some of the amino termini of VP-2 run to the exterior in full but not empty virions, which is consistent with the observation that some VP-2 polypeptides in full particles can be cleaved by trypsin. Eleven nucleotides are seen in each of 60 symmetry-related pockets on the interior surface of the capsid and together account for 13 percent of the genome.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; CORNELL UNIV,NEW YORK STATE COLL VET MED,JAMES A BAKER INST ANIM HLTH,ITHACA,NY 14853; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Cornell University; University of Alabama System; University of Alabama Birmingham			Compans, Richard W/I-4087-2013; Keller, Walter/AAW-1501-2021; Smith, Thomas J/K-9086-2013	Compans, Richard W/0000-0003-2360-335X; Keller, Walter/0000-0002-2261-958X; Smith, Thomas J/0000-0003-3528-6793; Chapman, Michael/0000-0001-8525-8585				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ANDERSON LJ, 1989, NEW ENGL J MED, V321, P536, DOI 10.1056/NEJM198908243210809; ARNOTT S, 1973, J MOL BIOL, V81, P107, DOI 10.1016/0022-2836(73)90183-6; BASAK S, 1989, J VIROL, V63, P3164, DOI 10.1128/JVI.63.7.3164-3167.1989; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P224; CARTER BJ, 1987, ANIMAL VIRUS STRUCTU, P325; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHAPMAN M, UNPUB; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CLINTON GM, 1976, VIROLOGY, V74, P57, DOI 10.1016/0042-6822(76)90127-6; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; COTMORE SF, 1989, J VIROL, V63, P3902, DOI 10.1128/JVI.63.9.3902-3911.1989; ERICKSON JW, 1985, SCIENCE, V229, P625, DOI 10.1126/science.4023701; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1984, J MOL BIOL, V177, P735, DOI 10.1016/0022-2836(84)90047-0; JONGENEEL CV, 1986, J VIROL, V59, P564, DOI 10.1128/JVI.59.3.564-573.1986; KELLY DC, 1977, J VIROL, V21, P408, DOI 10.1128/JVI.21.1.408-410.1977; KIM S, 1989, J APPL CRYSTALLOGR, V22, P53, DOI 10.1107/S0021889888010878; Koch G., 1985, MOL BIOL POLIOVIRUS; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; LILJAS L, 1982, J MOL BIOL, V159, P93, DOI 10.1016/0022-2836(82)90033-X; LUO M, 1988, J MOL BIOL, V200, P209, DOI 10.1016/0022-2836(88)90346-4; MATTHEWS BW, 1985, METHOD ENZYMOL, V115, P397; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PARRISH CR, 1988, VIROLOGY, V163, P230, DOI 10.1016/0042-6822(88)90255-3; PARRISH CR, 1988, J GEN VIROL, V69, P1111, DOI 10.1099/0022-1317-69-5-1111; PARRISH CR, 1985, SCIENCE, V230, P1046, DOI 10.1126/science.4059921; PARRISH CR, 1988, VIROLOGY, V166, P293, DOI 10.1016/0042-6822(88)90500-4; RANZ AI, 1989, J GEN VIROL, V70, P2541, DOI 10.1099/0022-1317-70-10-2541; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REED AP, 1988, J VIROL, V62, P266, DOI 10.1128/JVI.62.1.266-276.1988; RHODE SL, 1985, J VIROL, V54, P630, DOI 10.1128/JVI.54.2.630-633.1985; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; ROSSMANN MG, 1987, BIOESSAYS, V7, P99, DOI 10.1002/bies.950070302; ROSSMANN MG, 1988, VIROLOGY, V164, P373, DOI 10.1016/0042-6822(88)90550-8; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; Stauffacher C.V., 1987, CRYSTALLOGRAPHY MOL, P293; STUDDERT MJ, 1990, HDB PARVOVIRUSES, V2, P27; TATTERSALL P, 1988, P5; TATTERSALL P, 1977, J MOL BIOL, V111, P375, DOI 10.1016/S0022-2836(77)80060-0; TATTERSALL P, 1990, HDB PARVOVIRUSES, P123; TATTERSALL P, 1990, HDB PARVOVIRUSES, V1, P111; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WOBBE CR, 1984, BIOCHEMISTRY-US, V23, P6565, DOI 10.1021/bi00321a044; 1985, EUR J BIOCHEM, V150, P1	59	428	458	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1456	1464		10.1126/science.2006420	http://dx.doi.org/10.1126/science.2006420			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006420				2022-12-24	WOS:A1991FC85300040
J	HYMAN, C; HOFER, M; BARDE, YA; JUHASZ, M; YANCOPOULOS, GD; SQUINTO, SP; LINDSAY, RM				HYMAN, C; HOFER, M; BARDE, YA; JUHASZ, M; YANCOPOULOS, GD; SQUINTO, SP; LINDSAY, RM			BDNF IS A NEUROTROPHIC FACTOR FOR DOPAMINERGIC-NEURONS OF THE SUBSTANTIA-NIGRA	NATURE			English	Article							INVITRO MATURATION; MESENCEPHALIC NEURONS; GROWTH-FACTOR; CELLS; SURVIVAL; BRAIN; CULTURES; DENSITY; MPTP	Brain-derived neurotrophic factor (BDNF), present in minute amounts in the adult central nervous system 1, is a member of the nerve growth factor (NGF) (ref. 2) family, which includes neurotrophin-3 (NT-3) (refs 3-5). NGF, BDNF and NT-3 all support survival of subpopulations of neural crest-derived sensory neurons 3-5; most sympathetic neurons are responsive to NGF (ref. 2), but not to BDNF 1,6,7; NT-3 and BDNF, but not NGF (ref. 6), promote survival of sensory neurons of the nodose ganglion 3-8. BDNF, but not NGF, supports the survival of cultured retinal ganglion cells 9 but both NGF and BDNF promote the survival of septal cholinergic neurons in vitro 10,11. However, knowledge of their precise physiological role in development and maintenance of the nervous system neurons is still limited. The BDNF gene is expressed in many regions of the adult CNS 12-14, including the striatum 12. A protein partially purified from bovine striatum, a target of nigral dopaminergic neurons, with characteristics apparently similar to those of BDNF, can enhance the survival of dopaminergic neurons in mesencephalic cultures 15. BDNF seems to be a trophic factor for mesencephalic dopaminergic neurons, increasing their survival, including that of neuronal cells which degenerate in Parkinson's disease. Here we report the effects of BDNF on the survival of dopaminergic neurons of the developing substantia nigra.	MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, W-8033 PLANEGG, GERMANY	Max Planck Society	HYMAN, C (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Barde, Yves/F-6019-2011; Lindsay, Ronald/GQP-8001-2022	Barde, Yves/0000-0002-7627-461X				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; DALTOSO R, 1988, J NEUROSCI, V8, P733; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DENISDONINI S, 1983, J NEUROSCI, V3, P2292; DIPORZIO U, 1980, NATURE, V288, P370, DOI 10.1038/288370a0; FERRARI G, 1989, DEV BIOL, V133, P140, DOI 10.1016/0012-1606(89)90305-9; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KNUSEL B, 1990, J NEUROSCI, V10, P558; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MICHEL PP, 1990, J NEUROCHEM, V54, P1102, DOI 10.1111/j.1471-4159.1990.tb01935.x; OTTO D, 1990, J NEUROSCI, V10, P1912; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; PROCHIANTZ A, 1979, P NATL ACAD SCI USA, V76, P5387, DOI 10.1073/pnas.76.10.5387; PROCHIANTZ A, 1981, NATURE, V293, P570, DOI 10.1038/293570a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SANCHEZRAMOS J, 1986, NEUROSCI LETT, V72, P215, DOI 10.1016/0304-3940(86)90083-2; SANCHEZRAMOS JR, 1988, J NEUROCHEM, V50, P1934, DOI 10.1111/j.1471-4159.1988.tb02500.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANCOPOULOS GD, IN PRESS COLD SPRING; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	34	1330	1377	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1991	350	6315					230	232		10.1038/350230a0	http://dx.doi.org/10.1038/350230a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005978				2022-12-24	WOS:A1991FC77900057
J	JABLON, S; HRUBEC, Z; BOICE, JD				JABLON, S; HRUBEC, Z; BOICE, JD			CANCER IN POPULATIONS LIVING NEAR NUCLEAR-FACILITIES - A SURVEY OF MORTALITY NATIONWIDE AND INCIDENCE IN 2 STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD LEUKEMIA; POWER PLANT; INSTALLATIONS; PATTERNS; VICINITY; SITES	Reports from the United Kingdom have described increases in leukemia and lymphoma among young persons living near certain nuclear installations. Because of concerns raised by these reports, a mortality survey was conducted in populations living near nuclear facilities in the United States. All facilities began service before 1982. Over 900 000 cancer deaths occurred from 1950 through 1984 in 107 counties with or near nuclear installations. Each study county was matched for comparison to three "control counties" in the same region. There were 1.8 million cancer deaths in the 292 control counties during the 35 years studied. Deaths due to leukemia or other cancers were not more frequent in the study counties than in the control counties. For childhood leukemia mortality, the relative risk comparing the study counties with their controls before plant start-up was 1.08, while after start-up it was 1.03. For leukemia mortality at all ages, the relative risks were 1.02 before start-up and 0.98 after. For counties in two states, cancer incidence data were also available. For one facility, the standardized registration ratio for childhood leukemia was increased significantly after start-up. However, the increase also antedated the operation of this facility. The study is limited by the correlational approach and the large size of the geographic areas (counties) used. It does not prove the absence of any effect. If, however, any excess cancer risk was present in US counties with nuclear facilities, it was too small to be detected with the methods employed.			JABLON, S (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892, USA.							[Anonymous], 1990, HLTH EFFECTS EXPOSUR; ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BLOT WJ, 1978, NEW ENGL J MED, V299, P620, DOI 10.1056/NEJM197809212991202; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CLAPP RW, 1987, LANCET, V2, P1324; CLARKE EA, 1989, CHILDHOOD LEUKAEMIA; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI PJ, 1989, BRIT J CANCER, V59, P476, DOI 10.1038/bjc.1989.99; COOKMOZAFFARI PJ, 1987, CANCER INCIDENCE MOR; CRUMP KS, 1987, AM J EPIDEMIOL, V126, P127, DOI 10.1093/oxfordjournals.aje.a114644; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; DOUSSET M, 1989, HEALTH PHYS, V56, P875, DOI 10.1097/00004032-198906000-00005; ENSTROM JE, 1983, AM J PUBLIC HEALTH, V73, P83, DOI 10.2105/AJPH.73.1.83; EWINGS PD, 1989, BRIT MED J, V299, P289, DOI 10.1136/bmj.299.6694.289; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN MA, 1986, LANCET, V1, P266; HILL C, 1990, NATURE, V347, P755, DOI 10.1038/347755a0; JABLON S, 1990, NIH90874 PHS DEP HLT; Kemeny J, 1979, REPORT PRESIDENTS CO; KINLEN L, 1988, LANCET, V2, P1323; RIGGAN WB, 1983, US CANCER MORTALITY; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; VIEL JF, 1990, BRIT MED J, V300, P580, DOI 10.1136/bmj.300.6724.580; 1989, 3RD REPORT INCIDENCE; 1988, 2ND REPORT INVESTIGA; 1984, INVESTIGATION POSSIB; 1986, 1ST REPORT IMPLICATI; 1987, NCRP92 NAT COUNC RAD; 1990, PNL7410 HEDR DOC	30	79	80	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1403	1408						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB550	1999880				2022-12-24	WOS:A1991FB55000020
J	TALBOT, JD; MARRETT, S; EVANS, AC; MEYER, E; BUSHNELL, MC; DUNCAN, GH				TALBOT, JD; MARRETT, S; EVANS, AC; MEYER, E; BUSHNELL, MC; DUNCAN, GH			MULTIPLE REPRESENTATIONS OF PAIN IN HUMAN CEREBRAL-CORTEX	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; SOMATIC SUBMODALITY DISTRIBUTION; HUMAN SOMATOSENSORY CORTEX; RESPONSE CHARACTERISTICS; EPILEPTIC SEIZURES; CINGULATE CORTEX; M FASCICULARIS; PET IMAGES; NEURONS; MONKEY	The representation of pain in the cerebral cortex is less well understood than that of any other sensory system. However, with the use of magnetic resonance imaging and positron emission tomography in humans, it has now been demonstrated that painful heat causes significant activation of the contralateral anterior cingulate, secondary somatosensory, and primary somatosensory cortices. This contrasts with the predominant activation of primary somatosensory cortex caused by vibrotactile stimuli in similar experiments. Furthermore, the unilateral cingulate activation indicates that this forebrain area, thought to regulate emotions, contains an unexpectedly specific representation of pain.	UNIV MONTREAL, FAC MED DENT, NEUROPHYSIOL COMPORTEMENTALE LAB, MONTREAL H3C 3J7, QUEBEC, CANADA; MONTREAL NEUROL HOSP & INST, MCCONNELL BRAIN IMAGING CTR, POSITRON IMAGING LABS, MONTREAL H3A 2B4, QUEBEC, CANADA	Universite de Montreal; McGill University				Marrett, Sean/0000-0001-8179-6511				ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P108; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DEANE GE, 1961, J EXP PSYCHOL, V61, P489, DOI 10.1037/h0049220; DONG WK, 1989, BRAIN RES, V484, P314, DOI 10.1016/0006-8993(89)90375-2; DOSTROVSKY JR, 1990, APR S NEUR NOC KAW; DUCLAUX R, 1980, J NEUROPHYSIOL, V43, P1; Evans A.C., 1989, PROC SPIE, V1092, P264, DOI [10.1117/12.953267, DOI 10.1117/12.953267]; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; EVANS AC, IN PRESS IEEE T MED; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1987, J NEUROSURG, V67, P34, DOI 10.3171/jns.1987.67.1.0034; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; HENSEL H, 1971, PFLUG ARCH EUR J PHY, V329, P1, DOI 10.1007/BF00586896; Hurt R W, 1974, Clin Neurosurg, V21, P334; KENSHALO DR, 1988, BRAIN RES, V454, P378, DOI 10.1016/0006-8993(88)90841-4; LARSON MA, 1987, J NEUROSCI, V7, P547; LASSEN NA, 1978, SCI AM, V239, P62, DOI 10.1038/scientificamerican1078-62; MACLEAN PD, 1949, PSYCHOSOM MED, V11, P338, DOI 10.1097/00006842-194911000-00003; MAIXNER W, 1989, J NEUROPHYSIOL, V62, P437, DOI 10.1152/jn.1989.62.2.437; MANTZ J, 1988, NEUROSCIENCE, V27, P517, DOI 10.1016/0306-4522(88)90285-0; MELZACK R, 1968, P423; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MUSIL SY, 1988, J COMP NEUROL, V272, P203, DOI 10.1002/cne.902720205; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Penfield W, 1954, EPILEPSY FUNCTIONAL, P77; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; RAINVILLE P, 1989, AM PAIN SOC ABSTR, V8, P64; REIMAN EM, 1989, SCIENCE, V243, P1071, DOI 10.1126/science.2784226; ROBINSON CJ, 1980, J COMP NEUROL, V192, P93, DOI 10.1002/cne.901920106; SANTO JL, 1990, PAIN, V41, P55, DOI 10.1016/0304-3959(90)91109-V; SUMINO R, 1981, BRAIN RES REV, V3, P105, DOI 10.1016/0165-0173(81)90001-1; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1987, PAIN, V30, P221, DOI 10.1016/0304-3959(87)91078-5; TSUBOKAWA T, 1981, BRAIN RES, V217, P179, DOI 10.1016/0006-8993(81)90197-9; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; White JC., 1969, PAIN NEUROSURGEON, P6; WILLER JC, 1984, BRAIN, V107, P1095, DOI 10.1093/brain/107.4.1095; WILSON DH, 1974, CONFIN NEUROL, V36, P61; YASUI Y, 1988, J COMP NEUROL, V274, P91, DOI 10.1002/cne.902740109; YOUNG GB, 1986, ANN NEUROL, V19, P412, DOI 10.1002/ana.410190423; YOUNG GB, 1983, BRAIN, V106, P537, DOI 10.1093/brain/106.3.537	49	761	774	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1991	251	4999					1355	1358		10.1126/science.2003220	http://dx.doi.org/10.1126/science.2003220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003220				2022-12-24	WOS:A1991FB73300043
J	HUNT, AJ; DAVIES, PM; WEATHERBURN, P; COXON, APM; MCMANUS, TJ				HUNT, AJ; DAVIES, PM; WEATHERBURN, P; COXON, APM; MCMANUS, TJ			CHANGES IN SEXUAL-BEHAVIOR IN A LARGE COHORT OF HOMOSEXUAL MEN IN ENGLAND AND WALES, 1988-9	BRITISH MEDICAL JOURNAL			English	Article									UNIV ESSEX,COLCHESTER CO4 3SQ,ESSEX,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	University of Essex; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	HUNT, AJ (corresponding author), S BANK POLYTECH,DEPT SOCIAL SCI,PROJECT SIGMA,LONDON SE1 0AA,ENGLAND.		Weatherburn, Peter/AAC-2701-2019	Weatherburn, Peter/0000-0002-4950-6163				GELLAN MCA, 1986, LANCET, V2, P920; HUNT AJ, 1990, GENITOURIN MED, V66, P423; MCMANUS TJ, 1987, BRIT J SEX MED, V20, P110; WEATHERBURN P, 1990, AIDS Care, V2, P319, DOI 10.1080/09540129008257747; 1988, SHORT TERM PREDICTIO	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					505	506		10.1136/bmj.302.6775.505	http://dx.doi.org/10.1136/bmj.302.6775.505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	2012847	Green Published, Bronze			2022-12-24	WOS:A1991FB05500020
J	NORTH, CS; ALPERS, DH; HELZER, JE; SPITZNAGEL, EL; CLOUSE, RE				NORTH, CS; ALPERS, DH; HELZER, JE; SPITZNAGEL, EL; CLOUSE, RE			DO LIFE EVENTS OR DEPRESSION EXACERBATE INFLAMMATORY BOWEL-DISEASE - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						INFLAMMATORY BOWEL DISEASE; PSYCHIATRIC STATUS RATING SCALES; DEPRESSION; COLITIS, ULCERATIVE; CROHN DISEASE	CROHNS-DISEASE; PSYCHIATRIC-ILLNESS; ULCERATIVE-COLITIS; ASSOCIATION; DISORDERS	Objective: To determine whether depressed mood or life events are associated with an exacerbation of inflammatory bowel disease. Design: A prospective study of a consecutive sample of patients with relapsing inflammatory bowel disease, followed by monthly questionnaires and periodic office visits. Setting: A referral-based gastroenterology clinic at a medical school. Patients: A consecutive sample of 32 patients with inflammatory bowel disease who had had at least one relapse in a 2-year period after entry into the study. Measurements and Main Results: The Social Readjustment Rating Scale (measuring life events), the Beck Depression Inventory (a visual analog scale for depressed mood) and an inventory of intestinal symptoms were completed monthly by each subject with a 78% rate of compliance. A mean of 2.2 exacerbations was seen per subject during the study period. Life events were not temporally associated with changes in intestinal symptoms. Significant associations were found between intestinal symptoms and the two mood scales (P < 0.05 for each), but no directionality in symptom occurrence could be detected in a time-lagged analysis. The results were similar when the months preceding exacerbations of inflammatory bowel disease were analyzed separately. Conclusions: Although these findings suggest that mood changed concurrently with exacerbation of inflammatory bowel disease, no evidence indicated that stressful life events or depressed mood precipitated exacerbations in this study group.	WASHINGTON UNIV, SCH MED, DEPT BIOSTAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MATH, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	NORTH, CS (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, 4940 AUDUBON AVE, ST LOUIS, MO 63110 USA.							ANDREWS H, 1987, GUT, V28, P1600, DOI 10.1136/gut.28.12.1600; ARAPAKIS G, 1986, PSYCHOTHER PSYCHOSOM, V46, P171, DOI 10.1159/000287981; BACHMAN JG, 1984, PUBLIC OPIN QUART, V48, P491, DOI 10.1086/268845; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CAMPBELL D, 1986, GASTROENTEROLOGY, V90, P1364; CREED F, 1988, GUT, V29, P235, DOI 10.1136/gut.29.2.235; DROSSMAN DA, 1986, STRESS MEDICINE, V2, P119, DOI 10.1002/smi.2460020209; DRUSS RG, 1969, ARCH GEN PSYCHIAT, V20, P419; FAVA GA, 1977, PSYCHOTHER PSYCHOSOM, V27, P100; FINLAYJONES R, 1981, AUST NZ J PSYCHIAT, V15, P229, DOI 10.3109/00048678109159440; FREEMAN H, 1986, STRESS MEDICINE, V2, P291, DOI 10.1002/smi.2460020404; GAZZARD BG, 1978, BRIT MED J, V2, P1117, DOI 10.1136/bmj.2.6145.1117; GERBERT B, 1980, Journal of Behavioral Medicine, V3, P41, DOI 10.1007/BF00844913; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GOLDBERG D, 1970, GUT, V11, P459, DOI 10.1136/gut.11.6.459; HELZER JE, 1982, DIGEST DIS SCI, V27, P513, DOI 10.1007/BF01296730; HELZER JE, 1984, GASTROENTEROLOGY, V86, P324; HELZER JE, 1985, COLON RECTAL ANAL SU, P329; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; LATIMER PR, 1978, PSYCHOL MED, V8, P649, DOI 10.1017/S0033291700018857; Lourens P J, 1973, Ala J Med Sci, V10, P285; MURRAY JB, 1984, J GEN PSYCHOL, V110, P201, DOI 10.1080/00221309.1984.9709964; NORTH CS, 1990, AM J PSYCHIAT, V147, P974; PAYKEL ES, 1976, BRIT J MED PSYCHOL, V49, P237, DOI 10.1111/j.2044-8341.1976.tb02370.x; ROSE JDR, 1986, GUT, V27, P1025, DOI 10.1136/gut.27.9.1025; SCHWARTZ RA, 1982, INT J PSYCHIAT MED, V12, P67, DOI 10.2190/FL8Y-1WU6-1N5L-1FQV; SUDMAN S, 1974, RESPONSE EFFECTS SUR, P93; TARTER RE, 1987, INT J PSYCHIAT MED, V17, P173; WELLS KB, 1988, AM J PSYCHIAT, V145, P976; WHYBROW PC, 1968, PSYCHOSOM MED, V30, P209, DOI 10.1097/00006842-196803000-00006; WHYBROW PC, 1973, EMOTIONAL FACTORS GA, P82; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; YOUNG SJ, 1976, GASTROENTEROLOGY, V70, P162	33	135	136	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					381	386		10.7326/0003-4819-114-5-381	http://dx.doi.org/10.7326/0003-4819-114-5-381			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992880				2022-12-24	WOS:A1991EZ17400006
J	BARNARD, SM; WALT, DR				BARNARD, SM; WALT, DR			CHEMICAL SENSORS BASED ON CONTROLLED-RELEASE POLYMER SYSTEMS	SCIENCE			English	Article							FIBER	A novel chemical sensor has been developed in which the polymer ethylene-vinyl acetate is used as a controlled-release system to deliver reagents to the sensing region of an optical fiber for a homogeneous competitive immunoassay based on fluorescence energy transfer. A competition reaction is used to enable continuous measurements of the solution antigen concentration. More generally, the technique allows irreversible indicating chemistries to be used in the construction of chemical sensors that can measure continuously for long periods. Although the sensor configuration has not been optimized in all respects, data are presented for a model system in which a fluorescein-labeled antibody and Texas Red-labeled immunoglobulin G (IgG) are used.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155	Tufts University								ANDERSON FP, 1988, CLIN CHEM, V34, P1417; Bawa R., 1985, J CONTR RELEASE, V1, P259, DOI [10.1016/0168-3659(85)90002-1, DOI 10.1016/0168-3659(85)90002-1]; BRIGHT FV, 1990, ANAL CHEM, V62, P1065, DOI 10.1021/ac00209a019; CHRISTIAN LM, 1988, TALANTA, V35, P119, DOI 10.1016/0039-9140(88)80049-3; Forster T, 1959, DISCUSS FARADAY SOC, V27, P7, DOI DOI 10.1039/DF9592700007; HELLER J, 1980, BIOMATERIALS, V1, P51, DOI 10.1016/0142-9612(80)90060-5; INMAN SM, 1989, ANAL CHIM ACTA, V217, P249, DOI 10.1016/S0003-2670(00)80407-9; JANATA J, 1990, ANAL CHEM, V62, pR33, DOI 10.1021/ac00211a017; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LUO SF, 1989, ANAL CHEM, V61, P174, DOI 10.1021/ac00177a019; NISONOFF A, 1985, INTRO MOL IMMUNOLOGY, P29; ODONNELL CM, 1979, ANAL CHEM, V51, pA33, DOI 10.1021/ac50037a003; SCHULMAN SG, 1985, MOL LUMINESCENCE S 1, V77, P1; SEITZ WR, 1988, CRC CR REV ANAL CHEM, V19, P135, DOI 10.1080/10408348808542810; SOINI E, 1979, CLIN CHEM, V25, P353; TROMBERG BJ, 1987, ANAL CHEM, V59, P1226, DOI 10.1021/ac00135a033	16	52	55	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					927	929		10.1126/science.2000492	http://dx.doi.org/10.1126/science.2000492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000492				2022-12-24	WOS:A1991EY62900040
J	YELLEN, G; JURMAN, ME; ABRAMSON, T; MACKINNON, R				YELLEN, G; JURMAN, ME; ABRAMSON, T; MACKINNON, R			MUTATIONS AFFECTING INTERNAL TEA BLOCKADE IDENTIFY THE PROBABLE PORE-FORMING REGION OF A K+ CHANNEL	SCIENCE			English	Article							POTASSIUM CHANNELS; GIANT-AXONS; FLUX RATIO; IONS; CHARYBDOTOXIN; DROSOPHILA	The active site of voltage-activated potassium channels is a transmembrane aqueous pore that permits ions to permeate the cell membrane in a rapid yet highly selective manner. A useful probe for the pore of potassium-selective channels is the organic ion tetraethylammonium (TEA), which binds with millimolar affinity to the intracellular opening of the pore and blocks potassium current. In the potassium channel encoded by the Drosophila Shaker gene, an amino acid residue that specifically affects the affinity for intracellular TEA has now been identified by site-directed mutagenesis. This residue is in the middle of a conserved stretch of 18 amino acids that separates two locations that are both near the external opening of the pore. These findings suggest that this conserved region is intimately involved in the formation of the ion conduction pore of voltage-activated potassium channels. Further, a stretch of only eight amino acid residues must traverse 80 percent of the transmembrane electric potential difference.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS CHEM,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School	YELLEN, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.			Yellen, Gary/0000-0003-4228-7866	NIGMS NIH HHS [GM4399] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BEGENISICH T, 1980, J GEN PHYSIOL, V76, P83, DOI 10.1085/jgp.76.1.83; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; FRENCH RJ, 1981, BIOPHYS J, V34, P271, DOI 10.1016/S0006-3495(81)84849-7; GUY HR, 1989, MONOVALENT CATIONS B; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; HOROWICZ P, 1968, J GEN PHYSIOL, V51, pS193; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KOPPENHOFER E, 1969, PFLUG ARCH EUR J PHY, V313, P361, DOI 10.1007/BF00593959; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MACKINNON R, IN PRESS NATURE; MACKINNON RN, UNPUB; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SPALDING BC, 1981, AM J PHYSIOL, V241, pC68, DOI 10.1152/ajpcell.1981.241.1.C68; STANFIELD PR, 1983, REV PHYSIOL BIOCH P, V97, P1, DOI 10.1007/BFb0035345; Stryer L., 1988, BIOCHEMISTRY-US; TASAKI I, 1957, J GEN PHYSIOL, V40, P859, DOI 10.1085/jgp.40.6.859; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; VILLARROEL A, 1988, PFLUG ARCH EUR J PHY, V413, P118, DOI 10.1007/BF00582521; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YELLEN G, 1987, ANNU REV BIOPHYS BIO, V16, P227	32	562	569	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					939	942		10.1126/science.2000494	http://dx.doi.org/10.1126/science.2000494			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000494				2022-12-24	WOS:A1991EY62900045
J	KITZMILLER, JL; GAVIN, LA; GIN, GD; JOVANOVICPETERSON, L; MAIN, EK; ZIGRANG, WD				KITZMILLER, JL; GAVIN, LA; GIN, GD; JOVANOVICPETERSON, L; MAIN, EK; ZIGRANG, WD			PRECONCEPTION CARE OF DIABETES - GLYCEMIC CONTROL PREVENTS CONGENITAL-ANOMALIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RAT-EMBRYO CULTURE; EARLY-PREGNANCY; SPONTANEOUS-ABORTION; EARLY EMBRYOGENESIS; ARACHIDONIC-ACID; INFANTS; MALFORMATIONS; MOTHERS; ORGANOGENESIS; HYPERGLYCEMIA	To test the value of intensive management of diabetes before and during early pregnancy, 84 women recruited prior to conception were compared with 110 women who were already pregnant referred at 6 to 30 weeks' gestation. All underwent daily measurement of fasting and postprandial capillary blood glucose levels. Mean blood glucose levels during embryogenesis and organogenesis were within 3.3 to 7.8 mmol/L in 50% of preconception subjects and exceeded 10 mmol/L in 6.5%. One major congenital anomaly occurred in 84 infants (1.2%) of women treated before conception compared with 12 anomalies in 110 infants (10.9%) of mothers in the postconception group. Transient symptomatic hypoglycemia occurred during embryogenesis in 60% of women in the preconception group, with a median frequency of 2.7 episodes per week, but was not associated with excess malformations. We conclude that education and intensive management for glycemic control of diabetic women before and during early pregnancy will prevent excess rates of congenital anomalies in their infants.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; CHILDRENS HOSP,SAN FRANCISCO,CA 94119	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	KITZMILLER, JL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,ROOM M-1489,SAN FRANCISCO,CA 94143, USA.							AKAZAWA M, 1989, DIABETES, V38, P1573, DOI 10.2337/diabetes.38.12.1573; BUCHANAN TA, 1986, J CLIN INVEST, V78, P643, DOI 10.1172/JCI112622; BUCHANAN TA, 1989, DIABETES, V38, P1063, DOI 10.2337/diabetes.38.8.1063; COUSINS L, 1983, AM J OBSTET GYNECOL, V147, P333, DOI 10.1016/0002-9378(83)91122-5; CROCKROFT DL, 1977, TERATOLOGY, V16, P141; DAMM P, 1989, AM J OBSTET GYNECOL, V161, P1163, DOI 10.1016/0002-9378(89)90656-X; ERIKSSON UJ, 1988, TERATOLOGY, V37, P365, DOI 10.1002/tera.1420370410; FREINKEL N, 1986, AM J CLIN NUTR, V44, P986, DOI 10.1093/ajcn/44.6.986; FREINKEL N, 1984, NEW ENGL J MED, V310, P223, DOI 10.1056/NEJM198401263100404; FUHRMANN K, 1983, DIABETES CARE, V6, P219, DOI 10.2337/diacare.6.3.219; Gabbe S G, 1977, Obstet Gynecol Surv, V32, P125, DOI 10.1097/00006254-197703000-00001; GOLDMAN AS, 1985, P NATL ACAD SCI USA, V82, P8227, DOI 10.1073/pnas.82.23.8227; GOLDMAN JA, 1986, AM J OBSTET GYNECOL, V155, P293, DOI 10.1016/0002-9378(86)90812-4; GREENE MF, 1989, TERATOLOGY, V39, P225, DOI 10.1002/tera.1420390303; HARE JW, 1980, DIABETES CARE, V3, P294; HOD M, 1986, BIOCHEM BIOPH RES CO, V140, P974, DOI 10.1016/0006-291X(86)90731-X; HORTON WE, 1983, DIABETES, V32, P610, DOI 10.2337/diabetes.32.7.610; HUNTER ES, 1987, AM J PHYSIOL, V253, pE72, DOI 10.1152/ajpendo.1987.253.1.E72; KARLSSON K, 1972, AM J OBSTET GYNECOL, V112, P213, DOI 10.1016/0002-9378(72)90118-4; KEY TC, 1987, AM J OBSTET GYNECOL, V156, P1096, DOI 10.1016/0002-9378(87)90117-7; KITZMILLER JL, 1978, AM J OBSTET GYNECOL, V131, P560, DOI 10.1016/0002-9378(78)90120-5; KITZMILLER JL, 1988, CURR PROBL OBSTET GY, V11, P107; KITZMILLER JL, 1985, OBSTET GYNECOL, V66, P1177; LESLIE RDG, 1978, LANCET, V2, P958; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; MILLS JL, 1988, NEW ENGL J MED, V318, P671, DOI 10.1056/NEJM198803173181104; MIODOVNIK M, 1988, DIABETES CARE, V11, P713, DOI 10.2337/diacare.11.9.713; PEDERSEN J, 1977, PREGNANT DIABETIC HE; PIAQUADI K, 1990, DIABETES S1, V39, pA123; PINTER E, 1986, AM J OBSTET GYNECOL, V155, P691, DOI 10.1016/S0002-9378(86)80001-1; SADLER TW, 1980, TERATOLOGY, V21, P349, DOI 10.1002/tera.1420210311; SADLER TW, 1989, DIABETES, V38, P70, DOI 10.2337/diabetes.38.1.70; SOSENKO JM, 1982, DIABETES CARE, V5, P566, DOI 10.2337/diacare.5.6.566; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; SUSSMAN I, 1988, DIABETES, V37, P974, DOI 10.2337/diabetes.37.7.974; YLINEN K, 1984, BRIT MED J, V289, P345, DOI 10.1136/bmj.289.6441.345	38	350	359	2	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					731	736		10.1001/jama.265.6.731	http://dx.doi.org/10.1001/jama.265.6.731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990188				2022-12-24	WOS:A1991EW47900024
J	DENTON, M; MORGAN, MS; WHITE, RR				DENTON, M; MORGAN, MS; WHITE, RR			QUALITY OF PRESCRIBING OF INTRAVENOUS ANTIBIOTICS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									WALTON HOSP,DEPT MICROBIOL,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND	University of Liverpool; Walton Centre				morgan, marina/0000-0002-9336-481X				BAIN PG, 1990, BRIT MED J, V300, P1463; BAKKERWOUDENBERG IAJM, 1988, J ANTIMICROB CHEMOTH, V21, P145, DOI 10.1093/jac/21.2.145; BROWN B, 1989, ANN INTERN MED, V110, P247, DOI 10.7326/0003-4819-110-3-247; ZALIN AM, 1989, BRIT MED J, V299, P1279, DOI 10.1136/bmj.299.6710.1279	4	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					327	328		10.1136/bmj.302.6772.327-a	http://dx.doi.org/10.1136/bmj.302.6772.327-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001508	Bronze, Green Published			2022-12-24	WOS:A1991EX56900024
J	LAWSON, DM; ARTYMIUK, PJ; YEWDALL, SJ; SMITH, JMA; LIVINGSTONE, JC; TREFFRY, A; LUZZAGO, A; LEVI, S; AROSIO, P; CESARENI, G; THOMAS, CD; SHAW, WV; HARRISON, PM				LAWSON, DM; ARTYMIUK, PJ; YEWDALL, SJ; SMITH, JMA; LIVINGSTONE, JC; TREFFRY, A; LUZZAGO, A; LEVI, S; AROSIO, P; CESARENI, G; THOMAS, CD; SHAW, WV; HARRISON, PM			SOLVING THE STRUCTURE OF HUMAN H-FERRITIN BY GENETICALLY ENGINEERING INTERMOLECULAR CRYSTAL CONTACTS	NATURE			English	Article							HORSE SPLEEN APOFERRITIN; SUBUNIT GENE; ESCHERICHIA-COLI; CHAIN FERRITINS; IRON; EXPRESSION; RESOLUTION; IDENTIFICATION; CONSERVATION; PSEUDOGENE	FERRITIN is important in iron homeostasis. Its twenty-four chains of two types, H and L, assemble as a hollow shell providing an iron-storage cavity 1-3. Ferritin molecules in cells containing high levels of iron tend to be rich in L chains, and may have a long-term storage function, whereas H-rich ferritins are more active in iron metabolism 3-7. The molecular basis for the greater activity of H-rich ferritins has until now been obscure, largely because the structure of H-chain ferritin has remained unknown owing to the difficulties in obtaining crystals ordered enough for X-ray crystallographic analysis. Here we report the three-dimensional structure of a human ferritin H-chain homopolymer. By genetically engineering a change in the sequence of the intermolecular contact region, we obtained crystals isomorphous with the homologous rat L ferritin 8,9 and of high enough quality for X-ray diffraction analysis. The X-ray structure of human H ferritin shows a novel metal site embedded within each of its four-helix bundles and we suggest that ferroxidase activity associated with this site accounts for its rapid uptake of iron 10.	UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; UNIV MILANO,OSPED SAN RAFFAELE,DIPARTIMENTO SCI & TECNOL BIOMED,I-20132 MILAN,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO BIOL,I-00173 ROME,ITALY; UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7HR,ENGLAND	University of Sheffield; European Molecular Biology Laboratory (EMBL); Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Rome Tor Vergata; University of Leicester			Cesareni, Gianni/AAW-1382-2020; arosio, paolo/S-3272-2019; arosio, paolo/E-6817-2010; levi, sonia/A-3161-2015; Thomas, Christopher D./E-1236-2015; Lawson, David M/D-1810-2009	arosio, paolo/0000-0002-5343-8992; levi, sonia/0000-0002-5092-0847; Thomas, Christopher D./0000-0003-0316-6391; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AROSIO P, 1978, J BIOL CHEM, V253, P4451; AROSIO P, 1983, BIOCHIM BIOPHYS ACTA, V774, P230; BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BOYD D, 1985, J BIOL CHEM, V260, P1755; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CONNOLLY MJ, 1983, J APPL CRYSTALLOGR, V16, P23; DANIELSMCQUEEN S, 1988, NUCLEIC ACIDS RES, V16, P7741, DOI 10.1093/nar/16.15.7741; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FRASER RDB, 1978, J APPL CRYSTALLOGR, V11, P693, DOI 10.1107/S0021889878014296; HARRISON PM, 1989, BIOMINERALIZATION CH, P257; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1990, THESIS SHEFFIELD U; LEIBOLD EA, 1987, J BIOL CHEM, V262, P7335; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THOMAS CD, 1988, BIOCHEM SOC T, V16, P838, DOI 10.1042/bst0160838; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; TREFFRY A, 1989, FEBS LETT, V247, P268, DOI 10.1016/0014-5793(89)81350-X	30	668	690	2	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					541	544		10.1038/349541a0	http://dx.doi.org/10.1038/349541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992356				2022-12-24	WOS:A1991EW57100073
J	SIDDIQUE, T; FIGLEWICZ, DA; PERICAKVANCE, MA; HAINES, JL; ROULEAU, G; JEFFERS, AJ; SAPP, P; HUNG, WY; BEBOUT, J; MCKENNAYASEK, D; DENG, G; HORVITZ, HR; GUSELLA, JF; BROWN, RH; ROSES, AD				SIDDIQUE, T; FIGLEWICZ, DA; PERICAKVANCE, MA; HAINES, JL; ROULEAU, G; JEFFERS, AJ; SAPP, P; HUNG, WY; BEBOUT, J; MCKENNAYASEK, D; DENG, G; HORVITZ, HR; GUSELLA, JF; BROWN, RH; ROSES, AD			LINKAGE OF A GENE CAUSING FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS TO CHROMOSOME-21 AND EVIDENCE OF GENETIC-LOCUS HETEROGENEITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOTOR NEURON DISEASE; COMMITTEE; MAPS	Background. Amyotrophic lateral sclerosis is a progressive neurologic disorder that commonly results in paralysis and death. Despite more than a century of research, no cause of, cure for, or means of preventing this disorder has been found. In a minority of cases, it is familial and inherited as an autosomal dominant trait with age-dependent penetrance. In contrast to the sporadic form of amyotrophic lateral sclerosis, the familial form provides the opportunity to use molecular genetic techniques to localize an inherited defect. Furthermore, such studies have the potential to discover the basic molecular defect causing motor-neuron degeneration. Methods and Results. We evaluated 23 families with familial amyotrophic lateral sclerosis for linkage of the gene causing this disease to four DNA markers on the long arm of chromosome 21. Multipoint linkage analyses demonstrated linkage between the gene and these markers. The maximum lod score - 5.03 - was obtained 10 centimorgans distal (telomeric) to the DNA marker D21S58. There was a significant probability (P < 0.0001) of genetic-locus heterogeneity in the families. Conclusions. The localization of a gene causing familial amyotrophic lateral sclerosis provides a means of isolating this gene and studying its function. Insight gained from understanding the function of this gene may be applicable to the design of rational therapy for both the familial and sporadic forms of the disease.	MCGILL UNIV, CTR RES NEUROSCI, MONTREAL H3A 2T5, QUEBEC, CANADA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; MIT, CAMBRIDGE, MA 02139 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA	McGill University; Duke University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	SIDDIQUE, T (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT NEUROL, SEARLE 11-543, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Haines, Jonathan/C-3374-2012; halperin, john/X-6433-2019; Siddique, Teepu/AAT-8166-2021	Haines, Jonathan/0000-0002-4351-4728; halperin, john/0000-0003-1170-1710; Siddique, Teepu/0000-0001-7293-9146; mathews, katherine/0000-0003-4160-0435	NINDS NIH HHS [P0-NS-21442, P0-NS-26630, NS-20012] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630, P50NS021442, P01NS021442, R01NS020012] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Emery A E, 1982, Adv Neurol, V36, P139; ENGEL WK, 1959, BRAIN, V82, P203, DOI 10.1093/brain/82.2.203; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; HORTON WA, 1976, NEUROLOGY, V26, P460, DOI 10.1212/WNL.26.5.460; Hughes J T, 1982, Adv Neurol, V36, P61; KEATS B, 1989, CYTOGENET CELL GENET, V51, P459, DOI 10.1159/000132805; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KURLAND LT, 1955, NEUROLOGY, V5, P182, DOI 10.1212/WNL.5.3.182; KURLAND LT, 1955, NEUROLOGY, V5, P249, DOI 10.1212/WNL.5.4.249; Kurtzke J, 1989, CLIN NEUROLOGY, P1; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Mulder D W, 1982, Adv Neurol, V36, P15; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; MYRIANTHOPOULOS NC, 1954, AM J HUM GENET, V6, P387; OSLER W, 1880, ARCH MED, V4, P316; OTT J, 1985, ANAL HUMAN GENETIC L, P111; SIDDIQUE T, 1990, ANN NEUROL, V28, P269; SIDDIQUE T, 1989, NEUROLOGY, V39, P919, DOI 10.1212/WNL.39.7.919; SIDDIQUE T, 1990, Neurology, V40, P315; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; WILLIAMS DB, 1988, J NEUROL SCI, V86, P215, DOI 10.1016/0022-510X(88)90100-1	22	378	382	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1381	1384		10.1056/NEJM199105163242001	http://dx.doi.org/10.1056/NEJM199105163242001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020294				2022-12-24	WOS:A1991FL12500001
J	VANHOOFT, IMS; GROBBEE, DE; DERKX, FHM; DELEEUW, PW; SCHALEKAMP, MADH; HOFMAN, A				VANHOOFT, IMS; GROBBEE, DE; DERKX, FHM; DELEEUW, PW; SCHALEKAMP, MADH; HOFMAN, A			RENAL HEMODYNAMICS AND THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM IN NORMOTENSIVE SUBJECTS WITH HYPERTENSIVE AND NORMOTENSIVE PARENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CALCIUM ENTRY BLOCKADE; BLOOD-PRESSURE; RESPONSES; PLASMA; RADIOIMMUNOASSAY; TRANSPLANTATION; PREDICTION; PRORENIN; FAILURE	Background and Methods. The kidney is important in blood-pressure regulation, but its role in the development of essential hypertension is still subject to debate. We compared renal hemodynamics, measured in terms of the clearance of para-aminohippuric acid and inulin, and the characteristics of the renin-angiotensin-aldosterone system in three groups of normotensive subjects at different degrees of risk for hypertension: 41 subjects with two normotensive parents, 52 with one normotensive and one hypertensive parent, and 61 with two hypertensive parents. The subjects ranged in age from 7 to 32 years. Results. The mean renal blood flow was lower in the subjects with two hypertensive parents than in those with two normotensive parents (mean difference [+/- SE], 198 +/- 61 ml per minute per 1.73 m2 of body-surface area; P = 0.002). Moreover, both the filtration fraction and renal vascular resistance were higher in the subjects with two hypertensive parents (filtration fraction: mean difference, 3.0 +/- 1.1 percentage points; P = 0.006; renal vascular resistance: mean difference, 2.7 +/- 0.8 mm Hg per deciliter per minute per 1.73 m2; P = 0.006). The subjects with two hypertensive parents had lower plasma concentrations of renin (mean difference, 3.3 +/- 1.6 mU per liter; P = 0.03) and aldosterone (mean difference, 111 +/- 36 pmol per liter; P = 0.003) than those with two normotensive parents. The differences could not be explained by the small differences in blood pressure between the groups. The values in the subjects with one hypertensive and one normotensive parent fell between those for the other two groups. Conclusions. Renal vasoconstriction is increased and renin and aldosterone secretion is decreased in young persons at risk for hypertension. These findings support the hypothesis that alterations in renal hemodynamics occur at an early stage in the development of familial hypertension.	ERASMUS UNIV, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS; ZUIDERZIEKENHUIS, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS; ERASMUS UNIV, HOSP DIJKZIGT, DEPT INTERNAL MED 1, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC			Grobbee, Diederick/C-7651-2014; de Leeuw, Peter W./J-4552-2016	Grobbee, Diederick/0000-0003-4472-4468; de Leeuw, Peter W./0000-0002-4949-5812				BELLO CT, 1965, AM J MED SCI, V250, P24, DOI 10.1097/00000441-196507000-00005; BERGER EY, 1948, J CLIN INVEST, V27, P710, DOI 10.1172/JCI102020; BIANCHI G, 1983, KIDNEY INT, V23, P870, DOI 10.1038/ki.1983.109; BIANCHI G, 1974, CLIN SCI MOL MED, V47, P435, DOI 10.1042/cs0470435; BIANCHI G, 1979, LANCET, V1, P173, DOI 10.1016/S0140-6736(79)90577-4; BLACKSHEAR JL, 1987, HYPERTENSION, V9, P384, DOI 10.1161/01.HYP.9.4.384; BROWN JJ, 1976, LANCET, V1, P1217; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; De Leeuw P. W., 1981, HYPERTENSION YOUNG O, P57; DELEEUW PW, 1987, ACTA MED SCAND S, V622, P5; DERKX FHM, 1983, HYPERTENSION, V5, P244, DOI 10.1161/01.HYP.5.2.244; DERKX FHM, 1987, J CLIN ENDOCR METAB, V65, P349, DOI 10.1210/jcem-65-2-349; DLUHY RG, 1988, J CARDIOVASC PHARM, V12, pS149; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; GUIDI E, 1985, NEPHRON, V41, P14, DOI 10.1159/000183539; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; GUYTON AC, 1984, NETH J MED, V27, P117; HARRAP SB, 1986, J HYPERTENS, V4, pS249; HOFMAN A, 1980, EPIDEMIOLOGY ARTERIA, V8, P99; Hollenberg N K, 1970, Trans Assoc Am Physicians, V83, P93; HOLLENBERG NK, 1978, MEDICINE, V57, P167, DOI 10.1097/00005792-197803000-00004; HOLLENBERG NK, 1986, AM J MED, V81, P412, DOI 10.1016/0002-9343(86)90291-3; HOLLENBERG NK, 1981, HYPERTENSION, V3, P11, DOI 10.1161/01.HYP.3.1.11; LIJNEN PJ, 1978, CLIN CHIM ACTA, V88, P403, DOI 10.1016/0009-8981(78)90447-3; LONDON GM, 1988, AM J HYPERTENS, V1, pS127, DOI 10.1093/ajh/1.3.127S; LOWENSTEIN J, 1967, CIRCULATION, V35, P250, DOI 10.1161/01.CIR.35.2.250; MALVANO R, 1976, J NUCL BIOL MED, V20, P37; MESSERLI FH, 1978, CIRCULATION, V58, P441, DOI 10.1161/01.CIR.58.3.441; MONTANARI A, 1988, HYPERTENSION, V12, P498, DOI 10.1161/01.HYP.12.5.498; REUBI FC, 1978, AM J MED, V64, P556, DOI 10.1016/0002-9343(78)90573-9; SCHALEKAMP MA, 1970, CLIN SCI, V38, P101, DOI 10.1042/cs0380101; SHOBACK DM, 1983, J CLIN INVEST, V72, P2115, DOI 10.1172/JCI111176; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; UNEDA S, 1984, J HYPERTENS       S3, V2, P437; VANHOOFT IM, 1988, J HYPERTENS, V6, pS594, DOI 10.1097/00004872-198812040-00186; VANHOOFT IMS, 1988, INT J EPIDEMIOL, V17, P228, DOI 10.1093/ije/17.1.228; WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001	38	135	136	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1305	1311		10.1056/NEJM199105093241902	http://dx.doi.org/10.1056/NEJM199105093241902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017226				2022-12-24	WOS:A1991FK18600002
J	BACHORIK, PS; CLOEY, TA; FINNEY, CA; LOWRY, DR; BECKER, DM				BACHORIK, PS; CLOEY, TA; FINNEY, CA; LOWRY, DR; BECKER, DM			LIPOPROTEIN-CHOLESTEROL ANALYSIS DURING SCREENING - ACCURACY AND RELIABILITY	ANNALS OF INTERNAL MEDICINE			English	Article							PROGRAM; PRECISION; PLASMA	Objective: To evaluate the accuracy and reliability of lipoprotein-cholesterol measurements obtained during screening. Design: Cross-sectional study. Participants: From November 1989 to January 1990, 154 adults were screened. Measurements: Split venous samples from fasting participants were analyzed for total cholesterol, triglyceride, and high-density-lipoprotein (HDL) cholesterol with screening and standardized laboratory methods. Low-density-lipoprotein (LDL)-cholesterol levels were calculated using the Friedewald equation. Split venous samples from nonfasting participants were analyzed for total cholesterol. Capillary blood samples were analyzed for total cholesterol with the screening method. Main Results: Total cholesterol measurements in screening venous blood samples were 5.4% and 3.8% lower than the laboratory values in samples from fasting and nonfasting participants, respectively. Triglyceride and HDL-cholesterol values in venous samples obtained from fasting participants were, on average, 9.8% and 11.2% lower than the respective laboratory measurements. Screening HDL-cholesterol values varied, differing from the laboratory values by as much as 40% in 95% of participants. In fasting participants, total cholesterol in capillary samples averaged 5.5% higher than in venous samples; in nonfasting participants the capillary samples were 3.1% higher. Screening for either total cholesterol or LDL cholesterol identified 93% of the persons with LDL-cholesterol values of 3.36 mmol/L (130 mg/dL) or higher. Conclusions: Total cholesterol can be reliably measured in samples from fasting or nonfasting persons. The values in capillary blood samples were slightly higher than those in venous samples. Screening HDL-cholesterol values were too variable to establish the HDL-cholesterol level reliably. Participants with high LDL-cholesterol levels were identified as accurately by measuring total cholesterol only when compared with calculating the LDL-cholesterol level from total cholesterol, triglyceride, and HDL-cholesterol concentrations.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University								[Anonymous], 1977, CLIN CHEM, V23, P60; BACHORIK PS, 1989, CLIN CHEM, V35, P1734; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CLOEY T, 1990, JAMA-J AM MED ASSOC, V263, P2788, DOI 10.1001/jama.263.20.2788; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GREENLAND P, 1987, AM J PUBLIC HEALTH, V77, P73, DOI 10.2105/AJPH.77.1.73; HAVAS S, 1989, AM J PREV MED, V5, P337, DOI 10.1016/S0749-3797(18)31054-7; KOCH TR, 1987, CLIN CHEM, V33, P2262; KWITEROVICH PO, 1986, CIRCULATION, V73, P30; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; SNEDECOR GW, 1968, STATISTICAL METHODS, P56; WARNICK GR, 1978, J LIPID RES, V19, P65; WONES RG, 1989, PUBLIC HEALTH REP, V104, P425; 1984, JAMA-J AM MED ASSOC, V251, P1196; 1989, NIH893045 US DEP HLT	17	26	26	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					741	747		10.7326/0003-4819-114-9-741	http://dx.doi.org/10.7326/0003-4819-114-9-741			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012356				2022-12-24	WOS:A1991FJ11700006
J	HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH				HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH			INABILITY TO ASSESS BREATH SOUNDS DURING AIR MEDICAL TRANSPORT BY HELICOPTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								This study assessed the capabilities of a traditional and an amplified stethoscope used by flight nurses to assess breath sounds during air medical transport in an MBB BO-105 helicopter. We developed a normal breath sound model using a prerecorded tape of breath sounds interspersed with segments without breath sounds; the recorder had been placed in the chest wall of a resuscitation training manikin. Flight nurses completed control listening sessions in a quiet environment and experimental sessions during flight using a traditional stethoscope for half of the sessions and an amplified stethoscope for the remaining half. In the quiet environment, flight nurses accurately reported the presence or absence of breath sounds in 110 (92%) of 120 trials. During helicopter flight, none of the flight nurses heard breath sounds during any of the recorded segments with either the traditional stethoscope or the amplified stethoscope. We conclude that flight nurses are unable to hear normal breath sounds using a traditional or amplified stethoscope during flight in a medically configured MBB BO-105 helicopter. Improved stethoscopes, innovative methods of listening, and reduction of aircraft noise are potential solutions to the problems of breath sound assessment during air medical transport.	PITT CTY MEM HOSP,EASTCARE EMERGENCY AIR MED SERV,GREENVILLE,NC		HUNT, RC (corresponding author), E CAROLINA UNIV,SCH MED,DEPT EMERGENCY MED,MOYE BLVD,GREENVILLE,NC 27858, USA.							BISHOP LC, 1990, JAMA-J AM MED ASSOC, V263, P233, DOI 10.1001/jama.1990.03440020067017; COLLETT HM, 1990, J AIR MED TRANSP JUL, P20; DICK T, 1986, JEMS, V11, P77; GASAWAY DC, 1986, AVIAT SPACE ENVIR MD, V57, P103; HARMS T, 1990, J AIR MED TRANSP OCT, P76; HUNT RC, 1990, 1990 ROCK MOUNT C EM; PASIC TB, 1985, ARCH OTOLARYNGOL, V111, P507; WILKINS RL, 1988, LUNG SOUNDS PRACTICA; 1990, J AIR MED TRANSP MAR, P6	9	46	47	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1982	1984		10.1001/jama.265.15.1982	http://dx.doi.org/10.1001/jama.265.15.1982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008028				2022-12-24	WOS:A1991FF76800025
J	HAYES, JJ; STEWART, RB; GREENE, HL; BARDY, GH				HAYES, JJ; STEWART, RB; GREENE, HL; BARDY, GH			NARROW QRS VENTRICULAR-TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							BUNDLE-BRANCH-BLOCK; DIFFERENTIAL-DIAGNOSIS; FASCICULAR TACHYCARDIA; COMPLEX TACHYCARDIA; THERAPY; REENTRY	Objective: To determine the frequency and clinical characteristics of narrow Design: Consecutive survey of patients with ventricular tachycardia. Setting: Tertiary, referral-based arrhythmia service at a university medical center. Patients: Sequential sample of patients with inducible ventricular tachycardia who had a 12-lead electrocardiogram of the tachycardia available for review. Measurements and Main Results: Of 106 patients with ventricular tachycardia, 5 (4.7%; 95% CI, 2.1% to 10.6%) had ventricular tachycardia with a QRS duration less-than-or-equal-to 0.11 seconds. Three of the five patients were previously incorrectly diagnosed as having supraventricular tachycardia. All five patients had at least two electrocardiographic findings other than QRS duration to suggest ventricular tachycardia. Conclusions: Narrow QRS ventricular tachycardia should be considered in the differential diagnosis of narrow QRS tachycardias. Electrocardiographic findings other than QRS duration are usually present to suggest the diagnosis.			HAYES, JJ (corresponding author), UNIV WASHINGTON, MED CTR, MAIL STOP RG-22, 1959 NE PACIFIC, SEATTLE, WA 98195 USA.				PHS HHS [31472, 36170] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAR FW, 1984, AM J CARDIOL, V54, P555, DOI 10.1016/0002-9149(84)90247-9; BROHET C, 1988, ACTA CLIN BELG, V43, P236; CACERES J, 1989, CIRCULATION, V79, P256, DOI 10.1161/01.CIR.79.2.256; COHEN HC, 1972, CIRCULATION, V45, P1035, DOI 10.1161/01.CIR.45.5.1035; FORSSELL G, 1976, ACTA MED SCAND, V199, P143; GOOLSBY JP, 1974, AM HEART J, V88, P351, DOI 10.1016/0002-8703(74)90471-2; JOSEPHSON ME, 1978, CIRCULATION, V57, P431, DOI 10.1161/01.CIR.57.3.431; JOSEPHSON ME, 1979, CIRCULATION, V59, P459, DOI 10.1161/01.CIR.59.3.459; KINDWALL KE, 1988, AM J CARDIOL, V61, P1279, DOI 10.1016/0002-9149(88)91169-1; KREMERS MS, 1988, AM J CARDIOL, V62, P1208, DOI 10.1016/0002-9149(88)90261-5; KUCHAR DL, 1988, PACE, V11, P61, DOI 10.1111/j.1540-8159.1988.tb03930.x; MASON JW, 1978, CIRCULATION, V58, P971, DOI 10.1161/01.CIR.58.6.971; MASSUMI RA, 1973, CIRCULATION, V47, P543, DOI 10.1161/01.CIR.47.3.543; PRITCHETT EL, 1978, PRAC CARDIOL, V4, P84; REDDY CP, 1980, CIRCULATION, V61, P641, DOI 10.1161/01.CIR.61.3.641; ROELANDT J, 1969, DIS CHEST, V56, P166, DOI 10.1378/chest.56.2.166; RUFFY R, 1985, J AM COLL CARDIOL, V5, P1008, DOI 10.1016/S0735-1097(85)80451-4; SHIMIZU A, 1988, PACE, V11, P384, DOI 10.1111/j.1540-8159.1988.tb05997.x; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; VANDEPOL CJ, 1980, AM J CARDIOL, V45, P725, DOI 10.1016/0002-9149(80)90114-9; WEISS J, 1986, AM HEART J, V112, P843, DOI 10.1016/0002-8703(86)90485-0; WELLENS HJJ, 1978, AM J MED, V64, P27, DOI 10.1016/0002-9343(78)90176-6; WELLENS HJJ, 1979, AM J CARDIOL, V43, P400	23	19	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					460	463		10.7326/0003-4819-114-6-460	http://dx.doi.org/10.7326/0003-4819-114-6-460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994792				2022-12-24	WOS:A1991FB64000005
J	WILLIAMSON, DF; MADANS, J; ANDA, RF; KLEINMAN, JC; GIOVINO, GA; BYERS, T				WILLIAMSON, DF; MADANS, J; ANDA, RF; KLEINMAN, JC; GIOVINO, GA; BYERS, T			SMOKING CESSATION AND SEVERITY OF WEIGHT-GAIN IN A NATIONAL COHORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-WEIGHT; CIGARETTE-SMOKING; ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; NICOTINE; OBESITY; CONSUMPTION; WOMEN	Background. Many believe that the prospect of weight gain discourages smokers from quitting. Accurate estimates of the weight gain related to the cessation of smoking in the general population are not available, however. Methods. We related changes in body weight to changes in smoking status in adults 25 to 74 years of age who were weighed in the First National Health and Nutrition Examination Survey (NHANES I, 1971 to 1975) and then weighed a second time in the NHANES I Epidemiologic Follow-up Study (1982 to 1984). The cohort included continuing smokers (748 men and 1137 women) and those who had quit smoking for a year or more (409 men and 359 women). Results. The mean weight gain attributable to the cessation of smoking, as adjusted for age, race, level of education, alcohol use, illnesses related to change in weight, base-line weight, and physical activity, was 2.8 kg in men and 3.8 kg in women. Major weight gain (> 13 kg) occurred in 9.8 percent of the men and 13.4 percent of the women who quit smoking. The relative risk of major weight gain in those who quit smoking (as compared with those who continued to smoke) was 8.1 (95 percent confidence interval, 4.4 to 14.9) in men and 5.8 (95 percent confidence interval, 3.7 to 9.1) in women, and it remained high regardless of the duration of cessation. For both sexes, blacks, people under the age of 55, and people who smoked 15 cigarettes or more per day were at higher risk of major weight gain after quitting smoking. Although at base line the smokers weighed less than those who had never smoked, they weighed nearly the same at follow-up. Conclusions. Major weight gain is strongly related to smoking cessation, but it occurs in only a minority of those who stop smoking. Weight gain is not likely to negate the health benefits of smoking cessation, but its cosmetic effects may interfere with attempts to quit. Effective methods of weight control are therefore needed for smokers trying to quit.	CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333; NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ABRAHAM S, 1983, VITAL HLTH STATIS 11, V230; BENNETT W, 1987, ANN NY ACAD SCI, V499, P250, DOI 10.1111/j.1749-6632.1987.tb36216.x; BLITZER PH, 1977, J CHRON DIS, V30, P415, DOI 10.1016/0021-9681(77)90035-2; BOSSE R, 1980, INT J ADDICT, V15, P969, DOI 10.3109/10826088009040072; CARNEY RM, 1984, NEW ENGL J MED, V310, P614, DOI 10.1056/NEJM198403083101002; COHEN BB, 1987, VITAL HLTH STATIST 1, V22; FRIEDMAN GD, 1980, CIRCULATION, V61, P716, DOI 10.1161/01.CIR.61.4.716; GRITZ E R, 1989, Annals of Behavioral Medicine, V11, P144, DOI 10.1207/s15324796abm1104_4; GRUNBERG N E, 1989, Annals of Behavioral Medicine, V11, P154, DOI 10.1207/s15324796abm1104_5; GRUNBERG NE, 1987, PSYCHOPHARMACOLOGY, V91, P221; GRUNBERG NE, 1988, LIFE SCI, V42, P161, DOI 10.1016/0024-3205(88)90679-0; GRUNBERG NE, 1988, PSYCHOPHARMACOLOGY, V94, P536, DOI 10.1007/BF00212851; GRUNBERG NE, 1985, PHARMACOL BIOCHEM BE, V23, P851, DOI 10.1016/0091-3057(85)90081-4; GRUNBERG NE, 1985, PSYCHOPHARMACOLOGY, V87, P198, DOI 10.1007/BF00431807; Grunberg NE, 1986, ADV BEHAVIORAL MED, V2, P97; GRUNBERG NE, 1990, RES ADV ALCOHOL DRUG, P273; HATZIANDREU EJ, 1989, AM J PUBLIC HEALTH, V79, P1020, DOI 10.2105/AJPH.79.8.1020; HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KLESGES RC, 1989, ANN BEHAV MED, V11, P123; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; NOPPA H, 1980, PREV MED, V9, P534, DOI 10.1016/0091-7435(80)90048-1; PERKINS KA, 1989, NEW ENGL J MED, V320, P898, DOI 10.1056/NEJM198904063201404; RIGOTTI NA, 1989, NEW ENGL J MED, V320, P931, DOI 10.1056/NEJM198904063201409; RISSANEN A, 1988, INT J OBESITY, V12, P391; SCHWARTZ JL, 1987, NIH872940 DEP HLTH H; WACK JT, 1982, AM J CLIN NUTR, V35, P366, DOI 10.1093/ajcn/35.2.366; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; 1985, DHHS8550207 DEP HLTH; [No title captured]; 1990, DHHS CDC908416 PUBL; 1988, DHHS CDC888406 PUBL; 1989, DHHS CDC8988411 PUBL; 1985, SAS USERS GUIDE STAT, P655; 1990, OM902004 DEP HLTH HU	36	633	638	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					739	745		10.1056/NEJM199103143241106	http://dx.doi.org/10.1056/NEJM199103143241106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB556	1997840				2022-12-24	WOS:A1991FB55600006
J	MIRANKER, A; RADFORD, SE; KARPLUS, M; DOBSON, CM				MIRANKER, A; RADFORD, SE; KARPLUS, M; DOBSON, CM			DEMONSTRATION BY NMR OF FOLDING DOMAINS IN LYSOZYME	NATURE			English	Article							EGG-WHITE LYSOZYME; MOLTEN GLOBULE STATE; ALPHA-LACTALBUMIN; RIBONUCLEASE-A; PROTEIN; INTERMEDIATE; EXCHANGE; KINETICS	ALTHOUGH there has been much speculation on the pathways of protein folding, only recently have experimental data on the topic been available. The study of proteins under conditions where species intermediate between the fully folded and unfolded states are stable has provided important information, for example about the disulphide intermediates in BPTI 1,2, cis/trans proline isomers of RNase A3 and the molten globule state of alpha-lactalbumin 4. An alternative approach to investigating folding pathways has involved detection and characterization of transient conformers in refolding studies using stopped-flow methods coupled with NMR measurements of hydrogen exchange 5,6. The formation of intermediate structures has been detected in the early stages of folding of cytochrome c (ref. 7), RNaseA 8 and barnase 9. For alpha-lactalbumin, hydrogen exchange kinetics monitored by NMR proved to be crucial for identifying native-like molten globule state 10. An analogous partially folded protein stable under equilibrium conditions has not been observed for the structurally homologous protein hen egg-white lysozyme, although there is evidence that a similar but transient state is formed during refolding. Here we describe NMR experiments based on competition between hydrogen exchange and the refolding process which not only support the existence of such a transient species for lysozyme, but enable its structural characteristics to be defined. The results indicate that the two structural domains of lysozyme are distinct folding domains, in that they differ significantly in the extent to which compact, probably native-like, structure is present in the early stages of folding.	UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3QR,ENGLAND	University of Oxford; Harvard University; University of Oxford	MIRANKER, A (corresponding author), HARVARD UNIV,COMM HIGHER DEGREES BIOPHYS,7 DIVIN ST,CAMBRIDGE,MA 02138, USA.			Radford, Sheena/0000-0002-3079-8039				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; Imoto T., 1972, ENZYMES, V7, P665; JANIN J, 1983, PROG BIOPHYS MOL BIO, V42, P21, DOI 10.1016/0079-6107(83)90003-2; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATO S, 1981, BIOCHEMISTRY-US, V20, P1080, DOI 10.1021/bi00508a006; Kim P S, 1986, Methods Enzymol, V131, P136; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0; PEDERSEN TG, 1987, J MOL BIOL, V197, P111; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHMID FX, 1983, BIOCHEMISTRY-US, V22, P4690, DOI 10.1021/bi00289a013; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; TANFORD C, 1973, J MOL BIOL, V73, P185, DOI 10.1016/0022-2836(73)90322-7; TOPPING KD, 1988, THESIS U OXFORD; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0	29	240	240	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					633	636		10.1038/349633a0	http://dx.doi.org/10.1038/349633a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000138				2022-12-24	WOS:A1991EX57000067
J	RAUB, W				RAUB, W			RISK OF OCCUPATIONAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS EVALUATED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, ANN INTERN MED, V113, P740	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					706	706						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990184				2022-12-24	WOS:A1991EW47900009
J	RAVN, P; LUNDGREN, JD; KJAELDGAARD, P; HOLTENANDERSON, W; HOJLYNG, N; NIELSEN, JO; GAUB, J				RAVN, P; LUNDGREN, JD; KJAELDGAARD, P; HOLTENANDERSON, W; HOJLYNG, N; NIELSEN, JO; GAUB, J			NOSOCOMIAL OUTBREAK OF CRYPTOSPORIDIOSIS IN AIDS PATIENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIARRHEA	Objective-To describe a nosocomial outbreak of cryptosporidiosis during four months after June 1989. Setting-A department of infectious diseases in Copenhagen, seeing about half the patients with AIDS in Denmark. Subjects-73 HIV antibody negative subjects and 60 antibody positive subjects admitted as inpatients during the transmission period of the outbreak (20 June-14 August), of whom 18 (17 with AIDS, one with AIDS related complex), developed cryptosporidiosis. Two further HIV negative subjects (one departmental secretary, one visiting relative) developed cryptosporidiosis. Main outcome measures-Cryptosporidia in stool samples, clinical symptoms, CD4 cell count, HIV antigen concentration, chemotherapeutic treatment. Results-The source of the outbreak was identified as ice from an ice machine in the ward, contaminated by an incontinent, psychotic patient with cryptosporidiosis picking out ice for cold drinks. The mean incubation time was at least 13 days-that is, twice that in HIV-negative patients. Of the 18 patients with AIDS who developed cryptosporidiosis, five recovered, two were symptomless carriers, three died of unrelated causes, and eight died after prolonged diarrhoea. Among the 57 exposed HIV antibody positive inpatients (excluding two patients and the index case with cryptosporidiosis diagnosed elsewhere), significantly more of those who developed symptomatic cryptosporidiosis received oral sulphonamides than those who did not (91%, 10/11-upsilon-48%, 21/44, p < 0.05). Conclusions-The clinical and epidemiological findings indicate that infection was the consequence of very small inocula. Increased sensitivity to cryptosporidiosis may be an unrecognised side effect of oral sulphonamide treatment in patients with AIDS.	HVIDOVRE UNIV HOSP, DEPT INFECT DIS, 144, DK-2650 HVIDOVRE, DENMARK; HVIDOVRE UNIV HOSP, DEPT CLIN MICROBIOL, DK-2650 HVIDOVRE, DENMARK; STATENS SERUM INST, DEPT TOXOPLASMOSIS, DK-2300 COPENHAGEN, DENMARK	University of Copenhagen; University of Copenhagen; Statens Serum Institut			Lundgren, Jens/AAE-6876-2019	Lundgren, Jens/0000-0001-8901-7850				CASEMORE DP, 1990, EPIDEMIOL INFECT, V104, P1, DOI 10.1017/S0950268800054480; CONNOLLY GM, 1988, GUT, V29, P593, DOI 10.1136/gut.29.5.593; CURRENT WL, 1988, AM SOC MICROBIOLOGY, V54, P604; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109; HOLTENANDERSEN W, 1984, J INFECTION, V9, P277, DOI 10.1016/S0163-4453(84)90618-2; HORNICK RB, 1970, NEW ENGL J MED, V283, P686, DOI 10.1056/NEJM197009242831306; JANOFF EN, 1990, ANN INTERN MED, V112, P75, DOI 10.7326/0003-4819-112-1-75; JOKIPII AMM, 1985, LANCET, V2, P487; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; MARTINO P, 1988, J INFECT DIS, V158, P647, DOI 10.1093/infdis/158.3.647; NAVIN TR, 1987, J INFECT DIS, V155, P150, DOI 10.1093/infdis/155.1.150; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PEDERSEN C, 1990, AIDS, V4, P233, DOI 10.1097/00002030-199003000-00009; ROLSTON KVI, 1989, J ACQ IMMUN DEF SYND, V2, P426; UNGAR BLP, 1990, GASTROENTEROLOGY, V98, P486, DOI 10.1016/0016-5085(90)90842-O; ZAR F, 1985, J INFECT DIS, V151, P195, DOI 10.1093/infdis/151.1.195	17	61	66	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	1991	302	6771					277	280		10.1136/bmj.302.6771.277	http://dx.doi.org/10.1136/bmj.302.6771.277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998796	Green Published, Bronze			2022-12-24	WOS:A1991EX91900024
J	PETERS, BS; BECK, EJ; COLEMAN, DG; WADSWORTH, MJH; MCGUINNESS, O; HARRIS, JRW; PINCHING, AJ				PETERS, BS; BECK, EJ; COLEMAN, DG; WADSWORTH, MJH; MCGUINNESS, O; HARRIS, JRW; PINCHING, AJ			CHANGING DISEASE PATTERNS IN PATIENTS WITH AIDS IN A REFERRAL CENTER IN THE UNITED-KINGDOM - THE CHANGING FACE OF AIDS	BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; TRIMETHOPRIM; EXPERIENCE; EFFICACY; SURVIVAL	Objective-To study the changes in morbidity, mortality, and survival patterns in a population of patients with AIDS in the United Kingdom from 1982 to 1989. Design-A retrospective analysis of inpatient and outpatient records of patients with AIDS. Subjects-347 Patients with AIDS, predominantly homosexual or bisexual men. Setting-Department of immunology and genitourinary medicine, St Mary's Hospital, London. Main outcome measures-Presenting diagnosis of AIDS, occurrence of other opportunist diseases, cause of death, and survival since AIDS was diagnosed, in particular for those patients with Pneumocystis carinii pneumonia or Kaposi's sarcoma. Results-The overall proportion of patients who developed P carinii pneumonia dropped from 56% (20/36) in 1984 to 24% (46/194) in 1989, although it has remained the index diagnosis in about half of new patients. Kaposi's sarcoma has decreased as index diagnosis from 30% (20/67) to 20% (15/74) over the same period, though the prevalance has remained constant at around 35%. P carinii pneumonia accounted for 46% (16/35) of known causes of death in 1986 but only 3% (1/31) in 1989. Conversely, deaths due to Kaposi's sarcoma rose from 14% (1/7) to 32% (10/31) between 1984 and 1989. Lymphoma accounted for an increased proportion of deaths among these patients with 16% (5/31) of deaths in 1989. Their median survival increased from 10 months in 1984-6 to 20 months in 1987. Conclusions-The changing patterns of disease in patients with AIDS have important implications both for health care provision and future medical research. Medical and nursing provision must be made for the increased morbidity of these diseases and the increased survival of these patients. Research should now be directed towards developing effective treatments for the opportunist infections which are currently more difficult to treat, the secondary malignancies of AIDS, as well as more effective immunorestorative treatments. Future changes in disease patterns must be recognised at an early stage so that resources can be adequately planned and allocated.	ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED,LONDON W2 1PG,ENGLAND	Imperial College London; Imperial College London	PETERS, BS (corresponding author), ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND.							ARMITAGE P, 1987, STATISTICAL METHODS, P429; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GARDNER TD, 1989, J INFECTION, V18, P111, DOI 10.1016/S0163-4453(89)91038-4; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; PENN I, 1986, PROG ALLERGY, V37, P259; PETERS BS, 1990, LANCET, V335, P545, DOI 10.1016/0140-6736(90)90782-Z; PETERS BS, 1990, AIDS, V4, P367, DOI 10.1097/00002030-199004000-00016; PETERS BS, IN PRESS Q J MED; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; RUTHERFORD GW, 1989, J INFECT DIS, V159, P567; SELIK RM, 1987, AIDS, V1, P175; STAMBUK D, 1989, Q J MED, V262, P161; SWART AM, 1990, BRIT MED J, V301, P825, DOI 10.1136/bmj.301.6756.825; THOMAS S, 1990, BRIT MED J, V300, P211, DOI 10.1136/bmj.300.6719.211; 1987, MMWR S1S, V36, pS1	21	160	160	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					203	207		10.1136/bmj.302.6770.203	http://dx.doi.org/10.1136/bmj.302.6770.203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998759	Bronze, Green Published			2022-12-24	WOS:A1991EV22800023
J	HEALY, B				HEALY, B			GENETIC-MARKER FOR LONG QT SYNDROME IDENTIFIED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, SCIENCE, V252, P704	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046123				2022-12-24	WOS:A1991FT93400005
J	OBRIEN, RJ				OBRIEN, RJ			HEPATOXIC REACTION TO ANTITUBERCULOUS DRUGS - ADJUSTMENTS TO THERAPEUTIC REGIMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											OBRIEN, RJ (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.								0	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3323	3323		10.1001/jama.265.24.3323	http://dx.doi.org/10.1001/jama.265.24.3323			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046117				2022-12-24	WOS:A1991FR83500045
J	ABRAMSON, SB; DOBRO, J; EBERLE, MA; BENTON, M; REIBMAN, J; EPSTEIN, H; RAPOPORT, DM; BELMONT, HM; GOLDRING, RM				ABRAMSON, SB; DOBRO, J; EBERLE, MA; BENTON, M; REIBMAN, J; EPSTEIN, H; RAPOPORT, DM; BELMONT, HM; GOLDRING, RM			ACUTE REVERSIBLE HYPOXEMIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLEMENT ACTIVATION; NEUTROPHIL AGGREGATION; INCREASED EXPRESSION; C5A ANAPHYLATOXINS; RECEPTOR CR3; DISEASE; C3A; HEMODIALYSIS; GLYCOPROTEIN; LEUKOSTASIS	Objective: To determine the frequency of unexplained reversible hypoxemia in patients with systemic lupus erythematosus and to assess the relation between hypoxemia and elevated plasma levels of complement split products. Design: Cohort study. Setting: Inpatient and outpatient facilities of the New York University Medical Center/Bellevue Hospital and the Hospital for Joint Diseases. Patients: Case patients were 22 patients hospitalized with disease exacerbation and no evidence of parenchymal lung disease on chest roentgenogram. Four patients with stable disease were followed in the outpatient clinic, and five healthy normal volunteers served as controls. Measurements: Plasma levels of complement split products (C3a, factor Bb fragment), alveolar-arterial (A-a) Po2 gradients, and pulmonary function were measured. Main Results: Nine episodes of hypoxemia or hypocapnia (mean A-a gradient, 30.4 +/- 4.8 mm Hg) or both (despite normal chest roentgenogram results) were noted in six hospitalized patients (group 1). Gas exchange improved within 72 hours of steroid therapy (mean A-a gradient, 11.6 +/- 4.3 mm Hg; P < 0.01). These patients had an elevated initial mean C3a level (938.4 +/- 246.8 ng/mL) that decreased within 72 hours (407.8 +/- 80.9 ng/mL; P < 0.01), concomitant with improved oxygenation. Ventilation-perfusion scans, obtained for four of six group 1 patients, excluded pulmonary emboli. Four hospitalized patients (group 2) had a normal A-a gradient (mean, 7.5 +/- 2.7 mm Hg). The mean C3a level of this group (358.3 +/- 39.2 ng/mL) was lower than that of group 1 (P < 0.05). Four patients with stable disease (group 3) had a mean A-a gradient and a mean C3a level of 3.3 +/- 2.7 mm Hg and 237.8 +/- 105.7 ng/mL, respectively, similar to values found in five normal volunteers, in whom the mean A-a gradient was 3.7 +/- 1.7 mm Hg and the mean C3a level was 124.8 +/- 9.2 ng/mL. Conclusion: A syndrome of reversible hypoxemia, unassociated with parenchymal lung disease, is unexpectedly common in acutely ill, hospitalized patients with systemic lupus erythematosus. The pathogenesis of this syndrome is unclear, although the data are compatible with the hypothesis that hypoxemia may be related to pulmonary leukoaggregation.	NYU MED CTR, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT MED, DIV PULM CRIT CARE, NEW YORK, NY 10016 USA	New York University; New York University	ABRAMSON, SB (corresponding author), HOSP JOINT DIS & MED CTR, INST ORTHOPAED, DEPT RHEUMAT DIS, 301 E 17TH ST, NEW YORK, NY 10003 USA.		Benton, Michael J/A-5639-2008	Benton, Michael J/0000-0002-4323-1824; Abramson, Steven/0000-0002-0668-6344; Belmont, Howard/0000-0003-3389-2976; Reibman, Joan/0000-0001-7878-1511; goldring, roberta/0000-0003-3319-4932; Rapoport, David/0000-0002-4855-2600				ABRAMSON SB, 1983, ARTHRITIS RHEUM-US, V26, P630, DOI 10.1002/art.1780260509; ALARCONSEGOVIA D, 1961, DIS CHEST, V39, P7; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1985, NEW ENGL J MED, V312, P457, DOI 10.1056/NEJM198502213120801; BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; BURGESS JH, 1974, CIRCULATION, V49, P541, DOI 10.1161/01.CIR.49.3.541; BUYON J, 1988, CLIN RES, V36, pA531; BUYON JP, 1988, CLIN IMMUNOL IMMUNOP, V46, P141, DOI 10.1016/0090-1229(88)90014-1; BUYON JP, 1987, LEUKOCYTE TYPING, V3, P844; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; CHENOWETH DE, 1980, MOL IMMUNOL, V17, P151, DOI 10.1016/0161-5890(80)90067-X; CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401; CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; GIVEN WP, 1984, ARTHRITIS RHEUM, V27, P631, DOI 10.1002/art.1780270605; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; HAMMERSCHMIDT DE, 1980, LANCET, V1, P947; HAMMERSCHMIDT DE, 1978, BLOOD, V51, P721; HARVEY AM, 1954, MEDICINE, V33, P291, DOI 10.1097/00005792-195412000-00001; HOFFBRAND BI, 1965, BMJ-BRIT MED J, V1, P1273, DOI 10.1136/bmj.1.5445.1273; HOPKINS P, 1988, ARTHRITIS RHEUM, V31, P632, DOI 10.1002/art.1780310508; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JACOB HS, 1980, NEW ENGL J MED, V302, P789; JESSAR RA, 1953, ANN INTERN MED, V38, P717, DOI 10.7326/0003-4819-38-4-717; MOORE FD, 1986, NEW ENGL J MED, V314, P948, DOI 10.1056/NEJM198604103141503; MYERS JL, 1986, AM J CLIN PATHOL, V85, P552, DOI 10.1093/ajcp/85.5.552; MYHRE JR, 1959, ACTA MED SCAND, V165, P55; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; POLLEY MJ, 1983, J EXP MED, V158, P603, DOI 10.1084/jem.158.2.603; RATNOFF WD, 1985, COMPLEMENT, P215; SEGAL AM, 1985, SEMIN ARTHRITIS RHEU, V14, P202, DOI 10.1016/0049-0172(85)90040-X; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8	32	57	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					941	947		10.7326/0003-4819-114-11-941	http://dx.doi.org/10.7326/0003-4819-114-11-941			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024861				2022-12-24	WOS:A1991FM97900005
J	DINHXUAN, AT; HIGENBOTTAM, TW; CLELLAND, CA; PEPKEZABA, J; CREMONA, G; BUTT, AY; LARGE, SR; WELLS, FC; WALLWORK, J				DINHXUAN, AT; HIGENBOTTAM, TW; CLELLAND, CA; PEPKEZABA, J; CREMONA, G; BUTT, AY; LARGE, SR; WELLS, FC; WALLWORK, J			IMPAIRMENT OF ENDOTHELIUM-DEPENDENT PULMONARY-ARTERY RELAXATION IN CHRONIC OBSTRUCTIVE LUNG-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NITRIC-OXIDE; RELAXING FACTOR; SMOOTH-MUSCLE; GUANOSINE-MONOPHOSPHATE; RAT; VASOCONSTRICTION; CIRCULATION; CELLS; TRANSPLANTATION; INHIBITION	Background. Endothelial cells release endothelium-derived relaxing factor (EDRF) in a variety of vascular beds, including the pulmonary circulation. However, the role of EDRF-mediated pulmonary-artery relaxation in chronic hypoxic lung disease is unknown. Methods. We studied endothelium-dependent relaxation mediated by EDRF in vitro in pulmonary arteries that had been obtained from 22 patients undergoing heart-lung transplantation for end-stage chronic obstructive lung disease. Control pulmonary arteries were obtained from 15 patients undergoing lobectomy for lung carcinoma who did not have evidence of other chronic lung disease. The responses of all vascular rings (external diameter, 1.2 to 3.4 mm) to the endothelium-dependent vasodilators acetylcholine and adenosine diphosphate were studied immediately after lung excision. Results. Pulmonary arterial rings from the patients with chronic lung disease developed a greater tension (2.19 +/- 0.16 g) in response to phenylephrine (10(-6) M) than the rings from control patients (1.28 +/- 0.18 g, P < 0.05). Inhibition of EDRF synthesis by treatment with N(G)-monomethyl-L-arginine (10(-4) M) eliminated this difference, increasing the tension in the rings from the controls (P < 0.01) but not in those from the patients with chronic lung disease. Rings from control patients relaxed in response to cumulative doses (10(-10) to 10(-5) M) of acetylcholine (maximal relaxation, 81.3 +/- 3.9 percent) and adenosine diphosphate (maximal relaxation, 85.3 +/- 2.6 percent). By contrast, rings from patients with chronic obstructive lung disease achieved only 41.3 +/- 4.8 percent of maximal relaxation in response to acetylcholine (n = 32) and 49.4 +/- 5.5 percent in response to adenosine diphosphate (n = 24) (P < 0.001, as compared with control rings). Rings from both the controls and the patients with chronic lung disease relaxed similarly in response to the endothelium-independent vasodilator sodium nitroprusside (10(-4) M). There was an inverse correlation between the degree of intimal thickening and the level of maximal relaxation of the rings from the patients with chronic lung disease (r = -0.60, P < 0.001). Maximal relaxation was also related directly to the partial pressure of arterial oxygen before transplantation (r = 0.68, P < 0.01) and inversely to the partial pressure of arterial carbon dioxide before transplantation (r = -0.55, P < 0.01), but not to the forced expiratory volume in one second (r = 0.19, P not significant). Conclusions. Endothelium-dependent pulmonary-artery relaxation in vitro is impaired in arteries from patients with end-stage chronic obstructive lung disease. Such impairment may contribute to the development of pulmonary hypertension in chronic hypoxic lung disease.	PAPWORTH HOSP, DEPT RESP PHYSIOL, CAMBRIDGE CB3 8RE, ENGLAND; PAPWORTH HOSP, DEPT CARDIOTHORAC SURG, CAMBRIDGE CB3 8RE, ENGLAND; PAPWORTH HOSP, DEPT HISTOPATHOL, CAMBRIDGE CB3 8RE, ENGLAND	Papworth Hospital; Papworth Hospital; Papworth Hospital			Pepke-Zaba, Joanna/AGW-3073-2022; DINH-XUAN, Anh Tuan/A-9691-2008	DINH-XUAN, Anh Tuan/0000-0001-8651-5176				ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; [Anonymous], 1963, CIRCULATION, V27, P594, DOI DOI 10.1161/01.CIR.27.4.594; ARCHER SL, 1989, BIOCHEM BIOPH RES CO, V164, P1198, DOI 10.1016/0006-291X(89)91796-8; ARMITAGE P, 1987, STAT METHODS; BORLAND CDR, 1989, EUR RESPIR J, V2, P56; BRASHERS VL, 1988, J CLIN INVEST, V82, P1495, DOI 10.1172/JCI113757; BURROWS B, 1972, NEW ENGL J MED, V286, P912, DOI 10.1056/NEJM197204272861703; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CRAWLEY DE, 1990, BRIT J PHARMACOL, V101, P166; Dinh Xuan AT, 1989, EUR J PHARMACOL, V163, P401, DOI 10.1016/0014-2999(89)90217-3; Dinh Xuan AT, 1990, BRIT J PHARMACOL, V99, P9, DOI 10.1111/j.1476-5381.1990.tb14643.x; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KON V, 1990, J CLIN INVEST, V85, P1728, DOI 10.1172/JCI114628; LIU SF, 1991, AM REV RESPIR DIS, V143, P32, DOI 10.1164/ajrccm/143.1.32; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MAGEE F, 1988, THORAX, V43, P183, DOI 10.1136/thx.43.3.183; MAZMANIAN GM, 1989, J APPL PHYSIOL, V66, P1040, DOI 10.1152/jappl.1989.66.3.1040; MEYRICK B, 1978, LAB INVEST, V38, P188; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; MONCADA S, 1987, THROMB DIATH HAEMO, P597; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; OGAWA S, 1990, BRIT J HAEMATOL, V75, P517, DOI 10.1111/j.1365-2141.1990.tb07792.x; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANG JA, 1982, AM REV RESPIR DIS, V125, P194; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PENKETH A, 1987, BRIT MED J, V295, P311, DOI 10.1136/bmj.295.6593.311; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; REEVES JT, 1989, PULMONARY CIRCULATIO, P27; ROBERTSON BE, 1990, EXP PHYSIOL, V75, P255, DOI 10.1113/expphysiol.1990.sp003399; SCOTT J, 1988, LANCET, V2, P192; VANHOUTTE PM, 1988, NEW ENGL J MED, V319, P512, DOI 10.1056/NEJM198808253190809; WARREN JB, 1989, CLIN SCI, V77, P671, DOI 10.1042/cs0770671; WILKINSON M, 1988, Q J MED, V66, P65; XUAN ATD, 1989, J INT MED RES, V17, P305, DOI 10.1177/030006058901700401; YAMAGUCHI T, 1989, EUR J PHARMACOL, V161, P259, DOI 10.1016/0014-2999(89)90856-X	40	454	470	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1539	1547		10.1056/NEJM199105303242203	http://dx.doi.org/10.1056/NEJM199105303242203			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	2027358				2022-12-24	WOS:A1991FN05100003
J	PRETTYMAN, RJ; FRIEDMAN, T				PRETTYMAN, RJ; FRIEDMAN, T			CARE OF WOMEN WITH PUERPERAL PSYCHIATRIC-DISORDERS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND	University Hospitals of Leicester NHS Trust; Leicester General Hospital								KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; Marce LV, 1858, TRAITE FOLIE FEMMES; OATES M, 1988, MOTHERHOOD MENTAL IL, V2, P138	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1245	1246		10.1136/bmj.302.6787.1245	http://dx.doi.org/10.1136/bmj.302.6787.1245			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP272	2043849	Green Published, Bronze			2022-12-24	WOS:A1991FP27200025
J	SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL				SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL			BIRTH-WEIGHT, CURRENT BODY-WEIGHT, AND BLOOD-PRESSURE IN LATE ADOLESCENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ADULT LIFE; PREGNANCY; CHILDHOOD; CHILDREN; SIZE	Objective - To study the effect of birth weight and body weight on blood pressure in late adolescence. Design - Analysis of data on weight, height, and blood pressure at age 17 of subjects from the Jerusalem perinatal study, according to their birth weight. Data for men and women were analysed separately. Setting - Jerusalem, Israel. Subjects - 32 580 subjects (19 734 men and 12 846 women) born in the three major hospitals in Jerusalem during 1964-71 and subsequently drafted in to the army. Main outcome measures - Correlations between birth weight and blood pressure at age 17 and weight and height at age 17 and blood pressure. Results - Diastolic and systolic blood pressures were associated with birth weight in both young men and young women, but the correlation coefficients were low. A high body weight at age 17 (> 66 kg for women, > 75 kg for men) rather than a low birth weight (< 2500 g) was linked with higher systolic and diastolic blood pressures in both men and women (p < 0.01). Conclusions - Intrauterine environment, as reflected by birth weight, has little effect on blood pressure in young men and women. Modification of factors which lead to excess weight during adolescence may have a major role in preventing hypertension in adults.	ISRAELI DEF FORCES, MED CORPS, MED STAT BRANCH, JERUSALEM, ISRAEL; BIKUR CHOLIM HOSP, DEPT NEONATOL, JERUSALEM, ISRAEL; STANFORD UNIV, MED CTR, SCH MED, DEPT PAEDIAT, STANFORD, CA 94305 USA; TEL AVIV UNIV, SACKLER SCH MED, BEILINSON MED CTR, DIV PAEDIAT IMMUNOL, TEL AVIV, ISRAEL	Stanford University; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	SEIDMAN, DS (corresponding author), CHAIM SHEBA MED CTR, DEPT OBSTET & GYNAECOL, IL-52621 TEL HASHOMER, ISRAEL.							BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Cater J, 1984, LOW BIRTH WEIGHT MED, P191; DAVIES AM, 1969, ISRAEL J MED SCI, V5, P1095; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HACK M, 1990, PEDIATR RES, V27, pA93; HARLAP S, 1977, ISRAEL J MED SCI, V13, P1073; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; KARK JD, 1986, ISRAEL J MED SCI, V22, P318; LAUER RM, 1989, PEDIATRICS, V84, P633; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; SIMPSON A, 1981, HYPERTENSION YOUNG O, P154; WILSON SL, 1985, HYPERTENSION, V7, P417, DOI 10.1161/01.HYP.7.3_Pt_1.417; 1985, SAS USERS GUIDE	17	128	129	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1991	302	6787					1235	1237		10.1136/bmj.302.6787.1235	http://dx.doi.org/10.1136/bmj.302.6787.1235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043845	Bronze, Green Published			2022-12-24	WOS:A1991FP27200020
J	KONDRASHOV, AS; CROW, JF				KONDRASHOV, AS; CROW, JF			HAPLOIDY OR DIPLOIDY - WHICH IS BETTER	NATURE			English	Article							SELECTION	ALTHOUGH the evolutionary advantages of sexual reproduction have been extensively discussed 1-3, much less attention has been paid to haploid and diploid phases of the sexual life cycle. The relative lengths of these phases differ greatly in various taxa, including as extremes those with one or the other phase reduced to a single cell. Here we consider the efficiency of elimination of deleterious mutations as an evolutionary force and compare the mutation loads under haploid and diploid selection, L(n) and L2n. With truncation-like selection, partial dominance, and heterozygous effect of a mutation less than about 1/4 its hemizygous effect, L2n < L(n); otherwise L2n > L(n). The difference becomes important when the genomic deleterious mutation rate exceeds about 1 per genome. This suggests that the mutation rate, degree of dominance and mode of selection can be important in life-cycle evolution.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; ACAD SCI USSR,CTR RES COMP,PUSHCHINO 142292,USSR	University of Wisconsin System; University of Wisconsin Madison; Russian Academy of Sciences								CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; CROW JF, 1979, P NATL ACAD SCI USA, V76, P396, DOI 10.1073/pnas.76.1.396; EFROIMSON V, 1932, J BIOL, V1, P87; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; KARLIN S, 1974, THEOR POPUL BIOL, V5, P59, DOI 10.1016/0040-5809(74)90052-5; KIMURA M, 1961, JAPAN J GENET      S, V36, P179; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Michod R. E., 1988, THE EVOLUTION OF SEX; MILKMAN R, 1978, GENETICS, V88, P391	13	147	151	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					314	315		10.1038/351314a0	http://dx.doi.org/10.1038/351314a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034273				2022-12-24	WOS:A1991FM97600059
J	THELEN, M; ROSEN, A; NAIRN, AC; ADEREM, A				THELEN, M; ROSEN, A; NAIRN, AC; ADEREM, A			REGULATION BY PHOSPHORYLATION OF REVERSIBLE ASSOCIATION OF A MYRISTOYLATED PROTEIN-KINASE-C SUBSTRATE WITH THE PLASMA-MEMBRANE	NATURE			English	Article							PHORBOL ESTERS; GROWTH-FACTORS; OKADAIC ACID; ACTIVATION; RECEPTOR; BINDING; BRAIN	PROTEIN kinase C (PKC) transduces receptor-mediated signals by phosphorylating membrane-bound substrates which then act as effectors of specific cellular responses 1. The myristoylated alanine-rich C kinase substrate (MARCKS) is a specific PKC substrate which has been implicated in macrophage activation, neurosecretion and growth factor-dependent mitogenesis 2-5. Myristoylation of MARCKS is required for effective binding to the plasma membrane 6 where it colocalizes with PKC 7. Here we report that PKC-dependent phosphorylation displaces MARCKS from the membrane and that its subsequent dephosphorylation is accompanied by its reassociation with the membrane. This cycle of phosphorylation-dependent membrane attachment and detachment of a myristoylated protein represents a novel mechanism of reversible membrane targeting. As MARCKS is a calmodulin- and actin-binding protein (ref. 8, and J. Hartwig et al., manuscript submitted), the cycle of membrane attachment/detachment represents a mechanism through which PKC might reversibly regulate actin-membrane interaction.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University				Nairn, Angus/0000-0002-7075-0195				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; DEWALD B, 1988, J BIOL CHEM, V263, P16179; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	17	355	365	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					320	322		10.1038/351320a0	http://dx.doi.org/10.1038/351320a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034276				2022-12-24	WOS:A1991FM97600062
J	WILLEY, J; SANTAMARIA, R; GUIJARRO, J; GEISTLICH, M; LOSICK, R				WILLEY, J; SANTAMARIA, R; GUIJARRO, J; GEISTLICH, M; LOSICK, R			EXTRACELLULAR COMPLEMENTATION OF A DEVELOPMENTAL MUTATION IMPLICATES A SMALL SPORULATION PROTEIN IN AERIAL MYCELIUM FORMATION BY S-COELICOLOR	CELL			English	Article							STREPTOMYCES-COELICOLOR; COLONY MUTANTS; A-FACTOR; GRISEUS; DIFFERENTIATION; QUANTITIES; SEQUENCE; CLONING; A3(2)	The filamentous bacterium S. coelicolor differentiates by forming aerial hyphae, which protrude into the air and metamorphose into chains of spores. Aerial hyphae formation is associated with the production of a small, abundant protein, SapB, which is present in a zone around colonies of differentiating bacteria. Production of SapB is impaired in bld mutants, which are blocked in aerial hyphae formation, but not in whi mutants in which spore formation is prevented. We report that aerial hyphae formation by a newly identified bld mutant is restored by juxtaposition of the mutant near colonies of SapB-producing bacteria or by the application of the purified protein near mutant colonies. These observations implicate SapB in aerial mycelium formation and suggest that SapB is a morphogenetic protein that enables hyphae on the surface of colonies to grow into the air.			WILLEY, J (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.		Moya GUIJARRO, Arsenio Jesús/GXH-0909-2022; Santamaria, Ramon I/M-9069-2019; Santamaria, Ramon I/K-2870-2014	Santamaria, Ramon I/0000-0002-2181-6776; Santamaria, Ramon I/0000-0002-2181-6776; Willey, Joanne/0000-0003-4544-4417				ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; BIRO S, 1980, EUR J BIOCHEM, V103, P359, DOI 10.1111/j.1432-1033.1980.tb04322.x; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; Chater K. F., 1984, MICROBIAL DEV, P89; CHATER KF, 1972, J GEN MICROBIOL, V72, P9, DOI 10.1099/00221287-72-1-9; CHATER KF, 1989, REGULATION PROCARYOT, V1, P277; GUIJARRO J, 1988, J BACTERIOL, V170, P1895, DOI 10.1128/jb.170.4.1895-1901.1988; HARA O, 1982, J ANTIBIOT, V35, P349, DOI 10.7164/antibiotics.35.349; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KHOKHLOV AS, 1973, Z ALLG MIKROBIOL, V13, P647, DOI 10.1002/jobm.3630130803; KHOKHLOV AS, 1985, 6TH P INT S ACT BIOL, P791; KIM SK, 1990, CELL, V61, P19, DOI 10.1016/0092-8674(90)90211-V; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCANN PA, 1979, J ANTIBIOT, V32, P673, DOI 10.7164/antibiotics.32.673; MENDEZ C, 1987, J BACTERIOL, V169, P5715, DOI 10.1128/jb.169.12.5715-5720.1987; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; PIRET JM, 1985, J BACTERIOL, V163, P965, DOI 10.1128/JB.163.3.965-972.1985; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; Thomas J O, 1978, Methods Cell Biol, V18, P429	23	152	155	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					641	650		10.1016/0092-8674(91)90096-H	http://dx.doi.org/10.1016/0092-8674(91)90096-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032288				2022-12-24	WOS:A1991FM03700014
J	LITAM, P; SWAN, F; CABANILLAS, F; TUCKER, SL; MCLAUGHLIN, P; HAGEMEISTER, FB; RODRIGUEZ, MA; VELASQUEZ, WS				LITAM, P; SWAN, F; CABANILLAS, F; TUCKER, SL; MCLAUGHLIN, P; HAGEMEISTER, FB; RODRIGUEZ, MA; VELASQUEZ, WS			PROGNOSTIC VALUE OF SERUM BETA-2 MICROGLOBULIN IN LOW-GRADE LYMPHOMA	ANNALS OF INTERNAL MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LACTATE-DEHYDROGENASE LEVELS; HL-A ANTIGENS; MALIGNANT-LYMPHOMA; MULTIPLE-MYELOMA; HODGKINS-DISEASE; CELL LYMPHOMAS; SMALL SUBUNIT; BETA-2-MICROGLOBULIN; BETA2-MICROGLOBULIN	Objective: To evaluate serum beta-2 microglobulin (beta-2M) and other prognostic indicators in previously untreated low-grade lymphoma. Design: Cohort study of 80 patients with uniformly treated low-grade lymphoma, followed for a median of 21 months. These 80 patients, all of whom had serum beta-2M drawn within 2 weeks before starting therapy, were derived from a cohort of 119 previously untreated patients entered into one of three clinical trials. Setting: Tertiary referral cancer center. Patients: Eight previously untreated stage I to IV patients (mean age, 55 years). Intervention: Treatment was given according to Ann Arbor stage: Patients in stage IV were treated with CHOP-blemycin and maintained on interferon therapy; those in stage III received CHOP-bleomycin and radiotherapy; and those in stage I and II received COP-bleomycin and radiotherapy. Measurements: Outcome was determined by assessing complete remission rate and time to treatment failure. Univariate and multivariate analyses were used. Results: The complete remission rate for patients with a beta-2M level of 3.0 mg/L or greater was 36% compared with 71% for those with a level of less than 3.0 mg/L. Using multivariate analysis that tested beta-2M as a continuous variable, it was selected as the most significant factor for complete response. The adjusted odds ratio was 0.285 (95% CI, 0.101 to 0.809). The Ann Arbor stage had marginal significance (adjusted odds ratio, 0.435; CI, 0.150 to 1.263). For time to treatment failure, beta-2M was the only variable retained in the multivariate model. At 42 months, no patient with a beta-2M level of 3.0 mg/L or greater was projected to be in remission as compared with 85% of patients with a beta-2M level of less than 3.0 mg/L. Conclusions: The serum beta-2M level is a good predictor of complete response and time to treatment failure. A large number of patients should be studied to clarify the role of other potentially independent variables such as stage and age.	UNIV TEXAS, MD ANDERSON CANCER CTR, 1515 HOLCOMBE BLVD, BOX 68, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center				Cabanillas, Fernando/0000-0001-9234-7893				ALEXANIAN R, 1985, AM J HEMATOL, V20, P345, DOI 10.1002/ajh.2830200405; AMLOT PL, 1979, EUR J CANCER, V15, P791, DOI 10.1016/0014-2964(79)90155-5; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BACH FH, 1976, NEW ENGL J MED, V295, P872, DOI 10.1056/NEJM197610142951606; BACH FH, 1976, NEW ENGL J MED, V295, P927, DOI 10.1056/NEJM197610212951705; BATAILLE R, 1983, BRIT J HAEMATOL, V55, P439, DOI 10.1111/j.1365-2141.1983.tb02158.x; BERGGARD I, 1968, J BIOL CHEM, V243, P4095; BODMER WF, 1981, TISSUE ANTIGENS, V17, P9; CARBONE PP, 1971, CANCER RES, V31, P1860; CHILD JA, 1980, CANCER-AM CANCER SOC, V45, P318, DOI 10.1002/1097-0142(19800115)45:2<318::AID-CNCR2820450220>3.0.CO;2-C; COX DR, 1972, J R STAT SOC B, V34, P187; CRESSWEL.P, 1974, P NATL ACAD SCI USA, V71, P2123, DOI 10.1073/pnas.71.5.2123; DIXON DO, 1987, J CLIN ONCOL, V5, P1670, DOI 10.1200/JCO.1987.5.10.1670; EVRIN PE, 1973, CLIN CHIM ACTA, V43, P183, DOI 10.1016/0009-8981(73)90449-X; FERRARIS AM, 1979, BLOOD, V54, P928; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GOSPODAROWICZ MK, 1984, INT J RADIAT ONCOL, V10, P489, DOI 10.1016/0360-3016(84)90028-2; GREY HM, 1973, J EXP MED, V138, P1608, DOI 10.1084/jem.138.6.1608; HAGBERG H, 1983, CANCER, V51, P2220, DOI 10.1002/1097-0142(19830615)51:12<2220::AID-CNCR2820511212>3.0.CO;2-A; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEGROS M, 1987, P AN M AM SOC CLIN, V6, P748; MALE DK, 1986, IMMUNOLOGY, P57; MCLAUGHLIN P, 1987, J CLIN ONCOL, V5, P867, DOI 10.1200/JCO.1987.5.6.867; MCLAUGHLIN P, 1990, 4TH P INT C MAL LYMP; MOLLER P, 1987, INT J CANCER, V40, P32, DOI 10.1002/ijc.2910400107; MOLLER P, 1986, IMMUNOLOGY, V59, P411; NILSSON K, 1974, TRANSPLANT REV, V21, P53; PARHAM P, 1979, J IMMUNOL, V123, P342; PETERSON PA, 1972, P NATL ACAD SCI USA, V69, P1697, DOI 10.1073/pnas.69.7.1697; ROSENBERG SA, 1982, CANCER, V49, P2112; RUDDERS RA, 1979, CANCER, V43, P1643, DOI 10.1002/1097-0142(197905)43:5<1643::AID-CNCR2820430513>3.0.CO;2-J; SCHNEIDER RJ, 1980, CANCER, V46, P139, DOI 10.1002/1097-0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8; SHUSTER J, 1976, CLIN CHIM ACTA, V67, P307, DOI 10.1016/0009-8981(76)90339-9; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; SWAN F, 1988, BLOOD, V72, pA258; TROWSDALE J, 1980, J EXP MED, V152, pS11; VEZZONI MA, 1983, TUMORI, V69, P279, DOI 10.1177/030089168306900401; ZINKERNAGEL RM, 1979, ADV IMMUNOL, V27, P151	40	86	87	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					855	860		10.7326/0003-4819-114-10-855	http://dx.doi.org/10.7326/0003-4819-114-10-855			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014946				2022-12-24	WOS:A1991FL65000004
J	LERNER, RA; BENKOVIC, SJ; SCHULTZ, PG				LERNER, RA; BENKOVIC, SJ; SCHULTZ, PG			AT THE CROSSROADS OF CHEMISTRY AND IMMUNOLOGY - CATALYTIC ANTIBODIES	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; CLAISEN REARRANGEMENT; ENZYMIC CATALYSIS; COMBINING SITES; BINDING-ENERGY; NOBEL LECTURE; SPECIFICITY; GENERATION; AMIDE; HYDROLYSIS	Immunochemistry has historically focused on the nature of antigenicity and antibody-antigen recognition. However, in the last 5 years, the field of immunochemistry has taken a new direction. With the aid of mechanistic and synthetic chemistry, the vast network of molecules and cells of the immune system has been tapped to produce antibodies with a new function - catalytic antibodies. Because antibodies can be generated that selectively bind almost any molecule of interest, this new technology offers the potential to tailor-make highly selective catalysts for applications in biology, chemistry, and medicine. In addition, catalytic antibodies provide fundamental insight into important aspects of biological catalysis, including the importance of transition-state stabilization, proximity effects, general acid and base catalysts, electrophilic and nucleophilic catalysis, and strain.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Berkeley	LERNER, RA (corresponding author), Scripps Res Inst, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.							ARATA Y, 1990, J SYNTH ORG CHEM JPN, V6, P482; ARMSTRONG RW, 1989, J AM CHEM SOC, V111, P7530, DOI 10.1021/ja00201a038; BALAN A, 1988, J CHEM SOC CHEM COMM, P106, DOI 10.1039/c39880000106; BALDWIN E, 1989, SCIENCE, V245, P1104, DOI 10.1126/science.2672338; BARTLETT P, 1983, BIOCHEMISTRY-US, V22, P4168; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; BLACKBURN GF, IN PRESS ANAL CHEM; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P7246, DOI 10.1021/bi00397a008; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; CARTER EA, 1987, J CHEM PHYS, V86, P862, DOI 10.1063/1.452287; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; COCHRAN AG, 1990, J AM CHEM SOC, V112, P9414, DOI 10.1021/ja00181a065; COCHRAN AG, 1988, J AM CHEM SOC, V110, P7888, DOI 10.1021/ja00231a056; COCHRAN AG, UNPUB; CRAM DJ, 1988, ANGEW CHEM INT EDIT, V27, P1009, DOI 10.1002/anie.198810093; CRAM DJ, 1987, PRIX NOBEL, P129; CRAM DJ, 1987, PRIX NOBEL, P105; DAFFRON A, 1971, BIOCHEM BIOPH RES CO, V52, P779; DANISHEVSKY S, UNPUB; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DURFOR CN, 1988, J AM CHEM SOC, V110, P8713, DOI 10.1021/ja00234a032; ESCHENMOSER A, 1989, 25TH EUCHEM C STER B; GOODMAN JW, 1985, ANTIGEN, V3; HERMES JD, 1987, COLD SPRING HARB SYM, V52, P597, DOI 10.1101/SQB.1987.052.01.068; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HILVERT D, UNPUB; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; INAGAMI T, 1969, J BIOCHEM, V65, P809, DOI 10.1093/oxfordjournals.jbchem.a129081; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; IVERSON BL, 1990, J AM CHEM SOC, V112, P5320, DOI 10.1021/ja00169a044; JACKSON DY, 1988, J AM CHEM SOC, V110, P4841, DOI 10.1021/ja00222a060; JACKSON DY, IN PRESS J AM CHEM S; JACKSON DY, IN PRESS P NATL ACAD; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JACOBS JW, 1989, THESIS U CALIFORNIA; JACOBSEN JL, UNPUB; JANDA K, UNPUB; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1990, J AM CHEM SOC, V112, P8886, DOI 10.1021/ja00180a035; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANDA KD, 1988, J AM CHEM SOC, V110, P4835, DOI 10.1021/ja00222a056; JANJIC N, 1989, J AM CHEM SOC, V111, P6374, DOI 10.1021/ja00198a058; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KAISER ET, 1984, SCIENCE, V226, P505, DOI 10.1126/science.6238407; KEINAN E, 1990, PURE APPL CHEM, V62, P2013, DOI 10.1351/pac199062102013; KHORANA HG, 1968, P INT C BIOCH, V7, P17; KITAZUME T, IN PRESS J AM CHEM S; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOSHLAND DE, 1973, SCI AM, V229, P52, DOI 10.1038/scientificamerican1073-52; KRAFT GA, 1989, ANNU REP MED CHEM, V25, P299; LANDSTEINER K, 1944, SPECIFICITY SEROLOGI; Lavallee D. K., 1988, MOL STRUCT ENERG, V9, P279; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LERNER RA, 1984, ADV IMMUNOL, V36, P1, DOI 10.1016/S0065-2776(08)60898-6; LERNER RA, UNPUB; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; MARTIN JT, IN PRESS CIBA F S; MERRIFIELD RB, 1985, ANGEW CHEM INT EDIT, V24, P799, DOI 10.1002/anie.198507993; NAKAYAMA GR, IN PRESS CIBA F S; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; Nisonoff A, 1975, ANTIBODY MOL; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PAULING L, 1948, Am Sci, V36, P51; Pauling L, 1944, J AM CHEM SOC, V66, P784, DOI 10.1021/ja01233a039; POCKER Y, 1977, J AM CHEM SOC, V99, P2276, DOI 10.1021/ja00449a042; POLLACK SJ, 1987, COLD SPRING HARB SYM, V52, P97, DOI 10.1101/SQB.1987.052.01.014; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; POLLACK SJ, 1988, SCIENCE, V242, P1038, DOI 10.1126/science.3194752; POLLACK SJ, 1989, J AM CHEM SOC, V111, P1929, DOI 10.1021/ja00187a085; POLLACK SJ, 1988, METHOD ENZYMOL, V178, P551; PRESSMAN D, 1968, STRUCTURAL BASES ANT; RASO W, 1975, BIOCHEMISTRY-US, V14, P584; ROSTER MJ, 1988, SCIENCE, V241, P1200; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SEEBACH D, 1990, ANGEW CHEM INT EDIT, V29, P1320, DOI 10.1002/anie.199013201; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; SHOKAT KM, 1990, ANGEW CHEM INT EDIT, V29, P1296, DOI 10.1002/anie.199012961; SHOKAT KM, 1988, ANGEW CHEM INT EDIT, V27, P1172, DOI 10.1002/anie.198811721; SHOKAT R, IN PRESS CIBA F S; SUDHIR P, 1989, SCIENCE, V244, P1158; TAWFIK DS, 1990, BIOCHEMISTRY-US, V29, P9916, DOI 10.1021/bi00494a023; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; TRAMONTANO A, 1986, P NATL ACAD SCI USA, V83, P6736, DOI 10.1073/pnas.83.18.6736; WESTHEIMER FH, 1962, ADV ENZYMOL, V24, P456; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415; Woolley D., 1952, STUDY ANTIMETABOLITE; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016	102	653	698	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					659	667		10.1126/science.2024118	http://dx.doi.org/10.1126/science.2024118			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024118				2022-12-24	WOS:A1991FK18500037
J	BELL, LR; HORABIN, JI; SCHEDL, P; CLINE, TW				BELL, LR; HORABIN, JI; SCHEDL, P; CLINE, TW			POSITIVE AUTOREGULATION OF SEX-LETHAL BY ALTERNATIVE SPLICING MAINTAINS THE FEMALE DETERMINED STATE IN DROSOPHILA	CELL			English	Article								Sex-lethal is a binary switch gene that controls all aspects of Drosophila sexual dimorphism. It must be active in females and inactive in males. The on/off regulation reflects alternative RNA splicing in which full-length proteins are produced only in females. Here we investigate the role of Sxl in maintaining sexual pathway commitments. By ectopic expression of a female Sxl cDNA in transgenic male flies, we show that Sxl protein induces a rapid switch from male- to female-specific splicing. The ectopically expressed Sxl protein will trans-activate an endogenous wild-type Sxl gene. This establishes a feedback loop in which Sxl proteins induce their own synthesis by directing the female-specific splicing of Sxl transcripts. We conclude that the female determined state is maintained by Sxl through positive autoregulation, while the male determined state is maintained by default.	PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA	Princeton University								BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, IN PRESS GENES DEV; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; ERICKSON JW, 1991, IN PRESS SCIENCE; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHRING WJ, 1973, DEV SYSTEMS INSECTS, V2; GERGEN JP, 1987, GENETICS, V117, P477; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LINDALEY D, 1985, DROS INFORM SERV, V62, P1; Lindsley D.L., 1990, Drosophila Information Service, V68, P1; LINDSLEY DL, 1986, DROS INF SERV, V64, P1; LINDSLEY DL, 1987, DROS INFORM SERV, V65, P1; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; MAINE EM, 1985, COLD SPRING HARB SYM, V50, P595, DOI 10.1101/SQB.1985.050.01.072; MASON PJ, 1982, J MOL BIOL, V156, P21, DOI 10.1016/0022-2836(82)90456-9; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MULLER H. J., 1932, Proceedings. 6th Int. Congr. Genet., V1, P213; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; OLIVER B, 1990, GENETICS, V125, P535; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SANCHEZ L, 1982, ROUX ARCH DEV BIOL, V191, P211, DOI 10.1007/BF00848339; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SCHUPBACH T, 1985, GENETICS, V109, P529; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STEINMANNZWICKY M, 1989, CELL, V57, P157, DOI 10.1016/0092-8674(89)90181-5; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; ZUSMAN SB, 1987, GENETICS, V115, P725	49	282	289	1	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					229	239		10.1016/0092-8674(91)90157-T	http://dx.doi.org/10.1016/0092-8674(91)90157-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015624				2022-12-24	WOS:A1991FH09200006
J	CHAN, BMC; MATSUURA, N; TAKADA, Y; ZETTER, BR; HEMLER, ME				CHAN, BMC; MATSUURA, N; TAKADA, Y; ZETTER, BR; HEMLER, ME			INVITRO AND INVIVO CONSEQUENCES OF VLA-2 EXPRESSION ON RHABDOMYOSARCOMA CELLS	SCIENCE			English	Article							INHIBITS EXPERIMENTAL METASTASIS; MELANOMA-CELLS; MONOCLONAL-ANTIBODY; INTEGRIN RECEPTORS; DEPENDENT ADHESION; SURFACE RECEPTORS; COLLAGEN RECEPTOR; LAMININ RECEPTOR; T-CELLS; FIBRONECTIN	Cloned integrin alpha-2 subunit complementary DNA was expressed on human rhabdomyosarcoma (RD) cells to give a functional VLA-2 (alpha-2-beta-1) adhesion receptor. The VLA-2-positive RDA2 cells not only showed increased adhesion to collagen and laminin in vitro, but also formed substantially more metastatic tumor colonies in nude mice after either intravenous or subcutaneous injection. These results show that a specific adhesion receptor (VLA-2) can markedly enhance both experimental and spontaneous metastasis. In contrast to the metastasis results, there was no difference in either the in vitro growth rate or apparent in vivo tumorigenicity of RD and RDA2 cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School				takada, yoshikazu/0000-0001-5481-9589	NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37393] Funding Source: Medline; NIGMS NIH HHS [GM 38903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1990, CANCER RES, V50, P1601; ANICHINI A, 1990, INT J CANCER, V46, P508, DOI 10.1002/ijc.2910460330; BAND H, 1989, J IMMUNOL, V142, P3267; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; NATALI P, 1990, CANCER RES, V50, P1271; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OTOOLE TE, 1989, BLOOD, V74, P14; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIGNATELLI M, 1990, BRIT J CANCER, V61, P636, DOI 10.1038/bjc.1990.141; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAGA S, 1988, CANCER RES, V48, P5510; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILSON JM, 1990, SCIENCE, V248, P1413, DOI 10.1126/science.1972597; YAMADA KM, 1990, CANCER RES, V50, P4485; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; ZYLSTRA S, 1986, CANCER RES, V46, P6446	49	314	323	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1600	1602		10.1126/science.2011740	http://dx.doi.org/10.1126/science.2011740			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011740				2022-12-24	WOS:A1991FD89000034
J	MCKINNEY, PA; ALEXANDER, FE; CARTWRIGHT, RA; PARKER, L				MCKINNEY, PA; ALEXANDER, FE; CARTWRIGHT, RA; PARKER, L			PARENTAL OCCUPATIONS OF CHILDREN WITH LEUKEMIA IN WEST CUMBRIA, NORTH-HUMBERSIDE, AND GATESHEAD	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; LEUKEMIA; BIRTH; ASSOCIATION; EXPOSURES; AGE	Objective-To determine whether parental occupations and chemical and other specific exposures are risk factors for childhood leukaemia. Design-Case-control study. Information on parents was obtained by home interview. Setting-Three areas in north England: Copeland and South Lakeland (west Cumbria); Kingston upon Hull, Beverley, East Yorkshire, and Holderness (north Humberside), and Gateshead. Subjects-109 children aged 0-14 born and diagnosed as having leukaemia or non-Hodgkin's lymphoma in study areas during 1974-88. Two controls matched for sex and date and district of birth were obtained for each child. Main outcome measures-Occupations of parents and specific exposure of parents before the children's conception, during gestation, and after birth. Other adults living with the children were included in the postnatal analysis. Results-Few risk factors were identified for mothers, although preconceptional association with the food industry was significantly increased in case mothers (odds ratio 2.56; 95% confidence interval 1.32 to 5.00). Significant associations were found between childhood leukaemia and reported preconceptional exposure of fathers to wood dust (2.73, 1.44 to 5.16), radiation (3.23, 1.36 to 7.72), and benzene (5.81, 1.67 to 26.44); ionising radiation alone gave an odds ratio of 2.35 (0.92 to 6.22). Raised odds ratios were found for paternal exposure during gestation, but no independent postnatal effect was evident. Conclusion-These results should be interpreted cautiously because of the small numbers, overlap with another study, and multiple exposure of some parents. It is important to distinguish periods of parental exposures; identified risk factors were almost exclusively restricted to the time before the child's birth.	UNIV LEEDS,CTR CLIN EPIDEMIOL,LEUKAEMIA RES FUND,LEEDS LS2 9NG,W YORKSHIRE,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,CHILDRENS CANC UNIT,NEWCASTLE TYNE NE2 4HH,ENGLAND	University of Leeds; Newcastle University - UK				PARKER, LOUISE/0000-0002-5188-8113				ALEXANDER F, 1990, J EPIDEMIOL COMMUN H, V44, P39, DOI 10.1136/jech.44.1.39; ALEXANDER FE, IN PRESS PATTERN CHI; [Anonymous], 1980, CLASSIFICATION OCCUP; ARUNDEL SE, 1986, J EPIDEMIOL COMMUN H, V40, P30, DOI 10.1136/jech.40.1.30; BAXTER MS, 1990, REV RADIOACTIVITY CA; BLACK D, 1984, INVESTIGATION POSSIB; BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7; BUCKLEY JD, 1989, CANCER RES, V49, P4030; CARTWRIGHT RA, 1990, LEUKAEMIA LYMPHOMA A; CRAFT AW, 1983, LANCET, V2, P1299; CRONKITE EP, 1985, AM J IND MED, V7, P447, DOI 10.1002/ajim.4700070509; EVANS HJ, 1990, NATURE, V345, P16, DOI 10.1038/345016a0; FABIA J, 1974, BRIT J PREV SOC MED, V28, P98; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GOLD EB, 1982, J OCCUP ENVIRON MED, V24, P578, DOI 10.1097/00043764-198208000-00011; GRAHAM S, 1966, J NCI, V19, P347; HEMMINKI K, 1981, J EPIDEMIOL COMMUN H, V35, P11, DOI 10.1136/jech.35.1.11; HICKS N, 1984, CANCER, V53, P1637, DOI 10.1002/1097-0142(19840415)53:8<1637::AID-CNCR2820530802>3.0.CO;2-Y; INFANTE PF, 1990, LANCET, V336, P814, DOI 10.1016/0140-6736(90)93282-T; KWA SL, 1980, J OCCUP ENVIRON MED, V22, P792, DOI 10.1097/00043764-198012000-00012; LOWENGART RA, 1987, J NATL CANCER I, V79, P39; MACFARLANE GJ, 1988, SEARCH COMPUTER PACK; MCKINNEY PA, 1989, LEUKEMIA, V3, P880; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279, DOI 10.1136/adc.62.3.279; MELITA CR, 1990, STAT XACT; MELITA CR, 1985, J AM STATISTICS ASS, V80, P969; OPENSHAW S, 1988, LANCET, V1, P272; PETO J, 1990, NATURE, V345, P389, DOI 10.1038/345389a0; REEVES JD, 1981, LANCET, V2, P300; SANDERS BM, 1981, J EPIDEMIOL COMMUN H, V35, P245, DOI 10.1136/jech.35.4.245; SAVITZ DA, 1990, ENVIRON HEALTH PERSP, V88, P325, DOI 10.2307/3431095; SHAW G, 1984, AM J EPIDEMIOL, V119, P788, DOI 10.1093/oxfordjournals.aje.a113799; SHU XO, 1988, CANCER-AM CANCER SOC, V62, P635, DOI 10.1002/1097-0142(19880801)62:3<635::AID-CNCR2820620332>3.0.CO;2-3; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; VANSTEENSELMOLL HA, 1985, AM J EPIDEMIOL, V121, P214; VIANNA NJ, 1984, J OCCUP ENVIRON MED, V26, P679; [No title captured]; 1987, IARC MONOGRAPH S7, V1	40	72	75	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					681	687		10.1136/bmj.302.6778.681	http://dx.doi.org/10.1136/bmj.302.6778.681			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE333	2021741	Bronze, Green Published			2022-12-24	WOS:A1991FE33300020
J	LOWNDES, NF; JOHNSON, AL; JOHNSTON, LH				LOWNDES, NF; JOHNSON, AL; JOHNSTON, LH			COORDINATION OF EXPRESSION OF DNA-SYNTHESIS GENES IN BUDDING YEAST BY A CELL-CYCLE REGULATED TRANS FACTOR	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HO GENE; PERIODIC TRANSCRIPTION; GEL-ELECTROPHORESIS; LIGASE GENES; CDC9; IDENTIFICATION; ACTIVATION; SEQUENCES; BINDING	ALL of the DNA synthesis genes of budding yeast examined so far are periodically expressed and hence under cell-cycle control (Table 1). Expression occurs near the G1/S phase boundary and the genes seem to be coordinately regulated (reviewed in ref. 4). The upstream promoter sequences of these genes have only a hexamer element, ACGCGT (an MluI restriction site), in common. Here we show that this hexamer is able to impart periodic expression to a heterologous gene and, significantly, this expression occurs coincidentally with that of CDC9, one of the DNA synthesis genes (Table 1). We have also identified a protein that binds specifically to these sequences in a similar periodic manner. These ACGCGT sequences and the transcription factor that binds to them therefore seem to be the elements controlling both the periodic expression and coordinate regulation of the DNA synthesis genes.	NATL INST MED RES,CELL PROPAGAT LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research			Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427				ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARTISHEVSKY A, 1987, NATURE, V328, P822; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BARKER DG, 1985, MOL GEN GENET, V200, P458, DOI 10.1007/BF00425731; BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JOHNSON AL, 1986, CURR GENET, V11, P107, DOI 10.1007/BF00378201; Johnston LH, 1990, CURR OPIN CELL BIOL, V2, P274, DOI 10.1016/0955-0674(90)90019-B; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; JOHNSTON LH, 1990, MOL GEN GENET, V221, P44, DOI 10.1007/BF00280366; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Osley M. A., 1987, MOL CELL BIOL, V7, P4202; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STORMS RK, 1984, MOL CELL BIOL, V4, P2858, DOI 10.1128/MCB.4.12.2858; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WHITE JHM, 1988, THESIS COUNCIL NATIO	27	185	185	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					247	250		10.1038/350247a0	http://dx.doi.org/10.1038/350247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005980				2022-12-24	WOS:A1991FC77900063
J	KELLIE, SE; KELLY, JT				KELLIE, SE; KELLY, JT			MEDICARE PEER-REVIEW ORGANIZATION PREPROCEDURE REVIEW CRITERIA - AN ANALYSIS OF CRITERIA FOR 3 PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDARTERECTOMY; POPULATION	The Medicare Peer Review Organization (PRO) program includes preprocedure review using explicit criteria to assess the appropriateness of specific procedures. This study evaluates the variability in the PRO preprocedure criteria for the three procedures most frequently reviewed by PROs: carotid endarterectomy, cataract removal, and cardiac pacemaker implants. In August 1989, the PRO review criteria were received from the Health Care Financing Administration. To provide a reference point for reviewing the PRO criteria, national practice guidelines for these three procedures were identified. Wide variability was demonstrated in the PRO procedure-specific carotid endarterectomy and cataract removal review criteria among PROs, and the criteria differed significantly from the identified practice guidelines. The criteria for cardiac pacemaker implants were somewhat less variable, and were based, to varying degrees, on practice guidelines developed by the American College of Cardiology (ACC). Greater attention is needed to improve the development of review criteria, including the use of relevant practice guidelines, to ensure that review criteria are optimal.			KELLIE, SE (corresponding author), AMER MED ASSOC,DEPT TECHNOL ASSESSMENT,OFF QUAL ASSURANCE,515 N STATE ST,CHICAGO,IL 60610, USA.							[Anonymous], 1990, CLIN PRACTICE GUIDEL; DONABEDIAN A, 1981, AM J PUBLIC HEALTH, V71, P409, DOI 10.2105/AJPH.71.4.409; FALK RH, 1990, J AM COLL CARDIOL, V15, P1087, DOI 10.1016/0735-1097(90)90245-K; FRYE R L, 1984, Journal of the American College of Cardiology, V4, P434; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; Kelly J T, 1990, QRB Qual Rev Bull, V16, P54; KELLY JT, 1990, ARCH PATHOL LAB MED, V114, P1119; KELLY JT, 1990, DIRECTORY PRACTICE P; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LEVIT KR, 1990, HEALTH AFFAIR, V9, P171, DOI 10.1377/hlthaff.9.2.171; LOHR KN, 1989, MED CARE, V27, pS1, DOI 10.1097/00005650-198903001-00001; Mariano L A, 1989, Health Care Financ Rev, V10, P123; MERRICK NJ, 1986, R32046CWFHFPMTRWJ RA; MITCHELL JB, 1989, HEALTH AFFAIR, V8, P21, DOI 10.1377/hlthaff.8.1.21; PARK RE, 1989, R3280CWFHFPMTRWJ RAN; POKRAS R, 1988, STROKE, V19, P1289, DOI 10.1161/01.STR.19.10.1289; SCHAFFARZICK RW, 1988, QUALITY CARE TECHNOL; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; 1988, CATARACT SURGERY; 1989, MEDICARE IMPROVEMENT; 1989, MED REV SYSTEM; 1988, PB88954099; 1989, EFFECTIVENESS RES PR; 1990, MEDICARE STRATEGY QU; 1984, HCFA PRO MANUAL, V2, P37; 1989, CONTROLLING COSTS CH; 1989, CATARACT OTHERWISE H; 1989, ANN INTERN MED, V111, P675; 1989, MEDICARE COVERAGE IS; 1987, STUDY PREADMISSION R, P1; 1974, JAMA-J AM MED ASSOC, V229, P166; 1987, MINIMUM CRITERIA CAT	32	28	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1265	1270		10.1001/jama.265.10.1265	http://dx.doi.org/10.1001/jama.265.10.1265			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA511	1995973				2022-12-24	WOS:A1991FA51100020
J	LIP, GYH; MCCOLL, KEL; GOLDBERG, A; MOORE, MR				LIP, GYH; MCCOLL, KEL; GOLDBERG, A; MOORE, MR			SMOKING AND RECURRENT ATTACKS OF ACUTE INTERMITTENT PORPHYRIA	BRITISH MEDICAL JOURNAL			English	Article							ESTRADIOL		UNIV GLASGOW,WESTERN INFIRM,GARDINER INST,DEPT MED,GLASGOW G11 6NT,SCOTLAND	University of Glasgow			Moore, Michael R/C-4163-2012	Moore, Michael R/0000-0002-7012-9534				APPEL BR, 1990, AM J PUBLIC HEALTH, V80, P560, DOI 10.2105/AJPH.80.5.560; KANARKOWSKI R, 1988, CLIN PHARMACOL THER, V43, P23, DOI 10.1038/clpt.1988.7; KLAIBER EL, 1988, FERTIL STERIL, V50, P630; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; Moore M. R., 1987, DISORDERS PORPHYRIN	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 2	1991	302	6775					507	507		10.1136/bmj.302.6775.507	http://dx.doi.org/10.1136/bmj.302.6775.507			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB055	2012848	Green Published, Bronze			2022-12-24	WOS:A1991FB05500022
J	DESHAIES, RJ; SANDERS, SL; FELDHEIM, DA; SCHEKMAN, R				DESHAIES, RJ; SANDERS, SL; FELDHEIM, DA; SCHEKMAN, R			ASSEMBLY OF YEAST SEC PROTEINS INVOLVED IN TRANSLOCATION INTO THE ENDOPLASMIC-RETICULUM INTO A MEMBRANE-BOUND MULTISUBUNIT COMPLEX	NATURE			English	Article							LAMBDA-DNA-REPLICATION; HEAT-SHOCK PROTEIN; NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; INITIATION; GENE; SEQUENCE; ENCODES; MUTANT; ORIGIN	SECRETORY-protein translocation into the endoplasmic reticulum (ER) is thought to be catalysed by integral membrane proteins. Genetic selections uncovered three Saccharomyces cerevisiae genes (SEC61, SEC62 and SEC63), mutations in which block import of precursor proteins into the ER lumen in vivo 1-3 and in vitro 2-4. The DNA sequences of SEC62 (ref. 4) and SEC63 (ref. 5) predict multispanning membrane proteins, and biochemical characterization of the SEC62 protein (Sec62) confirms that it is an integral ER membrane protein6. Here we show that Sec61, Sec62 and Sec63 are assembled with two additional proteins into a multisubunit membrane-associated complex. These results confirm previous predictions, based upon genetic interactions between the SEC genes, that Sec61, Sec62 and Sec63 act together to facilitate protein translocation into the ER.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DODSON M, 1989, J BIOL CHEM, V264, P10719; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; RAPOPORT TA, 1990, NATO ADV SCI I H-CEL, V40, P231; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	22	276	281	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					806	808		10.1038/349806a0	http://dx.doi.org/10.1038/349806a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000150				2022-12-24	WOS:A1991EZ66600061
J	KEMPLE, TJ; HAYTER, SR				KEMPLE, TJ; HAYTER, SR			AUDIT OF DIABETES IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To complete a first audit cycle of diabetes care in a general practice and to develop a simple method for continuing the audit cycle. Design-Retrospective examination of the medical records of all diabetic patients in a general practice in 1990. Setting-A group general practice in a Bristol health centre with roughly 13 200 patients, which since 1983 has had a protocol for care of its diabetic patients. Patients-223 known diabetic patients in the practice. Main audited measures-Comparison against previously agreed standards of process and outcome of diabetes care in the practice, including number of patients whose care had been reviewed in accordance with the practice protocol, serum fructosamine and blood glucose concentrations in patients aged under 70, and number of newly diagnosed patients given explicit education and referred for diatetic advice. Results-Defined standards were not met for several criteria-for example, percentages of patients aged below 70 (n = 149) with serum fructosamine concentrations < 3.5 mmol/l (62% v 90% defined value) and < 2.8 mmol/l (35% v 70%) and last recorded blood glucose concentrations < 10 mmol/l in insulin dependent patients (n = 48) (23% v 90%) and < 8 mmol/l in non-insulin dependent patients (n = 101) (17% v 90%). Of newly identified diabetic patients (n = 32), 59% and 28% respectively were referred to dieticians and given educational material compared with the 100% standard. Conclusions-The practice has a high prevalence of diabetes (1.7%) but has the resources for their care. The format and implementation of the agreed systematic process of care for diabetic patients needs improvement. Implications-A simple audit suitable for most general practices might record two measures of the process of care-a disease register of all diabetic patients in a practice and an attendance register to determine whether they have regular check ups-and one measure of the outcome of care, such as serum fructosamine concentration (or local equivalent). A practice could establish its own standards for these measures and monitor its performance against them.			KEMPLE, TJ (corresponding author), HORFIELD HLTH CTR,LOCKLEAZE RD,BRISTOL BS7 9RR,ENGLAND.			Kemple, Terence/0000-0002-9217-4598				FLEMING PC, 1985, PRACTICAL DIABETES, V2, P26; FOSTER W, 1989, PRACTITIONER, V233, P1023; GROL R, 1990, BRIT J GEN PRACT, V40, P361; HILL RD, 1986, PRACTICAL DIABETES, V3, P67; HILL RD, 1990, PRACTICAL DIABETES, V7, P149; IRVING JMR, 1988, PRACTICAL DIABETES, V3, P125; MALINS JM, 1971, BRIT MED J, V4, P161, DOI 10.1136/bmj.4.5780.161; SMITH T, 1990, BRIT MED J, V300, P65, DOI 10.1136/bmj.300.6717.65; THORN PA, 1973, BRIT MED J, V2, P534, DOI 10.1136/bmj.2.5865.534; WAINE C, 1990, PRACTICAL DIABETES, V7, P152; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; Wood J, 1990, Health Trends, V22, P39; 1988, DIABETES; 1989, MED AUDIT 1ST REPORT; 1989, 6 SECRE STAT HLTH WO	15	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					451	453		10.1136/bmj.302.6774.451	http://dx.doi.org/10.1136/bmj.302.6774.451			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004174	Green Published, Bronze			2022-12-24	WOS:A1991EZ03300024
J	DECHIARA, TM; ROBERTSON, EJ; EFSTRATIADIS, A				DECHIARA, TM; ROBERTSON, EJ; EFSTRATIADIS, A			PARENTAL IMPRINTING OF THE MOUSE INSULIN-LIKE GROWTH FACTOR-II GENE	CELL			English	Article							RIBONUCLEIC-ACID; PATERNAL GENOMES; 2 PROMOTERS; EXPRESSION; EMBRYOGENESIS; METHYLATION; RECEPTOR; LOCALIZATION; CHICKEN; FETUS	We are studying mice that carry a targeted disruption of the gene encoding insulin-like growth factor II (IGF-II). Transmission of this mutation through the male germline results in heterozygous progeny that are growth deficient. In contrast, when the disrupted gene is transmitted maternally, the heterozygous offspring are phenotypically normal. Therefore, the difference in growth phenotypes depends on the type of gamete contributing the mutated allele. Homozygous mutants are indistinguishable in appearance from growth-deficient heterozygous siblings. Nuclease protection and in situ hybridization analyses of the transcripts from the wild-type and mutated alleles indicate that only the paternal allele is expressed in embryos, while the maternal allele is silent. An exception is the choroid plexus and leptomeninges, where both alleles are transcriptionally active. These results demonstrate that IGF-II is indispensable for normal embryonic growth and that the IGF-II gene is subject to tissue-specific parental imprinting.			DECHIARA, TM (corresponding author), COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							Adams R. L. P., 1985, MOL BIOL DNA METHYLA; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BELL GI, 1985, P NATL ACAD SCI USA, V82, P6450, DOI 10.1073/pnas.82.19.6450; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; BRILLIANT MH, 1987, J NEUROGENET, V4, P259, DOI 10.3109/01677068709102346; BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; CANFIELD WM, 1989, J BIOL CHEM, V264, P7100; CATTANACH BM, 1986, J EMBRYOL EXP MORPH, V97, P137; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CHARD T, 1989, J ENDOCRINOL, V123, P3, DOI 10.1677/joe.0.1230003; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAIRMONT KB, 1989, J BIOL CHEM, V264, P16390; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEPAGTERHOLTHUIZEN P, 1985, HUM GENET, V69, P170, DOI 10.1007/BF00293291; DERCOLE AJ, 1980, DEV BIOL, V75, P315, DOI 10.1016/0012-1606(80)90166-9; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; GAMMELTOFT S, 1989, PEPTIDE HORMONES PRO, P176; GIRARD J, 1989, INTRAUTERINE GROWTH, P23; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IKEJIRI K, 1990, BIOCHIM BIOPHYS ACTA, V1049, P350, DOI 10.1016/0167-4781(90)90110-N; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LALLEY PA, 1984, CYTOGENET CELL GENET, V37, P515; LEE JE, 1990, DEVELOPMENT, V110, P151; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MCGRATH J, 1984, NATURE, V308, P550, DOI 10.1038/308550a0; MILNER RDG, 1987, EUR J PEDIATR, V146, P113, DOI 10.1007/BF02343214; MONK M, 1990, PHILOS T R SOC B, V326, P299, DOI 10.1098/rstb.1990.0013; MONK M, 1988, GENE DEV, V2, P921, DOI 10.1101/gad.2.8.921; MOSES AC, 1980, P NATL ACAD SCI-BIOL, V77, P3649, DOI 10.1073/pnas.77.6.3649; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RAPPOLEE DA, 1990, UCLA SYM BI, V117, P11; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; Sambrook J., 1989, MOL CLONING LAB MANU; SAPIENZA C, 1989, PROG NUCLEIC ACID RE, V36, P145; SAPIENZA C, 1989, ANN NY ACAD SCI, V564, P24, DOI 10.1111/j.1749-6632.1989.tb25885.x; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SEARLE AG, 1985, ANEUPLOIDY ETIOLOGY, P363; SLACK J, 1991, NATURE, V349, P17, DOI 10.1038/349017a0; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SMITH JC, 1989, DEVELOPMENT, V107, P149; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SOLTER D, 1988, ANNU REV GENET, V22, P127; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; STYLIANOPOULOU F, 1988, DEVELOPMENT, V103, P497; SURANI MA, 1990, PHILOS T ROY SOC B, V326, P313, DOI 10.1098/rstb.1990.0014; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MA, 1986, EXPT APPROACHES MAMM, P431; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SURANI MAH, 1986, J EMBRYOL EXP MORPH, V97, P123; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; SZULMAN AE, 1984, HUMAN TROPHOBLAST NE, P135; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TRICOLI JV, 1984, NATURE, V310, P784, DOI 10.1038/310784a0; UENO T, 1989, BIOCHIM BIOPHYS ACTA, V1009, P27, DOI 10.1016/0167-4781(89)90074-2; UENO T, 1987, BIOCHEM BIOPH RES CO, V148, P344, DOI 10.1016/0006-291X(87)91116-8; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLPERT L, 1989, DEVELOPMENT, V107, P3; WYLIE C, 1990, NATURE, V347, P337, DOI 10.1038/347337a0	80	1477	1531	3	88	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					849	859		10.1016/0092-8674(91)90513-X	http://dx.doi.org/10.1016/0092-8674(91)90513-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997210				2022-12-24	WOS:A1991EZ47800019
J	MARGOTTIN, F; DUJARDIN, G; GERARD, M; EGLY, JM; HUET, J; SENTENAC, A				MARGOTTIN, F; DUJARDIN, G; GERARD, M; EGLY, JM; HUET, J; SENTENAC, A			PARTICIPATION OF THE TATA FACTOR IN TRANSCRIPTION OF THE YEAST U6 GENE BY RNA POLYMERASE-C	SCIENCE			English	Article							III TRANSCRIPTION; UPSTREAM PROMOTER; BINDING-PROTEIN; SEQUENCES; SNRNA; DNA; BOX; SUBSTITUTE; ELEMENTS; INVITRO	Fractionation of transcription extracts has led to the identification of multiple transcription factors specific for each form of nuclear RNA polymerase. Accurate transcription in vitro of the yeast U6 RNA gene by RNA polymerase C requires at least two factors. One of them was physically and functionally indistinguishable from transcription factor IID (TFIID or BTFI), a pivotal component of polymerase B transcription complexes, which binds to the TATA element. Purified yeast TFIID (yIID) or bacterial extracts that contained recombinant yIID were equally competent to direct specific transcription of the U6 gene by RNA polymerase C. The results suggest the formation of a hybrid transcription machinery, which may imply an evolutionary relation between class B and class C transcription factors.	CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	MARGOTTIN, F (corresponding author), CENS,DEPT BIOL,SERV BIOCHIM,F-91191 GIF SUR YVETTE,FRANCE.		Margottin-Goguet, Florence/F-9272-2013; GERARD, Matthieu/D-2235-2014	Margottin-Goguet, Florence/0000-0002-3124-6690; GERARD, Matthieu/0000-0001-8956-0597				BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEINERT H, 1988, NUCLEIC ACIDS RES, V16, P1319, DOI 10.1093/nar/16.4.1319; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; LEE DI, 1989, J BIOCHEM-TOKYO, V105, P526, DOI 10.1093/oxfordjournals.jbchem.a122700; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MANIATIS T, 1983, MOL CLONING; MARGOTTIN F, UNPUB; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MEMET S, 1988, J BIOL CHEM, V263, P10048; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SOLLNERWEBB B, 1988, CELL, V52, P153, DOI 10.1016/0092-8674(88)90500-4; WAIBEL G, 1990, NUCLEIC ACIDS RES, V18, P3451; WAIBEL G, 1990, NATURE, V346, P199	33	162	163	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					424	426		10.1126/science.1989075	http://dx.doi.org/10.1126/science.1989075			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989075				2022-12-24	WOS:A1991EU50400039
J	THANABALASINGHAM, T; BECKETT, MW; MURRAY, V				THANABALASINGHAM, T; BECKETT, MW; MURRAY, V			LESSON OF THE WEEK - HOSPITAL RESPONSE TO A CHEMICAL INCIDENT - REPORT ON CASUALTIES OF AN ETHYLDICHLOROSILANE SPILL	BRITISH MEDICAL JOURNAL			English	Editorial Material									GUYS & ST THOMAS HOSP,NATL POISONS UNIT,LONDON SE1 9RT,ENGLAND; W MIDDLESEX UNIV HOSP,DEPT ACCID & EMERGENCY,ISLEWORTH,MIDDX,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Imperial College London								BAXTER PJ, 1989, BRIT MED J, V298, P1437, DOI 10.1136/bmj.298.6685.1437; CANADINE IC, 1990, INT C S SERIES, V155, P33; DALLOS V, 1990, INT C S SERIES, V155, P73; JERROM DA, 1990, INT C S SERIES, V155, P51; ROWE VK, 1948, J IND HYG TOXICOL, V30, P332; SACH M, 1988, BRIT J ACCIDENT EMER, V3, P9; TAYLOR D, 1990, INT C S SERIES, V155, P203; TONG TG, 1990, INT C S SERIES, V155, P141; 1985, TRADE UNION REPORT B; 1988, MMWR, V37, P733	10	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					101	102		10.1136/bmj.302.6768.101	http://dx.doi.org/10.1136/bmj.302.6768.101			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995104	Green Published, Bronze			2022-12-24	WOS:A1991ER95100027
J	BUSCH, MP; EBLE, BE; KHAYAMBASHI, H; HEILBRON, D; MURPHY, EL; KWOK, S; SNINSKY, J; PERKINS, HA; VYAS, GN				BUSCH, MP; EBLE, BE; KHAYAMBASHI, H; HEILBRON, D; MURPHY, EL; KWOK, S; SNINSKY, J; PERKINS, HA; VYAS, GN			EVALUATION OF SCREENED BLOOD DONATIONS FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION BY CULTURE AND DNA AMPLIFICATION OF POOLED CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; LOW COPY NUMBERS; MONONUCLEAR-CELLS; HOMOSEXUAL MEN; WESTERN BLOT; HIV; TRANSFUSION; TRANSMISSION; ANTIBODY; INDIVIDUALS	Background. Reports of transmission of the human immunodeficiency virus type 1 (HIV-1) from transfusions of screened blood and reports of silent, antibody-negative HIV-1 infections in persons at high risk continue to foster concern about the safety of the blood supply. Previous estimates of the risk of HIV-1 range from 1 in 38,000 to 1 in 300,000 per unit of blood but are based on either epidemiologic models or the demonstration of seroconversion in recipients. Methods. We isolated peripheral-blood mononuclear cells from blood that was fully screened and found to be seronegative, combined them into pools of cells from 50 donors, and tested them for HIV-1 by viral culture and the polymerase chain reaction, using protocols specifically adapted for this analysis. Results. The 1530 pools of mononuclear cells were prepared from 76,500 blood donations made in San Francisco between November 1987 and December 1989. Of these pools, 1436 (representing 71,800 donations) were cultured successfully; 873 (43,650 donations) were evaluated by the polymerase chain reaction. Only one pool was confirmed as HIV-1-infected by both methods. After adjustment for sample-based estimates of the sensitivity of the detection systems using culture and the polymerase chain reaction, the probability that a screened donor will be positive for HIV-1 was estimated as 1 in 61,171 (95 percent upper confidence bound, 1 in 10,695). Conclusions. Silent HIV-1 infections are exceedingly rare among screened blood donors, so the current risk of HIV-1 transmission from blood transfusions, even in high-prevalence metropolitan areas, is extremely low.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; IRWIN MEM BLOOD CTR,SAN FRANCISCO,CA; CETUS CORP,EMERYVILLE,CA 94608	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Vyas, Girish/0000-0003-1090-4911	NHLBI NIH HHS [N01-HB-86-7024] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUGAWAN TL, 1988, BIO-TECHNOL, V6, P943, DOI 10.1038/nbt0888-943; BUSCH MP, 1987, AM J CLIN PATHOL, V88, P673, DOI 10.1093/ajcp/88.6.673; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; Cox DR., 1970, ANAL BINARY DATA; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; EBLE BE, 1990, 14TH INT C CLIN CHEM; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; GALLO D, 1987, J CLIN MICROBIOL, V25, P1291, DOI 10.1128/JCM.25.7.1291-1294.1987; GUATELLI JC, 1989, CLIN MICROBIOL REV, V2, P217, DOI 10.1128/CMR.2.2.217-226.1989; HWANG LY, 1989, TRANSFUSION, V29, P113, DOI 10.1046/j.1537-2995.1989.29289146827.x; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JULIEN AM, 1988, LANCET, V2, P1248; KELLOGG DE, 1990, ANAL BIOCHEM, V189, P202, DOI 10.1016/0003-2697(90)90108-L; KELLOGG DE, 1990, PCR PROTOCOLS GUIDE, P337; KLEINMAN S, 1988, TRANSFUSION, V28, P499, DOI 10.1046/j.1537-2995.1988.28588337347.x; KLEINMAN SH, 1989, TRANSFUSION, V29, P572, DOI 10.1046/j.1537-2995.1989.29789369672.x; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEE TH, IN PRESS AIDS; LIFSON AR, 1990, J INFECT DIS, V161, P436, DOI 10.1093/infdis/161.3.436; LOCHE M, 1988, LANCET, V2, P418; NETER J, 1974, APPLIED LINEAR STATI; PERKINS HA, 1987, TRANSFUSION, V27, P502, DOI 10.1046/j.1537-2995.1987.27688071706.x; PERKINS HA, 1989, NEW ENGL J MED, V320, P463; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P277; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SOBEL M, 1975, BIOMETRIKA, V62, P181, DOI 10.1093/biomet/62.1.181; ULRICH PP, 1988, J MED VIROL, V25, P1, DOI 10.1002/jmv.1890250102; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WOLINSKY SM, 1989, ANN INTERN MED, V111, P961, DOI 10.7326/0003-4819-111-12-961	36	129	130	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1991	325	1					1	5		10.1056/NEJM199107043250101	http://dx.doi.org/10.1056/NEJM199107043250101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU342	2046708				2022-12-24	WOS:A1991FU34200001
J	TAITZ, LS				TAITZ, LS			CHILD-ABUSE AND METABOLIC BONE-DISEASE - ARE THEY OFTEN CONFUSED	BRITISH MEDICAL JOURNAL			English	Article							OSTEOGENESIS IMPERFECTA				TAITZ, LS (corresponding author), CHILDRENS HOSP,PAEDIAT,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND.							PATERSON CR, 1989, BMJ-BRIT MED J, V299, P1451, DOI 10.1136/bmj.299.6713.1451; PATTERSON CR, 1989, BMJ, V295, P213; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; TAITZ LS, 1988, BRIT MED J, V296, P292, DOI 10.1136/bmj.296.6617.292-a; TAITZ LS, 1987, CHILD ABUSE REV, V1, P6	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1244	1244		10.1136/bmj.302.6787.1244	http://dx.doi.org/10.1136/bmj.302.6787.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP272	2043847	Green Published			2022-12-24	WOS:A1991FP27200023
J	SPIES, T; DEMARS, R				SPIES, T; DEMARS, R			RESTORED EXPRESSION OF MAJOR HISTOCOMPATIBILITY CLASS-I MOLECULES BY GENE-TRANSFER OF A PUTATIVE PEPTIDE TRANSPORTER	NATURE			English	Article							HLA-B ANTIGENS; LYMPHOBLASTOID CELLS; T-CELLS; MHC; COMPLEX; REGION; DETERMINANT; BINDING; PROTEIN; PATHWAY	CYTOTOXIC T lymphocytes recognize antigen-derived peptides bound to major histocompatibility complex (MHC) class I molecules with which they assemble in the endoplasmic reticulum or in an undefined subcompartment 1-10. There is genetic evidence that the peptides that are products of cytosolic protein degradation are transported into this compartment by a peptide supply factor (PSF), encoded in the MHC class II region 11. Like the corresponding genes RING4, HAM1 and mtp1 (refs 12-14), PSF is related to the multidrug-resistance family of transporters 11 and may be a peptide pump, as translocation of peptides across membranes must occur independently of the secretory pathway 15. There is, however, no functional evidence for this role so far. Here we report gene transfer experiment showing that expression of PSF complementary DNA in the human lymphoblastoid cell line mutant 721.134 (refs 11, 16, 17) restores normal levels of surface HLA-A2 and -B5. No similar effect was observed in 721.174 mutant cells, in which a homozygous deletion includes PSF among several other closely linked genes 11. At least one of these genes may therefore also be required for PSF function.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SPIES, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115, USA.							BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; LONG EO, IN PRESS HUM IMMUN; MANN DL, 1983, NATURE, V305, P58, DOI 10.1038/305058a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; WAYS JP, 1986, J IMMUNOL, V137, P217	25	417	432	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					323	324		10.1038/351323a0	http://dx.doi.org/10.1038/351323a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034277				2022-12-24	WOS:A1991FM97600063
J	RAUB, WF				RAUB, WF			COMBINATION THERAPY MOST BENEFICIAL AGAINST RECTAL-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P709	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-24	WOS:A1991FH87700008
J	NEIL, HAW				NEIL, HAW			CHOLESTEROL SCREENING AND LIFE ASSURANCE	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD LIPID CONCENTRATIONS; DEATH; RISK	Objectives-To examine how insurance companies assess proposals for life assurance from applicants with raised cholesterol concentrations and to determine the excess mortality rating applied. Design-Survey of 49 companies underwriting term life assurance. Setting-United Kingdom. Subjects-Four fictional men aged 30 seeking 20 year term policies paying benefit only on death. Two had total cholesterol concentrations of 6.4 and 8.1 mmol/l but no other cardiovascular risk factors; one was overweight, hypertensive, smoked 20 cigarettes daily, and had a total cholesterol concentration of 8.1 mmol/l; and one had possible familial hypercholesterolaemia and a total cholesterol concentration of 10.7 mmol/l after treatment. Main outcome measure-Percentage excess mortality rating. Results-All companies used explicit criteria to assess the mortality risk associated with hyperlipidaemias, and 47 companies applied the same criteria to men and women. No excess mortality rating was imposed on an applicant with a total cholesterol concentration of 6.4 mmol/l, but a small excess was applied to an applicant with a concentration of 8.1 mmol/l (median excess 50%, range 0-75%). When multiple cardiovascular risk factors were present the same concentration of 8.1 mmol/l resulted in a substantial excess (median 135%, range 50-200%). A smaller but more variable excess was applied to an applicant with possible familial hypercholesterolaemia (median 75%, range 0-200%). Conclusions-Despite considerable differences among companies in the excess mortality ratings applied, increases in term life assurance premiums are likely to be restricted to patients with severe hypercholesterolaemia, in particular those with familial hypercholesterolaemia. In the absence of other cardiovascular risk factors milder hypercholesterolaemia is unlikely to result in higher premiums.			NEIL, HAW (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.							Brackenridge R. D. C., 1985, MED SELECTION LIFE R; DURRINGTON PN, 1989, HYPERLIPIDAEMIA DIAG, P103; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MARTEAU TM, 1990, BRIT MED J, V301, P26, DOI 10.1136/bmj.301.6742.26; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; SLACK J, 1969, LANCET, V2, P1380; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476; 1988, EUR HEART J, V9, P571	11	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					891	893		10.1136/bmj.302.6781.891	http://dx.doi.org/10.1136/bmj.302.6781.891			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025730	Green Published, Bronze			2022-12-24	WOS:A1991FG42100027
J	GWINN, M; PAPPAIOANOU, M; GEORGE, JR; HANNON, WH; WASSER, SC; REDUS, MA; HOFF, R; GRADY, GF; WILLOUGHBY, A; NOVELLO, AC; PETERSEN, LR; DONDERO, TJ; CURRAN, JW				GWINN, M; PAPPAIOANOU, M; GEORGE, JR; HANNON, WH; WASSER, SC; REDUS, MA; HOFF, R; GRADY, GF; WILLOUGHBY, A; NOVELLO, AC; PETERSEN, LR; DONDERO, TJ; CURRAN, JW			PREVALENCE OF HIV-INFECTION IN CHILDBEARING WOMEN IN THE UNITED-STATES - SURVEILLANCE USING NEWBORN BLOOD-SAMPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; AIDS; SEROPREVALENCE; INFANTS	A national, population-based survey was initiated in 1988 to measure the prevalence of human immunodeficiency virus (HIV) infection in women giving birth to infants in the United States. Following standardized procedures, residual dried-blood specimens collected on filter paper for newborn metabolic screening were tested anonymously in state public health laboratories for maternal antibody to HIV. As of September 1990, annual survey data were available from 38 states and the District of Columbia. The highest HIV seroprevalence rates were observed in New York (5.8 per 1000), the District of Columbia (5.5 per 1000), New Jersey (4.9 per 1000), and Florida (4.5 per 1000). Nationwide, an estimated 1.5 per 1000 women giving birth to infants in 1989 were infected with HIV. Assuming a perinatal transmission rate of 30%, we estimate that approximately 1800 newborns acquired HIV infection during one 12-month period. Preventing transmission of HIV infection to women and infants is an urgent public health priority.	CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333; MASSACHUSETTS DEPT HLTH,BOSTON,MA; NICHHD,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	GWINN, M (corresponding author), CTR DIS CONTROL,DIV HIV AIDS,MAILSTOP E-49,ATLANTA,GA 30333, USA.							ANDIMAN WA, 1989, SEMIN PERINATOL, V13, P16; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; GRANT CM, 1990, 6TH INT C AIDS SAN F; GWINN M, 1990, 6TH INT C AIDS SAN F; HARDY LM, 1991, HIV SCREENING PREGNA; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; Hummel R. F., 1990, AIDS and Public Policy Journal, V5, P68; LEE FK, 1989, AIDS RES HUM RETROV, V5, P517, DOI 10.1089/aid.1989.5.517; MITCHELL JL, 1989, J NATL MED ASSOC, V81, P841; MOFENSON LM, 1989, 5TH INT AIDS C MONTR; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; PIZZO PA, 1990, PEDIATR INFECT DIS J, V9, P690, DOI 10.1097/00006454-199010000-00002; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SELIK RM, 1989, AIDS GYNECOLOGY CLIN, V1, P33; STRICOF RL, 1989, 5TH ANN NAT PED AIDS; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; 1989, CURRENT POPULATI P25, V1018; 1988, MMWR, V37, P341; 1988, ACOG TECHNICAL B, V123; 1990, MONTHLY VITAL STAT R, V38, P1; 1989, MMWR SS7, V38, P1; 1990, HIV AIDS SURVEILLANC, P1; 1988, MMWR, V37, P351; 1987, MMWR, V36, P509; 1988, MMWR, V37, P1	31	247	250	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1704	1708		10.1001/jama.265.13.1704	http://dx.doi.org/10.1001/jama.265.13.1704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002571				2022-12-24	WOS:A1991FD65900026
J	MCNEIL, JG; BRUNDAGE, JF; GARDNER, LI; WANN, ZF; RENZULLO, PO; REDFIELD, RR; BURKE, DS; MILLER, RN				MCNEIL, JG; BRUNDAGE, JF; GARDNER, LI; WANN, ZF; RENZULLO, PO; REDFIELD, RR; BURKE, DS; MILLER, RN			TRENDS OF HIV SEROCONVERSION AMONG YOUNG-ADULTS IN THE UNITED-STATES-ARMY, 1985 TO 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HTLV-III; INFECTION; AIDS; MEN; ANTIBODIES; TESTS	Because soldiers in the US Army are recurrently tested for the presence of antibody to the human immunodeficiency virus (HIV), HIV seroconversion rates can be directly measured. From November 1985 through October 1989, 429 HIV seroconversions were detected among 718 780 soldiers who contributed 1 088 447 person-years of follow-up time (HIV seroconversion rate, 0.39 per 1000 person-years). Period-specific seroconversion rates declined significantly, from 0.49 per 1000 person-years (November 1985 through October 1987) to 0.33 per 1000 person-years (November 1987 through October 1988) to 0.29 per 1000 person-years (November 1988 through October 1989). The HIV seroconversion risk among active-duty soldiers was significantly associated with race/ethnic group, age, gender, and marital status. Based on these trends, we estimate that approximately 220 soldiers (95% confidence interval, 160 to 297 soldiers) were infected with HIV during 1989 and 1990, with potentially fewer in future years.	SRA TECHNOL, ALEXANDRIA, VA USA; WALTER REED ARMY MED CTR, DIV RETROVIROL, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	MCNEIL, JG (corresponding author), WALTER REED ARMY MED CTR, DEPT EPIDEMIOL, DIV PREVENT MED, WASHINGTON, DC 20307 USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				Breslow N.E., 1987, STATISTICAL METHODS, V2, P133; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; BURKE DS, 1986, JAMA-J AM MED ASSOC, V256, P347, DOI 10.1001/jama.256.3.347; BURKE DS, 1989, CLIN LAB MED, V9, P369, DOI 10.1016/S0272-2712(18)30609-7; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; DETELS R, 1989, J ACQ IMMUN DEF SYND, V2, P77; DODD RY, 1988, 4TH INT C AIDS STOCK, V2, P347; GAIL MH, 1988, J NATL CANCER I, V80, P900, DOI 10.1093/jnci/80.12.900; GARLAND FC, 1989, JAMA-J AM MED ASSOC, V262, P3161, DOI 10.1001/jama.262.22.3161; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HERBOLD JR, 1986, MIL MED, V151, P623; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KELLEY PW, 1987, AIDS ACQUIRED IMMUNE, P67; MCNEIL JG, 1989, NEW ENGL J MED, V320, P1581, DOI 10.1056/NEJM198906153202403; MCNEIL JG, 1989, 5TH INT C AIDS OTT, V1, P158; MCNEIL JG, 1990, 6TH INT C AIDS SAN F, V1, P265; PETRICCIANI JC, 1985, ANN INTERN MED, V103, P726, DOI 10.7326/0003-4819-103-5-726; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; 1990, MMWR, V39, P81; 1990, EGRET VERSION 25; 1990, MMWR, V39, P110; 1983, HIV AIDS SURVEILLANC	29	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1709	1714		10.1001/jama.265.13.1709	http://dx.doi.org/10.1001/jama.265.13.1709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002572				2022-12-24	WOS:A1991FD65900027
J	JICK, H; JICK, SS; DERBY, LE				JICK, H; JICK, SS; DERBY, LE			VALIDATION OF INFORMATION RECORDED ON GENERAL-PRACTITIONER BASED COMPUTERIZED DATA RESOURCE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the extent of agreement between clinical information recorded on surgery computers of selected general practitioners and similar information in manual records of letters received from hospital consultants and kept in the general practitioners' files. Design-Hospital consultants' letters in the manual records of selected general practitioners were photocopied and the consultants' clinical diagnoses were compared with diagnoses recorded on computer. Setting-General practices in the United Kingdom using computers provided by VAMP Health for recording clinical information. Subjects-2491 patients who received one of three non-steroidal anti-inflammatory drugs and who attended 58 practices whose computer recorded data were considered after a preliminary review to be of satisfactory quality. Results-Among 1191 patients for whom consultants' letters were forwarded a clinical diagnosis reflecting the diagnosis noted on a consultant letter was present on the computer record for 1038 (87%). Conclusion-Clinical information available on the computer records of the general practitioners who participated in this study is satisfactory for many clinical studies.			JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067	FDA HHS [FD-U-000071-09] Funding Source: Medline	FDA HHS		FINDLAY GH, 1982, LANCET, V2, P95; JICK H, 1984, PHARMACOTHERAPY, V4, P99; JICK H, 1990, PHARMACOTHERAPY, V10, P395; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; SKEGG DCG, 1977, LANCET, V2, P475; TILSON H H, 1989, Journal of Clinical Research and Drug Development, V3, P39; WEST R, 1988, AM J PREVENTIVE ME S, P25	7	723	724	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					766	768		10.1136/bmj.302.6779.766	http://dx.doi.org/10.1136/bmj.302.6779.766			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021768	Bronze, Green Published			2022-12-24	WOS:A1991FF22900027
J	EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ				EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ			ADVANCE DIRECTIVES FOR MEDICAL-CARE - A CASE FOR GREATER USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; CARDIOPULMONARY RESUSCITATION; ELDERLY OUTPATIENTS; PHYSICIANS; DECISIONS; PREFERENCES; ATTITUDES; CHOICES; END	Background. Advance directives for medical care and the designation of proxy decision makers to guide medical care after a patient has become incompetent have been widely advocated but little studied. We investigated the attitudes of patients toward planning, perceived barriers to such planning, treatment preferences in four hypothetical scenarios, and the feasibility of using a particular document (the Medical Directive) in the outpatient setting to specify advance directives. Methods. We surveyed 405 outpatients of 30 primary care physicians at Massachusetts General Hospital and 102 members of the general public in Boston and asked them as part of the survey to complete the Medical Directive. Results. Advance directives were desired by 93 percent of the outpatients and 89 percent of the members of the general public (P > 0.2). Both the young and the healthy subgroups expressed at least as much interest in planning as those older than 65 and those in fair-to-poor health. Of the perceived barriers to issuing advance directives, the lack of physician initiative was among the most frequently mentioned, and the disturbing nature of the topic was among the least. The outpatients refused life-sustaining treatments in 71 percent of their responses to options in the four scenarios (coma with chance of recovery, 57 percent; persistent vegetative state, 85 percent; dementia, 79 percent; and dementia with a terminal illness, 87 percent), with small differences between widely differing types of treatments. Specific treatment preferences could not be usefully predicted according to age, self-rated state of health, or other demographic features. Completing the Medical Directive took a median of 14 minutes. Conclusions. When people are asked to imagine themselves incompetent with a poor prognosis, they decide against life-sustaining treatments about 70 percent of the time. Health, age, or other demographic features cannot be used, however, to predict specific preferences. Advance directives as part of a comprehensive approach such as that provided by the Medical Directive are desired by most people, require physician initiative, and can be achieved during a regular office visit.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,PROGRAM ETH & PROFESS,CAMBRIDGE,MA 02138	Harvard University; Beth Israel Deaconess Medical Center; Harvard University	EMANUEL, LL (corresponding author), MASSACHUSETTS GEN HOSP,GEN INTERNAL MED UNIT,BOSTON,MA 02114, USA.				AHRQ HHS [R01 HS06120] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; BUCHANAN A, 1988, PHILOS PUBLIC AFF, V17, P277; COLTON T, 1974, STAT MED, P120; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; Lubitz J, 1984, Health Care Financ Rev, V5, P117; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; READLEAF DL, 1979, STANFORD LAW REV, V31, P913; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; Shapiro R S, 1986, Wis Med J, V85, P17; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; STEIBER SR, 1987, HOSPITALS, V61, P72; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615; 1989, RESOLUTION LEGISLATI; 1989, CURRENT OPINIONS COU; 1987, HDB LIVING WILL LAWS	26	595	598	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					889	895		10.1056/NEJM199103283241305	http://dx.doi.org/10.1056/NEJM199103283241305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000111				2022-12-24	WOS:A1991FD11100005
J	WONG, KF; HUI, PK; CHAN, JKC; CHAN, YW; HA, SY				WONG, KF; HUI, PK; CHAN, JKC; CHAN, YW; HA, SY			THE ACUTE LUPUS HEMOPHAGOCYTIC SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						LUPUS ERYTHEMATOSUS, SYSTEMIC; PANCYTOPENIA; LUPUS HEMOPHAGOCYTIC SYNDROME; HISTIOCYTOSIS, NON-LANGERHANS-CELL; STEROIDS	MALIGNANT HISTIOCYTOSIS; ERYTHEMATOSUS	Objective: To characterize an unusual mode of presentation of systemic lupus erythematosus: acute and severe pancytopenia related to reactive hemophagocytosis. Design: Retrospective case series. Setting: Two general community hospitals in Hong Kong. Patients: Six patients presenting with a reactive hemophagocytic syndrome, identified over a 3.5 year period, diagnosed with systemic lupus erythematosus according to the criteria of the American Rheumatism Association. Results: In addition to severe pancytopenia and marrow hemophagocytosis, other characteristic features were fever, hypocomplementemia, high antinuclear antibody titer, and cutaneous and visceral vasculitis. There was no evidence of an underlying infection. The pancytopenia responded dramatically to treatment with steroids. Conclusion: Recognition of the acute lupus hemophagocytic syndrome and distinction from an infection-associated hemophagocytic syndrome is important because it responds well to steroid therapy. The evaluation of patients presenting with a hemophagocytic syndrome should include serologic tests for systemic lupus erythematosus.	KWONG WAH HOSP, CLIN PATHOL UNIT, KOWLOON, HONG KONG; KWONG WAH HOSP, MED UNIT A, KOWLOON, HONG KONG	Kwong Wah Hospital; Kwong Wah Hospital	WONG, KF (corresponding author), QUEEN ELIZABETH HOSP, INST PATHOL, KOWLOON, HONG KONG.			HA, Shau Yin/0000-0002-9191-8743				BUDMAN DR, 1977, ANN INTERN MED, V86, P220, DOI 10.7326/0003-4819-86-2-220; CHAN JKC, 1987, PATHOLOGY, V19, P43, DOI 10.3109/00313028709065134; CHAN JKC, 1987, LANCET, V1, P507; GOLD SC, 1953, Q J MED, V22, P457; HUANG LM, 1990, LANCET, V336, P60, DOI 10.1016/0140-6736(90)91580-4; JAFFE ES, 1983, AM J MED, V75, P741, DOI 10.1016/0002-9343(83)90402-3; KOFFLER D, 1982, ARTHRITIS RHEUM, V25, P858, DOI 10.1002/art.1780250729; Meyerhoff J, 1983, Md State Med J, V32, P935; MICHAEL SR, 1951, BLOOD, V6, P1059, DOI 10.1182/blood.V6.11.1059.1059; REINER AP, 1988, MEDICINE, V67, P369, DOI 10.1097/00005792-198811000-00002; Richert-Boe K E, 1987, Hematol Oncol Clin North Am, V1, P301; RISDALL RJ, 1979, CANCER, V44, P993, DOI 10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5; RISDALL RJ, 1984, CANCER, V54, P2968, DOI 10.1002/1097-0142(19841215)54:12<2968::AID-CNCR2820541226>3.0.CO;2-4; ROSENTHAL NS, 1989, AM J CLIN PATHOL, V92, P650, DOI 10.1093/ajcp/92.5.650; SAKURAI T, 1984, Henry Ford Hospital Medical Journal, V32, P142; SERDULA MK, 1979, ARTHRITIS RHEUM-US, V22, P328, DOI 10.1002/art.1780220403; SIMRELL CR, 1982, B T CELL TUMORS, P247; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WOO J, 1987, ASIAN J CLIN SCI, V7, P77	19	173	178	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					387	390		10.7326/0003-4819-114-5-387	http://dx.doi.org/10.7326/0003-4819-114-5-387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1992881				2022-12-24	WOS:A1991EZ17400007
J	GREENBERG, DP; VADHEIM, CM; BORDENAVE, N; ZIONTZ, L; CHRISTENSON, P; WATERMAN, SH; WARD, JI				GREENBERG, DP; VADHEIM, CM; BORDENAVE, N; ZIONTZ, L; CHRISTENSON, P; WATERMAN, SH; WARD, JI			PROTECTIVE EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B POLYSACCHARIDE AND CONJUGATE VACCINES IN CHILDREN 18 MONTHS OF AGE AND OLDER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE	To evaluate the protective efficacy of polyribosylribitol phosphate (PRP) and polyribosylribitol phosphate-diphtheria toxoid (PRP-D) vaccines in children 18 to 59 months of age, we conducted a case-control study in Los Angeles (Calif) County between July 1, 1988, and July 31, 1989. Seventy-nine children with invasive Haemophilus influenzae type b disease 18 to 59 months of age were identified, and 212 controls were selected by random-digit telephone dialing methods. Cases and controls were stratified by age and month of disease onset of the case. Seventeen PRP vaccine failures and two PRP-D vaccine failures occurred more than 2 weeks after vaccination. The PRP vaccine was shown not to be effective (point estimate -47%; 95% confidence interval, -307% to 47%), but the PRP-D vaccine was 88% protective (95% confidence interval, 42% to 97%). Adjustment of the efficacy estimates for potential confounding variables did not change the results significantly. The PRP-D vaccine provided significantly better protection than the PRP vaccine against invasive H influenzae type b disease in this population.	LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA		GREENBERG, DP (corresponding author), UNIV CALIF LOS ANGELES,HARBOR MED CTR,SCH MED,CTR VACCINE RES,1124 W CARSON ST,BLDG E-6,TORRANCE,CA 90502, USA.							BERKOWITZ CD, 1987, J PEDIATR-US, V110, P509, DOI 10.1016/S0022-3476(87)80540-1; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; Breslow N, 1980, STAT METHODS CANC RE, P248; ESKOLA J, 1987, NEW ENGL J MED, V317, P717, DOI 10.1056/NEJM198709173171201; ESKOLA J, 1989, 29TH INT C ANT AG CH; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; HARRISON LH, 1989, PEDIATRICS, V84, P255; KAYHTY H, 1984, PEDIATRICS, V74, P857; MURPHY TV, 1990, CLIN RES, V38, pA183; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; VADHEIM CM, 1990, PEDIATR INFECT DIS J, V9, P555, DOI 10.1097/00006454-199008000-00006; WARD J, 1990, NEW ENGL J MED, V323, P1393, DOI 10.1056/NEJM199011153232006; WENGER JD, 1990, 30TH INT C ANT AG CH; 1985, MMWR, V34, P201; 1990, MMWR, V39, P925; 1988, MMWR, V37, P13; 1990, MMWR, V39, P698; 1988, HAEMOPHILUS INFLUENZ, V81, P908	25	40	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					987	992		10.1001/jama.265.8.987	http://dx.doi.org/10.1001/jama.265.8.987			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EY432	1992212				2022-12-24	WOS:A1991EY43200026
J	FODOR, SPA; READ, JL; PIRRUNG, MC; STRYER, L; LU, AT; SOLAS, D				FODOR, SPA; READ, JL; PIRRUNG, MC; STRYER, L; LU, AT; SOLAS, D			LIGHT-DIRECTED, SPATIALLY ADDRESSABLE PARALLEL CHEMICAL SYNTHESIS	SCIENCE			English	Article								Solid-phase chemistry, photolabile protecting groups, and photolithography have been combined to achieve light-directed, spatially addressable parallel chemical synthesis to yield a highly diverse set of chemical products. Binary masking, one of many possible combinatorial synthesis strategies, yields 2n compounds in n chemical steps. An array of 1024 peptides was synthesized in ten steps, and its interaction with a monoclonal antibody was assayed by epifluorescence microscopy. High-density arrays formed by light-directed synthesis are potentially rich sources of chemical diversity for discovering new ligands that bind to biological receptors and for elucidating principles governing molecular interactions. The generality of this approach is illustrated by the light-directed synthesis of a dinucleotide. Spatially directed synthesis of complex compounds could also be used for microfabrication of devices.			FODOR, SPA (corresponding author), AFFYMAX RES INST,3180 PORTER DR,PALO ALTO,CA 94304, USA.							CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GELB MH, 1985, BIOCHEMISTRY-US, V24, P1813, DOI 10.1021/bi00329a001; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, CIBA F S, V119, P131; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; LATT SA, 1972, ANAL BIOCHEM, V50, P56, DOI 10.1016/0003-2697(72)90485-X; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; McGillis D. A., 1983, VLSI technology, P267; MEO T, 1983, P NATL ACAD SCI-BIOL, V80, P4084, DOI 10.1073/pnas.80.13.4084; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; NESTOR JJ, 1988, J MED CHEM, V31, P65, DOI 10.1021/jm00396a011; NEWMAN TH, 1987, J VAC SCI TECHNOL B, V5, P88, DOI 10.1116/1.583934; OHTSUKA E, 1977, SYNTHESIS-STUTTGART, P453; PATCHORNIK CA, 1970, J AM CHEM SOC, V92, P6333; PILLAI VNR, 1980, SYNTHESIS-STUTTGART, P1; ROGET A, 1989, NUCLEIC ACIDS RES, V17, P7643, DOI 10.1093/nar/17.19.7643; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	20	2203	3247	4	274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					767	773		10.1126/science.1990438	http://dx.doi.org/10.1126/science.1990438			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990438				2022-12-24	WOS:A1991EX57500036
J	MARSDEN, PD				MARSDEN, PD			AIDS - IT CAME FOR THE CARNIVAL	BRITISH MEDICAL JOURNAL			English	Editorial Material											MARSDEN, PD (corresponding author), UNIV BRASILIA,CP153121,BR-70010 BRASILIA,DF,BRAZIL.								0	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 9	1991	302	6772					337	337		10.1136/bmj.302.6772.337	http://dx.doi.org/10.1136/bmj.302.6772.337			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX569	2001511	Bronze, Green Published			2022-12-24	WOS:A1991EX56900028
J	ZHUKOVSKY, EA; ROBINSON, PR; OPRIAN, DD				ZHUKOVSKY, EA; ROBINSON, PR; OPRIAN, DD			TRANSDUCIN ACTIVATION BY RHODOPSIN WITHOUT A COVALENT BOND TO THE 11-CIS-RETINAL CHROMOPHORE	SCIENCE			English	Article							VISUAL PIGMENTS; BOVINE RHODOPSIN; SCHIFF-BASE; PROTEINS; FAMILY; BACTERIORHODOPSIN; RECEPTORS	Rhodopsin and the visual pigments are a distinct group within the family of G-protein-linked receptors in that they have as covalently bound ligand, the 11-cis-retinal chromophore, whereas all of the other receptors bind their agonists through noncovalent interactions. The retinal chromophore in rhodopsin is bound by means of a protonated Schiff base linkage to the epsilon-amino group of Lys-296. Two rhodopsin mutants have been constructed, K296G and K296A, in which the covalent linkage to the chromophore is removed. Both mutants form a pigment with an absorption spectrum close to that of the wild type when reconstituted with the Schiff base of an n-alkylamine and 11-cis-retinal. In addition, the pigment formed from K296G and the n-propylamine Schiff base of 11-cis-retinal was found to activate transducin in a light-dependent manner, with 30 to 40% of the specific activity measured for the wild-type protein. It appears that the covalent bond is not essential for binding of the chromophore or for catalytic activation of transducin.			ZHUKOVSKY, EA (corresponding author), BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254, USA.		Zhukovsky, Eugene/Q-3218-2019	Zhukovsky, Eugene/0000-0003-1822-8946	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007044] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007596] Funding Source: NIH RePORTER; NCRR NIH HHS [S07 RR07044] Funding Source: Medline; NEI NIH HHS [R01 EY007965, EY07965] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07596-11] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; HONIG B, 1979, P NATL ACAD SCI USA, V76, P2503, DOI 10.1073/pnas.76.6.2503; HONIG B, 1976, BIOCHEMISTRY-US, V15, P4593, DOI 10.1021/bi00666a008; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; STRADER CD, 1988, J BIOL CHEM, V263, P10267; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	20	129	130	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					558	560		10.1126/science.1990431	http://dx.doi.org/10.1126/science.1990431			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990431				2022-12-24	WOS:A1991EV45900050
J	MESSINEZY, M; AUBRY, S; OCONNELL, G; TREACHER, DF; PEARSON, TC				MESSINEZY, M; AUBRY, S; OCONNELL, G; TREACHER, DF; PEARSON, TC			OXYGEN DESATURATION IN APPARENT AND RELATIVE POLYCYTHEMIA	BRITISH MEDICAL JOURNAL			English	Article									UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,SLEEP LAB,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT MED,LUNG FUNCT LAB,LONDON SE1 7EH,ENGLAND	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	MESSINEZY, M (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DIV HAEMATOL,ST THOMASS CAMPUS,LONDON SE1 7EH,ENGLAND.							BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; ECKSTEIN JW, 1960, J LAB CLIN MED, V56, P847; MESSINEZY M, 1990, CLIN LAB HAEMATOL, V12, P121, DOI 10.1111/ijlh.1990.12.2.121; MOOREGILLON JC, 1986, BRIT MED J, V293, P588, DOI 10.1136/bmj.293.6547.588; PEARSON TC, 1984, CLIN LAB HAEMATOL, V6, P207	5	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					216	217		10.1136/bmj.302.6770.216	http://dx.doi.org/10.1136/bmj.302.6770.216			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV228	1998762	Bronze, Green Published			2022-12-24	WOS:A1991EV22800026
J	HAUKEBO, N				HAUKEBO, N			MEDICINE MAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2788	2788						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033731				2022-12-24	WOS:A1991FN85500007
J	DELORON, P; LEPERS, JP; RAHARIMALALA, L; DUBOIS, B; COULANGES, P; POCIDALO, JJ				DELORON, P; LEPERS, JP; RAHARIMALALA, L; DUBOIS, B; COULANGES, P; POCIDALO, JJ			PEFLOXACIN FOR FALCIPARUM-MALARIA - ONLY MODEST SUCCESS	ANNALS OF INTERNAL MEDICINE			English	Note							NORFLOXACIN; INVITRO; MICE; DRUG	To assess the efficacy of pefloxacin in treating Plasmodium falciparum malaria in Madagascar, an area of chloroquine resistance, we conducted a case series intervention study in a rural population. Twenty-two adults with pure P. falciparum parasitemia, and no glucose-6-phosphate dehydrogenase deficiency, pregnancy, or other illness, were given an oral dose of 400 mg of pefloxacin every 12 hours for 3 days. Pefloxacin and chloroquine susceptibilities of 10 isolates were measured by an in-vitro microtest. The overall success rate of treatment was 9 of 22 (41%; 95% CI, 20% to 61%). Sixteen patients cleared parasitemia, but late recrudescence occurred in 7. Early therapeutic failure occurred in the 6 other patients. Efficacy of pefloxacin treatment was not related to the in-vitro activity of chloroquine or pefloxacin against the corresponding strain. These data contrast with those from a preliminary report from India of successful malaria therapy with a similar regimen of norfloxacin, the main metabolite of pefloxacin in humans.	INST PASTEUR MADAGASCAR, ANTANANARIVO, MADAGASCAR	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar	DELORON, P (corresponding author), HOP CLAUDE BERNARD, INSERM, UB, 10 AVE PORT DAUBERVILLIERS, F-75019 PARIS, FRANCE.		Deloron, Philippe/G-6305-2010	Deloron, Philippe/0000-0003-4705-2484				[Anonymous], 1986, CHEMOTHERAPY MALARIA; ASTAGNEAU P, 1991, AM J EPIDEMIOL, V133, P177, DOI 10.1093/oxfordjournals.aje.a115856; DIVO AA, 1988, ANTIMICROB AGENTS CH, V32, P1182, DOI 10.1128/AAC.32.8.1182; LEPERS JP, 1989, T ROY SOC TROP MED H, V83, P491, DOI 10.1016/0035-9203(89)90263-0; MONTAY G, 1984, ANTIMICROB AGENTS CH, V25, P463, DOI 10.1128/AAC.25.4.463; RIOU JF, 1986, BIOCHEMISTRY-US, V25, P1471, DOI 10.1021/bi00355a001; SALMON D, 1990, ANTIMICROB AGENTS CH, V34, P2327, DOI 10.1128/AAC.34.12.2327; SARMA PS, 1989, ANN INTERN MED, V111, P336, DOI 10.7326/0003-4819-111-4-336; WISE R, 1984, J ANTIMICROB CHEMOTH, V13, P59, DOI 10.1093/jac/13.suppl_B.59; WOLFSON JS, 1985, ANTIMICROB AGENTS CH, V28, P581, DOI 10.1128/AAC.28.4.581	10	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					874	875		10.7326/0003-4819-114-10-874	http://dx.doi.org/10.7326/0003-4819-114-10-874			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014948				2022-12-24	WOS:A1991FL65000007
J	MCINTIRE, WS; WEMMER, DE; CHISTOSERDOV, A; LIDSTROM, ME				MCINTIRE, WS; WEMMER, DE; CHISTOSERDOV, A; LIDSTROM, ME			A NEW COFACTOR IN A PROKARYOTIC ENZYME - TRYPTOPHAN TRYPTOPHYLQUINONE AS THE REDOX PROSTHETIC GROUP IN METHYLAMINE DEHYDROGENASE	SCIENCE			English	Article							COVALENTLY BOUND PQQ; AMINO-ACID-SEQUENCE; PSEUDOMONAS SP-J; PYRROLOQUINOLINE QUINONE; PARACOCCUS-DENITRIFICANS; PYRIDOXO-QUINOPROTEIN; DIAMINE OXIDASE; BIOSYNTHESIS; PURIFICATION; TYROSINE	Methylamine dehydrogenase (MADH), an alpha-2-beta-2 enzyme from numerous methylotrophic soil bacteria, contains a novel quinonoid redox prosthetic group that is covalently bound to its small beta-subunit through two amino acyl residues. A comparison of the amino acid sequence deduced from the gene sequence of the small subunit for the enzyme from Methylobacterium extorquens AM1 with the published amino acid sequence obtained by the Edman degradation method, allowed the identification of the amino acyl constituents of the cofactor as two tryptophyl residues. This information was crucial for interpreting H-1 and C-13 nuclear magnetic resonance, and mass spectral data collected for the semicarbazide- and carboxymethyl-derivatized bis(tripeptidyl)-cofactor of MADH from bacterium W3A1. The cofactor is composed of two cross-linked tryptophyl residues. Although there are many possible isomers, only one is consistent with all the data: The first tryptophyl residue in the peptide sequence exists as an indole-6,7-dione, and is attached at its 4 position to the 2 position of the second, otherwise unmodified, indole side group. Contrary to earlier reports, the cofactor of MADH is not 2,7,9-tricarboxypyrroloquinoline quinone (PQQ), a derivative thereof, or pro-PQQ. This appears to be the only example of two cross-linked, modified amino acyl residues having a functional role in the active site of an enzyme, in the absence of other cofactors or metal ions.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; CALTECH, WM KECK LABS, PASADENA, CA 91125 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; California Institute of Technology	MCINTIRE, WS (corresponding author), DEPT VET AFFAIRS MED CTR, DIV MOLEC BIOL, SAN FRANCISCO, CA 94121 USA.				NHLBI NIH HHS [HL 16251] Funding Source: Medline; NIGMS NIH HHS [GM 36296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI O, 1989, PQQ AND QUINOPROTEINS, P145; AMEYAMA M, 1984, AGR BIOL CHEM TOKYO, V48, P561, DOI 10.1080/00021369.1984.10866184; ANTHONY C, 1989, PQQ AND QUINOPROTEINS, P1; BACKES G, UNPUB; CHISTOSERDOV AY, 1990, BIOCHEM BIOPH RES CO, V172, P211, DOI 10.1016/S0006-291X(05)80195-0; CLARK K, 1990, J AM CHEM SOC, V112, P6433, DOI 10.1021/ja00173a061; DAVIDSON VL, 1987, FEMS MICROBIOL LETT, V44, P121, DOI 10.1111/j.1574-6968.1987.tb02254.x; DEBEER R, 1980, BIOCHIM BIOPHYS ACTA, V622, P370, DOI 10.1016/0005-2795(80)90050-1; DOOLEY DM, 1990, J AM CHEM SOC, V112, P2782, DOI 10.1021/ja00163a047; DRYHURST G, 1990, CHEM REV, V90, P795, DOI 10.1021/cr00103a007; DUINE J A, 1989, Biofactors, V2, P87; GALLOP PM, 1989, TRENDS BIOCHEM SCI, V14, P343, DOI 10.1016/0968-0004(89)90169-2; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GLATZ Z, 1987, BIOCHEM J, V242, P603, DOI 10.1042/bj2420603; GROEN BW, 1988, FEBS LETT, V237, P98, DOI 10.1016/0014-5793(88)80179-0; HARTMANN C, 1988, Biofactors, V1, P41; HARTMANN C, 1990, FEBS LETT, V261, P441, DOI 10.1016/0014-5793(90)80611-L; HARTMANN C, 1987, J BIOL CHEM, V262, P962; HAYWOOD GW, 1982, FEMS MICROBIOL LETT, V15, P79, DOI 10.1111/j.1574-6968.1982.tb00042.x; HOUCK DR, 1989, PQQ AND QUINOPROTEINS, P177; HOUCK DR, 1988, J AM CHEM SOC, V110, P6920, DOI 10.1021/ja00228a070; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ISHII Y, 1983, J BIOCHEM, V93, P107, DOI 10.1093/oxfordjournals.jbchem.a134144; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JENKINS O, 1987, J GEN MICROBIOL, V133, P453; KARHUNEN E, 1990, FEBS LETT, V267, P6, DOI 10.1016/0014-5793(90)80273-L; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KENNEY WC, 1983, BIOCHEMISTRY-US, V22, P3858, DOI 10.1021/bi00285a022; KENNEY WC, 1984, MICROBIAL GROWTH C1, P165; KILLGORE J, 1989, SCIENCE, V245, P850, DOI 10.1126/science.2549636; LARGE PJ, 1988, METHYLOTROPHY BIOTEC, P18; Lee E, UNPUB; LERCH K, 1982, J BIOL CHEM, V257, P6414; LOBENSTEINVERBEEK CL, 1984, FEBS LETT, V170, P305, DOI 10.1016/0014-5793(84)81333-2; Martin G. E., 1988, 2 DIMENSIONAL NMR ME; MATHEWS FS, COMMUNICATION; MATSUMOTO T, 1978, J BIOCHEM-TOKYO, V83, P1591, DOI 10.1093/oxfordjournals.jbchem.a132070; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P303, DOI 10.1016/0005-2744(78)90064-5; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P291, DOI 10.1016/0005-2744(78)90063-3; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MCINTIRE WS, 1991, BIOCHEMISTRY-US, V30, P125, DOI 10.1021/bi00215a019; MCINTIRE WS, 1986, BIOCHEM BIOPH RES CO, V141, P562, DOI 10.1016/S0006-291X(86)80210-8; MCINTIRE WS, 1987, APPL ENVIRON MICROB, V53, P2183, DOI 10.1128/AEM.53.9.2183-2188.1987; MICHAUDSORET I, 1990, BIOCHEM BIOPH RES CO, V172, P1122, DOI 10.1016/0006-291X(90)91563-8; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; PENNINGS EJM, 1989, FEBS LETT, V255, P97, DOI 10.1016/0014-5793(89)81068-3; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; RAPHALS P, 1990, SCIENCE, V249, P619, DOI 10.1126/science.2166338; ROBERTSON JG, 1989, J BIOL CHEM, V264, P19916; RODRIGUEZ EJ, 1989, J AM CHEM SOC, V111, P7947, DOI 10.1021/ja00202a041; RUCKER R, 1989, PQQ AND QUINOPROTEINS, P159; RUCKER RB, 1988, FASEB J, V2, P2252, DOI 10.1096/fasebj.2.7.3127264; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; VANDERMEER RA, 1986, FEBS LETT, V206, P111, DOI 10.1016/0014-5793(86)81350-3; VANDERMEER RA, 1989, FEBS LETT, V254, P99, DOI 10.1016/0014-5793(89)81017-8; VANDERMEER RA, 1989, FEBS LETT, V246, P109, DOI 10.1016/0014-5793(89)80263-7; VANDERMEER RA, 1987, FEBS LETT, V221, P299, DOI 10.1016/0014-5793(87)80944-4; VANKLEEF MAG, 1988, FEBS LETT, V237, P91, DOI 10.1016/0014-5793(88)80178-9; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4; VELDINK GA, 1990, FEBS LETT, V270, P135, DOI 10.1016/0014-5793(90)81252-J; VELLIEUX FMD, 1989, FEBS LETT, V255, P460, DOI 10.1016/0014-5793(89)81145-7; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; Wuthrich K., 1986, NMR PROTEINS NUCL AC; 1990, MORB MORTAL WKLY REP, V39, P589; 1990, MORB MORTAL WKLY REP, V39, P789	74	341	345	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					817	824		10.1126/science.2028257	http://dx.doi.org/10.1126/science.2028257			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028257				2022-12-24	WOS:A1991FL12300039
J	MCCORMICK, MC; BROOKSGUNN, J; SHAPIRO, S; BENASICH, AA; BLACK, G; GROSS, RT				MCCORMICK, MC; BROOKSGUNN, J; SHAPIRO, S; BENASICH, AA; BLACK, G; GROSS, RT			HEALTH-CARE USE AMONG YOUNG-CHILDREN IN DAY-CARE - RESULTS IN A RANDOMIZED TRIAL OF EARLY INTERVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; MEDICAL-CARE; INFECTIOUS-DISEASES; RE-HOSPITALIZATION; MORBIDITY; INFANT; ILLNESS; CHILDHOOD; SERVICES; COSTS	Exposure of young children to group day-care settings increases the risk of illness and may result in higher use of medical care. These observations raise concerns that the use of such settings for early intervention programs for low-birth-weight infants may increase the already high burden of medical care costs incurred by these children and their families. To address the question of medical care use associated with center-based care, we examined the hospital-based and ambulatory care reported for participants of the Infant Health and Development Program. This project is a multisite randomized trial of an early intervention program for preterm low-birth-weight infants with an intervention including 2 years of center-based care. The Intervention group did not differ in hospital-based care and averaged only two more physicians' visits over the 3-year observation period than the comparison group. We conclude that early intervention programs involving high-quality group care are not accompanied by substantial increases in health care use.	INFANT HLTH & DEV PROGRAM,STANFORD,CA; HARVARD UNIV,SCH MED,DEPT PEDIAT,DIV NEONATOL,BOSTON,MA 02115; EDUC TESTING SERV,PRINCETON,NJ 08541; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR HLTH SERV RES & DEV,BALTIMORE,MD 21218; RUTGERS STATE UNIV,CTR MOLEC & BEHAV NEUROSCI,NEWARK,NJ 07102	Harvard University; Harvard Medical School; Educational Testing Service (ETS); Johns Hopkins University; Rutgers State University Newark; Rutgers State University New Brunswick				McCormmick, Marie/0000-0002-3938-1707; Benasich, April A/0000-0002-5137-776X	PHS HHS [MCJ-060515] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSON LJ, 1988, PEDIATRICS, V82, P300; Baker P. C., 1989, NLSY CHILD HDB 1989; BAYDAR N, IN PRESS DEV PSYCHOL; BELL DM, 1989, AM J PUBLIC HEALTH, V79, P479, DOI 10.2105/AJPH.79.4.479; BERG AT, 1991, AM J EPIDEMIOL, V133, P154, DOI 10.1093/oxfordjournals.aje.a115854; Berkelman R L, 1989, Public Health Rep, V104, P101; BOWMAN E, 1989, EARLY HUM DEV, V18, P165; BROOKSGUNN J, 1990, IMPROVING THE LIFE CHANCES OF CHILDREN AT RISK, P125; BROOKSGUNN J, 1990, APR INT C INF STUD M; CAFFERATA GL, 1985, MED CARE, V23, P250; DARLINGTON RB, 1980, SCIENCE, V208, P202, DOI 10.1126/science.208.4440.202; DEGRAW C, 1988, J PEDIATR-US, V113, P971, DOI 10.1016/S0022-3476(88)80565-1; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.1093/biomet/58.3.403; ELANDER G, 1986, AM J ORTHOPSYCHIAT, V56, P612, DOI 10.1111/j.1939-0025.1986.tb03494.x; FLEISS JL, 1986, CONTROL CLIN TRIALS, V7, P267, DOI 10.1016/0197-2456(86)90034-6; HACK M, 1983, J DEV BEHAV PEDIATR, V4, P243; HACK M, 1981, AM J DIS CHILD, V135, P263, DOI 10.1001/archpedi.1981.02130270055018; HASKINS R, 1986, PEDIATRICS, V77, P951; Hayes C, 1990, WHO CARES AM CHILDRE; HORWITZ SM, 1985, MED CARE, V23, P946, DOI 10.1097/00005650-198508000-00002; HURWITZ ES, 1991, PEDIATRICS, V87, P62; KRAEMER HS, IN PRESS J CLIN EPID; KRAMER MS, 1984, MED CARE, V22, P223, DOI 10.1097/00005650-198403000-00005; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCCORMICK MC, 1980, PEDIATRICS, V66, P991; MCCORMICK MC, IN PRESS PEDIATRICS; NEWACHECK PW, 1986, PEDIATRICS, V78, P813; OLDS DL, 1990, IMPROVING LIFE CHANC, P79; OSTERHOLM MT, 1986, REV INFECT DIS, V8, P513; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; RAMEY CT, IN PRESS PEDIATRICS; SCOTT DT, 1989, PEDIATR RES, V25, P263; SHANKARAN S, 1988, PEDIATRICS, V81, P372; SHAPIRO S, 1980, AM J OBSTET GYNECOL, V136, P363, DOI 10.1016/0002-9378(80)90863-7; SPARLING J, 1984, IN PRESS PARTNERS LE; SPARLING J, EARLY PARTNERS; STARFIELD B, 1979, PEDIATRICS, V63, P633; WASIK BH, COPING PARENTING EFF; WOLFE BL, 1980, MED CARE, V18, P1196, DOI 10.1097/00005650-198012000-00005; ZIGLER E, 1986, REV INFECT DIS, V8, P514; 1985, SAS USERS GUIDE STAT; 1990, JAMA-J AM MED ASSOC, V263, P3035; 1982, VITAL HLTH STATIS 10, V141	44	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2212	2217		10.1001/jama.265.17.2212	http://dx.doi.org/10.1001/jama.265.17.2212			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH877	2013954				2022-12-24	WOS:A1991FH87700033
J	AAMODT, EJ; CHUNG, MA; MCGHEE, JD				AAMODT, EJ; CHUNG, MA; MCGHEE, JD			SPATIAL CONTROL OF GUT-SPECIFIC GENE-EXPRESSION DURING CAENORHABDITIS-ELEGANS DEVELOPMENT	SCIENCE			English	Article							TRANSGENIC NEMATODES; CELL; TRANSFORMATION; LINEAGE; FUSION; EMBRYO	The nematode Caenorhabditis elegans was transformed with constructs containing upstream deletions of the gut-specific ges-1 carboxylesterase gene. With particular deletions, ges-1 was expressed, not as normally in the gut, but rather in muscle cells of the pharynx (which belong to a sister lineage of the gut) or in body wall muscle and hypodermal cells (which belong to a cousin lineage of the gut). These observations suggest that gut-specific gene expression in C. elegans involves not only gut-specific activators but also multiple repressors that are present in particular nongut lineages.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary				McGhee, James/0000-0001-7266-7275				AAMODT EJ, UNPUB; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DEAROLF CR, 1989, GENE DEV, V3, P384, DOI 10.1101/gad.3.3.384; DEPPE U, 1978, P NATL ACAD SCI USA, V75, P376, DOI 10.1073/pnas.75.1.376; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRANKS RR, 1988, GENE DEV, V2, P1, DOI 10.1101/gad.2.1.1; GOODBOURN S, 1990, BIOCHIM BIOPHYS ACTA, V1032, P53, DOI 10.1016/0304-419X(90)90012-P; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOUGHEVANS BR, 1990, DEVELOPMENT, V110, P41; JEFFERSON RA, 1987, J MOL BIOL, V193, P41, DOI 10.1016/0022-2836(87)90624-3; MCGHEE JD, 1990, GENETICS, V125, P505; MELLO CC, COMMUNICATION; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SPIETH J, 1988, DEV BIOL, V130, P285, DOI 10.1016/0012-1606(88)90434-4; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; STROEHER VL, UNPUB; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	23	84	90	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					579	582		10.1126/science.2020855	http://dx.doi.org/10.1126/science.2020855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020855				2022-12-24	WOS:A1991FJ12700052
J	FLANAGAN, PM; KELLEHER, RJ; SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD				FLANAGAN, PM; KELLEHER, RJ; SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD			A MEDIATOR REQUIRED FOR ACTIVATION OF RNA POLYMERASE-II TRANSCRIPTION INVITRO	NATURE			English	Article							PREINITIATION COMPLEX; GAL4 DERIVATIVES; FACTOR ATF; YEAST; GENE; INITIATION; MECHANISM; BINDING; PROMOTERS; INTERACTS	ACTIVATOR proteins bind to enhancer DNA elements and stimulate the initiation of transcription. It has been proposed 1-3 that activators contact general initiation factors at a promoter, and evidence for such direct interaction has been obtained 4-10. Studies of transcription in vitro, however, have suggested that activators might function through an intermediary molecule(s) distinct from the general factors. In the first of these studies 11,12, we exploited the finding that one activator could inhibit transcription stimulated by a second activator (activator interference or 'squelching') 13-15. This inhibition, which is attributed to competition between the activators for a common target factor, could not be relieved by addition of a large excess of general initiation factors, suggesting that the target for which activators compete is distinct from these factors. Similar conclusions came from the observation that TFIID's expressed from cloned genes 16-18 fail to replace partially purified 'natural' TFIID fractions in supporting activation, evidently because they lacked some component present in the impure fractions. While these lines of evidence for a novel 'mediator' of activation were negative, we also showed that a partially purified fraction from yeast would reverse activator interference 12. This positive effect of a presumptive mediator provided an assay for its activity, but its role in activation was still only inferred. We now present direct evidence for a mediator which is required for stimulation of transcription in vitro by the activators GAL4-VP16 and GCN4, but which has no effect on transcription in the absence of activator protein.			FLANAGAN, PM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,FAIRCHILD CTR,DEPT CELL BIOL,STANFORD,CA 94305, USA.							BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KORNBERG RD, 1989, GENE REGULATION AIDS, P9; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	27	296	308	3	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					436	438		10.1038/350436a0	http://dx.doi.org/10.1038/350436a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011193				2022-12-24	WOS:A1991FF04200055
J	HEITZ, D; ROUSSEAU, F; DEVYS, D; SACCONE, S; ABDERRAHIM, H; LEPASLIER, D; COHEN, D; VINCENT, A; TONIOLO, D; DELLAVALLE, G; JOHNSON, S; SCHLESSINGER, D; OBERLE, I; MANDEL, JL				HEITZ, D; ROUSSEAU, F; DEVYS, D; SACCONE, S; ABDERRAHIM, H; LEPASLIER, D; COHEN, D; VINCENT, A; TONIOLO, D; DELLAVALLE, G; JOHNSON, S; SCHLESSINGER, D; OBERLE, I; MANDEL, JL			ISOLATION OF SEQUENCES THAT SPAN THE FRAGILE-X AND IDENTIFICATION OF A FRAGILE-X RELATED CPG ISLAND	SCIENCE			English	Article							CHROMOSOME; DNA; EXPRESSION; SEGMENTS; SITES; YEAST; LOCUS	Yeast artificial chromosomes (YACs) were obtained from a 550-kilobase region that contains three probes previously mapped as very close to the locus of the fragile X syndrome. These YACs spanned the fragile site in Xq27.3 as shown by fluorescent in situ hybridization. An internal 200-kilobase segment contained four chromosomal breakpoints generated by induction of fragile X expression. A single CpG island was identified in the cloned region between markers DXS463 and DXS465 that appears methylated in mentally retarded fragile X males, but not in nonexpressing male carriers of the mutation nor in normal males. This CpG island may indicate the presence of a gene involved in the clinical phenotype of the syndrome.	UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL, I-27100 PAVIA, ITALY; CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE; CNR, IST GENET BIOCHIM & EVOLUT, I-27100 PAVIA, ITALY; WASHINGTON UNIV, SCH MED, CTR GENET MED, ST LOUIS, MO 63110 USA	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Washington University (WUSTL)	HEITZ, D (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Saccone, Salvatore/H-1548-2012; Toniolo, Daniela/AAE-2969-2019	Saccone, Salvatore/0000-0001-7568-5823; Toniolo, Daniela/0000-0001-9545-6032; Le Paslier, Denis/0000-0003-4335-9956; Devys, Didier/0000-0001-9655-3512				ABIDI FE, 1990, GENOMICS, V7, P363, DOI 10.1016/0888-7543(90)90170-Y; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; FUJITA R, 1990, P NATL ACAD SCI USA, V87, P1796, DOI 10.1073/pnas.87.5.1796; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HARRISON CJ, 1983, J MED GENET, V20, P280, DOI 10.1136/jmg.20.4.280; HEITZ D, UNPUB; KANDPAL RP, 1990, NUCLEIC ACIDS RES, V18, P3081, DOI 10.1093/nar/18.10.3081; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1987, GENETICS, V117, P587; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MAESTRINI E, 1990, GENOMICS, V8, P664, DOI 10.1016/0888-7543(90)90253-Q; MONTANARO V, IN PRESS AM J HUM GE; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; POUSTKA A, 1988, GENET ENG, V10, P169; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, UNPUB; SHAW J, 1990, CYTOGENET CELL GENET, V53, P221, DOI 10.1159/000132936; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SOUTHERN EM, 1987, NUCLEIC ACIDS RES, V15, P5925, DOI 10.1093/nar/15.15.5925; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERLAND GR, 1985, AM J MED GENET, V22, P433, DOI 10.1002/ajmg.1320220234; SVED JA, 1990, AM J HUM GENET, V46, P443; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; Vincent A. C., UNPUB; WADA M, 1990, AM J HUM GENET, V46, P95; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WILLARD HF, 1983, NUCLEIC ACIDS RES, V11, P2017, DOI 10.1093/nar/11.7.2017; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806	33	176	180	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 8	1991	251	4998					1236	1239		10.1126/science.2006411	http://dx.doi.org/10.1126/science.2006411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006411				2022-12-24	WOS:A1991FA69100043
J	LIN, YS; GREEN, MR				LIN, YS; GREEN, MR			MECHANISM OF ACTION OF AN ACIDIC TRANSCRIPTIONAL ACTIVATOR INVITRO	CELL			English	Article							RNA-POLYMERASE-II; PREINITIATION COMPLEX; INITIATION-FACTOR; FUNCTIONAL-ANALYSIS; GENE-TRANSCRIPTION; FACTOR ATF; PROMOTER; PURIFICATION; PROTEIN; GAL4	Transcription of a eukaryotic structural gene by RNA polymerase II requires the ordered assembly of general transcription factors on the promoter to form a preinitiation complex. Here we analyze affinity-purified complexes at various stages of assembly to determine the mechanism of action of an acidic transcriptional activator. We show that the activator can function in the absence of ATP and stimulates transcription by increasing the number of functional preinitiation complexes. The activator effects this increase by recruiting the general transcription factor TFIIB to the promoter. Using protein affinity chromatography we demonstrate a specific interaction between an acidic activating region and TFIIB. Based on these combined results, we propose that TFIIB is a direct target of an acidic activator.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University								ALBRECHT G, 1988, MOL CELL BIOL, V8, P1534, DOI 10.1128/MCB.8.4.1534; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEVAUX B, 1987, MOL CELL BIOL, V7, P4560, DOI 10.1128/MCB.7.12.4560; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TSUNG K, 1990, P NATL ACAD SCI USA, V87, P5940, DOI 10.1073/pnas.87.15.5940; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; ZINN K, 1986, CELL, V45, P611, DOI 10.1016/0092-8674(86)90293-X	47	490	499	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					971	981		10.1016/0092-8674(91)90321-O	http://dx.doi.org/10.1016/0092-8674(91)90321-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	2001592				2022-12-24	WOS:A1991FA94000014
J	ADEBONOJO, FO				ADEBONOJO, FO			INFANT HEAD SHAPING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ADEBONOJO, FO (corresponding author), E TENNESSEE STATE UNIV,JOHNSON CITY,TN 37614, USA.							EPSTEIN F, 1973, LANCET, V1, P634; HENSHEN P, 1966, HUMAN SKULL CULTURAL; MARSHALL DS, 1956, AM J PHYS ANTHROPOL, V13, P405; McGibbon Walter, 1912, LARYNGOSCOPE, V22, P1165; NICHTER LS, 1986, PLAST RECONSTR SURG, V77, P325; SCHENDEL SA, 1986, PLAST RECONSTR SURG, V78, P267, DOI 10.1097/00006534-198608000-00038; SHAPIRO HL, 1928, ANTHR PAPERS MUSEU 1, P30; TROPINARD P, 1878, ANTHROPOLOGY	8	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1179	1179						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996005				2022-12-24	WOS:A1991EZ47400037
J	RAUB, W				RAUB, W			IMMUNOGENETIC DISTINCTION FOUND BETWEEN PAUCIARTICULAR AND POLYARTICULAR JUVENILE ARTHRITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, ARTHRITIS RHEUM, V33, P1787	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-24	WOS:A1991EZ47400006
J	GOODBURN, E; MATTOSINHO, S; MONGI, P; WATERSTON, T				GOODBURN, E; MATTOSINHO, S; MONGI, P; WATERSTON, T			MANAGEMENT OF CHILDHOOD DIARRHEA BY PHARMACISTS AND PARENTS - IS BRITAIN LAGGING BEHIND THE THIRD-WORLD	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GASTROENTERITIS; CHILDREN; DRUGS	Objective-To investigate the role of community pharmacists in providing advice and treatment for children with diarrhoea; to investigate mothers' responses to diarrhoea in their children. Design-Cross sectional questionnaire study of a random selection of community pharmacists and of mothers attending child health clinics. Pharmacists were interviewed and given a questionnaire and a separate group was visited by a researcher posing as a parent; mothers were interviewed at the clinic. Setting-Newcastle upon Tyne. Subjects-20 pharmacists were interviewed and visits by a researcher posing as a parent were carried out to 10 different pharmacists; 58 mothers were interviewed. Main outcome measures-Advice given by pharmacists was contrasted with standard advice on management of diarrhoea in children. Results-Half the pharmacists interviewed and 70% of pharmacists visited by a researcher posing as a parent recommended inappropriate treatment of childhood diarrhoea (such as antidiarrhoeal drugs and withholding breast milk), and only 30% at interview stated that they would ask for the age of the child. Mothers' knowledge of home treatment was inadequate. All pharmacists in the posed visits recommended a purchased treatment. Conclusion-Pharmacists are widely used by parents for consultation for children's ailments but their advice is not always appropriate; hence they should be given more consistent training in recognising and managing clinical problems. Medical advice on management of diarrhoea is also inconsistent and should be modified to conform to the guidelines of the World Health Organisation.	NEWCASTLE GEN HOSP, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND; INST CHILD HLTH, TROP CHILD HLTH UNIT, LONDON WC1N 1EH, ENGLAND	Newcastle General Hospital; University of London; University College London								CONWAY SP, 1989, ARCH DIS CHILD, V64, P87, DOI 10.1136/adc.64.1.87; CUNNINGHAMBURLEY S, 1987, SOC SCI MED, V24, P371, DOI 10.1016/0277-9536(87)90155-9; CUTTING WAM, 1989, LANCET, V1, P1080; EDWARDS C, 1982, MINOR ILLNESS MAJOR; GALLAGER F, 1983, BMJ-BRIT MED J, V287, P397; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; MOBEY N, 1986, PHARM J, V3, P807; MORRELL DC, 1981, UPDATE, V1, P1187; PAUNCEFOR Z, 1989, PHARM HLTH CARE REPO; RYLANCE GW, 1988, BMJ-BRIT MED J, V297, P445, DOI 10.1136/bmj.297.6646.445; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P917, DOI 10.1136/adc.65.9.917; WATERSTON T, 1981, J MATERNAL CHILD HLT, V1, P34; WHARTON BA, 1988, BMJ-BRIT MED J, V296, P450, DOI 10.1136/bmj.296.6620.450; 1980, WHO CDDSER802; 1989, MED ETHICS GUIDE PHA	15	52	54	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 23	1991	302	6774					440	443		10.1136/bmj.302.6774.440	http://dx.doi.org/10.1136/bmj.302.6774.440			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004171	Green Published, Bronze			2022-12-24	WOS:A1991EZ03300020
J	BAUMGARTNER, M; DUTRILLAUX, B; LEMIEUX, N; LILIENBAUM, A; PAULIN, D; VIEGASPEQUIGNOT, E				BAUMGARTNER, M; DUTRILLAUX, B; LEMIEUX, N; LILIENBAUM, A; PAULIN, D; VIEGASPEQUIGNOT, E			GENES OCCUPY A FIXED AND SYMMETRICAL POSITION ON SISTER CHROMATIDS	CELL			English	Article							INSITU HYBRIDIZATION; NUCLEOTIDE-SEQUENCE; HUMAN-CHROMOSOMES; HUMAN VIMENTIN; DNA LIBRARIES; SV40 DNA; METAPHASE; CELLS; MICROSCOPY; ASSIGNMENT	A high-resolution fluorescence methodology for non-isotopic in situ hybridization was applied to determine the positions occupied by several single-copy genes, DNA sequences, and integrated viral genomes on sister chromatids. The lateral and longitudinal mapping of the probes was performed on prometaphase and metaphase chromosomes. A fixed lateral position, exterior or median in relation to the longitudinal axis of the chromatids, was observed for a given probe, with a symmetrical position of the double fluorescent spots. This position appears to be independent of chromosome condensation stage from prometaphase to metaphase. These observations suggest an opposite helical-handedness conformation of DNA on both chromatids with a mirror symmetry. They support the model of chromosome packaging recently proposed by Boy de la Tour and Laemmli. Moreover, our results indicate that the last stages of chromosome condensation occur by packing down the coils without further coiling.	UNIV PARIS 07, BIOL MOLEC DIFFERENTIAT LAB, F-75724 PARIS 15, FRANCE	UDICE-French Research Universities; Universite Paris Cite	BAUMGARTNER, M (corresponding author), INST CURIE, CNRS, URA CNRS, BIOL STRUCT & MUTAGENESE CHROMOSOM SECT, 26 RUE ULM, F-75231 PARIS 05, FRANCE.							BAK AL, 1977, P NATL ACAD SCI USA, V74, P1595, DOI 10.1073/pnas.74.4.1595; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DUPRAW EJ, 1965, NATURE, V206, P338, DOI 10.1038/206338a0; DUPRAW EJ, 1966, NATURE, V209, P577, DOI 10.1038/209577a0; FERRARI S, 1987, AM J HUM GENET, V41, P616; FUSCOE JC, 1989, GENOMICS, V5, P100, DOI 10.1016/0888-7543(89)90092-X; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LI ZL, 1989, GENE, V78, P243; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LILIENBAUM A, 1986, EMBO J, V5, P2809, DOI 10.1002/j.1460-2075.1986.tb04572.x; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; OHNUKI Y, 1968, CHROMOSOMA, V25, P402, DOI 10.1007/BF02327721; PERREAU J, 1988, GENE, V62, P7, DOI 10.1016/0378-1119(88)90575-6; QUAXJEUKEN Y, 1985, CYTOGENET CELL GENET, V40, P727; RUDDLE FH, 1989, CYTOGENET CELL GENET, V51, P1, DOI 10.1159/000132773; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; VELLARD M, 1991, IN PRESS ONCOGENE; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; WRAY W, 1977, COLD SPRING HARB SYM, V42, P361; ZEHNER ZE, 1983, P NATL ACAD SCI-BIOL, V80, P911, DOI 10.1073/pnas.80.4.911	27	52	52	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					761	766		10.1016/0092-8674(91)90505-S	http://dx.doi.org/10.1016/0092-8674(91)90505-S			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997205				2022-12-24	WOS:A1991EZ47800011
J	RAMACHANDRAN, VS				RAMACHANDRAN, VS			FORM, MOTION, AND BINOCULAR-RIVALRY	SCIENCE			English	Article									UNIV CALIF SAN DIEGO,NEUROSCI PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	RAMACHANDRAN, VS (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL,LA JOLLA,CA 92093, USA.							BARINAGA M, 1990, SCIENCE, V249, P856, DOI 10.1126/science.2392677; BLAKE R, 1974, NATURE, V249, P488, DOI 10.1038/249488a0; Crick F., 1990, Seminars in the Neurosciences, V2, P263; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Kaufman L., 1974, SIGHT MIND, DOI [10.1097/00006324-197411000, DOI 10.1097/00006324-197411000]; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MYERSON J, 1981, BEHAV ANAL LETT, V1, P149; RAMACHANDRAN VS, 1973, NATURE, V242, P412, DOI 10.1038/242412a0; RAMACHANDRAN VS, IN PRESS ARTFUL BRAI; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; TREISMAN A, 1962, Q J EXP PSYCHOL, V14, P23, DOI 10.1080/17470216208416507; VONHELMHOLTZ H, 1925, PHYSL OPTICS	13	10	10	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					950	951		10.1126/science.2000497	http://dx.doi.org/10.1126/science.2000497			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000497				2022-12-24	WOS:A1991EY62900049
J	OTTE, AP; KRAMER, IM; DURSTON, AJ				OTTE, AP; KRAMER, IM; DURSTON, AJ			PROTEIN-KINASE-C AND REGULATION OF THE LOCAL COMPETENCE OF XENOPUS ECTODERM	SCIENCE			English	Article							DIFFERENTIAL DOWN-REGULATION; NEURAL INDUCTION; CELLULAR SUBSTRATE; PROSPECTIVE AREAS; LAEVIS; EXPRESSION; GASTRULA; PHOSPHORYLATION; HETEROGENEITY; SPECIFICITY	The limited competence of embryonic tissue to respond to an inductive signal has an essential, regulatory function in embryonic induction. The molecular basis for the competence of Xenopus ectoderm to differentiate into neural tissue was investigated. Dorsal mesoderm or 12-O-tetradecanoyl phorbol-13-acetate (TPA) caused in vivo activation of protein kinase C (PKC) and neural differentiation mainly in dorsal ectoderm and to a lesser extent in ventral ectoderm. These data correlate with the observations that PKC preparations from dorsal and ventral ectoderm differ, the dorsal PKC preparation being more susceptible to activation by TPA and diolein than is the ventral PKC preparation. Monoclonal antibodies against the bovine PKC alpha plus beta or gamma isozymes immunostained dorsal and ventral ectoderm, respectively, which suggests different localizations of PKC isozymes. The results suggest that PKC participates in the establishment of embryonic competence.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)								ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BROOKS SF, 1990, FEBS LETT, V268, P291, DOI 10.1016/0014-5793(90)81030-R; CAZAUBON S, 1989, EUR J BIOCHEM, V182, P401, DOI 10.1111/j.1432-1033.1989.tb14845.x; COOKE J, 1987, DEVELOPMENT, V99, P197; DAVIDS M, 1987, ROUX ARCH DEV BIOL, V196, P137, DOI 10.1007/BF00402036; DENT JA, 1989, DEVELOPMENT, V105, P61; GIMLICH RL, 1983, NATURE, V306, P471, DOI 10.1038/306471a0; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; GURDON JB, 1987, DEVELOPMENT, V99, P285; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUANG KP, 1988, J BIOL CHEM, V263, P14839; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NIEDEL J E, 1986, P47; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; NIEUWKOOP PD, 1969, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTTE AP, 1990, DEVELOPMENT, V110, P461; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; OTTE AP, 1988, NATURE, V334, P618, DOI 10.1038/334618a0; OTTE AP, UNPUB; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SCHARF SR, 1989, DEV BIOL, V134, P175, DOI 10.1016/0012-1606(89)90087-0; SHARPE CR, 1988, DEVELOPMENT, V103, P269; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHEU FS, 1990, BIOCHEM BIOPH RES CO, V171, P1236, DOI 10.1016/0006-291X(90)90818-8; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x	41	63	63	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					570	573		10.1126/science.1990433	http://dx.doi.org/10.1126/science.1990433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990433				2022-12-24	WOS:A1991EV45900055
J	SHIBUTANI, S; TAKESHITA, M; GROLLMAN, AP				SHIBUTANI, S; TAKESHITA, M; GROLLMAN, AP			INSERTION OF SPECIFIC BASES DURING DNA-SYNTHESIS PAST THE OXIDATION-DAMAGED BASE 8-OXODG	NATURE			English	Article							POLYMERASE-DELTA; CALF THYMUS; 8-HYDROXY-2'-DEOXYGUANOSINE	OXIDATIVE damage to DNA, reflected in the formation of 8-oxo-7-hydrodeoxyguanosine (8-oxodG) 1, 2, may be important in mutagenesis, carcinogenesis and the ageing process 3,4. Kuchino et al. studied DNA synthesis on oligodeoxynucleotide templates containing 8-oxodG, concluding that the modified base lacked base pairing specificity and directed misreading of pyrimidine residues neighbouring the lesion 5. Here we report different results, using an approach in which the several products of a DNA polymerase reaction can be measured. In contrast to the earlier report 5, we find that dCMP and dAMP are incorporated selectively opposite 8-oxodG with transient inhibition of chain extension occurring 3' to the modified base. The potentially mutagenic insertion of dAMP is targeted exclusively to the site of the lesion. The ratio of dCMP to dAMP incorporated varies, depending on the DNA polymerase involved. Chain extension from the dA . 8-oxodG pair was efficiently catalysed by all polymerases tested.			SHIBUTANI, S (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.			Shibutani, Shinya/0000-0003-4190-9512				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; AIDA M, 1987, MUTAT RES, V192, P83, DOI 10.1016/0165-7992(87)90101-1; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BODEPUDI V, IN PRESS NUCLEOSIDES; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; KARAWYA EM, 1982, J BIOL CHEM, V257, P3129; KASAI H, 1987, B CHEM SOC JPN, V60, P3799, DOI 10.1246/bcsj.60.3799; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KOUCHAKDIJAN M, IN PRESS J BIOCH; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MORIYA M, IN PRESS MUT RES; Sambrook J., 1989, MOL CLONING; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; TAN CK, 1986, J BIOL CHEM, V261, P2310; UESUGI S, 1977, J AM CHEM SOC, V99, P3250, DOI 10.1021/ja00452a008; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	23	2044	2073	1	77	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					431	434		10.1038/349431a0	http://dx.doi.org/10.1038/349431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992344				2022-12-24	WOS:A1991EV51400057
J	TAYLOR, WC				TAYLOR, WC			INDIRECT LARYNGOSCOPY AS A SCREENING-TEST FOR LARYNGEAL-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ADULT HEALTH MAINTENANCE; PREVENTION; DISEASES				TAYLOR, WC (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, BOSTON, MA 02215 USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; DEWEESE DD, 1982, TXB OTOLARYNGOLOGY, P111; DRIPPS RD, 1988, INTRO ANESTHESIA PRI, P403; Frame P S, 1975, J Fam Pract, V2, P189; Frame P S, 1975, J Fam Pract, V2, P283; Frame P S, 1975, J Fam Pract, V2, P29; FRAME PS, 1986, J FAM PRACTICE, V22, P341; FRAME PS, 1986, J FAM PRACTICE, V22, P511; FRAME PS, 1986, J FAM PRACTICE, V22, P417; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; LEMORE T, 1987, PHS871250 DEP HLTH H; OBOLER SK, 1989, ANN INTERN MED, V110, P214, DOI 10.7326/0003-4819-110-3-214; SACKETT DL, 1987, J FAM PRACTICE, V24, P233; TAYLOR WC, 1980, ANN INTERN MED, V93, P773, DOI 10.7326/0003-4819-93-5-773; Wilson JMG, 1968, PRINCIPLES PRACTICE; 1979, CAN MED ASS J, V121, P1193; 1991, JAMA-J AM MED ASSOC, V265, P412; 1988, 8820M AM CANC SOC PR; 1989, 89450M AM CAN SOC PU, P8	19	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					3011	+		10.1001/jama.265.22.3011	http://dx.doi.org/10.1001/jama.265.22.3011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033776				2022-12-24	WOS:A1991FP63500043
J	JENNETT, B; DYER, C				JENNETT, B; DYER, C			PERSISTENT VEGETATIVE STATE AND THE RIGHT-TO-DIE - THE UNITED-STATES AND BRITAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FATE WORSE; DEATH				JENNETT, B (corresponding author), INST NEUROL SCI, NEUROSURG, GLASGOW G51 4TF, SCOTLAND.							ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BOYD K, 1991, LANCET, V337, P96; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRAHAMS D, 1988, LANCET, V1, P779; FEINBERG WM, 1984, AM J DIS CHILD, V138, P128, DOI 10.1001/archpedi.1984.02140400014003; GILLON R, 1988, J MED ETHICS, V14, P59, DOI 10.1136/jme.14.2.59; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, ARCH NEUROL-CHICAGO, V33, P595, DOI 10.1001/archneur.1976.00500090001001; JENNETT B, 1988, ANAESTHESIA, V43, P921, DOI 10.1111/j.1365-2044.1988.tb05650.x; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; LO B, 1990, NEW ENGL J MED, V322, P1228, DOI 10.1056/NEJM199004263221711; Minderhoud J M, 1985, Ned Tijdschr Geneeskd, V129, P2385; 1991, PROPOSALS ESTABLISHM; 1991, MENTALLY INCAPACITAT; 1986, JAMA-J AM MED ASSOC, V236, P471; 1990, JAMA-J AM MED ASSOC, V263, P426	18	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1991	302	6787					1256	1258		10.1136/bmj.302.6787.1256	http://dx.doi.org/10.1136/bmj.302.6787.1256			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043853	Bronze, Green Published			2022-12-24	WOS:A1991FP27200029
J	PRIME, KL; WHITESIDES, GM				PRIME, KL; WHITESIDES, GM			SELF-ASSEMBLED ORGANIC MONOLAYERS - MODEL SYSTEMS FOR STUDYING ADSORPTION OF PROTEINS AT SURFACES	SCIENCE			English	Article							HYDROPHOBIC CHROMATOGRAPHY; GOLD; THIOLS; CHAIN; FILMS; COADSORPTION; ELLIPSOMETRY; INTERFACES; POLYMERS; SERIES	Self-assembled monolayers (SAMs) of omega-functionalized long-chain alkanethiolates on gold films are excellent model systems with which to study the interactions of proteins with organic surfaces. Monolayers containing mixtures of hydrophobic (methyl-terminated) and hydrophilic [hydroxyl-, maltose-, and hexa(ethylene glycol)-terminated] alkanethiols can be tailored to select specific degrees of adsorption: the amount of protein adsorbed varies monotonically with the composition of the monolayer. The hexa(ethylene glycol)-terminated SAMs are the most effective in resisting protein adsorption. The ability to create interfaces with similar structures and well-defined compositions should make it possible to test hypotheses concerning protein adsorption.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								ALLMER K, 1990, J POLYM SCI POL CHEM, V28, P173, DOI 10.1002/pola.1990.080280112; ANDRADE JD, 1986, ADV POLYM SCI, V79, P1; [Anonymous], [No title captured]; ARNEBRANT T, 1985, PROG COLL POL SCI S, V70, P62; BAIN CD, 1989, J AM CHEM SOC, V111, P7155, DOI 10.1021/ja00200a039; BAIN CD, 1989, J PHYS CHEM-US, V93, P1670, DOI 10.1021/j100341a095; BAIN CD, 1989, J AM CHEM SOC, V111, P7164, DOI 10.1021/ja00200a040; BAIN CD, 1988, SCIENCE, V240, P62, DOI 10.1126/science.240.4848.62; BJORLING M, 1990, J PHYS CHEM-US, V94, P471, DOI 10.1021/j100364a082; BOHNERT JL, 1988, INVEST OPHTHALMOL VI, V29, P363; BORETOS JW, 1980, SYNTHETIC BIOMEDICAL, P187; BRASH JL, 1985, MAKROMOL CHEM S, V9, P69; CHIDSEY CED, 1989, J CHEM PHYS, V91, P4421, DOI 10.1063/1.456776; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; CUYPERS PA, 1978, ANAL BIOCHEM, V84, P56, DOI 10.1016/0003-2697(78)90483-9; DETTRE RH, 1965, J PHYS CHEM-US, V69, P1507, DOI 10.1021/j100889a012; EVERETT DH, 1988, BASIC PRINCIPLES COL, P45; FLEMINGER G, 1990, J CHROMATOGR, V510, P271, DOI 10.1016/S0021-9673(01)93761-6; GRAINGER DW, 1989, J COLLOID INTERF SCI, V132, P161, DOI 10.1016/0021-9797(89)90226-9; HALPERIN G, 1984, J CHROMATOGR, V317, P103, DOI 10.1016/S0021-9673(01)91651-6; Horbett T. A., 1986, HYDROGELS MED PHARM, V1, P127; IVERSSON B, 1986, CRIT REV BIOCOMPUT, V2, P1; JENNISSEN HP, 1989, BER BUNSEN PHYS CHEM, V93, P948, DOI 10.1002/bbpc.19890930905; Jeon I, 1991, J COLLOID INTERF SCI, V142, P149; JEON SI, 1991, J COLLOID INTERF SCI, V142, P159, DOI 10.1016/0021-9797(91)90044-9; KARLSTROM G, 1985, J PHYS CHEM-US, V89, P4962, DOI 10.1021/j100269a015; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; MATSUURA H, 1985, J MOL STRUCT, V126, P251, DOI 10.1016/0022-2860(85)80118-6; MATSUURA H, 1991, J AM CHEM SOC, V113, P1193, DOI 10.1021/ja00004a020; MIZUTANI T, 1985, J LIQ CHROMATOGR, V8, P925, DOI 10.1080/01483918508067122; MUIRHEAD H, 1987, BIOL MACROMOL, V3, P143; NUZZO RG, 1990, J AM CHEM SOC, V112, P558, DOI 10.1021/ja00158a012; NUZZO RG, 1990, J CHEM PHYS, V93, P767, DOI 10.1063/1.459528; PALEGROSDEMANGE C, 1991, J AM CHEM SOC, V113, P12, DOI 10.1021/ja00001a002; PORATH J, 1987, BIOTECHNOL PROGR, V3, P14, DOI 10.1002/btpr.5420030104; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SADA E, 1985, BIOTECHNOL BIOENG, V27, P514, DOI 10.1002/bit.260270418; SCHAKENRAAD JM, 1989, COLLOID SURFACE, V42, P331; SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; WEST TP, 1985, BIOCHIM BIOPHYS ACTA, V839, P32, DOI 10.1016/0304-4165(85)90178-3; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010	43	2056	2141	15	556	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1164	1167		10.1126/science.252.5009.1164	http://dx.doi.org/10.1126/science.252.5009.1164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031186				2022-12-24	WOS:A1991FN05600048
J	SASAKI, K; YAMANO, Y; BARDHAN, S; IWAI, N; MURRAY, JJ; HASEGAWA, M; MATSUDA, Y; INAGAMI, T				SASAKI, K; YAMANO, Y; BARDHAN, S; IWAI, N; MURRAY, JJ; HASEGAWA, M; MATSUDA, Y; INAGAMI, T			CLONING AND EXPRESSION OF A COMPLEMENTARY-DNA ENCODING A BOVINE ADRENAL ANGIOTENSIN-II TYPE-1 RECEPTOR	NATURE			English	Article							BINDING-SITES; SOLUBILIZATION; MEMBRANES; SEQUENCE; SUBTYPES; CORTEX	ANGIOTENSIN II elicits different responses which affect cardiovascular, neuronal and electrolyte transport regulation 1. To understand the mechanisms responsible for its various actions, the receptor for angiotensin II has long been sought, but numerous attempts to purify the receptor have been unsuccessful owing to its instability and low concentration 2-6. We report here the expression cloning of a complementary DNA encoding a bovine angiotensin II receptor to overcome these difficulties. The receptor cDNA encodes a protein of 359 amino-acid residues with a transmembrane topology similar to that of other G protein-coupled receptors. COS-7 cells transfected with cDNA expressed specific and high-affinity binding sites for angiotensin II, angiotensin II antagonist and a non-peptide specific antagonist for type-1 receptor. Dithiothreitol inhibited ligand binding. The concentration of intracellular Ca2+ and of inositol-1,4,5-trisphospate increased in the transfected COS-7 cells in response to angiotensin II or angiotensin III, indicating that this receptor is the type-1 receptor for angiotensin II. Northern blot analysis revealed that the messenger RNA for this receptor is expressed in bovine adrenal medulla, cortex and kidney.	VANDERBILT UNIV, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA; KYOWA HAKKO KOGYO CO LTD, TOKYO RES LABS, TOKYO 194, JAPAN	Vanderbilt University; Vanderbilt University; Kyowa Kirin Ltd								AKIYAMA F, 1984, BIOMED RES-TOKYO, V5, P9, DOI 10.2220/biomedres.5.9; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CAPPONI AM, 1980, J BIOL CHEM, V255, P2081; CARSON MC, 1987, MOL ENDOCRINOL, V1, P147, DOI 10.1210/mend-1-2-147; CHANG RSL, 1982, BIOCHEM PHARMACOL, V31, P1903, DOI 10.1016/0006-2952(82)90495-6; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; GLOSSMANN H, 1974, J BIOL CHEM, V249, P825; GUILLEMETTE G, 1983, BIOCHEMISTRY-US, V22, P5591, DOI 10.1021/bi00293a021; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAGLIN S, 1982, P NATL ACAD SCI-BIOL, V79, P3739, DOI 10.1073/pnas.79.12.3739; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; ROGERS TB, 1984, J BIOL CHEM, V259, P8106; RONDEAU JJ, 1990, BIOCHEM J, V268, P443, DOI 10.1042/bj2680443; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKORECKI KL, 1983, FED PROC, V42, P3064; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	26	807	825	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					230	233		10.1038/351230a0	http://dx.doi.org/10.1038/351230a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041569				2022-12-24	WOS:A1991FL99000056
J	BENJAMIN, RJ; MADRIGAL, JA; PARHAM, P				BENJAMIN, RJ; MADRIGAL, JA; PARHAM, P			PEPTIDE BINDING TO EMPTY HLA-B27 MOLECULES OF VIABLE HUMAN-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; ANKYLOSING-SPONDYLITIS; MONOCLONAL-ANTIBODIES; ANTIGEN; HLA; ASSOCIATION; RECOGNITION; MUTAGENESIS; CHAINS; VIRUS	INTRACELLULAR binding of antigenic peptides by polymorphic class I major histocompatibility complex molecules creates the ligands recognized by receptors of CD8+ T cells 1. Previously described in vitro assays of peptide binding to class I molecules have been limited by either the low proportion of accessible binding sites or the lack of allelic specificity 2-6. Here we describe a system in which the human class I molecule HLA-B27 binds considerable amounts of an influenza peptide with precise allelic discrimination. Binding requires viable cells, is stimulated by gamma-interferon and is inhibited by brefeldin A. Our results are consistent with the presence of fairly stable 'empty' HLA-B27 molecules at the cell surface. By contrast, analysis of the binding of a second influenza peptide indicates that empty HLA-Aw68 molecules are relatively short-lived. We speculate that HLA-B27 might bind extracellular peptides in vivo and that this property could underlie its association with autoimmune disease.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University	BENJAMIN, RJ (corresponding author), STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305, USA.							BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BREWERTON DA, 1973, LANCET, V1, P904; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MCMICHAEL AJ, 1980, HUM IMMUNOL, V1, P121, DOI 10.1016/0198-8859(80)90099-3; MCMICHAEL AJ, 1986, J EXP MED, V164, P1397, DOI 10.1084/jem.164.5.1397; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1987, J EXP MED, V166, P283, DOI 10.1084/jem.166.1.283; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WAYS JP, 1983, BIOCHEM J, V216, P423, DOI 10.1042/bj2160423; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	35	149	150	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					74	77		10.1038/351074a0	http://dx.doi.org/10.1038/351074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027387				2022-12-24	WOS:A1991FK19300064
J	TUCK, MW; CRICK, RP				TUCK, MW; CRICK, RP			EFFICIENCY OF REFERRAL FOR SUSPECTED GLAUCOMA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the efficiency of referral for suspected glaucoma to general practitioners and consultants by optometrists. Design-A prospective survey covering 5% of all sight tests performed by optometrists in England and Wales over six months, with analysis of referred patients. Setting-241 optometrists' practices in areas representative of England and Wales in socio-economic terms. Subjects-Of 275 600 people attending for a sight test, 1505 were referred with suspected glaucoma (0.9% of those aged over 40). Outcomes were recorded for 1228 patients, 1103 (90%) of whom attended for examination by a consultant ophthalmologist (8% on a private basis). The analysis was confined to the 704 cases in which the information on diagnosis was received directly from a consultant or general practitioner. Main outcome measures-Diagnoses reported by consultant ophthalmologists. Waiting times before an appointment for examination by a consultant ophthalmologist. Results-Glaucoma was confirmed in 283 of the 704 referred patients, and another 222 patients were considered to require further monitoring. In all, 112 (41%) of 275 confirmed cases of glaucoma were in patients with intraocular pressures greater-than-or-equal-to 30 mm Hg. At all levels of intraocular pressure the accuracy of referral was greater when the optometrist also recorded the presence of suspicious optic discs or loss of visual field, or both; but only 331 (47%) out of the 704 referred patients had been tested with a field screener. The median waiting time for an NHS clinic appointment was nine weeks. Almost a 10th of confirmed cases of glaucoma were in people in a high risk category for glaucoma who had to wait at least 14 weeks for an appointment. Conclusions-Closer cooperation, especially at the local level, among consultants, general practitioners, and optometrists is needed to improve testing and referral for suspected glaucoma. Optometrists should be encouraged to perform all the three main tests-ophthalmoscopy, tonometry, and perimetry-in patients before referral and to report precisely on reasons for referral to help prioritisation. The optometrist's referral letter to the general practitioner should always be passed on to the consultant. Similarly, the diagnosis should always be reported back to the optometrist.	UNIV LONDON KINGS COLL HOSP,INT GLAUCOMA ASSOC,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								Brittain G P, 1988, Health Trends, V20, P43; CLEARKIN L, 1983, T OPHTHAL SOC UK, V103, P284; CRICK RP, 1982, DISPENSING OPTICIAN, V34, P192; GILLIE RF, 1982, OPHTHALMIC OPT, V22, P586; GRANT WM, 1982, OPHTHALMOLOGY, V89, P991; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; HOWIE JGR, 1982, BRIT MED J, V285, P1009, DOI 10.1136/bmj.285.6347.1009-a; KLJAKOVIC M, 1985, BRIT MED J, V290, P1043, DOI 10.1136/bmj.290.6474.1043; MACKEAN M, 1982, BRIT MED J, V285, P1093; PORT MJA, 1988, OPHTHAL PHYSL OPT, V8, P323, DOI 10.1016/0275-5408(88)90182-2; PORT MJA, 1989, OPHTHAL PHYSL OPT, V9, P31, DOI 10.1111/j.1475-1313.1989.tb00801.x; PORT MJA, 1989, BCO SURVEY MED REFER; STEINMANN WC, 1982, BMJ-BRIT MED J, V285, P1091, DOI 10.1136/bmj.285.6348.1091; TUCK M, 1990, OPTICIAN, V191, P16; TUCK M, 1989, HLTH TRENDS, V21, P131; TUCK M, 1990, OPTICIAN, V199, P24; TUCK MW, 1991, OPHTHAL PHYSL OPT, V11, P22, DOI 10.1111/j.1475-1313.1991.tb00190.x; VOGEL R, 1990, BRIT J OPHTHALMOL, V74, P3, DOI 10.1136/bjo.74.1.3; WILSON R, 1982, ARCH OPHTHALMOL-CHIC, V100, P737, DOI 10.1001/archopht.1982.01030030741002	19	44	44	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					998	1000		10.1136/bmj.302.6783.998	http://dx.doi.org/10.1136/bmj.302.6783.998			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039899	Bronze, Green Published			2022-12-24	WOS:A1991FJ50800020
J	PAPADAKIS, MA; MANGIONE, CM; LEE, KK; KRISTOF, M				PAPADAKIS, MA; MANGIONE, CM; LEE, KK; KRISTOF, M			TREATABLE ABDOMINAL PATHOLOGICAL CONDITIONS AND UNSUSPECTED MALIGNANT NEOPLASMS AT AUTOPSY IN VETERANS WHO RECEIVED MECHANICAL VENTILATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Study Objective: To determine, in medical patients who received mechanical ventilation, the frequency and types of major unexpected diagnoses at autopsy that, if known before death, would probably have led to improved survival (class I errors) or substantively changed management but not survival (class IIB errors). Design: Retrospective cohort study. Setting: Six medical intensive care units in a Department of Veterans Affairs Cooperative Study. Patients: One hundred seventy-two autopsied patients of the 401 veterans who received mechanical ventilation and died in the hospital. Results: The class I error rate was 12%. Abdominal pathologic conditions-abscesses, bowel perforations, or infarction-were as frequent as pulmonary emboli as a cause of class I errors. While patients with abdominal pathologic conditions generally complained of abdominal pain, results of examination of the abdomen were considered unremarkable in most patients, and the symptom was not pursued. Six percent of patients had extensive malignant neoplasms (class IIb errors). Conclusions: Atypical presentation of potentially treatable abdominal pathologic conditions is a common cause of class I errors in veterans who receive mechanical ventilation. Conversely, several patients with unrecognized terminal conditions underwent intensive intervention. If the information gained at autopsy had been known before death, management would have probably changed substantively in 18% of patients.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; VET AFFAIRS MED CTR,DEPT BIOSTAT,PALO ALTO,CA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PAPADAKIS, MA (corresponding author), DEPT VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,4150 CLEMENT ST 111A1,SAN FRANCISCO,CA 94121, USA.							Fleiss JL, 1981, STAT METHODS RATES P; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V260, P3488; MCPHEE SJ, 1985, AM J MED, V78, P107, DOI 10.1016/0002-9343(85)90470-X; Reichert C M, 1985, Health Aff (Millwood), V4, P82, DOI 10.1377/hlthaff.4.2.82; ROBERTS WC, 1978, NEW ENGL J MED, V299, P332, DOI 10.1056/NEJM197808172990704; 1988, MMWR, V37, P191	10	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					885	887		10.1001/jama.265.7.885	http://dx.doi.org/10.1001/jama.265.7.885			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992186	Green Submitted			2022-12-24	WOS:A1991EX58700040
J	COVERLEY, D; KENNY, MK; MUNN, M; RUPP, WD; LANE, DP; WOOD, RD				COVERLEY, D; KENNY, MK; MUNN, M; RUPP, WD; LANE, DP; WOOD, RD			REQUIREMENT FOR THE REPLICATION PROTEIN SSB IN HUMAN DNA EXCISION REPAIR	NATURE			English	Article							HUMAN CELL-EXTRACTS; SIMIAN VIRUS-40 DNA; PURIFIED PROTEINS; POLYMERASE-DELTA; HELICASE-II; INVITRO; COMPLEX; ALPHA	REPLICATION and repair are essential processes that maintain the continuity of the genetic material. Dissection of simian virus 40 (SV40) DNA replication has resulted in the identification of many eukaryotic replication proteins, but the biochemistry of the multienzyme process of DNA excision repair is less well defined. One protein that is absolutely required for semiconservative replication of SV40 DNA in vitro is human single-stranded DNA-binding protein (SSB, also called RF-A and RP-A) 1-3. SSB consists of three polypeptides of relative molecular mass 70,000, 34,000 and 13,000, and acts with T antigen and topoisomerases to unwind DNA, allowing the access of other replication proteins. Human SSB can also stimulate the activity of polymerases- alpha and delta, suggesting a further role in elongation during DNA replication 4-6. We have now found a role for human SSB in DNA excision repair using a cell-free system that can carry out nucleotide excision repair in vitro 7. Monoclonal antibodies against human SSB caused extensive inhibition of DNA repair in plasmid molecules damaged by ultraviolet light or acetylaminofluorene. Addition of purified SSB reversed this inhibition and further stimulated repair synthesis by increasing the number of repair events. These results show that a mammalian DNA replication protein is also essential for repair.	YALE UNIV, SCH MED, RADIOBIOL LABS, NEW HAVEN, CT 06510 USA	Yale University	COVERLEY, D (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, BLANCHE LANE, S MIMMS EN6 3LD, HERTS, ENGLAND.		Wood, Richard D/M-6319-2018; Lane, David P/C-4920-2008	Wood, Richard D/0000-0002-9495-6892; Coverley, Dawn/0000-0001-8262-7023; Lane, David/0000-0003-0551-3545				CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; IKEDA JE, 1981, P NATL ACAD SCI-BIOL, V78, P884, DOI 10.1073/pnas.78.2.884; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; MANLEY JL, 1988, P NATN ACAD SCI US, V77; NISHIDA C, 1988, J BIOL CHEM, V263, P501; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TOULME JJ, 1983, EMBO J, V2, P505, DOI 10.1002/j.1460-2075.1983.tb01454.x; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1988, MECHANISMS CONSEQUEN, P57	23	233	234	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					538	541		10.1038/349538a0	http://dx.doi.org/10.1038/349538a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992355				2022-12-24	WOS:A1991EW57100072
J	BARLOW, DH; BROCKIE, JA; REES, CMP				BARLOW, DH; BROCKIE, JA; REES, CMP			STUDY OF GENERAL-PRACTICE CONSULTATIONS AND MENOPAUSAL PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT THERAPY	Objective-To investigate the nature of work related to the menopause in general practice. Design-Questionnaire study over six months among general practitioners after each consultation with a woman aged 40-69 at which issues related to the climacteric had been discussed. Setting-9 General practices in the Oxford area. Subjects-416 Women who had 572 consultations. Main outcome measures-Age, menopausal state, and first or subsequent consultation. Symptoms were classified together with the treatment and the outcome of the consultation. Results-The consultation rate varied greatly between practices, the overall rate being 4.4%. There were many premenopausal women and women in their 60s presenting; women with hysterectomies presented more often-36% (37/103) of women with hysterectomies had more than one consultation compared with 26% (38/144) for premenopausal women and 24% (38/155) for postmenopausal women. 409 women had symptoms and 218 were prescribed oestrogen treatment. 156 of the consultations involved discussion and advice only. Only four women were referred to a local specialist clinic. Conclusion-There is a low overall use of hormone replacement therapy in the general postmenopausal population despite the recent media coverage of its benefits in the prevention of osteoporosis and subsequent fractures.			BARLOW, DH (corresponding author), UNIV OXFORD,JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.		Barlow, David/F-8738-2011					AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; BALLINGER CB, 1975, BRIT MED J, V3, P344, DOI 10.1136/bmj.3.5979.344; BARLOW DH, 1989, BRIT J OBSTET GYNAEC, V96, P1192, DOI 10.1111/j.1471-0528.1989.tb03195.x; BELCHETZ P, 1989, BMJ-BRIT MED J, V298, P1467, DOI 10.1136/bmj.298.6686.1467; DRAPER J, 1990, BRIT MED J, V300, P786, DOI 10.1136/bmj.300.6727.786; SHEARS MR, 1989, PRACTITIONER, V233, P146; SPECTOR TD, 1989, BRIT MED J, V299, P1434, DOI 10.1136/bmj.299.6713.1434; THOMPSON B, 1973, J BIOSOC SCI, V5, P71, DOI 10.1017/S0021932000008956	8	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					274	276		10.1136/bmj.302.6771.274	http://dx.doi.org/10.1136/bmj.302.6771.274			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998795	Green Published, Bronze			2022-12-24	WOS:A1991EX91900023
J	MARTIN, LG				MARTIN, LG			POPULATION AGING POLICIES IN EAST-ASIA AND THE UNITED-STATES	SCIENCE			English	Article								As a result of successful efforts to reduce fertility and mortality, East Asian populations are beginning to age, in some cases rapidly. Policies in response to population aging range from attempts in Singapore to reverse it by encouraging more births to efforts in Japan to accommodate it by increasing employment opportunities for older workers. The populations of the United States, which had a longer postwar baby boom, is aging more slowly than these two countries and may be able to learn from the East Asian experience with aging policies.			MARTIN, LG (corresponding author), NATL ACAD SCI,NATL RES COUNCIL,COMM POPULAT,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							BURKHAUSER RV, IN PRESS RES LABOR E; BUTLER RN, 1990, WASHINGTON POST 0605, P6; Chen A.J., 1988, ELDERLY SINGAPORE; CHEUNG PL, 1989, 1989 INT POP C NEW D, P133; CHEUNG PPL, 1989, ASIA PAC POP J, V4, P41; Clark Robert, 1990, RETIREMENT SYSTEMS J; FAWCETT JT, 1980, POPUL DEV REV, V6, P549, DOI 10.2307/1972926; FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; GOLDSTEIN C, 1990, FAR E EC REV, V148, P49; HOON SJ, 1990, FAR E EC REV, V148, P19; KOJIMA H, 1990, AUG ANN M AM SOC ASS; KOTKIN J, 1988, 3RD CENTURY AM RESUR; LIANG J, 1989, CARING AGING WORLD, P278; MAEDA N, 1989, CARING AGING WORLD, P253; MANTON KG, 1989, MILBANK Q, V67, P13, DOI 10.2307/3350235; MARTIN LG, 1990, ANN AM ACAD POLIT SS, V510, P102, DOI 10.1177/0002716290510001008; MARTIN LG, 1988, J GERONTOL, V43, pS99, DOI 10.1093/geronj/43.4.S99; MARTIN LG, 1989, POP B, V44; MOORE J, 1990, FAR E EC REV, V148, P19; OGAWA N, 1988, EC SOCIAL IMPLICATIO, P272; OSAKO M, 1988, PROD AGING NEWS, V25, P1; Phua KH, 1987, WORLD HEALTH FORUM, V8, P38; ROBINSON WC, 1989, 1989 INT POP C NEW D, P143; ROGERS RG, 1989, MILBANK Q, V67, P370, DOI 10.2307/3350221; SALEM E, 1988, FAR E EC REV, V141, P141; Sanger David, 1990, NEW YORK TIMES  0707, pA9; SANGER DE, 1990, NY TIMES        0619, pA2; Schulz J., 1989, LIFETIME EMPLOYMENT; SEIKE A, 1989, 2862 RAND NOT; TASKER R, 1990, FAR E EC REV, V148, P18; WATTENBERG BJ, 1990, COMMENTARY, V23; YU YC, 1987, APR ANN M POP ASS AM; 1989, WORLD POPULATION PRO; 1988, EMPLOY EARN, V35, P160; 1987, REPORT INT COMP SURV; 1987, HLTH STATISTICS OLDE, P64; 1989, FAR E EC REV, V145, P14; 1987, EMPLOYMENT MANAGERME; 1988, 1987 JAP STAT BUR AN, P23; 1990, SCOPE CTR IMMIGRATIO, P8	40	24	24	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					527	531		10.1126/science.1990428	http://dx.doi.org/10.1126/science.1990428			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EV459	1990428				2022-12-24	WOS:A1991EV45900041
J	DURRIN, LK; MANN, RK; KAYNE, PS; GRUNSTEIN, M				DURRIN, LK; MANN, RK; KAYNE, PS; GRUNSTEIN, M			YEAST HISTONE H4 N-TERMINAL SEQUENCE IS REQUIRED FOR PROMOTER ACTIVATION INVIVO	CELL			English	Article								To search for histone domains that may regulate transcription in vivo, we made deletions and amino acid substitutions in the histone N-termini of S. cerevisiae. Histone H4 N-terminal residues 4-23, which include the extremely conserved, reversibly acetylated lysines (at positions 5, 8, 12, and 16), were found to encompass a region required for the activation of the GAL1 promoter. Deletions in the H4 N-terminus reduce GAL1 activation 20-fold. This effect is specific to histone H4 in that large deletions in the N-termini of H2A, H2B, and H3 do not similarly decrease induction. Activation of the PH05 promoter is reduced approximately 4- to 5-fold by these H4 deletions. Mutations in histone H4 acetylation sites and surrounding residues can cause comparable and, in some cases, even greater effects on induction of these two promoters. We postulate that the H4 N-terminus may interact with a component of the transcription initiation complex, allowing nucleosome unfolding and subsequent initiation.	UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	DURRIN, LK (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.				NIGMS NIH HHS [GM23674] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023674, R37GM023674] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Allfrey V. G, 1977, CHROMATIN CHROMOSOME, P167; ALLFREY VG, 1983, AFFINITY PROBES PROT; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HEREFORD L, 1979, CELL, V18, P1261, DOI 10.1016/0092-8674(79)90237-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHON A, 1982, P NATL ACAD SCI-BIOL, V79, P6827, DOI 10.1073/pnas.79.22.6827; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Maniatis T., 1982, MOL CLONING; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NELSON DA, 1982, J BIOL CHEM, V257, P1565; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RAINBOW M, 1989, BIOCHEMISTRY-US, V28, P7486, DOI 10.1021/bi00444a048; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROTH GP, 1990, FEBS LETT, V268, P117, DOI 10.1016/0014-5793(90)80987-T; SCHUSTER T, 1986, CELL, V45, P445, DOI 10.1016/0092-8674(86)90330-2; Sherman F., 1986, METHODS YEAST GENETI; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; STRAKA C, 1991, IN PRESS EMBO J, V10; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; van Holde K.E., 1988, CHROMATIN; WALLIS JW, 1983, CELL, V35, P711, DOI 10.1016/0092-8674(83)90104-6; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WHITLOCK JP, 1978, J BIOL CHEM, V253, P3857; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; XU HX, 1990, MOL CELL BIOL, V10, P2687, DOI 10.1128/MCB.10.6.2687	58	282	284	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					1023	1031		10.1016/0092-8674(91)90554-C	http://dx.doi.org/10.1016/0092-8674(91)90554-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044150				2022-12-24	WOS:A1991FR04700013
J	PARDES, H; WEST, A; PINCUS, HA				PARDES, H; WEST, A; PINCUS, HA			PHYSICIANS AND THE ANIMAL-RIGHTS MOVEMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; AMER PSYCHIAT ASSOC, RES OFF, WASHINGTON, DC 20009 USA	New York State Psychiatry Institute	PARDES, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, 630 W 168TH ST, NEW YORK, NY 10032 USA.							BEHAR R, 1989, FORBES MAGAZINE 0320, P43; COHEN C, 1986, NEW ENGL J MED, V315, P865, DOI 10.1056/NEJM198610023151405; COHEN C, 1987, NEW ENGL J MED, V316, P553; COWLEY G, 1988, NEWSWEEK        1226, P50; DeBakey M E, 1988, J Invest Surg, V1, P81, DOI 10.3109/08941938809141078; DEBAKEY ME, 1989, PHYSICIANS MANAGE, V29, P17; FEENEY DM, 1987, AM PSYCHOL, V42, P593, DOI 10.1037/0003-066X.42.6.593; HORTON L, 1989, J NATL CANCER I, V81, P736, DOI 10.1093/jnci/81.10.736; HORTON L, 1988, SRA-J SOC RES ADMIN, V19, P5; KOOP CE, 1990, COMMUNICATION; NASSAR R, 1988, AM HUMANE ASS ANIMAL; Regan T., 2004, CASE ANIMAL RIGHTS; SHARPE R, CRUEL DECEPTION USE; Singer Peter, 1977, ANIMAL LIBERATION; SMITH SJ, 1988, JAMA-J AM MED ASSOC, V259, P2007, DOI 10.1001/jama.259.13.2007; THOMAS JA, 1988, NEW ENGL J MED, V318, P1630, DOI 10.1056/NEJM198806163182429; WOOLSEY TA, 1988, CIRCULATION, V77, P1197, DOI 10.1161/01.CIR.77.6.1197; 1990, 1990 P HOUS DEL RES, P392; 1986, OTABA273 PUBL; 1990, PAMPHLET AM ASS ACCR	20	18	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1640	1643		10.1056/NEJM199106063242306	http://dx.doi.org/10.1056/NEJM199106063242306			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030720				2022-12-24	WOS:A1991FP30700006
J	ROSS, PD; DAVIS, JW; EPSTEIN, RS; WASNICH, RD				ROSS, PD; DAVIS, JW; EPSTEIN, RS; WASNICH, RD			PREEXISTING FRACTURES AND BONE MASS PREDICT VERTEBRAL FRACTURE INCIDENCE IN WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article							MINERAL MEASUREMENTS; OSTEOPOROSIS; ABSORPTIOMETRY; RISK	Objective: To determine the independent contributions of bone mass and existing fractures as predictors of the risk for new vertebral fractures. Subjects: Postmenopausal Japanese-American women. Measurements: Baseline measurements of the distal radius, the proximal radius, and the calcaneus were obtained in 1981 using single-photon absorptiometry. Measurements of the lumbar spine were obtained in 1984 using dual-photon absorptiometry. Prevalent vertebral fractures were identified using dimensions measured on lateral radiographs; vertebral height values more than 3 SD below vertebra-specific means were considered to indicate fracture. Statistical models were used to evaluate the utility of bone mass and existing (prevalent) fractures to predict the risk for new fractures during an average follow-up of 4.7 years. Main Results: Differences of 2 SD in bone mass were associated with fourfold to sixfold increases in the risk for new vertebral fractures. A single fracture at the baseline examination increased the risk for new vertebral fractures fivefold. Presence of two or more fractures at baseline increased the risk 12-fold. A combination of low bone mass (below the 33d percentile) and the presence of two or more prevalent fractures increased the risk 75-fold, relative to women with the highest bone mass (above the 67th percentile) and no prevalent fractures. Stature, body mass index, arm span, and spinal conditions such as scoliosis, osteoarthritis, and sacroiliitis did not predict fracture incidence (P > 0.05). Weight was marginally predictive (P = 0.04) of fracture incidence but became nonpredictive after adjusting for bone mass (P greater-than-or-equal-to 0.05). Conclusions: Both bone mass and prevalent vertebral fractures are powerful predictors of the risk for new vertebral fractures. Combining information about bone mass and prevalent fracture appears to be better for predicting new fractures than either variable alone. Physicians can use these risk factors to identify patients at greatest risk for new fractures.	MERCK SHARP & DOHME LTD, W POINT, PA 19486 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	Merck & Company; University System of Maryland; University of Maryland Baltimore	ROSS, PD (corresponding author), HAWAII OSTEOPOROSIS CTR, 932 WARD AVE, SUITE 400, HONOLULU, HI 96814 USA.							BENGNER U, 1988, CALCIFIED TISSUE INT, V42, P293, DOI 10.1007/BF02556362; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; Heilbrun L K, 1985, Hawaii Med J, V44, P294; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; ROSS PD, 1988, J BONE MINER RES, V3, P1; ROSS PD, 1991, BONE, V12, P107, DOI 10.1016/8756-3282(91)90008-7; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; WASNICH RD, 1989, J NUCL MED, V30, P1166; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WASNICH RD, 1987, OSTEOPOROSIS 1987, P394; WASNICH RD, 1989, OSTEOPOROSIS CRITIQU; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; YANO K, 1984, AM J EPIDEMIOL, V119, P751, DOI 10.1093/oxfordjournals.aje.a113796	16	882	917	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					919	923		10.7326/0003-4819-114-11-919	http://dx.doi.org/10.7326/0003-4819-114-11-919			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024857				2022-12-24	WOS:A1991FM97900001
J	ENGEL, AK; KONIG, P; KREITER, AK; SINGER, W				ENGEL, AK; KONIG, P; KREITER, AK; SINGER, W			INTERHEMISPHERIC SYNCHRONIZATION OF OSCILLATORY NEURONAL RESPONSES IN CAT VISUAL-CORTEX	SCIENCE			English	Article								Neurons in area 17 of cat visual cortex display oscillatory responses that can synchronize across spatially separate columns in a stimulus-specific way. Response synchronization has now been shown to occur also between neurons in area 17 of the right and left cerebral hemispheres. This synchronization was abolished by section of the corpus callosum. Thus, the response synchronization is mediated by corticocortical connections. These data are compatible with the hypothesis that temporal synchrony of neuronal discharges serves to bind features within and between the visual hemifields.			ENGEL, AK (corresponding author), MAX PLANCK INST HIRNFORSCH, DEUTSCHORDENSTR 46, W-6000 FRANKFURT 71, GERMANY.		König, Peter/ABB-2380-2020; Engel, Andreas K./AAH-6384-2019; Engel, Andreas K/C-7781-2012; Singer, Wolf/D-6874-2012	König, Peter/0000-0003-3654-5267; Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466; 				ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1990, PARALLEL PROCESSING IN NEURAL SYSTEMS AND COMPUTERS, P105; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; ENGEL AK, 1990, SOC NEUR ABSTR, V16, P5231; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1967, J NEUROPHYSIOL, V30, P1561, DOI 10.1152/jn.1967.30.6.1561; INNOCENTI GM, 1980, ARCH ITAL BIOL, V118, P124; Innocenti GM., 1986, GEN ORG CALLOSAL CON, P291, DOI [10.1007/978-1-4613-2149-1_9, DOI 10.1007/978-1-4613-2149-1_9]; Konig P, 1991, NEURAL COMPUT, V3, P155, DOI 10.1162/neco.1991.3.2.155; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; TOYAMA K, 1988, NEUROBIOLOGY NEOCORT, P203; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; Woelcke M, 1942, J PSYCHOL NEUROL, V51, P199	17	681	686	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1177	1179		10.1126/science.252.5009.1177	http://dx.doi.org/10.1126/science.252.5009.1177			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031188				2022-12-24	WOS:A1991FN05600052
J	SULLIVAN, LW				SULLIVAN, LW			CHILD SURVIVAL AND AIDS IN AFRICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		1991, PUBLIC HLTH REP, V106, P105	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2652	2652						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023337				2022-12-24	WOS:A1991FL98900005
J	KADUNCE, DP; BURR, R; GRESS, R; KANNER, R; LYON, JL; ZONE, JJ				KADUNCE, DP; BURR, R; GRESS, R; KANNER, R; LYON, JL; ZONE, JJ			CIGARETTE-SMOKING - RISK FACTOR FOR PREMATURE FACIAL WRINKLING	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-FLOW; SKIN; SMOKERS; FACE	Objective: To determine if cigarette smoking is a risk factor for the development of premature facial wrinkling. Design: Cross-sectional study. Setting: Smoking cessation clinic and community. Patients: Convenience sample of 132 adult smokers and nonsmokers in 1988. Measurements: A questionnaire was administered to quantify cigarette smoking and to obtain information about possibly confounding factors such as skin pigmentation, sun exposure, age, and sex. Wrinkling was assessed using photographs of the temple region, and a severity score based on predetermined criteria was assigned. A logistic regression model, which controlled for confounding variables, was developed to assess the risk for premature wrinkling in response to pack-years of smoking. Main Results: The prevalence of premature wrinkling was independently associated with sun exposure and pack-years of smoking. After controlling for age, sex, and sun exposure, premature wrinkling increased with increased pack-years of smoking. Heavy cigarette smokers (> 50 pack-years) were 4.7 times more likely to be wrinkled than nonsmokers (95% CI, 1.0 to 22.6; P value for trend = 0.05). Sun exposure of more than 50 000 lifetime hours also increased the risk of being excessively wrinkled 3.1-fold (CI, 1.2 to 7.1). When excessive sun exposure and cigarette smoking occurred together, the risk for developing excessive wrinkling was multiplicative (prevalence ratio of 12.0; CI, 1.5 to 530). Conclusion: Cigarette smoking is an independent risk factor for the development of premature wrinkling.			KADUNCE, DP (corresponding author), UNIV UTAH, HLTH SCI CTR,DEPT MED,DIV DERMATOL,ROOM 4B454, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.							BRESLOW N, 1978, BIOMETRICS, V34, P100, DOI 10.2307/2529594; BRESLOW NE, 1980, STATISTICAL METHODS; CHEN VL, 1986, J INVEST DERMATOL, V87, P334, DOI 10.1111/1523-1747.ep12524421; CRAIG S, 1985, PLAST RECONSTR SURG, V75, P842, DOI 10.1097/00006534-198506000-00015; DANIELL HW, 1971, ANN INTERN MED, V75, P873, DOI 10.7326/0003-4819-75-6-873; Fletcher CM, 1976, NATURAL HIST CHRONIC; Gilchrest BA., 1984, SKIN AGING PROCESSES; GILCHREST BA, 1986, AGING SKIN; GRAHAM S, 1985, AM J EPIDEMIOL, V122, P606, DOI 10.1093/oxfordjournals.aje.a114140; LEVER WF, 1983, HISTOPATHOLOGY SKIN, P30; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MODEL D, 1985, BMJ-BRIT MED J, V291, P1760, DOI 10.1136/bmj.291.6511.1760; NIEWOEHNER D, 1986, CURRENT PULMONOLOGY, V7, P23; READ RC, 1984, AM J SURG, V148, P706, DOI 10.1016/0002-9610(84)90421-5; REES TD, 1984, PLAST RECONSTR SURG, V73, P911, DOI 10.1097/00006534-198406000-00009; REUS WF, 1984, BRIT J PLAST SURG, V37, P213, DOI 10.1016/0007-1226(84)90011-0; SCOTTO J, 1983, DHHS NIH832433 PUBL; SOFFER A, 1986, ARCH INTERN MED, V146, P1496, DOI 10.1001/archinte.146.8.1496; WAEBER B, 1984, AM J PHYSIOL, V247, pH895, DOI 10.1152/ajpheart.1984.247.6.H895; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 1982, DHHS PHS8250179 PUBL, P21; 1986, EPILOGUE VER 3	22	170	180	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					840	844		10.7326/0003-4819-114-10-840	http://dx.doi.org/10.7326/0003-4819-114-10-840			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014944				2022-12-24	WOS:A1991FL65000002
J	DONADIO, S; STAVER, MJ; MCALPINE, JB; SWANSON, SJ; KATZ, L				DONADIO, S; STAVER, MJ; MCALPINE, JB; SWANSON, SJ; KATZ, L			MODULAR ORGANIZATION OF GENES REQUIRED FOR COMPLEX POLYKETIDE BIOSYNTHESIS	SCIENCE			English	Article							FATTY-ACID SYNTHASE; SACCHAROPOLYSPORA-ERYTHRAEA STREPTOMYCES; ERYTHROMYCIN RESISTANCE; MACROLIDE BIOSYNTHESIS; ANTIBIOTICS; SEQUENCE; CLONING; CDNA	In Saccharopolyspora erythraea, the genes that govern synthesis of the polyketide portion of the macrolide antibiotic erythromycin are organized in six repeated units that encode fatty acid synthase (FAS)-like activities. Each repeated unit is designated a module, and two modules are contained in a single open reading frame. A model for the synthesis of this complex polyketide is proposed, where each module encodes a functional synthase unit and each synthase unit participates specifically in one of the six FAS-like elongation steps required for formation of the polyketide. In addition, genetic organization and biochemical order of events appear to be colinear. Evidence for the model is provided by construction of a selected mutant and by isolation of a polyketide of predicted structure.	ABBOTT LABS,BIOACT MICROBIAL METABOLITE PROJECT,N CHICAGO,IL 60064	Abbott Laboratories	DONADIO, S (corresponding author), ABBOTT LABS,DEPT CORP MOLEC BIOL,N CHICAGO,IL 60064, USA.							BALTZ RH, 1988, ANNU REV MICROBIOL, V42, P547; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1985, GENE, V38, P215, DOI 10.1016/0378-1119(85)90220-3; BIRCH AJ, 1953, AUST J CHEM, V6, P360, DOI 10.1071/CH9530360; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CHIRALA SS, 1989, J BIOL CHEM, V264, P3750; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWITT JP, 1985, J BACTERIOL, V164, P969, DOI 10.1128/JB.164.2.969-971.1985; DONADIO S, IN PRESS GENE; HALE RS, 1987, FEBS LETT, V224, P133, DOI 10.1016/0014-5793(87)80436-2; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUBER MLB, 1990, ANTIMICROB AGENTS CH, V34, P1535, DOI 10.1128/AAC.34.8.1535; KINOSHITA K, 1988, J CHEM SOC CHEM COMM, V943; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; MACNEIL DJ, 1990, J CELL BIOL A S, V14, P92; Maniatis T., 1982, MOL CLONING; MARTIN JR, 1968, BIOCHEMISTRY-US, V7, P1728, DOI 10.1021/bi00845a016; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; MCALPINE JR, UNPUB; OMURA S, 1984, MACROLIDE ANTIBIOTIC, P199; RICHARDSON MA, 1990, J BACTERIOL, V172, P3790, DOI 10.1128/jb.172.7.3790-3798.1990; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; STAVER MJ, UNPUB; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; UCHIYAMA H, 1985, GENE, V38, P103, DOI 10.1016/0378-1119(85)90208-2; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; WEBER JM, 1988, GENE, V68, P173, DOI 10.1016/0378-1119(88)90019-4; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	39	758	830	1	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					675	679		10.1126/science.2024119	http://dx.doi.org/10.1126/science.2024119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024119				2022-12-24	WOS:A1991FK18500039
J	SULLIVAN, SJ; MAKI, T; BORLAND, KM; MAHONEY, MD; SOLOMON, BA; MULLER, TE; MONACO, AP; CHICK, WL				SULLIVAN, SJ; MAKI, T; BORLAND, KM; MAHONEY, MD; SOLOMON, BA; MULLER, TE; MONACO, AP; CHICK, WL			BIOHYBRID ARTIFICIAL PANCREAS - LONG-TERM IMPLANTATION STUDIES IN DIABETIC, PANCREATECTOMIZED DOGS	SCIENCE			English	Article							ISLET XENOGRAFT SURVIVAL; BIOARTIFICIAL PANCREAS; ENDOCRINE PANCREAS; CAPILLARY UNITS; TRANSPLANTATION; CULTURE; MOUSE; SERUM; CELLS; MICE	Diabetic complications such as neuropathy, retinopathy, and renal and cardiovascular disease continue to pose major health risks for diabetic patients. Consequently, much effort has focused on approaches that could replace conventional insulin therapy and provide more precise regulation of blood glucose levels. The biohybrid perfused artificial pancreas was designed to incorporate islet tissue and a selectively permeable membrane that isolates this tissue from the immune system of the recipient. Biohybrid pancreas devices containing canine islet allografts were implanted in ten pancreatectomized dogs requiring 18 to 32 units of injected insulin daily. These implants resulted in good control of fasting glucose levels in six of these animals without further exogenous insulin for periods of up to 5 months.	NEW ENGLAND DEACONESS HOSP, BROOKLINE, MA 02212 USA; HARVARD UNIV, SCH MED, DIV ORGAN TRANSPLANTAT, BROOKLINE, MA 02212 USA; WR GRACE & CO CONN, DIV RES, LEXINGTON, MA 02173 USA	Harvard University	SULLIVAN, SJ (corresponding author), BIOHYBRID TECHNOL INC, 910 TURNPIKE RD, SHREWSBURY, MA 01545 USA.							AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; BONNEVIENIELSEN V, 1983, ENDOCRINOLOGY, V112, P1049, DOI 10.1210/endo-112-3-1049; BORLAND KM, UNPUB; CHICK WL, 1977, SCIENCE, V197, P780, DOI 10.1126/science.407649; CHICK WL, 1975, SCIENCE, V187, P847, DOI 10.1126/science.187.4179.847; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; GOTOH M, 1988, TRANSPLANT P, V20, P997; HALL FF, 1970, AM J CLIN PATHOL, V53, P627; JONSSON S, 1974, EUR J IMMUNOL, V4, P29, DOI 10.1002/eji.1830040108; KAVAI M, 1989, TRANSPL P, V21, P2709; KRAEGEN EW, 1981, HORM METAB RES, V13, P365, DOI 10.1055/s-2007-1019271; KUPIECWEGLINSKI JW, 1988, TRANSPLANTATION, V46, P785, DOI 10.1097/00007890-198812000-00001; LIKE AA, 1978, LAB INVEST, V38, P470; MAKI T, IN PRESS; MAKI T, 1990, 16TH ANN M AM SOC TR; Michaels A.S., 1971, U.S. Patent, Patent No. [3,615,024, 3615024]; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; REACH G, 1984, DIABETES, V33, P752, DOI 10.2337/diabetes.33.8.752; REACH G, 1984, BIOMED BIOCHIM ACTA, V43, P569; RICORDI C, 1988, TRANSPLANTATION, V45, P994, DOI 10.1097/00007890-198805000-00035; SCHARP DW, 1989, INT HDB PANCREAS TRA, P455; SELAWRY HP, 1984, DIABETES, V33, P405, DOI 10.2337/diabetes.33.4.405; SOELDNER JS, 1971, DIABETES MELLITUS DI, V3, P107; SORENSEN JT, 1982, DIABETES CARE, V5, P148, DOI 10.2337/diacare.5.3.148; SULLIVAN FP, 1987, TRANSPLANTATION, V44, P465, DOI 10.1097/00007890-198710000-00001; SUN AM, 1977, DIABETES, V26, P1136, DOI 10.2337/diabetes.26.12.1136; SWOPE SL, 1984, P NATL ACAD SCI-BIOL, V81, P1822, DOI 10.1073/pnas.81.6.1822; TZE WJ, 1983, DIABETES, V32, P1185, DOI 10.2337/diabetes.32.12.1185; TZE WJ, 1980, DIABETOLOGIA, V19, P541; WARNOCK GL, 1988, DIABETES, V37, P467, DOI 10.2337/diabetes.37.4.467; 1989, DIABETES, V38; 1990, TRANSPLANT P, V22	32	181	210	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					718	721		10.1126/science.2024124	http://dx.doi.org/10.1126/science.2024124			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024124				2022-12-24	WOS:A1991FK18500053
J	WARING, DA; KENYON, C				WARING, DA; KENYON, C			REGULATION OF CELLULAR RESPONSIVENESS TO INDUCTIVE SIGNALS IN THE DEVELOPING C-ELEGANS NERVOUS-SYSTEM	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GENE; LINEAGES; HOMEOBOX	IN Caenorhabditis elegans, cell-cell communication is required to form a simple pattern of sensory ray neurons and cuticular structures (alae). The C. elegans pal-1 gene initiates one developmental pathway (ray lineages) simply by blocking a cell-cell interaction that induces an alternative pathway 1. Here we show by mosaic analysis that pal-1+ acts by preventing specific cells from responding to inductive signals. The results indicate that although cell signals play a critical role in generating this pattern, they do not provide spatial information. Instead, signals are sent to many, if not all, of the precursor cells, and the ability to respond is spatially restricted. This patterning strategy thus differs from many well known models for pattern formation in which localized inductive signals influence a subset of cells within a field. We find that pal-1 encodes a homeodomain protein and so is likely to regulate transcription. The pal-1+ protein could block the response to cell signals either by repressing genes involved in signal transduction or by acting directly on downstream genes in a way that neutralizes the effects of the intercellular signals. Genetic experiments indicate that one candidate for such a downstream gene is the Antennapedia-like homeotic selector gene mab-5.			WARING, DA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q	14	51	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					712	715		10.1038/350712a0	http://dx.doi.org/10.1038/350712a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023634				2022-12-24	WOS:A1991FJ13000062
J	MASON, JO				MASON, JO			UNITED-STATES-PUBLIC-HEALTH-SERVICES STRATEGIC PLAN TO ELIMINATE CHILDHOOD LEAD-POISONING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service	MASON, JO (corresponding author), US DEPT HHS,WASHINGTON,DC 20201, USA.							1988, NATURE EXTENT CHILDH; 1990, NEW ENGL J MED, V322, P83	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2049	2049						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG907	2013918				2022-12-24	WOS:A1991FG90700004
J	ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA				ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA			ANESTHESIA FOR PATIENTS WITH PREECLAMPSIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	ALBRIGHT, GA (corresponding author), NW MEM HOSP,CHICAGO,IL 60611, USA.							1986, SURV ANESTHESIOL, V30, P306	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1587	1587		10.1001/jama.265.12.1587	http://dx.doi.org/10.1001/jama.265.12.1587			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999909				2022-12-24	WOS:A1991FC60400038
J	PANLILIO, AL; FOY, DR; EDWARDS, JR; BELL, DM; WELCH, BA; PARRISH, CM; CULVER, DH; LOWRY, PW; JARVIS, WR; PERLINO, CA				PANLILIO, AL; FOY, DR; EDWARDS, JR; BELL, DM; WELCH, BA; PARRISH, CM; CULVER, DH; LOWRY, PW; JARVIS, WR; PERLINO, CA			BLOOD CONTACTS DURING SURGICAL-PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPERATIONS; RISK; AIDS	Operating room personnel are at risk for infection with blood-borne pathogens through blood contact. To describe the nature and frequency of blood contact and its risk factors, trained observers monitored a sample of operations performed by six surgical services at Grady Memorial Hospital, Atlanta, Ga, for 6 months. In 62 (30.1%) of 206 operations, at least one blood contact was observed. Of 1828 operating room person-procedures observed, 96 (5.3%) had 147 blood contacts (133 skin contacts [90%], 10 percutaneous injuries [7%], and four eye splashes [3%]). The mean number of blood contacts per 100 person-procedures was highest for surgeons (18.6). The frequency of percutaneous injury was similar among surgeons and scrub staff (mean, 1.2 per 100 worker-procedures for each group). Risk factors for surgeons' blood contacts were (1) performing a trauma, burn, or orthopedic emergency procedure (odds ratio [OR], 4.1; 95% confidence interval [Cl], 2.0 to 8.7); (2) patient blood loss exceeding 250mL (OR, 2.1; 95% Cl, 1.2 to 3.7); and (3) being in the operating room longer than 1 hour (OR, 3.3; 95% Cl, 1.6 to 7.1). Of 110 blood contacts among surgeons, 81 (74%) were potentially preventable by additional barrier precautions, such as face shields and fluid-resistant gowns. Twenty-one (84%) of 25 blood contacts among surgeons in procedures in which all three risk factors were present were potentially preventable by additional barriers. Of 29 blood contacts among anesthesia and circulating personnel, 20 (69%) would have been prevented by glove use. For surgical procedures in which operating room personnel are at increased risk of blood contact, reevaluation of surgical technique, use of appropriate barrier precautions, and development of puncture-resistant glove materials are indicated.	GRADY MEM HOSP,DEPT EPIDEMIOL,ATLANTA,GA; EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30322	Emory University	PANLILIO, AL (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP C-10,ATLANTA,GA 30333, USA.							ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; Breslow N.E., 1980, STAT METHODS CANC RE, P192; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GRAVES EJ, 1989, VITAL HLTH STAT, V13, P99; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; MCNICHOLAS TA, 1989, BRIT J UROL, V63, P565, DOI 10.1111/j.1464-410X.1989.tb05246.x; PANLILIO AL, 1990, 6TH INT C AIDS SAN F; POPEJOY SL, IN PRESS SURG GYNECO; TELFORD GL, 1987, SURG ROUNDS, V10, P30; TOKARS JI, 1990, 30TH INT C ANT AG CH; 1987, MMWR, V36, P285; 1987, MMWR, V36, P1; 1989, RECOMMENDATIONS PREV; 1987, MMWR, V36, P509	15	147	154	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1533	1537		10.1001/jama.265.12.1533	http://dx.doi.org/10.1001/jama.265.12.1533			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999903				2022-12-24	WOS:A1991FC60400027
J	BUCHI, K				BUCHI, K			RADIATION PROCTITIS - THERAPY AND PROGNOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							LASER THERAPY; ENTERITIS				BUCHI, K (corresponding author), UNIV UTAH,HLTH SCI CTR,SALT LAKE CITY,UT 84112, USA.							AHLQUIST DA, 1986, MAYO CLIN PROC, V61, P927, DOI 10.1016/S0025-6196(12)62631-7; BLOOMER WD, 1975, NEW ENGL J MED, V293, P80, DOI 10.1056/NEJM197507102930206; BUCHI KN, 1987, GASTROINTEST ENDOSC, V33, P27, DOI 10.1016/S0016-5107(87)71481-3; GALLAND RB, 1986, SURGERY, V99, P133; GOLDSTEIN F, 1976, AM J GASTROENTEROL, V65, P201; LEUCHTER RS, 1982, OBSTET GYNECOL, V59, pS65; NOVAK JM, 1979, J CLIN GASTROENTEROL, V1, P9, DOI 10.1097/00004836-197903000-00003; Walsh D, 1897, Br Med J, V2, P272	8	41	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1180	1180		10.1001/jama.265.9.1180	http://dx.doi.org/10.1001/jama.265.9.1180			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1996006				2022-12-24	WOS:A1991EZ47400039
J	GENBERG, L; RICHARD, L; MCLENDON, G; MILLER, RJD				GENBERG, L; RICHARD, L; MCLENDON, G; MILLER, RJD			DIRECT OBSERVATION OF GLOBAL PROTEIN MOTION IN HEMOGLOBIN AND MYOGLOBIN ON PICOSECOND TIME SCALES	SCIENCE			English	Article							ENERGY RELAXATION PROCESSES; HEME-PROTEINS; GEMINATE RECOMBINATION; RESONANCE RAMAN; LIGAND-BINDING; EXCITED-STATE; SPECTROSCOPY; DYNAMICS; (CARBONMONOXY)HEMOGLOBIN; CARBOXYMYOGLOBIN	Picosecond phase-grating spectroscopy is highly sensitive to density changes and provides a new holographic approach to the study of protein dynamics. Photodissociation of carbon monoxide from heme proteins induces a well-defined transition from a ligated to a deoxy structure that is important to hemoglobin and myoglobin functionality. Grating spectroscopy was used to observe protein-driven density waves on a picosecond time scale after carbon monoxide dissociation. This result demonstrates that global tertiary structure changes of proteins occur on an extremely fast time scale and provides new insight into the biomechanics of deterministic protein motion.	UNIV ROCHESTER,INST OPT,ROCHESTER,NY 14627	University of Rochester	GENBERG, L (corresponding author), UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627, USA.				NIGMS NIH HHS [1 R01 GM41909-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041909] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; [Anonymous], 1986, LASER INDUCED DYNAMI; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; CUSACK S, 1990, BIOPHYS J, V58, P243, DOI 10.1016/S0006-3495(90)82369-9; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; FINDSEN EW, 1985, SCIENCE, V229, P661, DOI 10.1126/science.4023704; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; GENBERG L, 1989, CHEM PHYS, V131, P81, DOI 10.1016/0301-0104(89)87082-X; GENBERG L, 1987, J PHYS CHEM-US, V91, P5521, DOI 10.1021/j100306a002; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; JANES SM, 1988, BIOPHYS J, V54, P545, DOI 10.1016/S0006-3495(88)82987-4; KOGELNIK H, 1969, AT&T TECH J, V48, P2909, DOI 10.1002/j.1538-7305.1969.tb01198.x; LEUNG WP, 1987, CHEM PHYS LETT, V141, P220, DOI 10.1016/0009-2614(87)85013-3; MILLER RJD, 1989, TIME RESOLVED SPECTR, V18, P1; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NELSON KA, 1982, J CHEM PHYS, V77, P1144, DOI 10.1063/1.443979; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PETRICH JW, 1987, BIOCHEMISTRY-US, V26, P7914, DOI 10.1021/bi00398a056; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; REYNOLDS AH, 1981, P NATL ACAD SCI-BIOL, V78, P2292, DOI 10.1073/pnas.78.4.2292; SIEGMAN AE, 1977, J OPT SOC AM, V67, P545, DOI 10.1364/JOSA.67.000545; WESTRICK JA, 1990, BIOCHEMISTRY-US, V29, P6741, DOI 10.1021/bi00480a026; ZIMMT MB, 1989, CHEM PHYS LETT, V160, P564, DOI 10.1016/0009-2614(89)80064-8	24	99	99	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1051	1054		10.1126/science.1998121	http://dx.doi.org/10.1126/science.1998121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998121				2022-12-24	WOS:A1991EZ66500042
J	WILLIAMS, T; TJIAN, R				WILLIAMS, T; TJIAN, R			CHARACTERIZATION OF A DIMERIZATION MOTIF IN AP-2 AND ITS FUNCTION IN HETEROLOGOUS DNA-BINDING PROTEINS	SCIENCE			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTOR; ENHANCER-BINDING; SEQUENCE; JUN; SPECIFICITY; ELEMENTS; COMMON; DOMAIN; C/EBP	The mammalian transcription factor AP-2 is a retinoic acid inducible sequence-specific DNA-binding protein that is developmentally regulated. In this report, the functional domains necessary for AP-2 DNA binding were studied. AP-2 required a dimerization domain and an adjacent region of net basic charge to achieve a sequence-specific protein: DNA interaction. The sequences responsible for dimerization consisted of two putative amphipathic alpha helices separated by a large intervening span region. This helix-span-helix (HSH) domain was unable to bind DNA when separated from the basic region, but was still capable of dimerization. The ability of the HSH domain to function as a module that promotes DNA binding through dimerization was further demonstrated by attaching it to the heterologous basic region of the c-Jun proto-oncogene product. The resulting chimeric protein specifically recognized an AP-1 DNA-binding site in the absence of an intact c-Jun leucine repeat and in a manner that was dependent on the presence of a functional AP-2 dimerization domain.			WILLIAMS, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WILLIAMS T, IN PRESS GENES DEV; Williams T. J., UNPUB	31	196	204	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1067	1071		10.1126/science.1998122	http://dx.doi.org/10.1126/science.1998122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1998122				2022-12-24	WOS:A1991EZ66500049
J	GANNON, JV; LANE, DP				GANNON, JV; LANE, DP			PROTEIN-SYNTHESIS REQUIRED TO ANCHOR A MUTANT P53 PROTEIN WHICH IS TEMPERATURE-SENSITIVE FOR NUCLEAR TRANSPORT	NATURE			English	Article							TRANSFORMED-CELLS; GENE-PRODUCT; MUTATIONS; EXPRESSION; ANTIGEN; CANCER	THE p53 protein is rendered temperature-sensitive by a point mutation 1. Rat cells transformed by this mutant p53 and an activated ras oncogene grow well at 37-degrees-C but cease DNA synthesis and cell division when shifted to 32-degrees-C (ref. 1). Immunostaining demonstrates that the mutant p53 protein is in the nucleus of the arrested cells at 32-degrees-C but in the cytoplasm of the growing cells at 37-degrees-C. This is the first example of a protein which is temperature-sensitive for nuclear transport. The translocation from cytoplasm to nucleus and vice versa occurs 6 h after temperature shift and is coincident with the inhibition of DNA synthesis; transport from cytoplasm to nucleus does not require protein synthesis. Remarkably, inhibition of protein synthesis at 37-degrees-C also results in the rapid appearance of mutant p53 in the cell nucleus. These results suggest the presence of a short-lived protein responsible for holding p53 in the cytoplasm at 37-degrees-C but not at 32-degrees-C. Analysis of a non-temperature-sensitive mutant p53 protein shows that its cytoplasmic location is sensitive to protein synthesis inhibitors but not to temperature.			GANNON, JV (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ANDENBERG FM, 1989, J PATHOL, V157, P193; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; Crawford L V, 1984, Mol Biol Med, V2, P261; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1988, ANTIBODIES LABORATOR; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WASEEM NH, 1990, J CELL SCI, V96, P121; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	29	200	203	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 28	1991	349	6312					802	806						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	2000149				2022-12-24	WOS:A1991EZ66600060
J	KLEIN, CB; CONWAY, K; WANG, XW; BHAMRA, RK; LIN, XH; COHEN, MD; ANNAB, L; BARRETT, JC; COSTA, M				KLEIN, CB; CONWAY, K; WANG, XW; BHAMRA, RK; LIN, XH; COHEN, MD; ANNAB, L; BARRETT, JC; COSTA, M			SENESCENCE OF NICKEL-TRANSFORMED CELLS BY AN X-CHROMOSOME - POSSIBLE EPIGENETIC CONTROL	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENES; CHINESE-HAMSTER; RETINOBLASTOMA; LOCALIZATION; CANCER; REGION; MOUSE; DNA	Transfer of a normal Chinese hamster X chromosome (carried in a mouse A9 donor cell line) to a nickel-transformed Chinese hamster cell line with an Xq chromosome deletion resulted in senescence of these previously immortal cells. At early passages of the A9/CX donor cells, the hamster X chromosome was highly active, inducing senescence in 100% of the colonies obtained after its transfer into the nickel-transformed cells. However, senescence was reduced to 50% when Chinese hamster X chromosomes were transferred from later passage A9 cells. Full senescing activity of the intact hamster X chromosome was restored by treatment of the donor mouse cells with 5-azacytidine, which induced demethylation of DNA. These results suggest that a senescence gene or genes, which may be located on the Chinese hamster X chromosome, can be regulated by DNA methylation, and that escape from senescence and possibly loss of tumor suppressor gene activity can occur by epigenetic mechanisms.	NYU MED CTR,INST ENVIRONM MED,NEW YORK,NY 10016; UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	New York University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			costa, max/H-1754-2012; Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Klein, Catherine/0000-0001-8588-3751	NIEHS NIH HHS [ES 04895, ES 05512, ES 04715] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004715, P42ES004895] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGGART NW, 1986, MUTAT RES, V175, P209, DOI 10.1016/0165-7992(86)90056-4; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN CJ, 1990, AM J HUM GENET, V46, P273; CONWAY K, 1989, CANCER RES, V49, P6032; CONWAY K, 1989, THESIS NEW YORK U GR; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FENWICK RG, 1980, SOMAT CELL GENET, V6, P477, DOI 10.1007/BF01539151; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOCKEY AJ, 1989, SOMAT CELL MOLEC GEN, V15, P421, DOI 10.1007/BF01534893; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HUEBNER K, 1986, AM J HUM GENET, V38, P819; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1989, P NATL ACAD SCI USA, V86, P8733; LIMON J, 1986, CANCER GENET CYTOGEN, V23, P87, DOI 10.1016/0165-4608(86)90152-4; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NISHIOKA H, 1975, MUTAT RES, V31, P185, DOI 10.1016/0165-1161(75)90088-6; PERIERASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SEN P, 1986, TOXICOL APPL PHARM, V84, P278, DOI 10.1016/0041-008X(86)90135-3; SEN P, 1985, CANCER RES, V45, P2320; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P9099, DOI 10.1073/pnas.84.24.9099; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WANG X, UNPUB; YAMADA H, 1990, ONCOGENE, V5, P141	35	167	168	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					796	799		10.1126/science.1990442	http://dx.doi.org/10.1126/science.1990442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990442				2022-12-24	WOS:A1991EX57500045
J	NIGGLI, E; LEDERER, WJ				NIGGLI, E; LEDERER, WJ			MOLECULAR OPERATIONS OF THE SODIUM CALCIUM EXCHANGER REVEALED BY CONFORMATION CURRENTS	NATURE			English	Article							GUINEA-PIG; VOLTAGE DEPENDENCE; VENTRICULAR CELLS; MECHANISM; VESICLES; PUMPS	THE sodium-calcium exchanger is critical in the normal functioning of many cells 1,2. In heart muscle, it is the principal way by which the cells keep the concentration of intracellular calcium low, pumping out the Ca2+ that enters the cytosol through L-type Ca2+ channels 3,4. The exchanger may also contribute to the triggering of Ca2+ release during voltage-activated excitation-contraction coupling in heart 5,6. Time resolved examination of the conformational changes of macromolecules in living cells has so far been largely restricted to ion-channel proteins whose gating is voltage-dependent 7,8. We have now directly measured electrical currents arising from the molecular rearrangements of the sarcolemmal Na-Ca exchanger. Changes in the conformation of the exchanger protein were activated by a rapid increase in the intracellular calcium concentration produced by flash photolysis of caged calcium 9 in voltage-clamped heart cells. Two components of membrane current were produced, reflecting a calcium-dependent conformational change of the transporter proteins and net transport of ions by the exchanger. The properties of these components provide evidence that the Na-Ca exchanger protein undergoes two consecutive membrane-crossing molecular transitions that each move charge, and that there are at least 250 exchangers per mu-m2 turning over up to 2,500 times per second.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; MED BIOTECHNOL CTR,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Niggli, Ernst/C-4884-2015; Lederer, William/B-1285-2010; Niggli, Ernst/AAL-4351-2020	Niggli, Ernst/0000-0003-4670-4903; Niggli, Ernst/0000-0003-4670-4903				ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CALLEWAERT G, 1986, PFLUG ARCH EUR J PHY, V406, P424, DOI 10.1007/BF00590947; CHEON J, 1988, J BIOL CHEM, V263, P2309; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; EHARA T, 1989, J PHYSIOL-LONDON, V410, P227, DOI 10.1113/jphysiol.1989.sp017530; EHARA T, 1988, J PHYSIOL-LONDON, V403, P117, DOI 10.1113/jphysiol.1988.sp017242; EISNER DA, 1985, AM J PHYSIOL, V248, pC189, DOI 10.1152/ajpcell.1985.248.3.C189; HILGEMANN DW, 1988, PROG BIOPHYS MOL BIO, V51, P1, DOI 10.1016/0079-6107(88)90009-0; HODGKIN AL, 1987, J PHYSIOL-LONDON, V391, P371, DOI 10.1113/jphysiol.1987.sp016743; HOROWICZ P, 1981, J PHYSIOL-LONDON, V314, P595, DOI 10.1113/jphysiol.1981.sp013726; KAPLAN JH, 1990, REV PHYSL, V52, P897; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LAUGER P, 1984, BIOCHIM BIOPHYS ACTA, V779, P307, DOI 10.1016/0304-4157(84)90015-7; LAUGER P, 1987, J MEMBRANE BIOL, V99, P1, DOI 10.1007/BF01870617; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LIPP P, 1988, J PHYSIOL-LONDON, V403, P355, DOI 10.1113/jphysiol.1988.sp017253; MULLINS LJ, 1977, J GEN PHYSIOL, V70, P681, DOI 10.1085/jgp.70.6.681; REUTER H, 1968, J PHYSL, V218, P908; SLAUGHTER RS, 1988, BIOCHEMISTRY-US, V27, P2403, DOI 10.1021/bi00407a023	27	130	132	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					621	624		10.1038/349621a0	http://dx.doi.org/10.1038/349621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000135				2022-12-24	WOS:A1991EX57000063
J	EELES, RA; TAN, S; WILTSHAW, E; FRYATT, I; AHERN, RP; SHEPHERD, JH; HARMER, CL; BLAKE, PR; CHILVERS, CED				EELES, RA; TAN, S; WILTSHAW, E; FRYATT, I; AHERN, RP; SHEPHERD, JH; HARMER, CL; BLAKE, PR; CHILVERS, CED			HORMONE REPLACEMENT THERAPY AND SURVIVAL AFTER SURGERY FOR OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN REPLACEMENT; POSTMENOPAUSAL WOMEN; MENOPAUSE; EPIDEMIOLOGY; CARCINOMA; RISK	Objective - To evaluate whether hormone replacement therapy affects survival in women who have undergone bilateral salpingo-oophorectomy because of epithelial ovarian cancer. Design - Retrospective analysis by review of patients' notes and questionnaires completed by general practitioners to compare the overall survival and disease free survival in patients with ovarian cancer who did or did not receive hormone replacement therapy after diagnosis. Data were analysed by Cox regression, with hormone replacement therapy as a time dependent covariate because patients who received hormone replacement did so at different times after diagnosis. Setting - Gynaecological oncology unit of Royal Marsden Hospital. Patients - 373 patients aged 50 years or younger who attended the hospital from 1972 to 1988. All of the women had undergone bilateral salpingo-oophorectomy for epithelial ovarian cancer. In all, 78 had received hormone replacement therapy, starting at a median of four months after diagnosis. Intervention - A questionnaire was sent to the general practitioners of all patients who were not recorded as having received hormone replacement therapy. Main outcome measures - Overall survival and disease free survival. Results - There was no significant difference in survival between women receiving hormone replacement therapy and those not receiving it after accounting for the effects of other known prognostic factors (stage of cancer, differentiation of tumour, histological results, and time to relapse). The relative risk of dying in those who received hormone replacement therapy was 0.73 (95% confidence interval 0.44 to 1.20). In addition, there was no significant difference in disease free survival (relative risk in those receiving hormone replacement therapy was 0.90; 95% confidence interval 0.52 to 1.54). Conclusions - This study shows that hormone replacement therapy is unlikely to have a detrimental effect on the prognosis of patients with ovarian cancer, but this would be shown conclusively only by a randomised controlled trial.	ROYAL MARSDEN HOSP,DEPT MED,GYNAECOL ONCOL UNIT,LONDON SW3 6JJ,ENGLAND; ROYAL MARSDEN HOSP,DEPT COMP,LONDON SW3 6JJ,ENGLAND; UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2RD,ENGLAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Nottingham				A'Hern, Roger/0000-0003-0593-8391; Eeles, Rosalind/0000-0002-3698-6241				ANDERSON JR, 1985, CANCER TREAT REP, V69, P1139; BARRETTCONNOR E, 1989, NEW ENGL J MED, V321, P319, DOI 10.1056/NEJM198908033210510; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; HENDERSON BE, 1988, FERTIL STERIL, V49, pS9; HILDRETH NG, 1981, AM J EPIDEMIOL, V114, P398, DOI 10.1093/oxfordjournals.aje.a113207; HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KUHNEL R, 1987, INT J GYNECOL PATHOL, V6, P248; LAVECCHIA C, 1982, J NATL CANCER I, V69, P1207; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; TOBIAS JS, 1976, NEW ENGL J MED, V294, P818, DOI 10.1056/NEJM197604082941506; TZONOU A, 1984, EUR J CANCER CLIN ON, V20, P1045, DOI 10.1016/0277-5379(84)90107-X; WEISS NS, 1982, J NATL CANCER I, V68, P95; WHITEHEAD M, 1988, LANCET, V2, P1243	20	104	123	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					259	262		10.1136/bmj.302.6771.259	http://dx.doi.org/10.1136/bmj.302.6771.259			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998789	Green Published, Bronze			2022-12-24	WOS:A1991EX91900017
J	LYNCH, TH; WAYMONT, B; BEACOCK, CJM; DUNN, JA; HUGHES, MA; WALLACE, DMA				LYNCH, TH; WAYMONT, B; BEACOCK, CJM; DUNN, JA; HUGHES, MA; WALLACE, DMA			FOLLOW-UP AFTER TRANSURETHRAL RESECTION OF PROSTATE - WHO NEEDS IT	BRITISH MEDICAL JOURNAL			English	Article											LYNCH, TH (corresponding author), QUEEN ELIZABETH MED CTR,DEPT UROL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.			Dunn, Janet/0000-0001-7313-4446				DORFLINGER T, 1988, J UROLOGY, V140, P1487, DOI 10.1016/S0022-5347(17)42081-7; Singh M, 1973, Br J Urol, V45, P93, DOI 10.1111/j.1464-410X.1973.tb00050.x; 1985, SERIES MB4 27; 1988, BMDP STATISTICAL SOF, V2; 1988, BMDP STATISTICAL SOF, V1	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					27	27		10.1136/bmj.302.6767.27	http://dx.doi.org/10.1136/bmj.302.6767.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER372	1991183	Bronze, Green Published			2022-12-24	WOS:A1991ER37200021
J	MILNER, J; MEDCALF, EA				MILNER, J; MEDCALF, EA			COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION	CELL			English	Article							TUMOR SUPPRESSOR PROTEIN; HEAT-SHOCK PROTEINS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; LUNG-CANCER; IMMUNOLOGICAL VARIANTS; TRANSFORMED-CELLS; ONCOGENE; GENE; MUTATIONS	Activating mutations of p53 promote tumor progression. The mutant protein adopts a characteristic conformation, which lacks the growth suppressor function of wild-type p53. We show that mutant p53 can drive cotranslated wild-type p53 into the mutant conformation: a similar effect in vivo would block wild-type suppressor function with dominant negative effect. The cotranslational effect of mutant p53 on wild-type conformation depends upon interaction between nascent polypeptides and oligomerization of the full-length proteins. We also show that oligomers of p53 proteins can be induced to change conformation in a cooperative manner. Cell growth stimulation induces a similar conformational change in p53, and our present results indicate that this may involve allosteric regulation.			MILNER, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; CHIBA I, 1990, ONCOGENE, V5, P1603; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1222; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	38	620	638	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					765	774		10.1016/0092-8674(91)90384-B	http://dx.doi.org/10.1016/0092-8674(91)90384-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040013				2022-12-24	WOS:A1991FP51600007
J	BITTLES, AH; MASON, WM; GREENE, J; RAO, NA				BITTLES, AH; MASON, WM; GREENE, J; RAO, NA			REPRODUCTIVE-BEHAVIOR AND HEALTH IN CONSANGUINEOUS MARRIAGES	SCIENCE			English	Article							SOUTH-INDIA; PARENTAL CONSANGUINITY; PREREPRODUCTIVE MORTALITY; GENETIC-DISEASE; TAMIL-NADU; CONGENITAL-ABNORMALITIES; PARNETAL CONSANGUINITY; POSTNATAL MORTALITY; FETAL GROWTH; JAPAN	In many regions of Asia and Africa, consanguineous marriages currently account for approximately 20 to 50% of all unions, and preliminary observations indicate that migrants from these areas continue to contract marriages with close relatives when resident in North America and Western Europe. Consanguinity is associated with increased gross fertility, due at least in part to younger maternal age at first livebirth. Morbidity and mortality also may be elevated, resulting in comparable numbers of surviving offspring in consanguineous and nonconsanguineous families. With advances in medicine and public health, genetic disorders will account for an increased proportion of disease worldwide. Predictably, this burden will fall more heavily on countries and communities in which consanguinity is strongly favored, as the result of the expression of deleterious recessive genes. However, studies conducted in such populations indicate that the adverse effects associated with inbreeding are experienced by a minority of families.	UNIV CALIF LOS ANGELES,SOCIOL,LOS ANGELES,CA 90024; UNIV MICHIGAN,CTR POPULAT STUDIES,ANN ARBOR,MI 48104; INDIAN INST SCI,BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; Indian Institute of Science (IISC) - Bangalore	BITTLES, AH (corresponding author), UNIV LONDON KINGS COLL,LONDON WC2R 2LS,ENGLAND.			Bittles, Alan/0000-0002-8176-2730				AFZAL M, 1988, BEHAV GENET, V18, P583, DOI 10.1007/BF01082310; AGRAWAL N, 1984, BEHAV GENET, V14, P579, DOI 10.1007/BF01068128; ALAWADI SA, 1986, CLIN GENET, V29, P384; Ansari SA, 1978, INDIAN J MED RES, V68, P295; B K, 1979, IND J HERED, V11, P77; Barth F, 1954, SOUTHWEST J ANTHROP, V10, P164, DOI 10.1086/soutjanth.10.2.3628823; BASHI J, 1977, NATURE, V266, P440, DOI 10.1038/266440a0; BASSARAN N, 1988, CLIN GENET, V34, P339; Basu S K, 1975, J Popul Res, V2, P57; BEER AE, 1981, AM J OBSTET GYNECOL, V141, P987; BEMISS SM, 1858, T AM MED ASS, V11, P319; BENALLEGUE A, 1984, ARCH FR PEDIATR, V41, P435; Bittles A. H, 1988, HUMAN MATING PATTERN, P153; BITTLES AH, 1987, MAN, V22, P736, DOI 10.2307/2803361; BITTLES AH, 1988, ANN HUM BIOL, V15, P455, DOI 10.1080/03014468800000062; BITTLES AH, 1990, FERTILITY RESOURCES, P62; BOOK JA, 1957, ANN HUM GENET, V21, P191; BRATT CS, 1984, FAM LAW QUART, V18, P257; BUMPASS LL, 1978, DEMOGRAPHY, V15, P75, DOI 10.2307/2060491; BUMPASS LL, 1977, SOC BIOL, V24, P31, DOI 10.1080/19485565.1977.9988259; BUNDEY S, 1990, J EPIDEMIOL COMMUN H, V44, P130, DOI 10.1136/jech.44.2.130; Bundey S, 1991, Paediatr Perinat Epidemiol, V5, P101, DOI 10.1111/j.1365-3016.1991.tb00689.x; CALDWELL JC, 1988, CAUSES DEMOGRAPHIC C, P239; Carr D H, 1971, Adv Hum Genet, V2, P201; CHAKRABORTY R, 1977, HUM GENET, V36, P47, DOI 10.1007/BF00390435; CHALEBY K, 1987, BRIT J PSYCHIAT, V150, P547, DOI 10.1192/bjp.150.4.547; CHITTY LS, 1989, ARCH DIS CHILD, V64, P1036, DOI 10.1136/adc.64.7.1036; COLEMAN DA, 1980, HUM HERED, V30, P278, DOI 10.1159/000153144; COOK ROBERT, 1966, J TROP PEDIAT AFR CHILD HEALTH, V11, P95; DARR A, 1988, J MED GENET, V25, P186, DOI 10.1136/jmg.25.3.186; DARWIN F, 1887, LIFE LETT C DARWIN, V2, P309; Darwin George, 1875, J STAT SOC, V38, P344; DARWIN GH, 1875, J STAT ASS, V37, P153; DECOSTA C, 1986, MED J AUSTRALIA, V144, P721; DEVI ARR, 1987, J MED GENET, V24, P362, DOI 10.1136/jmg.24.6.362; DIAMOND JM, 1987, NATURE, V329, P487, DOI 10.1038/329487a0; DRONAMRAJU KR, 1963, ACTA GENET STAT MED, V13, P21; DRONAMRAJU KR, 1963, J GENET, V58, P387, DOI 10.1007/BF02986307; ELALFI S, 1969, J KWT MED ASS, V3, P227; EMERY AEH, 1990, PRINCIPLES PRACTICE, P3; FARAG TI, 1988, CLIN GENET, V33, P78; Fei Hsiao-eung, 1939, PEASANT LIFE CHINA, P50; FREIREMAIA N, 1968, EUGEN QUART, V15, P22, DOI 10.1080/19485565.1968.9987749; FREIREMAIA N, 1984, AM J MED GENET, V18, P391, DOI 10.1002/ajmg.1320180306; FREIREMAIA N, 1983, AM J MED GENET, V16, P331, DOI 10.1002/ajmg.1320160306; FREUNDLICH E, 1984, ISRAEL J MED SCI, V20, P1035; GEDDES WR, 1963, PEASANT LIFE COMMUNI, P28; GINTER EK, 1987, HUM GENET, P547; GOLDSCHMIDT E, 1960, ANN HUM GENET, V24, P191, DOI 10.1111/j.1469-1809.1960.tb01732.x; GORDON RR, 1988, BMJ-BRIT MED J, V297, P774, DOI 10.1136/bmj.297.6651.774; GOSWAMI HK, 1970, ACTA GENET MED GEMEL, V19, P486, DOI 10.1017/S112096230001489X; HAFEZ M, 1983, J MED GENET, V20, P58, DOI 10.1136/jmg.20.1.58; HALL JG, 1978, AM J MED GENET, V1, P417, DOI 10.1002/ajmg.1320010405; HAMAMY HA, 1989, HUM HERED, V39, P271, DOI 10.1159/000153871; HENDRICKS CH, 1955, OBSTET GYNECOL, V6, P592, DOI 10.1097/00006250-195512000-00003; HONEYMAN MM, 1987, ARCH DIS CHILD, V62, P231, DOI 10.1136/adc.62.3.231; IMAIZUMI Y, 1975, JPN J HUM GENET, V20, P91; IMAIZUMI Y, 1986, CLIN GENET, V30, P230; KABARITY A, 1981, HUM GENET, V57, P444, DOI 10.1007/BF00281704; KHLAT M, 1986, AM J MED GENET, V25, P299, DOI 10.1002/ajmg.1320250215; KHLAT M, 1988, AM J HUM GENET, V43, P188; KHLAT M, 1989, AM J PHYS ANTHROPOL, V80, P481, DOI 10.1002/ajpa.1330800407; Khlat M, 1984, J BIOSOC SCI, V16, P369; KHOURY MJ, 1987, AM J EPIDEMIOL, V125, P251, DOI 10.1093/oxfordjournals.aje.a114524; Krishan G, 1986, AM J PHYS ANTHROPOL, V70, P60; KULKARNI ML, 1990, J MED GENET, V27, P348, DOI 10.1136/jmg.27.6.348; KUMAR S, 1967, ANN HUM GENET, V31, P141, DOI 10.1111/j.1469-1809.1967.tb00545.x; LEBEL RR, 1983, AM J MED GENET, V15, P543, DOI 10.1002/ajmg.1320150404; Lesthaeghe Ron., 1989, REPROD SOCIAL ORG SU, P238; MAGNUS P, 1985, CLIN GENET, V28, P335; MARCALLO FA, 1964, ANN HUM GENET, V27, P203, DOI 10.1111/j.1469-1809.1963.tb00787.x; McKusick Victor., 1978, MED GENETIC STUDIES; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; NADERI S, 1979, OBSTET GYNECOL, V53, P195; NEEL JV, 1962, P NATL ACAD SCI USA, V48, P573, DOI 10.1073/pnas.48.4.573; NEEL JV, 1962, AM J HUM GENET, V48, P573; OBER CL, 1983, AM J HUM GENET, V35, P994; OBRIEN E, 1988, AM J PHYS ANTHROPOL, V75, P477, DOI 10.1002/ajpa.1330750405; OBRIEN E, 1988, AM J PHYS ANTHROPOL, V77, P335, DOI 10.1002/ajpa.1330770306; OKSENBERG JR, 1984, FERTIL STERIL, V42, P389; PARISH WL, 1978, VILLAGE FAMILY CONT, P170; RAO NA, 1988, CLIN GENET, V34, P60; RAO PSS, 1977, SOC BIOL, V24, P281, DOI 10.1080/19485565.1977.9988298; RAO PSS, 1979, J MED GENET, V16, P24, DOI 10.1136/jmg.16.1.24; RAO PSS, 1977, ANN HUM GENET, V41, P87, DOI 10.1111/j.1469-1809.1977.tb01964.x; RAO PSSS, 1979, ANN HUM GENET, V42, P401, DOI 10.1111/j.1469-1809.1979.tb00672.x; REDDY PG, 1988, ANN HUM BIOL, V15, P263, DOI 10.1080/03014468800009731; REID RM, 1976, HUM BIOL, V48, P139; SAEDIWONG S, 1989, J ASIAN AFR STUD, V24, P247, DOI DOI 10.1177/002190968902400308; SAHA N, 1988, J BIOSOC SCI, V20, P333, DOI 10.1017/S0021932000006660; SANGHVI LD, 1966, EUGEN QUART, V13, P291, DOI 10.1080/19485565.1966.9987682; Sanghvi LD, 1956, ACTA GENET STAT MED, V6, P41; SAUGSTAD LF, 1977, ANN HUM GENET, V40, P481, DOI 10.1111/j.1469-1809.1977.tb01865.x; SCHORK MA, 1964, AM J HUM GENET, V16, P292; SCHULL WJ, 1970, AM J HUM GENET, V22, P239; SCHULL WJ, 1970, HUMANGENETIK, V9, P294, DOI 10.1007/BF00286995; SCHULL WJ, 1962, HUM BIOL, V34, P271; SCHULL WJ, 1972, AM J HUM GENET, V24, P425; SCHULL WJ, 1958, AM J HUM GENET, V10, P294; Schull WJ, 1965, EFFECTS INBREEDING J; SCOTTEMUAKPOR AB, 1974, AM J HUM GENET, V26, P674; SHAMI S A, 1982, Biologia (Lahore), V28, P1; SHAMI SA, 1989, J MED GENET, V26, P267, DOI 10.1136/jmg.26.4.267; SHAMI SA, 1990, ANN HUM BIOL, V17, P97, DOI 10.1080/03014469000000842; TANAKA K, 1964, P JPN ACAD, V40, P852, DOI 10.2183/pjab1945.40.852; Tanner R E, 1958, Eugen Rev, V49, P197; THOMAS ML, 1985, AM J OBSTET GYNECOL, V151, P1053, DOI 10.1016/0002-9378(85)90379-5; Tuncbilek E, 1989, Nufusbil Derg, V11, P35; WHYTE MK, 1984, URBAN LIFE CONT CHIN, P133; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; YADAV GC, 1988, J INHERIT METAB DIS, V11, P277, DOI 10.1007/BF01800370; 1989, STATE WORLDS CHILDRE, P94	112	236	237	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					789	794		10.1126/science.2028254	http://dx.doi.org/10.1126/science.2028254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL123	2028254				2022-12-24	WOS:A1991FL12300035
J	BRIDGES, ND; PERRY, SB; KEANE, JF; GOLDSTEIN, SAN; MANDELL, V; MAYER, JE; JONAS, RA; CASTENEDA, AR; LOCK, JE				BRIDGES, ND; PERRY, SB; KEANE, JF; GOLDSTEIN, SAN; MANDELL, V; MAYER, JE; JONAS, RA; CASTENEDA, AR; LOCK, JE			PREOPERATIVE TRANSCATHETER CLOSURE OF CONGENITAL MUSCULAR VENTRICULAR SEPTAL-DEFECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE; MULTIPLE	Background. Surgical repair of muscular ventricular septal defects, particularly those associated with complex heart lesions, carries a higher risk of reoperation and death than the repair of membranous defects. Closing a muscular defect through an incision in the systemic ventricle may cause late ventricular dysfunction. In a collaborative approach to this problem, we undertook preoperative transcatheter closure of muscular ventricular septal defects remote from the atrioventricular and semilunar valves, followed by the surgical repair of associated conditions. Methods. In 12 patients selected jointly by a cardiologist and a cardiac surgeon, we attempted preoperative transcatheter umbrella closure of 21 defects. Half the patients had associated complex heart lesions; the others had had pulmonary-artery banding to reduce the amount of left-to-right shunting. Half had severe ventricular septal deficiency. Results. All 21 defects were successfully closed without major complications. Subsequent cardiac surgery for associated conditions in 11 of the 12 patients resulted in a mean pulmonary-to-systemic flow ratio of 1.1, indicating minimal residual left-to-right shunting; 1 patient awaited surgical repair. No deaths, reoperations, or late complications have occurred after a follow-up of 7 to 20 months. Conclusions. A collaborative approach using transcatheter closure followed by the surgical repair of associated cardiac lesions may decrease rates of operative mortality, reoperation, and left ventricular dysfunction in patients with muscular ventricular septal defects.	CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT RADIOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT CARDIOVASC SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			miaoyue, chen/A-6575-2012; Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				Breckenridge I M, 1972, Ann Thorac Surg, V13, P128; BRIDGES ND, 1990, CIRCULATION, V82, P1681, DOI 10.1161/01.CIR.82.5.1681; Elliott L P, 1977, Circulation, V56, P1048; FELLOWS KE, 1977, CIRCULATION, V56, P485, DOI 10.1161/01.CIR.56.3.485; FOX KM, 1978, BRIT HEART J, V40, P141; FRIEDMAN WF, 1965, CIRCULATION, V32, P35, DOI 10.1161/01.CIR.32.1.35; GRIFFITHS SP, 1981, AM J CARDIOL, V48, P877, DOI 10.1016/0002-9149(81)90353-2; HANNA B, 1991, Journal of the American College of Cardiology, V17, p110A; KIRKLIN JK, 1980, J THORAC CARDIOVASC, V80, P458; KIRKLIN JW, 1986, CARDIAC SURG MORPHOL, P637; LOCK JE, 1988, CIRCULATION, V78, P361, DOI 10.1161/01.CIR.78.2.361; LOCK JE, 1989, CIRCULATION, V79, P1091, DOI 10.1161/01.CIR.79.5.1091; OLAUGHLIN MP, 1989, CATHETER CARDIO DIAG, V17, P175, DOI 10.1002/ccd.1810170311; RIZZOLI G, 1980, J THORAC CARDIOV SUR, V80, P494; RIZZOLI G, 1983, THORAC CARDIOV SURG, V31, P382, DOI 10.1055/s-2007-1022024; ROME JJ, 1990, CIRCULATION, V82, P751, DOI 10.1161/01.CIR.82.3.751; ROME JJ, 1988, CIRCULATION S2, V78, P291; SINGH AK, 1977, ANN SURG, V186, P577, DOI 10.1097/00000658-197711000-00006; TAYLOR JFN, 1971, BRIT HEART J, V33, P285; VANPRAAGH R, 1977, CIRCULATION, V56, P139, DOI 10.1161/01.CIR.56.2.139; VANPRAAGH R, 1978, HEART DISEASE INFANC, P68; WALDHAUSEN JA, 1964, SURGERY, V56, P868; ZAVANELLA C, 1977, ANN THORAC SURG, V24, P537, DOI 10.1016/S0003-4975(10)63453-4	23	116	124	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1312	1317		10.1056/NEJM199105093241903	http://dx.doi.org/10.1056/NEJM199105093241903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017227	Green Published			2022-12-24	WOS:A1991FK18600003
J	TOMIE, T; SHIMIZU, H; MAJIMA, T; YAMADA, M; KANAYAMA, T; KONDO, H; YANO, M; ONO, M				TOMIE, T; SHIMIZU, H; MAJIMA, T; YAMADA, M; KANAYAMA, T; KONDO, H; YANO, M; ONO, M			3-DIMENSIONAL READOUT OF FLASH X-RAY IMAGES OF LIVING SPERM IN WATER BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article								The imaging of living specimens in water by x-ray microscopy can be greatly enhanced with the use of an intense flash x-ray source and sophisticated technologies for reading x-ray images. A subpicosecond x-ray pulse from a laser-produced plasma was used to record the x-ray image of living sea urchin sperm in an x-ray resist. The resist relief was visualized at high resolution by atomic-force microscopy. Internal structure of the sperm head was evident, and the carbon density in a flagellum was estimated from the relief height.	NIKON INC,TSUKUBA LAB,TSUKUBA,IBARAKI 30026,JAPAN	Nikon Corporation	TOMIE, T (corresponding author), ELECTROTECH LAB,TSUKUBA,IBARAKI 305,JAPAN.							ALLEN RD, 1968, J CELL BIOL, V37, P825, DOI 10.1083/jcb.37.3.825; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Cheng P.C., 1987, XRAY MICROSCOPY INST, P65; EASON RW, 1985, ANN REPORT; FEDER R, 1985, SCIENCE, V227, P63, DOI 10.1126/science.3964958; FEDER R, 1977, SCIENCE, V197, P259, DOI 10.1126/science.406670; GIUDICE G, 1987, SEA URCHIN EMBRYO, P23; JACOBSEN C, 1988, XRAY MICROSCOPY, V2, P253; KIRZ J, 1984, XRAY MICROSCOPY, P262; LONDON RA, 1989, APPL OPTICS, V28, P3397, DOI 10.1364/AO.28.003397; ROSSER RJ, 1987, APPL OPTICS, V26, P4313, DOI 10.1364/AO.26.004313; SAYRE D, 1988, XRAY MICROSCOPY, V2; SOLEM JC, 1986, J OPT SOC AM B, V3, P1551, DOI 10.1364/JOSAB.3.001551; 1990, INT C XRAY MICROSCOP	14	80	81	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					691	693		10.1126/science.2024121	http://dx.doi.org/10.1126/science.2024121			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024121				2022-12-24	WOS:A1991FK18500043
J	YOUNG, S; LESOUEF, PN; GEELHOED, GC; STICK, SM; CHIR, B; TURNER, KJ; LANDAU, LI				YOUNG, S; LESOUEF, PN; GEELHOED, GC; STICK, SM; CHIR, B; TURNER, KJ; LANDAU, LI			THE INFLUENCE OF A FAMILY HISTORY OF ASTHMA AND PARENTAL SMOKING ON AIRWAY RESPONSIVENESS IN EARLY INFANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL RESPONSIVENESS; INHALED HISTAMINE; CHILDHOOD ASTHMA; NEWBORN-INFANTS; ATOPIC DISEASE; REACTIVITY; IGE; CHILDREN; ALLERGY	Background. Airway responsiveness to inhaled nonspecific bronchoconstrictive agents has been demonstrated in normal, healthy infants. However, it is unknown whether airway responsiveness is present from birth or if it develops as a result of subsequent insults to the respiratory tract. To investigate this question, we assessed airway responsiveness in 63 normal infants at a mean age of 4 1/2 weeks. Methods. Respiratory function was measured with use of the partial forced expiratory flow-volume technique to determine the maximal flow at functional residual capacity (V(maxFRC)). The infants inhaled nebulized histamine at sequentially doubled concentrations (0.125 to 8.0 g per liter), until a concentration was reached at which the V(maxFRC) fell by 40 percent from the base-line value (PC40) or until a concentration of 8.0 g per liter was reached. We also assessed maternal serum levels of IgE, cord-serum levels of IgE, the infants' skin reactivity to several allergens, and the parents' responsiveness to histamine and obtained family histories of asthma and smoking. Results. Airway responsiveness was increased in infants with a family history of asthma (n = 19; median PC40, 0.78 g per liter; 95 percent confidence interval, 0.44 to 1.15; P < 0.01), parental smoking (n = 13; median PC40, 0.52 g per liter; 95 percent confidence interval, 0.43 to 5.40; P < 0.05), or both (n = 20; median PC40, 0.69 g per liter; 95 percent confidence interval, 0.37 to 2.10; P < 0.05), as compared with the infants with no family history of asthma or smoking. The infants with no family history of asthma or smoking had a median PC40 of 2.75 g per liter (95 percent confidence interval, 1.48 to 4.00). No significant relations were detected between the immunologic variables and the PC40 in the infants. Conclusions. This study indicates that airway responsiveness can be present early in life and suggests that a family history of asthma or parental smoking contributes to elevated levels of airway responsiveness at an early age.	PRINCESS MARGARET HOSP,CLIN IMMUNOL RES UNIT,PERTH,WA 6001,AUSTRALIA		YOUNG, S (corresponding author), PRINCESS MARGARET HOSP,DEPT RESP MED,POB D184,PERTH,WA 6001,AUSTRALIA.		Le Souef, Peter N/H-5256-2014; Stick, Stephen/AAA-5945-2021; Stick, Stephen/O-5683-2014; Stick, Stephen/GZG-7584-2022	Stick, Stephen/0000-0002-5386-8482; Le Souef, Peter/0000-0003-0930-1654				BENSON MK, 1977, J APPL PHYSIOL, V43, P643, DOI 10.1152/jappl.1977.43.4.643; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; CADE JF, 1971, LANCET, V2, P186; CAMPBELL MJ, 1989, STATISTICS CONFIDENC, P71; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; GARDNER MJ, 1989, CONFIDENCE INTERVAL; GELLER DE, 1988, PEDIATR PULM, V4, P90, DOI 10.1002/ppul.1950040206; GELLERBERNSTEIN G, 1987, ALLERGY, V42, P85, DOI 10.1111/j.1398-9995.1987.tb02364.x; GERRARD JW, 1974, J PEDIATR, V5, P660; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; ORGEL HA, 1977, ANN ALLERGY, V39, P161; PRENDIVILLE A, 1987, THORAX, V42, P92, DOI 10.1136/thx.42.2.92; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P489, DOI 10.1111/j.1651-2227.1982.tb09457.x; Schwartz M, 1952, ACTA ALLERGOL S2, V5, P1; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SILVERMAN M, 1985, NEONATAL PEDIATRIC R, P161; STICK S M, 1990, American Review of Respiratory Disease, V141, pA283; TAUSSIG LM, 1982, J APPL PHYSIOL, V53, P1220, DOI 10.1152/jappl.1982.53.5.1220; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; TEPPER RS, 1987, J APPL PHYSIOL, V62, P1155, DOI 10.1152/jappl.1987.62.3.1155; TEPPER RS, 1987, AM REV RESPIR DIS, V136, P800; TURNER KJ, 1981, CLIN EXP IMMUNOL, V43, P458; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZAR JH, 1974, BIOSTAT ANAL, P109; [No title captured]	34	349	354	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1168	1173		10.1056/NEJM199104253241704	http://dx.doi.org/10.1056/NEJM199104253241704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011160				2022-12-24	WOS:A1991FH57200004
J	BUCHANAN, CR; PREECE, MA; MILNER, RDG				BUCHANAN, CR; PREECE, MA; MILNER, RDG			MORTALITY, NEOPLASIA, AND CREUTZFELDT-JAKOB DISEASE IN PATIENTS TREATED WITH HUMAN PITUITARY GROWTH-HORMONE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							DIABETES-INSIPIDUS; TURNERS SYNDROME; THERAPY; CHILDREN; TUMORS; LEUKEMIA; EXPERIENCE; DEFICIENCY; RECURRENCE; CHILDHOOD	Objective-To determine the cause of death and incidence of neoplasia in patients treated with human pituitary growth hormone. Design-A long term cohort study established to receive details of death certification and tumour registrations through the Office of Population Censuses and Surveys and NHS central register. Patients-All patients (1246 male, 662 female) treated for short stature with pituitary growth hormone under the Medical Research Council working party and health services human growth hormone committee. Main outcome measures-Death or development of neoplasia. Results-110 patients died (68 male, 42 female; aged 0.9-57 years) from 1972 to 1990. Fifty three deaths were from neoplasia responsible for growth hormone deficiency (27 craniopharyngioma, 24 other intracranial tumour, two leukaemia); two from histiocytosis X; and 13 from pituitary insufficiency. Six patients died of Creutzfeldt-Jakob disease, six of other neurological disorders, and eight of acute infection. Other deaths were apparently unrelated to growth hormone deficiency or its treatment. Seventeen tumours (in 16 patients) were identified during or after growth hormone treatment. Four were in patients with previous intracranial neoplasia and two were after cranial irradiation. Thirteen were intracranial, the others being Hodgkin's lymphoma, osteosarcoma, carcinoma of colon, and basal cell carcinoma. Conclusions-Recurrence or progression of intracranial tumours and potentially avoidable metabolic consequences of hypopituitarism were the main causes of death. Growth hormone treatment probably did not contribute to new tumour development. Creutzfeldt-Jakob disease after pituitary growth hormone treatment continues to occur in the United Kingdom. This cohort must remain under long term review.	INST CHILD HLTH,DEPT GROWTH & DEV,LONDON WC1N 1EH,ENGLAND; SHEFFIELD UNIV,CHILDRENS HOSP,DEPT PAEDIAT,SHEFFIELD S10 2TH,ENGLAND	University of London; University College London; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield								ARSLANIAN SA, 1985, AM J DIS CHILD, V139, P347, DOI 10.1001/archpedi.1985.02140060029020; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1988, NEUROLOGY, V38, P1135, DOI 10.1212/WNL.38.7.1135; BUCHANAN CR, 1987, ARCH DIS CHILD, V62, P912, DOI 10.1136/adc.62.9.912; CLAYTON PE, 1988, LANCET, V1, P642; CLAYTON PE, 1987, LANCET, V1, P711; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; DELEMARREVANDEWAAL HA, 1988, LANCET, V1, P1159; FARWELL J, 1984, J NEURO-ONCOL, V2, P371; FISHER DA, 1988, LANCET, V1, P1159; FRISCH H, 1988, LANCET, V1, P1335; GOUJARD J, 1988, INT J EPIDEMIOL, V17, P423, DOI 10.1093/ije/17.2.423; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; MILNER RDG, 1979, CLIN ENDOCRINOL, V11, P15, DOI 10.1111/j.1365-2265.1979.tb03043.x; MILNER RDG, 1987, ARCH DIS CHILD, V62, P776, DOI 10.1136/adc.62.8.776; NW MI, 1988, NEUROLOGY, V38, P1133; POWELLJACKSON J, 1985, LANCET, V2, P244; PREECE MA, 1986, NEUROPATH APPL NEURO, V12, P509, DOI 10.1111/j.1365-2990.1986.tb00061.x; PREECE MA, 1986, IMMUNOLOGICAL ASPECT, P9; RABEN MS, 1958, J CLIN ENDOCR METAB, V18, P901, DOI 10.1210/jcem-18-8-901; REDMAN GP, 1988, LANCET, V1, P1335; RODENS KP, 1987, ACTA ENDOCR-COP    S, V283, P188; SHERWOOD MC, 1986, ARCH DIS CHILD, V61, P1222, DOI 10.1136/adc.61.12.1222; STAHNKE N, 1989, EUR J PEDIATR, V148, P591, DOI 10.1007/BF00441506; STANDEN GR, 1989, AM J HEMATOL, V31, P280, DOI 10.1002/ajh.2830310413; STANHOPE R, 1989, BRIT J HOSP MED, V41, P490; TANNER JM, 1971, ARCH DIS CHILD, V46, P745, DOI 10.1136/adc.46.250.745; WATANABE S, 1988, LANCET, V1, P1159; WELLER RO, 1986, NEUROPATH APPL NEURO, V12, P117, DOI 10.1111/j.1365-2990.1986.tb00045.x; WHITEHEAD HM, 1989, ULSTER MED J, V58, P153; 1986, ANN NEUROL, V19, P75; 1986, MORTALITY STATIS DH2	32	108	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					824	828		10.1136/bmj.302.6780.824	http://dx.doi.org/10.1136/bmj.302.6780.824			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025705	Green Published, Bronze			2022-12-24	WOS:A1991FF37700025
J	WARREN, N; HOLMES, JA; ALJADER, L; WEST, RR; LEWIS, DC; PADUA, RA				WARREN, N; HOLMES, JA; ALJADER, L; WEST, RR; LEWIS, DC; PADUA, RA			FREQUENCY OF CARRIERS OF CYSTIC-FIBROSIS GENE AMONG PATIENTS WITH MYELOID MALIGNANCY AND MELANOMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL CARDIFF,DEPT HAEMATOL,PRELEUKAEMIA UNIT,LEUKAEMIA RES FUND,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			PADUA, Rose Ann/E-8621-2019; Padua, Rose Ann/GVT-5961-2022	PADUA, Rose Ann/0000-0001-9964-7864; 				ALJADER LN, 1989, BRIT MED J, V298, P164, DOI 10.1136/bmj.298.6667.164; ALJADER LN, 1991, ARCH DIS CHILD, V66, P317, DOI 10.1136/adc.66.3.317; ESTIVILL X, 1989, LANCET, V2, P140; MCINTOSH I, 1989, LANCET, V2, P1404; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657	5	19	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					760	761		10.1136/bmj.302.6779.760	http://dx.doi.org/10.1136/bmj.302.6779.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021766	Green Published, Bronze			2022-12-24	WOS:A1991FF22900023
J	BLUM, A				BLUM, A			THE MARLBORO GRAND-PRIX - CIRCUMVENTION OF THE TELEVISION BAN ON TOBACCO ADVERTISING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BLUM, A (corresponding author), BAYLOR UNIV,HOUSTON,TX 77005, USA.							BLUM A, 1985, NEW YORK STATE J MED, V85, P458; BUCHANAN DR, 1990, BEER FAST CARS BREWE, P25; DRAPE J, 1990, ATLANTA J CONST 0729, pA1; DRAPE J, 1990, ATLANTA J CONST 0729, pA12; FORKAN JP, 1986, ADVERTISING AGE 0324, P45; HARVEY P, 1991, RACETIME         NOV, P34; JOHNSON ME, 1990, ADVERTISING AGE 1105, P36; KING W, 1975, NY TIMES        0713, P36; KOTEN J, 1990, WALL STREET J   0524, pA1; KOTEN J, 1990, WALL STREET J   0524, P9; MILLER C, 1983, MED J AUSTRALIA, V1, P242; RAEBURN P, 1990, IDAHO STATESMAN 0115, pD1; WALTZ K, 1990, NATIONAL SPEED  1128, P8; 1989, TNN, V2, P1; 1991, RACETIME         NOV, P10; 1990, WHO REGIONAL PUBLICA, V30, P43; 1990, NATIONAL DRAGST 1207, P29; 1990, AUSTR HIGH COURT UPH; 1990, MMWR, V39, P261; 1989, CART, V7, P1	20	50	50	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					913	916		10.1056/NEJM199103283241310	http://dx.doi.org/10.1056/NEJM199103283241310			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000115				2022-12-24	WOS:A1991FD11100010
J	CLINTON, JJ				CLINTON, JJ			PHYSICIAN INPUT INVITED ON CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AGCY HLTH CARE POLICY & RES,ROCKVILLE,MD 20857	Agency for Healthcare Research & Quality								1990, FED REG         1210, P55	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1508	1508		10.1001/jama.265.12.1508	http://dx.doi.org/10.1001/jama.265.12.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999893				2022-12-24	WOS:A1991FC60400005
J	HUANG, S; LEE, WH; LEE, EYHP				HUANG, S; LEE, WH; LEE, EYHP			A CELLULAR PROTEIN THAT COMPETES WITH SV40 T-ANTIGEN FOR BINDING TO THE RETINOBLASTOMA GENE-PRODUCT	NATURE			English	Article							SUSCEPTIBILITY GENE; EXPRESSION; CELLS	TUMOUR-suppressor genes, such as the human retinoblastoma susceptibility gene (Rb), are widely recognized as being vital in the control of cell growth and tumour formation 1. This role is indicated, in part, by the suppression of tumorigenicity of human tumour cells after retrovirus-mediated Rb replacement 2-4. How Rb acts to bring about this suppression is not clear 5 but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses 6-8, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells 9,10. These observations suggest that endogenous cellular proteins might exist that bind to the same regions of Rb and thereby mediate its function. We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46). Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb. The apparent targeting of the RbAP46-Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.			HUANG, S (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093, USA.							BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; Lee W.-H., 1990, TUMOR SUPPRESSOR GEN, P169; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807	18	145	165	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					160	162		10.1038/350160a0	http://dx.doi.org/10.1038/350160a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005966				2022-12-24	WOS:A1991FB64500061
J	RAUB, W				RAUB, W			COMBINED AGENTS ELIMINATE HUMAN HIV-1 FROM T-CELL CULTURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1990, P NATL ACAD SCI USA, V87, P8889	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1075	1075						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995987				2022-12-24	WOS:A1991EZ47400005
J	SORIANO, P; MONTGOMERY, C; GESKE, R; BRADLEY, A				SORIANO, P; MONTGOMERY, C; GESKE, R; BRADLEY, A			TARGETED DISRUPTION OF THE C-SRC PROTOONCOGENE LEADS TO OSTEOPETROSIS IN MICE	CELL			English	Article							AVIAN-SARCOMA VIRUSES; DEVELOPING RAT-BRAIN; GENE-PRODUCT; STEM-CELLS; HOMOLOGOUS RECOMBINATION; NUCLEOTIDE-SEQUENCE; TYROSINE KINASE; SPLEEN-CELLS; PP60C-SRC; EXPRESSION	To understand the normal, physiological role of the c-src proto-oncogene, a null mutation was introduced into the gene by homologous recombination in mouse embryonic stem cells. Two independent targeted clones were used to generate chimeras that transmitted the mutated allele to their offspring. Intercrossing of heterozygotes gave rise to live born homozygotes, but most of these mice died within the first few weeks of birth. Histological and hematological examination of the homozygous mutants did not reveal detectable abnormalities in the brain or platelets, where src is most highly expressed. However, these mutants were deficient in bone remodeling, indicating impaired osteoclast function, and developed osteopetrosis. These results demonstrate that src is not required for general cell viability (possibly because of functional overlap with other tyrosine kinases related to src) and uncover an essential role for src in bone formation.	BAYLOR UNIV, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR UNIV, CTR COMPARAT MED, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor University; Baylor University	SORIANO, P (corresponding author), BAYLOR UNIV, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Bradley, Allan/0000-0002-2349-8839	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875, R01HD025326, R37HD025326] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24875, HD25326] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAIR GM, 1989, P NATL ACAD SCI USA, V86, P4574, DOI 10.1073/pnas.86.12.4574; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOLDEN A, 1988, ONCOGENE HDB, V7; Green MC., 1989, GENETIC VARIANTS STR, P12; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JONES KL, 1988, SMITHS RECOGNIZABLE, P353; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Luna LG, 1968, MANUAL HISTOLOGIC ST; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	51	1852	1923	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					693	702		10.1016/0092-8674(91)90499-O	http://dx.doi.org/10.1016/0092-8674(91)90499-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997203				2022-12-24	WOS:A1991EZ47800005
J	MIRKIN, G				MIRKIN, G			ESTROGEN IN YAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MIRKIN, G (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20057, USA.							BLUNDEN G, 1967, J PHARM SCI, V56, P948, DOI 10.1002/jps.2600560804; BLUNDEN G, 1968, J PHARM SCI, V57, P602, DOI 10.1002/jps.2600570411; Chakravarti R N, 1966, Bull Calcutta Sch Trop Med, V14, P45; CURNOW DH, 1954, BIOCHEM J, V58, P283, DOI 10.1042/bj0580283	4	13	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					912	912						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992191				2022-12-24	WOS:A1991EX58700048
J	WOOD, WB				WOOD, WB			EVIDENCE FROM REVERSAL OF HANDEDNESS IN C-ELEGANS EMBRYOS FOR EARLY CELL-INTERACTIONS DETERMINING CELL FATES	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LINEAGES; GLP-1	MANY animals with overall bilateral symmetry also exhibit some left-right asymmetries with generally invariant handedness. Therefore, the left-right embryonic axis must have a consistent polarity, whose origins and subsequent effects on development are not understood (reviewed in ref. 1). Caenorhabditis elegans exhibits such left-right asymmetries at all developmental stages. The embryonic cell lineage is asymmetric as well: although the animal is generally bilaterally symmetric, many of its contralaterally analogous cells arise from different lineages on the two sides of the embryo 2,3. I accomplished reversal of embryonic handedness by micromanipulation at the 6-cell stage, which resulted in mirror-image but otherwise normal development into healthy, fertile animals with all the usual left-right asymmetries reversed. This result demonstrates that in the 6-cell embryo the pair of anterior (AB) blastomeres on the right is equivalent to the pair on the left, and that the extensive differences in fates between lineally homologous derivatives of these cells on the two sides of the animals must be dictated by cell interactions, most of which are likely to occur early in embryogenesis.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	WOOD, WB (corresponding author), UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOX 347,BOULDER,CO 80309, USA.							Bonfig R, 1925, Z WISS ZOOL ABT A, V124, P407; BROWN NA, 1990, DEVELOPMENT, V109, P1; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; DEPPE U, 1978, P NATL ACAD SCI USA, V75, P376, DOI 10.1073/pnas.75.1.376; Dunschen F., 1929, Archiv fuer Entwicklungsmechanik der Organismen Berlin, V115, P237; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; STRASSEN OZ, 1896, ARCH ENTWICKLUNGSMEC, V3, P27; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1983, COLD SPRING HARB SYM, V48, P443, DOI 10.1101/SQB.1983.048.01.049; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	18	147	148	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					536	538		10.1038/349536a0	http://dx.doi.org/10.1038/349536a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992354				2022-12-24	WOS:A1991EW57100071
J	MASON, JO				MASON, JO			A MESSAGE TO HEALTH-PROFESSIONALS ABOUT FLUOROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US PHS,DIV NEWS,ROOM 719H,200 INDEPENDENCE AVE SW,WASHINGTON,DC 20201, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2939	2939						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033755				2022-12-24	WOS:A1991FP63500009
J	RANIERI, E; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; POLLARD, AC; ROBERTSON, EF				RANIERI, E; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; POLLARD, AC; ROBERTSON, EF			NEONATAL SCREENING STRATEGY FOR CYSTIC-FIBROSIS USING IMMUNOREACTIVE TRYPSINOGEN AND DIRECT GENE ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							ASSAY; POPULATION; MUTATIONS	Objective - To assess the effectiveness of a two tier neonatal screening strategy for cystic fibrosis, which combines estimation of immunoreactive trypsinogen followed by direct gene analysis in dried blood spot samples collected at age 5 days. Design - Prospective study of two tier screening strategy. The first tier of testing immunoreactive trypsinogen concentration was measured in dried blood spot samples from neonates aged 4-5 days. In the second tier direct gene analysis to detect cystic fibrosis mutations DELTA-F508 and DELTA-I506 was performed in those blood spot ssmples which produced the highest 1% of immunoreactive trypsinogen values. Direct gene analysis was also performed on blood spot samples from infants with suspected or confirmed meconium ileus, regardless of the immunoreactive trypsinogen value. Setting - The South Australian Neonatal Screening Programme, operating from the department of chemical pathology at Adelaide Children's Hospital. Subjects - All 12 056 neonates born in South Australia between December 1989 and June 1990. No selection criteria were applied. Interventions - All infants found to have two recognised cystic fibrosis mutations on direct gene analysis were referred directly for clinical management, and those with one recognised cystic fibrosis mutation were recalled for a sweat test; their families were given genetic counselling. Main outcome measures - Diagnosis or exclusion of cystic fibrosis by sweat testing of neonates identified as being at high risk of cystic fibrosis on screening and of those at minimum risk but whose subsequent clinical history raised suspicion about the disease. Results - Of the 12 056 infants screened, 11 907 (98.8%) were reported as "cystic fibrosis not indicated" on the basis of low immunoreactive trypsinogen values. Of the 148 (1.23%) infants with raised immunoreactive trypsinogen values and one (0.008%) with meconium ileus, 132 (1.09%) were reported as cystic fibrosis not indicated, four (0.033%) were identified as having cystic fibrosis, and 13 (0.108%) were recalled for sweat testing after direct gene analysis for the presence of the DELTA-F508 and DELTA-I506 cystic fibrosis mutations. No cases of affected infants are known to have been missed to date. Conclusion - The strategy of measurement of immunoreactive trypsinogen followed by direct gene analysis is a highly specific neonatal screen for cystic fibrosis, requiring only 2.8 families to be contacted for every case of cystic fibrosis diagnosed.	ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,SCREENING LAB,ADELAIDE,SA 5006,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,SPECIAL DIAGNOST LAB,ADELAIDE,SA 5006,AUSTRALIA					Morris, Phillip/0000-0001-8976-619X				ADRIAENSSENS K, 1981, LANCET, V1, P833; [Anonymous], 1983, PEDIATRICS; BOWLING FG, 1987, ADV NEONATAL SCREENI, P391; CASSIO A, 1984, ACTA PAEDIATR SCAND, V73, P554, DOI 10.1111/j.1651-2227.1984.tb09970.x; CHATFIELD S, 1991, ARCH DIS CHILD-FETAL, V66, P29, DOI 10.1136/adc.66.1_Spec_No.29; CORSSLEY JP, 1979, LANCET, V2, P472; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; DIAMANDIS EP, 1988, CLIN BIOCHEM, V21, P139, DOI 10.1016/S0009-9120(88)80104-8; GIBSON LE, 1959, PEDIATRICS, V23, P545; HAMMOND K, 1987, ADV NEONATAL SCREENI, P377; HEELEY AF, 1982, ARCH DIS CHILD, V57, P18; KEREM B, 1989, SCIENCE, V284, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KING DN, 1979, LANCET, V2, P1217; NELSON PV, 1990, MED J AUSTRALIA, V152, P328, DOI 10.5694/j.1326-5377.1990.tb120962.x; PEDERZINI F, 1984, LANCET, V1, P959; ROCK MJ, 1990, PEDIATRICS, V85, P1001; RYLEY HC, 1988, J CLIN PATHOL, V41, P726, DOI 10.1136/jcp.41.7.726; WESLEY AW, 1989, AUST PAEDIATR J, V25, P151; WILKEN B, 1985, LANCET, V2, P1319; WILKEN B, 1987, ADV NEONATAL SCREENI, P385; WILKEN B, 1983, J PEDIATR, V102, P383	23	54	54	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1237	1240		10.1136/bmj.302.6787.1237	http://dx.doi.org/10.1136/bmj.302.6787.1237			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043846	Green Published, Bronze			2022-12-24	WOS:A1991FP27200021
J	VAGELOS, PR				VAGELOS, PR			ARE PRESCRIPTION DRUG PRICES HIGH	SCIENCE			English	Article							COENZYME-A REDUCTASE; FAMILIAL HYPERCHOLESTEROLEMIA; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; HYDROXYMETHYLGLUTARYL-COENZYME; CHOLESTEROL; MEVINOLIN; INHIBITOR; FIBROBLASTS; ML-236A; COSTS	The U.S. pharmaceutical industry has been criticized because its products are perceived to be too expensive, yet prescription medicines remain the least expensive form of therapy. At this time, we are experiencing a dramatic increase in the risks and costs of pharmaceutical research and development (R&D). An example may be seen in the R&D history of lovastatin. The U.S. pharmaceutical industry continues to lead the world in the discovery and development of important new medicines because it assumes greater financial risk and invests more of its sales dollar in R&D than virtually any other industry. Where such a risk is posed, there must continue to be the potential for profits. Pharmaceutical companies must set responsible prices, must keep price increases down, and must help improve access to important medicines.			VAGELOS, PR (corresponding author), MERCK & CO INC,RAHWAY,NJ 07065, USA.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ALBERTSSCHONBERG G, 1980, Patent No. 4231938; Anitschkow N, 1913, BEITR PATHOL ANAT AL, V56, P379; BILHEIMER DW, 1983, T ASSOC AM PHYSICIAN, V96, P1; Bloch K, 1942, J BIOL CHEM, V145, P625; BROUN M, 1990, J NATL CANCER I, V82, P1811; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BUCHER NLR, 1960, BIOCHIM BIOPHYS ACTA, V40, P491, DOI 10.1016/0006-3002(60)91390-1; CHANG TY, 1976, P NATL ACAD SCI USA, V73, P24, DOI 10.1073/pnas.73.1.24; CHANG TY, 1977, P NATL ACAD SCI USA, V74, P832, DOI 10.1073/pnas.74.3.832; CLAYTON RB, 1956, J BIOL CHEM, V218, P319; DIMASI JA, IN PRESS J HLTH; ECKHOLM E, 1989, NY TIMES MAGAZI 0108, P20; EISENBERG JM, 1984, REV INFECT DIS S4, V6, P909; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENDO A, 1979, J ANTIBIOT, V32, P852, DOI 10.7164/antibiotics.32.852; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; GOLDSTEIN JL, 1973, P NATL ACAD SCI USA, V70, P2804, DOI 10.1073/pnas.70.10.2804; GOULD RG, 1950, FED PROC, V9, P179; GRABOWSKI H, 1990, MANAGE SCI, V36, P804, DOI 10.1287/mnsc.36.7.804; HANSEN R, 1976, THESIS U ROCHESTER; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HUANG LF, 1988, PUBLIC HEALTH REP, V103, P3; ILLINGWORTH DR, 1984, J CLIN INVEST, V74, P1972, DOI 10.1172/JCI111618; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; Lubitz J, 1985, Health Care Financ Rev, V6, P103; LYNEN F, 1959, ANGEW CHEM INT EDIT, V71, P657, DOI 10.1002/ange.19590712102; MACDONALD JS, 1988, AM J CARDIOL, V62, pJ16, DOI 10.1016/0002-9149(88)90003-3; MANDELLBROWN M, 1984, OTOLARYNG HEAD NECK, V92, P520, DOI 10.1177/019459988409200504; MOSSINGHOFF G, 1989, COMMUNICATION   0718; NARIN F, 1989, SCIENCE, V245, P600, DOI 10.1126/science.245.4918.600; OTTKE RC, 1951, J BIOL CHEM, V189, P429; RISTOW W, 1990, NOV IMS INT PLYM M; SILVERBERG SH, 1990, COMMUNICATION    NOV; SLOAN FA, 1989, UNPUB DRUG FORMULARI; TAVORMINA PA, 1956, J AM CHEM SOC, V78, P4498, DOI 10.1021/ja01598a089; TOBERT JA, 1982, ATHEROSCLEROSIS, V41, P61, DOI 10.1016/0021-9150(82)90070-3; TOBERT JA, 1982, J CLIN INVEST, V69, P913, DOI 10.1172/JCI110530; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; WOODWARD RB, 1953, J AM CHEM SOC, V75, P2023, DOI 10.1021/ja01104a535; WRIGHT LD, 1956, J AM CHEM SOC, V78, P5273, DOI 10.1021/ja01601a033; 1985, MODERN MED SAVINGS L; 1986, JAMA-J AM MED ASSOC, V256, P2829; 1988, JAMA-J AM MED ASSOC, V260, P359; 1988, PUBLIC HLTH REP, V103, P206; 1989, HLTH US 1989, P228; 1983, VITAL HLTH STATISTIC, V10; 1987, METROPOLITAN LIF JUL, P15; 1989, STATISTICAL ABSTRACT	50	95	98	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1080	1084		10.1126/science.252.5009.1080	http://dx.doi.org/10.1126/science.252.5009.1080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN056	2031182				2022-12-24	WOS:A1991FN05600032
J	MADSEN, EL; SINCLAIR, JL; GHIORSE, WC				MADSEN, EL; SINCLAIR, JL; GHIORSE, WC			INSITU BIODEGRADATION - MICROBIOLOGICAL PATTERNS IN A CONTAMINATED AQUIFER	SCIENCE			English	Article							DEEP SUBSURFACE SEDIMENTS; MICROBIAL ECOLOGY; ORGANIC-COMPOUNDS; WASTE SITE; BACTERIA; DEGRADATION; PROTOZOA; OKLAHOMA; WATER; FIELD	Conventional approaches for proving in situ biodegradation of organic pollutants in aquifers have severe limitations. In the approach described here, patterns in a comprehensive set of microbiological activity and distribution data were analyzed. Measurements were performed on sediment samples gathered at consistent depths in aquifer boreholes spanning a gradient of contaminant concentrations at a buried coal tar site. Microbial adaptation to polyaromatic hydrocarbons (PAHs) was demonstrated by mineralization of naphthalene and phenanthrene in samples from PAH-contaminated, but not adjacent pristine, zones. Furthermore, contaminant-stimulated in situ bacterial growth was indicated because enhanced numbers of protozoa and their bacterial prey were found exclusively in contaminated subsurface samples. The data suggest that many convergent lines of logically linked indirect evidence can effectively document in situ biodegradation of aquifer contaminants.			MADSEN, EL (corresponding author), CORNELL UNIV,DIV BIOL SCI,MICROBIOL SECT,ITHACA,NY 14853, USA.							ALEXANDER M, 1981, SCIENCE, V211, P132, DOI 10.1126/science.7444456; [Anonymous], 1984, PETROLEUM MICROBIOLO; BALKWILL DL, 1985, APPL ENVIRON MICROB, V50, P580, DOI 10.1128/AEM.50.3.580-588.1985; BORDEN RC, 1987, WATER RESOUR BULL, V23, P629; BROCK TD, 1988, BIOL MICROORGANISMS, P5; CHAPELLE FH, 1990, APPL ENVIRON MICROB, V56, P1865, DOI 10.1128/AEM.56.6.1865-1874.1990; CHIANG CY, 1989, GROUND WATER, V27, P823, DOI 10.1111/j.1745-6584.1989.tb01046.x; CLINE PV, 1985, WASTE MANAGE RES, V3, P351, DOI 10.1016/0734-242X(85)90128-4; CURDS CR, 1982, ANNU REV MICROBIOL, V36, P27, DOI 10.1146/annurev.mi.36.100182.000331; DAGLEY S, 1977, SURV PROG CHEM, V8, P121; EVANS WC, 1977, NATURE, V270, P17, DOI 10.1038/270017a0; FEDERLE TW, 1988, GROUND WATER, V26, P761, DOI 10.1111/j.1745-6584.1988.tb00427.x; Fenchel T., 1987, ECOLOGY OF PROTOZOA, DOI [10.1007/978-3-662-06817-5, DOI 10.1007/978-3-662-06817-5, DOI 10.1007/978-3-662-25981-8]; Floodgate G.D., 1984, PETROLEUM MICROBIOLO, P355; Foissner W., 1987, Progress in Protistology, V2, P69; FREDRICKSON JK, 1989, GEOMICROBIOL J, V7, P53, DOI 10.1080/01490458909377849; GHIORSE WC, 1988, ADV APPL MICROBIOL, V33, P107, DOI 10.1016/S0065-2164(08)70206-5; HARTWIG E, 1984, Senckenbergiana Maritima, V16, P121; Karl DM., 1986, METHODS SPECIAL APPL, V2, P85; KLECKA GM, 1990, GROUND WATER, V28, P534, DOI 10.1111/j.1745-6584.1990.tb01709.x; Kolwitz R., 1909, INT REV GES HYDROBIO, V2, P126; LEAHY JG, 1990, MICROBIOL REV, V54, P305, DOI 10.1128/MMBR.54.3.305-315.1990; LEE MD, 1988, CRIT REV ENV CONTR, V18, P29, DOI 10.1080/10643388809388342; LEVINS SN, 1991, 1ST P INT S MICR DEE; MARTIN JP, 1980, LIGNIN BIODEGRADATIO, V1, P77; Moriarty F., 1988, ECOTOXICOLOGY STUDY; PIATT JF, 1990, AUK, V107, P387, DOI 10.2307/4087623; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; RAYMOND RL, 1976, APPL ENVIRON MICROB, V31, P522, DOI 10.1128/AEM.31.4.522-535.1976; RIDGWAY HF, 1990, APPL ENVIRON MICROB, V56, P3565, DOI 10.1128/AEM.56.11.3565-3575.1990; ROGERSON A, 1983, J GEN APPL MICROBIOL, V29, P41, DOI 10.2323/jgam.29.41; ROSZAK DB, 1987, MICROBIOL REV, V51, P365, DOI 10.1128/MMBR.51.3.365-379.1987; SINCLAIR JL, 1989, GEOMICROBIOL J, V7, P15, DOI 10.1080/01490458909377847; SINCLAIR JL, 1987, APPL ENVIRON MICROB, V53, P1157, DOI 10.1128/AEM.53.5.1157-1163.1987; SINCLAIR JL, 1991, 1ST P INT S MICR DEE; SPAIN JC, 1984, APPL ENVIRON MICROB, V48, P944, DOI 10.1128/AEM.48.5.944-950.1984; Stout J.D., 1980, Advances in Microbial Ecology, V4, P1; TAYLOR BB, P ENV RES C GROUNDWA; THOMAS JM, 1989, J IND MICROBIOL, V4, P109, DOI 10.1007/BF01569795; TRIBE H. T., 1961, Soil Science, V92, P61, DOI 10.1097/00010694-196107000-00009; VESTAL JR, 1984, PETROLEUM MICROBIOLO, P475; VILLAUME JF, 1984, HAZARDOUS TOXIC WAST, P362; WILSON JT, 1985, ENVIRON TOXICOL CHEM, V4, P721, DOI 10.1002/etc.5620040602; WILSON JT, 1983, GROUND WATER, V21, P134, DOI 10.1111/j.1745-6584.1983.tb00710.x; 1990, GROUND WATER, V28, P715	45	168	170	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					830	833		10.1126/science.2028258	http://dx.doi.org/10.1126/science.2028258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028258				2022-12-24	WOS:A1991FL12300042
J	RAUB, WF				RAUB, WF			TRANSGENIC MICE ALLOW RAPID TESTING OF AGENTS THAT REVERSE MULTIDRUG RESISTANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P547	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-24	WOS:A1991FH87700007
J	MCHEYZERWILLIAMS, MG; NOSSAL, GJV; LALOR, PA				MCHEYZERWILLIAMS, MG; NOSSAL, GJV; LALOR, PA			MOLECULAR CHARACTERIZATION OF SINGLE MEMORY B-CELLS	NATURE			English	Article							SOMATIC MUTATION; IMMUNE-RESPONSE; ANTIBODY REPERTOIRE; MOUSE; HYPERMUTATION; GENERATION; ANTIGEN; MICE; DNA; NP	PRIMARY antigenic exposure results in an initial antibody response and the T cell-dependent induction of B-cell memory 1,2. Memory B-cell differentiation is characterized by somatic hypermutation in antibody variable region genes (V) and selection of B cells expressing high-affinity variants of this antigen receptor 3-5. Despite our current understanding of B-cell memory 6-8, the origin of memory B cells and the regulation of their differentiation remain elusive. This is largely due to the difficulties in observing and purifying this minor component of the immunized spleen. Further, molecular characterization of memory B cells requires hybridoma formation which restricts analyses to only those clones capable of fusion and does not allow isolation of cells in a normal physiological state. We have therefore developed a unique system which allows isolation and unambiguous enumeration of IgG1+ memory B cells, based on six-parameter flow cytometry, secretion of antibody in clonal cultures and analysis of clonally expressed V genes using the polymerase chain reaction 9. Here we report that single IgG1+ antigen-binding B cells from an early secondary immune response proliferate in lipopolysaccharide-driven microcultures and produce antigen-specific IgG1 antibodies. Individual B-cell clones in these cultures express somatically mutated heavy chain V genes, confirming their designation as memory B cells. Although isolated memory B cells undergo extensive proliferation in vitro, V gene sequence analysis of their individual progeny shows that further hypermutation does not occur.			MCHEYZERWILLIAMS, MG (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.							ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; IMANISHI T, 1973, EUR J IMMUNOL, V3, P323, DOI 10.1002/eji.1830030602; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; LALOR PA, 1990, EUR J IMMUNOL, V20, P485, DOI 10.1002/eji.1830200305; LALOR PA, 1989, EUR J IMMUNOL, V19, P501, DOI 10.1002/eji.1830190314; LEBECQUE SG, IN PRESS J EXP MED; LEVY NS, 1989, J EXP MED, V169, P2007, DOI 10.1084/jem.169.6.2007; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MANSER T, 1990, IMMUNOL TODAY, V11, P305, DOI 10.1016/0167-5699(90)90124-R; MCHEYZERWILLIAMS MG, 1989, EUR J IMMUNOL, V19, P2025, DOI 10.1002/eji.1830191109; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P6350, DOI 10.1073/pnas.79.20.6350; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; TAO W, 1990, J IMMUNOL, V145, P3216; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	30	136	137	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					502	505		10.1038/350502a0	http://dx.doi.org/10.1038/350502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014051				2022-12-24	WOS:A1991FG14300052
J	RITTER, AM; LEWIN, GR; KREMER, NE; MENDELL, LM				RITTER, AM; LEWIN, GR; KREMER, NE; MENDELL, LM			REQUIREMENT FOR NERVE GROWTH-FACTOR IN THE DEVELOPMENT OF MYELINATED NOCICEPTORS INVIVO	NATURE			English	Article							HAIRY SKIN; RAT; MECHANORECEPTORS; RECEPTOR; SURVIVAL	IN adult animals, sensory neurons innervating the skin are phenotypically diverse 1-3. We have now investigated whether nerve growth factor (NGF) has a physiological role in the development of this diversity. We gave antisera against NGF to rats from postnatal day 1 (PND 1) to adulthood (5 weeks). We found a virtually complete depletion of high threshold mechanoreceptors conducting in the A-delta range (2-13 m s-1) in the sural nerve. This afferent type, normally present in large numbers, appeared to have been replaced by D-hair afferents, sensitive mechanoreceptors which normally are relatively rare. NGF deprivation had this effect only in early postnatal life; treatment from postnatal day 14 to adulthood had no effect. We conclude that the presence of NGF postnatally in skin is necessary for the proper phenotypic development of A-delta cutaneous nociceptors.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Lewin, Gary R/B-8028-2011	Lewin, Gary/0000-0002-2890-6352; Mendell, Lorne/0000-0003-1540-8837				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BURGESS PR, 1967, J PHYSIOL-LONDON, V190, P541, DOI 10.1113/jphysiol.1967.sp008227; Burgess PR, 1973, HDB SENSORY PHYSIOLO, VII, P29; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; FITZGERALD M, 1987, J PHYSIOL-LONDON, V383, P79; FITZGERALD MI, 1966, J COMP NEUROL, V126, P37, DOI 10.1002/cne.901260103; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; HANDWERKER HO, 1985, DEV ORG PROCESSING S, P289; HORCH KW, 1977, J INVEST DERMATOL, V69, P75, DOI 10.1111/1523-1747.ep12497887; HULSEBOSCH CE, 1987, J COMP NEUROL, V259, P445, DOI 10.1002/cne.902590310; KOERBER HR, 1988, J NEUROPHYSIOL, V60, P1584, DOI 10.1152/jn.1988.60.5.1584; KRUGER L, 1981, J COMP NEUROL, V198, P137, DOI 10.1002/cne.901980112; LEWIN GR, 1989, J PHYSIOL-LONDON, V412, pP26; LYNN B, 1982, BRAIN RES, V238, P29, DOI 10.1016/0006-8993(82)90768-5; LYNN B, 1988, NEUROSCI LETT, V85, P71, DOI 10.1016/0304-3940(88)90431-4; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; YIP HK, 1984, J NEUROSCI, V4, P2986	17	140	141	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					500	502		10.1038/350500a0	http://dx.doi.org/10.1038/350500a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014050				2022-12-24	WOS:A1991FG14300051
J	LILJA, GMC				LILJA, GMC			SINGLE UMBILICAL ARTERY AND MATERNAL SMOKING	BRITISH MEDICAL JOURNAL			English	Article											LILJA, GMC (corresponding author), UNIV LUND,DEPT EMBRYOL,S-22362 LUND,SWEDEN.							ASMUSSEN I, 1975, CIRC RES, V36, P579, DOI 10.1161/01.RES.36.5.579; BRYAN EM, 1974, ARCH DIS CHILD, V49, P844, DOI 10.1136/adc.49.11.844; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; LILJA M, 1991, PAEDIATRIC PERINATAL, V1, P27; MANTEL N, 1959, J NATL CANCER I, V22, P719	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					569	570		10.1136/bmj.302.6776.569	http://dx.doi.org/10.1136/bmj.302.6776.569			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB936	2021721	Bronze, Green Published			2022-12-24	WOS:A1991FB93600020
J	ROSE, GE; PEARSON, RV				ROSE, GE; PEARSON, RV			UNEQUAL PUPIL SIZE IN PATIENTS WITH UNILATERAL RED EYE	BRITISH MEDICAL JOURNAL			English	Article											ROSE, GE (corresponding author), MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND.							ALEXANDRIDIS E, 1985, PUPIL; ARMITAGE P, 1985, STATISTICAL METHODS, P111; ELKINGTON AR, 1988, BRIT MED J, V296, P1720, DOI 10.1136/bmj.296.6638.1720; Loewenfeld IE., 1979, TOPICS NEUROOPHTHALM, P124; MEYER BC, 1947, ARCH NEURO PSYCHIATR, V57, P464, DOI 10.1001/archneurpsyc.1947.02300270082005	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					571	572		10.1136/bmj.302.6776.571	http://dx.doi.org/10.1136/bmj.302.6776.571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021723	Bronze, Green Published			2022-12-24	WOS:A1991FB93600022
J	GOLINO, P; PISCIONE, F; WILLERSON, JT; CAPPELLIBIGAZZI, M; FOCACCIO, A; VILLARI, B; INDOLFI, C; RUSSOLILLO, E; CONDORELLI, M; CHIARIELLO, M				GOLINO, P; PISCIONE, F; WILLERSON, JT; CAPPELLIBIGAZZI, M; FOCACCIO, A; VILLARI, B; INDOLFI, C; RUSSOLILLO, E; CONDORELLI, M; CHIARIELLO, M			DIVERGENT EFFECTS OF SEROTONIN ON CORONARY-ARTERY DIMENSIONS AND BLOOD-FLOW IN PATIENTS WITH CORONARY ATHEROSCLEROSIS AND CONTROL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; VASOCONSTRICTOR ACTIVITY; SUBSELECTIVE MEASUREMENT; RECEPTOR ANTAGONISTS; THROMBOXANE; KETANSERIN; DOGS; 5-HYDROXYTRYPTAMINE; VASODILATOR; RESPONSES	Background. Studies in animals have shown that serotonin constricts coronary arteries if the endothelium is damaged, but in vitro studies have revealed a vasodilating effect on isolated coronary segments with an intact endothelium. To investigate the effect of serotonin in humans, we studied coronary-artery cross-sectional area and blood flow before and after the infusion of serotonin in seven patients with angiographically normal coronary arteries and in seven with coronary artery disease. Methods. We measured the cross-sectional area of the coronary artery by quantitative angiography and coronary blood flow with an intracoronary Doppler catheter. Measurements were obtained at base line and during intracoronary infusions of serotonin (0.1, 1, and 10-mu-g per kilogram of body weight per minute, for two minutes). We repeated the measurements after an infusion of ketanserin, an antagonist of serotonin receptors that is thought to block the effect of serotonin on receptors in the arterial wall but not in the endothelium. Results. In patients with normal coronary arteries, the highest dose of serotonin increased cross-sectional area by 52 percent (P < 0.001) and blood flow by 58 percent (P < 0.01). The effect was significantly potentiated by administration of ketanserin. In patients with coronary-artery atherosclerosis, serotonin reduced cross-sectional area by 64 percent (P < 0.001) and blood flow by 59 percent (P < 0.001). Ketanserin prevented this effect. Conclusions. Serotonin has a vasodilating effect on normal human coronary arteries; when the endothelium is damaged, as in coronary artery disease, serotonin has a direct, unopposed vasoconstricting effect. When considered with other evidence, these data suggest that platelet-derived factors such as serotonin may have a role in certain acute coronary ischemic syndromes.	NAPLES UNIV, SCH MED 2, DEPT INTERNAL MED, I-80131 NAPLES, ITALY; UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, HOUSTON, TX 77225 USA; TEXAS HEART INST, HOUSTON, TX 77025 USA	University of Naples Federico II; University of Texas System; University of Texas Health Science Center Houston; Texas Heart Institute	GOLINO, P (corresponding author), NAPLES UNIV, SCH MED 2, DIV CARDIOL, VIA SERGIO PANSINI 5, I-80131 NAPLES, ITALY.			GOLINO, Paolo/0000-0002-3590-6983; INDOLFI, Ciro/0000-0003-1241-6487				ASHTON JH, 1986, CIRCULATION, V73, P572, DOI 10.1161/01.CIR.73.3.572; ASHTON JH, 1987, CIRCULATION, V76, P952, DOI 10.1161/01.CIR.76.4.952; ASHTON JH, 1986, CIRC RES, V59, P568, DOI 10.1161/01.RES.59.5.568; AWOUTERS F, 1985, DRUG DEVELOP RES, V6, P263, DOI 10.1002/ddr.430060402; BENEDICT CR, 1986, CIRC RES, V58, P58, DOI 10.1161/01.RES.58.1.58; BRAZENOR RM, 1982, EUR J PHARMACOL, V81, P569, DOI 10.1016/0014-2999(82)90346-6; BRUM JM, 1984, CIRCULATION, V70, P1066, DOI 10.1161/01.CIR.70.6.1066; BUSH LR, 1984, CIRCULATION, V69, P1161, DOI 10.1161/01.CIR.69.6.1161; CAPPELLIBIGAZZI M, 1990, AM J PHYSIOL, V259, pH1161, DOI 10.1152/ajpheart.1990.259.4.H1161; CHU A, 1987, CIRC RES, V61, P81; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN ML, 1988, J CARDIOVASC PHARM, V11, pS25; COHEN RA, 1983, AM J PHYSIOL, V245, P1077; COHEN RA, 1983, SCIENCE, V221, P273, DOI 10.1126/science.6574604; DECATERINA R, 1984, CIRCULATION, V69, P889, DOI 10.1161/01.CIR.69.5.889; GOLINO P, 1990, J AM COLL CARDIOL, V15, P718, DOI 10.1016/0735-1097(90)90652-6; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GOLINO P, 1988, CIRCULATION, V78, P701, DOI 10.1161/01.CIR.78.3.701; HEISTAD DD, 1984, CIRC RES, V54, P711, DOI 10.1161/01.RES.54.6.711; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; HOUSTON DS, 1985, AM J PHYSIOL, V248, pH389, DOI 10.1152/ajpheart.1985.248.3.H389; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; RUBANYI GM, 1987, J AM COLL CARDIOL, V9, P1243, DOI 10.1016/S0735-1097(87)80462-X; SCHMITZ JM, 1985, CIRC RES, V57, P223, DOI 10.1161/01.RES.57.2.223; SIBLEY DH, 1986, J AM COLL CARDIOL, V8, P1332, DOI 10.1016/S0735-1097(86)80305-9; SPEARS JR, 1983, CIRCULATION, V68, P453, DOI 10.1161/01.CIR.68.2.453; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; VANNUETEN JM, 1981, J PHARMACOL EXP THER, V218, P217; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WILSON RF, 1985, CIRCULATION, V72, P82, DOI 10.1161/01.CIR.72.1.82; WILSON RF, 1986, CIRCULATION, V73, P444, DOI 10.1161/01.CIR.73.3.444	33	414	430	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 7	1991	324	10					641	648		10.1056/NEJM199103073241001	http://dx.doi.org/10.1056/NEJM199103073241001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FA144	1994246				2022-12-24	WOS:A1991FA14400001
J	CYBULSKY, MI; GIMBRONE, MA				CYBULSKY, MI; GIMBRONE, MA			ENDOTHELIAL EXPRESSION OF A MONONUCLEAR LEUKOCYTE ADHESION MOLECULE DURING ATHEROGENESIS	SCIENCE			English	Article							CHEMOTACTIC FACTOR; INTERFERON-GAMMA; ATHEROSCLEROSIS; CELL; ACTIVATION; PROTEINS; LESION; RABBIT; PATHOGENESIS; CHOLESTEROL	An inducible rabbit endothelial adhesion molecule that is selective for mononuclear leukocytes has been identified. This adhesion protein was expressed on the surface of activated cultured endothelium in two forms, 118 and 98 kilodaltons, the amino-terminal sequence of each being highly homologous to human VCAM-1. In dietary hypercholesterolemic and Watanabe heritable hyperlipidemic rabbit models of atherosclerosis, this adhesion molecule was found to be expressed in a localized fashion by aortic endothelium that overlies early foam cell lesions. This lesion-localized expression suggests a potential endothelium-dependent mechanism for mononuclear leukocyte recruitment during atherogenesis and may provide a molecular marker for early atherosclerosis.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	CYBULSKY, MI (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115, USA.		Cybulsky, Myron I./AAD-6539-2019	Cybulsky, Myron/0000-0002-1696-2867	NHLBI NIH HHS [P01-HL-36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER JA, 1986, ARTERIOSCLEROSIS, V6, P254, DOI 10.1161/01.ATV.6.3.254; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; COTRAN RS, 1988, J IMMUNOL, V140, P1883; CYBULSKY MI, UNPUB; CYBULSKY MI, IN PRESS AM J PATHOL; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; GERRITY RG, 1985, ARTERIOSCLEROSIS, V5, P55, DOI 10.1161/01.ATV.5.1.55; Gimbrone M., 1986, VASCULAR ENDOTHELIUM, P1; GIMBRONE MA, 1980, ATHEROSCLEROSIS, V5, P415; GRYGLEWSKI RJ, 1988, HYPERTENSION, V12, P530, DOI 10.1161/01.HYP.12.6.530; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE L, 1989, PRODUCTIVITY OCEAN P, P49; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MUNRO JA, COMMUNICATION; MUNRO JM, 1989, AM J PATHOL, V135, P121; MUNRO JM, 1988, LAB INVEST, V58, P249; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P9, DOI 10.1161/01.ATV.7.1.9; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; WALKER LN, 1986, AM J PATHOL, V125, P450; WATANABE T, 1985, LAB INVEST, V53, P80	39	1367	1443	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					788	791		10.1126/science.1990440	http://dx.doi.org/10.1126/science.1990440			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1990440				2022-12-24	WOS:A1991EX57500042
J	APPLEBY, L				APPLEBY, L			SUICIDE DURING PREGNANCY AND IN THE 1ST POSTNATAL YEAR	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDER	Objectives-To calculate age adjusted mortality ratios for suicide by women in the first year after childbirth and during pregnancy, and to identify characteristics of postnatal suicide in childbearing women. Design-Retrospective study based on population data for England and Wales from 1973 to 1984. Subjects-Women aged 15-44 who committed suicide in the year after childbirth or during pregnancy. Main outcome measures-Observed to expected mortality ratios for the total postnatal sample, for five year age groups, for unmarried mothers, and for suicide after stillbirth; observed to expected mortality ratios for all suicides during pregnancy and for five year age groups; the timing of suicides in relation to delivery; and the frequency of the various methods of suicide. Results-The standardised mortality ratio for postnatal suicide was calculated to be 0.17-that is, the actual total was only one sixth of that expected. The low ratio was not found after stillbirth, which was associated with a rate six times that in all women after childbirth. The low ratio was less pronounced, but still present, in teenage mothers and in unmarried mothers. Women who committed suicide after childbirth most often did so in the first month, and there was a tendency to use violent methods. The standardised mortality ratio for suicide during pregnancy was calculated to be 0.05 of all pregnant women. Teenagers were at substantially increased risk. Conclusions-Women in the first year after childbirth and during pregnancy have a low risk of suicide despite their high rate of psychiatric morbidity. Underreporting of maternal suicides is unlikely to explain the findings, though it may affect their magnitude. Motherhood seems to protect against suicide. Concern for dependants may be an important focus for suicide prevention in clinical practice.			APPLEBY, L (corresponding author), INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND.							BECK AT, 1979, COGNITIVE THERAPY DE; Breslow N. E., 1987, STATISTICAL METHODS, VII; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KLEINER GJ, 1984, SUICIDE PREGNANCY; KUMAR R, 1984, BRIT J PSYCHIAT, V144, P35, DOI 10.1192/bjp.144.1.35; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; O'Hara M. W., 1988, MOTHERHOOD MENTAL IL, P17; PAFFENBARGER RS, 1964, BRIT J PREV SOC MED, V18, P189; WATSON JP, 1984, BRIT J PSYCHIAT, V144, P453, DOI 10.1192/bjp.144.5.453; 1990, REPORT CONFIDENTIAL; [No title captured]; 1982, REPORT CONFIDENTIAL; ANN PUBLICATION OFFI; 1979, REPORT CONFIDENTIAL; 1973, ANN PUBLICATION OFFI; 1986, REPORT CONFDENTIAL E	17	184	188	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					137	140		10.1136/bmj.302.6769.137	http://dx.doi.org/10.1136/bmj.302.6769.137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995132	Bronze, Green Published			2022-12-24	WOS:A1991EU02000018
J	HEALY, B				HEALY, B			REPLACEMENT THERAPY EFFECTIVE FOR PATIENTS WITH GAUCHERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P1464	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046123				2022-12-24	WOS:A1991FT93400003
J	KLEBANOFF, MA; SHIONO, PH; RHOADS, GG				KLEBANOFF, MA; SHIONO, PH; RHOADS, GG			SPONTANEOUS AND INDUCED-ABORTION AMONG RESIDENT PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANESTHETIC-GASES; PREGNANCY; COMPLICATIONS; EXPOSURE; OUTCOMES	Female resident physicians are believed to be at an increased risk for a variety of third-trimester pregnancy complications. However, early pregnancy complications have been less well studied. This report compares spontaneous and induced abortions in a nationally representative sample of 5096 female medical school graduates (who experienced 1284 pregnancies) and of the sexual partners of 5000 of their male classmates (who experienced 1481 pregnancies). The response to the survey was 86.1%. The life-table probability of spontaneous abortion was 14.8% for female residents compared with 12.6% for the sexual partners of male residents. However, female residents were more likely than the male residents' sexual partners to terminate a pregnancy voluntarily (8.2% vs 2.7%). The increased risk of voluntary termination persisted when only married women were studied (3.6% vs 1.4%). However, female residents' pregnancies were at approximately half the risk of voluntary termination compared with pregnancies among the general US population of women aged 25 to 34 years. These results provide reassurance to those residents who would like to become pregnant but are concerned about the possible effect of their occupation on the course of the pregnancy.	DAVID & LUCILE PACKARD FDN,CTR FUTURE CHILDREN,LOS ALTOS,CA; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	KLEBANOFF, MA (corresponding author), NICHHD,DIV PREVENT RES,BLDG EPN,ROOM 640,BETHESDA,MD 20892, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092923] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-9-2923] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AXELSSON G, 1982, INT J EPIDEMIOL, V11, P250, DOI 10.1093/ije/11.3.250; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS, P489; DIXON WJ, 1985, BMDP STATISTICAL SOF, P576; GRUNEBAUM A, 1987, AM J OBSTET GYNECOL, V157, P79, DOI 10.1016/S0002-9378(87)80350-2; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; KATZ VL, 1988, WESTERN J MED, V149, P704; KLEBANOFF MA, 1990, NEW ENGL J MED, V323, P1040, DOI 10.1056/NEJM199010113231506; KNILLJONES RP, 1975, LANCET, V2, P807; LEE ET, 1980, STATISTICAL METHODS; MILLER NH, 1989, J REPROD MED, V34, P790; OSBORN LM, 1990, J FAM PRACTICE, V31, P618; PHELAN ST, 1988, OBSTET GYNECOL, V72, P431; SCHENKER MB, 1990, AM J EPIDEMIOL, V132, P96, DOI 10.1093/oxfordjournals.aje.a115648; SCHWARTZ RW, 1985, OBSTET GYNECOL, V66, P672; SELEVAN SG, 1985, NEW ENGL J MED, V313, P1173, DOI 10.1056/NEJM198511073131901; TANNENBAUM TN, 1985, J OCCUP ENVIRON MED, V27, P659; VENTURA S J, 1988, American Journal of Public Health, V78, P506, DOI 10.2105/AJPH.78.5.506; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; 1985, SAS USERS GUIDE STAT, P529	19	34	34	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2821	2825		10.1001/jama.265.21.2821	http://dx.doi.org/10.1001/jama.265.21.2821			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033738				2022-12-24	WOS:A1991FN85500030
J	SATTLER, FR; KO, R; ANTONISKIS, D; SHIELDS, M; COHEN, J; NICOLOFF, J; LEEDOM, J; KODA, R				SATTLER, FR; KO, R; ANTONISKIS, D; SHIELDS, M; COHEN, J; NICOLOFF, J; LEEDOM, J; KODA, R			ACETAMINOPHEN DOES NOT IMPAIR CLEARANCE OF ZIDOVUDINE	ANNALS OF INTERNAL MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; DOUBLE-BLIND; PHARMACOKINETICS	Objective: To determine whether concurrent treatment with acetaminophen and zidovudine impairs clearance of zidovudine, thereby increasing the risk for zidovudine-induced hematologic toxicity. Design: Dose escalation, drug interaction study. Setting: University clinical research center. Patients: Patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Interventions: Acetaminophen and 200 mg of zidovudine simultaneously every 4 hours. For 13 patients, the unit dosage of acetaminophen was 325 mg for 3 days; for 8 patients, the dosage was 650 mg for 3 days; and, for 6 patients, the dosage was 650 mg for 7 days. Measurements: Zidovudine clearance and production of the glucuronide conjugate of zidovudine were assessed after acetaminophen treatment. Main Results: Neither zidovudine clearance nor production of the glucuronide conjugate of zidovudine was impaired after treatment with acetaminophen. Clearance of zidovudine was actually accelerated by 5%, 11%, and 33% with the three acetaminophen regimens,respectively (P = 0.002 by analysis of variance; P = 0.04 for linear trend when changes in the area-under-the-curve for zidovudine were compared). Conclusion: Because serum concentrations of zidovudine decrease after the coadministration of acetaminophen, a pharmacokinetic interaction between zidovudine and acetaminophen is unlikely to increase the risk for hematologic toxicity associated with zidovudine.			SATTLER, FR (corresponding author), UNIV SO CALIF, LOS ANGELES CTY MED CTR, 1175 N CUMMINGS ST, LOS ANGELES, CA 90033 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI062540] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR-43] Funding Source: Medline; NIAID NIH HHS [N0I-AI-62540] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLUM MR, 1988, AM J MED, V85, P189; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOOD SS, 1988, J CHROMATOGR-BIOMED, V431, P123, DOI 10.1016/S0378-4347(00)83075-3; JENNRICH R, 1988, BMDP STATISTICAL SOF, V1, P483; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; LEVY G, 1971, J PHARM SCI, V60, P215, DOI 10.1002/jps.2600600212; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROCCI ML, 1983, COMPUT PROG BIOMED, V16, P203, DOI 10.1016/0010-468X(83)90082-X; SINGLAS E, 1989, EUR J CLIN PHARMACOL, V36, P639, DOI 10.1007/BF00637752; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	12	22	22	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					937	940		10.7326/0003-4819-114-11-937	http://dx.doi.org/10.7326/0003-4819-114-11-937			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024860				2022-12-24	WOS:A1991FM97900004
J	MURPHY, TJ; ALEXANDER, RW; GRIENDLING, KK; RUNGE, MS; BERNSTEIN, KE				MURPHY, TJ; ALEXANDER, RW; GRIENDLING, KK; RUNGE, MS; BERNSTEIN, KE			ISOLATION OF A CDNA-ENCODING THE VASCULAR TYPE-1 ANGIOTENSIN-II RECEPTOR	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CONVERTING ENZYME; MOLECULAR-CLONING; SYSTEM; EXPRESSION; CAPTOPRIL; PROTEINS; SUBTYPES; CALCIUM; FAMILY	ANGIOTENSIN II is an important effector molecule controlling blood pressure and volume in the cardiovascular system 1. Its importance is manifested by the efficacy of angiotensin-converting enzyme inhibitors in the treatment of hypertension and congestive heart failure 2,3. Angiotensin II interacts with two pharmacologically distinct subtypes of cell-surface receptors, AT1 and AT2 (ref. 4). AT1 receptors seem to mediate the major cardiovascular effects of angiotensin II 5,6. Here we report the isolation by expression cloning of a complementary DNA encoding a unique protein with the pharmacological specificity of a vascular AT1 receptor. Hydropathic modelling of the deduced protein suggests that it shares the seven-transmembrane-region motif with the G protein-coupled receptor superfamily 7. Knowledge of the AT1 receptor primary sequence should now permit structural analysis, definition of the angiotensin II receptor gene family and delineation of the contribution of AT receptors to the genetic component of hypertension.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322	Emory University	MURPHY, TJ (corresponding author), EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322, USA.			Griendling, Kathy/0000-0002-9456-8582; Bernstein, Kenneth/0000-0001-8097-3272				ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAUER JH, 1984, AM J MED, V77, P43, DOI 10.1016/S0002-9343(84)80057-1; BOUSCAREL B, 1988, J BIOL CHEM, V263, P14913; BUMPUS FM, IN PRESS HYPERTENSIO; CAPPONI AM, 1981, BIOCH REGULATION BLO, P205; CHANG RSL, 1990, MOL PHARMACOL, V29, P347; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIU AT, 1989, J PHARMACOL EXP THER, V250, P867; CHIU AT, 1989, EUR J PHARMACOL, V170, P117, DOI 10.1016/0014-2999(89)90145-3; DAVIS R, 1979, NEW ENGL J MED, V301, P117, DOI 10.1056/NEJM197907193010301; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOUGLAS JG, 1987, AM J PHYSIOL, V253, pF1, DOI 10.1152/ajprenal.1987.253.1.F1; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ESCHER E, 1988, PHARMACOL THERAPEUT, V37, P37, DOI 10.1016/0163-7258(88)90018-6; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MILLAN MA, 1989, SCIENCE, V244, P1340, DOI 10.1126/science.2734613; MURPHY TJ, 1988, J PHARMACOL EXP THER, V244, P571; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; Sakarai T., 1990, NATURE, V348, P732; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	31	1236	1262	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					233	236		10.1038/351233a0	http://dx.doi.org/10.1038/351233a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041570				2022-12-24	WOS:A1991FL99000057
J	SONIES, BC; DALAKAS, MC				SONIES, BC; DALAKAS, MC			DYSPHAGIA IN PATIENTS WITH THE POSTPOLIO SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROMUSCULAR SYMPTOMS; OLD POLIOMYELITIS	Background and Methods. Dysphagia may develop in some patients many years after an attack of acute paralytic poliomyelitis. To identify clinical or subclinical signs of oropharyngeal dysfunction, we examined 32 patients (mean age, 48.9 years) with the post-polio syndrome (defined by new weakness in the limbs). Of the 32 patients, 14 had symptoms of new swallowing difficulties, and 18 were asymptomatic in this respect; 12 had a history of bulbar involvement during acute poliomyelitis. Swallowing function was assessed objectively by ultrasonography, videofluoroscopy, and an oral motor index score for 10 components of oral function. Results. All but 1 of the 32 patients, regardless of whether they had new symptoms or previous bulbar involvement, had some abnormality on detailed testing of oropharyngeal function; only 2 patients had any signs of aspiration. The mean oral motor index score (a quantitative measure of oral sensorimotor function) in the patients was higher than that in age-matched normal subjects (P < 0.001). Videofluoroscopy showed abnormalities of varying severity, including unilateral bolus transport through the pharynx, pooling in the valleculae or pyriform sinuses, delayed pharyngeal constriction, and impaired tongue movements. On ultrasonography, the mean (+/- SD) duration of wet swallows was significantly longer in the symptomatic patients than in the asymptomatic patients (2.67 +/- 0.70 vs. 1.65 +/- 0.42 seconds). The four patients who were reexamined two years later had objective signs of worsening oropharyngeal function and corresponding new symptoms. Conclusions. In patients with the post-polio syndrome, the bulbar muscles often have clinical or subclinical signs of dysfunction. These abnormalities suggest that in bulbar neurons there is a slowly progressive deterioration similar to that in the muscles of the limbs.	NINCDS,NEUROMUSCULAR DIS SECT,RM 4N248,BLDG 10,BETHESDA,MD 20892; WARREN G MAGNUSON CLIN CTR,DEPT REHABIL MED,SPEECH PATHOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								BAKER AB, 1950, ARCH NEURO PSYCHIATR, V63, P257, DOI 10.1001/archneurpsyc.1950.02310200065007; BODIAN D, 1949, POLIOMYELITIS PAPERS, P62; BOSMA JF, 1976, PHYSL ORAL TISSUES, V2, P78; BROWN S, 1987, RES CLIN ASPECTS LAT, V23, P83; BUCHHOLZ D, 1987, RES CLIN ASPECTS LAT, V23, P55; CASHMAN NR, 1987, NEW ENGL J MED, V317, P7, DOI 10.1056/NEJM198707023170102; DALAKAS M, 1990, Current Opinion in Rheumatology, V2, P901; DALAKAS MC, 1984, REV INFECT DIS, V6, pS562; DALAKAS MC, 1986, NEW ENGL J MED, V314, P959, DOI 10.1056/NEJM198604103141505; DALAKAS MC, 1986, EUR NEUROL, V25, P381, DOI 10.1159/000116038; DALAKAS MC, 1988, NEUROLOGY, V38, P99, DOI 10.1212/WNL.38.1.99; DALAKAS MC, 1988, ADV CONT NEUROLOGY, V29, P51; DALAKAS MC, 1984, MIAMI S F, P73; DALAKAS MC, 1990, POSTPOLIO SYNDROME, P31; DALAKAS MC, 1987, RES CLIN ASPECTS LAT, V23, P241; Darley FL, 1975, MOTOR SPEECH DISORDE; Groher M, 1984, DYSPHAGIA DIAGNOSIS; HALSTEAD LS, 1987, RES CLIN ASPECTS LAT, V23; Logemann JA, 1986, DYSPHAGIA, V1, P34, DOI 10.1007/bf02408238; LOGEMANN JA, 1985, EVALUATION TREATMENT; LOGEMANN JA, 1983, MANUAL VIDEO FLUOROG; MUNSAAT TL, 1987, RES CLIN ASPECTS LAT, V23, P329; MUNSAT TL, 1990, POSTPOLIO SYNDROME; PEZESHKPOUR GH, 1988, ARCH NEUROL-CHICAGO, V45, P505, DOI 10.1001/archneur.1988.00520290033010; RAVITS J, 1990, MUSCLE NERVE, V13, P667, DOI 10.1002/mus.880130802; SHAWKER TH, 1984, ULTRASOUND ANN, P237; Sonies B C, 1988, Dysphagia, V3, P1, DOI 10.1007/BF02406274; SONIES BC, 1988, OTOLARYNG CLIN N AM, V21, P637; SONIES BC, 1987, DYSPHAGIA, V1, P178	29	61	61	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1162	1167		10.1056/NEJM199104253241703	http://dx.doi.org/10.1056/NEJM199104253241703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011159	Bronze			2022-12-24	WOS:A1991FH57200003
J	CHEN, JH; SEEMAN, NC				CHEN, JH; SEEMAN, NC			SYNTHESIS FROM DNA OF A MOLECULE WITH THE CONNECTIVITY OF A CUBE	NATURE			English	Article							NUCLEIC-ACID JUNCTIONS; DESIGN	A PRINCIPAL goal of biotechnology is the assembly of novel biomaterials for analytical, industrial and therapeutic purposes. The advent of stable immobile nucleic acid branched junctions 1-4 makes DNA a good candidate for building frameworks to which proteins or other functional molecules can be attached and thereby juxtaposed 5-7. The addition of single-stranded 'sticky' ends 8 to branched DNA molecules converts them into macromolecular valence clusters that can be ligated together 1. The edges of these frameworks are double-helical DNA, and the vertices correspond to the branch points of junctions. Here, we report the construction from DNA of a covalently closed cube-like molecular complex containing twelve equal-length double-helical edges arranged about eight vertices. Each of the six 'faces' of the object is a single-stranded cyclic molecule, doubly catenated to four neighbouring strands, and each vertex is connected by an edge to three others. Each edge contains a unique restriction site for analytical purposes. This is the first construction of a closed polyhedral object from DNA.			CHEN, JH (corresponding author), NYU,DEPT CHEM,NEW YORK,NY 10003, USA.		Chen, Junghuei/B-5217-2011					CARUTHERS MH, 1981, CHEM ENZYMATIC SYNTH, P71; CHEN JH, 1989, J AM CHEM SOC, V111, P6402, DOI 10.1021/ja00198a063; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; HOPFIELD JJ, 1988, SCIENCE, V241, P817, DOI 10.1126/science.241.4867.817; KALLENBACH NR, 1983, NATURE, V305, P829, DOI 10.1038/305829a0; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; ROBINSON BH, 1987, PROTEIN ENG, V1, P295, DOI 10.1093/protein/1.4.295; SEEMAN NC, 1988, J BIOMOL STRUCT DYN, V5, P997, DOI 10.1080/07391102.1988.10506445; SEEMAN NC, 1983, BIOPHYS J, V44, P201, DOI 10.1016/S0006-3495(83)84292-1; SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9; SEEMAN NC, 1990, J BIOMOL STRUCT DYN, V8, P573, DOI 10.1080/07391102.1990.10507829; SEEMAN NC, 1985, J BIOMOL STRUCT DYN, V3, P11, DOI 10.1080/07391102.1985.10508395; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; Wells AF, 1977, 3 DIMENSIONAL NETS P; [No title captured]	15	1027	1093	13	353	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					631	633		10.1038/350631a0	http://dx.doi.org/10.1038/350631a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017259				2022-12-24	WOS:A1991FH11200067
J	LEVINSKY, NG; RETTIG, RA				LEVINSKY, NG; RETTIG, RA			THE MEDICARE END-STAGE RENAL-DISEASE PROGRAM - A REPORT FROM THE INSTITUTE-OF-MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NATL ACAD SCI,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine	LEVINSKY, NG (corresponding author), BOSTON UNIV,MED CTR,BOSTON,MA 02118, USA.							EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GARCIA JR, 1990, STAFFING DIALYSIS UN; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1990, PRICE DIALYSIS HOSPI; HELD PJ, 1990, MORTALITY PRICE DIAL; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; Lohr KN, 1990, MEDICARE STRATEGY QU, V2; RENNIE D, 1981, NEW ENGL J MED, V304, P351, DOI 10.1056/NEJM198102053040609; RETTIG RA, IN PRESS KIDNEY FAIL; 1990, 1990 NAT I DIAB DIG; 1990, UNITED NETWORK ORGAN; 1990, HLTH CARE FINANCING; 1990, DISTRIBUTION ORGANS	14	63	63	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1143	1148		10.1056/NEJM199104183241628	http://dx.doi.org/10.1056/NEJM199104183241628			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008193	Bronze			2022-12-24	WOS:A1991FG91200027
J	WIERSMA, SR; ORTEGA, J; SOBEL, E; WEINBERG, KI				WIERSMA, SR; ORTEGA, J; SOBEL, E; WEINBERG, KI			CLINICAL IMPORTANCE OF MYELOID-ANTIGEN EXPRESSION IN ACUTE LYMPHOBLASTIC-LEUKEMIA OF CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER-STUDY-GROUP; PROGNOSTIC-SIGNIFICANCE; LINEAGE LEUKEMIA; DISCRETE STAGES; DIFFERENTIATION; LYMPHOMA; CLASSIFICATION; TRANSLOCATION; PHENOTYPES; PROTOCOL	Background. Leukemic cells in 15 to 25 percent of patients with acute lymphoblastic leukemia (ALL) express myeloid antigens as well as lymphoid antigens (the latter reflecting B-cell or T-cell lineage). The relations of myeloid-antigen expression to other features of ALL and to prognosis have been controversial. Methods. We analyzed clinical and laboratory features present at diagnosis in 236 consecutive cases of ALL in children. Immunophenotyping, including single- and dual-fluorescence analyses, was used to classify leukemic cells as B or T lymphoblasts and also to identify myeloid-antigen expression - the simultaneous expression of lymphoid-associated antigens and at least one of three myeloid-associated antigens and at least one of three myeloid-associated antigens (CD33, CD13, and CD14) on cells classified as L1 or L2 according to the French-American-British system. Results. Forty-five of 185 patients with B-lineage ALL had myeloid-antigen expression, as did 8 of 41 patients with T-lineage ALL. In 10 patients, the lineage could not be determined. Myeloid-antigen expression was associated with L2 morphology (P < 0.05), but it did not correlate with other prognostic features recognized previously. Multivariate analysis showed that myeloid-antigen expression was an important predictor of relapse in childhood ALL and the most significant prognostic factor statistically (P < 0.0001). A white-cell count greater-than-or-equal-to 50 x 10(9) per liter at diagnosis was also an important and highly significant prognostic feature (P < 0.001). After 40 months, the estimated disease-free survival for patients with ALL was 84 percent for those without myeloid-antigen expression and with a low white-cell count, 57 percent for those without myeloid-antigen expression and with a high white-cell count, 47 percent for those with myeloid-antigen expression and a low white-cell count, and 26 percent for those with myeloid-antigen expression and a high white-cell count (P < 0.00001). Conclusions. Myeloid-antigen expression is an important independent predictor of a poor response to chemotherapy in childhood ALL.	UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90089; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California								ARTHUR DC, 1982, BLOOD, V59, P96; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BLEYER WA, 1986, MED PEDIATR ONCOL, V14, P271, DOI 10.1002/mpo.2950140506; CIVIN CI, 1990, EXP HEMATOL, V18, P461; COX DR, 1972, J R STAT SOC B, V34, P187; CROCE CM, 1985, BLOOD, V65, P1; DUQUEHAMMERSHAIMB L, 1983, CANCER, V52, P39, DOI 10.1002/1097-0142(19830701)52:1<39::AID-CNCR2820520109>3.0.CO;2-S; FOON KA, 1986, BLOOD, V68, P1; GAYNON P, 1985, P AM SOC CLIN ONCOL, V4, P173; GAYNON PS, 1988, LANCET, V2, P921; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GREAVES MF, 1986, BLOOD, V67, P1; GRIESINGER F, 1989, J EXP MED, V169, P1101, DOI 10.1084/jem.169.3.1101; HANECAK R, 1989, MOL CELL BIOL, V9, P2264, DOI 10.1128/MCB.9.5.2264; HERSHFIELD MS, 1984, P NATL ACAD SCI-BIOL, V81, P253, DOI 10.1073/pnas.81.1.253; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERSEY JH, 1979, AM J CLIN PATHOL, V72, P746; LAWLESS JF, 1982, STATISTICAL MODELS M; MCCULLOCH EA, 1983, BLOOD, V62, P1; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; MIRRO J, 1985, BLOOD, V66, P1115; MIRRO J, 1986, BLOOD, V67, P689; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; NEAME PB, 1985, BLOOD, V65, P142; PUI CH, 1990, BLOOD, V75, P198; PUI CH, 1984, BRIT J HAEMATOL, V56, P121, DOI 10.1111/j.1365-2141.1984.tb01277.x; REAMAN G, 1989, P AN M AM SOC CLIN, V8, P211; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RIEHM H, 1983, LEUKEMIA RES ADV CEL, P251; ROBISON LL, 1980, AM J PEDIAT HEMATOL, V2, P5; SALLAN SE, 1980, BLOOD, V55, P395; SMITH LJ, 1983, BLOOD, V61, P1138; SOBOL RE, 1987, NEW ENGL J MED, V316, P111; STASS S, 1984, BLOOD, V64, P701; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; STOCKINGER H, 1984, J NATL CANCER I, V73, P7	36	172	176	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					800	808		10.1056/NEJM199103213241204	http://dx.doi.org/10.1056/NEJM199103213241204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997852				2022-12-24	WOS:A1991FC44200004
J	SEPKOWITZ, KA; TELZAK, EE; GOLD, JWM; BERNARD, EM; BLUM, S; CARROW, M; DICKMEYER, M; ARMSTRONG, D				SEPKOWITZ, KA; TELZAK, EE; GOLD, JWM; BERNARD, EM; BLUM, S; CARROW, M; DICKMEYER, M; ARMSTRONG, D			PNEUMOTHORAX IN AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; FEATURES	Objective: To determine risk factors for the development of pneumothorax in p Design: Prospective cohort study. Setting: Tertiary care center. Patients: Of 1030 patients with AIDS who were followed at Memorial Sloan-Kettering Cancer Center between 1 January 1980 and 30 September 1989, 20 (2%) developed pneumothorax that was unrelated to trauma or a pulmonary procedure. Results: Of 20 patients with AIDS who presented with pneumothorax, 19 had compelling evidence of concurrent Pneumocystis carinii pneumonia. Using bivariate analysis, patients receiving aerosol pentamidine prophylaxis (relative risk, 17.6) and those with a history of P. carinii pneumonia (relative risk, 14.5) were more likely to develop pneumothorax. By Mantel-Haenszel stratified analysis, aerosol pentamidine use was a statistically significant risk factor independent of a history of P. carinii pneumonia. The pneumothorax-related mortality rate was 10% and there was considerable morbidity. Conclusions: Patients with AIDS at the highest risk for developing pneumothorax are those with a history of P. carinii pneumonia who are receiving aerosol pentamidine prophylaxis but who nevertheless develop P. carinii pneumonia. The benefits of aerosol pentamidine prophylaxis in these patients far outweigh this risk. Pneumocystis carinii pneumonia should be considered as the most likely diagnosis in any patient with AIDS who develops a pneumothorax.	MEM SLOAN KETTERING CANC CTR, INFECT DIS SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	Memorial Sloan Kettering Cancer Center; New York City Department of Health & Mental Hygiene					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027669] Funding Source: NIH RePORTER; NIAID NIH HHS [5 UO1 AI27669-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFESSA B, 1988, ARCH INTERN MED, V148, P2651, DOI 10.1001/archinte.148.12.2651; BERNARD EM, 1989, 5 P INT C AIDS MONTR; BYRNES TA, 1989, J THORAC CARDIOV SUR, V98, P546; DELORENZO LJ, 1987, CHEST, V91, P323, DOI 10.1378/chest.91.3.323; DOPPMAN JL, 1975, RADIOLOGY, V114, P39, DOI 10.1148/114.1.39; ENG RHK, 1987, ARCH INTERN MED, V147, P746, DOI 10.1001/archinte.147.4.746; FELZENBERG JD, 1987, CHEST, V91, P934, DOI 10.1378/chest.91.6.934a; FEUERSTEIN IM, 1990, RADIOLOGY, V174, P697, DOI 10.1148/radiology.174.3.2305052; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEISHER AG, 1988, ANN THORAC SURG, V45, P21, DOI 10.1016/S0003-4975(10)62388-0; GOODMAN PC, 1986, AM J ROENTGENOL, V147, P29, DOI 10.2214/ajr.147.1.29; HOPEWELL PC, 1985, CHEST, V87, P104, DOI 10.1378/chest.87.1.104; JACOBSON SJ, 1989, 5 P INT C AIDS MONTR; JOE L, 1986, ARCH INTERN MED, V146, P1816, DOI 10.1001/archinte.146.9.1816; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; LEE M, 1990, CHEST, V97, P510, DOI 10.1378/chest.97.2.510-c; LEOUNG GS, 1989, 5 P INT C AIDS MONTR; LOVE L, 1954, ANN INTERN MED, V40, P153, DOI 10.7326/0003-4819-40-1-153; MARTINEZ CM, 1988, CHEST, V94, P1317, DOI 10.1378/chest.94.6.1317b; MELTON LJ, 1979, AM REV RESPIR DIS, V120, P1379; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; NEWSOME GS, 1989, 5 P INT C AIDS MONTR; SANDHU JS, 1989, RADIOLOGY, V173, P33, DOI 10.1148/radiology.173.1.2789413; SCANNELL KA, 1990, CHEST, V97, P479, DOI 10.1378/chest.97.2.479; SELIK RM, 1987, AIDS, V1, P175; SEPKOWITZ KA, 1989, 5 P INT C AIDS MONTR; SHERMAN M, 1986, CHEST, V90, P609, DOI 10.1378/chest.90.4.609; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WOLLSCHLAGER CM, 1984, CHEST, V85, P197, DOI 10.1378/chest.85.2.197; 1990, CHEST, V97, P510	30	104	106	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					455	459		10.7326/0003-4819-114-6-455	http://dx.doi.org/10.7326/0003-4819-114-6-455			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994791				2022-12-24	WOS:A1991FB64000004
J	BALARAJAN, R				BALARAJAN, R			ETHNIC-DIFFERENCES IN MORTALITY FROM ISCHEMIC-HEART-DISEASE AND CEREBROVASCULAR-DISEASE IN ENGLAND AND WALES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-DENSITY-LIPOPROTEIN; ASIAN POPULATION GROUPS; CORONARY RISK-FACTORS; BLOOD-PRESSURE; INDIAN DESCENT; EAST LONDON; BIRMINGHAM; PREVALENCE; WHITE; MEN	Objective - To examine mortality from ischaemic heart disease and cerebrovascular disease in England and Wales by country of birth of the deceased. Design - Standardised mortality ratios were computed by country of birth groups for ischaemic heart disease and cerebrovascular disease for 1979-83 and 1970-2 by using the five year age-sex specific rates for England and Wales for 1979-83 as standard. Setting - England and Wales 1970-2 and 1979-83. Results - In 1979-83 mortality from ischaemic heart disease was highest in men and women born in the Indian subcontinent (standardised mortality ratio 136 and 146 respectively). Young Indian men suffered the greatest excess (313 at ages 20-29). Other groups with raised mortality included Irish, Scottish, and Polish born immigrants. Those born in the Caribbean, the old Commonwealth, west Europe, and the United States had low death rates. In England and Wales mortality from ischaemic heart disease declined by 5% in men and 1% in women between 1970-2 and 1979-83, with greatest percentage declines in immigrants born in the United States, South Africa, the old Commonwealth, the Caribbean, and France. Immigrant groups with raised mortality in the earlier period showed little improvement, and mortality from ischaemic heart disease increased among Indians (6% in men and 13% in women). In 1979-83 mortality from cerebrovascular disease was highest in Caribbeans (standardised mortality ratios 176 in men and 210 in women), followed by Africans, Indians, and Irish. Rates were low in west Europeans. Mortality from stroke declined by 28% overall in this period, a rate of decline shared by most groups. Men from the Indian subcontinent showed a decline of only 3%. Conclusion - In the 1980s mortality from ischaemic heart disease and cerebrovascular disease differed significantly between ethnic groups in England and Wales. In general, ethnic groups that experienced lower mortality from ischaemic heart disease in the 1970s showed the greatest improvement over the following decade.			BALARAJAN, R (corresponding author), UNIV SURREY, EPIDEMIOL & PUBL HLTH RES UNIT, GUILDFORD GU2 5XH, SURREY, ENGLAND.							BALARAJAN R, 1986, COMMUNITY MED, V8, P237; BALARAJAN R, 1990, DS9 OFF POP CENS SUR; BALARAJAN R, 1984, BRIT MED J, V289, P185; BECKLES GLA, 1986, LANCET, V1, P1298; CRUICKSHANK JK, 1980, BRIT MED J, V281, P1108, DOI 10.1136/bmj.281.6248.1108; CRUICKSHANK JK, 1983, POSTGRAD MED J, V59, P622, DOI 10.1136/pgmj.59.696.622; DEGIOVANNI JV, 1983, POSTGRAD MED J, V59, P627, DOI 10.1136/pgmj.59.696.627; DERRY CW, 1987, S AFR MED J, V72, P698; DISLER PB, 1987, S AFR MED J, V72, P408; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRELL GAC, 1983, POSTGRAD MED J, V59, P616, DOI 10.1136/pgmj.59.696.616; KEIL JE, 1980, J EPIDEMIOL COMMUN H, V34, P45, DOI 10.1136/jech.34.1.45; Malhotra S L, 1971, J Assoc Physicians India, V19, P211; MARMOR MG, 1984, 47 OFF POP CENS SURV; MARMOT MG, 1984, SCI F CARDIOLOGY; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1985, LANCET, V2, P1086; MILLER GJ, 1982, LANCET, V2, P200; MILLER GJ, 1975, LANCET, V1, P16; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; OMAR MAK, 1985, S AFR MED J, V67, P924; POCOCK SJ, 1986, BMJ-BRIT MED J, V292, P515, DOI 10.1136/bmj.292.6519.515; POONKING T, 1968, LANCET, V1, P155; Seedat Y K, 1983, J Hypertens, V1, P7; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SILMAN A, 1985, J EPIDEMIOL COMMUN H, V39, P301, DOI 10.1136/jech.39.4.301; STOUT RW, 1987, LANCET, V1, P1077; STOUT RW, 1969, LANCET, V1, P1078; ZIMMET P, 1983, AM J EPIDEMIOL, V118, P673, DOI 10.1093/oxfordjournals.aje.a113678; 1986, LANCET, V1, P1307; 1988, CORONARY HEART DISEA, V1; 1989, NATIONAL HLTH SERVIC	34	328	328	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	1991	302	6776					560	564		10.1136/bmj.302.6776.560	http://dx.doi.org/10.1136/bmj.302.6776.560			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021718	Bronze, Green Published			2022-12-24	WOS:A1991FB93600017
J	JACOBS, KM; DONOGHUE, JP				JACOBS, KM; DONOGHUE, JP			RESHAPING THE CORTICAL MOTOR MAP BY UNMASKING LATENT INTRACORTICAL CONNECTIONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NMDA RECEPTORS; CORTEX; INHIBITION; NEURONS; INVITRO	The primary motor cortex (MI) contains a map organized so that contralateral limb or facial movements are elicited by electrical stimulation within separate medial to lateral MI regions. Within hours of a peripheral nerve transection in adult rats, movements represented in neighboring MI areas are evoked from the cortical territory of the affected body part. One potential mechanism for reorganization is that adjacent cortical regions expand when preexisting lateral excitatory connections are unmasked by decreased intracortical inhibition. During pharmacological blockade of cortical inhibition in one part of the MI representation, movements of neighboring representations were evoked by stimulation in adjacent MI areas. These results suggest that intracortical connections form a substrate for reorganization of cortical maps and that inhibitory circuits are critically placed to maintain or readjust the form of cortical motor representations.			JACOBS, KM (corresponding author), BROWN UNIV,CTR NEURAL SCI,BOX 1953,PROVIDENCE,RI 02912, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022517, R01NS025074, R37NS025074] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22517, NS25074] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKHTAR N D, 1987, Society for Neuroscience Abstracts, V13, P77; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; Brown TG, 1912, P R SOC LOND B-CONTA, V85, P250, DOI 10.1098/rspb.1912.0050; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; CRAGGS MD, 1976, BRAIN, V99, P575, DOI 10.1093/brain/99.3.575; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1987, BRAIN RES, V408, P367, DOI 10.1016/0006-8993(87)90407-0; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P492; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; HENDRY SHC, 1986, NATURE, V320, P750, DOI 10.1038/320750a0; IRIKI A, 1989, SCIENCE, V245, P1385, DOI 10.1126/science.2551038; KRNJEVIC K, 1963, J PHYSIOL-LONDON, V166, P296, DOI 10.1113/jphysiol.1963.sp007106; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; METHERATE R, 1988, J NEUROPHYSIOL, V59, P1231, DOI 10.1152/jn.1988.59.4.1231; STELZER A, 1987, NATURE, V326, P698, DOI 10.1038/326698a0; WELKER E, 1989, EXP BRAIN RES, V74, P441, DOI 10.1007/BF00247346; WHITE EL, 1989, CORTICAL CIRCUITS SY, P46; WIGSTROM H, 1986, J PHYSIOL-PARIS, V81, P228; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x	19	749	761	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					944	947		10.1126/science.2000496	http://dx.doi.org/10.1126/science.2000496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000496				2022-12-24	WOS:A1991EY62900047
J	CELANDER, DW; CECH, TR				CELANDER, DW; CECH, TR			VISUALIZING THE HIGHER-ORDER FOLDING OF A CATALYTIC RNA MOLECULE	SCIENCE			English	Article							SELF-SPLICING RNA; GROUP-I INTRONS; NUCLEAR MAGNETIC-RESONANCE; PHENYLALANINE TRANSFER-RNA; TETRAHYMENA RIBOZYME; ENDORIBONUCLEASE ACTIVITY; INTERVENING SEQUENCE; TERTIARY STRUCTURE; BINDING-SITE; PROTEIN	The higher order folding process of the catalytic RNA derived from the self-splicing intron of Tetrahymena thermophila was monitored with the use of Fe(II)-EDTA-induced free radical chemistry. The overall tertiary structure of the RNA molecule forms cooperatively with the uptake of at least three magnesium ions. Local folding transitions display different metal ion dependencies, suggesting that the RNA tertiary structure assembles through a specific folding intermediate before the catalytic core is formed. Enzymatic activity, assayed with an RNA substrate that is complementary to the catalytic RNA active site, coincides with the cooperative structural transition. The higher order RNA foldings produced by Mg(II), Ca(II), and Sr(II) are similar; however, only the Mg(II)-stabilized RNA is catalytically active. Thus, these results directly demonstrate that divalent metal ions participate in general folding of the ribozyme tertiary structure, and further indicate a more specific involvement of Mg(II) in catalysis.			CELANDER, DW (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA.							ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; [Anonymous], COMMUNICATION; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1987, COLD SPRING HARB SYM, V52, P147, DOI 10.1101/SQB.1987.052.01.019; BOGUSKI MS, 1980, J BIOL CHEM, V255, P2160; BOYLE J, 1980, J MOL BIOL, V139, P601, DOI 10.1016/0022-2836(80)90051-0; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, UNPUB; CHANDRY S, COMMUNICATION; Creighton TE, 1983, PROTEINS STRUCTURES; CROTHERS DM, 1979, COLD SPRING HARBOR A, V9, P163; DANCHIN A, 1972, BIOCHIMIE, V54, P333, DOI 10.1016/S0300-9084(72)80212-8; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; FRESCO JR, 1966, COLD SPRING HARB SYM, V31, P527, DOI 10.1101/SQB.1966.031.01.068; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, COMMUNICATION; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HEUER T, UNPUB; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JEZEWSKA MJ, 1990, BIOCHEMISTRY-US, V29, P5220, DOI 10.1021/bi00473a032; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KAYNE MS, 1972, BIOCHEM BIOPH RES CO, V46, P1285; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; NAZAR RN, COMMUNICATION; PACE NR, 1990, J BIOL CHEM, V265, P3587; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; ROBILLARD GT, 1977, BIOCHEMISTRY-US, V16, P5261, DOI 10.1021/bi00643a016; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANDERHORST G, IN PRESS P NATL ACAD; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WILLIAMS AP, 1989, BIOCHEMISTRY-US, V28, P4283, DOI 10.1021/bi00436a025; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	69	346	355	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 25	1991	251	4992					401	407		10.1126/science.1989074	http://dx.doi.org/10.1126/science.1989074			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989074				2022-12-24	WOS:A1991EU50400034
J	CECCARELLI, A; MAHBUBANI, H; WILLIAMS, JG				CECCARELLI, A; MAHBUBANI, H; WILLIAMS, JG			POSITIVELY AND NEGATIVELY ACTING SIGNALS REGULATING STALK CELL AND ANTERIOR-LIKE CELL-DIFFERENTIATION IN DICTYOSTELIUM	CELL			English	Article							PRESTALK GENE-EXPRESSION; DISCOIDEUM; DIF; CAMP; TRANSFORMATION; MORPHOGEN; PROTEINS; FATE; SLUG	The Dictyostelium ecmB gene encodes an extracellular matrix protein and is inducible by the stalk cell morphogen DIF. It is expressed in a subset of prestalk (pstB) cells in the slug and surrounding pstA cells first express it at culmination. A region of the ecmB promoter can direct transcription in all anterior prestalk cells, but a separate, downstream region acts to prevent its expression in pstA cells prior to culmination. Th is may be the site of interaction of a repressor, regulated by an extracellular antagonist to DIF. At culmination, expression of the ecmB gene also becomes greatly elevated in anterior-like cells as they move to surround the spore mass. A distal region of the ecmB promoter directs increased expression in those anterior-like cells that surmount the spore head. This divergence in gene expression suggests that anterior-like cells and anterior prestalk cells experience different inductive conditions at culmination.			CECCARELLI, A (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,BLANCHE LANE,POTTERS BAR EN6 3LD,HERTS,ENGLAND.							AYRES K, 1987, MOL CELL BIOL, V7, P1823, DOI 10.1128/MCB.7.5.1823; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BLASCHKE A, 1986, DIFFERENTIATION, V32, P1, DOI 10.1111/j.1432-0436.1986.tb00549.x; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; GREGG JH, 1982, DIFFERENTIATION, V21, P200, DOI 10.1111/j.1432-0436.1982.tb01214.x; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAKUTANI T, 1986, DEV BIOL, V115, P439, DOI 10.1016/0012-1606(86)90264-2; MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023; MCROBBIE SJ, 1988, DEV BIOL, V125, P59, DOI 10.1016/0012-1606(88)90058-9; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MORRISSEY JH, 1984, DEV BIOL, V103, P414, DOI 10.1016/0012-1606(84)90329-4; NEAVE N, 1986, BIOCHEM CELL BIOL, V64, P85, DOI 10.1139/o86-015; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; RILEY BB, 1990, DEVELOPMENT, V109, P715; SCHAAP P, 1985, DEV BIOL, V111, P51, DOI 10.1016/0012-1606(85)90434-8; SCHINDLER J, 1977, J MOL BIOL, V116, P161, DOI 10.1016/0022-2836(77)90124-3; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; THALLER C, 1987, NATURE, V327, P626; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9	34	112	113	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					983	989		10.1016/0092-8674(91)90550-I	http://dx.doi.org/10.1016/0092-8674(91)90550-I			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044155				2022-12-24	WOS:A1991FR04700009
J	GEISER, JR; VANTUINEN, D; BROCKERHOFF, SE; NEFF, MM; DAVIS, TN				GEISER, JR; VANTUINEN, D; BROCKERHOFF, SE; NEFF, MM; DAVIS, TN			CAN CALMODULIN FUNCTION WITHOUT BINDING CALCIUM	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST CALMODULIN; SCHIZOSACCHAROMYCES-POMBE; GENETIC-EVIDENCE; DNA-POLYMERASE; PROTEIN-KINASE; CA-2+; CELLS; VERTEBRATE	Calmodulin is a small Ca2+-binding protein proposed to act as the intracellular Ca2+ receptor that translates Ca2+ signals into cellular responses. We have constructed mutant yeast calmodulins in which the Ca2+-binding loops have been altered by site-directed mutagenesis. Each of the mutant proteins has a dramatically reduced affinity for Ca2+; one does not bind detectable levels of Ca-45(2+) either during gel filtration or when bound to a solid support. Furthermore, none of the mutant proteins change conformation even in the presence of high Ca2+ concentrations. Surprisingly, yeast strains relying on any of the mutant calmodulins not only survive but grow well. In contrast, yeast strains deleted for the calmodulin gene are not viable. Thus, calmodulin is required for growth, but it can perform its essential function without the apparent ability to bind Ca2+.			GEISER, JR (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.		Davis, Trisha/F-8584-2010	Davis, Trisha/0000-0003-4797-3152				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACHS O, 1990, J BIOL CHEM, V265, P18595; BLUMBERG H, 1987, NATURE, V328, P443, DOI 10.1038/328443a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRADLEY DE, 1980, J BACTERIOL, V143, P1466, DOI 10.1128/JB.143.3.1466-1470.1980; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COHEN P, 1988, MOL ASPECTS CELL REG, V5, P123; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COOPER JA, 1987, ONCOGENE RES, V1, P297; COX JA, 1981, BIOCHIM BIOPHYS ACTA, V670, P441, DOI 10.1016/0005-2795(81)90119-7; CRABTREE S, 1984, J BACTERIOL, V158, P354, DOI 10.1128/JB.158.1.354-356.1984; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GARRETT J, 1981, MOL GEN GENET, V182, P326, DOI 10.1007/BF00269678; GRATZNER WB, 1988, CALMODULIN, V5, P329; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HARMON AC, 1985, BIOCHEM BIOPH RES CO, V127, P31, DOI 10.1016/S0006-291X(85)80121-2; HINRICHSEN RD, 1986, SCIENCE, V232, P503, DOI 10.1126/science.2421410; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; IIDA H, 1990, J BIOL CHEM, V265, P13391; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KEITH CH, 1987, CELL MOTIL CYTOSKEL, V7, P1, DOI 10.1002/cm.970070102; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEE CB, 1988, CALMODULIN MOL ASPEC, V5, P35; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LONDESBOROUGH J, 1987, FEBS LETT, V219, P249, DOI 10.1016/0014-5793(87)81226-7; LUAN Y, 1987, J BIOCHEM-TOKYO, V102, P1531, DOI 10.1093/oxfordjournals.jbchem.a122201; Marme D., 1983, CALCIUM CELL FUNCTIO, VIV, p263 ; Miller J.H., 1972, EXPT MOL GENETICS; MINDICH L, 1976, J BACTERIOL, V126, P177, DOI 10.1128/JB.126.1.177-182.1976; MIYAKAWA T, 1989, J BACTERIOL, V171, P1417, DOI 10.1128/jb.171.3.1417-1422.1989; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1989, BIOCHEM BIOPH RES CO, V158, P541, DOI 10.1016/S0006-291X(89)80083-X; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; PERSECHINI A, 1991, P NATL ACAD SCI USA, V88, P449, DOI 10.1073/pnas.88.2.449; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; RASMUSSEN CD, 1990, J BIOL CHEM, V265, P13767; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; RATAN RR, 1986, TRENDS BIOCHEM SCI, V11, P456, DOI 10.1016/0968-0004(86)90246-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAEFER WH, 1987, P NATL ACAD SCI USA, V84, P3931, DOI 10.1073/pnas.84.11.3931; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; Sherman F., 1986, METHODS YEAST GENETI; SLOTBOOM AJ, 1978, BIOCHEMISTRY-US, V17, P4593, DOI 10.1021/bi00615a003; STABEN C, 1986, J BIOL CHEM, V261, P4629; STULL JT, 1988, MOL ASPECTS CELLULAR, V5, P91; SWEET SC, 1988, J CELL BIOL, V107, P2243, DOI 10.1083/jcb.107.6.2243; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEDA T, 1989, P NATL ACAD SCI USA, V86, P9737, DOI 10.1073/pnas.86.24.9737; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; YOUDERIAN P, 1980, VIROLOGY, V107, P258, DOI 10.1016/0042-6822(80)90291-3	65	277	280	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					949	959		10.1016/0092-8674(91)90547-C	http://dx.doi.org/10.1016/0092-8674(91)90547-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044154	Green Published			2022-12-24	WOS:A1991FR04700006
J	KIM, CM; KOIKE, K; SAITO, I; MIYAMURA, T; JAY, G				KIM, CM; KOIKE, K; SAITO, I; MIYAMURA, T; JAY, G			HBX GENE OF HEPATITIS-B VIRUS INDUCES LIVER-CANCER IN TRANSGENIC MICE	NATURE			English	Article							HEPATOCELLULAR-CARCINOMA; X-PROTEIN; MOUSE MODEL; TAT GENE; EXPRESSION; ANTIGEN; TUMORS; ACTIVATION; INTEGRATION; SECRETION	THE exact role of hepatitis B virus in the development of liver cancer is not known. The recent identification of a viral regulatory gene HBx suggests a possible direct involvement of the virus whereby the HBx protein, acting as a transcriptional transactivator of viral genes, may alter host gene expression and lead to the development of hepatocellular carcinoma. We have tested this possibility by placing the entire HBx gene under its own regulatory elements directly into the germline of mice. Transgenic animals harbouring this viral gene succumbed to progressive histopathological changes specifically in the liver, beginning with multifocal areas of altered hepatocytes, followed by the appearance of benign adenomas, and proceeding to the development of malignant carcinomas. Male mice developed disease and died much earlier than females. This transgenic animal model appears ideal for defining the molecular events that follow the expression of the viral HBx gene and are responsible for the development of liver cancer.	AMER RED CROSS,JEROME H HOLLAND LAB,VIROL LAB,ROCKVILLE,MD 20855; NATL INST HLTH,DEPT ENTEROVIRUSES,HEPATITIS VIRUSES LAB,TOKYO 141,JAPAN	American Red Cross; National Institute of Health Sciences - Japan			Ibrahim, Essam Hassan/G-1960-2018; Jay, Gregory/C-6346-2013	Ibrahim, Essam Hassan/0000-0003-0130-2257; 				ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BANNASCH P, 1985, DIGESTIVE SYSTEM, P10; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BEASLEY RP, 1981, LANCET, V2, P1129; BECKER FF, 1982, CANCER RES, V42, P3918; BROOKS PN, 1985, DIGESTIVE SYSTEM, P47; BURK RD, 1988, J VIROL, V62, P649, DOI 10.1128/JVI.62.2.649-654.1988; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; COSMAN D, 1982, P NATL ACAD SCI-BIOL, V79, P4947, DOI 10.1073/pnas.79.16.4947; DEJEAN A, 1984, J GEN VIROL, V65, P651, DOI 10.1099/0022-1317-65-3-651; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FARZA H, 1988, J VIROL, V62, P4149; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; KLIMEK F, 1984, CARCINOGENESIS, V5, P265, DOI 10.1093/carcin/5.2.265; KOIKE K, 1989, P NATL ACAD SCI USA, V86, P5615, DOI 10.1073/pnas.86.14.5615; KOIKE K, 1988, VIROLOGY, V163, P233, DOI 10.1016/0042-6822(88)90256-5; KRESS M, 1983, CELL, V34, P189, DOI 10.1016/0092-8674(83)90149-6; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POPP JA, 1985, DIGESTIVE SYSTEM, P39; ROGLER CE, 1985, SCIENCE, V230, P319, DOI 10.1126/science.2996131; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545	39	1013	1054	8	57	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					317	320		10.1038/351317a0	http://dx.doi.org/10.1038/351317a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034275				2022-12-24	WOS:A1991FM97600061
J	ROCK, KL; GAMBLE, S; ROTHSTEIN, L; GRAMM, C; BENACERRAF, B				ROCK, KL; GAMBLE, S; ROTHSTEIN, L; GRAMM, C; BENACERRAF, B			DISSOCIATION OF BETA-2-MICROGLOBULIN LEADS TO THE ACCUMULATION OF A SUBSTANTIAL POOL OF INACTIVE CLASS-I MHC HEAVY-CHAINS ON THE CELL-SURFACE	CELL			English	Article							RESTRICTED T-CELLS; HISTOCOMPATIBILITY MOLECULES; ANTIGEN PRESENTATION; DENOVO SYNTHESIS; LYMPHOMA-CELLS; MOUSE LYMPHOMA; LYMPHOCYTES-T; RECOGNITION; PEPTIDES; BINDING	A large pool of free class I heavy chains is detected in situ on the plasma membrane of living cells. These chains are present on cells of different MHC genotypes and appear to exist under physiological conditions in vivo. These molecules arise from the dissociation of previously assembled class I heterodimers at the cell surface. The ratio of intact to dissociated heterodimers is strongly affected by the occupancy of the peptide-binding site of the class I molecule. Upon dissociation of the heterodimer, the class I molecule is functionally inactive. These finding may help to explain why class I molecules on the cell surface are unreceptive to binding peptides yet readily associated with peptides in the presence of exogenous beta-2-microglobulin. These results have implications for understanding the distinct functions of class I versus class II molecules and how the immunological identify of cells is preserved.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	ROCK, KL (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA.				PHS HHS [A120248] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BEVAN MJ, 1989, NATURE, V342, P478, DOI 10.1038/342478a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; CRESSWEL.P, 1974, P NATL ACAD SCI USA, V71, P2123, DOI 10.1073/pnas.71.5.2123; FALO LD, 1985, P NATL ACAD SCI USA, V82, P6647, DOI 10.1073/pnas.82.19.6647; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HAUSTEIN D, 1975, BIOCHEMISTRY-US, V14, P1826, DOI 10.1021/bi00680a004; HICKLING JK, 1990, INT IMMUNOL, V2, P435, DOI 10.1093/intimm/2.5.435; HYAFIL F, 1979, P NATL ACAD SCI USA, V76, P5834, DOI 10.1073/pnas.76.11.5834; HYMAN R, 1976, IMMUNOGENETICS, V3, P75, DOI 10.1007/BF01576940; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; KVIST S, 1979, EUR J IMMUNOL, V9, P991, DOI 10.1002/eji.1830091214; KVIST S, 1978, BIOCHEMISTRY-US, V17, P4794, DOI 10.1021/bi00615a029; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MYERS NB, 1989, J IMMUNOL, V142, P2751; NATORI T, 1976, J IMMUNOGENET, V3, P123; OZATO K, 1981, J IMMUNOL, V126, P317; PARHAM P, 1983, HUM IMMUNOL, V8, P207, DOI 10.1016/0198-8859(83)90038-1; PARKER KC, 1985, BIOCHEMISTRY-US, V24, P5543, DOI 10.1021/bi00341a039; PERKINS DL, 1989, J EXP MED, V170, P279, DOI 10.1084/jem.170.1.279; REISER H, 1986, CELL, V47, P365, DOI 10.1016/0092-8674(86)90593-3; ROBINSON PJ, 1983, TRANSPLANT P, V15, P2051; ROCK KL, 1983, J EXP MED, V157, P1618, DOI 10.1084/jem.157.5.1618; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; STALLCUP KC, 1981, J IMMUNOL, V127, P923; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TADA N, 1980, IMMUNOGENETICS, V11, P441, DOI 10.1007/BF01567813; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796	49	161	163	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					611	620		10.1016/0092-8674(91)90093-E	http://dx.doi.org/10.1016/0092-8674(91)90093-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032286				2022-12-24	WOS:A1991FM03700011
J	BACHELERIE, F; ALCAMI, J; ARENZANASEISDEDOS, F; VIRELIZIER, JL				BACHELERIE, F; ALCAMI, J; ARENZANASEISDEDOS, F; VIRELIZIER, JL			HIV ENHANCER ACTIVITY PERPETUATED BY NF-KAPPA-B INDUCTION ON INFECTION OF MONOCYTES	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; GENE-EXPRESSION; ALPHA; TRANSCRIPTION; INTERLEUKIN-1; ACTIVATION; MITOGENS	PERMISSIVENESS to replication of human immunodeficiency virus (HIV) differs in T lymphocytes and macrophages. In T cells, HIV transcription is poorly detected in vivo 1. Cloned, normal T lymphocytes show very little, if any, basal activity of the HIV enhancer and low nuclear expression of NF-kappa-B 2, a potent transcriptional activator of the HIV enhancer 3-5. In contrast, fixed tissue macrophages express detectable HIV proteins, indicating permanent virus transcription 6. One explanation for the perpetuation of virus infection in macrophages could be sustained nuclear NF-kappa-B expression. However, the U937 monocytic cell line, which is fully permissive to HIV replication, is known to express only low levels of nuclear NF-kappa-B 7. We show here that chronic HIV infection results in both induction of a nuclear factor with antigenic properties indistinguishable from those of NF-kappa-B and permanently increased HIV enhancer activity. This phenomenon, which is independent of tumour necrosis factor, is associated with HIV replication, and is thus likely to explain at least in part the perpetuation of HIV infection in monocytes.	INST PASTEUR,UNITE IMMUNOL VIRALE,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Alcami, Pepe/T-2242-2018; BACHELERIE, FRANCOISE/F-8823-2013; Arenzana-Seisdedos, Fernando/E-5835-2016	Alcami, Pepe/0000-0003-0023-7377; BACHELERIE, FRANCOISE/0000-0002-0399-3277; 				BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; DU EJ, 1990, P NATL ACAD SCI USA, V86, P5974; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; GHOSH R, 1990, CELL, V62, P1019; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRIFFIN G, 1990, NATURE, V343, P219, DOI 10.1038/343219a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HAASE AT, 1984, METHOD VIROL, V7, P189; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISRAEL N, 1989, J IMMUNOL, V143, P3956; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WANG Y, 1987, J EXP MED, V166, P625, DOI 10.1084/jem.166.3.625	26	179	182	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					709	712		10.1038/350709a0	http://dx.doi.org/10.1038/350709a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023633				2022-12-24	WOS:A1991FJ13000061
J	BEEN, MD; PERROTTA, AT				BEEN, MD; PERROTTA, AT			GROUP-I INTRON SELF-SPLICING WITH ADENOSINE - EVIDENCE FOR A SINGLE NUCLEOSIDE-BINDING SITE	SCIENCE			English	Article							TETRAHYMENA PRE-RRNA; BIOLOGICAL CATALYSIS; SECONDARY STRUCTURE; RNA; SEQUENCE; MITOCHONDRIA; RIBOZYME; IVS	For self-splicing of Tetrahymena ribosomal RNA precursor, guanosine binding is required for 5' splice-site cleavage and exon ligation. Whether these two reactions use the same or different guanosine-binding sites has been debated. A double mutation in a previously identified guanosine-binding site within the intron resulted in preference for adenosine (or adenosine triphosphate) as the substrate for cleavage at the 5' splice site. However, splicing was blocked in the exon ligation step. Blockage was reversed by a change from guanine to adenine at the 3' splice site. These results indicate that a single determinant specifies nucleoside binding for both steps of splicing. Furthermore, it suggests that RNA could form an active site specific for adenosine triphosphate.			BEEN, MD (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.bi.55.070186.003123; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; GARRIGA G, 1984, CELL, V39, P631, DOI 10.1016/0092-8674(84)90470-7; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; KAY PS, 1988, EMBO J, V7, P3531, DOI 10.1002/j.1460-2075.1988.tb03229.x; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PERROTTA AJ, UNPUB; PRICE JV, 1988, GENE DEV, V2, P1439, DOI 10.1101/gad.2.11.1439; TANNER NK, 1987, BIOCHEMISTRY-US, V26, P3330, DOI 10.1021/bi00386a013; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	20	105	108	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					434	437		10.1126/science.2017681	http://dx.doi.org/10.1126/science.2017681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017681				2022-12-24	WOS:A1991FH10300041
J	LEONE, A; FLATOW, U; KING, CR; SANDEEN, MA; MARGULIES, IMK; LIOTTA, LA; STEEG, PS				LEONE, A; FLATOW, U; KING, CR; SANDEEN, MA; MARGULIES, IMK; LIOTTA, LA; STEEG, PS			REDUCED TUMOR-INCIDENCE, METASTATIC POTENTIAL, AND CYTOKINE RESPONSIVENESS OF NM23-TRANSFECTED MELANOMA-CELLS	CELL			English	Article							GENE; NM23; DROSOPHILA; PROTEIN	Reduced expression of the nm23 gene in certain rodent model systems and human breast tumors has been correlated with high tumor metastatic potential. To investigate the functional effects of nm23 expression, we have transfected a constitutive murine nm23-1 expression construct into highly metastatic K-1735 TK murine melanoma cells. TK clones expressing the exogenous nm23-1 construct exhibited a reduced incidence of primary tumor formation, significant reductions in tumor metastatic potential independent of tumor cell growth, and altered responses to the cytokine transforming growth factor-beta-1 in soft agar colonization assays, compared with control-transfected TK clones. In contrast, nm23-1-transfected TK clones exhibited no significant differences in intrinsic tumor cell growth, i.e., primary tumor size in vivo, anchorage-dependent growth rate in vitro, and anchorage-independent colony formation in soft agar in vitro. The data demonstrate a suppressive effect of nm23 on several aspects of the cancer process, including tumor metastasis.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21740; MOLEC ONCOL INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LEONE, A (corresponding author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA.		Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DAROLF CR, 1988, DEV BIOL, V129, P169; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KALEBIC T, 1988, CLIN EXP METASTAS, V6, P301, DOI 10.1007/BF01753577; KIKKAWA S, 1991, IN PRESS J BIOL CHEM; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; ROSENBERG SA, 1987, SURGICAL TREATMENT M; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHWARZ LC, 1988, CANCER RES, V48, P6999; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199	23	575	614	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					25	35		10.1016/0092-8674(91)90404-M	http://dx.doi.org/10.1016/0092-8674(91)90404-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013093	Bronze			2022-12-24	WOS:A1991FF77300005
J	SALONEN, JT; SALONEN, R; SEPPANEN, K; KANTOLA, M; SUNTIOINEN, S; KORPELA, H				SALONEN, JT; SALONEN, R; SEPPANEN, K; KANTOLA, M; SUNTIOINEN, S; KORPELA, H			INTERACTIONS OF SERUM COPPER, SELENIUM, AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN ATHEROGENESIS	BRITISH MEDICAL JOURNAL			English	Article							PLASMA; OXIDATION; MAGNESIUM; SMOKING; ADULTS; ZINC	Objective-To investigate the interactions between serum cooper, selenium, and low density lipoprotein cholesterol concentrations with regard to the progression of carotid atherosclerosis. Design-Longitudinal study of a cohort of middle aged men followed up for 24 months. Setting-Epidemiological survey of the population of seven communities in eastern Finland. Subjects-126 men aged 42, 48, 54, or 60 at examination randomly selected from a population based sample of 2682 men. Main outcome measures-Increase in maximal carotid intima media thickness. Results-The mean increase in the maximal common carotid intima media thickness after two years was greater in men with high serum copper concentrations (0.16 mm compared with 0.08 mm in men with concentrations < 17.6-mu-mol/l; p = 0.010), those with low serum selenium concentrations (0.15 mm compared with 0.09 mm in men with concentrations greater-than-or-equal-to 1.40-mu-mol/l; p = 0.035), and those with raised serum low density lipoprotein cholesterol concentrations (0.15 mm compared with 0.08 mm in men with concentrations < 4.0-mmol/l; p = 0.032) after adjustment for age and cigarette pack years in a three way analysis of covariance. A raised serum low density lipoprotein concentration was associated with accelerated progression of atherosclerosis only in men with higher than median serum copper concentrations (net difference 0.22 mm; p < 0.001 for two way interaction), and this synergism was even more pronounced in men with serum selenium concentrations below the median value (net difference 0.41 mm; p = 0.042 for three way interaction). Conclusion-These data provide evidence of a synergistic effect of copper (a pro-oxidant), a low serum concentration of selenium (a cofactor of an enzyme that scavenges free radicals), and low density lipoprotein cholesterol concentration in atherogenesis.	KUOPIO RES INST EXERCISE MED,KUOPIO,FINLAND; UNIV KUOPIO,DEPT CHEM,KUOPIO,FINLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND	University of Eastern Finland; University of Eastern Finland	SALONEN, JT (corresponding author), UNIV KUOPIO,PUBL HLTH RES INST,POB 6,SF-70211 KUOPIO,FINLAND.							AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BLANKENHORN DH, 1990, CIRCULATION, V81, P470, DOI 10.1161/01.CIR.81.2.470; CARLSON K, 1973, J CLIN PATHOL S5, V26, P32; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P342; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HATANO S, 1982, AM J CLIN NUTR, V35, P120, DOI 10.1093/ajcn/35.1.120; HIISVIRTA L, 1985, FINN J WATER EC HYDR, V26, P30; JEANDEL C, 1989, GERONTOLOGY, V35, P275, DOI 10.1159/000213037; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KANT AK, 1989, NUTR RES, V9, P717, DOI 10.1016/S0271-5317(89)80015-6; LEWIS KO, 1982, LANCET, V2, P188; LLOYD B, 1983, J EPIDEMIOL COMMUN H, V37, P213, DOI 10.1136/jech.37.3.213; LUDWIG PW, 1982, LANCET, V1, P348; MAKINEN P, 1989, WATER ENV, V38; MOORE JA, 1984, CLIN CHEM, V30, P1171; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARVIAINEN MT, 1986, J LIQ CHROMATOGR, V9, P2185, DOI 10.1080/01483918608074142; PUNSAR S, 1975, J CHRON DIS, V28, P259, DOI 10.1016/0021-9681(75)90009-0; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1982, LANCET, V2, P175; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SALONEN R, IN PRESS ULTRASOUND; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SHAMBERGER RJ, 1984, BIOCH ESSENTIAL ULTR, P201; SINGH A, 1989, AM J CLIN NUTR, V49, P695, DOI 10.1093/ajcn/49.4.695; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; 1983, SPSS X USERS GUIDE C; 1988, ARCH INTERN MED, V148, P36; 1989, INT J EPIDEMIOL S1, V18, pS46; 1988, EUR HEART J, V9, P571	33	196	202	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					756	760		10.1136/bmj.302.6779.756	http://dx.doi.org/10.1136/bmj.302.6779.756			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021765	Green Published, Bronze			2022-12-24	WOS:A1991FF22900022
J	GASSER, RA; MAGILL, AJ; OSTER, CN; TRAMONT, EC				GASSER, RA; MAGILL, AJ; OSTER, CN; TRAMONT, EC			THE THREAT OF INFECTIOUS-DISEASE IN AMERICANS RETURNING FROM OPERATION DESERT STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGO HEMORRHAGIC-FEVER; SAUDI-ARABIA; CUTANEOUS LEISHMANIASIS; NOSOCOMIAL OUTBREAK; TYPHOID-FEVER; WILD ANIMALS; CLINICAL EFFICACY; DRUG-RESISTANCE; WESTERN REGION; KUWAIT		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	GASSER, RA (corresponding author), WALTER REED ARMY MED CTR, INFECT DIS SERV, WASHINGTON, DC 20307 USA.							ABDELHAFEZ MMA, 1986, ANN TROP MED PARASIT, V80, P631, DOI 10.1080/00034983.1986.11812078; AHMED M M, 1989, Journal of the Egyptian Society of Parasitology, V19, P583; ALAWADI AR, 1982, B WORLD HEALTH ORGAN, V60, P283; ALMOFLEH IA, 1990, ANN SAUDI MED, V10, P620, DOI 10.5144/0256-4947.1990.620; ALNAKIB W, 1984, T ROY SOC TROP MED H, V78, P474, DOI 10.1016/0035-9203(84)90065-8; ALORAINEY IO, 1989, TUBERCLE, V70, P207, DOI 10.1016/0041-3879(89)90052-4; ALTIKRITI SK, 1981, B WORLD HEALTH ORGAN, V59, P85; ALTIKRITI SK, 1981, J TROP MED HYG, V84, P117; ALZAHRANI MA, 1989, T ROY SOC TROP MED H, V83, P621, DOI 10.1016/0035-9203(89)90376-3; ALZAHRANI MA, 1989, T ROY SOC TROP MED H, V83, P503, DOI 10.1016/0035-9203(89)90267-8; ASHI J, 1989, J TROP MED HYG, V92, P27; ASPERILLA MO, 1990, REV INFECT DIS, V12, P873; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BADARO R, 1986, LANCET, V1, P647; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BAHMANYAR M, 1972, AM J TROP MED HYG, V21, P123, DOI 10.4269/ajtmh.1972.21.123; BARTELLONI PJ, 1976, AM J TROP MED HYG, V25, P456, DOI 10.4269/ajtmh.1976.25.456; BASSILY S, 1970, T ROY SOC TROP MED H, V64, P723, DOI 10.1016/0035-9203(70)90013-1; BERMAN JD, 1988, REV INFECT DIS, V10, P560; BIENZLE U, 1978, TROPENMED PARASITOL, V29, P188; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; CHUGH TD, 1983, TROP GEOGR MED, V35, P37; CHUGH TD, 1985, J HYG-CAMBRIDGE, V95, P391, DOI 10.1017/S0022172400062811; DAMJANOVIC V, 1984, J HYG-CAMBRIDGE, V92, P205, DOI 10.1017/S0022172400064226; EITREM R, 1990, AM J TROP MED HYG, V43, P207, DOI 10.4269/ajtmh.1990.43.207; ELBIHARI S, 1987, TROP MED PARASITOL, V38, P89; ELHAZMI MAF, 1989, J TROP MED HYG, V92, P427; ELHAZMI MAF, 1989, J TROP MED HYG, V92, P56; FARID Z, 1970, J TROP MED HYG, V73, P153; GAMRA EMA, 1983, J EGYPT SOC PARASITO, V13, P227; GILMAN RH, 1975, LANCET, V1, P1211; GUERRACACERES JG, 1979, T ROY SOC TROP MED H, V73, P680, DOI 10.1016/0035-9203(79)90020-8; GUNN RA, 1981, B WORLD HEALTH ORGAN, V59, P61; HATHOUT SED, 1967, AM J TROP MED HYG, V16, P462, DOI 10.4269/ajtmh.1967.16.462; Hertig M., 1964, PREVENTIVE MED WORLD, V7, P109; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; ISLAM A, 1988, J INFECT DIS, V158, P742, DOI 10.1093/infdis/158.4.742; JOPLING WH, 1955, BRIT MED J, V2, P1013, DOI 10.1136/bmj.2.4946.1013-a; KAPLAN M M, 1955, Bull World Health Organ, V13, P829; KARAWYA EM, 1990, ANN SAUDI MED, V10, P165, DOI 10.5144/0256-4947.1990.165; KASIM AA, 1983, ACTA TROP, V40, P155; KASSIMI MA, 1985, J HOSP INFECT, V6, P234; KHAIRY N, 1980, ANN TROP MED PARASIT, V74, P29, DOI 10.1080/00034983.1980.11687307; Khuffash F A, 1982, Ann Trop Paediatr, V2, P123; KIEL FW, 1987, J CLIN MICROBIOL, V25, P1384, DOI 10.1128/JCM.25.8.1384-1387.1987; KILLICKKENDRICK R, 1985, T ROY SOC TROP MED H, V79, P252, DOI 10.1016/0035-9203(85)90350-5; Marrie T. J., 1988, Biology of rickettsial diseases. Volume II., P1; MATOSSIAN RM, 1963, AM J TROP MED HYG, V12, P82, DOI 10.4269/ajtmh.1963.12.82; MCKEE K, 1990, DIAGNOSIS TREATMENT; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; MOORE PS, 1989, LANCET, V2, P260; MOUSA ARM, 1988, REV INFECT DIS, V10, P211; MURPHY C, 1991, WASHINGTON POST 0126, pA1; MURPHY C, 1991, WASHINGTON POST 0126, pA15; NEVES J, 1967, T ROY SOC TROP MED H, V61, P541, DOI 10.1016/0035-9203(67)90105-8; NEVES J, 1969, T ROY SOC TROP MED H, V63, P79, DOI 10.1016/0035-9203(69)90070-4; NOAH MS, 1986, ANN TROP MED PARASIT, V80, P607, DOI 10.1080/00034983.1986.11812075; OLDFIELD EC, 1991, REV INFECT DIS, V13, pS199; PETERS W, 1987, SAUDI MED J, V8, P333; PETERS W, 1988, T ROY SOC TROP MED H, V82, P179, DOI 10.1016/0035-9203(88)90400-2; QADRI MH, 1990, ANN SAUDI MED, V10, P280, DOI 10.5144/0256-4947.1990.280; QADRI SMH, 1989, J NATL MED ASSOC, V81, P1061; RAMIA S, 1987, T ROY SOC TROP MED H, V81, P317, DOI 10.1016/0035-9203(87)90251-3; RAMIA S, 1986, TROP GEOGR MED, V38, P63; RAMIREZ CA, 1985, ANTIMICROB AGENTS CH, V28, P128, DOI 10.1128/AAC.28.1.128; SALIH SY, 1977, J TROP MED HYG, V80, P14; SCHIOTT CR, 1985, SAUDI MED J, V6, P375; SCOTT DA, 1990, T ROY SOC TROP MED H, V84, P288, DOI 10.1016/0035-9203(90)90290-U; SEBAI ZA, 1988, TROP DOCT, V18, P183, DOI 10.1177/004947558801800415; SETHI S K, 1989, Journal of Diarrhoeal Diseases Research, V7, P85; SETHI SK, 1989, PEDIATR INFECT DIS J, V8, P593, DOI 10.1097/00006454-198909000-00005; SHOBOKSHI OA, 1987, T ROY SOC TROP MED H, V81, P219, DOI 10.1016/0035-9203(87)90220-3; SULEIMAN MNEH, 1980, LANCET, V2, P939; TESH RB, 1989, ISRAEL J MED SCI, V25, P214; VANDEWAL BW, 1985, S AFR MED J, V68, P729; VANEEDEN PJ, 1985, S AFR MED J, V68, P718; VANEEDEN PJ, 1985, S AFR MED J, V68, P711; VASSALLO L, 1985, ANN TROP MED PARASIT, V79, P349, DOI 10.1080/00034983.1985.11811931; WATTS DM, 1989, AM J TROP MED HYG, V41, P581, DOI 10.4269/ajtmh.1989.41.581; WEINRAUCH L, 1987, BRIT J DERMATOL, V117, P666, DOI 10.1111/j.1365-2133.1987.tb07504.x; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680; YOUSIF AA, 1989, J BAHRAIN MED SOC, V1, P52; 1985, WHO TECH REP SER, V721, P1; 1990, MED LETT DRUGS THER, V32, P23; 1990, WORLD HLTH STAT Q, V43, P68; 1990, WKLY EPIDEMIOL REC, V65, P321; 1987, MMWR, V36, P559; 1990, WKLY EPIDEMIOL REC, V65, P337	89	41	41	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					859	864		10.1056/NEJM199103213241229	http://dx.doi.org/10.1056/NEJM199103213241229			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997866	Bronze			2022-12-24	WOS:A1991FC44200036
J	WING, S; SHY, CM; WOOD, JL; WOLF, S; CRAGLE, DL; FROME, EL				WING, S; SHY, CM; WOOD, JL; WOLF, S; CRAGLE, DL; FROME, EL			MORTALITY AMONG WORKERS AT OAK RIDGE NATIONAL LABORATORY - EVIDENCE OF RADIATION EFFECTS IN FOLLOW-UP THROUGH 1984	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RATES; COHORT; MISCLASSIFICATION; SELECTION; SURVIVAL; EXPOSURE; PLANT	White men hired at the Oak Ridge (Tenn) National Laboratory between 1943 and 1972 were followed up for vital status through 1984 (N = 8318, 1524 deaths). Relatively low mortality compared with that in US white men was observed for most causes of death, but leukemia mortality was elevated in the total cohort (63% higher, 28 deaths) and in workers who had at some time been monitored for internal radionuclide contamination (123% higher, 16 deaths). Median cumulative dose of external penetrating radiation was 1.4 mSv; 638 workers had cumulative doses above 50 mSv (5 rem). After accounting for age, birth cohort, a measure of socioeconomic status, and active worker status, external radiation with a 20-year exposure lag was related to all causes of death (2.68% increase per 10 mSv) primarily due to an association with cancer mortality (4.94% per 10 mSv). Studies of this population through 1977 did not find radiation-cancer mortality associations, and identical analyses using the shorter follow-up showed that associations with radiation did not appear until after 1977. The radiation-cancer dose response is 10 times higher than estimates from the follow-up of survivors of the bombings of Hiroshima and Nagasaki, Japan, but similar to one previous occupational study. Dose-response estimates are subject to uncertainties due to potential problems, including measurement of radiation doses and cancer outcomes. Longer-term follow-up of this and other populations with good measurement of protracted low-level exposures will be critical to evaluating the generalizability of the results reported herein.	OAK RIDGE TENN ASSOCIATED UNIV,CTR EPIDEMIOL RES,OAK RIDGE,TN; OAK RIDGE NATL LAB,MATH SCI SECT,OAK RIDGE,TN 37830	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory	WING, S (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CB 7400,CHAPEL HILL,NC 27599, USA.							[Anonymous], 1990, HLTH EFFECTS EXPOSUR; AXELSON O, 1989, BRIT J IND MED, V46, P505; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHECKOWAY H, 1985, BRIT J IND MED, V42, P525; CLAPP RW, 1987, LANCET, V2, P1324; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; DEVESA SS, 1989, J NATL CANCER I, V81, P1568, DOI 10.1093/jnci/81.20.1568; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GILBERT ES, 1990, AM J EPIDEMIOL, V131, P917, DOI 10.1093/oxfordjournals.aje.a115581; GILBERT ES, 1983, BIOMETRICS, V39, P161, DOI 10.2307/2530816; GILBERT ES, 1989, RADIAT RES, V120, P19, DOI 10.2307/3577633; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; LAND CE, 1980, SCIENCE, V209, P1197, DOI 10.1126/science.7403879; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; MCMICHAEL AJ, 1976, J OCCUP ENVIRON MED, V18, P165, DOI 10.1097/00043764-197603000-00009; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MORRIS M, 1990, INVESTIGATION LEUKEM; PEARCE N, 1986, SCAND J WORK ENV HEA, V12, P97, DOI 10.5271/sjweh.2161; SHORE RE, 1990, HEALTH PHYS, V59, P63, DOI 10.1097/00004032-199007000-00007; SHY CM, 1978, B NEW YORK ACAD MED, V54, P1155; TORNQVIST L, 1985, AM STAT, V39, P43, DOI 10.2307/2683905; UPTON AC, 1990, JNCI-J NATL CANCER I, V82, P448, DOI 10.1093/jnci/82.6.448; WILCOSKY T, 1987, SCAND J WORK ENV HEA, V13, P70, DOI 10.5271/sjweh.2078; WING S, 1988, AM J PUBLIC HEALTH, V78, P1415, DOI 10.2105/AJPH.78.11.1415; WOOLHANDLER S, 1985, LANCET, V1, P1375; 1985, NIH852748 PUBL	29	153	156	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1397	1402		10.1001/jama.265.11.1397	http://dx.doi.org/10.1001/jama.265.11.1397			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999879				2022-12-24	WOS:A1991FB55000019
J	DOUGLAS, SE; MURPHY, CA; SPENCER, DF; GRAY, MW				DOUGLAS, SE; MURPHY, CA; SPENCER, DF; GRAY, MW			CRYPTOMONAD ALGAE ARE EVOLUTIONARY CHIMERAS OF 2 PHYLOGENETICALLY DISTINCT UNICELLULAR EUKARYOTES	NATURE			English	Article							SUBUNIT RIBOSOMAL-RNA; C-CONTAINING ALGA; ORGANELLES; ORIGINS; DNA	ALTHOUGH it is widely accepted that the plastids of plants and algae originated as endosymbionts 1, the details of this evolutionary process are unclear 2,3. It has been proposed that in organisms whose plastids are surrounded by more than two membranes, the endosymbiont was a eukaryotic alga rather than a photosynthetic prokaryote 4. The DNA-containing 5 nucleomorph 6 of cryptomonad algae appears to be the vestigial nucleus of such an algal endosymbiont 7. Eukaryotic-type ribosomal RNA sequences have been localized to a nucleolus-like structure in the nucleomorph 8. In support of the hypothesis that cryptomonads are evolutionary chimaeras of two distinct eukaryotic cells, we show here that Cryptomonas PHI contains two phylogenetically separate, nuclear-type small-subunit rRNA genes, both of which are transcriptionally active. We incorporate our rRNA sequence data into phylogenetic trees, from which we infer the evolutionary ancestry of the host and symbiont components of Cryptomonas PHI. Such trees do not support the thesis 3 that chromophyte algae evolved directly from a cryptomonad-like ancestor.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX B3H 4H7,NS,CANADA	Dalhousie University	DOUGLAS, SE (corresponding author), NATL RES COUNCIL CANADA,ATLANTIC REG LAB,INST MARINE BIOSCI,1411 OXFORD ST,HALIFAX B3H 3Z1,NS,CANADA.			Gray, Michael/0000-0001-7125-2625				BHATTACHARYA D, 1990, J PHYCOL, V26, P181, DOI 10.1111/j.0022-3646.1990.00181.x; BIRD CJ, 1990, NUCLEIC ACIDS RES, V18, P4023, DOI 10.1093/nar/18.13.4023; Cavalier-Smith T., 1986, Progress phycol. Res., V4, P309; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DOUGLAS SE, 1989, PLANT MOL BIOL, V13, P13, DOI 10.1007/BF00027331; DOUGLAS SE, 1988, CURR GENET, V14, P591, DOI 10.1007/BF00434085; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; GRAY MW, 1984, NUCLEIC ACIDS RES, V12, P5837, DOI 10.1093/nar/12.14.5837; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; GREENWOOD A D, 1977, British Phycological Journal, V12, P119; GUNDERSON JH, 1987, P NATL ACAD SCI USA, V84, P5823, DOI 10.1073/pnas.84.16.5823; HENDRIKS L, 1989, SYST APPL MICROBIOL, V12, P223, DOI 10.1016/S0723-2020(89)80066-9; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; LUDWIG M, 1987, ANN NY ACAD SCI, V503, P198, DOI 10.1111/j.1749-6632.1987.tb40609.x; LUDWIG M, 1985, PROTOPLASMA, V127, P9, DOI 10.1007/BF01273697; Maxam A M, 1980, Methods Enzymol, V65, P499; MCFADDEN GI, 1990, J CELL SCI, V95, P303; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; PERASSO R, 1989, NATURE, V339, P142, DOI 10.1038/339142a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNARE MN, 1986, J BIOL CHEM, V261, P5187; Sogin M. L, 1990, PCR PROTOCOLS GUIDE, P307, DOI DOI 10.1016/B978-0-12-372180-8.50041-X; SWOFFORD DL, 1989, PAUP VERSION 3 0 ILL; WHATLEY JM, 1981, NEW PHYTOL, V87, P233, DOI 10.1111/j.1469-8137.1981.tb03195.x	27	244	246	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					148	151		10.1038/350148a0	http://dx.doi.org/10.1038/350148a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005963				2022-12-24	WOS:A1991FB64500056
J	KUHLBRANDT, W; WANG, DN				KUHLBRANDT, W; WANG, DN			3-DIMENSIONAL STRUCTURE OF PLANT LIGHT-HARVESTING COMPLEX DETERMINED BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							A/B-PROTEIN COMPLEX; PHOTOSYNTHETIC REACTION CENTER; RHODOPSEUDOMONAS-VIRIDIS; SENSITIVE SPECIMENS; PURPLE MEMBRANE; CHLOROPHYLL; RESOLUTION; MICROGRAPHS; CRYSTALS; BEAM	The structure of the light-harvesting chlorophyll a/b-protein complex, a membrane protein serving as the major antenna of solar energy in plant photosynthesis, has been determined at 6 angstrom resolution by electron crystallography. Within the complex, three membrane-spanning alpha-helices and 15 chlorophyll molecules are resolved. There is an intramolecular diad relating two of the alpha-helices and some of the chlorophylls. The spacing of the chlorophylls suggests energy transfer by delocalized exciton coupling and Forster mechanisms.			KUHLBRANDT, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.			Kuhlbrandt, Werner/0000-0002-2013-4810; Wang, Da-Neng/0000-0002-6496-4699				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BALDWIN J, 1984, ULTRAMICROSCOPY, V14, P319, DOI 10.1016/0304-3991(84)90217-1; BRODY SS, 1957, REV SCI INSTRUM, V28, P1021, DOI 10.1063/1.1715792; BULLOUGH P, 1987, ULTRAMICROSCOPY, V21, P223, DOI 10.1016/0304-3991(87)90147-1; BURGI R, 1987, BIOCHIM BIOPHYS ACTA, V890, P346, DOI 10.1016/0005-2728(87)90162-9; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHOTHIA C, 1985, REV BIOCH, V53, P537; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DOWNING KH, 1986, ULTRAMICROSCOPY, V20, P269, DOI 10.1016/0304-3991(86)90191-9; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GLAESER RM, 1989, ULTRAMICROSCOPY, V27, P307, DOI 10.1016/0304-3991(89)90021-1; HAYWARD SB, 1980, ULTRAMICROSCOPY, V5, P3, DOI 10.1016/0304-3991(80)90005-4; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HENDERSON R, 1985, ULTRAMICROSCOPY, V16, P139, DOI 10.1016/0304-3991(85)90069-5; HOFFMANN NE, 1986, P NATL ACAD SCI USA, V84, P8844; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; KARLINNEUMANN GA, 1985, J MOL APPL GENET, V3, P45; KUHLBRANDT W, 1984, NATURE, V307, P478, DOI 10.1038/307478a0; KUHLBRANDT W, 1983, J CELL BIOL, V96, P1414, DOI 10.1083/jcb.96.5.1414; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MICHEL H, 1986, ENCY PLANT PHYSL PHO, V19, P371; MULLET JE, 1983, J BIOL CHEM, V258, P9941; SAUER K, 1986, ENCY PLANT PHYSL, V19, P85; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SHIPMAN LL, 1976, J AM CHEM SOC, V98, P8222, DOI 10.1021/ja00441a056; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; SIMPSON DJ, 1979, CARLSBERG RES COMMUN, V44, P305, DOI 10.1007/BF02906493; STARK W, 1984, EMBO J, V3, P777, DOI 10.1002/j.1460-2075.1984.tb01884.x; VANGRONDELLE R, 1985, BIOCHIM BIOPHYS ACTA, V811, P147, DOI 10.1016/0304-4173(85)90017-5; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG DN, 1991, IN PRESS J MOL BIOL; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438	39	425	432	5	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					130	134						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005962				2022-12-24	WOS:A1991FB64500048
J	RAYMOND, M; CALLAGHAN, A; FORT, P; PASTEUR, N				RAYMOND, M; CALLAGHAN, A; FORT, P; PASTEUR, N			WORLDWIDE MIGRATION OF AMPLIFIED INSECTICIDE RESISTANCE GENES IN MOSQUITOS	NATURE			English	Article							ORGANO-PHOSPHATE RESISTANCE; CULEX-PIPIENS L; DROSOPHILA-MELANOGASTER; L DIPTERA; QUINQUEFASCIATUS DIPTERA; DETOXIFYING ESTERASES; ALCOHOL-DEHYDROGENASE; CULICIDAE; COMPLEX; POPULATIONS	IN Culex pipiens, overproduction of nonspecific esterases is a common mechanism of resistance to organophosphate insecticides 1,2. The esterases are attributed to closely linked loci named A and B according to substrate preference 3-6, and overproduction of all esterases B is due to gene amplification 7,8. Distribution of electrophoretically distinct variants of overproduced esterases A and B is geographically restricted, with the exception of esterases A2 and B2, always found together throughout at least three continents (Fig. 1). To determine whether this situation is due to migration or to a high mutation rate, esterase B structural genes and their flanking regions were compared by sequence and/or restriction fragment length polymorphism analysis. Whereas structural genes were similar, flanking regions of electrophoretically dissimilar esterases B varied considerably. In contrast, flanking sequences of esterases B2 from different geographical locations (Africa, Asia, North America) were identical. These results suggest that amplified esterase B2 genes originated from an initial event that has subsequently spread organophosphate insecticide resistance by migration.	UNIV MONTPELLIER 2,BIOL MOLEC LAB,URA 1191,F-34095 MONTPELLIER,FRANCE	Universite de Montpellier	RAYMOND, M (corresponding author), INST SCI EVOLUT,GENET & ENVIRONM LAB,URA 327,CASE COURRIER 64,F-34095 MONTPELLIER,FRANCE.		Fort, Philippe/M-9498-2015; Raymond, Michel/C-9049-2015	Fort, Philippe/0000-0001-5997-8722; Callaghan, Amanda/0000-0002-2731-3352; Raymond, Michel/0000-0002-1714-6984				AGUADE M, 1988, GENETICS, V119, P135; ANDREADIS TG, 1988, J AM MOSQUITO CONTR, V4, P256; AQUADRO CF, 1986, GENETICS, V114, P1165; ASAHINA S, 1970, JPN J MED SCI BIOL, V23, P255, DOI 10.7883/yoken1952.23.255; BEYSSATARNAOUTY V, 1989, J AM MOSQUITO CONTR, V5, P196; BEYSSATARNAOUTY V, 1989, THESIS U MONTPELLIER; CALLAGHAN A, 1989, THESIS U LONDON; CURTIS CF, 1981, B ENTOMOL RES, V71, P153, DOI 10.1017/S0007485300051129; DESTORDEUR E, 1976, BIOCHEM GENET, V14, P481, DOI 10.1007/BF00486128; FOURNIER D, 1987, PESTIC BIOCHEM PHYS, V27, P211, DOI 10.1016/0048-3575(87)90048-4; GEORGHIOU GP, 1980, J ECON ENTOMOL, V73, P489, DOI 10.1093/jee/73.4.489; GEORGHIOU GP, 1966, B WORLD HEALTH ORGAN, V35, P691; HEMINGWAY J, 1989, MED VET ENTOMOL, V3, P445; HIGHTON RB, 1970, B WORLD HEALTH ORGAN, V42, P334; KREITMAN M, 1986, P NATL ACAD SCI USA, V83, P3562, DOI 10.1073/pnas.83.10.3562; MAGNIN M, 1988, J MED ENTOMOL, V25, P99, DOI 10.1093/jmedent/25.2.99; MAGNIN M, 1986, THESIS U PARIS 6; MOUCHES C, 1990, P NATL ACAD SCI USA, V87, P2574, DOI 10.1073/pnas.87.7.2574; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; MOUCHES C, 1987, P NATL ACAD SCI USA, V84, P2113, DOI 10.1073/pnas.84.8.2113; PASTEUR N, 1981, BIOCHEM GENET, V19, P499, DOI 10.1007/BF00484622; PASTEUR N, 1981, BIOCHEM GENET, V19, P909, DOI 10.1007/BF00504256; PASTEUR N, 1989, J ECON ENTOMOL, V82, P347, DOI 10.1093/jee/82.2.347; RAYMOND M, 1987, J MED ENTOMOL, V24, P24, DOI 10.1093/jmedent/24.1.24; RAYMOND M, 1985, CR ACAD SCI III-VIE, V300, P509; RAYMOND M, 1989, BIOCHEM GENET, V27, P417, DOI 10.1007/BF02399670; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONS GM, 1989, EVOLUTION, V43, P393, DOI 10.1111/j.1558-5646.1989.tb04235.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; URBANELLI S, 1985, B ENTOMOL RES, V75, P291, DOI 10.1017/S0007485300014383; VILLANI F, 1987, PESTIC BIOCHEM PHYS, V27, P218, DOI 10.1016/0048-3575(87)90049-6; VILLANI F, 1983, B ENTOMOL RES, V73, P153, DOI 10.1017/S0007485300013882; WIRTH MC, 1990, J MED ENTOMOL, V27, P202, DOI 10.1093/jmedent/27.2.202	33	262	290	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					151	153		10.1038/350151a0	http://dx.doi.org/10.1038/350151a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005964				2022-12-24	WOS:A1991FB64500057
J	COHEN, C; BENJAMIN, M				COHEN, C; BENJAMIN, M			ALCOHOLICS AND LIVER-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Two arguments underlie a widespread unwillingness to consider patients with alcoholic cirrhosis of the liver as candidates for transplantation. First, alcoholics are morally blameworthy, their condition the result of their own misconduct; such blameworthiness disqualifies alcoholics in unavoidable competition for organs with others who are equally sick but blameless. Second, because of their habits, alcoholics will not exhibit satisfactory rates of survival after transplantation; good stewardship of a scarce lifesaving resource therefore requires that alcoholics not be considered for liver transplantation. These arguments are carefully analyzed and shown to be defective. There is not good moral or medical reason for categorically precluding alcoholics as candidates for liver transplantation. It would, in addition, be unjust to implement such a preclusion simply because others might respond negatively if we do not.			COHEN, C (corresponding author), TRANSPLANT & HLTH POLICY CTR,115 WASHTENAW PL,BOX 0716,ANN ARBOR,MI 48109, USA.							BERESFORD TP, 1990, PSYCHOSOMATICS, V31, P241, DOI 10.1016/S0033-3182(90)72160-3; BERGLUND M, 1984, ACTA PSYCHIAT SCAND, V70, P407, DOI 10.1111/j.1600-0447.1984.tb01228.x; Childress JF., 1970, SOUNDINGS, V53, P339; FINGARETTE H, 1988, PUBLIC INTEREST, V91, P3; FINGARETTE H, 1989, PUBLIC INTEREST, V95, P118; Gordon R D, 1987, Clin Transpl, P43; GORDON RD, 1988, ORGAN TRANSPLANTATIO, P511; JELLINEK EM, 1960, DISEASE CONCEPT ALCO; KLERMAN GL, 1989, NEW ENGL J MED, V320, P394, DOI 10.1056/NEJM198902093200611; MADSEN W, 1989, PUBLIC INTEREST, V95, P112; ROSE RM, 1988, ALCOHOLISM ORIGINS O; SCHARSCHMIDT BF, 1984, HEPATOLOGY, V4, P95; SCHENKER S, 1990, HEPATOLOGY, V11, P314, DOI 10.1002/hep.1840110223; STARZL TE, 1988, JAMA-J AM MED ASSOC, V260, P2542, DOI 10.1001/jama.260.17.2542; STARZL TE, 1988, TRANSPLANT P, V20, P131; Vaillant G.E., 1995, WISDOM EGO; 1987, DHHS ADM871519 US DE; 1983, JAMA-J AM MED ASSOC, V250, P2961	18	94	94	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	1991	265	10					1299	1301		10.1001/jama.265.10.1299	http://dx.doi.org/10.1001/jama.265.10.1299			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FA511	1995978				2022-12-24	WOS:A1991FA51100027
J	JEWETT, ME; KRONAUER, RE; CZEISLER, CA				JEWETT, ME; KRONAUER, RE; CZEISLER, CA			LIGHT-INDUCED SUPPRESSION OF ENDOGENOUS CIRCADIAN AMPLITUDE IN HUMANS	NATURE			English	Article							RHYTHM; OSCILLATOR; INDUCTION; GONYAULAX; PULSES; CLOCK	WINFREE reported 20 years ago the intriguing finding that a light stimulus of a critical strength applied at a critical circadian phase could essentially stop the circadian clock in Drosophila pseudo-obscura by resetting the circadian oscillator close to its singularity (a phaseless position at which the amplitude of circadian oscillation is zero) 1. Since then, similar observations of attenuated circadian amplitude in response to critical stimuli have been limited to unicells, insects and plants 2-7. Our recent demonstration that the phase of the human circadian pacemaker could be inverted using an unconventional three-cycle stimulus 8,9 led us to investigate whether critically timed exposure to a more moderate stimulus could drive that oscillator towards its singularity. Here we report that exposure of humans to fewer cycles of bright light, centred around the time at which the human circadian pacemaker is most sensitive to light-induced phase shifts, can markedly attenuate endogenous circadian amplitude. In some cases this results in an apparent loss of rhythmicity, as expected to occur in the region of singularity.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CIRCADIAN & SLEEP DISORDERS MED LAB,BOSTON,MA 02115; HARVARD UNIV,DIV APPL SCI,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University								BROWN EN, 1987, THESIS HARVARD U, P1; CZEISLER CA, 1990, NEW ENGL J MED, V322, P1253, DOI 10.1056/NEJM199005033221801; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; ENGELMANN W, 1978, PHYSIOL PLANTARUM, V43, P68, DOI 10.1111/j.1399-3054.1978.tb01569.x; ENRIGHT JT, 1986, LECT MATH LIFE SCI, V19, P121; Eskin A., 1971, P55; GANDER PH, 1983, AM J PHYSIOL, V245, pR10, DOI 10.1152/ajpregu.1983.245.1.R10; Kronauer R.E., 1990, SLEEP 90 P 10 EUR C, P306; MALINOWSKI JR, 1985, J COMP PHYSIOL B, V155, P257, DOI 10.1007/BF00685221; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; PETERSON EL, 1980, J COMP PHYSIOL, V138, P201, DOI 10.1007/BF00657038; SAUNDERS DS, 1978, J COMP PHYSIOL, V124, P75, DOI 10.1007/BF00656393; STROGATZ SH, 1990, J BIOL RHYTHM, V5, P169, DOI 10.1177/074873049000500208; TAYLOR W, 1982, J COMP PHYSIOL, V148, P11, DOI 10.1007/BF00688883; WALZ B, 1979, P NATL ACAD SCI USA, V76, P6443, DOI 10.1073/pnas.76.12.6443; Winfree A.T., 1987, TIMING BIOL CLOCKS; WINFREE AT, 1973, J COMP PHYSIOL, V85, P105, DOI 10.1007/BF00696471; WINFREE AT, 1970, J THEOR BIOL, V28, P327, DOI 10.1016/0022-5193(70)90075-5	18	200	203	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					59	62		10.1038/350059a0	http://dx.doi.org/10.1038/350059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002845				2022-12-24	WOS:A1991FA69300064
J	KLAMBT, C; JACOBS, JR; GOODMAN, CS				KLAMBT, C; JACOBS, JR; GOODMAN, CS			THE MIDLINE OF THE DROSOPHILA CENTRAL-NERVOUS-SYSTEM - A MODEL FOR THE GENETIC-ANALYSIS OF CELL FATE, CELL-MIGRATION, AND GROWTH CONE GUIDANCE	CELL			English	Article							AXON PATHWAYS; EMBRYONIC-DEVELOPMENT; NEURONAL DEVELOPMENT; LARVAL CUTICLE; ZYGOTIC LOCI; MELANOGASTER; GRASSHOPPER; EXPRESSION; PATTERN; CNS	A row of mesectodermal cells separates the two lateral neurogenic regions in the Drosophila embryo and generates a discrete set of glia and neurons. Most CNS growth cones initially head straight toward the midline, suggesting that these midline cells play a key role in the formation of the axon commissures. We have used antibodies that stain the first axons, beta-galactosidase enhancer trap lines that selectively stain the different midline cells, and electron microscopic studies to elucidate the cells and interactions that mediate the normal formation of the two major commissures in each segment. This analysis has led to a model that proposes a series of sequential cell interactions controlling the development of the axon commissures. A genetic test of this model has utilized a number of mutations that, by either eliminating or altering the differentiation of various midline cells, perturb the development of the axon commissures in a predictable fashion.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	KLAMBT, C (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.			jacobs, j roger/0000-0002-5878-5416	NINDS NIH HHS [NS18366] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BATE CM, 1981, J EMBRYOL EXP MORPH, V61, P317; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; Bridges CB., 1919, CARNEGIE I WASH PUBL, V278, P123; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FERDIEU JR, 1989, DEVELOPMENT, V106, P749; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FOE VE, 1989, DEVELOPMENT, V107, P1; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HOYLE G, 1986, J COMP NEUROL, V246, P85, DOI 10.1002/cne.902460106; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JESSELL TM, 1989, CIBA F SYMP, V144, P255; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLAMBT C, 1991, IN PRESS GLIA; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MEYER MR, 1987, J NEUROSCI, V7, P512; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; Poulson D. F., 1950, BIOL DROSOPHILA, P168; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; ZAK NB, 1990, DEVELOPMENT, V109, P865	43	457	457	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					801	815		10.1016/0092-8674(91)90509-W	http://dx.doi.org/10.1016/0092-8674(91)90509-W			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997208				2022-12-24	WOS:A1991EZ47800015
J	GURURAJAN, R; PERRYOKEEFE, H; MELTON, DA; WEEKS, DL				GURURAJAN, R; PERRYOKEEFE, H; MELTON, DA; WEEKS, DL			THE XENOPUS LOCALIZED MESSENGER-RNA AN3 MAY ENCODE AN ATP-DEPENDENT RNA HELICASE	NATURE			English	Article							UNWINDING ACTIVITY; FACTOR EIF-4A; PROTEIN; CLONING; EGGS; GENES; VASA	THE maternal messenger RNA An3 was originally identified localized to the animal hemisphere of Xenopus laevis oocytes, eggs and early embryos 1,2. Xenopus embryos depend on mRNA and protein present in the egg before fertilization (maternal molecules) to provide the information needed for early development. Localization of maternal mRNA gives cells derived from different regions of the egg distinctive capacities for protein synthesis. We show here that An3 mRNA encodes a protein with 74% identity to a protein encoded by the testes-specific mRNA PL10 found in mouse 3, which is proposed to have RNA helicase activity. Because the gene encoding An3 mRNA is reactivated after gastrulation and remains active throughout embryogenesis 1,2, we have examined its distribution in embryonic and adult tissues. Unlike PL10 mRNA, which is primarily restricted to the testes, An3 mRNA is broadly distributed in later development.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	University of Iowa; Harvard University			Young, Richard A/F-6495-2012; Weeks, Daniel/F-6216-2010	Young, Richard A/0000-0001-8855-8647; Weeks, Daniel/0000-0002-4977-2410				BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOER D, 1990, NUCLEIC ACIDS RES, V18, P5489; DUMONT JN, 1972, J MORPHOL, V136, P155; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; KREIG PA, 1989, DEV BIOL, V133, P93; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PERRYOKEEFE H, 1990, IN SITU HYBRIDISATIO, P115; RAY BK, 1985, J BIOL CHEM, V260, P7651; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICHTER JD, 1984, J MOL BIOL, V173, P227, DOI 10.1016/0022-2836(84)90191-8; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WEEKS DL, 1985, COLD SPRING HARB SYM, V50, P21, DOI 10.1101/SQB.1985.050.01.005	25	78	81	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					717	719		10.1038/349717a0	http://dx.doi.org/10.1038/349717a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996140				2022-12-24	WOS:A1991EY62700055
J	RATNER, J; LISBONA, A; ROSENBLOOM, M; PALAYEW, M; SZABOLCSI, S; TUPAZ, T				RATNER, J; LISBONA, A; ROSENBLOOM, M; PALAYEW, M; SZABOLCSI, S; TUPAZ, T			THE PREVALENCE OF GALLSTONE DISEASE IN VERY OLD INSTITUTIONALIZED PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							POPULATION; SYMPTOMS; AUTOPSY	We present the results of a study that was undertaken at a large geriatric nursing home to assess the prevalence of gallstone disease in very old institutionalized persons. One hundred seventeen residents underwent ultrasound examination of the gallbladder. Two thirds of 82 women and half of 35 men had gallstone disease. When stratified for age, 80% of women and men over the age of 90 years were positive for the disease. In summary, the prevalence of gallstone disease in our very old nursing home population was found to be unexpectedly high.	SIR MORTIMER B DAVIS JEWISH HOSP,MONTREAL H3T 1E2,QUEBEC,CANADA	McGill University	RATNER, J (corresponding author), MAIMONIDES HOSP,CTR GERIATR,PROFESS SERV,5795 CALDWELL AVE,MONTREAL H4W 1W3,QUEBEC,CANADA.							BATESON MC, 1975, BMJ-BRIT MED J, V4, P427; CLINCH D, 1984, AGE AGEING, V13, P120, DOI 10.1093/ageing/13.2.120; EINARSSON K, 1985, NEW ENGL J MED, V313, P277, DOI 10.1056/NEJM198508013130501; FENYO G, 1982, AM J SURG, V143, P751, DOI 10.1016/0002-9610(82)90052-6; GILAT T, 1985, AM J CLIN NUTR, V41, P336, DOI 10.1093/ajcn/41.2.336; GLAMBEK I, 1989, SCAND J GASTROENTERO, V24, P277, DOI 10.3109/00365528909093046; GLAMBEK I, 1987, SCAND J GASTROENTERO, V22, P1089, DOI 10.3109/00365528708991963; GRUNDY SM, 1987, HEPATOLOGY, V7, P946, DOI 10.1002/hep.1840070526; JANZON L, 1985, SCAND J GASTROENTERO, V20, P706, DOI 10.3109/00365528509089199; LICHTAROWICZ AM, 1987, J ROY SOC MED, V80, P692, DOI 10.1177/014107688708001111; LONGINO CF, 1988, GERONTOLOGIST, V28, P515, DOI 10.1093/geront/28.4.515; LOWBEER TS, 1985, RECENT ADV GERIATRIC, P37; MOGENSEN NB, 1984, SURG GYNECOL OBSTET, V159, P353; ROSENWAIKE I, 1987, GERONTOLOGIST, V27, P275, DOI 10.1093/geront/27.3.275; Strom BL, 1985, GALLSTONES, P1; VITETTA L, 1988, AUST NZ J SURG, V58, P561; ZAHOR Z, 1974, SCAND J GASTROENTERO, V9, P3	17	36	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	1991	265	7					902	903		10.1001/jama.265.7.902	http://dx.doi.org/10.1001/jama.265.7.902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX587	1992189				2022-12-24	WOS:A1991EX58700044
J	HARDY, SJS; RANDALL, LL				HARDY, SJS; RANDALL, LL			A KINETIC PARTITIONING MODEL OF SELECTIVE BINDING OF NONNATIVE PROTEINS BY THE BACTERIAL CHAPERONE SECB	SCIENCE			English	Article							ESCHERICHIA-COLI SECB; MEMBRANE TRANSLOCATION; TRYPTOPHAN-SYNTHETASE; TRIGGER FACTOR; EXPORT; SEQUENCE; INVITRO; PRECURSOR; GROEL; GENE	An in vitro assay for the interaction of SecB, a molecular chaperone from Escherichia coli, with polypeptide ligands was established based on the ability of SecB to block the refolding of denatured maltose-binding protein. Competition experiments show that SecB binds selectively to nonnative proteins with high affinity and without specificity for a particular sequence of amino acids. It is proposed that selectivity in binding is due to a kinetic partitioning of polypeptides between folding and association with SecB.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University								ADACHI O, 1974, J BIOL CHEM, V249, P7756; ANDERER FA, 1966, J BIOL CHEM, V241, P1568; BAGSHAW CR, 1987, SPECTROPHOTOMETRY SP, P109; BEASTY AM, 1985, BIOCHEMISTRY-US, V24, P3547, DOI 10.1021/bi00335a024; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUPLAY P, 1984, J BIOL CHEM, V259, P606; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Fersht A., 1985, ENZYME STRUCTURE MEC; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GANNON PM, 1989, J BACTERIOL, V171, P813, DOI 10.1128/jb.171.2.813-818.1989; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; HAGERMAN PJ, 1976, BIOCHEMISTRY-US, V15, P1462, DOI 10.1021/bi00652a017; HARTL FU, IN PRESS CELL; HIRS CHW, 1960, J BIOL CHEM, V235, P633; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; KUMAMOTO CA, UNPUB; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LAMINET AA, IN PRESS EMBO J; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LI SH, 1972, J BIOL CHEM, V247, P1031; LIU G, 1988, J BIOL CHEM, V263, P14790; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; Randall L., UNPUB; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TESCHKE CM, UNPUB; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WEIS SJB, 1990, J BACTERIOL, V172, P3023; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	56	202	205	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					439	443		10.1126/science.1989077	http://dx.doi.org/10.1126/science.1989077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989077				2022-12-24	WOS:A1991EU50400045
J	OFFNER, H; HASHIM, GA; VANDENBARK, AA				OFFNER, H; HASHIM, GA; VANDENBARK, AA			T-CELL RECEPTOR PEPTIDE THERAPY TRIGGERS AUTOREGULATION OF EXPERIMENTAL ENCEPHALOMYELITIS	SCIENCE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; VACCINATION; RAT; SUPPRESSION; DISEASES; GENES	Encephalitogenic T cells specific for myelin basic protein share common V-beta-8 peptide sequences in their T cell receptor (TCR) that can induce autoregulatory T cells and antibodies that prevent clinical signs of experimental autoimmune encephalomyelitis (EAE). It is not known, however, if TCR peptides can treat established disease. To test its therapeutic value, TCR-V-beta-8-39-59 peptide was injected into rats with clinical signs of EAE. This treatment reduced disease severity and speeded recovery, apparently by boosting anti-V-beta-8 T cells and antibodies raised naturally in response to encephalitogenic V-beta-8+ T cells. These results demonstrate that synthetic TCR be used therapeutically, and implicate the TCR-V-beta-8-39-59 sequence as a natural idiotope involved in EAE recovery. Similarly, human TCR peptides may be effective in enhancing natural regulation of autoreactive T cells that share common V genes.	ST LUKES ROOSEVELT HOSP,DEPT MICROBIOL & SURG,NEW YORK,NY 10025; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL AAV,PORTLAND,OR 97201; COLUMBIA UNIV,NEW YORK,NY 10027	Mount Sinai St. Luke's; Mount Sinai West; Oregon Health & Science University; Oregon Health & Science University; Columbia University	OFFNER, H (corresponding author), VET ADM MED CTR,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS23444, NS21466, NS23221] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021466, R01NS023221, R01NS023444] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BERNARD CCA, 1977, CLIN EXP IMMUNOL, V29, P100; BURNS FR, 1989, J EXP MED, V169, P27, DOI 10.1084/jem.169.1.27; CHLUBA J, 1989, EUR J IMMUNOL, V19, P279, DOI 10.1002/eji.1830190210; CHOU YK, IN PRESS J NEUROSCI; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; HASHIM GA, 1981, NEUROCHEM RES, V6, P699, DOI 10.1007/BF00963886; HASHIM GA, 1990, J IMMUNOL, V144, P4621; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KUMAR V, 1989, ANNU REV IMMUNOL, V7, P657, DOI 10.1146/annurev.iy.07.040189.003301; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; LOHSE AW, 1989, SCIENCE, V244, P820, DOI 10.1126/science.2471264; LYMAN WD, 1984, CELL IMMUNOL, V85, P542, DOI 10.1016/0008-8749(84)90266-1; OFFNER H, 1989, J NEUROIMMUNOL, V21, P13, DOI 10.1016/0165-5728(89)90154-9; OFFNER H, 1988, J IMMUNOL, V141, P3828; OFFNER H, 1984, J NEUROIMMUNOL, V9, P147; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VARRIALE S, 1989, J IMMUNOL, V125, P186; WELCH AM, 1980, J IMMUNOL, V125, P186; WHITHAM RH, 1990, CELL IMMUNOL, V126, P290, DOI 10.1016/0008-8749(90)90322-I; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	28	236	271	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					430	432		10.1126/science.1989076	http://dx.doi.org/10.1126/science.1989076			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1989076				2022-12-24	WOS:A1991EU50400041
J	PIATIGORSKY, J; WISTOW, G				PIATIGORSKY, J; WISTOW, G			THE RECRUITMENT OF CRYSTALLINS - NEW FUNCTIONS PRECEDE GENE DUPLICATION	SCIENCE			English	Editorial Material							ALPHA-B-CRYSTALLIN; LENS CRYSTALLINS; TRANSGENIC MICE; ALDEHYDE DEHYDROGENASE; ENZYME-CRYSTALLINS; STRUCTURAL PROTEIN; DELTA-CRYSTALLIN; DUCK LENS; EYE LENS; EXPRESSION				PIATIGORSKY, J (corresponding author), NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892, USA.							ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HENDRIKS W, 1988, P NATL ACAD SCI USA, V85, P7114, DOI 10.1073/pnas.85.19.7114; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KIMURA M, 1974, P NATL ACAD SCI USA, V71, P2848, DOI 10.1073/pnas.71.7.2848; KLEMENT JF, 1989, J BIOL CHEM, V264, P19837; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KONDOH H, 1987, DEV BIOL, V120, P177, DOI 10.1016/0012-1606(87)90116-3; LOK S, 1985, MOL CELL BIOL, V5, P2221, DOI 10.1128/MCB.5.9.2221; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; PIATIGORSKY J, ADV DEV BIOCH, V1; RAO PSS, COMMUNICATION; THOMAS G, 1990, New Biologist, V2, P903; WAWROUSEK EF, 1990, DEV BIOL, V137, P68, DOI 10.1016/0012-1606(90)90008-7; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, P NATL ACAD SCI USA, V87, P6277, DOI 10.1073/pnas.87.16.6277; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	39	274	275	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1078	1079		10.1126/science.252.5009.1078	http://dx.doi.org/10.1126/science.252.5009.1078			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031181				2022-12-24	WOS:A1991FN05600031
J	ALCOLADO, JC; ALCOLADO, R				ALCOLADO, JC; ALCOLADO, R			IMPORTANCE OF MATERNAL HISTORY OF NON-INSULIN-DEPENDENT DIABETIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the family history of diabetes in non-insulin dependent diabetes mellitus with particular emphasis on parental phenotype. Design - Family histories were obtained from an existing computerised database and supplemented by postal questionnaires. Setting - Diabetic service of a provincial teaching hospital. Subjects - A total of 1326 patients with non-insulin dependent diabetes who had been referred to diabetic clinics over the past 10 years and from whom data had been collected for inclusion in the database, of whom 347 had affected first degree relatives. Nineteen non-white patients were excluded because of the differential hereditability of the disease, and 230 (70%) patients with an affected first degree relative responded to the postal questionnaire. Results - Mothers were implicated in significantly more cases than fathers in patients with a single affected parent: 125 mothers and 48 fathers from database; 82 mothers and 34 fathers from postal questionnaire; p < 0.001 in both cases. Conclusions - Maternal influences seem to have an important role in the inheritance of non-insulin dependent diabetes.	SOUTHAMPTON GEN HOSP,MED PROFESSORIAL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton	ALCOLADO, JC (corresponding author), ST BARTHOLOMEWS HOSP,MED PROFESSORIAL UNIT,LONDON EC1A 7BE,ENGLAND.		Alcolado, John/B-4999-2009	Alcolado, John/0000-0003-0666-0352				Bell G I, 1987, Ciba Found Symp, V130, P167; HARDING AE, 1988, J MED GENET, V25, P528, DOI 10.1136/jmg.25.8.528; KAHN LB, 1990, DIABETES CARE, V7, P796; Mohan V., 1986, PRACT DIAB, V3, P254; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; PETTITT DJ, 1986, DIABETES, V37, P622; 1983, CENSUS 1981 NATIONAL	7	175	177	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1178	1180		10.1136/bmj.302.6786.1178	http://dx.doi.org/10.1136/bmj.302.6786.1178			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043812	Green Published, Bronze			2022-12-24	WOS:A1991FN04500019
J	PARK, JK; ROSENSTEIN, YJ; REMOLDODONNELL, E; BIERER, BE; ROSEN, FS; BURAKOFF, SJ				PARK, JK; ROSENSTEIN, YJ; REMOLDODONNELL, E; BIERER, BE; ROSEN, FS; BURAKOFF, SJ			ENHANCEMENT OF T-CELL ACTIVATION BY THE CD43 MOLECULE WHOSE EXPRESSION IS DEFECTIVE IN WISKOTT-ALDRICH SYNDROME	NATURE			English	Article							LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; SIALOPHORIN CD43; HUMAN-LEUKOCYTES; LEUKOSIALIN; PROLIFERATION; ANTIGEN; CD2; PHOSPHORYLATION; RECEPTOR	CD43 (sialophorin, leukosialin, leukocyte large sialoglycoprotein), a heavily sialylated molecule found on most leukocytes and platelets, was initially identified as a major glycoprotein of mouse, rat and human T cells 1-8. CD43 expression is defective on the T cells of males with the Wiskott-Aldrich syndrome, an X chromosome-linked recessive immunodeficiency disorder 9. Affected males are susceptible to opportunistic infections and do not respond to polysaccharide antigens, reflecting defects in cytotoxic and helper T-cell functions. Anti-CD43 monoclonal antibodies have a modest costimulatory effect on T cells, natural killer cells, B cells and monocytes 10-14, and one such antibody has been shown to activate T cells directly 15. To investigate a possible physiological role for CD43, a complementary DNA encoding the human protein 16,17 was introduced into an antigen-responsive murine T-cell hybridoma 18. We observed that CD43 enhances the antigen-specific activation of T cells and that the intracellular domain of CD43, which is hyperphosphorylated during T-cell activation 19-21, is required for this function. We also found that antigen-presenting cells can bind specifically to immobilized purified CD43 and that the binding can be inhibited by liposomes containing CD43 as well as by anti-CD43 monoclonal antibodies.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SCH MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PARK, JK (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Bierer, Barbara/0000-0001-6448-8170				AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BEYERS AD, 1989, IMMUNOL REV, V111, P59, DOI 10.1111/j.1600-065X.1989.tb00542.x; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CHATILA TA, 1988, J IMMUNOL, V140, P4308; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARKMAN R, 1981, LANCET, V2, P1387; PILLER V, 1989, J BIOL CHEM, V264, P18824; POTTER H, 1987, CURRENT PROTOCOLS MO; REMOLDODONNELL E, 1987, BLOOD, V70, P104; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; VARGASCORTES M, 1988, SCAND J IMMUNOL, V27, P661, DOI 10.1111/j.1365-3083.1988.tb02399.x; WIKEN M, 1989, SCAND J IMMUNOL, V29, P363, DOI 10.1111/j.1365-3083.1989.tb01135.x	26	138	141	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					706	709		10.1038/350706a0	http://dx.doi.org/10.1038/350706a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023632				2022-12-24	WOS:A1991FJ13000060
J	CHAPMAN, S; WOODWARD, S				CHAPMAN, S; WOODWARD, S			AUSTRALIAN COURT RULES THAT PASSIVE SMOKING CAUSES LUNG-CANCER, ASTHMA ATTACKS, AND RESPIRATORY-DISEASE	BRITISH MEDICAL JOURNAL			English	Editorial Material									ACT SMOKING & HLTH,SURREY HILLS 2010,AUSTRALIA		CHAPMAN, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,WESTMEAD 2145,AUSTRALIA.							BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; CHAPMAN S, 1980, BRIT MED J, V281, P1187, DOI 10.1136/bmj.281.6249.1187; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; Chapman S, 1984, MEDIA INFORMATION AU, V31, P47; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; WINSTANLEY M, 1989, TOBACCO AUSTR FACTS; WOODWARD SD, 1990, MED J AUSTRALIA, V153, P682, DOI 10.5694/j.1326-5377.1990.tb126321.x; 1987, EFFECTS PASSIVE SMOK; 1978, STUDY PUBLIC ATTITUD, V1	9	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					943	945		10.1136/bmj.302.6782.943	http://dx.doi.org/10.1136/bmj.302.6782.943			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH487	2032037	Green Published, Bronze			2022-12-24	WOS:A1991FH48700022
J	STAMATOYANNOPOULOS, G				STAMATOYANNOPOULOS, G			HUMAN HEMOGLOBIN SWITCHING	SCIENCE			English	Editorial Material							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; TRANSGENIC MICE; EXPRESSION				STAMATOYANNOPOULOS, G (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.							BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; LI QL, 1990, P NATL ACAD SCI USA, V87, P8207, DOI 10.1073/pnas.87.21.8207; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RYAN TM, 1989, P NATL ACAD SCI USA, V86, P37, DOI 10.1073/pnas.86.1.37; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; SPANGLER EA, 1990, NUCLEIC ACIDS RES, V18, P7093, DOI 10.1093/nar/18.23.7093; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2	17	53	53	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					383	383		10.1126/science.2017679	http://dx.doi.org/10.1126/science.2017679			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017679				2022-12-24	WOS:A1991FH10300029
J	SILVER, ML; PARKER, KC; WILEY, DC				SILVER, ML; PARKER, KC; WILEY, DC			RECONSTITUTION BY MHC-RESTRICTED PEPTIDES OF HLA-A2 HEAVY-CHAIN WITH BETA-2-MICROGLOBULIN, INVITRO	NATURE			English	Article							TOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGENS; ASSOCIATION; MOLECULES; EPITOPES; BINDING	CYTOTOXIC T lymphocytes kill virally infected cells when they detect antigenic fragments presented by class I major histocompatibility complex (MHC) antigens (HLA in humans). The crystal structures of HLA-A2 and HLA-Aw68 reveal that peptide-antigen forms an integral part of the HLA structure, being retained in a prominent groove even after purification and crystallization 1-3. Here we report that the heavy chain and beta-2-microglobulin of HLA-A2, after separation and fractionation in denaturants, reassemble efficiently under renaturing conditions only in the presence of MHC-restricted 4 peptides. A complex of heavy chain, beta-2-microglobulin, and viral peptide in the ratio 1:1:1 is formed in up to 46% yield. Reconstitution is not stimulated by either of two peptides not restricted to HLA-A2. The reconstituted complex of HLA-A2 and the influenza virus (B/Lee/40) nucleoprotein peptide, Np (85-94), crystallizes under conditions previously used to crystallize HLA-A2 (ref. 5). Peptide-linked folding and assembly suggests mechanisms for the unusual capacity of HLA to bind many peptides of diverse sequence.	HARVARD UNIV,HOWARD HUGHES MED INST,7 DIVIN AVE,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University				Parker, Kenneth/0000-0002-6282-2478				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BJORKMAN PJ, 1985, J MOL BIOL, V186, P205, DOI 10.1016/0022-2836(85)90271-2; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BUSHKIN Y, 1984, MOL IMMUNOL, V21, P821, DOI 10.1016/0161-5890(84)90135-4; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH FM, 1987, NATURE, V326, P882; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; PARHAM P, 1978, NATURE, V276, P397, DOI 10.1038/276397a0; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; SAPER MA, IN PRESS J MOL BIOL; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; ZINKERNAGEL RM, 1974, NATURE, V251, P548	24	110	117	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					619	622		10.1038/350619a0	http://dx.doi.org/10.1038/350619a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017257				2022-12-24	WOS:A1991FH11200062
J	BIGIANI, AR; ROPER, SD				BIGIANI, AR; ROPER, SD			MEDIATION OF RESPONSES TO CALCIUM IN TASTE CELLS BY MODULATION OF A POTASSIUM CONDUCTANCE	SCIENCE			English	Article							RECEPTOR-CELLS; MEMBRANE-PROPERTIES; K+ CHANNELS; TRANSDUCTION; MUDPUPPY; SOUR	Calcium salts are strong taste stimuli in vertebrate animals. However, the chemosensory transduction mechanisms for calcium are not known. In taste buds of Necturus maculosus (mud puppy), calcium evokes depolarizing receptor potentials by acting extracellularly on the apical ends of taste cells to block a resting potassium conductance. Therefore, divalent cations elicit receptor potentials in taste cells by modulating a potassium conductance rather than by permeating the cell membrane, the mechanism utilized by monovalent cations such as sodium and potassium ions.	UNIV COLORADO,HLTH SCI CTR,ROCKY MT TASTE & SMELL CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	BIGIANI, AR (corresponding author), COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523, USA.		Bigiani, Albertino/G-3024-2015	Bigiani, Albertino/0000-0001-6987-488X; Roper, Stephen/0000-0001-6049-8320	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS020486, R01NS024107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006557] Funding Source: NIH RePORTER; NIA NIH HHS [5 RO1 AG06557] Funding Source: Medline; NINDS NIH HHS [2 RO1 NS24107, 2 POI NS 20486] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; AKAIKE N, 1976, J PHYSIOL-LONDON, V254, P87, DOI 10.1113/jphysiol.1976.sp011223; ARMSTRONG CM, 1986, J GEN PHYSIOL, V87, P817, DOI 10.1085/jgp.87.5.817; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AVENET P, 1987, J MEMBRANE BIOL, V95, P265, DOI 10.1007/BF01869488; AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; JUNGE D, 1970, COMP BIOCHEM PHYSIOL, V35, P623, DOI 10.1016/0010-406X(70)90979-5; KINNAMON SC, 1987, J PHYSIOL-LONDON, V383, P601; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1989, ANN NY ACAD SCI, V560, P112, DOI 10.1111/j.1749-6632.1989.tb24085.x; KINNAMON SC, 1988, CHEM SENSES, V13, P115, DOI 10.1093/chemse/13.1.115; KINNAMON SC, 1988, J GEN PHYSIOL, V91, P351, DOI 10.1085/jgp.91.3.351; KITADA Y, 1978, JPN J PHYSIOL, V28, P413; KURIHARA K, 1989, BIOSIGNAL RANSDUCTIO, P181; MCPHEETERS M, 1985, CHEM SENSES, V10, P341, DOI 10.1093/chemse/10.3.341; Moncrieff R.W., 1967, CHEM SENSES, V3rd; ROPER SD, 1989, J MEMBRANE BIOL, V109, P29, DOI 10.1007/BF01870788; ROPER SD, 1989, ANNU REV NEUROSCI, V12, P329, DOI 10.1146/annurev.ne.12.030189.001553; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SAND O, 1986, ACTA PHYSIOL SCAND, V126, P173, DOI 10.1111/j.1748-1716.1986.tb07803.x; SATO T, 1980, PROG NEUROBIOL, V14, P25, DOI 10.1016/0301-0082(80)90003-9; SCHIFFMAN SS, 1990, CHEM SENSES, V15, P129, DOI 10.1093/chemse/15.1.129; SPIELMAN AI, 1989, BRAIN RES, V503, P326, DOI 10.1016/0006-8993(89)91684-3; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; VANDEMORTEL JBJ, 1990, BIOCHIM BIOPHYS ACTA, V1026, P220, DOI 10.1016/0005-2736(90)90067-X	25	41	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					126	128		10.1126/science.2011748	http://dx.doi.org/10.1126/science.2011748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011748				2022-12-24	WOS:A1991FE95200050
J	WEBER, JM; LEUNG, JO; SWANSON, SJ; IDLER, KB; MCALPINE, JB				WEBER, JM; LEUNG, JO; SWANSON, SJ; IDLER, KB; MCALPINE, JB			AN ERYTHROMYCIN DERIVATIVE PRODUCED BY TARGETED GENE DISRUPTION IN SACCHAROPOLYSPORA-ERYTHRAEA	SCIENCE			English	Article							RAT MAMMARY-GLAND; STREPTOMYCES-ERYTHREUS; MACROLIDE ANTIBIOTICS; MYCOBACTERIUM-AVIUM; NUCLEOTIDE-SEQUENCE; INVITRO ACTIVITIES; BIOSYNTHESIS; CLONING; IDENTIFICATION; HYDROLASE	Derivatives of erythromycin with modifications at their C-6 position are generally sought for their increased stability at acid pH, which in turn may confer improved pharmacological properties. A recombinant mutant of the erythromycin-producing bacterium, Saccharopolyspora erythraea, produced an erythromycin derivative, 6-deoxyerythromycin A, that could not be obtained readily by chemical synthesis. This product resulted from targeted disruption of the gene, designated eryF (systematic nomenclature, CYP107), that apparently codes for the cytochrome P450, 6-deoxyerythronolide B (DEB) hydroxylase, which converts DEB to erythronolide B (EB). Enzymes normally acting on EB can process the alternative substrate DEB to form the biologically active erythromycin derivative lacking the C-6 hydroxyl group.	ABBOTT LABS,ANTIINFECT RES,ABBOTT PK,IL 60064; ABBOTT LABS,CORP MOLEC BIOL,ABBOTT PK,IL 60064	Abbott Laboratories; Abbott Laboratories	WEBER, JM (corresponding author), ABBOTT LABS,DEPT 451-R5,BIOPROC DEV,N CHICAGO,IL 60064, USA.		Weber, J. Mark/AAF-5739-2020					Corcoran JW, 1981, ANTIBIOTICS, P132; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; EPP JK, 1989, GENE, V85, P293, DOI 10.1016/0378-1119(89)90421-6; FERNANDES PB, 1989, ANTIMICROB AGENTS CH, V33, P1531, DOI 10.1128/AAC.33.9.1531; FERNANDES PB, 1986, ANTIMICROB AGENTS CH, V30, P865, DOI 10.1128/AAC.30.6.865; HARDY DJ, 1988, ANTIMICROB AGENTS CH, V32, P1710, DOI 10.1128/AAC.32.11.1710; HARDY DR, UNPUB; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HOPWOOD DA, 1989, GENETICS MOL BIOL IN, P12; ISHIZAKI T, 1989, J BACTERIOL, V171, P596, DOI 10.1128/jb.171.1.596-601.1989; KANEMOTO RH, 1989, J BACTERIOL, V171, P2506, DOI 10.1128/jb.171.5.2506-2512.1989; KIRST HA, 1989, ANTIMICROB AGENTS CH, V33, P1413, DOI 10.1128/AAC.33.9.1413; MARTIN JR, 1974, J ANTIBIOT, V27, P570, DOI 10.7164/antibiotics.27.570; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; MCALPINE JR, UNPUB; NAGGERT J, 1987, BIOCHEM J, V243, P597, DOI 10.1042/bj2430597; NAIK S, 1989, ANTIMICROB AGENTS CH, V33, P1614, DOI 10.1128/AAC.33.9.1614; NEBERT DW, 1987, DNA-J MOLEC CELL BIO, V6, P1, DOI 10.1089/dna.1987.6.1; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OMER CA, 1990, J BACTERIOL, V172, P3335, DOI 10.1128/jb.172.6.3335-3345.1990; PAULUS TJ, 1990, J BACTERIOL, V172, P2541, DOI 10.1128/jb.172.5.2541-2546.1990; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RINEHART KL, 1977, PURE APPL CHEM, V49, P1361, DOI 10.1351/pac197749091361; SAFFORD R, 1987, BIOCHEMISTRY-US, V26, P1358, DOI 10.1021/bi00379a023; SAKAKIBARA H, 1984, MACROLIDE ANTIBIOTIC, P85; SANGLARD D, 1989, GENE, V76, P121, DOI 10.1016/0378-1119(89)90014-0; SHAFIEE A, 1987, BIOCHEMISTRY-US, V26, P6204, DOI 10.1021/bi00393a037; SHIER WT, 1969, BIOCHEMISTRY-US, V63, P198; SWANSON RN, UNPUB; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WEBER JM, 1989, GENE, V75, P235, DOI 10.1016/0378-1119(89)90269-2; ZALKIN H, 1988, J BIOL CHEM, V263, P1595	34	138	156	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					114	117		10.1126/science.2011746	http://dx.doi.org/10.1126/science.2011746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011746				2022-12-24	WOS:A1991FE95200046
J	CIESIELSKI, SD; SEED, JR; ESPOSITO, DH; HUNTER, N				CIESIELSKI, SD; SEED, JR; ESPOSITO, DH; HUNTER, N			THE EPIDEMIOLOGY OF TUBERCULOSIS AMONG NORTH-CAROLINA MIGRANT FARM-WORKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULMONARY TUBERCULOSIS; BCG VACCINATION; SKIN-TEST; INFECTION; PRISON; SENSITIVITY; REACTIVITY; COMMUNITY; SHELTERS; FEATURES	Although tuberculosis (TB) has been recognized as a significant health problem of migrant farm workers, the nature and extent of the problem have been poorly defined. We report the first population-based study of TB in a random sample of farm workers (n = 543) and the first use of recall antigens in an epidemiologic study of TB. Purified protein derivative positivity ranged from 33% in Hispanics to 54% in US-born blacks and 76% in Haitians. Active tubercular disease occurred in 3.6% of US-born blacks and 0.47% of Hispanics. Among US-born blacks, risk factors associated with farm work were most significant. Blacks born in the United States also had the highest prevalence of anergy. The use of recall antigens made possible a better description of the epidemiology of TB by excluding false negatives and clarifying associations between infection and risk factors. We conclude that TB among farm workers represents a serious public health problem with previously unrecognized risk factors. Additional resources for migrant health care, improvements in health care access, and fundamental changes in the system of migrant labor are all necessary to reduce the transmission of TB.	N CAROLINA STATE LAB PUBL HLTH,DIV LAB SERV,MICROBIOL BRANCH,RALEIGH,NC; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,SCH PUBL HLTH,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	CIESIELSKI, SD (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT PARASITOL & LAB PRACTICE,CHAPEL HILL,NC 27599, USA.							ABELES H, 1970, AM REV RESPIR DIS, V101, P706; American Thoracic Society, 1981, AM REV RESPIR DIS, V124, P356; [Anonymous], 1988, MMWR, V36, P817; BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487; BATTERSHILL JH, 1980, CHEST, V77, P188, DOI 10.1378/chest.77.2.188; BHATNAGAR R, 1977, AM REV RESPIR DIS, V115, P207; BLEIKER MA, 1983, TUBERCLE, V64, P255, DOI 10.1016/0041-3879(83)90022-3; BONANNO G, 1983, DRUG ALCOHOL DEPEN, V12, P189, DOI 10.1016/0376-8716(83)90044-3; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P37, DOI 10.1016/0007-0971(86)90007-0; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAPARAS SD, 1982, CRIT REV MICROBIOL, V9, P193; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; COMSTOCK GW, 1986, AM J EPIDEMIOL, V124, P1; HERSHFIELD L, 1977, CHEST, V76, P805; HOLDEN M, 1971, NEW ENGL J MED, V285, P1506, DOI 10.1056/NEJM197112302852704; JACOBSON ML, 1987, AM J PUBLIC HEALTH, V77, P29, DOI 10.2105/AJPH.77.1.29; JONCAS JH, 1975, CAN MED ASSOC J, V113, P127; Kent PT, 1985, GUIDE LEVEL 3 LAB; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; KIRKPATRICK CH, 1964, J EXP MED, V119, P727, DOI 10.1084/jem.119.5.727; MCKEOWN T, 1976, ROLE MED; MCMURRAY DN, 1978, AM REV RESPIR DIS, V118, P827; MORLAND B, 1982, ACTA PHARMACOL TOX, V50, P221; NASH DR, 1980, CHEST, V77, P32, DOI 10.1378/chest.77.1.32; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; PEREZSTABLE EJ, 1986, AM J PUBLIC HEALTH, V76, P643, DOI 10.2105/AJPH.76.6.643; PIO A, 1976, B OFIC SANIT PANAM, V80, P281; PITCHENIK AE, 1982, NEW ENGL J MED, V307, P162, DOI 10.1056/NEJM198207153070306; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; RUST GS, 1990, AM J PUBLIC HEALTH, V80, P1213, DOI 10.2105/AJPH.80.10.1213; SALIMUDDIN A, 1985, TUBERCLE, V66, P133; SHAH BV, 1986, SURVEY DATA ANAL SOF; SHANNON DC, 1966, NEW ENGL J MED, V275, P690, DOI 10.1056/NEJM196609292751302; SHOTLAND J, 1989, FULL FIELDS EMPTY CU; SLUTKIN G, 1986, PUBLIC HEALTH REP, V101, P481; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007; TERRIS M, 1948, AM J PUBLIC HEALTH, V38, P1061; TRACHTMAN L, 1978, JAMA-J AM MED ASSOC, V240, P739, DOI 10.1001/jama.1978.03290080029014; WATSON H, 1984, ARIZ MED, V41, P665; WEBER DJ, 1989, SOUTHERN MED J, V82, P1204, DOI 10.1097/00007611-198910000-00003; ZEITZ SJ, 1974, J ALLERGY CLIN IMMUN, V53, P20, DOI 10.1016/0091-6749(74)90095-5; 1979, TUBERCLE, V60, P191; 1987, MMWR, V36, P212; 1988, MMWR, V37, P517; 1987, MMWR, V36, P785; 1982, TUBERCULOSIS US 1979; 1987, MMWR, V36, P493; 1985, ALCOHOL ALCOHOLISM, V20, P89; 1989, MMWR, V38, P236; 1982, MMWR, V31, P237; 1987, MMWR, V36, P257; 1987, MMWR, V36, P795; 1977, RECOMMENDATIONS COUN; 1986, 1985 TUBERCULOSIS ST; 1987, MMWR, V34, P429; 1986, JAMA-J AM MED ASSOC, V256, P977; 1989, MMWR, V38, P313; 1961, RECOMMENDATIONS REPO; 1985, TUBERCULOSIS MIGRANT; 1989, MMWR, V38, pS3; 1987, MMWR, V36, P77	63	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1715	1719		10.1001/jama.265.13.1715	http://dx.doi.org/10.1001/jama.265.13.1715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD659	2002573				2022-12-24	WOS:A1991FD65900028
J	LOBOS, E; WEISS, N; KARAM, M; TAYLOR, HR; OTTESEN, EA; NUTMAN, TB				LOBOS, E; WEISS, N; KARAM, M; TAYLOR, HR; OTTESEN, EA; NUTMAN, TB			AN IMMUNOGENIC ONCHOCERCA-VOLVULUS ANTIGEN - A SPECIFIC AND EARLY MARKER OF INFECTION	SCIENCE			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI; SEQUENCE	Onchocerciasis (river blindness) is a serious health problem and a severe obstacle to social and economic development, especially in Africa. A complementary DNA fragment coding for an Onchocerca volvulus antigen (OV-16) was cloned and expressed in the plasmid vector pCG808fx. Immune responses to this O. volvulus-specific recombinant antigen were detectable in patients with documented onchocerciasis; the antibody response was also detectable at 3 months and at more than 1 year before infection could otherwise be detected in humans and in chimpanzees experimentally infected with O. volvulus third-stage larvae.	JOHNS HOPKINS UNIV,WILMER OPHTHALMOL INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205; SWISS TROP INST,CH-4051 BASEL,SWITZERLAND; WHO,ONCHOCERCIASIS CONTROL PROGRAMME,OUAGADOUGOU,BURKINA FASO	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of Basel; Swiss Tropical & Public Health Institute; World Health Organization	LOBOS, E (corresponding author), NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.			Taylor, Hugh/0000-0002-9437-784X				AZIZ M A, 1986, Parasitology Today, V2, P233, DOI 10.1016/0169-4758(86)90001-3; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; GUAN C, 1987, GENE, V67, P21; KARAM M, 1985, AM J TROP MED HYG, V40, P261; LOBOS E, 1986, PARASITOLOGY, V93, P389, DOI 10.1017/S0031182000051556; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; LOBOS E, UNPUB; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MORT JS, 1988, BIOL CHEM H-S, V369, P163; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; TAYLOR HR, 1990, SCIENCE, V250, P116, DOI 10.1126/science.2218502; TAYLOR HR, 1988, AM J TROP MED HYG, V39, P86, DOI 10.4269/ajtmh.1988.39.86; VERNET T, 1989, GENE, V77, P229, DOI 10.1016/0378-1119(89)90071-1; WALSH J, 1986, SCIENCE, V232, P922, DOI 10.1126/science.3754652; WEISS N, UNPUB; WEISS N, 1987, CIBA F S, V27, P180; 1976, WHO TECH REP SER, V597; 1987, WHO TECH REP SER, V752	18	123	125	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1603	1605		10.1126/science.2011741	http://dx.doi.org/10.1126/science.2011741			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011741				2022-12-24	WOS:A1991FD89000035
J	SATO, J; PERL, ER				SATO, J; PERL, ER			ADRENERGIC EXCITATION OF CUTANEOUS PAIN RECEPTORS INDUCED BY PERIPHERAL-NERVE INJURY	SCIENCE			English	Article							REFLEX SYMPATHETIC DYSTROPHY; UNMYELINATED C FIBERS; POLYMODAL NOCICEPTORS; STIMULATION; SENSITIVITY; CAUSALGIA; RAT; MECHANISMS; ACTIVATION; UNITS	The mechanisms by which peripheral nerve injuries sometimes lead to causalgia, aberrant burning pain peripheral to the site of nerve damage, are uncertain, although the sympathetic nervous system is known to be involved. Whether such syndromes could be the result of the development of responsiveness by some cutaneous pain receptors (C-fiber nociceptors) to sympathetic efferent activity as a consequence of the nerve injury was tested in an animal model. After nerve damage but not in its absence, sympathetic stimulation and norepinephrine were excitatory for a subset of skin C-fiber nociceptors and enhanced the responsiveness of these nociceptors to tissue-damaging stimulation. These effects were demonstrable within days after nerve lesions, occurred at the cutaneous receptive terminal region, were manifest in sensory fibers that had not degenerated after the injury, and were mediated by alpha-2-adrenergic-like receptors.	UNIV N CAROLINA,DEPT PHYSIOL,CB 7545,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014899] Funding Source: NIH RePORTER; NINDS NIH HHS [NS14899, NS10321] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARASI S, 1986, BRAIN RES, V378, P21, DOI 10.1016/0006-8993(86)90282-9; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; BESSOU P, 1969, J NEUROPHYSIOL, V32, P1025, DOI 10.1152/jn.1969.32.6.1025; CANNON WB, 1949, SUPERSENSITIVITY DEN, P25; COHEN RH, 1990, J NEUROPHYSIOL, V64, P457, DOI 10.1152/jn.1990.64.2.457; DAVIES B, 1982, J CLIN INVEST, V69, P779, DOI 10.1172/JCI110516; DEVOR M, 1983, J AUTONOM NERV SYST, V7, P371, DOI 10.1016/0165-1838(83)90090-5; DEVOR M, 1981, NEUROSCI LETT, V24, P43, DOI 10.1016/0304-3940(81)90356-6; ECKER A, 1984, PSYCHIAT ANN, V14, P787, DOI 10.3928/0048-5713-19841101-08; Feldberg W, 1926, J PHYSIOL-LONDON, V61, P518, DOI 10.1113/jphysiol.1926.sp002313; HANNINGTONKIFF JG, 1974, PAIN RELIEF, P75; HU SJ, 1989, PAIN, V38, P85, DOI 10.1016/0304-3959(89)90077-8; KORENMAN EMD, 1981, EXP NEUROL, V72, P63, DOI 10.1016/0014-4886(81)90127-8; Levitzki A, 1978, Rev Physiol Biochem Pharmacol, V82, P1, DOI 10.1007/BFb0030496; Mitchell SW., 1864, GUNSHOT WOUNDS OTHER; NATHAN PW, 1947, BRAIN, V70, P145, DOI 10.1093/brain/70.2.145; OCHOA J, 1983, ADV PAIN RES THER, V5, P99; RICHARDS RL, 1967, ARCH NEUROL-CHICAGO, V16, P339, DOI 10.1001/archneur.1967.00470220003001; ROBERTS WJ, 1985, SOMATOSENS RES, V3, P33, DOI 10.3109/07367228509144575; ROBERTS WJ, 1986, PAIN, V24, P297, DOI 10.1016/0304-3959(86)90116-8; SCADDING JW, 1981, EXP NEUROL, V73, P345, DOI 10.1016/0014-4886(81)90271-5; SCHOTT GD, 1986, BRAIN, V109, P717, DOI 10.1093/brain/109.4.717; SCHWARTZMAN RJ, 1987, ARCH NEUROL-CHICAGO, V44, P555, DOI 10.1001/archneur.1987.00520170081028; SHEA VK, 1985, J NEUROPHYSIOL, V54, P502, DOI 10.1152/jn.1985.54.3.502; SHEA VK, 1985, J NEUROPHYSIOL, V54, P491, DOI 10.1152/jn.1985.54.3.491; SHEA VK, 1985, J NEUROPHYSIOL, V54, P513, DOI 10.1152/jn.1985.54.3.513; TOREBJOR.HE, 1974, ACTA PHYSIOL SCAND, V92, P374, DOI 10.1111/j.1748-1716.1974.tb05755.x; WALLIN G, 1976, SENSORY FUNCTIONS SK, P489; WIESENFELDHALLIN Z, 1984, HUM NEUROBIOL, V3, P41	29	480	492	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1608	1610		10.1126/science.2011742	http://dx.doi.org/10.1126/science.2011742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011742				2022-12-24	WOS:A1991FD89000037
J	ORCI, L; TAGAYA, M; AMHERDT, M; PERRELET, A; DONALDSON, JG; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD; ROTHMAN, JE				ORCI, L; TAGAYA, M; AMHERDT, M; PERRELET, A; DONALDSON, JG; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD; ROTHMAN, JE			BREFELDIN-A, A DRUG THAT BLOCKS SECRETION, PREVENTS THE ASSEMBLY OF NON-CLATHRIN-COATED BUDS ON GOLGI CISTERNAE	CELL			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; VESICULAR TRANSPORT; INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; FUSION PROTEIN; STACK; YEAST; RECONSTITUTION; COMPLEX	We report that brefeldin A prevents the assembly of non-clathrin-coated vesicles from Golgi cisternae in a cell-free system. This finding provides a simple molecular explanation for the primary effect of this remarkable compound in blocking constitutive secretion. We further report that when coated vesicle assembly is blocked, extensive tubule networks form that connect previously separate cisternae and stacks into a single topological unit, allowing the intermixing of contents of Golgi cisternae, presumably by lateral diffusion. Formation of the tubule networks requires ATP, cytosol, and the general fusion protein NSF. Tubule networks may be related to the membrane tubules mediating retrograde transport in vivo.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544; NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	Princeton University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	ORCI, L (corresponding author), UNIV GENEVA,SCH MED,INST HISTOL & EMBRYOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027044, R37DK027044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 27044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ARMBRUSTER BL, 1982, J MICROSC-OXFORD, V126, P77, DOI 10.1111/j.1365-2818.1982.tb00358.x; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; COREY E J, 1976, Tetrahedron Letters, V51, P4701; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, IN PRESS J CELL BIOL; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; LEDRIAN C, 1982, J AM CHEM SOC, V104, P5473, DOI 10.1021/ja00384a038; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P215; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	40	439	447	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1183	1195						13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004424				2022-12-24	WOS:A1991FD55800016
J	EDDY, DM				EDDY, DM			THE INDIVIDUAL VS SOCIETY - IS THERE A CONFLICT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,DURHAM,NC 27706	Duke University								CANELLOS GP, 1990, J CLIN ONCOL, V8, P1775, DOI 10.1200/JCO.1990.8.11.1775; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1169; EDDY DM, 1986, NCI MONOGRAPHS, V2, P75; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1165; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1170	7	39	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1446	&		10.1001/jama.265.11.1446	http://dx.doi.org/10.1001/jama.265.11.1446			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB550	1999888				2022-12-24	WOS:A1991FB55000029
J	SCHILLER, PH; LEE, KM				SCHILLER, PH; LEE, KM			THE ROLE OF THE PRIMATE EXTRASTRIATE AREA V4 IN VISION	SCIENCE			English	Article							MONKEY VISUAL-CORTEX; STATE DEPENDENT ACTIVITY; DISCRIMINATION; MACAQUE; COLOR; HUE	Area V4 is a part of the primate visual cortex. Its role in vision has been extensively debated. Inferences about the functions of this area have now been made by examination of a broad range of visual capacities after ablation of V4 in rhesus monkeys. The results obtained suggest that this area is involved in more complex aspects of visual information processing than had previously been suggested. Monkeys had particularly severe deficits in situations where the task was to select target stimuli that had a lower contrast, smaller size, or slower rate of motion than the array of comparison stimuli from which they had to be discriminated. Extensive training on each specific task resulted in improved performance. However, after V4 ablation, the monkeys could not generalize the specific task to new stimulus configurations and to new spatial locations.			SCHILLER, PH (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139, USA.		Lee, Kyoung Min/J-2775-2012		NATIONAL EYE INSTITUTE [R01EY000676, R37EY000676] Funding Source: NIH RePORTER; NEI NIH HHS [EY00676] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Blake R., 1990, PERCEPTION; CAVANAGH P, 1990, J EXP PSYCHOL HUMAN, V16, P479, DOI 10.1037/0096-1523.16.3.479; DEAN P, 1979, EXP BRAIN RES, V35, P69; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; GROSS CG, 1973, PROGR PHYSL PSYCHOL; GROSS CG, 1977, LATERAL NERVOUS SYST; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; HAENNY PE, 1988, EXP BRAIN RES, V69, P245, DOI 10.1007/BF00247570; HEYWOOD CA, 1987, J NEUROSCI, V7, P2601; LOGOTHETIS NK, 1990, SCIENCE, V247, P214, DOI 10.1126/science.2294602; MAGUIRE WM, 1984, J NEUROSCI, V4, P1690; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; ROBINSON DA, 1963, IEEE T BIOMED ENG, V101, P131; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; SCHILLER PH, 1990, VISUAL NEUROSCI, V5, P321, DOI 10.1017/S0952523800000420; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; SCHILLER PH, 1990, TRENDS NEUROSCI, V13, P392, DOI 10.1016/0166-2236(90)90117-S; TREISMAN A, 1988, PSYCHOL REV, V95, P15, DOI 10.1037/0033-295X.95.1.15; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOR; WILD HM, 1985, NATURE, V313, P133, DOI 10.1038/313133a0; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	24	173	174	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1251	1253		10.1126/science.2006413	http://dx.doi.org/10.1126/science.2006413			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	2006413				2022-12-24	WOS:A1991FA69100048
J	ITO, N; PHILLIPS, SEV; STEVENS, C; OGEL, ZB; MCPHERSON, MJ; KEEN, JN; YADAV, KDS; KNOWLES, PF				ITO, N; PHILLIPS, SEV; STEVENS, C; OGEL, ZB; MCPHERSON, MJ; KEEN, JN; YADAV, KDS; KNOWLES, PF			NOVEL THIOETHER BOND REVEALED BY A 1.7-A CRYSTAL-STRUCTURE OF GALACTOSE-OXIDASE	NATURE			English	Article							RIBONUCLEOTIDE REDUCTASE; SUPEROXIDE-DISMUTASE; RADICAL SITE; COPPER; RESOLUTION; ENZYME; IDENTIFICATION; INVOLVEMENT; CATALYSIS; SYSTEM	GALACTOSE oxidase is an extracellular enzyme secreted by the fungus Dactylium dendroides. It is monomeric, with a relative molecular mass of 68,000, catalyses the stereospecific oxidation of a broad range of primary alcohol substrates and possesses a unique mononuclear copper site essential for catalysing a two-electron transfer reaction during the oxidation of primary alcohols to corresponding aldehydes 1. Recent evidence 2 arguing against a Cu(III)-Cu(I) couple 3 implies the existence of a second redox-active site proposed to involve pyrroloquinoline quinone 4 or a tyrosine radical 5,6. We now report the crystal structure of galactose oxidase at 1.7 angstrom resolution. This reveals a unique structural feature at the copper site with a novel thioether bond linking Cys 228 and Tyr 272 in a stacking interaction with Trp 290. We propose that these molecular components stabilize the protein free-radical species essential for catalysis and thus provide a 'built-in' secondary cofactor. This feature may represent a new mechanism for mediating electron transfer in metalloenzymes in the absence of exogenous cofactors.			ITO, N (corresponding author), UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			McPherson, Michael/0000-0002-0719-6427; Phillips, Simon/0000-0001-8922-0250				ADMAN ET, 1981, ISRAEL J CHEM, V21, P8, DOI 10.1002/ijch.198100003; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BLACKBURN NJ, 1984, BIOCHEM J, V219, P985, DOI 10.1042/bj2190985; DOOLEY DM, 1987, LIFE CHEM REPORTS, V5, P91; GUSS JM, 1983, J MOL BIOL, V169, P521; HAMILTON GA, 1978, J AM CHEM SOC, V100, P1899, DOI 10.1021/ja00474a042; JACOBSON RR, 1988, J AM CHEM SOC, V110, P3690, DOI 10.1021/ja00219a071; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KOSMAN DJ, 1974, ARCH BIOCHEM BIOPHYS, V165, P456, DOI 10.1016/0003-9861(74)90271-9; KOSMAN DJ, 1984, COPPER PROTEINS COPP, V1, P1; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LERCH K, 1982, J BIOL CHEM, V257, P6414; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; POULOS TL, 1980, J BIOL CHEM, V255, P8199; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TRESSEL P, 1980, BIOCHEM BIOPH RES CO, V92, P781, DOI 10.1016/0006-291X(80)90771-8; VANDERMEER RA, 1989, J BIOL CHEM, V264, P7792; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104	30	694	706	2	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					87	90		10.1038/350087a0	http://dx.doi.org/10.1038/350087a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002850				2022-12-24	WOS:A1991FA69300073
J	RIGOTTI, NA; NEER, RM; SKATES, SJ; HERZOG, DB; NUSSBAUM, SR				RIGOTTI, NA; NEER, RM; SKATES, SJ; HERZOG, DB; NUSSBAUM, SR			THE CLINICAL COURSE OF OSTEOPOROSIS IN ANOREXIA-NERVOSA - A LONGITUDINAL-STUDY OF CORTICAL BONE MASS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY HYPERPARATHYROIDISM; GROWTH-HORMONE; FRACTURE RISK; SOMATOMEDIN-C; WOMEN; OSTEOPENIA; DENSITY; AMENORRHEA; PREDICTION; CALCIUM	Women with anorexia nervosa have reduced bone mass and may develop fractures. Neither the pathophysiology of this osteoporosis nor its natural history is known. To study the clinical course of osteoporosis, we followed up 27 women with anorexia nervosa for a median of 25 months (range, 9 to 53 months). At study entry, cortical bone density, measured by single-photon absorptiometry of the radial shaft, was low (mean +/- SD, 0.63 +/- 0.07 g/cm2) and inversely related to the duration of amenorrhea (r = -0.49). During follow-up, most patients gained weight (n = 19), took calcium supplements (n = 16), and exercised regularly (n = 22), but fewer than half reached 80% or more of ideal body weight (n = 11), resumed menses (n = 6), or received estrogen (n = 4). Cortical bone density was stable during follow-up for the group as a whole; the mean annual change (+/-SD) was +0.005 (+/- .015) g/cm2 (95% confidence interval, -0.0009 to +0.0109). There was no significant difference in the mean change in bone density between women who attained 80% of ideal weight and those who did not or between groups who did or did not regain menses, take estrogen or calcium, or exercise vigorously. Four fractures were clinically observed in three women during follow-up. The rate of 0.05 nonspine fractures per person-year (95% confidence interval, 0.02 to 0.13) exceeds that of normal women in this age range (relative risk, 7.1; 95% confidence interval, 2.3 to 18.5). We conclude that reductions in cortical bone density appear not to be rapidly reversed recovery from anorexia nervosa and that anorectic women may have an increased risk of fracture.	MASSACHUSETTS GEN HOSP,MED SERV,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PSYCHIAT SERV,EATING DISORDERS UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	RIGOTTI, NA (corresponding author), MASSACHUSETTS GEN HOSP,MED SERV,GEN INTERNAL MED UNIT,BULFINCH 1,FRUIT ST,BOSTON,MA 02114, USA.				NCRR NIH HHS [RR-1066] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AYERS JWT, 1984, FERTIL STERIL, V41, P224; BACHRACH LK, 1990, PEDIATRICS, V86, P440; BILLER BMK, 1989, J CLIN ENDOCR METAB, V68, P548, DOI 10.1210/jcem-68-3-548; BLOCK G, 1982, AM J EPIDEMIOL, V115, P492, DOI 10.1093/oxfordjournals.aje.a113331; Cameron J R, 1968, Invest Radiol, V3, P141, DOI 10.1097/00004424-196805000-00001; CANN CE, 1985, BONE, V6, P1, DOI 10.1016/8756-3282(85)90399-0; CHOLST IN, 1984, NEW ENGL J MED, V310, P1221, DOI 10.1056/NEJM198405103101904; CLEMMONS DR, 1979, NEW ENGL J MED, V301, P1138, DOI 10.1056/NEJM197911223012102; CLEMMONS DR, 1981, J CLIN ENDOCR METAB, V53, P1247, DOI 10.1210/jcem-53-6-1247; CROSBY LO, 1985, CLIN ORTHOP RELAT R, V201, P271; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DAVIES KM, 1990, BONE, V11, P143, DOI 10.1016/8756-3282(90)90207-F; DRINKWATER BL, 1984, NEW ENGL J MED, V311, P277, DOI 10.1056/NEJM198408023110501; DRINKWATER BL, 1986, JAMA-J AM MED ASSOC, V256, P380, DOI 10.1001/jama.256.3.380; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; FONESCA VA, 1988, J CLIN PATHOL, V41, P195; GARDSELL P, 1989, CALCIFIED TISSUE INT, V44, P235, DOI 10.1007/BF02553757; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P701; GRANDE F, 1980, MODERN NUTRITION HLT, P7; HINTZ RL, 1978, J PEDIATR-US, V92, P153, DOI 10.1016/S0022-3476(78)80099-7; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem-67-4-701; JOYCE JM, 1990, J NUCL MED, V31, P325; KAPLAN FS, 1986, CLIN ORTHOP RELAT R, V212, P250; KLIBANSKI A, 1980, NEW ENGL J MED, V303, P1511, DOI 10.1056/NEJM198012253032605; KLIBANSKI A, 1986, NEW ENGL J MED, V315, P542, DOI 10.1056/NEJM198608283150903; LINDBERG JS, 1984, ANN INTERN MED, V101, P647, DOI 10.7326/0003-4819-101-5-647; MARCUS R, 1985, ANN INTERN MED, V102, P158, DOI 10.7326/0003-4819-102-2-158; MARTIN P, 1986, ARCH INTERN MED, V146, P689, DOI 10.1001/archinte.146.4.689; MAZESS RB, 1974, AT1111422 U WISC MED; MELTON LJ, 1983, OSTEOPOROTIC SYNDROM, P45; MERIMEE TJ, 1982, J CLIN ENDOCR METAB, V55, P999, DOI 10.1210/jcem-55-5-999; NEWMAN MM, 1989, PSYCHIAT RES, V29, P105, DOI 10.1016/0165-1781(89)90190-X; PHILLIPS LS, 1978, ENDOCRINOLOGY, V103, P121, DOI 10.1210/endo-103-1-121; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RIGOTTI NA, 1986, JAMA-J AM MED ASSOC, V256, P385, DOI 10.1001/jama.256.3.385; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P601; SZMUKLER GI, 1985, BRIT MED J, V290, P26, DOI 10.1136/bmj.290.6461.26; TREASURE J, 1986, SCOT MED J, V31, P206; TREASURE JL, 1987, BRIT MED J, V295, P474, DOI 10.1136/bmj.295.6596.474-a; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WYSHAK G, 1989, J ORTHOPAED RES, V7, P91, DOI 10.1002/jor.1100070113; 1987, DIAGNOSTIC STATISTIC; 1986, NEW ENGL J MED, V314, P39	46	287	288	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1133	1138		10.1001/jama.265.9.1133	http://dx.doi.org/10.1001/jama.265.9.1133			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995999				2022-12-24	WOS:A1991EZ47400030
J	GORE, SM; TAYLOR, RMR; WALLWORK, J				GORE, SM; TAYLOR, RMR; WALLWORK, J			AVAILABILITY OF TRANSPLANTABLE ORGANS FROM BRAIN-STEM DEAD DONORS IN INTENSIVE-CARE UNITS	BRITISH MEDICAL JOURNAL			English	Article								Objective-By audit from January to June 1989 to quantify, separately for hearts, kidneys, liver, lungs and corneas, the possible increases in transplantable organs from brain stem dead potential donors in intensive care units and to compare them with the increases achieved in October-November 1989, during intense, national publicity about transplantation. Design-Prospective audit of all deaths in intensive care units in England from 1 January to 30 June 1989 and subsequent case study of the impact of publicity on offers and donations during October-November 1989. Setting-15 regional and special health authorities in England. Patients-5803 patients dying in intensive care units, of whom 497 were confirmed as brain stem dead and had no general medical contraindication to organ donation. Main outcome measures-Organ specific suitability for transplantation (as reported by intensive care units); consent for donation of specific suitable organs; and procurement of specific organs reported as suitable for transplantation and offered. Results-In the 497 (8.6%) brain stem dead potential donors we estimated the organ specific suitability for heart as 63%, kidneys 95%, liver 70%, lungs 29%, and corneas 91%. Refusal of relatives (30%) accounted for major losses of suitable organs of all types. For kidneys the loss was equivalent to 44% of brain stem dead actual kidney donors. No discussion of organ donation was the second most important reason for missed kidney donors, the loss being equivalent to 10% of brain stem dead actual donors. Non-procurement or difficulties with allocating organs was the second most notable cause of missed suitable liver and lung donors; 29% (55) of the offered total of 189 liver donors and 27% (21) of 78 offered suitable lung donors in six months. Non-procurement of suitable, offered organs was rare for kidneys and modest, of the order of 13% and 10% respectively, for heart and corneas. Corneal donation from brain stem dead potential donors might be improved nearly as much (that is, a 78% increase in brain stem dead actual corneal donors) by specific measures to promote corneal donation when other organs are offered as by reducing the overall refusal rate. Restricted offers, non-procurement, and no discussion of donation accounted for nearly equal numbers of lost donations of hearts (each equivalent to 15% of donated hearts). During October-November 1989 when there was intense, positive publicity about transplantation the rates of refusal and non-discussion fell compared with during January-June (22%, 36/163 upsilon 30%, 138/460; 7%, 33/497 upsilon 2%, 4/167 respectively). Offers of suitable donors increased significantly (p < 0.02) compared with the first six months of 1989, most notably for heart donors (80 upsilon 60.1 expected) and kidney donors (122 upsilon 102.1 expected) but only for kidneys was there a noticeable 17% increase in actual donors (118 actual audited donors upsilon 100.8 expected donors; p = 0.09). Conclusions-Four strategies to increase the supply of transplantable organs from brain stem dead potential donors in intensive care units were identified: (a) reducing refusal of relatives (b) avoiding non-procurement of actually suitable organs (by logistical initiatives) and deterioration of initially suitable organs (by donor care initiatives); (c) converting restricted offers to unrestricted offers; and (d) ensuring discussion with families. Early referral to the transplant team or coordinator gives time for discussion about donor care and agreement on medical suitability for donation of specific organs. Solving some of the logistical problems of non-procurement may be a prerequisite for increased offers to be translated into increased donations. The impact of publicity therefore needs to be measured on offers of suitable donors as well as by actual donations.	ROYAL VICTORIA INFIRM,ORGAN GRAFTING UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; PAPWORTH HOSP,THORAC SURG UNIT,CAMBRIDGE CB3 8RE,ENGLAND	Newcastle University - UK; Papworth Hospital	GORE, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND.							GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; GREBENCK CR, 1987, BR J HOSP MED    JUL, P62; JENNETT B, 1981, BRIT J ANAESTH, V53, P1111, DOI 10.1093/bja/53.11.1111; KEMP G, 1989, SUNDAY EXPRESS  0827, P1; ODOM NJ, 1990, BMJ-BRIT MED J, V300, P1571, DOI 10.1136/bmj.300.6739.1571; WALLWORK J, 1989, BRIT MED J, V299, P1291, DOI 10.1136/bmj.299.6711.1291; 1987, REPORT	7	54	55	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					149	153		10.1136/bmj.302.6769.149	http://dx.doi.org/10.1136/bmj.302.6769.149			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995135	Green Published, Bronze			2022-12-24	WOS:A1991EU02000023
J	LINDBERG, G; EKLUND, GA; GULLBERG, B; RASTAM, L				LINDBERG, G; EKLUND, GA; GULLBERG, B; RASTAM, L			SERUM SIALIC-ACID CONCENTRATION AND CARDIOVASCULAR MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							CANCER; CHOLESTEROL; FIBRINOGEN	Objective - To determine whether serum sialic acid concentration may be used to predict short and long term cardiovascular mortality. Design - Prospective study on all men and women who had their serum sialic acid concentration measured as part of a general health survey in 1964 or in 1965. All were followed up for an average of 20.5 years. Setting - Geographical part of the county of Varmland, Sweden. Subjects - Residents in the area participating in a health check up in 1964-5 (27 065 men and 28 037 women), of whom 372 men (169 with incomplete data and 203 lost to follow up) and 345 women (143 and 202 respectively) were excluded; thus 26 693 men and 27 692 women entered the study. The study sample was restricted to subjects aged 40-74 during any of the 20 years' follow up. Main outcome measures - Serum sialic acid concentration, serum cholesterol concentration, diastolic blood pressure, body mass index at the general health survey visit; cardiovascular and noncardiovascular deaths during three periods of follow up (0-6 years, 7-13 years, and 14-20 years), according to the Swedish mortality register, in subjects aged 45-74. Results - Mean serum sialic acid concentration (mg/100 ml) was 68.8 (SD 8.0) for men and 69.2 (8.0) for women; the average concentration increasing with age in both sexes. A total of 5639 (21%) men and 3307 (12%) women died during the follow up period, in whom death in 3052 (54%) men and 1368 (41%) women was from cardiovascular causes. During short (0-6 years), medium (7-13 years), and long (14-20 years) term follow up the relative risk of death from cardiovascular disease increased with increasing serum sialic acid concentration. The relative risk (95% confidence interval) associated with the highest quartile of sialic acid concentration compared with the lowest quartile was 2.38 (2.01 to 2.83) in men and 2.62 (1.93 to 3.57) in women. Similar results were found for deaths from noncardiovascular disease with relative risks of 1.50 (1.34 to 2.68) in men and 1.89 (1.57 to 2.28) in women, but these relative risks were significantly lower than those for deaths from cardiovascular disease (p < 0.001 and p < 0.005 respectively). In multivariate analysis of total mortality and of cardiovascular mortality with sialic acid concentration, serum cholesterol concentration, diastolic blood pressure, and body mass index as independent variables the impact of sialic acid concentration was virtually the same as in univariate analysis. Conclusion - Serum sialic acid concentration is a strong predictor of cardiovascular mortality. A possible explanation of these findings is that the serum sialic acid concentration may reflect the existence or the activity of an atherosclerotic process, and this may warrant further investigation.	KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Lund University	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							BOLANDER AM, 1981, MED ASPECTS MORTALIT, P236; Hrncir Z, 1975, Vnitr Lek, V21, P436; KROLIKOWSKI FJ, 1976, PHARMACOLOGY, V14, P47, DOI 10.1159/000136578; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MEADE TW, 1980, LANCET, V1, P1050; Ng S.-S., 1976, BIOL ROLES SIALIC AC, P59; PETREN S, 1989, BIOCHIM BIOPHYS ACTA, V994, P161, DOI 10.1016/0167-4838(89)90155-6; RADHAKRISHNAMURTHY B, 1976, LAB INVEST, V34, P159; SCHWICK HG, 1986, BEHRING I MITT, V80, P1; SHANBERGER RJ, 1984, J CLIN CHEM CLIN BIO, V22, P647; SHVARTS L S, 1971, Problemy Endokria, V17, P37; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; SUCCARI M, 1982, PATHOL BIOL, V30, P151; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SWAHN E, 1989, SCAND J CLIN LAB INV, V49, P49, DOI 10.3109/00365518909089077; TANIUCHI K, 1981, Kobe Journal of Medical Sciences, V27, P91; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VARMA R, 1983, J CLIN CHEM CLIN BIO, V21, P273; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; 1967, MANUAL INT STATISTIC; 1955, MANUAL INT STATISTIC; 1971, VARMLAND SURVEY	24	205	209	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					143	146		10.1136/bmj.302.6769.143	http://dx.doi.org/10.1136/bmj.302.6769.143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1995133	Green Published, Bronze			2022-12-24	WOS:A1991EU02000020
J	SELLAR, C; FERGUSON, JA; GOLDACRE, MJ				SELLAR, C; FERGUSON, JA; GOLDACRE, MJ			OCCURRENCE AND REPETITION OF HOSPITAL ADMISSIONS FOR ACCIDENTS IN PRESCHOOL-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD INJURIES; EPIDEMIOLOGY; RATES	Objectives - To examine trends over time in the rates of admission to hospital for accidents of preschool children and to study patterns of repeated admissions for accidents in these children. Design - Analysis of linked, routine abstracts of hospital inpatient records for accidents. Setting - Six districts in the Oxford Regional Health Authority covered by the Oxford record linkage study. Subjects - Records for 19 427 children aged 5 years and under at the time of first recorded admission to hospital. Main outcome measure - Number of admissions to hospital. Results - Records were analysed in three groups: person based annual admission rates were calculated for each calendar year; each child's first recorded admission in 1976-85 was identified, and the child's record was followed up by linkage for one year from that admission; each child's first recorded admission in 1976-81 was identified and followed up for five years. Overall, 19 427 children from an average annual resident population of 163 000 children in 1976-86 had 20 657 admissions for accidents before they were 6 years of age. Of these admissions 13 983 were for injuries, 5717 for poisonings, and 957 for burns. Admission rates declined after 1976 for poisoning, but no substantial changes over time were found in admission rates for injuries or burns. A total of 17 724 children were followed up for one year and 10 889 for five years; 470 (2.6%) of the children who were followed up for one year and 926 (8.5%) of those followed up for five years had at least one further admission for an accident. Of those followed up for one year the 4 and 5 year old children were least likely and those under 1 and 1 year old were most likely to have a further admission for an accident. The number of children who had more than one accident was greater than would be expected if accidents were random occurrences. Those who had a poisoning at first admission were more likely to have another poisoning than an injury or burn; and those who had a burn at first admission were more likely to have another burn. Conclusions - Hospital admissions for accidents in children are common: on average 1 child in 88 in this population was admitted each year. Multiple admissions are uncommon but none the less occur more often than would be expected by chance.			SELLAR, C (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,HEADINGTON,OXFORD OX3 7LF,ENGLAND.							AGASS M, 1990, BRIT J GEN PRACT, V40, P202; ARMITAGE P, 1987, STATISTICAL METHODS, P371; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1988, PEDIATRICS, V82, P707; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; BOYCE WT, 1989, AM J DIS CHILD, V143, P338, DOI 10.1001/archpedi.1989.02150150096024; EMINSON CJ, 1986, J EPIDEMIOL COMMUN H, V40, P170, DOI 10.1136/jech.40.2.170; GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; HUSBAND P, 1973, PRACTITIONER, V211, P335; JACKSON RH, 1983, BRIT MED J, V287, P1468, DOI 10.1136/bmj.287.6403.1468-a; JACKSON RH, 1983, HUM TOXICOL, V2, P285, DOI 10.1177/096032718300200218; RIVARA FP, 1982, AM J DIS CHILD, V136, P399, DOI 10.1001/archpedi.1982.03970410017003; RIVARA FP, 1982, AM J DIS CHILD, V136, P502, DOI 10.1001/archpedi.1982.03970420026004; STEWARTBROWN S, 1986, INT J EPIDEMIOL, V15, P352, DOI 10.1093/ije/15.3.352; 1989, BASIC PRINCIPLES CHI; 1990, ELM901 DEP HLTH; 1967, MANUAL INT STATISTIC; 1990, ACTION ACCIDENT UNIQ; HOSPITAL PATIENT ENQ; MORTALITY STATISTICS; 1989, EL89P96 DEP HLTH SOC; [No title captured]	22	25	25	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 5	1991	302	6767					16	19		10.1136/bmj.302.6767.16	http://dx.doi.org/10.1136/bmj.302.6767.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER372	1991180	Bronze, Green Published			2022-12-24	WOS:A1991ER37200018
J	SRA, JS; ANDERSON, AJ; SHEIKH, SH; AVITALL, B; TCHOU, PJ; TROUP, PJ; GILBERT, CJ; AKHTAR, M; JAZAYERI, MR				SRA, JS; ANDERSON, AJ; SHEIKH, SH; AVITALL, B; TCHOU, PJ; TROUP, PJ; GILBERT, CJ; AKHTAR, M; JAZAYERI, MR			UNEXPLAINED SYNCOPE EVALUATED BY ELECTROPHYSIOLOGIC STUDIES AND HEAD-UP TILT TESTING	ANNALS OF INTERNAL MEDICINE			English	Article							NEURALLY-MEDIATED SYNCOPE; VAGAL C-FIBERS; RECURRENT SYNCOPE; DISOPYRAMIDE; ISOPROTERENOL; BRADYCARDIA; HYPOTENSION; REVERSAL	Objective: To determine the clinical characteristics of subgroups of patients with unexplained syncope having electrophysiologic studies and head-up tilt testing and to assess the efficacy of various therapies. Design: Retrospective study. Setting: Inpatient services of a tertiary referral center. Patients: Eighty-six consecutively referred patients with unexplained syncope. Measurements: All patients had electrophysiologic examinations. Patients with negative results subsequently had head-up tilt testing. Main Results: Twenty-nine (34%) patients (group 1) had abnormal electrophysiologic results, with sustained monomorphic ventricular tachycardia induced in 72%. Thirty-four (40%) patients (group 2) had syncope provoked by head-up tilt testing. The cause of syncope remained unexplained in 23 (26%) patients (group 3). Structural heart disease was present in 76%, 6%, and 30% of groups 1, 2, and 3, respectively. In group 1, pharmacologic or nonpharmacologic therapy was recommended based on electrophysiologic evaluation. All group 2 patients had negative results on head-up tilt testing while receiving oral beta blockers (27 patients) or disopyramide (7 patients). Group 3 patients did not receive any specific therapy. During a median follow-up period of 18.5 months, syncope recurred in 9 (10%) patients. Conclusions: The combination of electrophysiologic evaluation and head-up tilt testing can identify the underlying cause of syncope in as many as 74% of patients presenting with unexplained syncope. Therapeutic strategies formulated according to the results of these diagnostic tests appear to prevent syncope effectively in most patients.	MILWAUKEE CARDIOVASC DATA REGISTRY, MILWAUKEE, WI 53215 USA; SANDAHA HOME, LAHORE, PAKISTAN; PRESBYTERIAN UNIV HOSP, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	SRA, JS (corresponding author), SINAI SAMARITAN MED CTR, 950 N 12TH ST, POB 342, MILWAUKEE, WI 53201 USA.							ABBOUD FM, 1976, PROG CARDIOVASC DIS, V18, P371, DOI 10.1016/0033-0620(76)90003-7; ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; AKHTAR M, 1983, PACE, V6, P192, DOI 10.1111/j.1540-8159.1983.tb04346.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; DANILO P, 1976, AM HEART J, V92, P532; DERMKSIAN G, 1958, JAMA-J AM MED ASSOC, V168, P1200, DOI 10.1001/jama.1958.03000090030007; DIMARCO JP, 1981, ANN INTERN MED, V95, P542, DOI 10.7326/0003-4819-95-5-542; GOLDENBERG IF, 1987, CIRCULATION, V76, P133; JAZAYERI MR, 1989, J AM COLL CARDIOL, V14, P705, DOI 10.1016/0735-1097(89)90114-9; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KUSHNER JA, 1989, J AM COLL CARDIOL, V14, P391, DOI 10.1016/0735-1097(89)90191-5; Lewis T, 1932, BRIT MED J, V1932, P873, DOI 10.1136/bmj.1.3723.873; LUBROOK J, 1989, INT UNION PHYSL SCI, V4, P120; MILSTEIN S, 1987, CIRCULATION, V76, P175; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; PODRID PJ, 1980, NEW ENGL J MED, V302, P614, DOI 10.1056/NEJM198003133021106; SHALEV Y, 1990, Journal of the American College of Cardiology, V15, p98A; SHARPEYSCHAFER EP, 1958, BMJ-BRIT MED J, V2, P878, DOI 10.1136/bmj.2.5101.878; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; SJOSTRAND T, 1952, ACTA PHYSIOL SCAND, V26, P312, DOI 10.1111/j.1748-1716.1952.tb00912.x; THAMES MD, 1980, AM J PHYSIOL, V238, pH465, DOI 10.1152/ajpheart.1980.238.4.H465; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; TONKIN AM, 1978, AUST NZ J MED, V8, P594, DOI 10.1111/j.1445-5994.1978.tb04846.x; WALTER PF, 1978, AM J CARDIOL, V42, P396, DOI 10.1016/0002-9149(78)90934-7	24	209	209	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1013	1019		10.7326/0003-4819-114-12-1013	http://dx.doi.org/10.7326/0003-4819-114-12-1013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	2029096				2022-12-24	WOS:A1991FQ55500004
J	ATTIE, M				ATTIE, M			HYPOCALCEMIC SYMPTOMS FOLLOWING PARATHYROIDECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ATTIE, M (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.							Parfitt A. M., 1989, ENDOCRINOLOGY, P1049; PORTER RH, 1978, NEW ENGL J MED, V298, P577, DOI 10.1056/NEJM197803162981101	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2888	2888						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033749				2022-12-24	WOS:A1991FN85500043
J	OLSON, DJ; CHRISTIAN, JL; MOON, RT				OLSON, DJ; CHRISTIAN, JL; MOON, RT			EFFECT OF WNT-1 AND RELATED PROTEINS ON GAP JUNCTIONAL COMMUNICATION IN XENOPUS EMBRYOS	SCIENCE			English	Article							EARLY AMPHIBIAN EMBRYO; PROTO-ONCOGENE INT-1; MURINE INT-1; DROSOPHILA HOMOLOG; CELL COMMUNICATION; GENE; PROTOONCOGENE; EXPRESSION; WINGLESS; PATTERNS	The proto-oncogene wnt-1 (previously referred to as int-1) is thought to be important in embryonic pattern formation although its mechanisms of action are unknown. Premature and increased expression of the Wnt-1 protein, achieved by injection of synthetic wnt-1 RNA into fertilized Xenopus eggs, enhanced gap junctional communication between ventral cells of the developing embryo. This result is consistent with the hypothesis that Wnt proteins activate a receptor-mediated signal transduction pathway and that gap junctional communication can be a target of this pathway. The effects of two Wnt-1-related proteins on gap junctional communication were also investigated: overexpression of Xwnt-8 increased gap junctional coupling in a manner similar to Wnt-1, whereas Xwnt-5A did not. These findings are consistent with the existence of multiple receptors for Wnt proteins.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040089, K04AR001837] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007023] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR40089, KO4-AR01837] Funding Source: Medline; NIDCR NIH HHS [DE-07023] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BERRIDGE MJ, 1982, BIOCHEM J, V206, P507; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, IN PRESS DEVELOPMENT; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; FAWCETT DW, 1981, CELL, P124; FRASER SE, 1987, SCIENCE, V237, P49, DOI 10.1126/science.3037697; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GUTHRIE S, 1988, DEVELOPMENT, V103, P769; GUTHRIE SC, 1984, NATURE, V311, P149, DOI 10.1038/311149a0; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Moon R. T., 1989, TECHNIQUE, V1, P76; MOON RT, UNPUB; NAGAJSKI DJ, 1989, DEVELOPMENT, V105, P747; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; OLSON DA, UNPUB; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, IN PRESS GENES DEV; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WARNER AE, 1982, CELL, V28, P243, DOI 10.1016/0092-8674(82)90342-7; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WARNER AE, 1986, SOMITES DEV EMBRYOS, P91; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	42	128	129	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1173	1176		10.1126/science.252.5009.1173	http://dx.doi.org/10.1126/science.252.5009.1173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031187				2022-12-24	WOS:A1991FN05600051
J	KUNG, AWC; PUN, KK				KUNG, AWC; PUN, KK			BONE-MINERAL DENSITY IN PREMENOPAUSAL WOMEN RECEIVING LONG-TERM PHYSIOLOGICAL DOSES OF LEVOTHYROXINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE; OSTEOPOROSIS; HYPERTHYROIDISM; THYROTOXICOSIS; CALCITONIN; HYPOTHYROIDISM; REPLACEMENT; DEFICIENCY; THERAPY	Total body and regional bone mineral density (BMD) levels were determined in 26 premenopausal women with Hashimoto's thyroiditis receiving long-term physiological doses of levothyroxine sodium replacement therapy. The BMD levels of each patient were compared with the mean of the BMD levels of age-matched normal controls. The mean levothyroxine sodium dose was 111 +/- 6-mu-g/d, and the mean duration of treatment was 7.5 +/- 5.3 years (range, 1 to 24 years). Dietary calcium intake was similar in both groups, as were serum thyroxine, triiodothyronine, free thyroxine index, and thyrotropin levels. Women receiving the levothyroxine treatment had normal total body BMD levels but had significantly lower BMD levels at the femoral neck (-5.7%), femoral trochanter (-7.0%), Ward's triangle (-10.6%), both arms (right,-7.8%; left, -8.9%), and pelvis (-4.9%). In contrast, lumbar spine BMD levels were similar in the two groups. There was no correlation between the total body or different regional BMD levels and the duration or dosage of levothyroxine treatment or thyroid function test results. However, the z score of the femoral neck of these patients showed a significant negative correlation with their serum free thyroxine index levels. We conclude that patients receiving physiological doses of levothyroxine may have decreased bone density. Thyroid functions in patients receiving long-term levothyroxine treatment should be closely monitored and bone densitometry should be performed in patients at risk for osteoporosis.			KUNG, AWC (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG.							CALDWELL G, 1985, LANCET, V1, P1117; COINDRE JM, 1986, ARCH INTERN MED, V146, P48, DOI 10.1001/archinte.146.1.48; DANIELL HW, 1974, NEW ENGL J MED, V291, P102; ERIKSEN EF, 1986, BONE, V7, P101, DOI 10.1016/8756-3282(86)90681-2; ETTINGER B, 1982, WESTERN J MED, V136, P473; FALLON MD, 1983, ARCH INTERN MED, V143, P442, DOI 10.1001/archinte.143.3.442; FLEISH H, 1987, OSTEOPOROSIS, P1159; FRAME B, 1983, ANN INTERN MED, V99, P725, DOI 10.7326/0003-4819-99-5-725; FRASER SA, 1971, LANCET, V1, P981; GARREL DR, 1986, J CLIN ENDOCR METAB, V62, P1052, DOI 10.1210/jcem-62-5-1052; GONZALEZ D, 1986, CALCIFIED TISSUE INT, V38, P71, DOI 10.1007/BF02556832; HENNESSEY JV, 1986, ANN INTERN MED, V105, P11, DOI 10.7326/0003-4819-105-1-11; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; MCDERMOTT MT, 1983, J CLIN ENDOCR METAB, V56, P936, DOI 10.1210/jcem-56-5-936; MEEMA HE, 1970, RADIOLOGY, V97, P9, DOI 10.1148/97.1.9; MELSEN F, 1977, ACTA PATH MICRO IM A, V85, P141; Meunier PJ, 1972, ORTHOPEDIA CLINICS N, V3, P745; MULLEN BJ, 1984, AM J CLIN NUTR, V39, P136, DOI 10.1093/ajcn/39.1.136; NIELSEN HE, 1979, ACTA RADIOL ONCOL, V18, P122, DOI 10.3109/02841867909128198; NORD RH, 1989, 21 EUR S CALC TISS J; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PERRY HM, 1986, ARCH INTERN MED, V146, P41, DOI 10.1001/archinte.146.1.41; PUN KK, IN PRESS OSTEOPOROSI; PUN KK, IN PRESS J APPL NUTR; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; TIEGS RD, 1985, NEW ENGL J MED, V312, P1097, DOI 10.1056/NEJM198504253121705; TIEGS RD, 1983, CALCIFIED TISSUE INT, V369, P479	30	74	75	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2688	2691		10.1001/jama.265.20.2688	http://dx.doi.org/10.1001/jama.265.20.2688			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023349				2022-12-24	WOS:A1991FL98900033
J	KOOPMAN, P; GUBBAY, J; VIVIAN, N; GOODFELLOW, P; LOVELLBADGE, R				KOOPMAN, P; GUBBAY, J; VIVIAN, N; GOODFELLOW, P; LOVELLBADGE, R			MALE DEVELOPMENT OF CHROMOSOMALLY FEMALE MICE TRANSGENIC FOR SRY	NATURE			English	Article							TESTIS-DETERMINING GENE; SEX-REVERSED MICE; Y-CHROMOSOME; MOUSE; DUPLICATION; EXPRESSION	The initiation of male development in mammals requires one or more genes on the Y chromosome. A recently isolated gene, termed SRY in humans and Sry in mouse, has many of the genetic and biological properties expected of a Y-located testis-determining gene. It is now shown that Sry on a 14-kilobase genomic DNA fragment is sufficient to induce testis differentiation and subsequent male development when introduced into chromosomally female mouse embryos.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,LONDON WC2A 3PX,ENGLAND	MRC National Institute for Medical Research; Cancer Research UK			Koopman, Peter A/C-9416-2009	Koopman, Peter A/0000-0001-6939-0914; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BETA P, 1990, NATURE, V348, P448; BISHOP CE, 1985, NATURE, V315, P70, DOI 10.1038/315070a0; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; BURGOYNE PS, 1988, DEVELOPMENT, V102, P443; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; EICHER EM, 1988, PHILOS T R SOC B, V322, P109, DOI 10.1098/rstb.1988.0118; EICHER EM, 1980, CYTOGENET CELL GENET, V28, P104, DOI 10.1159/000131518; ELLIS NA, 1989, NATURE, V337, P81, DOI 10.1038/337081a0; FORD CE, 1959, LANCET, V1, P711; FREDGA K, 1988, PHILOS T R SOC B, V322, P83, DOI 10.1098/rstb.1988.0116; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1990, DEVELOPMENT, V109, P647; Hogan B., 1986, MANIPULATING MOUSE E; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JAGER RJ, 1990, HUM GENET, V85, P666; Josso N., 1981, Mechanisms of sex differentiation in animals and man., P165; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; JOST A, 1988, PHILOS T ROY SOC B, V322, P55, DOI 10.1098/rstb.1988.0113; Jost A., 1973, Recent Progress Hormone Res, V29, P1; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P153; Maniatis T., 1982, MOL CLONING; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MCLAREN A, 1982, NATURE, V300, P446, DOI 10.1038/300446a0; MCLAREN A, 1988, PHILOS T ROY SOC B, V322, P3, DOI 10.1098/rstb.1988.0109; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PALMER SJ, 1991, DEVELOPMENT, V111, P1017; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6646; SCHERER G, 1989, HUM GENET, V81, P291; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; WELSHONS W. J., 1959, PROC NATL ACAD SCI, V45, P560, DOI 10.1073/pnas.45.4.560; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; [No title captured]	42	1679	1764	3	125	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					117	121		10.1038/351117a0	http://dx.doi.org/10.1038/351117a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030730				2022-12-24	WOS:A1991FL03500040
J	LAWRENCE, RA				LAWRENCE, RA			CORTICOSTEROID EFFECT ON LACTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PREDNISOLONE; MILK				LAWRENCE, RA (corresponding author), UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY 14642, USA.							Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; LAWRENCE RA, 1989, BREASTFEEDING GUIDE, P256; MCKENZIE SA, 1975, ARCH DIS CHILD, V50, P894, DOI 10.1136/adc.50.11.894; Neville M. C., 1983, Lactation. Physiology, nutrition, and breast-feeding, P141; OST L, 1985, J PEDIATR-US, V106, P1008, DOI 10.1016/S0022-3476(85)80259-6; SIETSEMA WK, 1989, INT J CLIN PHARM TH, V27, P179; TAUBER U, 1984, INT J CLIN PHARM TH, V22, P48	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2409	2409						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016840				2022-12-24	WOS:A1991FJ95500041
J	SIDRANSKY, D; VONESCHENBACH, A; TSAI, YC; JONES, P; SUMMERHAYES, I; MARSHALL, F; PAUL, M; GREEN, P; HAMILTON, SR; FROST, P; VOGELSTEIN, B				SIDRANSKY, D; VONESCHENBACH, A; TSAI, YC; JONES, P; SUMMERHAYES, I; MARSHALL, F; PAUL, M; GREEN, P; HAMILTON, SR; FROST, P; VOGELSTEIN, B			IDENTIFICATION OF P53 GENE-MUTATIONS IN BLADDER CANCERS AND URINE SAMPLES	SCIENCE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RAS ONCOGENE; SHORT ARM; TRANSFORMATION; DNA; CHROMOSOME-11; CARCINOMA; ANTIONCOGENES; COOPERATION	Although bladder cancers are very common, little is known about their molecular pathogenesis. In this study, invasive bladder cancers were evaluated for the presence of gene mutations in the p53 suppressor gene. Of 18 tumors evaluated, 11 (61 percent) were found to have genetic alterations of p53. The alterations included ten point mutations resulting in single amino acid substitutions, and one 24-base pair deletion. In all but one case, the mutations were associated with chromosome 17p allelic deletions, leaving the cells with only mutant forms of the p53 gene product. Through the use of the polymerase chain reaction and oligomer-specific hybridization, p53 mutations were identified in 1 to 7 percent of the cells within the urine sediment of each of three patients tested. The p53 mutations are the first genetic alterations demonstrated to occur in a high proportion of primary invasive bladder cancers. Detection of such mutations ex vivo has clinical implications for monitoring individuals whose tumor cells are shed extracorporeally.	JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21231; MD ANDERSON HOSP & TUMOR INST,DEPT UROL,HOUSTON,TX 77054; UNIV SO CALIF,KENNETH J NORRIS COMPREHENS CANC CTR,LOS ANGELES,CA 90033; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT UROL,BALTIMORE,MD 21215; JOHNS HOPKINS UNIV,DEPT PATHOL,BALTIMORE,MD 21231; MD ANDERSON HOSP & TUMOR INST,DEPT CELL BIOL,HOUSTON,TX 77054	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Southern California; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA43460, CA09071, CA49758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009071, R37CA043460, R01CA043460, R35CA049758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; Badalament R A, 1988, Semin Urol, V6, P22; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, IN PRESS NUCLEAR PRO; BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; COON JM, COMMUNICATION; DEITCH AD, 1990, J UROLOGY, V143, P700, DOI 10.1016/S0022-5347(17)40064-4; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DELSENNO L, 1989, J UROLOGY, V142, P146; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOOT NC, 1958, CANCER BRUSSELS, V11, P137; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GIBAS Z, 1984, CANCER RES, V44, P1257; HANSEN MF, 1987, CANCER RES, V47, P5518; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Koss L. G, 1979, DIAGNOSTIC CYTOLOGY; KOSS LG, 1985, ACTA CYTOL, V29, P810; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASKUS JR, 1988, UROL RES, V6, P341; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WF, 1990, J CELL BIOCHEM, V14, P285; MUNROE DG, 1988, ONCOGENE, V2, P621; NAKAZAWA H, 1990, MOL CARCINOGEN, V3, P202, DOI 10.1002/mc.2940030407; NEAL DE, 1985, LANCET, V1, P366; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SIDRANSKY D, UNPUB; SPEISSL B, 1982, UICC INT UNION CANCE; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TSAI YC, 1990, CANCER RES, V50, P40; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; WEINBERG RA, 1989, CANCER RES, V49, P3713	54	839	869	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					706	709		10.1126/science.2024123	http://dx.doi.org/10.1126/science.2024123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024123				2022-12-24	WOS:A1991FK18500049
J	LIU, SC; DERICK, LH; ZHAI, S; PALEK, J				LIU, SC; DERICK, LH; ZHAI, S; PALEK, J			UNCOUPLING OF THE SPECTRIN-BASED SKELETON FROM THE LIPID BILAYER IN SICKLED RED-CELLS	SCIENCE			English	Article							HUMAN-ERYTHROCYTES; MEMBRANE SKELETON; ATP DEPLETION; FREE VESICLES; CATION; RELEASE; SODIUM; PHOSPHATIDYLCHOLINE; TRANSFORMATION	The distribution of spectrin and band 3 in deoxygenated reversibly sickled cells was visualized by immunofluorescence and immunoelectron microscopy. Antibodies against band 3, the major lipid-associated transmembrane protein, labeled the entire cell body, including the entire length of the long protruding spicule, whereas antibodies against spectrin labeled only the cell body and the base region of the spicules. The results suggest that the formation of long spicules during sickling is associated with a continuous polymerization of hemoglobin S polymers, presumably through gaps in the spectrin-actin meshwork, and a subsequent uncoupling of the lipid bilayer from the submembrane skeleton.	TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT MED,BOSTON,MA 02135	Tufts University; Tufts University	LIU, SC (corresponding author), TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02135, USA.				NHLBI NIH HHS [HL-15157-7, HL-37462, HL-27215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462, P60HL015157, R01HL027215, R37HL027215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1982, NATURE, V295, P612, DOI 10.1038/295612a0; BERKOWITZ LR, 1985, AM J PHYSIOL, V249, pC208, DOI 10.1152/ajpcell.1985.249.3.C208; BERTLES JF, 1969, BLOOD-J HEMATOL, V33, P884, DOI 10.1182/blood.V33.6.884.884; BOOKCHIN RM, 1981, J PHYSIOL-LONDON, V312, P265, DOI 10.1113/jphysiol.1981.sp013628; BRUGNARA C, 1986, SCIENCE, V232, P388, DOI 10.1126/science.3961486; CANESSA M, 1987, BLOOD, V70, P1861; COAKLEY WT, 1978, BIOCHIM BIOPHYS ACTA, V512, P318, DOI 10.1016/0005-2736(78)90256-0; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; FRANCK PFH, 1983, J BIOL CHEM, V258, P8435; JENSEN WN, 1970, SEMIN HEMATOL, V7, P409; JOINER CH, 1986, J CLIN INVEST, V78, P1487, DOI 10.1172/JCI112740; JOINER CH, 1988, BLOOD CELLS, V13, P339; LIU SC, 1989, EUR J CELL BIOL, V49, P358; Liu Shun-Wei, UNPUB; LUTZ HU, 1977, J CELL BIOL, V73, P548, DOI 10.1083/jcb.73.3.548; MIDDELKOOP E, 1988, BIOCHIM BIOPHYS ACTA, V937, P281, DOI 10.1016/0005-2736(88)90250-7; MOHANDAS N, 1986, BLOOD, V68, P450; OTT P, 1981, BIOCHIM BIOPHYS ACTA, V641, P79, DOI 10.1016/0005-2736(81)90570-8; PALEK J, 1978, ERYTHROCYTE MEMBRANE, P75; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; RUMSBY MG, 1977, BIOCHEM SOC T, V5, P126, DOI 10.1042/bst0050126; TOSTESON DC, 1952, J CLIN INVEST, V31, P406, DOI 10.1172/JCI102623; WAGNER GM, 1986, J LAB CLIN MED, V108, P315	24	67	67	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					574	576		10.1126/science.2020854	http://dx.doi.org/10.1126/science.2020854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020854				2022-12-24	WOS:A1991FJ12700050
J	BALDWIN, DC; HUGHES, PH; CONARD, SE; STORR, CL; SHEEHAN, DV				BALDWIN, DC; HUGHES, PH; CONARD, SE; STORR, CL; SHEEHAN, DV			SUBSTANCE USE AMONG SENIOR MEDICAL-STUDENTS - A SURVEY OF 23 MEDICAL-SCHOOLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-USE; RELIABILITY	Senior students at 23 regionally distributed medical schools received an anonymous questionnaire designed to examine current and prior use of tobacco, alcohol, and nine other drugs. The overall response rate was 67% (N = 2046). Substance use prevalence rates during the 30 days preceding the survey included alcohol, 87.5%; marijuana, 10.0%; cigarettes, 10.0%; cocaine, 2.8%; tranquilizers, 2.3%; opiates other than heroin, 1.1%; psychedelics other than LSD (lysergic acid diethylamide), 0.6%; amphetamines, 0.3%; barbiturates, 0.2%; LSD, 0.1%; and heroin, 0.0%. Compared with national, age-related comparison groups, senior medical students reported less use of all substances during the past 30 days and the past 12 months, except for alcohol, tranquilizers, and psychedelics other than LSD. Substantial new drug use after entry into medical school was reported only for tranquilizers. Seven students (0.2%) admitted to current dependence on a substance other than tobacco, four of these implicating marijuana. Thirty-three students (1.6%) believed that they currently needed help for substance abuse. Only 25.7% were aware of any policy on substance abuse at their own school.	UNIV S FLORIDA, DEPT PSYCHIAT & BEHAV MED, CTR STUDY IMPAIRED PROFESS, TAMPA, FL 33620 USA; UNIV TEXAS, HLTH SCI CTR, DEPT FAMILY & COMMUNITY MED, DALLAS, TX 75235 USA	State University System of Florida; University of South Florida; University of Texas System; University of Texas Dallas	BALDWIN, DC (corresponding author), AMER MED ASSOC, DIV MED EDUC RES & INFORMAT, 515 N STATE ST, CHICAGO, IL 60610 USA.		Sheehan, David V/L-6879-2013	Sheehan, David V/0000-0002-5118-7050				BACHMAN JG, 1990, J HEALTH SOC BEHAV, V31, P173, DOI 10.2307/2137171; BORKMAN T, 1986, ALCOHOL HEALTH RES W, V10, P54; CLARK DC, 1987, JAMA-J AM MED ASSOC, V257, P2921, DOI 10.1001/jama.257.21.2921; COLLINS J, 1989, NATIONAL ADOLESCENT; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; CONARD S, 1989, AM J PSYCHIAT, V146, P382; CROWLEY AE, 1986, JAMA-J AM MED ASSOC, V256, P1545, DOI 10.1001/jama.1986.03380120015003; CROWLEY AE, 1987, JAMA-J AM MED ASSOC, V258, P1013, DOI 10.1001/jama.258.8.1013; JOHNSTON LD, 1985, STUDYING DRUG USE, P117; JOHNSTON LD, 1989, ADM891638US DEP HLTH; KING FW, 1970, AM PSYCHOL, V25, P982, DOI 10.1037/h0029859; LUETGERT MJ, 1973, INT J ADDICT, V8, P683, DOI 10.3109/10826087309057494; MADDUX JF, 1986, AM J PSYCHIAT, V143, P187; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; OMALLEY PM, 1983, INT J ADDICT, V18, P805, DOI 10.3109/10826088309033049; ROWLEY BD, 1988, J MED EDUC, V63, P759; SCHWARTZ RH, 1990, ARCH INTERN MED, V150, P883, DOI 10.1001/archinte.150.4.883; SINGLE E, 1975, J DRUG ISSUES, V5, P426, DOI 10.1177/002204267500500411	18	103	106	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2074	2078		10.1001/jama.265.16.2074	http://dx.doi.org/10.1001/jama.265.16.2074			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013926				2022-12-24	WOS:A1991FG90700023
J	FROST, CD; LAW, MR; WALD, NJ				FROST, CD; LAW, MR; WALD, NJ			BY HOW MUCH DOES DIETARY SALT REDUCTION LOWER BLOOD-PRESSURE .2. ANALYSIS OF OBSERVATIONAL DATA WITHIN POPULATIONS	BRITISH MEDICAL JOURNAL			English	Article							URINARY SODIUM; POTASSIUM; VARIABILITY; EXCRETION; MEN; ASSOCIATION; CATIONS	Objective-To determine whether the estimates of the size of the association between blood pressure and sodium intake derived from studies of individuals within populations can be quantitatively reconciled with our estimates derived from comparisons of the average blood pressure and sodium intake between different populations. Design-Examination of data from 14 published studies that correlated blood pressure recordings in individuals against measurements of their 24 hour sodium intake (within population studies). Main outcome measure-Comparison of observed differences in blood pressure per 100 mmol/24 h difference in sodium intake in each within population study with predicted differences calculated from the between population data, after allowing for the underestimation of the true association of blood pressure with sodium intake caused by the large day to day variation in 24 hour sodium intake within individuals. Results-The underestimation bias inherent in the within population studies reduced the regression slope of blood pressure on single measures of 24 hour sodium intake to between a half and a quarter of the true value (for example, in one study from 6.0 to 2.4 mm Hg/100 mmol/24 h). Estimates from between population comparisons of the regression slope of blood pressure on sodium intake, after adjustment to take this underestimation bias into account, were similar to the values actually observed in the within population studies. Conclusion-The within population studies confirm our estimates from between population comparisons of the magnitude of the association between blood pressure and sodium intake.	ST BARTHOLOMEWS HOSP,COLL MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London			Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					[Anonymous], 1988, BMJ, V297, P319; ARMITAGE P, 1987, STATISTICAL METHODS; BULPITT CJ, 1986, J CHRON DIS, V39, P211, DOI 10.1016/0021-9681(86)90026-3; CONNOR SL, 1984, CIRCULATION, V70, P76, DOI 10.1161/01.CIR.70.1.76; ELLIOTT P, 1988, J HUM HYPERTENS, V2, P89; Joossens J. V., 1980, EPIDEMIOLOGY ARTERIA, P45; KESTELOOT H, 1980, EUR J CARDIOL, V11, P169; KESTELOOT H, 1987, HYPERTENSION, V9, P654, DOI 10.1161/01.HYP.9.6.654; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LISHENG L, 1987, J HYPERTENS, V5, P331, DOI 10.1097/00004872-198706000-00011; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; LUFT FC, 1986, AM J KIDNEY DIS, V7, P375, DOI 10.1016/S0272-6386(86)80085-3; SIANI A, 1989, HYPERTENSION, V13, P38, DOI 10.1161/01.HYP.13.1.38; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; STAESSEN J, 1983, AM J EPIDEMIOL, V117, P676, DOI 10.1093/oxfordjournals.aje.a113601; STRAZZULLO P, 1983, EUR HEART J, V4, P608, DOI 10.1093/oxfordjournals.eurheartj.a061532; WATT GCM, 1982, J EPIDEMIOL COMMUN H, V36, P197, DOI 10.1136/jech.36.3.197; 1989, J HUM HYPERTENSION, V3, P279	19	169	171	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					815	818		10.1136/bmj.302.6780.815	http://dx.doi.org/10.1136/bmj.302.6780.815			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025704	Bronze, Green Published			2022-12-24	WOS:A1991FF37700021
J	GILSTRAP, LC				GILSTRAP, LC			ELECTIVE APPENDECTOMY DURING ABDOMINAL-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GILSTRAP, LC (corresponding author), UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DALLAS,TX 75235, USA.							PARSONS AK, 1986, OBSTET GYNECOL, V68, P479; WATERS EG, 1977, OBSTET GYNECOL, V50, P511; WESTERMANN C, 1986, SURG GYNECOL OBSTET, V162, P307	3	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1736	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002579				2022-12-24	WOS:A1991FD65900034
J	BASLER, K; CHRISTEN, B; HAFEN, E				BASLER, K; CHRISTEN, B; HAFEN, E			LIGAND-INDEPENDENT ACTIVATION OF THE SEVENLESS RECEPTOR TYROSINE KINASE CHANGES THE FATE OF CELLS IN THE DEVELOPING DROSOPHILA EYE	CELL			English	Article							PROTO-ONCOGENE PRODUCT; PUTATIVE RECEPTOR; POINT MUTATION; OPSIN GENE; RETINA; MELANOGASTER; DOMAIN; EXPRESSION; PATTERN; MUTANT	Cell fate in the developing eye is determined by a cascade of inductive interactions. In this process, the sevenless protein-a receptor tyrosine kinase-is required for the specification of the R7 photoreceptor cell fate. We have constructed a gain-of-function sevenless mutation (Sev(S11)) by overexpressing a truncated sevenless protein in the cells where sevenless is normally expressed. In Sev(S11) mutant flies, all sevenless-expressing cells initiate neural development. This results in the formation of multiple R7-like photoreceptors per ommatidium. Therefore, sevenless activity appears to be necessary and sufficient for the determination of R7 cell fate. These results illustrate the central role receptor tyrosine kinases can play in the specification of cell fate during development.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich				Basler, Konrad/0000-0003-3534-1529				BALLINGER DG, 1988, P NATL ACAD SCI USA, V85, P3960, DOI 10.1073/pnas.85.11.3960; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, IN PRESS GENES DEV; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; JARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MISMER D, 1987, GENETICS, V116, P565; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONTELL C, 1987, J NEUROSCI, V7, P1558; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SNYDER M, 1982, CELL, V29, P1027, DOI 10.1016/0092-8674(82)90466-4; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STARK WS, 1987, J NEUROGENET, V4, P227, DOI 10.3109/01677068709102343; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOMILINSON A, 1989, CIBA F S, V144, P281; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; ZUKER CS, 1987, J NEUROSCI, V7, P1550	51	223	225	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1069	1081		10.1016/0092-8674(91)90262-W	http://dx.doi.org/10.1016/0092-8674(91)90262-W			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004416	Green Accepted			2022-12-24	WOS:A1991FD55800005
J	YELLAND, A; GRAHAM, MD; TROTT, PA; FORD, HT; COOMBES, RC; GAZET, JC; POLSON, NG				YELLAND, A; GRAHAM, MD; TROTT, PA; FORD, HT; COOMBES, RC; GAZET, JC; POLSON, NG			DIAGNOSING BREAST-CARCINOMA IN YOUNG-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							ASPIRATION CYTOLOGY; MAMMOGRAPHY; MANAGEMENT; CANCER	Objective-To assess the individual and combined diagnostic accuracy of clinical examination, mammography, and fine needle aspiration biopsy in young women with breast cancer. Design-Analysis based on case notes of patients presenting with breast cancer during 1971-89. Setting-A combined breast clinic. Patients-Consecutive series of 81 women aged < 36 with histologically proved breast cancer presenting with a discrete mass over 19 years. Main outcome measures-Results of clinical examination, xeromammography or conventional mammography, fine needle aspiration biopsy, and examination of tissue removed by surgery. Results-The clinical diagnosis was correct in 47 women and radiography in 35. Fine needle aspiration biopsy was correct in 47 of the 63 women in whom it was successfully performed. Fine needle aspiration was significantly more accurate than mammography (78% v 45%, p < 0.01). Ten (16%) patients had negative results on clinical examination, mammography, and fine needle aspiration. Conclusion-Mammography alone seems inadequately sensitive to detect breast cancer in young patients. When all investigations give negative results excision biopsy is the only way of obtaining a definitive diagnosis.	ST GEORGE HOSP,COMBINED BREAST CLIN,LONDON SW17 0QT,ENGLAND	St Georges University London				Coombes, Raoul Charles/0000-0002-4811-1100				ASHLEY S, 1989, BRIT J SURG, V76, P835, DOI 10.1002/bjs.1800760825; CAHILL CJ, 1981, BRIT J SURG, V68, P882, DOI 10.1002/bjs.1800681215; CANT PJ, 1987, BRIT J SURG, V74, P857, DOI 10.1002/bjs.1800740936; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; SMALLWOOD J, 1985, BRIT J SURG, V72, P841, DOI 10.1002/bjs.1800721022; TEIXIDOR HS, 1977, AM J ROENTGENOL, V128, P409, DOI 10.2214/ajr.128.3.409; THOMAS MJ, 1978, BMJ, V2, P1139; TROTT PA, 1981, DIAGNOSIS PRIMARY BR, P1; WARWICK DJ, 1988, BRIT J SURG, V75, P243, DOI 10.1002/bjs.1800750319; WILKINSON S, 1985, BRIT J SURG, V72, P838, DOI 10.1002/bjs.1800721021; 1989, LANCET, V1, P973	11	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					618	620		10.1136/bmj.302.6777.618	http://dx.doi.org/10.1136/bmj.302.6777.618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012873	Bronze, Green Published			2022-12-24	WOS:A1991FC07100018
J	HANZLICK, R; GOWITT, GT				HANZLICK, R; GOWITT, GT			COCAINE METABOLITE DETECTION IN HOMICIDE VICTIMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							COUNTY; DEATHS; EPIDEMIC; HUMANS; ABUSE	We analyzed the blood of homicide victims for the presence of cocaine's major metabolite, benzoylecgonine. During 1989 in Fulton County, Georgia, 81% of 275 homicide victims were tested for benzoylecgonine; 40% tested positive. The proportions of blacks and victims of firearm injuries who tested positive for benzoylecgonine were significantly larger than the respective proportions for whites and victims of injuries not involving firearms. The data show overall proportions of benzoylecgonine positivity much larger than those previously reported in the literature. The relationships between homicide, race, firearms, and cocaine use deserve further study.			HANZLICK, R (corresponding author), OFF MED EXAMINER FULTON CTY,50 COCA COLA PL SE,ATLANTA,GA 30303, USA.							BAILEY DN, 1989, J FORENSIC SCI, V34, P407; BASELT RC, 1982, DISPOSITION TOXIC DR, P193; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; FAIRBANKS DNF, 1983, ANN PLAS SURG, V10, P452, DOI 10.1097/00000637-198306000-00003; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; ROGERS JN, 1986, J FORENSIC SCI, V31, P1404; SANDER R, 1985, J FORENSIC SCI, V30, P478; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; WETLI CV, 1985, J FORENSIC SCI, V30, P873; 1988, DATA DRUG ABUSE WARN, V7, P26	14	22	23	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					760	761		10.1001/jama.265.6.760	http://dx.doi.org/10.1001/jama.265.6.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EW479	1990194				2022-12-24	WOS:A1991EW47900030
J	NIGRO, JM; CHO, KR; FEARON, ER; KERN, SE; RUPPERT, JM; OLINER, JD; KINZLER, KW; VOGELSTEIN, B				NIGRO, JM; CHO, KR; FEARON, ER; KERN, SE; RUPPERT, JM; OLINER, JD; KINZLER, KW; VOGELSTEIN, B			SCRAMBLED EXONS	CELL			English	Article							MESSENGER-RNA PRECURSORS; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; ENZYMATIC AMPLIFICATION; SPLICING INVITRO; LEADER SEQUENCE; DNA-POLYMERASES; CDNA LIBRARIES; EVOLUTION; GENES; INTERMEDIATE	Using a sensitive assay for RNA expression, we identified several abnormally spliced transcripts in which exons from a candidate tumor suppressor gene (DCC) were scrambled during the splicing process in vivo. Cloning and sequencing of PCR-amplified segments of the abnormally spliced transcripts showed that exons were joined accurately at consensus splice sites, but in an order different from that present in the primary transcript. Four scrambled transcripts were identified, each involving a different pair of exons. The scrambled transcripts were found at relatively low levels in a variety of normal and neoplastic cells of rodent and human origin, primarily in the nonpolyadenylated component of cytoplasmic RNA. These results demonstrate that the splicing process does not always pair sequential exons in the order predicted from their positions in genomic DNA, thus creating a novel type of RNA product.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET,BALTIMORE,MD 21231	Johns Hopkins University; Johns Hopkins University	NIGRO, JM (corresponding author), JOHNS HOPKINS UNIV,CTR ONCOL,SCH MED,BALTIMORE,MD 21231, USA.			Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460] Funding Source: Medline; NIGMS NIH HHS [GM07309, GM07184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAUER A, 1983, NUCLEIC ACIDS RES, V11, P3503, DOI 10.1093/nar/11.11.3503; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KOLLER B, 1987, CELL, V48, P111, DOI 10.1016/0092-8674(87)90361-8; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; REANNEY D, 1979, NATURE, V277, P598, DOI 10.1038/277598b0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; VANDOREN K, 1988, NATURE, V335, P556; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215	41	704	754	6	68	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					607	613		10.1016/0092-8674(91)90244-S	http://dx.doi.org/10.1016/0092-8674(91)90244-S			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991322				2022-12-24	WOS:A1991EX36100016
J	WILKIE, AOM; HIGGS, DR; RACK, KA; BUCKLE, VJ; SPURR, NK; FISCHELGHODSIAN, N; CECCHERINI, I; BROWN, WRA; HARRIS, PC				WILKIE, AOM; HIGGS, DR; RACK, KA; BUCKLE, VJ; SPURR, NK; FISCHELGHODSIAN, N; CECCHERINI, I; BROWN, WRA; HARRIS, PC			STABLE LENGTH POLYMORPHISM OF UP TO 260 KB AT THE TIP OF THE SHORT ARM OF HUMAN CHROMOSOME-16	CELL			English	Article							GLOBIN GENE-CLUSTER; MOUSE ERYTHROLEUKEMIA-CELLS; REPETITIVE DNA-SEQUENCE; SACCHAROMYCES-CEREVISIAE; PSEUDOAUTOSOMAL REGION; RECOMBINATION NODULES; HUMAN TELOMERE; HUMAN MEIOSIS; HUMAN GENOME; LINKAGE MAP	We have completed a long-range restriction map of the terminal region of the short arm of human chromosome 16 (16p13.3) by physically linking a distal genetic locus (alpha-globin) with two recently isolated probes to telomere-associated repeats (TelBam3.4 and TelBam-11). Comparison of 47 chromosomes has revealed major polymorphic length variation in this region: we have identified three alleles in which the alpha-globin genes lie 170 kb, 350 kb, or 430 kb from the telomere. The two most common alleles contain different terminal segments, starting 145 kb distal to the alpha-globin genes. Beyond this boundary these alleles are nonhomologous, yet each contains sequences related to other (different) chromosome termini. This chromosome size polymorphism has probably arisen by occasional exchanges between the subtelomeric regions of nonhomologous chromosomes; analogous length variation is likely to be present at other human telomeres.	IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND; CEDARS SINAI MED CTR,LOS ANGELES,CA 90048; INST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Cedars Sinai Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Oxford	WILKIE, AOM (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Ceccherini, Isabella/P-8195-2014; Wilkie, Andrew/AAC-3820-2020	Ceccherini, Isabella/0000-0001-8732-1955; Wilkie, Andrew/0000-0002-2972-5481; Brown, William RA/0000-0001-5340-3645	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALTHERR MR, 1989, GENOMICS, V5, P581, DOI 10.1016/0888-7543(89)90026-8; BATES GP, 1990, AM J HUM GENET, V46, P762; BERNARDI G, 1989, ANNU REV GENET, V23, P637, DOI 10.1146/annurev.genet.23.1.637; BOJKO M, 1983, CARLSBERG RES COMMUN, V48, P457, DOI 10.1007/BF02911920; Bond D, 1983, OXFORD MONOGRAPHS ME, P198; BROWN WRA, 1990, J CELL SCI, V95, P521; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BUCAN M, 1990, GENOMICS, V6, P1; BUCKLE VJ, 1989, NEURON, V3, P647, DOI 10.1016/0896-6273(89)90275-4; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHANDLEY AC, 1989, J MED GENET, V26, P546, DOI 10.1136/jmg.26.9.546; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHENG JF, 1989, NUCLEIC ACIDS RES, V17, P6109, DOI 10.1093/nar/17.15.6109; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; DANIEL A, 1989, AM J MED GENET, V31, P14; DEISSEROTH A, 1978, CELL, V15, P55, DOI 10.1016/0092-8674(78)90082-X; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P6197, DOI 10.1093/nar/15.15.6197; GERMINO GG, 1990, AM J HUM GENET, V46, P925; HARRIS PC, 1990, GENOMICS, V7, P195, DOI 10.1016/0888-7543(90)90541-2; HATTON CSR, 1990, BLOOD, V76, P221; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HELDER J, 1987, P NATL ACAD SCI USA, V84, P2387, DOI 10.1073/pnas.84.8.2387; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; JEFFREYS AJ, 1984, NUCLEIC ACIDS RES, V12, P3235, DOI 10.1093/nar/12.7.3235; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAMB J, 1989, LANCET, V2, P819; LAURIE DA, 1985, ANN HUM GENET, V49, P203, DOI 10.1111/j.1469-1809.1985.tb01694.x; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MARCUS M, 1976, NATURE, V262, P63, DOI 10.1038/262063a0; MATTEI MG, 1982, HUM GENET, V61, P295; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURRAY AW, 1986, MOL CELL BIOL, V6, P3166, DOI 10.1128/MCB.6.9.3166; Old JM., 1983, METHODS HEMATOLOGY T, V6, P74; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; RAPPOLD GA, 1988, NUCLEIC ACIDS RES, V16, P5361, DOI 10.1093/nar/16.12.5361; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; RIETHMAN HC, 1989, P NATL ACAD SCI USA, V86, P6240, DOI 10.1073/pnas.86.16.6240; ROUYER F, 1990, EMBO J, V9, P505, DOI 10.1002/j.1460-2075.1990.tb08137.x; ROYLE NJ, 1988, GENOMICS, V3, P352, DOI 10.1016/0888-7543(88)90127-9; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SPEED RM, 1988, HUM GENET, V78, P260, DOI 10.1007/BF00291673; SPEED RM, 1990, HUM GENET, V84, P547; SPURR NK, 1988, HUM GENET, V78, P333, DOI 10.1007/BF00291730; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; WEBER B, 1990, NUCLEIC ACIDS RES, V18, P3353, DOI 10.1093/nar/18.11.3353; WELLS RA, 1990, GENOMICS, V8, P699, DOI 10.1016/0888-7543(90)90257-U; WELLS RA, 1989, GENOMICS, V5, P761, DOI 10.1016/0888-7543(89)90118-3; WILKIE AOM, 1990, AM J HUM GENET, V46, P1127; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; Zeitlin H C, 1983, Mol Biol Med, V1, P489	64	157	157	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					595	606		10.1016/0092-8674(91)90243-R	http://dx.doi.org/10.1016/0092-8674(91)90243-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991321				2022-12-24	WOS:A1991EX36100015
J	DIXON, AK; SOUTHERN, JP; TEALE, A; FREER, CEL; HALL, LD; WILLIAMS, A; SIMS, C				DIXON, AK; SOUTHERN, JP; TEALE, A; FREER, CEL; HALL, LD; WILLIAMS, A; SIMS, C			MAGNETIC-RESONANCE-IMAGING OF THE HEAD AND SPINE - EFFECTIVE FOR THE CLINICIAN OR THE PATIENT	BRITISH MEDICAL JOURNAL			English	Article							COMPUTED-TOMOGRAPHY; POOR QUALITY	Objectives - To test how the results of magnetic resonance imaging influence clinicians' diagnoses and management plans for patients with cranial and spinal problems and to assess changes in the quality of life of these patients. Design - Survey of patients undergoing cranial and spinal magnetic resonance imaging with questionnaires about diagnoses and intended management plans before and after imaging and quality of life questionnaires at the time of imaging and again four months later. Setting - Regional magnetic resonance imaging and spectroscopy unit. Subjects - 100 consecutive patients referred for cranial imaging in early 1989; 100 similar patients referred for spinal imaging. Main outcome measures - Changes in clinicians' leading diagnoses after magnetic resonance imaging and their confidence in these diagnoses;changes in intended management plans; assessment of the contribution to the future management of the patient; changes in patients' quality of life. Results - Magnetic resonance imaging altered the clinicians' leading diagnoses in 35 of 169 (21%) cases. The clinicians became more confident about their leading diagnoses in 90 of 167 (54%). There was a change in management plan in 113 of 182 (62%). The clinicians considered that magnetic resonance imaging made an important contribution to management in 119 of 162 (73%) patients. Overall, the patients' quality of life was unchanged at the four month assessment. Conclusions - Magnetic resonance imaging of patients with cranial and spinal problems influences clinicians' diagnoses and management plans, but the quality of life of these patients remains unchanged.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	DIXON, AK (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND.							COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; DIXON AK, 1981, LANCET, V1, P1199; DOLLERY C, 1978, END AGE OPTIMISM, P59; FRANKEN EA, 1986, RADIOLOGY, V161, P377, DOI 10.1148/radiology.161.2.3763904; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; GUDEX C, 1988, 38 U YORK CTR HLTH E; Hillman B J, 1986, Invest Radiol, V21, P289, DOI 10.1097/00004424-198603000-00019; HILLMAN BJ, 1988, AM J ROENTGENOL, V151, P858, DOI 10.2214/ajr.151.5.858; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; Moore A T, 1987, Health Trends, V19, P8; SHUMAN WP, 1988, AM J ROENTGENOL, V151, P857, DOI 10.2214/ajr.151.5.857; SIEGEL S, 1988, NONPARAMETRIC STAT, P298; STLEGER AS, 1989, BRIT MED J, V299, P1017, DOI 10.1136/bmj.299.6706.1017; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; 1984, LANCET, V2, P961; [No title captured]; [No title captured]; 1979, LANCET, V1, P809	18	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					79	82		10.1136/bmj.302.6768.79	http://dx.doi.org/10.1136/bmj.302.6768.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995119	Bronze, Green Published			2022-12-24	WOS:A1991ER95100016
J	LONERGAN, ET; KREVANS, JR				LONERGAN, ET; KREVANS, JR			A NATIONAL AGENDA FOR RESEARCH ON AGING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											LONERGAN, ET (corresponding author), UNIV CALIF SAN FRANCISCO,INST MED STUDY,SAN FRANCISCO,CA 94143, USA.								0	52	52	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1825	1828		10.1056/NEJM199106203242527	http://dx.doi.org/10.1056/NEJM199106203242527			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR681	2038376				2022-12-24	WOS:A1991FR68100029
J	GOLIC, KG				GOLIC, KG			SITE-SPECIFIC RECOMBINATION BETWEEN HOMOLOGOUS CHROMOSOMES IN DROSOPHILA	SCIENCE			English	Article							GENETIC MOSAICS; CELL LINEAGE; MELANOGASTER; PARAMETERS	The ability to mark a cell and its descendants genetically so that the resulting cell clone can be distinguished from neighboring cells facilitates studies in animal biology and development. A method of generating clones by inducing homologous mitotic recombination in Drosophila with a site-specific yeast recombinase is described. This method allows for frequent mosaicism after mitotic exchange is induced at predefined sites in the genome.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025874, R01GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25874-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER HJ, 1976, GENETICS BIOL DROS C, V1, pCH25; FRIESEN H., 1936, ZEITSCHR INDUKT ABSTAMM U VERER BUNGSL, V71, P501, DOI 10.1007/BF01848879; GARCIABE.A, 1972, MOL GEN GENET, V115, P54, DOI 10.1007/BF00272218; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GOLIC K, UNPUB; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HALL JC, 1976, GENETICS BIOL DROS A, V1, pCH6; HERMAN RK, 1984, GENETICS, V108, P165; KIMMEL CB, 1988, TRENDS GENET, V4, P68, DOI 10.1016/0168-9525(88)90043-1; Le Douarin N., 1984, CHIMERAS DEV BIOL; LINDSLEY DL, 1968, PUBLICATION CARNEGIE, V627; POETHIG S, 1989, TRENDS GENET, V5, P273, DOI 10.1016/0168-9525(89)90101-7; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, pCH24; RUSSELL LB, 1978, GENETIC MOSAICS CHIM; Stern C, 1936, GENETICS, V21, P625; SZABAD J, 1983, MUTAT RES, V113, P117, DOI 10.1016/0165-1161(83)90224-8; WOODRUFF RC, 1977, HEREDITY, V38, P291, DOI 10.1038/hdy.1977.92	17	353	362	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					958	961		10.1126/science.2035025	http://dx.doi.org/10.1126/science.2035025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035025				2022-12-24	WOS:A1991FM04000034
J	HYMAN, AA; MITCHISON, TJ				HYMAN, AA; MITCHISON, TJ			2 DIFFERENT MICROTUBULE-BASED MOTOR ACTIVITIES WITH OPPOSITE POLARITIES IN KINETOCHORES	NATURE			English	Article							CYTOPLASMIC DYNEIN; PROTEIN; SPINDLE; KINESIN; DROSOPHILA; POLEWARD; MITOSIS; FORCE; DEPHOSPHORYLATION; MICROMANIPULATION	The movement of microtubules on the kinetochores of isolated chromosomes has been examined by video microscopy. Two different microtubule-based motors on the kinetochore were identified, which have opposite directions of movement. The activities of these two motors can be regulated by factors that can influence phosphorylation.			HYMAN, AA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.		Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; 				BAJER AS, 1972, INT REV CYTOL      S, V3, P1; BEGG DA, 1979, J CELL BIOL, V82, P528, DOI 10.1083/jcb.82.2.528; CHLEBOWSKI JF, 1972, J BIOL CHEM, V247, P6007; COHN SA, 1989, J BIOL CHEM, V264, P4290; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; Dustin P., 1984, MICROTUBULES; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; EUTENEUER U, 1982, J CELL BIOL, V94, P644, DOI 10.1083/jcb.94.3.644; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HAYMAN AA, IN PRESS J CELL SCI; HAYS TS, 1990, J CELL BIOL, V110, P391, DOI 10.1083/jcb.110.2.391; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; INOUE S, 1975, BIOPHYS J, V15, P725, DOI 10.1016/S0006-3495(75)85850-4; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KOSHLAND D, 1988, NATURE, V311, P499; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cb.04.110188.002523; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1989, CELL MOVEMENT, V2, P421; MITCHISON TJ, 1985, J CELL BIOL, V101, P767; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; Salmon E. D., 1989, CELL MOVEMENT, P431; SAXTON WM, IN PRESS CELL; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WORDEMAN L, 1987, CELL, V50; WORDEMAN L, IN PRESS J CELL BIOL; WRIGHT BD, IN PRESS J CELL BIOL; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1846	43	179	180	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					206	211		10.1038/351206a0	http://dx.doi.org/10.1038/351206a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041567				2022-12-24	WOS:A1991FL99000047
J	FINCH, EA; TURNER, TJ; GOLDIN, SM				FINCH, EA; TURNER, TJ; GOLDIN, SM			CALCIUM AS A COAGONIST OF INOSITOL 1,4,5-TRISPHOSPHATE INDUCED CALCIUM RELEASE	SCIENCE			English	Article							CARDIAC PURKINJE-CELL; SARCOPLASMIC-RETICULUM; SUPERFUSION SYSTEM; TRISPHOSPHATE; RECEPTOR; CHANNELS; NUCLEOTIDES; MICROSOMES; ACTIVATION; VESICLES	Inositol 1,4,5-trisphosphate (IP3)-induced calcium release from intracellular stores is a regulator of cytosolic-free calcium levels. The subsecond kinetics and regulation of IP3-induced calcium-45 release from synaptosome-derived microsomal vesicles were resolved by rapid superfusion. Extravesicular calcium acted as a coagonist, potentiating the transient IP3-induced release of calcium-45. Thus, rapid elevation of cytosolic calcium levels may trigger IP3-induced calcium release in vivo. Extravesicular calcium also produced a more slowly developing, reversible inhibition of IP3-induced calcium-45 release. Sequential positive and negative feedback regulation by calcium of IP3-induced calcium release may contribute to transients and oscillations of cytosolic-free calcium in vivo.	HARVARD UNIV, SCH MED, DEPT NEUROBIOL, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; CAMBRIDGE NEUROSCI RES INC, CAMBRIDGE, MA 02139 USA	Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School				Turner, Timothy/0000-0001-9770-2647	NIGMS NIH HHS [GM35423] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035423] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, UNPUB; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARCIA AM, 1984, J GEN PHYSIOL, V83, P819, DOI 10.1085/jgp.83.6.819; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JEAN T, 1986, J BIOL CHEM, V261, P6414; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PEARCE LB, 1988, BIOCHEMISTRY-US, V27, P4396, DOI 10.1021/bi00412a029; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; SHAH J, 1987, BRAIN RES, V419, P1, DOI 10.1016/0006-8993(87)90562-2; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; TURNER TJ, 1989, BIOCHEMISTRY-US, V28, P586, DOI 10.1021/bi00428a026; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Whittaker VP, 1969, HDB NEUROCHEMISTRY, VII, P327, DOI DOI 10.1007/978-1-4899-7321-4_14	35	788	795	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1991	252	5004					443	446		10.1126/science.2017683	http://dx.doi.org/10.1126/science.2017683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017683				2022-12-24	WOS:A1991FH10300044
J	NEARING, BD; HUANG, AH; VERRIER, RL				NEARING, BD; HUANG, AH; VERRIER, RL			DYNAMIC TRACKING OF CARDIAC VULNERABILITY BY COMPLEX DEMODULATION OF THE T-WAVE	SCIENCE			English	Article							SYMPATHETIC NERVOUS-SYSTEM; VENTRICULAR-FIBRILLATION; MYOCARDIAL ISCHEMIA; NEURAL ACTIVITY; ALTERNATION; REPERFUSION; ARRHYTHMIAS; MECHANISMS; HEART	A link is found between T wave alternans and vulnerability to ventricular fibrillation, and a new approach is provided for quantification of susceptibility to malignant arrhythmias. Complex demodulation reveals that alternation of the electrocardiogram is concentrated during the first half of the T wave, coinciding with the vulnerable period of the cardiac cycle. During myocardial ischemia and reperfusion, there are marked increases in the degree of T wave alternans that parallel the established time course of changes in vulnerability. The influence of the sympathetic nervous system in arrhythmogenesis is also accurately detected. Ultimately, complex demodulation of the electrocardiogram could provide a technique for identification and management of individuals at risk for sudden cardiac death.			VERRIER, RL (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20007, USA.		Verrier, Richard L/H-3083-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033567] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM DR, 1984, J ELECTROCARDIOL, V17, P209, DOI 10.1016/S0022-0736(84)80057-6; Bloomfield P., 1976, FOURIER ANAL TIME SE; CARSON DL, 1986, CARDIOVASC RES, V20, P521, DOI 10.1093/cvr/20.7.521; CHIALVO DR, 1987, NATURE, V330, P749, DOI 10.1038/330749a0; CHIALVO DR, 1990, CIRC RES, V66, P525, DOI 10.1161/01.RES.66.2.525; CORBALAN R, 1976, AM HEART J, V92, P223, DOI 10.1016/S0002-8703(76)80258-X; CORR PB, 1986, HEART CARDIOVASCULAR, pCH58; ELSHERIF N, 1988, CIRC RES, V63, P286, DOI 10.1161/01.RES.63.2.286; FRIEHLING TD, 1985, AM J CARDIOL, V55, P1339, DOI 10.1016/0002-9149(85)90500-4; GUEVARA MR, 1981, SCIENCE, V214, P1350, DOI 10.1126/science.7313693; HAN J, 1964, CIRC RES, V14, P44, DOI 10.1161/01.RES.14.1.44; LOMBARDI F, 1983, AM HEART J, V105, P958, DOI 10.1016/0002-8703(83)90397-6; LOWN B, 1976, NEW ENGL J MED, V294, P1165; Oppenheim A.V., 1975, DIGIT SIGNAL PROCESS; PRIORI SG, 1990, CIRCULATION, V81, P1911, DOI 10.1161/01.CIR.81.6.1911; RITZENBERG AL, 1984, NATURE, V307, P159, DOI 10.1038/307159a0; ROSEN MR, 1990, CARDIAC ELECTROPHYSI, pCH34; ROZANSKI JJ, 1982, PACE, V5, P359, DOI 10.1111/j.1540-8159.1982.tb02243.x; RUSSELL DC, 1979, BRIT HEART J, V42, P88; SCHWARTZ PJ, 1977, CIRC RES, V41, P51, DOI 10.1161/01.RES.41.1.51; SCHWARTZ PJ, 1975, AM HEART J, V89, P45, DOI 10.1016/0002-8703(75)90008-3; SCHWARTZ PJ, 1985, AM HEART J, V109, P399, DOI 10.1016/0002-8703(85)90626-X; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, pCH37; SHIN SJ, 1989, IEEE T BIO-MED ENG, V36, P274; SMITH JM, 1984, P NATL ACAD SCI-BIOL, V81, P233, DOI 10.1073/pnas.81.1.233; SMITH JM, 1988, CIRCULATION, V77, P110, DOI 10.1161/01.CIR.77.1.110; SMITH JM, 1990, CARDIAC ELECTROPHYSI, pCH25; SURAWICZ B, 1985, J AM COLL CARDIOL, V5, pB43, DOI 10.1016/S0735-1097(85)80526-X; VERRIER RL, 1986, EUR HEART J, V7, P13; VERRIER RL, 1978, AM J PHYSIOL, V234, pH592, DOI 10.1152/ajpheart.1978.234.5.H592; ZIPES DP, 1990, CARDIAC ELECTROPHYSI, pCH36; 1990, AM J PHYSL, V259; 1985, PUBL NIH, V8623	33	252	271	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					437	440		10.1126/science.2017682	http://dx.doi.org/10.1126/science.2017682			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017682				2022-12-24	WOS:A1991FH10300042
J	PERROTTA, AT; BEEN, MD				PERROTTA, AT; BEEN, MD			A PSEUDOKNOT-LIKE STRUCTURE REQUIRED FOR EFFICIENT SELF-CLEAVAGE OF HEPATITIS DELTA-VIRUS RNA	NATURE			English	Article							GENOME; SITE	HEPATITIS delta virus genomic and antigenomic RNAs contain a self-cleavage site hypothesized to function in processing the viral RNA during replication 1-3. Self-cleavage requires only a divalent cation 1-3 and is mediated at the genomic site by a sequence of less than 85 nucleotides 4. We propose that the genomic self-cleaving sequence element 4 and a corresponding sequence from the antigenomic RNA could generate related secondary structures. The region of the antigenomic sequence, predicted from the proposed structure, was synthesized and shown to be sufficient for self-cleavage. Evidence for two stems which form a tertiary interaction was obtained by site-specific mutagenesis of the antigenomic sequence. Efficient self-cleavage in 10 M formamide or 5 M urea, also a property of the genomic sequence 5, was dependent on base-pairing in both stems. But in the absence of denaturants, the stem distal to the site of cleavage was not required, suggesting that the tertiary interaction stabilizes the structure required for self-cleavage.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; PFEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143; ROSENSTEIN SP, 1990, BIOCHEMISTRY-US, V29, P8011, DOI 10.1021/bi00487a002; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; VEIRIA J, 1987, METHOD ENZYMOL, V154, P3; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	14	300	346	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					434	436		10.1038/350434a0	http://dx.doi.org/10.1038/350434a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011192				2022-12-24	WOS:A1991FF04200054
J	JUST, U; STOCKING, C; SPOONCER, E; DEXTER, TM; OSTERTAG, W				JUST, U; STOCKING, C; SPOONCER, E; DEXTER, TM; OSTERTAG, W			EXPRESSION OF THE GM-CSF GENE AFTER RETROVIRAL TRANSFER IN HEMATOPOIETIC STEM-CELL LINES INDUCES SYNCHRONOUS GRANULOCYTE-MACROPHAGE DIFFERENTIATION	CELL			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTORS; AUTOCRINE STIMULATION; AUTONOMOUS GROWTH; SELF-RENEWAL; EGF RECEPTOR; INTERLEUKIN-3; MICROENVIRONMENT; IDENTIFICATION; TUMORIGENICITY	Multipotent murine stem cell lines (FDC-Pmix) depend on IL-3 for self-renewal and proliferation and can be induced to differentiate into multiple hematopoietic lineages. Single FDC-Pmix cells infected with retroviral vectors expressing GM-CSF are induced to differentiate into granulocytes and macrophages. This results in a complete loss of clonogenic cells if IL-3 is not exogenously supplied; however, multipotent variants can be selected that do not terminally differentiate if cells are kept in the presence of IL-3. Unidirectional and synchronous granulocyte and macrophage differentiation accompanied with loss of self-renewal capacity is induced when IL-3 is removed. Our data indicate that activation of the GM-CSF receptor induces differentiation of stem cells by an instructive mechanism that can be blocked by the activated IL-3 receptor. A model of how receptors can induce proliferation and cell-specific differentiation by two separate pathways is discussed.	PATERSON INST CANC RES,MANCHESTER M20 9BX,ENGLAND	Paterson Institute for Cancer Research	JUST, U (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Just, Ursula/E-6992-2010					ALLEN TD, 1984, EXP HEMATOL, V12, P517; BOETTIGER D, 1984, CELL, V36, P763, DOI 10.1016/0092-8674(84)90356-8; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; EISEN H, 1978, COLD SPRING HARBOR C, V5, P277; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; Hayhoe FGJ, 1988, HAEMATOLOGICAL CYTOC; HEYWORTH CM, 1988, J CELL SCI, V91, P239; HOUSMAN D, 1978, COLD SPRING HARBOR C, V5, P193; IHLE JN, 1983, J IMMUNOL, V131, P282; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAKER C, 1989, MOL CELL BIOL, V9, P5746, DOI 10.1128/MCB.9.12.5746; LAKER C, 1989, MOD TRENDS HUM LEUK, V8, P188; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1984, HEMOPOIETIC COLONIES; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUESENBERRY P, 1988, BLOOD S, V1, P116; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SPOONCER E, 1989, CURR TOP MICROBIOL, V149, P109; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	39	77	80	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1163	1173		10.1016/0092-8674(91)90271-Y	http://dx.doi.org/10.1016/0092-8674(91)90271-Y			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004422				2022-12-24	WOS:A1991FD55800014
J	SAVITZ, DA				SAVITZ, DA			POWER-LINES AND CANCER RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SAVITZ, DA (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,CHAPEL HILL,NC 27514, USA.		Savitz, David A/I-2211-2014					AHLBOM A, 1988, SCAND J WORK ENV HEA, V14, P337, DOI 10.5271/sjweh.1909; COLEMAN M, 1988, INT J EPIDEMIOL, V17, P1, DOI 10.1093/ije/17.1.1; MORGAN M, 1988, PUBLIC UTILITIES MAR, P49; WILSON BW, 1990, EXTREMELY LOW FREQUE	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1458	1458						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999890				2022-12-24	WOS:A1991FB55000030
J	MUNOZ, DP; PELISSON, D; GUITTON, D				MUNOZ, DP; PELISSON, D; GUITTON, D			MOVEMENT OF NEURAL ACTIVITY ON THE SUPERIOR COLLICULUS MOTOR MAP DURING GAZE SHIFTS	SCIENCE			English	Article							SACCADIC EYE-MOVEMENTS; RETICULO-SPINAL NEURONS; VESTIBULO-OCULAR REFLEX; ALERT CAT; HEAD COORDINATION; PRIMATE; STIMULATION; ORIENTATION; HUMANS	The superior colliculus contains neurons that cause displacements of the visual axis (gaze shifts). These cells are arranged topographically in a motor map on which the vector (amplitude and direction) of the coded movement varies continuously with location. How this spatial representation becomes a temporal code (frequency and duration) in the motoneurons is unknown. During a gaze shift, a zone of neural activity moved continuously on the map from an initial location, defining the vector of the desired gaze shift, to a final "zero" position containing neurons that were active during fixation. Thus, the spatial-temporal transformation may be accomplished by control of gaze throughout the spatial trajectory of activity on the motor map.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,3801 UNIV,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University			Pelisson, Denis/H-2916-2017	Pelisson, Denis/0000-0002-9114-7758				BERTHOZ A, 1986, NEUROSCI LETT, V72, P289, DOI 10.1016/0304-3940(86)90528-8; CROMMELINCK M, 1990, Society for Neuroscience Abstracts, V16, P1082; DROULEZ J, 1988, NEURAL COMPUTERS, P345; DROULEZ J, IN PRESS P NATL ACAD; FULLER JH, 1983, BRAIN RES, V271, P241, DOI 10.1016/0006-8993(83)90286-X; GRANTYN A, 1985, EXP BRAIN RES, V57, P417; GRANTYN A, 1982, EXP BRAIN RES, V46, P243; GUITTON D, 1980, EXP BRAIN RES, V39, P63; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; GUITTON D, 1984, J NEUROPHYSIOL, V52, P1030, DOI 10.1152/jn.1984.52.6.1030; GUITTON D, 1990, J NEUROPHYSIOL, V64, P509, DOI 10.1152/jn.1990.64.2.509; GUITTON D, IN PRESS EYE MOVEMEN; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; LEFEVRE P, 1990, Society for Neuroscience Abstracts, V16, P1084; MEREDITH MA, 1986, J NEUROPHYSIOL, V56, P640, DOI 10.1152/jn.1986.56.3.640; MOSCHOVAKIS AK, 1985, J COMP NEUROL, V239, P276, DOI 10.1002/cne.902390304; MUNOZ D, UNPUB; MUNOZ D P, 1988, Society for Neuroscience Abstracts, V14, P956; MUNOZ D P, 1990, Society for Neuroscience Abstracts, V16, P1084; MUNOZ DP, 1986, BRAIN RES, V398, P185, DOI 10.1016/0006-8993(86)91267-9; MUNOZ DP, 1989, REV NEUROL-FRANCE, V145, P567; MUNOZ DP, 1988, THESIS MCGILL U MONT; PELISSON D, 1986, BRAIN RES, V380, P397, DOI 10.1016/0006-8993(86)90244-1; PELISSON D, 1988, J NEUROPHYSIOL, V59, P997, DOI 10.1152/jn.1988.59.3.997; PELISSON P, 1989, EXP BRAIN RES, V78, P654; Pitts Walter, 1947, BULL MATH BIOPHYS, V9, P127, DOI 10.1007/BF02478291; ROUCOUX A, 1980, EXP BRAIN RES, V39, P75; SPARKS DL, 1990, ANNU REV NEUROSCI, V13, P309, DOI 10.1146/annurev.ne.13.030190.001521; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; TOMLINSON RD, 1986, J NEUROPHYSIOL, V56, P1558, DOI 10.1152/jn.1986.56.6.1558; WURTZ RH, 1980, ANNU REV NEUROSCI, V3, P189, DOI 10.1146/annurev.ne.03.030180.001201	31	129	129	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1358	1360		10.1126/science.2003221	http://dx.doi.org/10.1126/science.2003221			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003221				2022-12-24	WOS:A1991FB73300044
J	DALLOS, P; EVANS, BN; HALLWORTH, R				DALLOS, P; EVANS, BN; HALLWORTH, R			NATURE OF THE MOTOR ELEMENT IN ELECTROKINETIC SHAPE CHANGES OF COCHLEAR OUTER HAIR-CELLS	NATURE			English	Article							MECHANICAL RESPONSES	IT is the prevailing notion that cochlear outer hair cells function as mechanical effectors as well as sensory receptors 1-3. Electrically induced changes in the shape of mammalian outer hair cells 4,5, studied in vitro, are commonly assumed to represent an aspect of their effector process that may occur in vivo. The nature of the motile process is obscure, even though none of the established cellular motors can be involved 6. Although it is known that the motile response is under voltage control 7, it is uncertain whether the stimulus is a drop in the voltage along the long axis of the cell or variation in the transmembrane potential. We have now performed experiments with cells partitioned in differing degrees between two chambers. Applied voltage stimulates the cell membrane segments in opposite polarity to an amount dependent on the partitioning. The findings show, in accordance with previous suggestions 6,8, that the driving stimulus is a local transmembrane voltage drop and that the cellular motor consists of many independent elements, distributed along the cell membrane and its associated cortical structures. We further show that the primary action of the motor elements is along the longitudinal dimension of the cell without necessarily involving changes in intracellular hydrostatic pressure. This establishes the outer hair cell motor as unique among mechanisms that control cell shape 9.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University	DALLOS, P (corresponding author), NORTHWESTERN UNIV,HUGH KNOWLES CTR,AUDITORY PHYSIOL LAB,EVANSTON,IL 60208, USA.		Dallos, Peter/Q-9360-2019	Dallos, Peter/0000-0002-9731-6591				ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; Bannister L H, 1988, Prog Brain Res, V74, P213; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; BROWNELL WE, 1990, EAR HEARING, V11, P82, DOI 10.1097/00003446-199004000-00003; BROWNELL WE, 1986, PERIPHERAL AUDITORY, P369; BROWNELL WE, 1983, MECHANISMS HEARING, P5; CLARK BA, 1990, PFLUG ARCH EUR J PHY, V415, P490, DOI 10.1007/BF00373629; DALLOS P, 1985, P207; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365, DOI 10.1152/jn.1978.41.2.365; DALLOS P, 1988, AUDITORY FUNCTION NE, P153; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; EVANS BN, 1990, HEARING RES, V45, P265, DOI 10.1016/0378-5955(90)90126-A; EVANS BN, 1988, THESIS U TEXAS HLTH; FLOCK A, 1986, ARCH OTO-RHINO-LARYN, V243, P83, DOI 10.1007/BF00453755; GUINAN JJ, 1983, J COMP NEUROL, V221, P358, DOI 10.1002/cne.902210310; HOLLEY MC, 1988, NATURE, V335, P635, DOI 10.1038/335635a0; HOLLEY MC, 1990, J CELL SCI, V96, P283; HOLLEY MC, 1988, PROC R SOC SER B-BIO, V232, P413, DOI 10.1098/rspb.1988.0004; JEN DH, 1987, J ACOUST SOC AM, V82, P1667, DOI 10.1121/1.395158; KIM DO, 1986, HEARING RES, V22, P105, DOI 10.1016/0378-5955(86)90088-2; Lackie J.M., 1986, CELL MOVEMENT CELL B, P253, DOI [10.1007/978-94-009-4071-0_10, DOI 10.1007/978-94-009-4071-0_10]; SAITO K, 1983, CELL TISSUE RES, V229, P467; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SMITH CA, 1957, AM J ANAT, V100, P337, DOI 10.1002/aja.1001000304; SPOENDLIN H, 1969, ACTA OTO-LARYNGOL, V67, P239, DOI 10.3109/00016486909125448	26	190	196	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					155	157		10.1038/350155a0	http://dx.doi.org/10.1038/350155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005965				2022-12-24	WOS:A1991FB64500059
J	CALLAHAM, M; BARTON, CW; KAYSER, S				CALLAHAM, M; BARTON, CW; KAYSER, S			POTENTIAL COMPLICATIONS OF HIGH-DOSE EPINEPHRINE THERAPY IN PATIENTS RESUSCITATED FROM CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT VASOPRESSOR RESPONSE; MYOCARDIAL OXYGEN DELIVERY; CARDIOPULMONARY RESUSCITATION; HUMAN-BEINGS; CPR	Adults resuscitated from nontraumatic cardiac arrest who received intravenous epinephrine in doses chosen by the treating physician and who survived at least 6 hours were studied to determine if high-dose epinephrine produced more complications than standard-dose. A total of 68 patients were enrolled and evaluated for postresuscitation complications attributable to epinephrine, using a two-tailed t test, and contingency analysis. The 33 patients receiving high-dose epinephrine and 35 patients receiving standard-dose epinephrine were similar in demographics and variables known to affect outcome. There was no difference in potential complications between groups except serum calcium, which was 1.97 mmol/L (SD, 0.20) in the high-dose epinephrine group and 2.10 (SD, 0.20) in the standard-dose group. Hospital discharge rates (18% in the high-dose vs 30% in the standard-dose group) and neurological status on discharge were not significantly different. High-dose epinephrine did not produce increased direct complications in this cardiac arrest population compared with standard-dose epinephrine.	UNIV CALIF SAN FRANCISCO,DIV CLIN PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	CALLAHAM, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,DIV EMERGENCY MED,SAN FRANCISCO,CA 94143, USA.			Callaham, Michael/0000-0003-2284-256X				BARTON CW, 1990, ANN EMERG MED, V19, P490; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1988, CRIT CARE MED, V16, P536, DOI 10.1097/00003246-198805000-00013; BROWN DD, 1988, SKELETAL RADIOL, V17, P302, DOI 10.1007/BF00401818; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; ERSOZ N, 1971, BRIT J ANAESTH, V43, P709, DOI 10.1093/bja/43.7.709; FRIEDMAN B, 1955, LANCET, P575; GOETTING MG, 1989, CRIT CARE MED, V17, P1258, DOI 10.1097/00003246-198912000-00004; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HALL AH, 1987, AM J EMERG MED, V5, P64, DOI 10.1016/0735-6757(87)90293-2; KARCH SB, 1987, AM J FOREN MED PATH, V8, P3, DOI 10.1097/00000433-198703000-00002; KELLNER M, 1966, ACTA MED HUNG, V23, P37; KELLNER M, 1966, ACTA MED HUNG, V22, P335; KIRIMLI B, 1969, ANESTH ANAL CURR RES, V48, P649; KOSCOVE EM, 1988, JAMA-J AM MED ASSOC, V259, P3031, DOI 10.1001/jama.259.20.3031; KURACHEK SC, 1985, JAMA-J AM MED ASSOC, V253, P1441, DOI 10.1001/jama.253.10.1441; LONGSTRETH WT, 1987, WESTERN J MED, V147, P175; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MARTIN D, 1990, ANN EMERG MED, V19, P322, DOI 10.1016/S0196-0644(05)82055-4; MARTIN GB, 1985, ANN EMERG MED, V14, P293, DOI 10.1016/S0196-0644(85)80089-5; MUSCH W, 1987, ANN EMERG MED, V16, P514; NOVEY HS, 1969, J AMER MED ASSOC, V207, P2435, DOI 10.1001/jama.207.13.2435; PARADIS N A, 1990, Critical Care Medicine, V18, pS221, DOI 10.1097/00003246-199012001-00087; PARADIS NA, 1990, ANN EMERG MED, V19, P491; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; SALERNO DM, 1989, CRIT CARE MED, V17, P1181, DOI 10.1097/00003246-198911000-00016; STEINGRUB J, 1990, Critical Care Medicine, V18, pS223, DOI 10.1097/00003246-199012001-00090; URBAN P, 1988, ANN INTERN MED, V109, P110, DOI 10.7326/0003-4819-109-2-110; 1986, JAMA-J AM MED ASSOC, V255, P2905	29	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1117	1122		10.1001/jama.265.9.1117	http://dx.doi.org/10.1001/jama.265.9.1117			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995996				2022-12-24	WOS:A1991EZ47400027
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - BENEFITS FOR PEOPLE IN HOSPITAL, NURSING-HOMES, AND RESIDENTIAL CARE HOMES	BRITISH MEDICAL JOURNAL			English	Editorial Material											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 23	1991	302	6774					463	465		10.1136/bmj.302.6774.463	http://dx.doi.org/10.1136/bmj.302.6774.463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ033	2004176	Green Published, Bronze			2022-12-24	WOS:A1991EZ03300029
J	RAUB, W				RAUB, W			SALIVARY-GLAND FUNCTION NOT AFFECTED BY MENOPAUSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, J GERONTOL, V46, pM11	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					706	706						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EW479	1990184				2022-12-24	WOS:A1991EW47900008
J	THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT				THOMAS, KJ; CARR, J; WESTLAKE, L; WILLIAMS, BT			USE OF NON-ORTHODOX AND CONVENTIONAL HEALTH-CARE IN GREAT-BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINE	Objective-To describe the characteristics of patients using non-orthodox health care and their pattern of use of conventional health care with respect to a particular problem. Design-Postal survey of all 2152 practitioners of acupuncture, chiropractic, homoeopathy, naturopathy, and osteopathy identified from 11 national professional association registers. Patients attending a representative sample of 101 responding practitioners completed questionnaires covering demographic characteristics, presenting problems, and use of the health service. Setting-Practices of practitioners of non-orthodox health care in England, Scotland, and Wales. Subjects-Qualified, non-medical practitioners of non-orthodox health care working in Great Britian and 2473 patients who had attended one of the sampled practitioners in an allocated time period between August 1987 and July 1988. Results-An estimated 1909 practitioners were actively practising one of the study treatments in Great Britian in 1987. Of the estimated 70 600 patients seen by this group of practitioners in an average week, most (78%) were attending with a musculoskeletal problem. Two thirds of the patients were women. Only 2% were aged under 16, but 15% were aged 65 or over. One in three patients had not received previous conventional care for their main problem; 18% were receiving concurrent non-orthodox and conventional care. Twenty two per cent of the patients reported having seen their general practitioner for any reason in the two weeks before the surveyed consultation. Conclusions-Patients of non-orthodox health care, as provided by this group of practitioners, had not turned their backs on conventional health care. Non-orthodox treatment was sought for a limited range of problems and used most frequently as a supplement to orthodox medicine.			THOMAS, KJ (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							DAVIES P, 1987, REPORT TRENDS COMPLE; FULDER SJ, 1986, LANCET, V2, P542; INGLIS B, 1985, LANCET, V1, P95; Lamberts H., 1987, ICPC INT CLASSIFICAT; MURRAY J, 1988, J ROY COLL GEN PRACT, V38, P511; 1984, GENERAL HOUSEHOLD SU; 1987, PROFESSIONAL CONDUCT; 1986, WHICH            OCT, P443; 1986, ALTERNATIVE THERAPIE	9	159	160	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 26	1991	302	6770					207	210		10.1136/bmj.302.6770.207	http://dx.doi.org/10.1136/bmj.302.6770.207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EV228	1998760	Bronze, Green Published			2022-12-24	WOS:A1991EV22800024
J	LEW, JF; GLASS, RI; GANGAROSA, RE; COHEN, IP; BERN, C; MOE, CL				LEW, JF; GLASS, RI; GANGAROSA, RE; COHEN, IP; BERN, C; MOE, CL			DIARRHEAL DEATHS IN THE UNITED-STATES, 1979 THROUGH 1987 - A SPECIAL PROBLEM FOR THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GASTROENTERITIS; COMMUNITY	Objective. - Diarrhea is an important cause of death among young children in both developing and developed countries, but little is known about diarrheal deaths among adults. In this study, we examined trends in diarrheal deaths among all age groups in the United States. Design/Setting/Participants. - We reviewed national mortality data compiled by the National Center for Health Statistics, Hyattsville, Md, which consist of information from all death certificates filed in the United States for the period 1979 through 1987. A death for which diarrhea was listed as an immediate or underlying cause was considered a "diarrheal death" and included in the analysis. Results. - We found that 28 538 persons died of diarrhea cited as either an immediate or the underlying cause of death during the 9-year period. A majority of diarrheal deaths occurred among the elderly (older than 74 years of age, 51%), followed by adults 55 to 74 years of age (27%), and young children (younger than 5 years of age, 11 %). For the elderly, adjusted risk factors for dying of diarrhea included being white, female, and residing in a long-term care facility. Only the elderly and young children had clear, distinct winter peaks of diarrheal deaths, suggesting that the diarrhea may, in part, be infectious in origin. Conclusion. - For the elderly, more directed studies of those at risk, such as nursing home residents, are needed to determine if oral rehydration therapy, vaccines, or other preventive measures might benefit this population.	EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA 30322; LYCEE ST LOUIS,PARIS,FRANCE	Emory University	LEW, JF (corresponding author), CTR DIS CONTROL,DIV VIRAL & RICKETTSIAL DIS,RESP & ENTER VIRUS BRANCH,ATLANTA,GA 30333, USA.		Moe, Christine L/G-6118-2012					AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BRESLOW L, 1990, ANNU REV PUBL HEALTH, V11, P1; FITZGERALD JF, 1989, PEDIATR INFECT DIS J, V8, P564, DOI 10.1097/00006454-198908000-00044; GELLERT GA, 1990, INFECT CONT HOSP EP, V11, P459; GORDON SM, 1990, AM J EPIDEMIOL, V131, P702, DOI 10.1093/oxfordjournals.aje.a115554; HING E, 1989, VITA HLTH STAT, V102, P24; HING E, 1987, PHS871270 US DEP HLT; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; HO MS, 1988, JAMA-J AM MED ASSOC, V260, P3281, DOI 10.1001/jama.260.22.3281; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; LEBARON CW, 1990, JAMA-J AM MED ASSOC, V264, P983, DOI 10.1001/jama.264.8.983; MAASDAM CF, 1981, GERIATRICS, V36, P127; MATSON DO, 1990, J INFECT DIS, V162, P598, DOI 10.1093/infdis/162.3.598; Smith P W, 1989, Infect Dis Clin North Am, V3, P763; WING S, 1985, J GERONTOL, V40, P78, DOI 10.1093/geronj/40.1.78; 1990, PHS901232 US DEP HLT; [No title captured]; 1982, US BUREAU CENSUS P25, V917; 1987, MMWR, V36, P1; 1988, US BUREAU CENSUS P25, V1022; 1990, STATE WORLDS CHILDRE	21	119	121	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3280	3284		10.1001/jama.265.24.3280	http://dx.doi.org/10.1001/jama.265.24.3280			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	2046110				2022-12-24	WOS:A1991FR83500035
J	CARTER, WG; RYAN, MC; GAHR, PJ				CARTER, WG; RYAN, MC; GAHR, PJ			EPILIGRIN, A NEW CELL-ADHESION LIGAND FOR INTEGRIN ALPHA-3-BETA-1 IN EPITHELIAL BASEMENT-MEMBRANES	CELL			English	Article							EXTRACELLULAR-MATRIX; LAMININ RECEPTOR; KERATINOCYTE ADHESION; FIBRONECTIN RECEPTOR; SURFACE RECEPTORS; ANCHORING FIBRILS; VII COLLAGEN; MULTIPLE; BINDING; ALPHA-2-BETA-1	Epiligrin is a new glycoprotein in most epithelial basement membranes (BMs) and is a ligand for cell adhesion via integrin alpha-3-beta-1. In the extracellular matrix of human foreskin keratinocytes (HFKs), epiligrin contains three disulfide-bonded, glycoprotein subunits, E170, E145, and E135, based on molecular size in kilo-daltons. Epiligrin, immunopurified with MAb P1E1, induced cell adhesion and localization of integrin alpha-3-beta-1 in focal adhesions (FAs). Cell adhesion to epiligrin was inhibited with an anti-alpha-3-beta-1 MAb. Epiligrin also colocalized with integrin alpha-6-beta-4 in hemidesmosome-like stable anchoring contacts (SACs). Alpha-3-beta-1-FAs encircled alpha-6-beta-4-SACs in a complex adhesion structure. Alpha-3-beta-1 and epiligrin localized in BM junctions of epithelial cells primarily in organs of endodermal/ectodermal origin. In epidermis, epiligrin was detected in the lamina lucida of BMs. Alpha-3-beta-1 localized in plasma membranes of basal cells in contact with epiligrin and also in lateral/apical membranes. Epiligrin is the ligand of an adhesion super complex composed of alpha-3-beta-1-FAs and alpha-6-beta-4-SACs (hemidesmosomes).	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	CARTER, WG (corresponding author), UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GRIEPP EB, 1988, EPITHELIUM CELL TISS; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; HEMLER ME, 1989, J BIOL CHEM, V26, P1; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IZZARD CS, 1976, J CELL SCI, V21, P129; JONES JCR, 1986, CELL MOTIL CYTOSKEL, V6, P560, DOI 10.1002/cm.970060604; KATZ SI, 1984, J AM ACAD DERMATOL, V11, P1025, DOI 10.1016/S0190-9622(84)80189-9; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; Lever W. F., 1990, HISTOPATHOLOGY SKIN; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MAR H, 1989, COLLOIDAL GOLD PRINC; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; NEYFAKH AA, 1983, EXP CELL RES, V149, P387, DOI 10.1016/0014-4827(83)90351-8; Oi V.T., 1980, SELECTED METHODS CEL, P351; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; POTTEN CS, 1988, J CELL SCI S, V10, P45; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SHIENVOLD FL, 1976, CELL TISSUE RES, V172, P289, DOI 10.1007/BF00399513; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WOLPERT L, 1988, J CELL SCI S, V10, P1; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	60	583	599	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					599	610		10.1016/0092-8674(91)90092-D	http://dx.doi.org/10.1016/0092-8674(91)90092-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032285				2022-12-24	WOS:A1991FM03700010
J	MEYRAND, P; SIMMERS, J; MOULINS, M				MEYRAND, P; SIMMERS, J; MOULINS, M			CONSTRUCTION OF A PATTERN-GENERATING CIRCUIT WITH NEURONS OF DIFFERENT NETWORKS	NATURE			English	Article								RHYTHMIC motor behaviours are generated within the central nervous system by neuronal circuits called central pattern generators (CPG) 1. Although a CPG can produce several forms of the same behaviour 2-5 and several circuits may interact to generate different behaviours 6, it is generally assumed that a given CPG consists of a predefined assemblage of neurons that is functionally distinguishable from other circuits. However, recent studies on the stomatogastric nervous system of crustacea have suggested that CPGs may not be immutable functional entities 7-10. We now report that under an identified neuromodulatory stimulus, the CPG that produces swallowing-like behaviour of the foregut in lobsters is constructed de novo from neurons belonging to other CPGs. Consequently neurons operating independently as members of different circuits may be reconfigured into a new pattern-generating circuit that operates differently from the original circuits. This not only challenges the concept of the CPG being a discrete functional entity, but also demonstrates that a modulatory input can specify an appropriate CPG from a pool of individual neurons of diverse origins.	UNIV BORDEAUX 1,CNRS,NEUROBIOL & PHYSIOL COMPAREES LAB,PL DR PEYNEAU,F-33120 ARCACHON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux								CAZALETS JR, 1990, J NEUROSCI, V10, P448; CAZALETS JR, 1990, J NEUROSCI, V10, P458; DELCOMYN F, 1980, SCIENCE, V210, P492, DOI 10.1126/science.7423199; DICKINSON PS, 1990, NATURE, V344, P155, DOI 10.1038/344155a0; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; HOOPER SL, 1989, SCIENCE, V244, P1587, DOI 10.1126/science.2740903; MARDER E, 1988, NATURE, V335, P296, DOI 10.1038/335296a0; MEYRAND P, 1988, SOC NEUR ABSTR, V14; Nagy F., 1987, P205; ROBERTSON RM, 1979, PROC R SOC SER B-BIO, V206, P235, DOI 10.1098/rspb.1979.0103; Selverston A.I., 1987, CRUSTACEAN STOMATOGA; STEIN PSG, 1988, NEUROBIOLOGY VERTEBR, P201; WEIMANN JM, 1991, J NEUROPHYSIOL, V65, P111, DOI 10.1152/jn.1991.65.1.111; [No title captured]	14	179	179	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					60	63		10.1038/351060a0	http://dx.doi.org/10.1038/351060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027383				2022-12-24	WOS:A1991FK19300059
J	BRUNS, FJ; ADLER, S; FRALEY, DS; SEGEL, DP				BRUNS, FJ; ADLER, S; FRALEY, DS; SEGEL, DP			SUSTAINED REMISSION OF MEMBRANOUS GLOMERULONEPHRITIS AFTER CYCLOPHOSPHAMIDE AND PREDNISONE	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; FOLLOW-UP; UNTREATED PATIENTS; NEPHROTIC SYNDROME; NATURAL-HISTORY; RENAL-FUNCTION; NEPHROPATHY; CHLORAMBUCIL; ADULTS; METHYLPREDNISOLONE	Objective: To determine the effect of cyclophosphamide and prednisone on progressive renal failure and on nephrotic features in patients with membranous glomerulonephritis. Design: Prospective, nonrandomized time series. Setting: Outpatient clinic at a university medical center. Patients: Eleven consecutive patients with biopsy-proven membranous glomerulonephritis and rising plasma creatinine levels over at least 6 months. Intervention: Cyclophosphamide and prednisone in ten patients and cyclophosphamide alone in one patient. Measurements and Main Results: In ten patients treated with both agents, the median plasma creatinine rose 53-mu-mol/L (0.6 mg/dL) over the months before treatment from 141 to 194-mu-mol/L (1.6 to 2.2 mg/dL) (95% CI, 27 to 141-mu-mol/L; P = 0.002). After combined therapy for 6 months, the median plasma creatinine fell to 133-mu-mol/L (1.5 mg/dL) for a median decline of 62-mu-mol/L (0.7 mg/dL) (CI, 44 to 150-mu-mol/L; P = 0.006). Pretreatment plasma creatinine levels, which ranged from 159 to 371-mu-mol/L (1.8 to 4.2 mg/dL), decreased in the ten patients by 6 months and remained stable in seven of the eight patients followed 24 to 54 months after therapy was completed. The median urine protein excretion decreased by 9.6 g/d with 12 months of therapy in the ten patients from 11.9 to 2.3 g/d (CI, 6.0 to 15.1 g/d; P < 0.001). The median plasma albumin rose by 14 g/L from 24 to 38 g/L (CI, 11 to 19 g/L; P < 0.001). The median plasma cholesterol fell by 3.26-mu-mol/L (140 mg/dL) from 10.45 to 6.52-mu-mol/L (405 to 252 mg/dL) (CI, 1.42 to 7.16-mu-mol/L; P = 0.01). One patient who had a relapse 30 months after completing therapy responded to re-treatment with renal function and nephrotic variables returning toward normal. The eleventh patient received cyclophosphamide alone and had a course similar to that of the combined therapy group. Conclusion: Cyclophosphamide plus prednisone can promote prolonged remissions in membranous glomerulonephritis even when renal function is already declining.	UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BRUNS, FJ (corresponding author), MONTEFIORE UNIV HOSP, 3459 5TH AVE, PITTSBURGH, PA 15213 USA.							BAILAR JC, 1984, NEW ENGL J MED, V311, P156, DOI 10.1056/NEJM198407193110306; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BLACK DAK, 1970, BRIT MED J, V3, P421, DOI 10.1136/bmj.3.5720.421; BRUNS FJ, 1989, AM J MED, V86, P400, DOI 10.1016/0002-9343(89)90336-7; CAMERON JS, 1979, KIDNEY INT, V15, P88; CAMERON JS, 1982, AM J KIDNEY DIS, V1, P371; CATTRAN D, 1984, 9TH P INT C NEPHR A, V74; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COGGINS CH, 1979, NEW ENGL J MED, V301, P1301; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DONADIO JV, 1974, KIDNEY INT, V6, P431, DOI 10.1038/ki.1974.129; Ehrenreich T., 1968, PATHOL ANNU, V3, P145; EVANOFF GV, 1987, ARCH INTERN MED, V147, P492, DOI 10.1001/archinte.147.3.492; FRANKLIN WA, 1973, KIDNEY INT, V4, P36, DOI 10.1038/ki.1973.78; GARTNER HV, 1974, NEPHRON, V13, P288, DOI 10.1159/000180405; GLASSOCK RJ, 1982, AM J KIDNEY DIS, V1, P376, DOI 10.1016/S0272-6386(82)80011-5; HONKANEN E, 1986, CLIN NEPHROL, V25, P122; IDELSON BA, 1977, ARCH INTERN MED, V137, P891, DOI 10.1001/archinte.137.7.891; LAVORI PW, 1983, NEW ENGL J MED, V309, P1291, DOI 10.1056/NEJM198311243092105; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; MANOS J, 1982, CLIN NEPHROL, V18, P286; MATHIESON PW, 1988, LANCET, V2, P869; MOSES LE, 1985, NEW ENGL J MED, V312, P890, DOI 10.1056/NEJM198504043121405; NOEL LH, 1979, AM J MED, V66, P82, DOI 10.1016/0002-9343(79)90486-8; PIERIDES AM, 1977, Q J MED, V46, P163; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; Ponticelli C, 1987, Adv Nephrol Necker Hosp, V16, P195; RANDALL RE, 1970, AM SOC NEPHROL, V4, P65; RELMAN AS, 1989, NEW ENGL J MED, V320, P248, DOI 10.1056/NEJM198901263200411; RYAN BF, 1985, MINITAB HDB, P292; SUKI WN, 1981, AM J NEPHROL, V1, P11, DOI 10.1159/000166481; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; TILLER DJ, 1981, 8TH P INT C NEPHR, P345; TU WH, 1984, NEPHRON, V36, P118, DOI 10.1159/000183130; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247	37	72	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					725	730		10.7326/0003-4819-114-9-725	http://dx.doi.org/10.7326/0003-4819-114-9-725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012353				2022-12-24	WOS:A1991FJ11700003
J	PIPER, JM; RAY, WA; DAUGHERTY, JR; GRIFFIN, MR				PIPER, JM; RAY, WA; DAUGHERTY, JR; GRIFFIN, MR			CORTICOSTEROID USE AND PEPTIC-ULCER DISEASE - ROLE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS	ANNALS OF INTERNAL MEDICINE			English	Article							GASTRIC-ULCER; ADRENOCORTICOSTEROID THERAPY; ASPIRIN; ASSOCIATION; PREVENTION; SECRETION	Objective: To estimate the relative risk for peptic ulcer disease that is associated with the use of oral corticosteroids. Design: A nested case-control study. Setting: Tennessee Medicaid program. Participants: The case patients (n = 1415) were hospitalized between 1984 and 1986 for gastric or duodenal ulcer or for upper gastrointestinal hemorrhage of unknown cause. The controls (n = 7063) were randomly selected from Medicaid enrollees not meeting the study criteria for inclusion as case patients. Measurements and Main Results: The estimated relative risk for the development of peptic ulcer disease among current users of oral corticosteroids was 2.0 (95% CI, 1.3 to 3.0). However, the risk was increased only in those who concurrently received nonsteroidal anti-inflammatory drugs (NSAIDS); these persons had an estimated relative risk associated with current corticosteroid use of 4.4 (CI, 2.0 to 9.7). In contrast, the estimated relative risk for those corticosteroid users not receiving corticosteroids and NSAIDs had a risk for peptic ulcer disease that was 15 times greater than that of nonusers of either drug. Conclusion: Discrepant findings among earlier studies regarding steroids and the risk for peptic ulcer disease could in part be due to differences in the use of NSAIDs among study participants. The high risk for peptic ulcer disease associated with combined use of NSAIDs and corticosteroids indicates the need to prescribe this drug combination cautiously.			PIPER, JM (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT PREVENT MED, MED CTR N A-1112, NASHVILLE, TN 37232 USA.				FDA HHS [FD-U-000073] Funding Source: Medline	FDA HHS		BECK JC, 1950, CAN MED ASSOC J, V62, P423; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; CONN HO, 1976, NEW ENGL J MED, V294, P473, DOI 10.1056/NEJM197602262940905; DAVIS TA, 1952, JAMA-J AM MED ASSOC, V150, P31, DOI 10.1001/jama.1952.63680010004008c; DEAN AG, 1988, AM J EPIDEMIOL, V127, P654, DOI 10.1093/oxfordjournals.aje.a114840; DELANEY JP, 1979, GASTROENTEROLOGY, V76, P913; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; GRAHAM DY, 1988, LANCET, V2, P1277; GRAY SJ, 1951, JAMA-J AM MED ASSOC, V147, P1529, DOI 10.1001/jama.1951.03670330021007; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HAWLEY CJ, 1990, BMJ-BRIT MED J, V300, P278; JANOWITZ HD, 1958, GASTROENTEROLOGY, V34, P11; KAHN DS, 1961, AM J PATHOL, V38, P177; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P379; LANZA FL, 1989, SCAND J GASTROENTERO, V24, P24, DOI 10.3109/00365528909091171; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MALONE DE, 1986, BRIT J RHEUMATOL, V25, P342; MCINTOSH JH, 1988, AM J EPIDEMIOL, V128, P761, DOI 10.1093/oxfordjournals.aje.a115029; MCINTOSH JH, 1985, GUT, V26, P789, DOI 10.1136/gut.26.8.789; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MOE AE, 1952, GASTROENTEROLOGY, V20, P343; PAYNE CD, 1986, GLIM SYSTEM RELEASE; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROBERT A, 1964, ARCH PATHOL, V77, P407; SEINO S, 1978, GUT, V19, P10, DOI 10.1136/gut.19.1.10; SELLING JA, 1987, ANN INTERN MED, V106, P368, DOI 10.7326/0003-4819-106-3-368; SOMERVILLE K, 1986, LANCET, V1, P462; SPIRO HM, 1983, NEW ENGL J MED, V309, P45, DOI 10.1056/NEJM198307073090110; SPIRO HM, 1950, J LAB CLIN MED, V35, P899; STRUM WB, 1986, ANN INTERN MED, V105, P757, DOI 10.7326/0003-4819-105-5-757; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; 1985, CLIN MODIFICATION, V2	35	426	434	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					735	740		10.7326/0003-4819-114-9-735	http://dx.doi.org/10.7326/0003-4819-114-9-735			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012355				2022-12-24	WOS:A1991FJ11700005
J	KROBER, MS; STRACENER, CE; BASS, JW				KROBER, MS; STRACENER, CE; BASS, JW			DECREASED MEASLES ANTIBODY-RESPONSE AFTER MEASLES-MUMPS-RUBELLA VACCINE IN INFANTS WITH COLDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							INTERFERON-PRODUCTION	We examined the possibility that the common cold or afebrile upper respiratory tract infection might interfere with successful immunization in children who receive standard measles-mumps-rubella vaccine. Infants 15 to 18 months of age presenting at our well-child clinics for routine examination and immunizations were divided into two groups. Those infants with a history and physical findings of upper respiratory tract infection were compared with healthy control group infants who did not have upper respiratory tract infections, and who did not have a history of upper respiratory tract infection symptoms within the previous month. Both groups were studied for their serologic response to measles-mumps-rubella vaccination. Prevaccination serum samples were obtained prior to vaccine administration and postvaccination serum samples were obtained 6 to 8 weeks later. Measles antibody was measured in these serum samples by an indirect fluorescein-tagged antibody test. Ten (21%) of 47 infants with colds failed to develop measles antibody, while only one (2%) of 51 well infants failed to develop antibody. We conclude that infants with colds have a significant seroconversion failure rate associated with measles vaccine administration and that this may be the cause of some primary measles vaccine failures.	TRIPLER ARMY MED CTR,DEPT PEDIAT,HONOLULU,HI 96859	United States Department of Defense; United States Army	KROBER, MS (corresponding author), MADIGAN ARMY MED CTR,DEPT PEDIAT,BOX 295,TACOMA,WA 98431, USA.							BRUNELL PA, 1990, PEDIATRICS, V83, P474; CHESHIK SG, 1988, PEDIATRIIA, V9, P10; DESMYTER J, 1968, PROG MED VIROL, V10, P268; GRIFFIN DE, 1990, J INFECT DIS, V161, P449, DOI 10.1093/infdis/161.3.449; Grimes D E, 1989, J Pediatr Health Care, V3, P187, DOI 10.1016/0891-5245(89)90082-5; HALL CB, 1981, ANN INTERN MED, V94, P53, DOI 10.7326/0003-4819-94-1-53; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; IZBICKY A, 1977, J HYG EPID MICROB IM, V21, P191; MARKOWITZ L, 1990, PEDIATR INFECT DIS J, V9, P530; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MIRCHAMSY H, 1969, J GEN VIROL, V4, P413; NAKAYAMA T, 1988, J INFECT DIS, V158, P1386, DOI 10.1093/infdis/158.6.1386; NDKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448; NKOWANE BM, 1987, AM J PUBLIC HEALTH, V77, P434, DOI 10.2105/AJPH.77.4.434; RAY CG, 1967, J PEDIATR, V72, P27; TOLCHIN D, 1973, J PEDIATR-US, V83, P890, DOI 10.1016/S0022-3476(73)80401-9; WHEELOCK EF, 1964, LANCET, V2, P382	18	40	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2095	2096		10.1001/jama.265.16.2095	http://dx.doi.org/10.1001/jama.265.16.2095			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013930				2022-12-24	WOS:A1991FG90700027
J	HANSPAL, RS; FISHER, K				HANSPAL, RS; FISHER, K			ASSESSMENT OF COGNITIVE AND PSYCHOMOTOR FUNCTION AND REHABILITATION OF ELDERLY PEOPLE WITH PROSTHESES	BRITISH MEDICAL JOURNAL			English	Article									HAROLD WOOD HOSP,NE THAMES REG DISABLEMENT SERV CTR,ROMFORD,ESSEX,ENGLAND		HANSPAL, RS (corresponding author), ROYAL NATL ORTHOPAED HOSP,DISABLEMENT SERV CTR,REHABIL UNIT,STANMORE,MIDDX,ENGLAND.							GUTTMAN L, 1952, MEASUREMENT PREDICTI; NIE N, 1976, STATISTICAL PACKAGE; Pattie A., 1979, MANUAL CLIFTON ASSES; VITALI M, 1986, AMPUTATIONS PROSTHES	4	16	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					940	940		10.1136/bmj.302.6782.940	http://dx.doi.org/10.1136/bmj.302.6782.940			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH487	2032036	Bronze, Green Published			2022-12-24	WOS:A1991FH48700020
J	BARONDESS, JA				BARONDESS, JA			THE RISK OF CONTRACTING HIV-INFECTION IN THE COURSE OF HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BARONDESS, JA (corresponding author), NEW YORK ACAD MED,2 E 103RD ST,NEW YORK,NY 10029, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1872	1873						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005738				2022-12-24	WOS:A1991FE86200031
J	PETITTO, LA; MARENTETTE, PF				PETITTO, LA; MARENTETTE, PF			BABBLING IN THE MANUAL MODE - EVIDENCE FOR THE ONTOGENY OF LANGUAGE	SCIENCE			English	Article							AMERICAN SIGN LANGUAGE; SPEECH-PERCEPTION; CONTINUITY	Infant vocal babbling has been assumed to be a speech-based phenomenon that reflects the maturation of the articulatory apparatus responsible for spoken language production. Manual babbling has now been reported to occur in deaf children exposed to signed languages from birth. The similarities between manual and vocal babbling suggest that babbling is a product of an amodal, brain-based language capacity under maturational control, in which phonetic and syllabic units are produced by the infant as a first step toward building a mature linguistic system. Contrary to prevailing accounts of the neurological basis of babbling in language ontogeny, the speech modality is not critical in babbling. Rather, babbling is tied to the abstract linguistic structure of language and to an expressive capacity capable of processing different types of signals (signed or spoken).			PETITTO, LA (corresponding author), MCGILL UNIV,DEPT PSYCHOL,MONTREAL H3A 1B1,QUEBEC,CANADA.		Marentette, Paula/D-2888-2011	Marentette, Paula/0000-0002-4098-0571				CHOMSKY N, 1980, BEHAV BRAIN SCI, V3, P1, DOI 10.1017/S0140525X00001515; ELBERS L, 1982, COGNITION, V12, P45, DOI 10.1016/0010-0277(82)90029-4; GLEITMAN LR, 1981, COGNITION, V10, P103; HUTTENLOCHER J, 1987, COGNITIVE PSYCHOL, V19, P63, DOI 10.1016/0010-0285(87)90004-1; JUSCZYK PW, 1986, INVARIANCE VARIABILI, P1; Klima E., 1979, SIGNS LANGUAGE; LENNEBERG EH, 1967, BIOL F LANGUAGE; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; LIDDELL SK, 1984, LANGUAGE, V60, P372, DOI 10.2307/413645; Lieberman P., 1984, BIOL EVOLUTION LANGU; Locke J., 1983, PHONOLOGICAL ACQUISI, DOI DOI 10.2307/414500; MARENTETTE PF, UNPUB; MEHLER J, 1986, CR ACAD SCI III-VIE, V303, P637; Oller D. K., 1980, CHILD PHONOLOGY, V1, P93, DOI [10.1016/B978-0-12-770601-6.50011-5, DOI 10.1016/B978-0-12-770601-6.50011-5]; OLLER DK, 1988, CHILD DEV, V59, P441, DOI 10.1111/j.1467-8624.1988.tb01479.x; PETITTO LA, 1987, COGNITION, V27, P1, DOI 10.1016/0010-0277(87)90034-5; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; SHATZ M, 1985, MERRILL PALMER QUART, V31, P211; Stokoe W. C., 1976, DICT AM SIGN LANGUAG; van der Stelt J. M., 1986, WENNER GREN CTR IN B, P163; VIHMAN MM, 1985, LANGUAGE, V61, P397, DOI 10.2307/414151; VIHMAN MM, 1986, APPL PSYCHOLINGUIST, V7, P3, DOI 10.1017/S0142716400007165	23	242	248	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1493	1496		10.1126/science.2006424	http://dx.doi.org/10.1126/science.2006424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC853	2006424				2022-12-24	WOS:A1991FC85300051
J	JUNG, LJ; SCHELLER, RH				JUNG, LJ; SCHELLER, RH			PEPTIDE PROCESSING AND TARGETING IN THE NEURONAL SECRETORY PATHWAY	SCIENCE			English	Article							EGG-LAYING HORMONE; BAG CELL NEURONS; LARGE HERMAPHRODITIC DUCT; ATRIAL GLAND PEPTIDES; SEMLIKI FOREST VIRUS; APLYSIA-CALIFORNICA; BEHAVIORAL-PATTERNS; ELICITED BEHAVIORS; PROLONGED ACTIONS; ENDOCRINE CELLS	The abdominal ganglion of the marine mollusk Aplysia contains a pair of identified neuronal clusters, the bag cells, which control egg laying by means of a number of unique regulatory mechanisms. Each neuron in the bag cell clusters synthesizes several peptides derived from a single prohormone and packages them into separate vesicles. These vesicles are then differentially localized in specific neuronal processes, thus segregating peptides destined for autocrine and hormonal release sites. Therefore in this system, protein trafficking through the secretory pathway organizes multiple peptide neurochemical messengers to efficiently regulate simple behaviors.			JUNG, LJ (corresponding author), STANFORD UNIV, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.							ARCH S, 1977, BEHAV BIOL, V19, P45, DOI 10.1016/S0091-6773(77)91331-1; ARCH S, 1980, J COMP PHYSIOL, V141, P131, DOI 10.1007/BF00611886; ARCH S, 1978, J COMP PHYSIOL, V128, P67, DOI 10.1007/BF00668374; ARCH S, 1976, AM ZOOL, V16, P167; AUDESIRK TE, 1977, BEHAV BIOL, V20, P235, DOI 10.1016/S0091-6773(77)90799-4; BEARD M, 1982, TISSUE CELL, V14, P297, DOI 10.1016/0040-8166(82)90028-3; BERRY RW, 1986, PEPTIDES, V7, P637, DOI 10.1016/0196-9781(86)90039-2; BLANKENSHIP JE, 1979, J NEUROPHYSIOL, V42, P347, DOI 10.1152/jn.1979.42.2.347; BRANTON WD, 1978, P NATL ACAD SCI USA, V75, P5732, DOI 10.1073/pnas.75.11.5732; BRANTON WD, 1978, NATURE, V274, P70, DOI 10.1038/274070a0; CAREFOOT TH, 1967, J MAR BIOL ASSOC UK, V47, P565, DOI 10.1017/S0025315400035190; CHIU AY, 1979, P NATL ACAD SCI USA, V76, P6656, DOI 10.1073/pnas.76.12.6656; COBBS JS, 1982, J COMP PHYSIOL, V147, P523, DOI 10.1007/BF00612018; COBBS JS, 1982, J COMP PHYSIOL, V147, P537, DOI 10.1007/BF00612019; COGGESHALL RE, 1967, J NEUROPHYSIOL, V30, P1263, DOI 10.1152/jn.1967.30.6.1263; COGGESHALL RE, 1972, AM ZOOL, V12, P521; DALE HENRY, 1935, PROC ROY SOC MED, V28, P319; DUDEK FE, 1977, J NEUROPHYSIOL, V40, P1301, DOI 10.1152/jn.1977.40.6.1301; EALES NB, 1921, LIVERPOOL MARINE BIO, V24, P183; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; FINK LA, 1988, J NEUROSCI, V8, P2544; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FRAZIER WT, 1967, J NEUROPHYSIOL, V30, P1288, DOI 10.1152/jn.1967.30.6.1288; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HAND AR, 1977, J CELL BIOL, V74, P399, DOI 10.1083/jcb.74.2.399; HASKINS JT, 1981, J NEUROCYTOL, V10, P729, DOI 10.1007/BF01262650; HELLER E, 1980, P NATL ACAD SCI-BIOL, V77, P2328, DOI 10.1073/pnas.77.4.2328; JOHNSON DC, 1980, VIROLOGY, V103, P407, DOI 10.1016/0042-6822(80)90200-7; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KACZMAREK LK, 1978, P NATL ACAD SCI USA, V75, P5200, DOI 10.1073/pnas.75.10.5200; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; KACZMAREK LK, 1982, BRAIN RES, V238, P105, DOI 10.1016/0006-8993(82)90774-0; Kandel ER., 1976, CELLULAR BASIS BEHAV; KANDEL ER, 1979, BEHAVIORAL BIOL APLY; KAUER JA, 1987, J NEUROSCI, V7, P3623; KUPFERMA.I, 1974, BEHAV BIOL, V12, P317, DOI 10.1016/S0091-6773(74)91503-X; KUPFERMANN I, 1976, J GEN PHYSIOL, V67, P113, DOI 10.1085/jgp.67.1.113; KUPFERMANN I, 1967, NATURE, V216, P814, DOI 10.1038/216814a0; LEVITAN ES, 1987, P NATL ACAD SCI USA, V84, P6307, DOI 10.1073/pnas.84.17.6307; LOECHNER KJ, 1990, J NEUROPHYSIOL, V63, P738, DOI 10.1152/jn.1990.63.4.738; Macginitie GE, 1934, BIOL BULL-US, V67, P300, DOI 10.2307/1537166; MAHON AC, 1985, J NEUROSCI, V5, P1872; Mayeri E., 1985, P285; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1185, DOI 10.1152/jn.1979.42.4.1185; MAYERI E, 1981, NEUROSECRETION MOL C, P305; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NAGLE GT, 1986, J BIOL CHEM, V261, P7853; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; NAMBU JR, 1986, J NEUROSCI, V6, P2026; NEWCOMB R, 1988, J BIOL CHEM, V263, P12514; NEWCOMB R, 1987, J NEUROSCI, V7, P854; NEWCOMB RW, 1990, BRAIN RES, V521, P229, DOI 10.1016/0006-8993(90)91547-T; NOVIKOFF PM, 1971, J CELL BIOL, V50, P859, DOI 10.1083/jcb.50.3.859; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PAINTER SD, 1985, J MORPHOL, V186, P167, DOI 10.1002/jmor.1051860204; PAINTER SD, 1989, BEHAV NEURAL BIOL, V51, P222, DOI 10.1016/S0163-1047(89)90857-1; PINSKER HM, 1977, SCIENCE, V197, P490, DOI 10.1126/science.197.4302.490; ROCK MK, 1986, J NEUROBIOL, V17, P273, DOI 10.1002/neu.480170403; ROSEN SC, 1979, J NEUROPHYSIOL, V42, P954, DOI 10.1152/jn.1979.42.4.954; ROTHMAN BS, 1986, J BIOL CHEM, V261, P1616; ROTHMAN BS, 1983, P NATL ACAD SCI-BIOL, V80, P5753, DOI 10.1073/pnas.80.18.5753; ROTHMAN BS, 1983, GEN COMP ENDOCR, V52, P134, DOI 10.1016/0016-6480(83)90166-1; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; SOSSIN WS, 1990, P NATL ACAD SCI USA, V87, P4845, DOI 10.1073/pnas.87.12.4845; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; SUSSWEIN AJ, 1984, BEHAV NEURAL BIOL, V41, P7, DOI 10.1016/S0163-1047(84)90667-8; SUSSWEIN AJ, 1984, BEHAV NEURAL BIOL, V42, P127, DOI 10.1016/S0163-1047(84)90968-3; SUSSWEIN AJ, 1985, NEUROSCI LETT, V59, P325, DOI 10.1016/0304-3940(85)90153-3; SWEETCORDERO A, 1990, J NEUROCHEM, V55, P1933, DOI 10.1111/j.1471-4159.1990.tb05779.x; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1986, SCIENCE, V232, P1641, DOI 10.1126/science.3754979; THOMPSON T E, 1969, Malacologia, V7, P347; TOOZE J, 1987, J CELL BIOL, V105, P155, DOI 10.1083/jcb.105.1.155; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551	90	101	105	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1991	251	4999					1330	1335		10.1126/science.2003219	http://dx.doi.org/10.1126/science.2003219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003219				2022-12-24	WOS:A1991FB73300037
J	WICKNER, S; HOSKINS, J; MCKENNEY, K				WICKNER, S; HOSKINS, J; MCKENNEY, K			FUNCTION OF DNAJ AND DNAK AS CHAPERONES IN ORIGIN-SPECIFIC DNA-BINDING BY REPA	NATURE			English	Article							P1 PLASMID REPLICATION; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; GENE	HEAT-shock proteins are normal constituents of cells whose synthesis is increased on exposure to various forms of stress. They are interesting because of their ubiquity and high conservation during evolution. Two families of heat-shock proteins, hsp60s and hsp70s, have been implicated in accelerating protein folding and oligomerization and also in maintaining proteins in an unfolded state, thus facilitating membrane transport 1-5. The Escherichia coli hsp70 analogue, DnaK, and two other heat-shock proteins, DnaJ and GrpE, are required for cell viability at high temperatures and are involved in DNA replication of phage-lambda and plasmids P1 and F 6-10. These three proteins are involved in replication in vitro of P1 DNA along with many host replication proteins and the P1 RepA initiator protein 11,12. RepA exists in a stable protein complex with DnaJ containing a dimer each of RepA and DnaJ 11. We report here that DnaK and DnaJ mediate an alteration in the P1 initiator protein, rendering it much more active for oriP1 DNA binding.	NATL INST STAND & TECHNOL,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850	National Institute of Standards & Technology (NIST) - USA	WICKNER, S (corresponding author), NCI,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; ABELES AL, 1986, J BIOL CHEM, V261, P3548; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MORIMOTO R I, 1990, P1; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; TILLY K, 1990, NEW BIOL, V2, P1; WICKNER SH, 1987, P NATL ACAD SCI USA, V84, P3668, DOI 10.1073/pnas.84.11.3668; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	16	199	201	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					165	167		10.1038/350165a0	http://dx.doi.org/10.1038/350165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005967				2022-12-24	WOS:A1991FB64500063
J	DSOUZA, SE; GINSBERG, MH; MATSUEDA, GR; PLOW, EF				DSOUZA, SE; GINSBERG, MH; MATSUEDA, GR; PLOW, EF			A DISCRETE SEQUENCE IN A PLATELET INTEGRIN IS INVOLVED IN LIGAND RECOGNITION	NATURE			English	Article							IIB-IIIA COMPLEX; MEMBRANE GLYCOPROTEIN-IIB; CELL-BINDING DOMAIN; FIBRINOGEN BINDING; GAMMA-CHAIN; SYNTHETIC PEPTIDES; ALPHA-SUBUNITS; ACID SEQUENCES; FIBRONECTIN; RECEPTOR	PLATELET membrane glycoprotein IIb-IIIa (gpIIb-IIIa; alpha-IIb-beta-3), the most prominent member of the integrin family of adhesion receptors on these cells, mediates platelet aggregation by binding fibrinogen and is critical in thrombosis and haemostasis 1-5. A short amino-acid sequence at the carboxy terminus of the gamma-chain of fibrinogen is recognized by gpIIb-IIIa (ref. 6) and peptides containing this sequence are selectively crosslinked to residues 294-314 of gpIIb (ref. 7). Here we show that an 11-residue peptide from this region of gpIIb inhibits platelet aggregation and binding of fibrinogen to platelets and to purified gpIIb-IIIa, and that it interacts directly with fibrinogen. These results implicate this segment of gpIIb-IIIa in the ligand-binding function of the receptor. Moreover, as this region is highly conserved among integrins, it may have a general function in ligand recognition by this broadly distributed family of adhesion receptors.	PRINCETON UNIV, SQUIBB LABS BIOL, PRINCETON, NJ 08544 USA	Princeton University	DSOUZA, SE (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; CHARO IF, 1989, BLOOD, V74, pA497; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; HAVERSTICK DM, 1985, BLOOD, V66, P946; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MATSUEDA GR, 1988, FASEB J, V2, P6480; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1987, BLOOD, V70, P110; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446	29	197	202	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					66	68		10.1038/350066a0	http://dx.doi.org/10.1038/350066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	2002847				2022-12-24	WOS:A1991FA69300066
J	HARTMANN, HA; KIRSCH, GE; DREWE, JA; TAGLIALATELA, M; JOHO, RH; BROWN, AM				HARTMANN, HA; KIRSCH, GE; DREWE, JA; TAGLIALATELA, M; JOHO, RH; BROWN, AM			EXCHANGE OF CONDUCTION PATHWAYS BETWEEN 2 RELATED K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNEL; RAT-BRAIN; TETRAETHYLAMMONIUM; MEMBRANE; NEURONS	The structure of the ion conduction pathway or pore of voltage-gated ion channels is unknown, although the linker between the membrane spanning segments S5 and S6 has been suggested to form part of the pore in potassium channels. To test whether this region controls potassium channel conduction, a 21-amino acid segment of the S5-S6 linker was transplanted from the voltage-activated potassium channel NGK2 to another potassium channel DRK1, which has very different pore properties. In the resulting chimeric channel, the single channel conductance and blockade by external and internal tetraethylammonium (TEA) ion were characteristic of the donor NGK2 channel. Thus, this 21-amino acid segment controls the essential biophysical properties of the pore and may form the conduction pathway of these potassium channels.	BAYLOR UNIV,DEPT ANESTHESIOL,HOUSTON,TX 77030	Baylor University	HARTMANN, HA (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/A-2062-2019; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/ABH-4262-2020	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; 	NINDS NIH HHS [NS08805, NS23877, NS28407] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028407, F32NS008805, R01NS023877] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Erlich H.A., 1989, PCR TECHNOLOGY; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERMANN A, 1979, NEUROSCI LETT, V12, P87, DOI 10.1016/0304-3940(79)91485-X; Hille B, 1984, IONIC CHANNELS EXCIT; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KOPPENHOFER E, 1969, PFLUG ARCH EUR J PHY, V313, P361, DOI 10.1007/BF00593959; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; MOORMAN JR, 1990, SCIENCE, V250, P688; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; TAGLIALATELA M, UNPUB; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THOMPSON SH, 1977, J PHYSIOL-LONDON, V265, P465, DOI 10.1113/jphysiol.1977.sp011725; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	25	373	377	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					942	944		10.1126/science.2000495	http://dx.doi.org/10.1126/science.2000495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	2000495				2022-12-24	WOS:A1991EY62900046
J	PARKS, GD; LAMB, RA				PARKS, GD; LAMB, RA			TOPOLOGY OF EUKARYOTIC TYPE-II MEMBRANE-PROTEINS - IMPORTANCE OF N-TERMINAL POSITIVELY CHARGED RESIDUES FLANKING THE HYDROPHOBIC DOMAIN	CELL			English	Article							PARAMYXOVIRUS SIMIAN VIRUS-5; ENDOPLASMIC-RETICULUM MEMBRANE; CLEAVABLE SIGNAL SEQUENCE; INFLUENZA-VIRUS; INVARIANT CHAIN; MESSENGER-RNA; CELL-SURFACE; NH2 TERMINUS; AMINO-ACID; TRANSLOCATION	We have tested the role of different charged residues flanking the sides of the signal/anchor (S/A) domain of a eukaryotic type II (N(cyt)C(exo)) integral membrane protein in determining its topology. The removal of positively charged residues on the N-terminal side of the S/A yields proteins with an inverted topology, while the addition of positively charged residues to only the C-terminal side has very little effect on orientation. Expression of chimeric proteins composed of domains from a type II protein (HN) and the oppositely oriented membrane protein M2 indicates that the HN N-terminal domain is sufficient to confer a type II topology and that the M2 N-terminal ectodomain can direct a type II topology when modified by adding positively charged residues. These data suggest that eukaryotic membrane protein topology is governed by the presence or absence of an N-terminal signal for retention in the cytoplasm that is composed in part of positive charges.	NORTHWESTERN UNIV,HOWARD HUGHES MED INST,EVANSTON,IL 60208	Howard Hughes Medical Institute; Northwestern University	PARKS, GD (corresponding author), NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI023173, R01AI020201] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20201, AI-23173] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, MOL CELL BIOL, V5, P1442, DOI 10.1128/MCB.5.6.1442; AKITA M, 1990, J BIOL CHEM, V265, P8164; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1979, J BIOL CHEM, V254, P1771; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIEBERT SW, 1985, J VIROL, V55, P744, DOI 10.1128/JVI.55.3.744-751.1985; HIEBERT SW, 1985, J VIROL, V54, P1; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; LAMB RA, 1982, VIROLOGY, V123, P237, DOI 10.1016/0042-6822(82)90258-6; LAMB RA, 1978, VIROLOGY, V91, P60, DOI 10.1016/0042-6822(78)90355-0; LAMB RA, 1976, VIROLOGY, V74, P504, DOI 10.1016/0042-6822(76)90356-1; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 1981, VIROLOGY, V112, P746, DOI 10.1016/0042-6822(81)90319-6; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LIPP J, 1986, J CELL BIOL, V102, P2169, DOI 10.1083/jcb.102.6.2169; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NGDTW, 1989, J CELL BIOL, V109, P3273; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PARKS GD, 1989, J CELL BIOL, V109, P2023, DOI 10.1083/jcb.109.5.2023; PATERSON RG, 1985, P NATL ACAD SCI USA, V82, P7520, DOI 10.1073/pnas.82.22.7520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STRUBIN M, 1984, EMBO J, V3, P869, DOI 10.1002/j.1460-2075.1984.tb01898.x; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WEINSTEIN JN, 1982, J MEMBRANE BIOL, V66, P203, DOI 10.1007/BF01868495; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	49	149	152	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					777	787		10.1016/0092-8674(91)90507-U	http://dx.doi.org/10.1016/0092-8674(91)90507-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997206				2022-12-24	WOS:A1991EZ47800013
J	RAUB, W				RAUB, W			NEW CONJUGATE VACCINE PROTECTS YOUNGER CHILDREN AGAINST MENINGITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 13	1991	265	6					706	706						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW479	1990184				2022-12-24	WOS:A1991EW47900007
J	SEATON, D; YOGANATHAN, K; COADY, T; BARKER, R				SEATON, D; YOGANATHAN, K; COADY, T; BARKER, R			SPONTANEOUS PNEUMOTHORAX - MARKER GAS TECHNIQUE FOR PREDICTING OUTCOME OF MANUAL ASPIRATION	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether in a patient with spontaneous pneumothorax the presence or absence of a pleural leak can be shown at the time of manual aspiration by use of a marker gas. Also, to find out if the technique can predict whether manual aspiration will be successful, hence avoiding the need for intercostal tube drainage. Design-Prospective study of 25 episodes of pneumothorax during which patients breathed air from a Douglas bag that contained chlorofluorocarbon gases from a metered dose inhaler while the pneumothorax was aspirated. Setting-Medical unit of a district general hospital. Patients-22 patients who presented over nine months with acute pneumothorax. Main outcome measures-Presence or absence of chlorofluorocarbon marker gases in the aspirate. Presence or absence of sustained re-expansion of the affected lung in the chest radiograph. Results-Marker gas was detected in the aspirate from 16 out of 25 pneumothoraces. Of these, 13 required intercostal tube drainage because of failure of the lung to re-expand. Marker gas was not detected in nine cases, and in all of these cases manual aspiration resulted in sustained re-expansion of the lung. Conclusions-The presence or absence of a pleural leak during manual aspiration of spontaneous pneumothorax can be shown by using this technique. The absence of marker gas in the aspirate implies that manual aspiration will be successful, whereas its presence predicts, in most cases, either failure of manual aspiration to expand the lung or early recollapse of the lung.			SEATON, D (corresponding author), IPSWICH HOSP,DEPT THORAC MED,IPSWICH IP4 5PD,SUFFOLK,ENGLAND.							BEVELAQUA FA, 1982, CHEST, V81, P693, DOI 10.1378/chest.81.6.693; COADY TJ, 1988, LANCET, V2, P1286; CUMMINGS JH, 1988, RECENT ADV GASTROENT, V7, P328; HAMILTON AAD, 1983, THORAX, V38, P934, DOI 10.1136/thx.38.12.934; JONES JS, 1985, THORAX, V40, P66, DOI 10.1136/thx.40.1.66; RAJA OG, 1981, BR J DIS CHEST, V75, P27; Seaton A, 1989, CROFTON DOUGLASS RES, P761	7	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					262	265		10.1136/bmj.302.6771.262	http://dx.doi.org/10.1136/bmj.302.6771.262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998790	Green Published, Bronze			2022-12-24	WOS:A1991EX91900018
J	TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A				TIERNEY, AJ; LEONARD, RCF; TAYLOR, J; CLOSS, SJ; CHETTY, U; RODGER, A			SIDE-EFFECTS EXPECTED AND EXPERIENCED BY WOMEN RECEIVING CHEMOTHERAPY FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									LONGMORE HOSP,BREAST UNIT,EDINBURGH,SCOTLAND; WESTERN GEN HOSP,CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	TIERNEY, AJ (corresponding author), UNIV EDINBURGH,DEPT NURSING STUDIES,NURSING RES UNIT,EDINBURGH EH8 9JT,SCOTLAND.			Closs, Susan Jose/0000-0002-3257-5277				TIERNEY AJ, 1989, STUDY INFORM NURSING	1	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 2	1991	302	6771					272	272		10.1136/bmj.302.6771.272	http://dx.doi.org/10.1136/bmj.302.6771.272			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX919	1998793	Bronze, Green Published			2022-12-24	WOS:A1991EX91900021
J	RIQUIMAROUX, H; GAIONI, SJ; SUGA, N				RIQUIMAROUX, H; GAIONI, SJ; SUGA, N			CORTICAL COMPUTATIONAL MAPS CONTROL AUDITORY-PERCEPTION	SCIENCE			English	Article							CF-FM BAT; FINE FREQUENCY-ANALYSIS; MUSTACHED BAT; RHINOLOPHUS-FERRUMEQUINUM; CORTEX; REPRESENTATION; VOCALIZATIONS; ECHOLOCATION; MACAQUES; COCHLEA	Mustached bats orient and find insects by emitting ultrasonic pulses and analyzing the returning echoes. Neurons in the Doppler-shifted constant-frequency (DSCF) and frequency-modulated (FM-FM) areas of the auditory cortex form maps of echo frequency (target velocity) and echo delay (target range), respectively. Bats were trained to discriminate changes in echo frequency or delay, and then these areas were selectively inactivated with muscimol. Inactivation of the DSCF area disrupted frequency but not delay discriminations; inactivation of the FM-FM area disrupted delay but not frequency discriminations. Thus, focal inactivation of specific cortical maps produces specific disruptions in the perception of biosonar signals.	WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Washington University (WUSTL)					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017333] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17333] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN WF, 1945, AM J PHYSIOL, V144, P415, DOI 10.1152/ajplegacy.1945.144.3.415; Bekhterev V, 1913, PSYCHOL OBJECTIVE; BRUNS V, 1976, J COMP PHYSIOL, V106, P77, DOI 10.1007/BF00606573; BRUNS V, 1976, J COMP PHYSIOL, V106, P87, DOI 10.1007/BF00606574; BUTLER RA, 1957, J NEUROPHYSIOL, V20, P108, DOI 10.1152/jn.1957.20.1.108; CRANFORD JL, 1976, J NEUROPHYSIOL, V39, P143, DOI 10.1152/jn.1976.39.1.143; DIAMOND IT, 1962, J NEUROPHYSIOL, V25, P223, DOI 10.1152/jn.1962.25.2.223; EVARTS EV, 1952, J NEUROPHYSIOL, V15, P443, DOI 10.1152/jn.1952.15.6.443; GAIONI SJ, 1988, ABSTR SOC NEUROSCI, V14, P1100; GAIONI SJ, IN PRESS J NEUROPHYS; GOLDBERG JM, 1961, J NEUROPHYSIOL, V24, P119, DOI 10.1152/jn.1961.24.2.119; HEFFNER HE, 1986, J NEUROPHYSIOL, V56, P683, DOI 10.1152/jn.1986.56.3.683; HEFFNER HE, 1984, SCIENCE, V226, P75, DOI 10.1126/science.6474192; HEFNER HE, 1987, 10TH MIDW M ASS RES, P87; Henson OW., 1980, ANIMAL SONAR SYSTEMS, P913, DOI [10.1007/978-1-4684-7254-7_56, DOI 10.1007/978-1-4684-7254-7_56]; HIKOSAKA O, 1985, BRAIN RES, V325, P375, DOI 10.1016/0006-8993(85)90344-0; KRNJEVIC K, 1967, EXP BRAIN RES, V3, P320, DOI 10.1007/BF00237558; KRNJEVIC K, 1963, J PHYSIOL-LONDON, V165, P274, DOI 10.1113/jphysiol.1963.sp007057; Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN; MEYER DR, 1952, J NEUROPHYSIOL, V15, P149, DOI 10.1152/jn.1952.15.2.149; ONEILL WE, 1979, SCIENCE, V203, P69, DOI 10.1126/science.758681; Schnitzler H., 1980, ANIMAL SONAR SYSTEMS, V28, P109, DOI [10.10007/978-1-4684-7254-7_6, DOI 10.1007/978-1-4684-7254-7_6]; SCHNITZLER HU, 1970, Z VERGL PHYSIOL, V68, P25, DOI 10.1007/BF00297809; SUGA N, 1987, J NEUROPHYSIOL, V58, P643, DOI 10.1152/jn.1987.58.4.643; SUGA N, 1982, J NEUROPHYSIOL, V47, P225, DOI 10.1152/jn.1982.47.2.225; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1986, J NEUROPHYSIOL, V55, P776, DOI 10.1152/jn.1986.55.4.776; SUGA N, 1976, SCIENCE, V194, P542, DOI 10.1126/science.973140; SUGA N, 1975, J EXP BIOL, V63, P161; Suga N, 1984, DYNAMIC ASPECTS NEOC, P315; THOMPSON RF, 1960, J NEUROPHYSIOL, V23, P321, DOI 10.1152/jn.1960.23.3.321	31	96	96	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					565	568		10.1126/science.1990432	http://dx.doi.org/10.1126/science.1990432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990432				2022-12-24	WOS:A1991EV45900053
J	KOLCH, W; HEIDECKER, G; LLOYD, P; RAPP, UR				KOLCH, W; HEIDECKER, G; LLOYD, P; RAPP, UR			RAF-1 PROTEIN-KINASE IS REQUIRED FOR GROWTH OF INDUCED NIH/3T3 CELLS	NATURE			English	Article							SIGNAL TRANSDUCTION; V-RAF; ONCOGENE; PHOSPHORYLATION	MANY growth factors regulate the cytoplasmic RAF-1 protein kinase 1-10, consistent with its having a central role in transduction of growth signals. The kinase is ubiquitously expressed 11 and can promote proliferation 12, presumably in a manner dependent on growth-factor receptors and membrane-associated oncogenes 13-15. We have now examined the dependence of serum- and TPa (12-O-tetradecanoylphorbol-13-acetate)-regulated NIH/3T3 cell growth on RAF-1 kinase to determine whether Raf-1 is essential for receptor signalling. We inhibited Raf-1 function by expressing c-raf-1 antisense RNA or kinase-defective c-raf-1 mutants. Antisense RNA for c-raf-1 interferes with proliferation of normal NIH/3T3 cells and reverts raf-transformed cells. In revertant cells, DNA replication induced by serum or TPA was eliminated or reduced proportionately to the reduction in Raf protein levels. Expression of a kinase-defective Raf-1 mutant (craf301) or a regulatory domain fragment (HCR) inhibited serum-induced NIH/3T3-cell proliferation and raf transformation even more efficiently. Inhibition by antisense RNA or craf301 blocked proliferation and transformation by Ki- and Ha-ras oncogenes. We conclude that raf functions as an essential signal transducer downstream of serum growth factor receptors, protein kinase C and ras.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016				APP H, IN PRESS MOLEC CELL; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; KOLCH W, 1990, ONCOGENE, V5, P713; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STORM SM, 1990, ONCOGENE, V5, P345; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TURNER BC, IN PRESS P NATN ACAD; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	26	472	512	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					426	428		10.1038/349426a0	http://dx.doi.org/10.1038/349426a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992343	Green Published			2022-12-24	WOS:A1991EV51400055
J	ROBLES, L; RUGGERO, MA; RICH, NC				ROBLES, L; RUGGERO, MA; RICH, NC			2-TONE DISTORTION IN THE BASILAR-MEMBRANE OF THE COCHLEA	NATURE			English	Article							MECHANICS; NONLINEARITY; RESPONSES; 2F1-F2; MOTION; TONES; NERVE	WHEN humans listen to pairs of thnes they hear additional tones, or distortion products, that are not present in the stimulus 1. Two-tone distortion products are also known as combination tones, because their pitches match combinations of the primary frequencies (f1 and f2,f2 > f1), such as f2 - f1, (n+1)f1 - nf2 and (n + 1)f2 - nf1 (n = 1,2,3...) (refs 2-4). Physiological correlates of the perceived distortion products exist in responses of auditory-nerve fibres 5-8 and inner hair cells 9 and in otoacoustic emissions (sounds generated by the cochlea, recordable at the ear canal) 7, 10-12. Because the middle ear responds linearly to sound 13, 14 and neural responses to distortion products can be abolished by damage to hair cells at cochlear sites preferentially tuned to the frequencies of the primary tones 8, it was hypothesized that distortion products are generated at these sites and propagate mechanically along the basilar membrane to the location tuned to the distortion-product frequency 7,8. But until now, efforts to confirm this hypothesis have failed 15,16. Here we report the use of a new laser-velocimetry technique 17 to demonstrate two-tone distortion in basilar-membrane motion at low and moderate stimulus intensities.	UNIV CHILE,FAC MED,DEPT FISIOL & BIOFIS,SANTIAGO,CHILE	Universidad de Chile	ROBLES, L (corresponding author), UNIV MINNESOTA,DEPT OTOLARYNGOL,2630 UNIV AVE SE,MINNEAPOLIS,MN 55414, USA.		Ruggero, Mario A/A-9860-2009	Ruggero, Mario A/0000-0001-8240-3644	NIDCD NIH HHS [R01 DC000419] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000419] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BUUNEN TJF, 1978, J ACOUST SOC AM, V64, P772, DOI 10.1121/1.382042; BUUNEN TJF, 1981, J ACOUST SOC AM, V69, P744, DOI 10.1121/1.385574; GOLDSTEI.JL, 1968, PR INST ELECTR ELECT, V56, P981, DOI 10.1109/PROC.1968.6449; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; GUINAN JJ, 1967, J ACOUST SOC AM, V41, P1237, DOI 10.1121/1.1910465; Jones AT., 1935, AM J PHYS, V3, P49, DOI [10.1119/1.1992920, DOI 10.1119/1.1992920]; KEMP DT, 1979, ARCH OTO-RHINO-LARYN, V224, P37, DOI 10.1007/BF00455222; KIM DO, 1980, J ACOUST SOC AM, V67, P1704, DOI 10.1121/1.384297; MOUNTAIN DC, 1980, SCIENCE, V210, P71, DOI 10.1126/science.7414321; NUTTALL AL, 1990, J ACOUST SOC AM, V87, P782, DOI 10.1121/1.398890; NUTTALL AL, IN PRESS MECHANICS B; PATUZZI R, 1984, HEARING RES, V13, P19, DOI 10.1016/0378-5955(84)90091-1; Rhode WS., 1977, PSYCHOPHYSICS PHYSL, P27; ROBLES L, 1986, J ACOUST SOC AM, V80, P1364, DOI 10.1121/1.394389; ROBLES L, IN PRESS MECHANICS B; Robles L, 1989, COCHLEAR MECHANISMS, P369; RUGGERO MA, IN PRESS HEAR RES; RUGGERO MA, IN PRESS J NEUROSCI; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SIEGEL JH, 1982, J NEUROPHYSIOL, V47, P303, DOI 10.1152/jn.1982.47.2.303; SIEGEL JH, 1982, HEARING RES, V6, P171, DOI 10.1016/0378-5955(82)90052-1; SMOORENBURG GF, 1972, J ACOUST SOC AM, V52, P615, DOI 10.1121/1.1913152; WILSON JP, 1973, NATURE, V241, P206, DOI 10.1038/241206a0; ZUREK PM, 1979, SCIENCE, V205, P600, DOI 10.1126/science.451625	24	136	145	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					413	414		10.1038/349413a0	http://dx.doi.org/10.1038/349413a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1992342	Green Accepted			2022-12-24	WOS:A1991EV51400050
J	FLEISSIG, A				FLEISSIG, A			UNINTENDED PREGNANCIES AND THE USE OF CONTRACEPTION - CHANGES FROM 1984 TO 1989	BRITISH MEDICAL JOURNAL			English	Article											FLEISSIG, A (corresponding author), INSTITUTE SOCIAL STUDIES MED CARE,14 S HILL PK,LONDON NW3 2SB,ENGLAND.							CARTWRIGHT A, 1988, SOC SCI MED, V27, P249, DOI 10.1016/0277-9536(88)90128-1; Griffiths M, 1990, BRIT J FAM PLANN, V16, P16; Guillebaud J, 2017, CONTRACEPTION YOUR Q; SMITH T, 1990, BRIT MED J, V300, P1154, DOI 10.1136/bmj.300.6733.1154	4	50	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 19	1991	302	6769					147	147		10.1136/bmj.302.6769.147	http://dx.doi.org/10.1136/bmj.302.6769.147			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EU020	1995134	Green Published, Bronze			2022-12-24	WOS:A1991EU02000021
J	JORDAN, TJ; LEWIT, EM; MONTGOMERY, RL; REICHMAN, LB				JORDAN, TJ; LEWIT, EM; MONTGOMERY, RL; REICHMAN, LB			ISONIAZID AS PREVENTIVE THERAPY IN HIV-INFECTED INTRAVENOUS DRUG-ABUSERS - A DECISION-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; AGE THRESHOLD; TUBERCULOSIS; RISK; CHEMOTHERAPY; FLORIDA; LEAVE; AIDS	Tuberculin skin testing is a notoriously poor marker of tuberculosis infection in patients who are serologically positive for the human immunodeficiency virus. A decision analysis was performed to determine if and when isoniazid should be prescribed to prevent tuberculosis in these patients. The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied. The assumptions and parameter estimates selected for this investigation represent a highly conservative vantage point opposing the use of isoniazid as a preventive therapy. Nevertheless, results showed a benefit from the use of isoniazid as a preventive therapy for all groups, even without tuberculin testing, except tuberculin-negative black women. This benefit of isoniazid therapy increased patient life expectancy as much as 285 days. Further, the decisions continue to favor prescribing isoniazid even when the suspected incidence of tuberculosis infection falls as low as 3% to 8%. Tuberculin testing appears important primarily for black women, since those who have negative tuberculin skin tests may not be candidates for isoniazid therapy.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DIV PULM MED,150 BERGEN ST,I-354,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DIV INFORMAT,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MED,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [1-K07-HL-02095-04, 1-HR-76032A] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR076032] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Thoracic Society, 1981, AM REV RESPIR DIS, V124, P356; BROWN LS, 1989, JAMA-J AM MED ASSOC, V262, P615; BRUDNEY D, 1989, 5TH INT C AIDS MONTR; CANESSA PA, 1989, CHEST, V96, P1215, DOI 10.1378/chest.96.5.1215; CHIASSON RE, 1987, AM REV RESPIR DIS, V136, P570; DIPERRI G, 1989, LANCET, V2, P1502; FREBEE SH, 1970, ADV TUBERC RES, V17, P28; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; MARKOWITZ N, 1990, AM REV RESPIR DIS, V141, P617; MEDLEY GF, 1988, PROC R SOC SER B-BIO, V233, P367, DOI 10.1098/rspb.1988.0026; MEHTA JB, 1988, CHEST, V94, P138, DOI 10.1378/chest.94.1.138; MOULDING TS, 1989, AM REV RESPIR DIS, V140, P700, DOI 10.1164/ajrccm/140.3.700; MURRAY JF, 1990, AM REV RESPIR DIS, V141, P1356, DOI 10.1164/ajrccm/141.5_Pt_1.1356; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1986, NEW ENGL J MED, V314, P447; REICHMAN LB, 1979, ARCH INTERN MED, V139, P337, DOI 10.1001/archinte.139.3.337; REICHMAN LB, 1987, JAMA-J AM MED ASSOC, V257, P1728, DOI 10.1001/jama.1987.03390130046012; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; SNIDER DE, 1988, AM REV RESPIR DIS, V137, P2, DOI 10.1164/ajrccm/137.1.2; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; SUNDERAM G, 1987, AM REV RESPIR DIS, V136, P1475, DOI 10.1164/ajrccm/136.6.1475; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; THEUER CP, 1989, WESTERN J MED, V150, P700; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; 1989, MMWR S3, V38, P1; 1909, MMWR, V38, P236; 1989, MMWR, V38, P243; 1990, MMWR, V39, P645; [No title captured]; 1990, MMWR, V39, P638	38	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2987	2991		10.1001/jama.265.22.2987	http://dx.doi.org/10.1001/jama.265.22.2987			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP635	2033771				2022-12-24	WOS:A1991FP63500037
J	COWAN, DN; BRUNDAGE, JF; POMERANTZ, RS; MILLER, RN; BURKE, DS				COWAN, DN; BRUNDAGE, JF; POMERANTZ, RS; MILLER, RN; BURKE, DS			HIV-INFECTION AMONG MEMBERS OF THE UNITED-STATES-ARMY RESERVE COMPONENTS WITH MEDICAL AND HEALTH OCCUPATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARITAL-STATUS; CANCER; RISK; MEN; AIDS; PREVALENCE	Over 58 000 members of the US Army Reserve Components tested for human immunodeficiency virus (HIV) antibody had military or civilian medical occupations. The availability of HIV status and occupational information permits the assessment of prevalence and incidence of infection in this population. Levels of infection were not higher among women or among currently married men with medical occupations compared with those with nonmedical occupations. Prevalence and incidence were elevated among never-married men with either military or civilian medical occupations compared with never-married men with nonmedical occupations. Based on reported civilian occupation, male registered nurses and men with other medical occupations, excluding physicians and dentists, had a significantly higher prevalence of infection than men with nonmedical occupations. The patterns of infection suggest that the higher levels of infection found among never-married men with medical occupations may not be entirely due to occupational exposure. These findings may have applications in the design and interpretation of results of health care worker HIV surveillance programs.	WALTER REED ARMY MED CTR,DIV RETROVIROL,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DIV PREVENT MED,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	COWAN, DN (corresponding author), SRA TECHNOL INC,4700 KING ST,SUITE 300,ALEXANDRIA,VA 22302, USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BEEKMANN SE, 1990, INFECT CONT HOSP EP, V11, P371; BERNSTEIN L, 1989, CANCER RES, V49, P466; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BLAND RC, 1988, ACTA PSYCHIAT SCAND, V77, P24, DOI 10.1111/j.1600-0447.1988.tb08544.x; BURKE DS, 1987, NEW ENGL J MED, V317, P132; CHAMBERLAND M, 1990, 6TYH INT C AIDS SAN; COWAN DN, 1990, J INFECT DIS, V162, P827, DOI 10.1093/infdis/162.4.827; FAY RE, 1989, SCIENCE, V243, P338, DOI 10.1126/science.2911744; GAGNON JH, 1989, AIDS SEXUAL DEHAVIOR, P102; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GUENEL P, 1990, BRIT J IND MED, V47, P473; HARRY J, 1990, J HOMOSEXUAL, V19, P89, DOI 10.1300/J082v19n01_05; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KATO I, 1989, JPN J CANCER RES, V80, P306, DOI 10.1111/j.1349-7006.1989.tb02311.x; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; LEMESHOW S, 1984, AM J EPIDEMIOL, V119, P147, DOI 10.1093/oxfordjournals.aje.a113732; MCKUSICK L, 1985, PUBLIC HEALTH REP, V100, P622; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NUTTER RD, 1990, SOC SCI MED, V30, P83, DOI 10.1016/0277-9536(90)90331-L; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; WELLS JA, 1990, 6TH INT C AIDS SAN F; 1988, JAMA-J AM MED ASSOC, V259, P2817; 1990, RCS DDRAM11471148 PU; 1977, DICT OCCUPATIONAL TI	25	19	20	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2826	2830		10.1001/jama.265.21.2826	http://dx.doi.org/10.1001/jama.265.21.2826			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN855	2033739				2022-12-24	WOS:A1991FN85500031
J	CROSS, FR; TINKELENBERG, AH				CROSS, FR; TINKELENBERG, AH			A POTENTIAL POSITIVE FEEDBACK LOOP CONTROLLING CLN1 AND CLN2 GENE-EXPRESSION AT THE START OF THE YEAST-CELL CYCLE	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; MATING-PHEROMONE; FISSION YEAST; DIVISION; CONJUGATION; MITOSIS; ARREST	The CLN1, CLN2, and CLN3 genes of S. cerevisiae form a redundant family essential for the G1-to-S phase transition. CLN1 and CLN2 mRNAs were previously shown to be negatively regulated by mating pheromone and by cell cycle progression out of G1, whereas CLN3 mRNA is not. The CLN3-2 (DAF1-1) allele prevents both cell cycle arrest and the turnoff of CLN1 and CLN2 mRNAs in response to mating pheromone, but only in the presence of an active CDC28 gene. An internally deleted nonfunctional cln2 gene was used as a reporter gene to demonstrate that in the absence of mating pheromone, efficient expression of cln2 mRNA requires both an active CDC28 gene and at least one functional CLN gene. mRNA from a nonfunctional cln1 gene was regulated similarly. Thus, CLN function and CDC28 activity jointly stimulate CLN1 and CLN2 mRNA levels, potentially forming a positive feedback loop for CLN1 and CLN2 expression.			CROSS, FR (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; CARTER BLA, 1980, GENETICS, V96, P561; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, 1989, J CELL SCI S12, V94, P117; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; SHERMAN F, 1989, METHODS YEAST GENETI; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	37	297	299	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					875	883		10.1016/0092-8674(91)90394-E	http://dx.doi.org/10.1016/0092-8674(91)90394-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040016				2022-12-24	WOS:A1991FP51600017
J	MAHADEVAN, LC; WILLIS, AC; BARRATT, MJ				MAHADEVAN, LC; WILLIS, AC; BARRATT, MJ			RAPID HISTONE H3 PHOSPHORYLATION IN RESPONSE TO GROWTH-FACTORS, PHORBOL ESTERS, OKADAIC ACID, AND PROTEIN-SYNTHESIS INHIBITORS	CELL			English	Article							SWISS 3T3 CELLS; C-FOS; KINASE-C; CHROMATIN STRUCTURE; MOUSE FIBROBLASTS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME STRUCTURE; CELLULAR-REGULATION; REVERSIBLE CHANGES	When quiescent cells are stimulated with growth factors, phorbol esters, okadaic acid, or protein synthesis inhibitors, the early-response genes, which include c-fos and c-jun, are rapidly induced. The earliest growth factor- and phorbol ester-stimulated nuclear signaling events concomitant with proto-oncogene induction are the rapid phosphorylation of two chromatin-associated proteins, pp33 and pp15. We show here that the tumor promoter okadaic acid, which inhibits protein phosphatases 1 and 2A, and the protein synthesis inhibitors anisomycin and cycloheximide also stimulate pp33 and pp15 phosphorylation. Using transcriptional inhibitors, we show that this response is not a consequence of early gene induction. By peptide mapping and microsequencing, chromatin-associated pp15 is identified as histone H3. Upon stimulation, histone H3 is rapidly phosphorylated on serine residues within its highly charged, basic N-terminal domain. Thus, these diverse agents elicit a common early nuclear signal modulating nucleosomal structure or function, potentially contributing to conformational regulation of proto-oncogene induction.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford								ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL HA, 1990, IN PRESS CELLULAR RE; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Dixon G. H., 1975, CIBA F S, V28, P229; FALK MM, 1990, J VIROL, V64, P748, DOI 10.1128/JVI.64.2.748-756.1990; FENG JL, 1990, MOL CELL BIOL, V10, P1126, DOI 10.1128/MCB.10.3.1126; GLOTOV BO, 1978, FEBS LETT, V91, P149, DOI 10.1016/0014-5793(78)80037-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HARDISON RC, 1977, CELL, V12, P417, DOI 10.1016/0092-8674(77)90118-0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; JONES SD, 1988, COLD SPRING HARB SYM, V53, P531, DOI 10.1101/SQB.1988.053.01.061; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIM RW, 1987, ONCOGENE, V1, P263; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MAHADEVAN LC, 1989, ONCOGENE, V4, P699; MAHADEVAN LC, 1988, ONCOGENE, V2, P249; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MAHADEVAN LC, 1990, RECEPTOR EFFECTOR CO, P181; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAZEN A, 1987, J MOL BIOL, V194, P741, DOI 10.1016/0022-2836(87)90251-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAPINSKI BR, 1986, NATURE, V321, P81; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PYRWES R, 1988, P NATL ACAD SCI USA, V85, P7206; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P935; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VACQUIER VD, 1989, DEV BIOL, V133, P111, DOI 10.1016/0012-1606(89)90302-3; VAZQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V130, P513; WELLS D, 1989, NUCLEIC ACIDS RES, V17, pR311, DOI 10.1093/nar/17.suppl.r311; WHITLOCK JP, 1983, J BIOL CHEM, V258, P1299; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	60	388	402	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					775	783		10.1016/0092-8674(91)90385-C	http://dx.doi.org/10.1016/0092-8674(91)90385-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040014				2022-12-24	WOS:A1991FP51600008
J	LUESCHER, IF; ROMERO, P; CEROTTINI, JC; MARYANSKI, JL				LUESCHER, IF; ROMERO, P; CEROTTINI, JC; MARYANSKI, JL			SPECIFIC BINDING OF ANTIGENIC PEPTIDES TO CELL-ASSOCIATED MHC CLASS-I MOLECULES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOLYTIC T-CELLS; IMMUNOGENIC PEPTIDES; RECOGNITION; HLA; CAPACITY; GENE	T LYMPHOCYTES recognize antigen in the form of peptides that associate with specific alleles of class I or class II major histocompatibility (MHC) molecules 1,2. By contrast with the clear MHC allele-specific binding of peptides to purified class II molecules 3-6 purified solubilized class I molecules either bind relatively poorly 7 or show degenerate specificity 8-11. Using photoaffinity labelling, we demonstrate here the specific interaction of peptides with cell-associated MHC class I molecules and show that this involves metabolically active processes.			LUESCHER, IF (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.		Maryanski, Janet/G-3161-2013					BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAYLEY H, 1984, AZIDES NITRENES REAC, P434; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LUESCHER IF, 1988, P NATL ACAD SCI USA, V85, P871, DOI 10.1073/pnas.85.3.871; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1987, NATURE, V330, P660, DOI 10.1038/330660a0; MARYANSKI JL, 1986, J IMMUNOL, V136, P4340; MARYANSKI JL, 1988, J EXP MED, V167, P1391, DOI 10.1084/jem.167.4.1391; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PALA P, 1988, J IMMUNOL, V141, P2289; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; Schwartz R H, 1986, Adv Immunol, V38, P31, DOI 10.1016/S0065-2776(08)60006-1; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213	32	60	75	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					72	74		10.1038/351072a0	http://dx.doi.org/10.1038/351072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027386				2022-12-24	WOS:A1991FK19300063
J	CUMMINS, D; HEUSCHKEL, R; DAVIES, SC				CUMMINS, D; HEUSCHKEL, R; DAVIES, SC			PENICILLIN PROPHYLAXIS IN CHILDREN WITH SICKLE-CELL DISEASE IN BRENT	BRITISH MEDICAL JOURNAL			English	Article							ORAL PENICILLIN; ANEMIA; INFECTION	Objective-To assess compliance with oral penicillin prophylaxis in children with sickle cell disease and identify possible reasons for poor compliance. Design-Closed questionnaires given to parents of children with sickle cell disease and general practitioners in Brent. Urine samples from 23 children were tested for penicillin. Setting-Paediatric haematology clinic, Central Middlesex Hospital, and general practices in Brent. Subjects-50 children (aged less-than-or-equal-to 16) attending clinic with sickle cell disease over six months (33 HbSS, 12 HbSC, five HbS beta-thalassaemia). 30 general practitioners: 15 with the greatest number of patients with sickle cell disease on the Brent register; 15 selected randomly from family practitioner committee's list. Main outcome measures-Reported compliance with and awareness of importance of penicillin prophylaxis. Results of urine tests for penicillin. Results-31 parents claimed that their children received penicillin every day and 19 that they received it most days (greater-than-or-equal-to 5 days a week). Penicillin was detected in only 10 of 23 urine samples tested. Parents and doctors seemed not to appreciate the importance of treatment: only eight parents were aware of the risk of death if penicillin were discontinued, and 16 doctors were unaware that regular penicillin prophylaxis prevents pneumococcal septicaemia and death in these children. Conclusions-Education for families with children with sickle cell disease must be improved. Specialised information and training are needed for doctors working in areas with a high prevalence of the disorder.	CENT MIDDLESEX HOSP,DEPT HAEMATOL,LONDON NW10 7NS,ENGLAND	Imperial College London								BARRETTCONNOR E, 1971, MEDICINE, V50, P97, DOI 10.1097/00005792-197103000-00002; BROWN AK, 1989, PEDIATRICS, V83, P897; BROZOVIC M, 1984, J CLIN PATHOL, V37, P1321, DOI 10.1136/jcp.37.12.1321; BUCHANAN GR, 1982, PEDIATRICS, V70, P926; FRANKLIN IM, 1988, BRIT MED J, V296, P592, DOI 10.1136/bmj.296.6622.592; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GORDIS L, 1969, J PEDIATR-US, V75, P957, DOI 10.1016/S0022-3476(69)80332-X; GORDIS L, 1969, PEDIATRICS, V43, P173; Grove D.C., 1955, ASSAY METHODS ANTIBI, P14; JOHN AB, 1984, BRIT MED J, V288, P1567, DOI 10.1136/bmj.288.6430.1567; MILNE RIG, 1990, BRIT MED J, V300, P371, DOI 10.1136/bmj.300.6721.371; POWARS D, 1987, AM J DIS CHILD, V141, P250, DOI 10.1001/archpedi.1987.04460030028017; Prashar Usha, 1985, SICKLE CELL ANAEMIA; ROBINSON MG, 1966, NEW ENGL J MED, V274, P1006, DOI 10.1056/NEJM196605052741806; ROWLEY PT, 1978, NEW YORK STATE J MED, V78, P42; 1986, LANCET, V2, P1432	16	35	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					989	990		10.1136/bmj.302.6783.989	http://dx.doi.org/10.1136/bmj.302.6783.989			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039895	Bronze, Green Published			2022-12-24	WOS:A1991FJ50800016
J	ZAHLER, AM; WILLIAMSON, JR; CECH, TR; PRESCOTT, DM				ZAHLER, AM; WILLIAMSON, JR; CECH, TR; PRESCOTT, DM			INHIBITION OF TELOMERASE BY G-QUARTET DNA STRUCTURES	NATURE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; TETRAHYMENA; RIBONUCLEOPROTEIN; OXYTRICHA; REPEATS; ENZYME; MODEL	THE ends or telomeres of the linear chromosomes of eukaryotes are composed of tandem repeats of short DNA sequences, one strand being rich in guanine (G strand) and the complementary strand in cytosine 1,2. Telomere synthesis involves the addition of telomeric repeats to the G strand by telomere terminal transferase (telomerase) 3-6. Telomeric G-strand DNAs from a variety of organisms adopt compact structures 7, the most stable of which is explained by the formation of G-quartets 8,9. Here we investigate the capacity of the different folded forms of telomeric DNA to serve as primers for the Oxytricha nova telomerase in vitro. Formation of the K+-stabilized G-quartet structure in a primer inhibits its use by telomerase. Furthermore, the octanucleotide T4G4, which does not fold, is a better primer than (T4G4)2, which can form a foldback structure 7-10. We conclude that telomerase does not require any folding of its DNA primer. Folding of telomeric DNA into G-quartet structures seems to influence the extent of telomere elongation in vitro and might therefore act as a negative regulator of elongation in vivo.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder			Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X; Zahler, Alan/0000-0003-0027-1647				BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; Klobutcher L.A., 1986, P111; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAHLER AM, 1990, THESIS U COLORADO; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	21	1001	1049	6	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					718	720		10.1038/350718a0	http://dx.doi.org/10.1038/350718a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023635				2022-12-24	WOS:A1991FJ13000064
J	CERVERA, R; RAMIREZ, G; FERNANDEZSOLA, J; DCRUZ, D; CASADEMONT, J; GRAU, JM; ASHERSON, RA; KHAMASHTA, MA; URBANOMARQUEZ, A; HUGHES, GRV				CERVERA, R; RAMIREZ, G; FERNANDEZSOLA, J; DCRUZ, D; CASADEMONT, J; GRAU, JM; ASHERSON, RA; KHAMASHTA, MA; URBANOMARQUEZ, A; HUGHES, GRV			ANTIBODIES TO ENDOTHELIAL-CELLS IN DERMATOMYOSITIS - ASSOCIATION WITH INTERSTITIAL LUNG-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									ST THOMAS HOSP,RAYNE INST,LUPUS ARTHRIT RES UNIT,LONDON SE1 7EH,ENGLAND; HOSP CLIN BARCELONA,DEPT INTERNAL MED,MUSCLE RES UNIT,BARCELONA,SPAIN	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Barcelona; Hospital Clinic de Barcelona			Casademont, Jordi/A-6828-2010; SOLA, JOAQUIM FERNANDEZ/K-3991-2019; Casademont, Jordi/GPK-8669-2022	Casademont, Jordi/0000-0002-8100-1827; SOLA, JOAQUIM FERNANDEZ/0000-0002-3218-0582; Casademont, Jordi/0000-0002-8100-1827				ARSURA EL, 1988, SEMIN ARTHRITIS RHEU, V18, P29, DOI 10.1016/0049-0172(88)90032-7; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; ROSENBAUM J, 1988, CLIN EXP IMMUNOL, V72, P450	5	49	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					880	881		10.1136/bmj.302.6781.880-a	http://dx.doi.org/10.1136/bmj.302.6781.880-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025728	Bronze, Green Published			2022-12-24	WOS:A1991FG42100023
J	LIPSHULTZ, SE; COLAN, SD; GELBER, RD; PEREZATAYDE, AR; SALLAN, SE; SANDERS, SP				LIPSHULTZ, SE; COLAN, SD; GELBER, RD; PEREZATAYDE, AR; SALLAN, SE; SANDERS, SP			LATE CARDIAC EFFECTS OF DOXORUBICIN THERAPY FOR ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTHRACYCLINE CARDIOTOXICITY; INTENSIVE ASPARAGINASE; BICYCLE EXERCISE; CHILDREN; ADRIAMYCIN; GROWTH; INDUCTION; TREADMILL; FAILURE; HEART	Background. Cardiotoxicity is a recognized complication of doxorubicin therapy, but the long-term effects of doxorubicin are not well documented. We therefore-assessed the cardiac status of 115 children who had been treated for acute lymphoblastic leukemia with doxorubicin 1 to 15 years earlier in whom the disease was in continuous remission. Methods. Eighteen patients received one dose of doxorubicin (45 mg per square meter of body-surface area), and 97 received multiple doses totaling 228 to 550 mg per square meter (median, 360). The median interval between the end of treatment and the cardiac evaluation was 6.4 years. Our evaluation consisted of a history, 24-hour ambulatory electrocardiographic recording, exercise testing, and echocardiography. Results. Fifty-seven percent of the patients had abnormalities of left ventricular afterload (measured as end-systolic wall stress) or contractility (measured as the stress-velocity index). The cumulative dose of doxorubicin was the most significant predictor of abnormal cardiac function (P < 0.002). Seventeen percent of patients who received one dose of doxorubicin had slightly elevated-age-adjusted afterload, and none had decreased contractility. In contrast, 65 percent of patients who received at least 228 mg of doxorubicin per square meter had increased afterload (59 percent of patients), decreased contractility (23 percent), or both. Increased afterload was due to reduced ventricular wall thickness, not to hypertension or ventricular dilatation. In multivariate analyses restricted to patients who received at least 228 mg of doxorubicin per square meter, the only significant predictive factors were a higher cumulative dose (P = 0.01), which predicted decreased contractility, and an age of less than four years at treatment (P = 0.003), which predicted increased afterload. Afterload increased progressively in 24 of 34 patients evaluated serially (71 percent). Reported symptoms correlated poorly with indexes of exercise tolerance or ventricular function. Eleven patients had congestive heart failure within one year of treatment with doxorubicin; five of them had recurrent heart failure 3.7 to 10.3 years after completing doxorubicin treatment, and two required heart transplantation. No patient had late heart failure as a new event. Conclusions. Doxorubicin therapy in childhood impairs myocardial growth in a dose-related fashion and results in a progressive increase in left ventricular afterload, sometimes accompanied by reduced contractility. We hypothesize that the loss of myocytes during doxorubicin therapy in childhood might result in inadequate left ventricular mass and clinically important heart disease in later years.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NATIONAL CANCER INSTITUTE [P01CA034183, P30CA006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001816] Funding Source: NIH RePORTER; NCI NIH HHS [CA06516, CA34183] Funding Source: Medline; NHLBI NIH HHS [HL01816] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOROW KM, 1985, CIRCULATION, V72, P515, DOI 10.1161/01.CIR.72.3.515; BRISTOW MR, 1978, AM J MED, V65, P823, DOI 10.1016/0002-9343(78)90802-1; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; BRUCE R A, 1963, Pediatrics, V32, P742; CAULFIELD JB, 1988, AM J PATHOL, V133, P298; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; CLUBB FJ, 1987, LAB INVEST, V56, P189; CLUBB FJ, 1984, LAB INVEST, V50, P571; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; Cox DR., 1989, ANAL BINARY DATA; CUMMING GR, 1978, AM J CARDIOL, V41, P69, DOI 10.1016/0002-9149(78)90134-0; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; FURMAN L, 1976, Medical and Pediatric Oncology, V2, P157, DOI 10.1002/mpo.2950020205; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; HAUSDORF G, 1988, BRIT HEART J, V60, P309; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; JAMES FW, 1980, CIRCULATION, V61, P902, DOI 10.1161/01.CIR.61.5.902; KANTROWITZ NE, 1984, PROG CARDIOVASC DIS, V27, P195, DOI 10.1016/0033-0620(84)90004-5; KOH E, 1988, PEDIATR HEMAT ONCOL, V5, P245, DOI 10.3109/08880018809031275; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEWIS AB, 1978, MED PEDIATR ONCOL, V5, P167, DOI 10.1002/mpo.2950050123; LIPSHULTZ SE, 1990, PEDIATR RES, V27, pA145; LIPSHULTZ SE, 1989, AM J CARDIOL, V64, P416; LIPSHULTZ SE, 1989, PEDIATR RES S, V25, pA53; LIPSHULTZ SE, 1987, BLOOD, V70, pA234; LOWN B, 1977, AM J CARDIOL, V39, P910, DOI 10.1016/S0002-9149(77)80046-5; NAG AC, 1980, CYTOBIOS, V28, P41; Riehm H, 1990, Haematol Blood Transfus, V33, P439; SALLAN SE, 1978, BLOOD, V51, P425; SALLAN SE, 1983, CANCER RES, V43, P5601; SALLAN SE, 1989, BLOOD S, V74, pA79; SALLAN SE, 1984, LEUKAMIEBEHANDLUNG K, P35; STEINHERZ LJ, 1988, AM J CARDIOL, V62, P505; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WETHERBEE JN, 1988, J AM COLL CARDIOL, V11, P330, DOI 10.1016/0735-1097(88)90098-8; ZAK R, 1974, CIRC RES, V35, P17	37	1095	1113	1	45	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					808	815		10.1056/NEJM199103213241205	http://dx.doi.org/10.1056/NEJM199103213241205			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997853	Bronze			2022-12-24	WOS:A1991FC44200005
J	STEWART, DJ; LEVY, RD; CERNACEK, P; LANGLEBEN, D				STEWART, DJ; LEVY, RD; CERNACEK, P; LANGLEBEN, D			INCREASED PLASMA ENDOTHELIN-1 IN PULMONARY-HYPERTENSION - MARKER OR MEDIATOR OF DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							RELAXING FACTOR; RELEASE; CELLS; SHOCK	Objective: To explore the role of endothelin-1, a potent endothelial-derived vasoconstrictor peptide, in pulmonary hypertension, by measuring its concentration in arterial and venous plasma. Design: A survey, case series study. Setting: University-affiliated hospitals and outpatient clinics. Patients: Twenty-seven patients with pulmonary hypertension: 7 with primary, and 20 with secondary pulmonary hypertension of various causes. The control groups (n = 16) comprised 8 healthy volunteers and 8 patients with coronary artery disease but without evidence of pulmonary hypertension. Measurements and Main Results: Pulmonary artery pressure was markedly increased (94/43 +/- 23/13 mm Hg) in the patients with pulmonary hypertension. Venous plasma immunoreactive endothelin-1, measured by a specific radioimmunoassay, was significantly higher in patients with pulmonary hypertension (3.5 +/- 2.5 pg/mL, P < 0.001) than in normal subjects (1.45 +/- 0.45 pg/mL), or patients with coronary disease (0.75 +/- 0.64 pg/mL). The arterial-to-venous ratio of immunoreactive endothelin-1 was significantly greater than unity in primary pulmonary hypertension (2.21 +/- 0.72, P = 0.01), whereas the patients with secondary pulmonary hypertension had a mean ratio not different from 1 (0.97 +/- 0.42). In contrast, the mean arterial-to-venous ratios were significantly less than unity in both control groups (0.59 +/- 0.35, and 0.54 +/- 0.64; P < 0.02, for normal subjects and coronary disease patients, respectively), indicating a possible clearance of endothelin-1 across the healthy lung. Conclusions: Patients with pulmonary hypertension have substantial alterations in plasma immunoreactive endothelin-1, which may reflect changes in net release or clearance of endothelin-1 by the lung. In patients with primary pulmonary hypertension, the high levels in arterial compared with venous plasma suggest pulmonary production of endothelin-1, which may contribute to elevated pulmonary vascular resistance.	SIR MORTIMER B DAVIS JEWISH HOSP, MONTREAL H3T 1E2, QUEBEC, CANADA	McGill University	STEWART, DJ (corresponding author), ROYAL VICTORIA HOSP, DIV CARDIOL, ROOM M476, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA.		Langleben, David/AAJ-9152-2020					ANGGARD E, 1989, J CARDIOVASC PHARM, V13, pS46; BRAQUET P, 1989, J CARDIOVASC PHARM, V13, pS143, DOI 10.1097/00005344-198900135-00036; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DINH XUAN AT, 1989, EUR RESPIR J, V2, P409; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; Dubin D, 1989, J VASC MED BIOL, V1, P150; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HEATH D, 1987, BRIT HEART J, V58, P204; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HILEY CR, 1989, J CARDIOVASC PHARM, V13, pS197, DOI 10.1097/00005344-198900135-00055; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; LIPPTON HL, 1989, J APPL PHYSIOL, V66, P1008, DOI 10.1152/jappl.1989.66.2.1008; Meyrick B, 1989, Prog Clin Biol Res, V308, P91; MONCADA S, 1978, PHARMACOL REV, V30, P293; MOON DG, 1989, P NATL ACAD SCI USA, V86, P9529, DOI 10.1073/pnas.86.23.9529; MOREL DR, 1989, EUR J PHARMACOL, V167, P427, DOI 10.1016/0014-2999(89)90454-8; NEWMAN JH, 1989, J AM COLL CARDIOL, V14, P551, DOI 10.1016/0735-1097(89)90091-0; NICOD P, 1989, CIRCULATION, V80, P1486, DOI 10.1161/01.CIR.80.5.1486; OHTSUKA M, 1989, American Review of Respiratory Disease, V139, pA51; PERNOW J, 1989, ACTA PHYSIOL SCAND, V137, P317, DOI 10.1111/j.1748-1716.1989.tb08756.x; RAE GA, 1989, J CARDIOVASC PHARM, V13, pS89, DOI 10.1097/00005344-198900135-00022; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RIMAR S, 1989, CIRCULATION S2, V80, P213; RYAN US, 1989, J CARDIOVASC PHARM, V13, pS57, DOI 10.1097/00005344-198900135-00014; RYAN US, 1987, PULMONARY ENDOTHELIU, P3; SIRVIO ML, 1990, BIOCHEM BIOPH RES CO, V167, P1191, DOI 10.1016/0006-291X(90)90649-8; STELZNER TJ, 1990, FASEB J, V4, pA1147; STEWART DJ, 1990, CARDIOVASC RES, V24, P7, DOI 10.1093/cvr/24.1.7; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V161, P1220, DOI 10.1016/0006-291X(89)91372-7; VIERHAPPER H, 1990, CIRCULATION, V81, P1415, DOI 10.1161/01.CIR.81.4.1415; VOELKEL NF, 1989, PULMONARY VASCULAR P, P513; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WOOD P, 1958, BRIT HEART J, V20, P557; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	40	843	889	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					464	469		10.7326/0003-4819-114-6-464	http://dx.doi.org/10.7326/0003-4819-114-6-464			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994793				2022-12-24	WOS:A1991FB64000006
J	SCHNORR, TM; GRAJEWSKI, BA; HORNUNG, RW; THUN, MJ; EGELAND, GM; MURRAY, WE; CONOVER, DL; HALPERIN, WE				SCHNORR, TM; GRAJEWSKI, BA; HORNUNG, RW; THUN, MJ; EGELAND, GM; MURRAY, WE; CONOVER, DL; HALPERIN, WE			VIDEO DISPLAY TERMINALS AND THE RISK OF SPONTANEOUS-ABORTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINNISH CASE-REFERENT; BIRTH-DEFECTS; PREGNANCY; WORK; EXPOSURE; SCREENS	Background. The relation between spontaneous abortion and the use of video display terminals (VDTs) is of great public health concern. Previous investigators of this issue have reported inconsistent findings. Methods. To determine whether electromagnetic fields emitted by VDTs are associated with an increased risk of spontaneous abortion, a cohort of female telephone operators who used VDTs at work was compared with a cohort of operators who did not use VDTs. To obtain reliable estimates of exposure, we determined the number of hours of VDT use per week from company records and measured electromagnetic fields at VDT workstations and, for purposes of comparison, at workstations without VDTs. Operators who used VDTs had higher abdominal exposure to very-low-frequency (15 kHz) electromagnetic fields (workstations without VDTs did not emit very-low-frequency energy). Abdominal exposure to extremely-low-frequency fields (45 to 60 Hz) was similar for both operators who used VDTs and those who did not. Among 2430 women interviewed, there were 882 pregnancies that met our criteria for inclusion in the study. Results. We found no excess risk of spontaneous abortion among women who used VDTs during the first trimester of pregnancy (odds ratio = 0.93; 95 percent confidence interval, 0.63 to 1.38), and no dose-response relation was apparent when we examined the women's hours of VDT use per week (odds ratio for 1 to 25 hours per week = 1.04; 95 percent confidence interval, 0.61 to 1.79; odds ratio for >25 hours per week = 1.00; 95 percent confidence interval, 0.61 to 1.64). There continued to be no risk associated with the use of VDTs when we accounted for multiple pregnancies, conducted separate analyses of early abortion, late abortion, and all fetal losses, or limited our analyses to spontaneous abortions for which a physician was consulted. Conclusions. The use of VDTs and exposure to the accompanying electromagnetic fields were not associated with an increased risk of spontaneous abortion in this study.	AMER CANC SOC,ATLANTA,GA	American Cancer Society	SCHNORR, TM (corresponding author), NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,CINCINNATI,OH 45226, USA.							BARNES FS, 1985, JUN ANN M BIOEL SOC; Bergquist U.O., 1984, SCAND J WORK ENV S2, V10, P62; Bowman JD, 1988, APPL IND HYG, V3, P189; BRANDT LPA, 1990, SCAND J WORK ENV HEA, V16, P329, DOI 10.5271/sjweh.1776; BRYANT HE, 1989, INT J EPIDEMIOL, V18, P132, DOI 10.1093/ije/18.1.132; ERICSON A, 1986, AM J IND MED, V9, P459, DOI 10.1002/ajim.4700090507; ERICSON A, 1986, AM J IND MED, V9, P447, DOI 10.1002/ajim.4700090506; GOLDHABER MK, 1988, AM J IND MED, V13, P695, DOI 10.1002/ajim.4700130608; GUY AW, 1987, MEASUREMENT ANAL ELE; GUY AW, 1987, WORK DISPLAY UNITS 8, P69; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; HARRELL FE, 1986, LOGIST PROCEDURE SUG; KLINE J, 1980, LANCET, V2, P176, DOI 10.1016/S0140-6736(80)90062-8; Kline J, 1989, MONOGRAPHS EPIDEMIOL, V14; KURPPA K, 1985, SCAND J WORK ENV HEA, V11, P353, DOI 10.5271/sjweh.2213; MCDONALD AD, 1988, BRIT J IND MED, V45, P509; NIELSEN CV, 1990, SCAND J WORK ENV HEA, V16, P323, DOI 10.5271/sjweh.1777; NURMINEN T, 1988, SCAND J WORK ENV HEA, V14, P293, DOI 10.5271/sjweh.1917; POTTER JD, 1980, SURG GYNECOL OBSTET, V150, P251; SCHNORR TM, 1991, INVSTIGATION SPONTAN; SCHNORR TM, 1985, CURRENT CONCEPTS, V8; STUCHLY MA, 1983, HEALTH PHYS, V45, P713, DOI 10.1097/00004032-198309000-00013; TELL R, 1990, PB91130500; TELL RA, 1983, BIOL EFFECTS DOSIMET, P95; WERTHEIMER N, 1986, BIOELECTROMAGNETICS, V7, P13, DOI 10.1002/bem.2250070103; WERTHEIMER N, 1989, AM J EPIDEMIOL, V129, P220, DOI 10.1093/oxfordjournals.aje.a115112; WESTERHOLM P, 1987, WORK DISPLAY UNITS 8, P104; WINDHAM GC, 1990, AM J IND MED, V18, P675, DOI 10.1002/ajim.4700180606; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1983, DHHS NIOSH833291498; 1984, DHHS NIOSH842971609; 1984, 84191 NAT I OCC SAF	32	107	106	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					727	733		10.1056/NEJM199103143241104	http://dx.doi.org/10.1056/NEJM199103143241104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997838				2022-12-24	WOS:A1991FB55600004
J	DIXON, JM; ELTON, RA; RAINEY, JB; MACLEOD, DAD				DIXON, JM; ELTON, RA; RAINEY, JB; MACLEOD, DAD			RECTAL EXAMINATION IN PATIENTS WITH PAIN IN THE RIGHT LOWER QUADRANT OF THE ABDOMEN	BRITISH MEDICAL JOURNAL			English	Article							APPENDICITIS	Objective-To determine whether rectal examination provides any diagnostic information in patients admitted to hospital with pain in the right lower quadrant of the abdomen. Design-Casualty officer or surgical registrar recorded symptoms and signs on admission on detailed forms. Final diagnosis was noted on discharge from hospital. Setting-District general hospital. Patients-1204 Consecutive patients admitted to hospital with pain in the right lower quadrant of the abdomen as their major complaint; 1028 had a rectal examination on admission. Main outcome measures-Odds ratio for each symptom and sign related to final diagnosis. Results of multiple logistic regression analysis for acute appendicitis. Results-Right sided rectal tenderness, present in 309 of those examined, was more common in patients with acute appendicitis (odds ratio 1.34, p < 0.05). This odds ratio was considerably less than that for other clinical signs-namely, tenderness in the right lower quadrant (odds ratio 5.09), rebound tenderness (3.34), guarding (3.07), and muscular rigidity in the abdomen (5.03). In the logistic regression analysis of patients with acute appendicitis, when allowance was made for the presence or absence of rebound tenderness, rectal tenderness on the right lost its significance. Six patients had masses palpable rectally, of which three were palpable on abdominal examination; the other three patients had acute appendicitis. No other unexpected diagnoses were established, and no useful additional diagnostic information was obtained by routine rectal examination. Conclusion-If patients presenting with pain in the right lower quadrant of the abdomen are tested for rebound tenderness then rectal examination does not give any further diagnostic information.	UNIV EDINBURGH,MED STAT UNIT,EDINBURGH,SCOTLAND; ST JOHNS HOSP HOWDEN,DEPT SURG,LIVINGSTON,W LOTHIAN,SCOTLAND	University of Edinburgh	DIXON, JM (corresponding author), UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							Armitage P., 1987, STATISTICAL METHODS, P386; BONNELLO JC, 1979, DIS COLON RECTUM, V22, P97; CAIN A, 1986, H BAILEYS DEMONSTRAT, P297; CONDON R, 1986, TXB SURG, P971; DICKSON AP, 1985, ARCH DIS CHILD, V60, P666, DOI 10.1136/adc.60.7.666; KAZARIAN KK, 1970, AM J SURG, V119, P681, DOI 10.1016/0002-9610(70)90239-4; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; Magee R B, 1967, Pa Med, V70, P47; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; NAUTA RJ, 1986, AM J SURG, V151, P746, DOI 10.1016/0002-9610(86)90057-7; OSLER W, 1901, PRINCIPLES PRACTICES, P525; SMITH PH, 1965, POSTGRAD MED J, V41, P2, DOI 10.1136/pgmj.41.471.2; TEICHER I, 1983, ANN SURG, V198, P753, DOI 10.1097/00000658-198312000-00014	13	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					386	388		10.1136/bmj.302.6773.386	http://dx.doi.org/10.1136/bmj.302.6773.386			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	2004144	Bronze, Green Published			2022-12-24	WOS:A1991EX85800027
J	GOTTFRIED, DS; STEFFEN, MA; BOXER, SG				GOTTFRIED, DS; STEFFEN, MA; BOXER, SG			LARGE PROTEIN-INDUCED DIPOLES FOR A SYMMETRICAL CAROTENOID IN A PHOTOSYNTHETIC ANTENNA COMPLEX	SCIENCE			English	Article							ELECTROCHROMIC ABSORBANCE CHANGES; RHODOPSEUDOMONAS-SPHAEROIDES; RHODOBACTER-SPHAEROIDES; ABSORPTION-SPECTRUM; REACTION CENTERS; ELECTRIC-FIELDS; DYE MOLECULES; LIPID LAYERS; STATE; MEMBRANES	Unusually large electric field effects have been measured for the absorption spectra of carotenoids (spheroidene) in the B800-850 light-harvesting complex from the photosynthetic bacterium Rhodobacter sphaeroides. Quantitative analysis shows that the difference in the permanent dipole moment between the ground state and excited states in this protein complex is substantially larger than for pure spheroidene extracted from the protein. The results demonstrate the presence of a large perturbation on the electronic structure of this nearly symmetric carotenoid due to the organized environment in the protein. This work also provides an explanation for the seemingly anomalous dependence of carotenoid band shifts on transmembrane potential and a generally useful approach for calibrating electric field-sensitive dyes that are widely used to probe potentials in biological systems.			GOTTFRIED, DS (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.			Boxer, Steven/0000-0001-9167-4286; Gottfried, David/0000-0002-2729-2504	NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JP, 1985, ANTENNAS REACTION CT, P82; BOXER SG, 1989, J PHYS CHEM-US, V93, P8280, DOI 10.1021/j100363a004; BRETON J, 1987, TOP PHOTOSYNTH, V8, P159; CHANCE B, 1955, NATURE, V175, P803, DOI 10.1038/175803b0; CHANCE BRITTON, 1958, BROOKHAVEN SYMPOSIA IN BIOL, V11, P74; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; COGDELL RJ, 1978, BIOCHIM BIOPHYS ACTA, V502, P409, DOI 10.1016/0005-2728(78)90074-9; COGDELL RJ, 1985, ANTENNAS REACTION CT, P85; CRIELAARD W, 1988, BIOCHIM BIOPHYS ACTA, V973, P505; DEGROOTH BG, 1977, BIOCHIM BIOPHYS ACTA, V462, P237, DOI 10.1016/0005-2728(77)90122-0; DEGROOTH BG, 1980, BIOCHIM BIOPHYS ACTA, V589, P299, DOI 10.1016/0005-2728(80)90046-8; EVANS MB, 1988, BIOCHIM BIOPHYS ACTA, V935, P292, DOI 10.1016/0005-2728(88)90224-1; Goodwin T. W., 1988, Plant pigments., P61; GOTTFRIED DS, UNPUB; HAYASHI H, 1989, PHOTOCHEM PHOTOBIOL, V49, P337, DOI 10.1111/j.1751-1097.1989.tb04116.x; JACKSON JB, 1969, FEBS LETT, V4, P185, DOI 10.1016/0014-5793(69)80230-9; JUNGE W, 1982, PHOTOSYNTHESIS ENERG, V1, P589; KAKITANI T, 1982, BIOPHYS J, V39, P57, DOI 10.1016/S0006-3495(82)84490-1; KRAMER HJM, 1984, BIOCHIM BIOPHYS ACTA, V765, P156, DOI 10.1016/0005-2728(84)90009-4; LIPTAY W, 1988, CHEM PHYS, V120, P439, DOI 10.1016/0301-0104(88)87230-6; LIPTAY W, 1974, EXCITED STATES, P129; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P2958; LOCKHART DJ, 1988, P NATL ACAD SCI USA, V85, P107, DOI 10.1073/pnas.85.1.107; LOCKHART DJ, 1987, BIOCHEMISTRY-US, V26, P664, DOI 10.1021/bi00377a001; LOCKHART DJ, UNPUB; MANTELE W, 1985, ANTENNAS REACTION CT, P88; MATHIES R, 1976, P NATL ACAD SCI USA, V73, P2169, DOI 10.1073/pnas.73.7.2169; MYERS AB, 1981, J AM CHEM SOC, V103, P1881, DOI 10.1021/ja00398a001; PONDER M, 1983, J PHYS CHEM-US, V87, P5090, DOI 10.1021/j150643a010; Rau W., 1988, PLANT PIGMENTS, P231; REICH R, 1972, BERICH BUNSEN GESELL, V76, P589; REICH R, 1976, BIOCHIM BIOPHYS ACTA, V449, P285, DOI 10.1016/0005-2728(76)90140-7; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; SYMONS M, 1977, BIOCHIM BIOPHYS ACTA, V462, P706, DOI 10.1016/0005-2728(77)90112-8; SYMONS M, 1983, BIOCHIM BIOPHYS ACTA, V723, P454, DOI 10.1016/0005-2728(83)90052-X; TRAUTMAN JK, 1990, P NATL ACAD SCI USA, V87, P215, DOI 10.1073/pnas.87.1.215; WRAIGHT CA, 1978, PHOTOSYNTHETIC BACTE, P471; ZUBER H, 1986, TRENDS BIOCHEM SCI, V11, P414, DOI 10.1016/0968-0004(86)90175-1	38	68	69	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					662	665		10.1126/science.1992518	http://dx.doi.org/10.1126/science.1992518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1992518				2022-12-24	WOS:A1991EW39900042
J	MEYER, B; HANSEN, T; NUTE, D; ALBERSHEIM, P; DARVILL, A; YORK, W; SELLERS, J				MEYER, B; HANSEN, T; NUTE, D; ALBERSHEIM, P; DARVILL, A; YORK, W; SELLERS, J			IDENTIFICATION OF THE H-1-NMR SPECTRA OF COMPLEX OLIGOSACCHARIDES WITH ARTIFICIAL NEURAL NETWORKS	SCIENCE			English	Article								Artificial neural networks can be used to identify hydrogen nuclear magnetic resonance (H-1-NMR) spectra of complex oligosaccharides. Feed-forward neural networks with back-propagation of errors can distinguish between spectra of oligosaccharides that differ by only one glycosyl residue in twenty. The artificial neural networks use features of the strongly overlapping region of the spectra (hump region) as well as features of the resolved regions of the spectra (structural reporter groups) to recognize spectra and efficiently recognized H-1-NMR spectra even when the spectra were perturbed by minor variations in their chemical shifts. Identification of spectra by neural network-based on pattern recognition techniques required less than 0.1 second. It is anticipated that artificial neural networks can be used to identify the structures of any complex carbohydrate that has been previously characterized and for which a H-1-NMR spectrum is available.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,ARTIFICIAL INTELLIGENCE PROGRAM,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	MEYER, B (corresponding author), UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602, USA.		Meyer, Bernd/A-8828-2008					GOUX WJ, 1989, J MAGN RESON, V85, P457, DOI 10.1016/0022-2364(89)90237-0; HISAMATSU M, UNPUB; KIEFER LL, 1990, CARBOHYD RES, V197, P139, DOI 10.1016/0008-6215(90)84137-J; McClelland J. L., 1988, EXPLORATIONS PARALLE; Rumelhart D. E., 1986, PARALLEL DISTRIBUTED, V1; SELLERS J, IN PRESS CARBOHYDR R; THOMSEN JU, 1989, J MAGN RESON, V84, P212, DOI 10.1016/0022-2364(89)90021-8; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YORK WS, 1990, CARBOHYD RES, V200, P9, DOI 10.1016/0008-6215(90)84179-X	9	85	92	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					542	544		10.1126/science.1990429	http://dx.doi.org/10.1126/science.1990429			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1990429				2022-12-24	WOS:A1991EV45900044
J	KNEKT, P; REUNANEN, A; TEPPO, L				KNEKT, P; REUNANEN, A; TEPPO, L			SERUM-CHOLESTEROL CONCENTRATION AND RISK OF PRIMARY BRAIN-TUMORS	BRITISH MEDICAL JOURNAL			English	Article							CANCER		FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND	Finnish Cancer Registry	KNEKT, P (corresponding author), SOCIAL INSURANCE INST,SOCIAL SECUR RES INST,SF-00380 HELSINKI,FINLAND.							ABRAMSON ZH, 1985, BRIT J CANCER, V52, P93, DOI 10.1038/bjc.1985.154; BASU TK, 1974, INT J VITAM NUTR RES, V44, P14; DAVEYSMITH G, 1989, BMJ-BRIT MED J, V299, P26; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; NEUGUT AI, 1989, INT J EPIDEMIOL, V18, P798, DOI 10.1093/ije/18.4.798	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 12	1991	302	6768					90	90		10.1136/bmj.302.6768.90	http://dx.doi.org/10.1136/bmj.302.6768.90			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER951	1995123	Bronze, Green Published			2022-12-24	WOS:A1991ER95100021
J	ENGLER, P; HAASCH, D; PINKERT, CA; DOGLIO, L; GLYMOUR, M; BRINSTER, R; STORB, U				ENGLER, P; HAASCH, D; PINKERT, CA; DOGLIO, L; GLYMOUR, M; BRINSTER, R; STORB, U			A STRAIN-SPECIFIC MODIFIER ON MOUSE CHROMOSOME-4 CONTROLS THE METHYLATION OF INDEPENDENT TRANSGENE LOCI	CELL			English	Article								A transgene, pHRD, is highly methylated in 12 independent mouse lines when in a C57BL/6 strain background, but becomes progressively less methylated when bred into a DBA/2 background. Transgenes inherited from the mother are generally more methylated; however, this parental effect disappears following continued breeding into the nonmethylating strain. Mapping experiments using BXD recombinant inbred mice as well as other inbred strains indicate that a single strain-specific modifier (Ssm-1) linked to, but distinct from, Fv-1 is responsible for the strain effect. In addition to the methylated and unmethylated transgenic phenotypes, certain mice exhibit a partial methylation pattern that is a consequence of an unusual cellular mosaicism. The pHRD transgene, containing target sequences for the V(D)J recombinase, undergoes site-specific recombination only in lymphoid tissues. This V-J joining is restricted primarily to unmethylated transgene copies.	UNIV PENN, SCH VET MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	ENGLER, P (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Brinster, Ralph/0000-0003-1408-7656; Pinkert, Carl/0000-0001-7460-3881	NIAID NIH HHS [AI24780] Funding Source: Medline; NICHD NIH HHS [HD23089, HD07136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024780, R01AI024780] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; DYNAN WS, 1989, TRENDS GENET, V5, P35, DOI 10.1016/0168-9525(89)90016-4; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1987, P NATL ACAD SCI USA, V84, P4949, DOI 10.1073/pnas.84.14.4949; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; Hogan B., 1986, MANIPULATING MOUSE E; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; Lyon ML, 1989, GENETIC VARIANTS STR, P773; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1989, PROG NUCLEIC ACID RE, V36, P145; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPOFFORD JB, 1976, GENET BIOL DROSOPHIL, V1, P953; SPRADLING AC, 1990, GENETICS, V126, P779; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TABAK HF, 1978, NUCLEIC ACIDS RES, V5, P2321, DOI 10.1093/nar/5.7.2321; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YANCOPOULOS GD, 1988, J EXP MED, V168, P417, DOI 10.1084/jem.168.1.417	37	193	196	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					939	947		10.1016/0092-8674(91)90546-B	http://dx.doi.org/10.1016/0092-8674(91)90546-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	2044153				2022-12-24	WOS:A1991FR04700005
J	HEITZLER, P; SIMPSON, P				HEITZLER, P; SIMPSON, P			THE CHOICE OF CELL FATE IN THE EPIDERMIS OF DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; NEURONAL PRECURSOR CELLS; CAENORHABDITIS-ELEGANS; C-ELEGANS; EARLY NEUROGENESIS; NOTCH LOCUS; GROWTH-FACTOR; GENE-PRODUCT; MELANOGASTER; LIN-12	In Drosophila, neural precursors are formed in a spaced pattern separated by intervening epidermal cells. Segregation of neural and epidermal lineages relies on cellular interactions. Failure of this cell communication, as in the mutants Notch (N), Delta, and shaggy, results in most or all of the cells becoming neural. Cells mutant for N and shaggy, but not Delta, autonomously adopt the neural fate when adjacent to wild-type cells in mosaics. Furthermore, wild-type cells adopt the epidermal fate if adjacent cells express a lower level of N activity than themselves, but produce neural precursors if adjacent cells express a higher level of N activity. This shows that there is competition between the cells and that the N protein is required for the mechanism whereby the cells choose between alternative fates. It also suggests that N acts as a receptor for an inhibitory signal emanating from the neural precursors.			HEITZLER, P (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, F-67085 STRASBOURG, FRANCE.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1986, ROUX ARCH DEV BIOL, V195, P210, DOI 10.1007/BF02438953; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAWRENCE PA, 1966, J CELL SCI, V1, P475; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MITCHELL HK, 1990, DEV GENET, V11, P133, DOI 10.1002/dvg.1020110203; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SIMPSON P, 1989, DEVELOPMENT, V106, P57; STERN CURT, 1954, AMER SCI, V42, P213; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TECHNAU GM, 1987, P NATL ACAD SCI USA, V84, P4500, DOI 10.1073/pnas.84.13.4500; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILCOX M, 1973, J CELL SCI, V12, P707; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	655	664	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1083	1092		10.1016/0092-8674(91)90263-X	http://dx.doi.org/10.1016/0092-8674(91)90263-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004417				2022-12-24	WOS:A1991FD55800006
J	RUDEN, DM; MA, J; LI, Y; WOOD, K; PTASHNE, M				RUDEN, DM; MA, J; LI, Y; WOOD, K; PTASHNE, M			GENERATING YEAST TRANSCRIPTIONAL ACTIVATORS CONTAINING NO YEAST PROTEIN SEQUENCES	NATURE			English	Article								WE previously reported that roughly 1% of the short peptides encoded by Escherichia coli genomic DNA fragments act as transcriptional activating regions in yeast when fused to GAL4(1-147), a DNA-binding portion of the yeast transcriptional activator GAL4 (ref. 1). Struhl questioned the conclusion that we had identified new transcriptional activating sequences that function in the absence of yeast transcriptional activating sequences 2. His criticism was based on two considerations: first, GAL4(1-147) contains an acidic segment (and subsequent experiments have shown that this region contains a weak activating region in vitro 3); second, attempts to isolate new activating regions failed when the DNA-binding domain of a bacterial repressor, LexA(1-87), was used as the DNA-binding unit 2. We report here a repeat of our original experiment using the complete LexA molecule LexA(1-202) as the DNA-binding region, instead of GAL4(1-147) or LexA(1-87). We find that, as in the original experiment, about 1% of the short peptides encoded by E. coli genomic fragments act as transcriptional activating regions when fused to intact LexA. All of the new activating regions whose sequences we determined bore an excess of acidic amino acids (see Table 1).	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138	Harvard University			Ma, Jun/GLT-4809-2022; Ruden, Douglas/ABE-1418-2021; Ruden, Douglas/A-5008-2016	Ma, Jun/0000-0002-1609-3294; Ruden, Douglas/0000-0002-0070-437X				BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0	8	136	143	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					250	252		10.1038/350250a0	http://dx.doi.org/10.1038/350250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005981				2022-12-24	WOS:A1991FC77900064
J	LESTINA, DC; WILLIAMS, AF; LUND, AK; ZADOR, P; KUHLMANN, TP				LESTINA, DC; WILLIAMS, AF; LUND, AK; ZADOR, P; KUHLMANN, TP			MOTOR-VEHICLE CRASH INJURY PATTERNS AND THE VIRGINIA SEAT-BELT LAW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAFETY BELTS; SEVERITY; CARE	Injuries to front seat occupants in tow-away crashes in the Charlottesville, Va, area were compared for 1 year before and 1 year after Virginia's seat belt use law took effect. Vehicle and occupant data were combined to examine crash and injury patterns. Reported seat belt use in crashes increased after the law, and there were substantial decreases in injuries. Front seat occupants were less likely to receive medical treatment following a crash in the postlaw period. The reduction in the number of injuries was greater for passengers in the right front seat than for drivers and for frontal crashes than for other types of crashes. The injury reduction effects occurred primarily through reductions in the number of head and face injuries, particularly those that occur from contact with windshields and instrument panels.	INSURANCE INST HIGHWAY SAFETY,ARLINGTON,VA; UNIV VIRGINIA,EMERGENCY MED SERV,CHARLOTTESVILLE,VA 22903	University of Virginia								BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARANCIK JI, 1988, B NEW YORK ACAD MED, V64, P742; BERNSTEIN E, 1989, AM J EMERG MED, V7, P271, DOI 10.1016/0735-6757(89)90168-X; Campbell B, 1988, PREVENTING AUTOMOBIL, P24; CAMPBELL BJ, 1987, J TRAUMA, V27, P733, DOI 10.1097/00005373-198707000-00007; CRUBUIB JD, 1975, ACCIDENT ANAL PREV, V7, P81; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; GLOYNS PF, 1990, 12TH P EXP SAF C WAS, P529; LUND AK, 1987, SAE870224 SOC AUT EN; ORSAY EM, 1988, JAMA-J AM MED ASSOC, V260, P3598, DOI 10.1001/jama.260.24.3598; Partyka SC, 1990, COMP BELT EFFECTIVEN; Preusser D F, 1986, J Public Health Policy, V7, P470, DOI 10.2307/3342236; RUTHERFORD WH, 1985, MED EFFECTS SEAT BEL; SAALBERG JH, 1990, IMPACT MICHIGAN SAFE; SKINNER D, 1988, DOTTSC81570PM885 NAT; STATES JD, 1989, 33RD P AM ASS AUT ME, P265; WILLIAMS AF, 1988, PREVENTING AUTOMOBIL, P51; 1986, NASS DATA COLLECTION; 1988, INSURANCE INJURY LOS; 1985, SAS USERS GUIDE STAT; 1982, COLLISION DEFORMATIO; 1985, COMPULSORY SEAT BELT; 1985, ABBREVIATED INJURY S	23	23	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1409	1413		10.1001/jama.265.11.1409	http://dx.doi.org/10.1001/jama.265.11.1409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999881				2022-12-24	WOS:A1991FB55000021
J	THORPEBEESTON, JG; NICOLAIDES, KH; GOSDEN, CM; MCGREGOR, AM				THORPEBEESTON, JG; NICOLAIDES, KH; GOSDEN, CM; MCGREGOR, AM			THYROID-FUNCTION IN FETUSES WITH CHROMOSOMAL-ABNORMALITIES	BRITISH MEDICAL JOURNAL			English	Article							FETAL		KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London; University of Edinburgh; University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				CUTLER AT, 1986, AM J DIS CHILD, V140, P479, DOI 10.1001/archpedi.1986.02140190089034; DEESCOBAR GM, 1987, HORM RES, V26, P12, DOI 10.1159/000180681; NICOLAIDES KH, 1986, LANCET, V1, P1065; PUESCHEL SM, 1985, AM J DIS CHILD, V139, P636, DOI 10.1001/archpedi.1985.02140080106045; THORPEBEESTON JG, 1991, NEW ENGL J MED, V324, P532, DOI 10.1056/NEJM199102213240805	5	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					628	628		10.1136/bmj.302.6777.628	http://dx.doi.org/10.1136/bmj.302.6777.628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012878	Bronze, Green Published			2022-12-24	WOS:A1991FC07100024
J	LAITINEN, K; LAMBERG-ALLARDT, C; TUNNINEN, R; KARONEN, SL; TAHTELA, R; YLIKAHRI, R; VALIMAKI, M				LAITINEN, K; LAMBERG-ALLARDT, C; TUNNINEN, R; KARONEN, SL; TAHTELA, R; YLIKAHRI, R; VALIMAKI, M			TRANSIENT HYPOPARATHYROIDISM DURING ACUTE ALCOHOL-INTOXICATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAGNESIUM-DEFICIENCY; PARATHYROID-HORMONE; MINERAL METABOLISM; CALCIUM; ETHANOL; SERUM; BONE; SECRETION; OSTEOPOROSIS; ABSORPTION	Background. Persons with chronic alcoholism frequently have hypocalcemia, hypomagnesemia, and osteoporosis. The short-term effects of alcohol ingestion on calcium and magnesium metabolism are poorly understood, however. Methods. We measured serum calcium, magnesium, and phosphate concentrations in 17 normal men and 7 normal women before and at intervals up to 16 hours after the ingestion of 1.2 to 1.5 g of alcohol per kilogram of body weight over a 3-hour period (doses sufficient to cause acute intoxication). Urinary excretion of calcium, magnesium, and phosphate and serum calciotropic hormone levels were measured in 16 of these subjects. As a control, the same measurements were made after the ingestion of fruit juice instead of alcohol. Results. The mean (+/- SE) peak blood alcohol level in the men was 37.5 +/- 1.6 mmol per liter, and in the women it was 38.0 +/- 3.2 mmol per liter. In the men the mean serum parathyroid hormone concentration decreased from 16.1 +/- 2.1 to 6.8 +/- 0.9 ng per liter at the end of the three-hour drinking period. The value at this time was 30 percent of that at the end of the three-hour session during which the men drank fruit juice (P = 0.004). The serum concentration of ionized calcium reached a nadir eight hours after the beginning of alcohol administration (decreasing from 1.18 +/- 0.01 to 1.15 +/- 0.01 mmol per liter; P < 0.001 as compared with values during the fruit-juice study), and urinary excretion of calcium increased from 0.34 +/- 0.08 to 0.36 +/- 0.08 mmol per hour (P < 0.01 as compared with values during the fruit-juice study). Serum parathyroid hormone levels exceeded base-line values during the last 4 hours of the 16-hour study period; this increase was accompanied by a decrease in the urinary excretion of calcium. Both serum levels of magnesium (in the first 6 hours) and urinary levels (in the first 12 hours) increased after the ingestion of alcohol. In the women, serum parathyroid hormone levels decreased from 29.2 +/- 2.8 to 17.3 +/- 2.6 ng per liter two hours after the administration of alcohol was begun (P < 0.001) and increased above base-line values during the last four hours of the study period. The serum concentration of ionized calcium decreased from 1.20 +/- 0.01 to 1.16 +/- 0.01 mmol per liter, reaching a nadir 8 to 12 hours after alcohol administration was begun (P < 0.001). Conclusions. Short-term alcohol administration causes transitory hypoparathyroidism. This decline in the secretion of parathyroid hormone accounts at least in part for the transient hypocalcemia, hypercalciuria, and hypermagnesuria that follow alcohol ingestion.	UNIV HELSINKI, ALCOHOL DIS RES UNIT, SF-00100 HELSINKI 10, FINLAND; UNITED LABS, HELSINKI, FINLAND; MINERVA FDN, INST MED RES, HELSINKI, FINLAND; ALKO LTD, FINNISH STATE ALCOHOL CO, RES LABS, HELSINKI, FINLAND; UNIV HELSINKI, DEPT MED 3, SF-00100 HELSINKI 10, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, SF-00100 HELSINKI 10, FINLAND	University of Helsinki; University of Helsinki; University of Helsinki								AVERY DH, 1983, J STUD ALCOHOL, V44, P205, DOI 10.15288/jsa.1983.44.205; BETHUNE JE, 1968, J CLIN ENDOCR METAB, V28, P673, DOI 10.1210/jcem-28-5-673; BIKLE DD, 1985, ANN INTERN MED, V103, P42, DOI 10.7326/0003-4819-103-1-42; BJORNEBOE GEA, 1988, ALCOHOL CLIN EXP RES, V12, P229, DOI 10.1111/j.1530-0277.1988.tb00185.x; BJORNEBOE GEA, 1986, AM J CLIN NUTR, V44, P678, DOI 10.1093/ajcn/44.5.678; BOHMER T, 1982, SCAND J CLIN LAB INV, V42, P633; Chanard J, 1980, Adv Exp Med Biol, V128, P495; DECHAVANNE M, 1974, NOUV PRESSE MED, V3, P2549; DIAMOND T, 1989, AM J MED, V86, P282, DOI 10.1016/0002-9343(89)90297-0; DICK M, 1969, J CLIN PATHOL, V22, P152, DOI 10.1136/jcp.22.2.152; DIXON WJ, 1988, BMDP STATISTICAL SOF; EARLL JM, 1976, AVIAT SPACE ENVIR MD, V47, P808; ERIKSSON CJP, 1977, ANAL BIOCHEM, V80, P116, DOI 10.1016/0003-2697(77)90631-5; FEITELBERG S, 1987, METABOLISM, V36, P322, DOI 10.1016/0026-0495(87)90201-0; FLINK EB, 1986, ALCOHOL CLIN EXP RES, V10, P590, DOI 10.1111/j.1530-0277.1986.tb05150.x; GRAHAM LA, 1960, METABOLISM, V9, P646; HEMMINGSEN R, 1980, PSYCHOPHARMACOLOGY, V67, P255, DOI 10.1007/BF00431266; JOHNELL O, 1982, BRIT J ADDICT, V77, P93; KALBFLEISCH JM, 1963, J CLIN INVEST, V42, P1471, DOI 10.1172/JCI104831; LALOR BC, 1986, Q J MED, V59, P497; LINDEMAN RD, 1967, J LAB CLIN MED, V70, P236; LINKOLA J, 1979, ACTA PHYSIOL SCAND, V107, P333, DOI 10.1111/j.1748-1716.1979.tb06484.x; LJUNGHALL S, 1985, EXP CLIN ENDOCRINOL, V85, P365, DOI 10.1055/s-0029-1210464; LUISIER M, 1977, SCHWEIZ MED WSCHR, V107, P1529; LUND B, 1977, ACTA MED SCAND, V202, P221; MARKKANEN T, 1966, EXPERIENTIA, V22, P753, DOI 10.1007/BF01901361; MARX SJ, 1987, CLIN DISORDERS FLUID, P207; MILSOM S, 1987, BRIT MED J, V295, P231, DOI 10.1136/bmj.295.6592.231; NIKKILA EA, 1975, DIABETES, V24, P933, DOI 10.2337/diabetes.24.10.933; PAK CYC, 1988, CALCIFIED TISSUE INT, V43, P55, DOI 10.1007/BF02555147; Pitts T O, 1986, Recent Dev Alcohol, V4, P357; Quamme GA, 1987, CLIN DISORDERS FLUID, P297; RATCLIFFE WA, 1989, CLIN CHEM, V35, P1957; RICO H, 1987, BONE MINER, V2, P221; RUDE RK, 1978, J CLIN ENDOCR METAB, V47, P800, DOI 10.1210/jcem-47-4-800; RUDE RK, 1976, CLIN ENDOCRINOL, V5, P209, DOI 10.1111/j.1365-2265.1976.tb01947.x; SAVILLE PD, 1965, J BONE JOINT SURG AM, VA 47, P492, DOI 10.2106/00004623-196547030-00005; SPENCER H, 1986, AM J MED, V80, P393, DOI 10.1016/0002-9343(86)90712-6; TORNQUIST K, 1987, ACTA ENDOCRINOL-COP, V115, P225, DOI 10.1530/acta.0.1150225; TORNQUIST K, 1987, ACTA ENDOCRINOL-COP, V116, P568, DOI 10.1530/acta.0.1160568; VODOZ JF, 1977, SCHWEIZ MED WSCHR, V107, P1525; WILLIAMS GA, 1978, P SOC EXP BIOL MED, V159, P187	42	79	82	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	1991	324	11					721	727		10.1056/NEJM199103143241103	http://dx.doi.org/10.1056/NEJM199103143241103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB556	1997837				2022-12-24	WOS:A1991FB55600003
J	WORKMAN, JL; TAYLOR, ICA; KINGSTON, RE				WORKMAN, JL; TAYLOR, ICA; KINGSTON, RE			ACTIVATION DOMAINS OF STABLY BOUND GAL4 DERIVATIVES ALLEVIATE REPRESSION OF PROMOTERS BY NUCLEOSOMES	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONALLY ACTIVE CHROMATIN; IMMEDIATE EARLY PROTEIN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; HYPERSENSITIVE SITES; REGULATORY PROTEIN; MAJOR LATE; TATA-BOX; YEAST	GAL4 derivatives containing an activation domain alleviated repression of a promoter during nucleosome assembly. A GAL4 derivative lacking an activation domain stably bound the promoter during nucleosome assembly but was not sufficient to preserve promoter function. The activation domain of GAL4 derivatives was essential for preserving promoter function, and thus the transcriptional stimulatory activity attributable to these activation domains increased dramatically during nucleosome assembly. Furthermore, promoter-bound activation domains allowed the formation of preinitiation complexes after nucleosome assembly. Finally, GAL4 derivatives containing activation domains significantly stimulated transcription through bacterially produced yeast TFIID only from nucleosome-assembled templates. These data indicate that acidic activation domains stimulate transcription by enhancing the ability of basal transcription factors to compete with nucleosomes for occupancy of the promoter.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	WORKMAN, JL (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAZVI F, 1983, GENE, V23, P175, DOI 10.1016/0378-1119(83)90049-5; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4349; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SHURE M, 1976, CELL, V8, P215, DOI 10.1016/0092-8674(76)90005-2; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YANIV M, 1986, CRIT REV BIOCHEM MOL, V21, P1, DOI 10.3109/10409238609113607	66	213	213	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					533	544		10.1016/0092-8674(91)90237-S	http://dx.doi.org/10.1016/0092-8674(91)90237-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1991320				2022-12-24	WOS:A1991EX36100009
J	FRIEDMAN, Y; FRANKLIN, C; FREELS, S; WEIL, MH				FRIEDMAN, Y; FRANKLIN, C; FREELS, S; WEIL, MH			LONG-TERM SURVIVAL OF PATIENTS WITH AIDS, PNEUMOCYSTIS-CARINII PNEUMONIA, AND RESPIRATORY-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; LIFE-SUSTAINING TREATMENT; INTENSIVE-CARE UNIT; MECHANICAL VENTILATION; PROGNOSTIC FACTORS; CORTICOSTEROIDS; EXPERIENCE; ADMISSION	Objective. - To evaluate the long-term survival of patients admitted to the medical intensive care unit, Cook County Hospital, Chicago, Ill, with Pneumocystis carinii pneumonia and acute respiratory failure. Design. - Cohort study over a 4-year period. Setting. - Municipal teaching hospital. Patients. - Seventy-three consecutive patients who had 75 episodes of P carinii pneumonia and acute respiratory failure were followed up from the time of hospital admission until their deaths or the termination of the study. Outcome Measures. - Duration of survival from the time of initial hospital admission with diagnoses of P carinii pneumonia and acute respiratory failure. Results. - Consistent with recent reports of improved short-term outcome, the immediate hospital survival was 47% (35/75). The 1-year survival was 37% (95% confidence interval, 26% to 49%). Two patients have survived for 40 months. Almost three quarters of the patients who survived hospitalization lived for at least 1 year. Conclusions. - The long-term prognosis for patients with the acquired immunodeficiency syndrome, P carinii pneumonia, and acute respiratory failure is now substantially better than anticipated. Respiratory failure due to P carinii pneumonia does not necessarily signify the terminal phase of human immunodeficiency virus infection. Accordingly, patients with the acquired immunodeficiency syndrome, P carinii pneumonia, and acute respiratory failure can be appropriate candidates for life support in medical intensive care units.	UNIV HLTH SCI CHICAGO MED SCH,N CHICAGO,IL 60064; UNIV ILLINOIS,SCH PUBL HLTH,DEPT EPIDEMIOL BIOSTAT,CHICAGO,IL 60680	Chicago Medical School; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	FRIEDMAN, Y (corresponding author), COOK CTY HOSP,DEPT MED,DIV CRIT CARE MED,1835 W HARRISON ST,CHICAGO,IL 60612, USA.							ALLEGRA CJ, 1987, NEW ENGL J MED, V317, P978, DOI 10.1056/NEJM198710153171602; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDMAN Y, 1990, CRIT CARE MED, V18, P346, DOI 10.1097/00003246-199003000-00027; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; HARDY WD, 1989, 1989 AIDS CLIN REV, P125; KAPLAN RM, 1989, MED CARE, V27, pS27, DOI 10.1097/00005650-198903001-00003; LUCE JM, 1988, AM REV RESPIR DIS, V137, P1261, DOI 10.1164/ajrccm/137.6.1261; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; VEACH L, 1990, CHEST, V97, P1499, DOI 10.1378/chest.97.6.1499-b; WACHTER RM, 1990, CHEST, V97, P1499, DOI 10.1378/chest.97.6.1499-b; WACHTER RM, 1989, CHEST, V96, P714, DOI 10.1378/chest.96.4.714; WACHTER RM, 1988, ARCH INTERN MED, V148, P149, DOI 10.1001/archinte.148.1.149; WACHTER RM, 1989, CHEST, V95, P647, DOI 10.1378/chest.95.3.647; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1989, 5TH INT C AIDS MONTR; 1985, MMWR, V34, P373	29	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					89	92		10.1001/jama.266.1.89	http://dx.doi.org/10.1001/jama.266.1.89			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046133				2022-12-24	WOS:A1991FT93400033
J	HEALY, B				HEALY, B			ALLELIC LOSS CORRELATED WITH PRIMARY BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P3847	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	1991	266	1					19	19						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT934	2046123				2022-12-24	WOS:A1991FT93400004
J	LISSNER, L; ODELL, PM; DAGOSTINO, RB; STOKES, J; KREGER, BE; BELANGER, AJ; BROWNELL, KD				LISSNER, L; ODELL, PM; DAGOSTINO, RB; STOKES, J; KREGER, BE; BELANGER, AJ; BROWNELL, KD			VARIABILITY OF BODY-WEIGHT AND HEALTH OUTCOMES IN THE FRAMINGHAM POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK; MEN	Background. Fluctuation in body weight is a common phenomenon, due in part to the high prevalence of dieting. In this study we examined the associations between variability in body weight and health end points in subjects participating in the Framingham Heart Study, which involves follow-up examinations every two years after entry. Methods. The degree of variability of body weight was expressed as the coefficient of variation of each subject's measured body-mass-index values at the first eight biennial examinations during the study and on their recalled weight at 25 years of age. Using the 32-year follow-up data, we analyzed total mortality, mortality from coronary heart disease, and morbidity due to coronary heart disease and cancer in relation to intraindividual variation in body weight, including only end points that occurred after the 10th biennial examination. We used age-adjusted proportional-hazards regression for the data analysis. Results. Subjects with highly variable body weights had increased total mortality (P = 0.005 for men, P = 0.01 for women), mortality from coronary heart disease (P = 0.009 for men, P = 0.009 for women), and morbidity due to coronary heart disease (P = 0.0009 for men, P = 0.006 for women). Using a multivariate analysis that also controlled for obesity, trends in weight over time, and five indicators of cardiovascular risk, we found that the positive associations between fluctuations in body weight and end points related to mortality and coronary heart disease could not be attributed to these potential confounding factors. The relative risks of these end points in subjects whose weight varied substantially, as compared with those whose weight was relatively stable, ranged from 1.27 to 1.93. Conclusions. Fluctuations in body weight may have negative health consequences, independent of obesity and the trend of body weight over time.	YALE UNIV, DEPT PSYCHOL, 2 HILLHOUSE AVE, BOX 11A, NEW HAVEN, CT 06520 USA; BRYANT COLL, DEPT MATH, SMITHFIELD, RI 02917 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; DEPT PRIMARY HLTH CARE, GOTHENBURG, SWEDEN; BOSTON UNIV, MED CTR, DEPT PREVENT MED & EPIDEMIOL, BOSTON, MA 02215 USA	Yale University; Bryant University; Boston University; Boston University				Kreger, Bernard/0000-0002-8593-3795	NCI NIH HHS [S-232-CA09430] Funding Source: Medline; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIMH NIH HHS [MH00319] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1976, INT CLASSIFICATION D; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; BROWNELL KD, 1986, AM PSYCHOL, V41, P765, DOI 10.1037/0003-066X.41.7.765; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; Marlatt GA., 1985, RELAPSE PREVENTION; PERCY C, 1984, CANCER-AM CANCER SOC, V54, P1435, DOI 10.1002/1097-0142(19841001)54:7<1435::AID-CNCR2820540734>3.0.CO;2-O; STEVENS J, 1990, INT J OBESITY, V14, P385; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; 1986, STATISTICAL ANAL SYS; 1985, ADV DATA VITAL HLTH, V113, P2	15	534	543	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1839	1844		10.1056/NEJM199106273242602	http://dx.doi.org/10.1056/NEJM199106273242602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	2041550				2022-12-24	WOS:A1991FT58000002
J	TUTTLE, KR; BRUTON, JL; PERUSEK, MC; LANCASTER, JL; KOPP, DT; DEFRONZO, RA				TUTTLE, KR; BRUTON, JL; PERUSEK, MC; LANCASTER, JL; KOPP, DT; DEFRONZO, RA			EFFECT OF STRICT GLYCEMIC CONTROL ON RENAL HEMODYNAMIC-RESPONSE TO AMINO-ACIDS AND RENAL ENLARGEMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; DIETARY-PROTEIN RESTRICTION; INCREASED KIDNEY SIZE; NEPHROPATHY; TRANSPLANTATION; INFUSION; DISEASE; SURFACE; PATHOGENESIS; AMELIORATION	Background. Many patients with insulin-dependent diabetes mellitushave an increase in the glomerular filtration rate and renal enlargement early in the course of their disease. Both these changes may be risk factors for the later development of diabetic nephropathy. Their cause is not known, but they could be due to augmented renal responses to the increase in plasma amino acid concentrations that occurs when dietary protein intake is high, a factor known to increase glomerular filtration and renal blood flow in normal subjects. Methods. We measured the glomerular filtration rate and renal plasma flow after an overnight fast and during an infusion of amino acids in 12 patients with insulin-dependent diabetes mellitus and 9 normal subjects. The diabetic patients were studied when they were hyperglycemic, when they were euglycemic after an insulin infusion for 36 hours, and after intensive insulin therapy for 3 weeks. Kidney volume was measured by ultrasonography before and after the period of intensive insulin therapy. Results. The glomerular filtration rate and renal plasma flow were normal after fasting when the patients were hyperglycemic (mean [+/- SE] fasting plasma glucose level, 11.5 +/- 0.7 mmol per liter). After the amino acid infusion, these values increased more in the patients (glomerular filtration rate, 2.65 +/- 0.07 ml per second per 1.73 m2 of body-surface area; renal plasma flow, 13.30 +/- 0.68 ml per second per 1.73 m2; P < 0.05 for both) than in the normal subjects (2.25 +/- 0.08 and 11.20 +/- 0.65 ml per second per 1.73 m2, respectively). The 36-hour infusion of insulin in the diabetic patients did not alter the glomerular filtration rate or renal plasma flow either before or during the amino acid infusion. After three weeks of intensive insulin therapy (fasting plasma glucose level, 5.3 +/- 0.2 mmol per liter), the glomerular filtration rate and renal plasma flow after the amino acid infusion (2.33 +/- 0.03 and 11.30 +/- 0.43 ml per second per 1.73 m2, respectively) were similar to those in the normal subjects. The kidney volumes in the normal subjects and the patients with diabetes were 219 +/- 14 and 312 +/- 14 ml per 1.73 m2, respectively (P < 0.01); the volume decreased to 267 +/- 22 ml per 1.73 m2 (P < 0.001) in the diabetic patients after three weeks of intensive insulin therapy, which was not significantly different from the volume in the normal subjects (P = 0.1). Conclusions. Conventionally treated diabetic patients who have normal renal function while fasting have augmented renal hemodynamic responses to increased plasma amino acid concentrations. The concomitant decrease in these hemodynamic responses and in kidney size with strict glycemic control suggests that these phenomena are related and influenced by the metabolic state.	UNIV TEXAS,HLTH SCI CTR,DEPT RADIOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV DIABET,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	TUTTLE, KR (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV NEPHROL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Lancaster, Jack L/F-2994-2010	Tuttle, Katherine/0000-0002-2235-0103	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001346] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR01346] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABOUNA GM, 1983, LANCET, V2, P1274; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BOSCH JP, 1986, AM J MED, V81, P809, DOI 10.1016/0002-9343(86)90350-5; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BROUHARD BH, 1986, AM J DIS CHILD, V140, P473, DOI 10.1001/archpedi.1986.02140190083032; CASTELLINO P, 1986, AM J PHYSIOL, V251, pF132, DOI 10.1152/ajprenal.1986.251.1.F132; CHRISTIANSEN JS, 1981, DIABETOLOGIA, V20, P451; CIAVARELLA A, 1987, DIABETES CARE, V10, P407, DOI 10.2337/diacare.10.4.407; DEFRONZO RA, 1982, DIABETES, V31, P795, DOI 10.2337/diab.31.9.795; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELLIS EN, 1986, KIDNEY INT, V29, P889, DOI 10.1038/ki.1986.82; EVANOFF G, 1989, ARCH INTERN MED, V149, P1129, DOI 10.1001/archinte.149.5.1129; FELDTRASMUSSEN B, 1986, NEW ENGL J MED, V314, P665, DOI 10.1056/NEJM198603133141101; HIROSE K, 1980, LAB INVEST, V43, P434; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; JONES TB, 1983, J ULTRAS MED, V2, P151; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KUPIN WL, 1987, DIABETES, V36, P73, DOI 10.2337/diabetes.36.1.73; LEE CS, 1974, J EXP MED, V139, P793, DOI 10.1084/jem.139.4.793; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MOGENSEN CE, 1976, DIABETES, V25, P872; MOGENSEN CE, 1973, DIABETES, V22, P706, DOI 10.2337/diab.22.9.706; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; NOSADINI R, 1989, DIABETES, V38, P75, DOI 10.2337/diabetes.38.1.75; PARVING HH, 1980, DIABETOLOGIA, V19, P350, DOI 10.1007/BF00280519; PETERSEN J, 1988, DIABETES, V37, P1346, DOI 10.2337/diabetes.37.10.1346; Pitts RF, 1944, AM J PHYSIOL, V142, P0355, DOI 10.1152/ajplegacy.1944.142.3.355; PULLMAN TN, 1954, J LAB CLIN MED, V44, P320; SCHWIEGER J, 1990, SEMIN NEPHROL, V10, P242; SLOMOWITZ LA, 1988, AM J PHYSIOL, V255, pF755, DOI 10.1152/ajprenal.1988.255.4.F755; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; STACKHOUSE S, 1990, DIABETES, V39, P989, DOI 10.2337/diabetes.39.8.989; STALDER G, 1959, ANN PAEDIATR-BASEL, V193, P129; STEFFES MW, 1980, DIABETES, V29, P509, DOI 10.2337/diab.29.7.509; TANK GW, 1954, AM J PHYSIOL, V178, P165, DOI 10.1152/ajplegacy.1954.178.1.165; VIBERTI GC, 1988, DIABETES METAB REV, V4, P147, DOI 10.1002/dmr.5610040205; WALKER JD, 1989, LANCET, V2, P1411; WALSER M, 1955, J CLIN INVEST, V34, P1520, DOI 10.1172/JCI103204; WISEMAN M, 1983, DIABETOLOGIA, V25, P530; WISEMAN MJ, 1985, NEW ENGL J MED, V312, P617, DOI 10.1056/NEJM198503073121004; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	43	154	156	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1626	1632		10.1056/NEJM199106063242304	http://dx.doi.org/10.1056/NEJM199106063242304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030719				2022-12-24	WOS:A1991FP30700004
J	OSTLERE, LS; LANGTRY, JAA				OSTLERE, LS; LANGTRY, JAA			ALLERGY TO SPIRAMYCIN DURING PROPHYLACTIC TREATMENT OF FETAL TOXOPLASMOSIS	BRITISH MEDICAL JOURNAL			English	Letter											OSTLERE, LS (corresponding author), WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND.							DAFFOS F, 1988, NEW ENGL J MED, V318, P281; DESCOTERS J, 1988, J ANTIMICROBIAL C SB, P207; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; GALLAND MC, 1987, THERAPIE, V42, P227; HOHFELD P, 1989, J PEDIATR, V115, P765; 1990, LANCET, V336, P346	6	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					970	970		10.1136/bmj.302.6782.970	http://dx.doi.org/10.1136/bmj.302.6782.970			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032060	Bronze, Green Published			2022-12-24	WOS:A1991FH48700071
J	STECKELBERG, JM; MURPHY, JG; BALLARD, D; BAILEY, K; TAJIK, AJ; TALIERCIO, CP; GIULIANI, ER; WILSON, WR				STECKELBERG, JM; MURPHY, JG; BALLARD, D; BAILEY, K; TAJIK, AJ; TALIERCIO, CP; GIULIANI, ER; WILSON, WR			EMBOLI IN INFECTIVE ENDOCARDITIS - THE PROGNOSTIC VALUE OF ECHOCARDIOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Article							DIMENSIONAL ECHOCARDIOGRAPHY; BACTERIAL-ENDOCARDITIS; VALVE-REPLACEMENT; VEGETATION SIZE	Objective: To determine whether vegetations visualized on two-dimensional echocardiography are an independent risk factor for the development of subsequent emboli in patients with infective endocarditis and to assess the timing of emboli relative to the initiation of antimicrobial therapy. Design: Investigator-blinded, retrospective incidence cohort study. Setting: Tertiary referral center. Patients: Patients with left-sided native valve infective endocarditis who had two-dimensional echocardiography within 72 hours of beginning antimicrobial therapy. Measurements and Main Results: The crude incidence rate of first embolic events in patients receiving antimicrobial therapy was 6.2 per 1000 patient-days (95% CI, 4.2 to 9.2). The rates in patients with and without vegetations were 7.1 and 4.9 per 1000 patient-days, respectively (incidence rate ratio, 1.4; 95% CI, 0.6 to 3.3). The relation between vegetations and risk for emboli was microorganism-dependent: Stratified incidence rate ratios were 6.9 (95% CI, 1.1 to 42.5; P < 0.05) and 1.0 (95% CI, 0.2 to 3.9) for viridans streptococcal and Staphylococcus aureus endocarditis, respectively. The rate of first embolic events diminished over time (P < 0.001), falling from 13 per 1000 patient-days during the first week of therapy to less than 1.2 per 1000 patient-days after completion of the second week of therapy. Conclusions: Overall, the presence of vegetations on echocardiography was not associated with a significantly higher risk for embolus in patients with left-sided native valve infective endocarditis. The relative risk for embolic events associated with echocardiographically visualized vegetations may be microorganism-dependent, with a significantly increased risk seen only in patients with viridans streptococcal infection. The rate of embolic events declines with time after initiation of antimicrobial treatment.			STECKELBERG, JM (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BAIN RJI, 1987, J ANTIMICROB CHEMOTH, V20, P17, DOI 10.1093/jac/20.suppl_A.17; BRANDENBURG RO, 1983, J AM COLL CARDIOL, V1, P280, DOI 10.1016/S0735-1097(83)80029-1; BUDA AJ, 1986, AM HEART J, V112, P1291, DOI 10.1016/0002-8703(86)90362-5; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS RS, 1980, AM J MED, V69, P57, DOI 10.1016/0002-9343(80)90500-8; EGEBLAD H, 1979, EUR J CARDIOL, V10, P369; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LUTAS EM, 1986, AM HEART J, V112, P107, DOI 10.1016/0002-8703(86)90687-3; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MARTIN RP, 1980, AM J CARDIOL, V46, P379, DOI 10.1016/0002-9149(80)90004-1; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; OBRIEN JT, 1984, AM HEART J, V108, P386, DOI 10.1016/0002-8703(84)90630-6; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROY P, 1976, CIRCULATION, V53, P474, DOI 10.1161/01.CIR.53.3.474; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; STEWART JA, 1980, CIRCULATION, V61, P374, DOI 10.1161/01.CIR.61.2.374; STULZ P, 1989, J CARDIOVASC SURG, V30, P20; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; WANN LS, 1979, CIRCULATION, V60, P728, DOI 10.1161/01.CIR.60.4.728	19	274	283	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					635	640		10.7326/0003-4819-114-8-635	http://dx.doi.org/10.7326/0003-4819-114-8-635			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003709				2022-12-24	WOS:A1991FG03100004
J	ANDERSON, DC; BLOWER, AL; PACKER, JMV; GANGULI, LA				ANDERSON, DC; BLOWER, AL; PACKER, JMV; GANGULI, LA			PREVENTING NEEDLESTICK INJURIES	BRITISH MEDICAL JOURNAL			English	Article							HIV INFECTION; SEROCONVERSION; DEVICE; NURSE; RISK		HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND; HOPE HOSP,DEPT MED MICROBIOL,SALFORD M6 8HD,LANCS,ENGLAND; SALFORD AREA HLTH AUTHOR,DEPT PUBL HLTH MED,ECCLES M3O 0NJ,ENGLAND		ANDERSON, DC (corresponding author), HOPE HOSP,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND.							BESSENT RG, 1987, BRIT MED J, V295, P307, DOI 10.1136/bmj.295.6593.307; Centers for Disease Control reports include, 1988, MMWR, V37, P229; EDMOND M, 1988, INFECT CONT HOSP EP, V9, P114, DOI 10.1086/645806; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GIOANNINI P, 1988, EUR J EPIDEMIOL, V4, P119, DOI 10.1007/BF00152703; GOLDWTER PN, 1987, INFECT CONT HOSP EP, V10, P21; GREEN ST, 1986, LANCET, V1, P1096; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; KENNEDY DA, 1988, J HOSP INFECT, V12, P315, DOI 10.1016/0195-6701(88)90074-6; KRASINSKI K, 1987, INFECT CONT HOSP EP, V8, P59, DOI 10.1017/S0195941700067084; MARCUS R, 1988, NEW ENGL J MED, V319, P1117; NEISSONVERNANT C, 1986, LANCET, V2, P814; NIXON AD, 1986, LANCET, V1, P888; OKSENHENDLER E, 1986, NEW ENGL J MED, V315, P582; RAMSEY KM, 1988, CLIN RES, V36, pA1; RIBNER BS, 1987, INFECT CONT HOSP EP, V8, P63, DOI 10.1017/S0195941700067096; STRICOF RL, 1986, NEW ENGL J MED, V314, P1115; 1984, LANCET, V2, P1376; 1983, MMWR, V32, P450; 1987, MMWR, V36, P285; 1990, GUIDANCE CLIN HLTH C; 1990, HIV CAUSATIVE AGENTS; 1987, MMWR, V36, P4; 1990, CODE PRACTICE SAFE U; 1990, BMJ, V300, P766; 1986, LAVHTLV 3 CAUSATIVE, P6	26	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					769	770		10.1136/bmj.302.6779.769	http://dx.doi.org/10.1136/bmj.302.6779.769			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2043216	Green Published, Bronze			2022-12-24	WOS:A1991FF22900028
J	WILLIS, WD; KOPPE, JA				WILLIS, WD; KOPPE, JA			BRAIN BROWSER - HYPERCARD APPLICATION FOR THE MACINTOSH	SCIENCE			English	Software Review									UNIV TEXAS,MED BRANCH,INST MARINE BIOMED,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	WILLIS, WD (corresponding author), UNIV TEXAS,MED BRANCH,DEPT ANAT & NEUROSCI,GALVESTON,TX 77550, USA.							MACINTOSH HYPERCARD; BRAIN BROWSER	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1500	1502		10.1126/science.2006425	http://dx.doi.org/10.1126/science.2006425			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006425				2022-12-24	WOS:A1991FC85300052
J	POUW, EM; PRUMMEL, MF; OOSTING, H; ROOS, CM; ENDERT, E				POUW, EM; PRUMMEL, MF; OOSTING, H; ROOS, CM; ENDERT, E			BECLOMETHASONE INHALATION DECREASES SERUM OSTEOCALCIN CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article									UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam								BARNES PJ, 1989, NEW ENGL J MED, V321, P571; BROWN JP, 1984, LANCET, V1, P1091; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem-72-2-382	5	130	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					627	628		10.1136/bmj.302.6777.627	http://dx.doi.org/10.1136/bmj.302.6777.627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012877	Bronze, Green Published			2022-12-24	WOS:A1991FC07100023
J	WONG, ES; STOTKA, JL; CHINCHILLI, VM; WILLIAMS, DS; STUART, CG; MARKOWITZ, SM				WONG, ES; STOTKA, JL; CHINCHILLI, VM; WILLIAMS, DS; STUART, CG; MARKOWITZ, SM			ARE UNIVERSAL PRECAUTIONS EFFECTIVE IN REDUCING THE NUMBER OF OCCUPATIONAL EXPOSURES AMONG HEALTH-CARE WORKERS - A PROSPECTIVE-STUDY OF PHYSICIANS ON A MEDICAL-SERVICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NOSOCOMIAL INFECTIONS; RISK; HEPATITIS; HIV; PREVENTION; GUIDELINE; BLOOD; AIDS	Using a daily questionnaire, we prospectively studied 277 physicians from two hospital medical services for incidents of exposure to blood and body fluids and barrier use before and after the implementation of universal precautions. We found that implementation significantly increased the frequency of barrier use during exposure incidents from 54% before implementation to 73% after implementation of universal precautions. Implementation led to a decrease in the number of exposure incidents that resulted in direct contact with blood and body fluids (actual exposures), from 5.07 to 2.66 exposures per physician per patient care month, and to an increase in averted exposures in which direct contact was prevented by the use of barrier devices, from 3.41 exposures per patient care month before implementation to 5.90 exposures per patient care month after implementation. Implementation affected neither the types of body fluid or procedures involved nor the overall rate of exposure incidents (8.5 per patient care month) but, through an increase in barrier use, it did prevent direct contact with blood and body fluids and thus converted what would have been an actual exposure into an averted one. We conclude that universal precautions were effective in reducing the risk of occupational exposures among physicians on a medical service.	HUNTER HOLMES MCGUIRE DEPT VET AFFAIRS MED CTR,MED SERV,HOSP EPIDEMIOL UNIT,RICHMOND,VA 23249; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298	Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University	WONG, ES (corresponding author), HUNTER HOLMES MCGUIRE DEPT VET AFFAIRS MED CTR,MED SERV,INFECT DIS SECT 111C,RICHMOND,VA 23249, USA.							BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; DOEBBELING BN, 1990, JAMA-J AM MED ASSOC, V264, P2083, DOI 10.1001/jama.264.16.2083; Francis D P, 1981, Semin Liver Dis, V1, P27, DOI 10.1055/s-2008-1063927; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HAGAN MD, 1989, ARCH INTERN MED, V149, P1541; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; HOOFNAGLE JH, 1979, ANN INTERN MED, V91, P813, DOI 10.7326/0003-4819-91-6-813; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; KUHLS TL, 1987, AM J PUBLIC HEALTH, V77, P1306, DOI 10.2105/AJPH.77.10.1306; LYNCH P, 1987, ANN INTERN MED, V107, P243, DOI 10.7326/0003-4819-107-2-243; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCEVOY M, 1987, BRIT MED J, V294, P1595, DOI 10.1136/bmj.294.6587.1595; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; PRENTICE RL, 1988, BIOMETRICS, V44, P1033, DOI 10.2307/2531733; SIMMONS BP, 1983, AM J INFECT CONTROL, V11, P183, DOI 10.1016/0196-6553(83)90079-2; WEISS SH, 1985, JAMA-J AM MED ASSOC, V254, P2089, DOI 10.1001/jama.254.15.2089; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; 1970, US DHEW PHS702054 PU; 1989, MMWR SS4, V38, P1; 1985, SAS USERS GUIDE BASI; 1987, MMWR S2S, V36, pS3; 1985, PROC IML VERSION 5	28	115	121	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1123	1128		10.1001/jama.265.9.1123	http://dx.doi.org/10.1001/jama.265.9.1123			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1995997				2022-12-24	WOS:A1991EZ47400028
J	DINSMORE, JH; SOLOMON, F				DINSMORE, JH; SOLOMON, F			INHIBITION OF MAP2 EXPRESSION AFFECTS BOTH MORPHOLOGICAL AND CELL-DIVISION PHENOTYPES OF NEURONAL DIFFERENTIATION	CELL			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; EMBRYONAL CARCINOMA-CELLS; DEPENDENT PHOSPHORYLATION; MAMMALIAN NEURONS; TAU; RNA; INVITRO; LINE; DNA; IDENTIFICATION	Expression of the differentiated neuronal phenotype is typically manifest in several properties: distinct morphologies and organizations of the underlying cytoskeleton; appearance of specific macromolecules; and cessation of cell division. All of these properties are induced in undifferentiated embryonal carcinoma cells exposed to retinoic acid. We show here that the mRNA and protein for the microtubule component MAP2 is also induced by retinoic acid. Stable transfectants of undifferentiated cells, constitutively expressing MAP2 antisense RNA, show significantly reduced levels of MAP2 protein upon induction compared with controls. These cells do express other neuronal markers, but they do not undergo normal morphological differentiation nor do they withdraw from the cell cycle. The results suggest that MAP2 expression may be necessary for both neurite extension and cessation of cell division.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	DINSMORE, JH (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; DOTTI CG, 1987, NEUROSCIENCE, V23, P121, DOI 10.1016/0306-4522(87)90276-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HARRIS PJ, 1986, METHOD CELL BIOL, V27, P243, DOI 10.1016/S0091-679X(08)60352-0; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KIM S, 1987, J CELL BIOL, V104, P51, DOI 10.1083/jcb.104.1.51; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MONARD D, 1973, P NATL ACAD SCI USA, V70, P1894, DOI 10.1073/pnas.70.6.1894; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY DB, 1977, J MOL BIOL, V117, P33, DOI 10.1016/0022-2836(77)90021-3; OGDEN RC, 1987, METHOD ENZYMOL, V152, P61; Rudnicki M.A., 1987, TERATOCARCINOMAS EMB; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; SAMBROOK S, 1989, MOL CLONING; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; SLOBODA RD, 1979, BIOCHEMISTRY-US, V18, P48, DOI 10.1021/bi00568a008; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SLOBODA RD, 1976, BIOCHEMISTRY-US, V15, P4497, DOI 10.1021/bi00665a026; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; TUCKER RP, 1988, J NEUROSCI, V8, P4503; WALLACE DM, 1987, METHOD ENZYMOL, V152, P33	54	197	202	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					817	826		10.1016/0092-8674(91)90510-6	http://dx.doi.org/10.1016/0092-8674(91)90510-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997209				2022-12-24	WOS:A1991EZ47800016
J	BUDRENE, EO; BERG, HC				BUDRENE, EO; BERG, HC			COMPLEX PATTERNS FORMED BY MOTILE CELLS OF ESCHERICHIA-COLI	NATURE			English	Article							CHEMOTAXIS; MIGRATION; MOVEMENT	WHEN chemotactic strains of the bacterium Escherichia coli are inoculated on semi-solid agar containing mixtures of amino acids or sugars, the cells swarm outwards in a series of concentric rings: they respond to spatial gradients of attractants generated by uptake and catabolism 1-3. Cells also drift up gradients generated artificially, for example by diffusion from the tip of a capillary tube 4 or by mixing 5. Here we describe conditions under which cells aggregate in response to gradients of attractant which they excrete themselves. When cells are grown in semi-solid agar on intermediates of the tricarboxylic acid cycle, they form symmetrical arrays of spots or stripes that arise sequentially. When cells in a thin layer of liquid culture are exposed to these compounds, spots appear synchronously, more randomly arrayed. In either case, the patterns are stationary. The attractant is a chemical sensed by the aspartate receptor. Its excretion can be triggered by oxidative stress. As oxygen is limiting at high cell densities, aggregation might serve as a mechanism for collective defence.	ROWLAND INST SCI INC,CAMBRIDGE,MA 02142		BUDRENE, EO (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; BERG HC, 1979, NATURE, V278, P349, DOI 10.1038/278349a0; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BERG HC, 1990, BIOPHYS J, V58, P919, DOI 10.1016/S0006-3495(90)82436-X; BERG HC, 1990, COLD SPRING HARB SYM, V55, P539; DAHLQUIS.FW, 1972, NATURE-NEW BIOL, V236, P120, DOI 10.1038/newbio236120a0; GERHART J, 1989, TRENDS GENET, V5, P233, DOI 10.1016/0168-9525(89)90093-0; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; LOSICK R, 1984, MICROBIAL DEV; MACNAB RM, 1987, ESCHERICHIA COLI SAL, V1, P732; MESIBOV R, 1972, J BACTERIOL, V112, P315, DOI 10.1128/JB.112.1.315-326.1972; Miller J. H., 1972, EXPT MOL GENETICS, P431; NEIDHARDT FC, 1990, PHYSL BACTERIAL CELL, pCH7; NOSSAL R, 1972, EXP CELL RES, V75, P138, DOI 10.1016/0014-4827(72)90529-0; OSTER GF, 1989, J EXP ZOOL, V251, P186, DOI 10.1002/jez.1402510207; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; QU Y, 1989, P NATL ACAD SCI USA, V86, P8358; SHIMKETS LJ, 1982, J BACTERIOL, V152, P451; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973	22	426	430	3	60	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 14	1991	349	6310					630	633		10.1038/349630a0	http://dx.doi.org/10.1038/349630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	2000137				2022-12-24	WOS:A1991EX57000066
J	BLUMBERG, MS				BLUMBERG, MS			BIASED ESTIMATES OF EXPECTED ACUTE MYOCARDIAL-INFARCTION MORTALITY USING MEDISGROUPS ADMISSION SEVERITY GROUPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVAL; SYSTEM	This study examines whether the MedisGroups admission severity groups give unbiased estimates of 30-day mortality in 3037 Medicare-aged patients who were hospitalized in 1985 through 1986 with acute myocardial infarction. The average observed death rate for all acute myocardial infarction patients in the study who were in a given admission severity group was used to estimate the expected death probability for each case in a given group. (This is the same method used by the Pennsylvania Health Care Cost Containment Council for risk adjusting hospital mortality by diagnosis related groups in that state.) When compared with observed deaths, estimates of expected mortality were significantly biased for many patient attributes (eg, age, location of acute myocardial infarction, history of congestive heart failure, serum potassium level, serum urea nitrogen level, pulse rate, and blood pressure). These results are consistent with a conclusion that the MedisGroups scoring algorithm omits some important risk variables, inappropriately includes some other variables reflecting postadmission status, and gives the wrong weights to some appropriate risk variables. To the extent that these findings are also applicable to current MedisGroups scoring algorithms and to other conditions and procedures, MedisGroups admission severity groups cannot fairly adjust for interhospital case mix differences in outcome studies.			BLUMBERG, MS (corresponding author), KAISER FDN HLTH PLAN INC,ONE KAISER PLAZA,OAKLAND,CA 94612, USA.		Blumberg, Mark/K-3221-2019					ALEMI F, 1990, MED CARE, V28, P762, DOI 10.1097/00005650-199009000-00006; [Anonymous], 1986, MED THINKING PSYCHOL; Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; BLUMBERG MS, 1991, STAT MED, V10, P637, DOI 10.1002/sim.4780100414; BLUMBERG MS, 1989, RISK ADJUSTED 30 DAY; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; IEZZONI LI, 1991, AM J PUBLIC HEALTH, V81, P74, DOI 10.2105/AJPH.81.1.74; Iezzoni LI, 1988, ABILITY MEDISGROUPS; IEZZONI LI, 1987, MEDISGROUP CLIN ANAL; IEZZONI LI, 1989, ADMISSION MIDSTAY ME; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1987, ICU COST BENEFIT ANA; Mosteller F., 1968, HDB SOC PSYCHOL, V2, P80; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V147, P1181; SACHS L, 1984, APPLIED STATISTICS H, P66; 1990, HE189 PENNS HLTH CAR, pB4; 1990, HE5488 PENNS HLTH CA, P3	19	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2965	2970						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033767				2022-12-24	WOS:A1991FP63500033
J	LEVIN, BW; DRISCOLL, JM; FLEISCHMAN, AR				LEVIN, BW; DRISCOLL, JM; FLEISCHMAN, AR			TREATMENT CHOICE FOR INFANTS IN THE NEONATAL-INTENSIVE-CARE-UNIT AT RISK FOR AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; INFECTION; TYPE-1; WOMEN; BORN	Many infants admitted to neonatal intensive care units are the children of women infected with the human immunodeficiency virus (HIV); they have approximately a 30% risk of infection. To investigate attitudes surrounding treatment for such newborns, we conducted a survey of professionals at six neonatal intensive care units in New York City. A significant proportion of the 247 respondents recommended less aggressive treatment for non-HIV-related conditions for infants at risk for HIV compared with those not at risk. For example, 97% of respondents recommended open heart surgery for an infant with no known HIV risk but only 77% recommended surgery for an infant whose mother had acquired immunodeficiency syndrome; if certain the infant was infected, 42% of respondents recommended surgery. We conclude that perceived HIV status may influence decision making about treatment for non-HIV-related conditions for critically ill patients, including infants not actually infected. Ethical issues concerning the relevance of HIV status need to be examined.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,DIV NEONATOL,BRONX,NY 10461; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,DIV PERINATAL MED,NEW YORK,NY 10032; MONTEFIORE MED CTR,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine; Columbia University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	LEVIN, BW (corresponding author), CUNY BROOKLYN COLL,DEPT HLTH & NUTR,BROOKLYN,NY 11210, USA.		Levin, Betty Wolder/L-3479-2019	Levin, Betty Wolder/0000-0002-4288-6052				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CONDIT D, 1989, ANN THORAC SURG, V47, P182, DOI 10.1016/0003-4975(89)90266-X; CRANE D, 1975, SANCTITY SOCIAL LIFE; Guillemin J, 1986, MIXED BLESSINGS INTE; KATZ BZ, 1989, SEMIN PERINATOL, V13, P27; LEVIN BW, 1988, CHILDBIRTH AM ANTHR; LEVIN BW, 1985, WHICH BABIES LIVE ME; NICHOLAS SW, 1989, PEDIATRICS, V83, P293; OLESKE JM, 1988, PEDIATR ANN, V17, P332, DOI 10.3928/0090-4481-19880501-07; PIZZO PA, 1989, JAMA-J AM MED ASSOC, V262, P1989, DOI 10.1001/jama.262.14.1989; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEPTIMUS A, 1989, SEMIN PERINATOL, V13, P49; SHEARER W, 1990, SEMIN PEDIATR INFECT, V1, P1; STEVENS A, 1990, BRIT MED J, V300, P447, DOI 10.1136/bmj.300.6722.447; Weir Robert F., 1984, SELECTIVE NONTREATME; 1987, HASTINGS CTR REP, V17, P5	17	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					2976	2981		10.1001/jama.265.22.2976	http://dx.doi.org/10.1001/jama.265.22.2976			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033769				2022-12-24	WOS:A1991FP63500035
J	PAVLETICH, NP; PABO, CO				PAVLETICH, NP; PABO, CO			ZINC FINGER DNA RECOGNITION - CRYSTAL-STRUCTURE OF A ZIF268-DNA COMPLEX AT 2.1-A	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; FUNCTIONAL REGIONS; BINDING DOMAINS; 5S-RNA GENE; PROTEIN; RESOLUTION; REPRESSOR; GROWTH; OPERATOR; KRUPPEL	The zinc finger DNA-binding motif occurs in many proteins that regulate eukaryotic gene expression. The crystal structure of a complex containing the three zinc fingers from Zif268 (a mouse immediate early protein) and a consensus DNA-binding site has been determined at 2.1 angstroms resolution and refined to a crystallographic R factor of 18.2 percent. In this complex, the zinc fingers bind in the major groove of B-DNA and wrap partway around the double helix. Each finger has a similar relation to the DNA and makes its primary contacts in a three-base pair subsite. Residues from the amino-terminal portion of an alpha-helix contact the bases, and most of the contacts are made with the guanine-rich strand of the DNA. This structure provides a framework for understanding how zinc fingers recognize DNA and suggests that this motif may provide a useful basis for the design of novel DNA-binding proteins.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	PAVLETICH, NP (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.		Wilson, Matthew H/K-3193-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31471] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS TH, 1988, CELL, V54, P353, DOI 10.1016/0092-8674(88)90198-5; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR V21 MANUAL; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; JACOBS G, 1990, New Biologist, V2, P583; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; ONEIL KT, 1990, CELL, V249, P774; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, UNPUB; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WANG JC, 1990, J BIOL CHEM, V265, P6513; 1979, SERC4 DAR LAB COLL C	45	1764	1921	3	192	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					809	817		10.1126/science.2028256	http://dx.doi.org/10.1126/science.2028256			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028256				2022-12-24	WOS:A1991FL12300038
J	MOORE, RD; KESSLER, H; RICHMAN, DD; FLEXNER, C; CHAISSON, RE				MOORE, RD; KESSLER, H; RICHMAN, DD; FLEXNER, C; CHAISSON, RE			NON-HODGKINS-LYMPHOMA IN PATIENTS WITH ADVANCED HIV-INFECTION TREATED WITH ZIDOVUDINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPSTEIN-BARR VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; KAPOSIS SARCOMA; INSITU HYBRIDIZATION; SAN-FRANCISCO; AIDS; MALIGNANCIES; TRENDS; MEN	We wished to determine the incidence of human immunodeficiency virus-related high-grade non-Hodgkin's lymphoma (NHL) and identify factors associated with the development of NHL in patients receiving zidovudine. Data are from a 2-year prospective, observational, multisite study of 1030 patients with the acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex who received zidovudine. Non-Hodgkin's lymphoma developed in 24 (2.3%) of 1030 patients who received zidovudine during 1463 person-years of follow-up (rate, 1.6 per 100 person-years of therapy). The relative hazard for development of NHL was stable throughout 2 years of therapy, with the risk of developing NHL 0.8% for each additional 6 months of therapy. Factors associated with development of NHL were a prior diagnosis of Kaposi's sarcoma, herpes simplex virus infection, or lower mean neutrophil count. Less strongly associated was a prior diagnosis of oral hairy leukoplakia or homosexual transmission of HIV. By Cox proportional hazards analysis, a prior diagnosis of Kaposi's sarcoma, cytomegalovirus disease, or oral hairy leukoplakia was most strongly associated with development of NHL. Our study demonstrates a relatively high incidence of NHL in patients with advanced human immunodeficiency virus disease who are undergoing antiretroviral therapy and suggests possible risk factors for development of NHL.	UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; VET ADM MED CTR,SAN DIEGO,CA 92161; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Johns Hopkins University; Rush University; Rush University								BASHIR RM, 1989, NEUROLOGY, V39, P813, DOI 10.1212/WNL.39.6.813; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERNSTEIN L, 1989, CANCER RES, V49, P466; DREW WL, 1988, LANCET, V1, P66; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; HOLMBERG SD, 1988, LANCET, V2, P746; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KRUEGER GRF, 1989, ANTICANCER RES, V9, P1457; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MOORE RD, IN PRESS ARCH INTERN; MURRAY RS, 1987, ANN NEUROL, V22, P155; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RABKIN CS, 1990, LANCET, V336, P248, DOI 10.1016/0140-6736(90)91775-6; RUTHERFORD GW, 1989, J INFECT DIS, V159, P569, DOI 10.1093/infdis/159.3.569; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; 1990, COMPREHENSIVE INFORM, P48; 1991, PHYSICIANS DESK REFE, P790; 1985, MMWR, V34, P373	22	82	82	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2208	2211		10.1001/jama.265.17.2208	http://dx.doi.org/10.1001/jama.265.17.2208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013953				2022-12-24	WOS:A1991FH87700032
J	RAUB, WF				RAUB, WF			LONG-TERM PROPHYLAXIS EFFECTIVE AGAINST RECURRENT URINARY-TRACT INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, REV INFECT DIS, V13, P77	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-24	WOS:A1991FH87700006
J	ANDERSON, RM; GUPTA, S; MAY, RM				ANDERSON, RM; GUPTA, S; MAY, RM			POTENTIAL OF COMMUNITY-WIDE CHEMOTHERAPY OR IMMUNOTHERAPY TO CONTROL THE SPREAD OF HIV-1	NATURE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; ZIDOVUDINE AZT; DOUBLE-BLIND; INFECTION	WHETHER zidovudine (3'-azido-3'-deoxythymidine, AZT) should be offered to symptomless individuals infected with human immunodeficiency virus type-1 (HIV-1), in the hope of delaying or even preventing progression to AIDS, has been much debated 1. The discussion has focused on the efficacy of the drug in delaying progression to disease 2, the severity of its side-effects 3, and the likelihood of its prolonged and widespread use resulting in zidovudine-resistant strains of the virus 4. Little attention has been given to the degree to which treatment reduces the infectiousness of symptomless patients, and to the concomitant implications for the overall transmission rate of HIV-1 in the community. Here we use simple mathematical models to show that community treatment with antiviral drugs or immunotherapies that lengthen the incubation period of AIDS without significantly reducing the infectiousness of treated individuals, can increase the rate at which HIV-1 infection spreads (which is fairly obvious) and can even, under certain circumstances, increase the AIDS-related death rate in the community (which is less obvious).			ANDERSON, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOL,LONDON SW7 2BB,ENGLAND.			Anderson, Roy/0000-0002-9528-3175				ANDERSON R M, 1986, IMA Journal of Mathematics Applied in Medicine and Biology, V3, P229; ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185; ANDERSON RM, 1990, J ACQ IMMUN DEF SYND, V3, P417; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; CAPON DJ, 1989, NATURE, V337, P325; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MCLEAN AR, IN PRESS J MATH BIOL; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; RATNER L, 1989, AIDS RES HUM RETROV, V5, P115, DOI 10.1089/aid.1989.5.115; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, LANCET, V1, P415	18	95	95	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					356	359		10.1038/350356a0	http://dx.doi.org/10.1038/350356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008214				2022-12-24	WOS:A1991FD83800098
J	DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL				DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL			A PROSPECTIVE-STUDY OF ADVANCE DIRECTIVES FOR LIFE-SUSTAINING CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The use of advance directives is recommended so that people can determine the medical care they will receive when they are no longer competent, but the effectiveness of such directives is not clear. Methods. In a prospective study conducted over a two-year period, 126 competent residents of a nursing home and 49 family members of incompetent patients were interviewed to determine their preferences with respect to hospitalization, intensive care, cardiopulmonary resuscitation, artificial ventilation, surgery, and tube feeding in the event of critical illness, terminal illness, or permanent unconsciousness. Advance directives, consisting of signed statements of treatment preferences, were placed in the medical record to assist in care in the nursing home and to be forwarded to the hospital if necessary. Results. In an analysis of 96 outcome events (hospitalization or death in the nursing home), care was consistent with previously expressed wishes 75 percent of the time; however, the presence of the written advance directive in the medical record did not facilitate consistency. Among the 24 events in which inconsistencies occurred, care was provided more aggressively than had been requested in 6 cases, largely because of unanticipated surgery or artificial ventilation, and less aggressively than requested in 18, largely because hospitalization or cardiopulmonary resuscitation was withheld. Inconsistencies were more likely in the nursing home than in the hospital. Conclusions. The effectiveness of written advance directives is limited by inattention to them and by decisions to place priority on considerations other than the patient's autonomy. Since our study was performed in only one nursing home and one hospital, other studies are necessary to determine the generalizability of our findings.	UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	DANIS, M (corresponding author), UNIV N CAROLINA,DEPT MED,DIV GEN MED & CLIN EPIDEMIOL,CAMPUS BOX 7110,5025A OLD CLIN BLDG,CHAPEL HILL,NC 27599, USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; EISENDRATH SJ, 1983, JAMA-J AM MED ASSOC, V249, P2054, DOI 10.1001/jama.249.15.2054; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; HACKLER C, 1989, ADV DIRECTIVES MED S; JONSEN AR, 1982, CLIN ETHICS; KUTNER L, 1969, INDIANA LAW J, V44, P537; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; REDLEAF DL, 1979, STANFORD LAW REV, V31, P913, DOI 10.2307/1228530; 1982, SUDOC198203835158763; 1987, GUIDELINES TERMINATI; 1983, AM J PUBLIC HEALTH, V73, P918	12	387	389	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					882	888		10.1056/NEJM199103283241304	http://dx.doi.org/10.1056/NEJM199103283241304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000110				2022-12-24	WOS:A1991FD11100004
J	BEAL, PA; DERVAN, PB				BEAL, PA; DERVAN, PB			2ND STRUCTURAL MOTIF FOR RECOGNITION OF DNA BY OLIGONUCLEOTIDE-DIRECTED TRIPLE-HELIX FORMATION	SCIENCE			English	Article							SEQUENCE-SPECIFIC CLEAVAGE; STRANDED-DNA; DUPLEX DNA; BINDING; SITE; INHIBITION; GUANINE	Relative orientations of the DNA strands within a purine.purine.pyrimidine triple helix have been determined by affinity cleaving. A purine-rich oligonucleotide bound in the major groove of double-helical DNA antiparallel to the Watson-Crick purine strand. Binding depended upon the concentration of multivalent cations such as spermine or Mg2+, and appeared to be relatively independent of pH. Two models with specific hydrogen-bonding patterns for base triplets (G.GC, A.AT, and T.AT) are proposed to explain the sequence specificity of binding. The two models differ in the conformation about the glycosyl bond (syn or anti) and the location of the phosphate-deoxyribose backbone in the major groove of DNA. This motif broadens the structural frameworks available as a basis for the design of sequence-specific DNA binding molecules.	CALTECH,DIV CHEM & CHEM ENGN,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125	California Institute of Technology								BROITMAN SL, 1987, P NATL ACAD SCI USA, V85, P3781; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P192; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DERVAN PB, UNPUB; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1989, J BIOL CHEM, V264, P5891; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; IVERSON BL, 1987, NUCLEIC ACIDS RES, V15, P7823, DOI 10.1093/nar/15.19.7823; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P7749; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARK C, 1978, NUCLEIC ACIDS RES, V5, P1017; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJOGOPAL P, 1989, NATURE, V339, P637; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P119; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1989, J AM CHEM SOC, V111, P7286, DOI 10.1021/ja00200a073; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUN JS, 1989, P NATL ACAD SCI USA, V86, P8198; WILLIAMS NG, 1989, J AM CHEM SOC, V111, P7205, DOI 10.1021/ja00200a046	28	586	732	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1360	1363		10.1126/science.2003222	http://dx.doi.org/10.1126/science.2003222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003222				2022-12-24	WOS:A1991FB73300045
J	DAVIES, MJ; WILSON, RG; KESTON, M; NIXON, SJ				DAVIES, MJ; WILSON, RG; KESTON, M; NIXON, SJ			AN IMPLANTABLE DEVICE FOR LONG-TERM VENOUS ACCESS IN CHRONIC LUNG CONDITIONS	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,SURG UNIT,D BLOCK,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh								BALL ABS, 1989, RESP MED, V83, P429, DOI 10.1016/S0954-6111(89)80076-9; CASSEY J, 1988, CLIN PEDIATR, V27, P91, DOI 10.1177/000992288802700206; GEBARSKI SS, 1984, CANCER, V54, P38, DOI 10.1002/1097-0142(19840701)54:1<38::AID-CNCR2820540110>3.0.CO;2-9; THOMPSON AM, 1989, INTENSIVE THERAP MAY, P142	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					570	571		10.1136/bmj.302.6776.570	http://dx.doi.org/10.1136/bmj.302.6776.570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	2021722	Green Published, Bronze			2022-12-24	WOS:A1991FB93600021
J	HANKEY, GJ; SLATTERY, JM; WARLOW, CP				HANKEY, GJ; SLATTERY, JM; WARLOW, CP			PROGNOSIS AND PROGNOSTIC FACTORS OF RETINAL INFARCTION - A PROSPECTIVE COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-STROKE-PROJECT; CAROTID-ARTERY DISEASE; AMAUROSIS FUGAX; YOUNG-ADULTS; OCCLUSION; OBSTRUCTION; PATIENT; RISK	Objective - To determine the prognosis and adverse prognostic factors in patients with retinal infarction due to presumed atheromatous thromboembolism or cardiogenic embolism. Design - Prospective cohort study. Setting - University hospital departments of clinical neurology. Patients - 99 patients with retinal infarction, without prior stroke, referred to a single neurologist between 1976 and 1986 and evaluated and followed up prospectively until death or the end of 1986 (mean follow up 4.2 years). Interventions - Cerebral angiography (55 patients), aspirin treatment (37), oral anticoagulant treatment (eight), carotid endarterectomy (13), cardiac surgery (six), and peripheral vascular surgery (two). Main outcome measures - Death, stroke, coronary events, contralateral retinal infarction; survival analysis confined to 98 patients with retinal infarction due to presumed atheromatous thromboembolism or cardiogenic embolism (one patient with giant cell arteritis excluded), and Cox's proportional hazards regression analysis, including age as a prognostic factor. Results - During follow up 29 patients died (21 of vascular causes and eight of non-vascular or unknown causes), 10 had a first ever stroke, 19 had a coronary event, and only one developed contralateral retinal infarction. A coronary event accounted for more than half (59%) of the deaths whereas stroke was the cause of only one death (3%). Over the first five years after retinal infarction the actuarial average absolute risk of death was 8% per year; of stroke 2.5% per year (7.4% in the first year); of coronary events 5.3% per year, exceeding that of stroke; and of stroke, myocardial infarction, or vascular death 7.4% per year. Prognostic factors associated with an increased risk of death were increasing age, peripheral vascular disease, cardiomegaly, and carotid bruit. Adverse prognostic factors for serious vascular events were increasing age and carotid bruit for stroke, and increasing age, cardiomegaly, and carotid bruit both for coronary events and for stroke, myocardial infarction, or vascular death. Conclusions - Patients who present with retinal infarction due to presumed atherothromboembolism or cardiogenic embolism are at considerable risk of a coronary event. The risk of stroke, although high, is not so great. Not all strokes occurring after retinal infarction relate directly to disease of the ipsilateral carotid system, although this is probably the most common cause. Few patients experience contralateral retinal infarction. Non-arteritic retinal infarction should be diagnosed or confirmed by an ophthalmologist, and the long term care of patients with the condition should involve a physician who has an active interest in managing vascular disease.			HANKEY, GJ (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				[Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; APPEN RE, 1975, AM J OPHTHALMOL, V79, P374, DOI 10.1016/0002-9394(75)90609-1; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BROWN GC, 1981, OPHTHALMOLOGY, V88, P18; CHAWLUK JB, 1988, NEUROLOGY, V38, P858, DOI 10.1212/WNL.38.6.858; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; DOUGLAS DJ, 1988, ANN SURG, V208, P85, DOI 10.1097/00000658-198807000-00012; GOODMAN GK, 1982, CAN J OPHTHALMOL, V17, P124; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, IN PRESS J NEUROL NE; HARBISON JW, 1982, ANN NEUROL, V12, P74; HOLLENHORST RW, 1987, OCCLUSIVE CEREBROVAS, P82; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; HOWARD RS, 1987, J NEUROL NEUROSUR PS, V50, P1142, DOI 10.1136/jnnp.50.9.1142; JORGENSEN R, 1988, SURGERY, V104, P507; KOLLARITS CR, 1972, J AMER MED ASSOC, V222, P1273, DOI 10.1001/jama.222.10.1273; LIVERSEDGE L A, 1962, Trans Ophthalmol Soc U K, V82, P571; LORENTZEN SE, 1969, ACTA OPHTHALMOL, V47, P690; MACHIN D, 1989, STATISTICS CONFIDENC, P64; MARSHALL J, 1968, BRAIN, V91, P419, DOI 10.1093/brain/91.3.419; MERCHUT MP, 1988, STROKE, V19, P1239, DOI 10.1161/01.STR.19.10.1239; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PFAFFENBACH DD, 1973, AM J OPHTHALMOL, V75, P66, DOI 10.1016/0002-9394(73)90653-3; POOLE CJM, 1985, J NEUROL NEUROSUR PS, V48, P902, DOI 10.1136/jnnp.48.9.902; ROS MA, 1989, ANN OPHTHALMOL, V21, P103; RUSSELL RW, 1961, LANCET, V2, P1422; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; SAVINO PJ, 1977, ARCH OPHTHALMOL-CHIC, V95, P1185, DOI 10.1001/archopht.1977.04450070083005; TIPPIN J, 1989, ANN NEUROL, V26, P69, DOI 10.1002/ana.410260111; TOMSAK RL, 1979, CLEVELAND CLIN Q, V46, P7, DOI 10.3949/ccjm.46.1.7; WILSON LA, 1979, LANCET, V1, P292; WRAY SH, 1988, AMAUROSIS FUGAX, P81	37	56	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					499	504		10.1136/bmj.302.6775.499	http://dx.doi.org/10.1136/bmj.302.6775.499			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012845	Green Published, Bronze			2022-12-24	WOS:A1991FB05500018
J	CLEVES, AE; MCGEE, TP; WHITTERS, EA; CHAMPION, KM; AITKEN, JR; DOWHAN, W; GOEBL, M; BANKAITIS, VA				CLEVES, AE; MCGEE, TP; WHITTERS, EA; CHAMPION, KM; AITKEN, JR; DOWHAN, W; GOEBL, M; BANKAITIS, VA			MUTATIONS IN THE CDP CHOLINE PATHWAY FOR PHOSPHOLIPID BIOSYNTHESIS BYPASS THE REQUIREMENT FOR AN ESSENTIAL PHOSPHOLIPID TRANSFER PROTEIN	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST GOLGI; GENE; CLONING; ACTIN; CELLS; TRANSFORMATION; MUTANTS	SEC14p is the yeast phosphatidylinositol (PI)/phosphatidylcholine (PC) transfer protein, and it effects an essential stimulation of yeast Golgi secretory function. We now report that the SEC14p localizes to the yeast Golgi and that the SEC14p requirement can be specifically and efficiently bypassed by mutations in any one of at least six genes. One of these suppressor genes was the structural gene for yeast choline kinase (CKI), disruption of which rendered the cell independent of the normally essential SEC14p requirement. The antagonistic action of the CKI gene product on SEC14p function revealed a previously unsuspected influence of biosynthetic activities of the CDP-choline pathway for PC biosynthesis on yeast Golgi function and indicated that SEC14p controls the phospholipid content of yeast Golgi membranes in vivo.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225; INDIANA UNIV,WALTHER ONCOL CTR,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	University of Texas System; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	CLEVES, AE (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.			Cleves, Ann/0000-0002-1622-2770; McGee, Todd/0000-0002-3901-1001	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35143, R01 GM044530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; Goldstein A, 1975, Methods Enzymol, V42, P504; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASON TL, 1973, J BIOL CHEM, V248, P1346; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMAN JE, 1990, NATURE, V347, P519, DOI 10.1038/347519a0; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Sherman F., 1983, METHODS YEAST GENETI; Silhavy T.J., 1984, EXPT GENE FUSIONS; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	36	304	306	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					789	800		10.1016/0092-8674(91)90508-V	http://dx.doi.org/10.1016/0092-8674(91)90508-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997207	Green Submitted, Green Accepted			2022-12-24	WOS:A1991EZ47800014
J	MANN, SJ; JAMES, GD; WANG, RS; PICKERING, TG				MANN, SJ; JAMES, GD; WANG, RS; PICKERING, TG			ELEVATION OF AMBULATORY SYSTOLIC BLOOD-PRESSURE IN HYPERTENSIVE SMOKERS - A CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CIGARETTE-SMOKING; EXERCISE	Although smoking raises blood pressure, the office blood pressure measurements of smokers are the same as, or lower than, those of nonsmokers. To resolve this paradox, we compared the office and 24-hour ambulatory blood pressures of 59 untreated hypertensive smokers with 118 nonsmoking hypertensives matched for age, sex, and race. The office blood pressures of the smoking and nonsmoking groups were 141/93 and 142/93 mm Hg, respectively. The awake ambulatory systolic blood pressure was significantly higher in the smokers (145 vs 140 mm Hg). This difference was greater among patients over the age of 50 years (153 vs 142 mm Hg), and absent among patients under 50 years (140 vs 139 mm Hg). Blood pressures during sleep did not differ between the two groups (121/76 vs 123/77 mm Hg). We conclude that, among white hypertensives above the age of 50 years, smokers maintain a higher daytime ambulatory systolic blood pressure than nonsmokers even though blood pressure measured in the office is similar.	CORNELL UNIV,MED CTR,NEW YORK HOSP,CTR CARDIOVASC & HYPERTENS,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital			Mann, Samuel J./AAI-5510-2020					BENOWITZ NL, 1984, CLIN PHARMACOL THER, V36, P74, DOI 10.1038/clpt.1984.142; BERGLUND G, 1975, ACTA MED SCAND, V198, P291; BERLIN I, 1990, EUR J CLIN PHARMACOL, V38, P57, DOI 10.1007/BF00314804; CELLINA GU, 1975, AM HEART J, V89, P18, DOI 10.1016/0002-8703(75)90004-6; DEVEREUX RB, 1988, AM HEART J, V116, P1124, DOI 10.1016/0002-8703(88)90176-7; FREESTONE S, 1982, AM J MED, V73, P348, DOI 10.1016/0002-9343(82)90725-2; GOFIN R, 1982, ISRAEL J MED SCI, V18, P1217; GOLDBOURT U, 1977, AM J EPIDEMIOL, V105, P75, DOI 10.1093/oxfordjournals.aje.a112358; GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8; GREEN MS, 1986, AM HEART J, V111, P932, DOI 10.1016/0002-8703(86)90645-9; GREENE SB, 1977, J CHRON DIS, V30, P401, DOI 10.1016/0021-9681(77)90034-0; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; HIGGINS MW, 1967, AM J EPIDEMIOL, V86, P60, DOI 10.1093/oxfordjournals.aje.a120734; JAMES GD, 1988, HYPERTENSION, V11, P545, DOI 10.1161/01.HYP.11.6.545; JENKINS CD, 1968, CIRCULATION, V38, P1140, DOI 10.1161/01.CIR.38.6.1140; LEVENSON J, 1987, ARTERIOSCLEROSIS, V7, P572, DOI 10.1161/01.ATV.7.6.572; LORENTSEN E, 1972, CIRCULATION, V46, P257, DOI 10.1161/01.CIR.46.2.257; MANN SJ, 1989, AM J MED, V86, P79, DOI 10.1016/0002-9343(89)90137-X; OROURKE M, 1990, HYPERTENSION, V15, P339, DOI 10.1161/01.HYP.15.4.339; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; SPOHR U, 1979, ATHEROSCLEROSIS, V33, P271, DOI 10.1016/0021-9150(79)90179-5; THOMAS CB, 1956, ANN INTERN MED, V44, P874, DOI 10.7326/0003-4819-44-5-874; THULESIUS O, 1978, ANGIOLOGY, V29, P374, DOI 10.1177/000331977802900504; 1964, PUBLICATION US PHS, V1130	24	199	208	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2226	2228		10.1001/jama.265.17.2226	http://dx.doi.org/10.1001/jama.265.17.2226			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013955				2022-12-24	WOS:A1991FH87700035
J	FRANKLIN, RCG; SPIEGELHALTER, DJ; MACARTNEY, FJ; BULL, K				FRANKLIN, RCG; SPIEGELHALTER, DJ; MACARTNEY, FJ; BULL, K			EVALUATION OF A DIAGNOSTIC ALGORITHM FOR HEART-DISEASE IN NEONATES	BRITISH MEDICAL JOURNAL			English	Article							EXPERT SYSTEMS; CHEST PAIN; EMERGENCY; PROTOCOL; INFANTS	Objective-To develop, test, and validate an algorithm for diagnosing disease in neonates during an over the telephone referral to a specialist cardiac centre. Design-A draft algorithm requiring only data available to a referring paediatrician was generated. This was modified in the light of a retrospective review of case records. A questionnaire to elicit all the data required by the algorithm was then generated. There followed a prospective three phase evaluation during consecutive over the telephone referrals. This consisted of (a) a conventional phase with unstructured referral consultations, (b) a phase with referrals structured around the questionnaire but independent of the algorithm, and (c) a validation phase with the algorithm (and its previous errors) available during the referral consultation. Setting-59 paediatric centres in south east England and a central specialist paediatric cardiology unit. Patients-Consecutive neonates (aged < 31 days) referred with suspected heart disease. The retrospective review was of records of 174 neonates from 1979. In the prospective evaluation (1987-90) the conventional phase comprised 71 neonates (over 5.5 months), the structured phase 203 neonates (over 14 months), and the validation phase 195 neonates (over 12 months). Main outcome measures-Diagnostic accuracy (assigning patients to the correct diagnostic category (out of 27)), of the referring paediatrician, the specialist after the referral consultation, and the algorithm as compared with the definitive diagnosis by echocardiography at the specialist centre, and score for the appropriateness of management in transit. Results-Simply structuring the consultation by questionnaire (that is, proceeding from the conventional phase to the structured phase) improved the diagnostic accuracy of both paediatricians (from 34% (24/71 cases) to 48% (97/203) correct) and specialists (from 54% (38/71 cases) to 64% (130/203) correct). The algorithm (structured phase) would have been even more accurate (78% (158/203 cases); p < 0.01). Management scores in the structured phase were also better than in the conventional phase (80% (162/203 cases) upsilon-58% (41/71) appropriate; p < 0.01). Management scores would have improved to 91% appropriate (185/203; p < 0.001) had the algorithmic diagnoses dictated management. The superiority of the algorithm was maintained but not bettered in the validation phase. Conclusions-Applying the algorithm should reduce the morbidity and mortality of neonates with critical heart disease by aiding clinicians in therapeutic decisions for in transit care.	HOSP SICK CHILDREN,PAEDIAT CARDIOL,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; MRC Biostatistics Unit								ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BOVE EL, 1983, ARCH DIS CHILD, V58, P137, DOI 10.1136/adc.58.2.137; Breiman L, 1983, CLASSIFICATION REGRE; COOK DH, 1978, CAN J PUBLIC HEALTH, V69, P297; DANFORD DA, 1986, J AM COLL CARDIOL, V8, P1125, DOI 10.1016/S0735-1097(86)80391-6; FRANKLIN RCG, 1989, INT J CLIN MONIT COM, V6, P157, DOI 10.1007/BF01721028; FRANKLIN RCG, IN PRESS J THORAC CA; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; LAURITZEN SL, 1988, J ROY STAT SOC B MET, V50, P157; LEWIS AB, 1981, CIRCULATION, V64, P893, DOI 10.1161/01.CIR.64.5.893; REALE A, 1908, COMPUT BIOMED RES, V1, P533; ROETHLINGSBURGE.FJ, 1939, MANAGEMENT WORKER; RUBAY J, 1988, CIRCULATION, V78, P1; SCHWARTZ WB, 1987, NEW ENGL J MED, V316, P685, DOI 10.1056/NEJM198703123161109; TEACH RL, 1981, COMPUT BIOMED RES, V14, P542, DOI 10.1016/0010-4809(81)90012-4; WARBURTON D, 1981, ARCH DIS CHILD, V56, P94, DOI 10.1136/adc.56.2.94; WARNER HR, 1961, JAMA-J AM MED ASSOC, V177, P177, DOI 10.1001/jama.1961.03040290005002; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	19	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					935	939		10.1136/bmj.302.6782.935	http://dx.doi.org/10.1136/bmj.302.6782.935			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032035	Green Published, Bronze			2022-12-24	WOS:A1991FH48700017
J	KEMP, AM; SIBERT, JR				KEMP, AM; SIBERT, JR			OUTCOME IN CHILDREN WHO NEARLY DROWN - A BRITISH-ISLES STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the outcome in nearly drowned children in the British Isles and identify factors that might predict a poor prognosis. Design-Study of drowned and of nearly drowned children aged less-than-or-equal-to 14. Information on nearly drowned children admitted to hospital obtained from consultant paediatricians returning monthly notification cards through the British Paediatric Surveillance Unit. Information on drowned children obtained from Office of Population Censuses and Surveys and other national epidemiological offices. Setting-British Isles, 1988 and 1989. Subjects-330 children who had confirmed submersion incidents. 142 died before admission to hospital and 188 children were admitted after nearly drowning. Main outcome measures-Death, full recovery, or degree of handicap after near drowning and signs on admission to hospital. Results-All of the children who were conscious on admission fully recovered. Of the 64 children unconscious on admission, 31 had normally reactive pupils and all but three (all of whom had severe pre-existing neurological disease) recovered fully. Of the 33 children with fixed dilated pupils on admission, 10 fully recovered, 13 died, and 10 had severe neurological deficit. Spontaneous respiratory effect on admission was associated with normal survival. Pupils that remained dilated six hours after admission and fits continuing 24 hours after admission predicted a poor outcome. Conclusion-Children can survive normally after near drowning in the British Isles, particularly if they have been hypothermic. Resuscitation should not be abandoned in nearly drowned children until they have been rewarmed.	UNIV COLL CARDIFF,LLANDOUGH HOSP,COLL MED,DEPT CHILD HLTH,CARDIFF CF6 1XX,S GLAM,WALES	Cardiff University								CONN AW, 1984, CAN ANAESTH SOC J, V31, pS38, DOI 10.1007/BF03007034; FRATES RC, 1981, AM J DIS CHILD, V135, P1006, DOI 10.1001/archpedi.1981.02130350010004; FREWEN TC, 1985, J PEDIATR-US, V106, P615, DOI 10.1016/S0022-3476(85)80085-8; GOLDEN F, 1980, BR J HOSP MED, V23, P373; HARRIES M, 1986, BMJ, V293, P123; MODELL JH, 1976, CHEST, V70, P231, DOI 10.1378/chest.70.2.231; MODELL JH, 1981, CRIT CARE MED, V9, P351; OCARROLL PW, 1988, JAMA-J AM MED ASSOC, V260, P380, DOI 10.1001/jama.260.3.380; ORLOWSKI JP, 1988, JAMA-J AM MED ASSOC, V26, P390; PEARN J, 1977, LANCET, V1, P7; PEARN J, 1985, BRIT MED J, V291, P1447, DOI 10.1136/bmj.291.6507.1447; PEARN JH, 1979, MED J AUSTRALIA, V1, P463, DOI 10.5694/j.1326-5377.1979.tb127044.x; PEARN JH, 1979, PEDIATRICS, V64, P187; PETERSON B, 1977, PEDIATRICS, V59, P364; RAMEY CA, 1987, J APPL PHYSIOL, V63, P665, DOI 10.1152/jappl.1987.63.2.665; 1989, DEATHS CAUSE 1988 RE	16	44	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					931	933		10.1136/bmj.302.6782.931	http://dx.doi.org/10.1136/bmj.302.6782.931			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032033	Green Published, Bronze			2022-12-24	WOS:A1991FH48700015
J	LECHLEITER, J; GIRARD, S; PERALTA, E; CLAPHAM, D				LECHLEITER, J; GIRARD, S; PERALTA, E; CLAPHAM, D			SPIRAL CALCIUM WAVE-PROPAGATION AND ANNIHILATION IN XENOPUS-LAEVIS OOCYTES	SCIENCE			English	Article							SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; RELEASE; ACTIVATION; CURVATURE; MODEL	Intracellular calcium (Ca2+) is a ubiquitous second messenger. Information is encoded in the magnitude, frequency, and spatial organization of changes in the concentration of cytosolic free Ca2+. Regenerative spiral waves of release of free Ca2+ were observed by confocal microscopy in Xenopus laevis oocytes expressing muscarinic acetylcholine receptor subtypes. This pattern of Ca2+ activity is characteristic of an intracellular milieu that behaves as a regenerative excitable medium. The minimal critical radius for propagation of focal Ca2+ waves (10.4 micrometers) and the effective diffusion constant for the excitation signal (2.3 x 10(-6) square centimeters per second) were estimated from measurements of velocity and curvature of circular wavefronts expanding from foci. By modeling Ca2+ release with cellular automata, the absolute refractory period for Ca2+ stores (4.7 seconds) was determined. Other phenomena expected of an excitable medium, such as wave propagation of undiminished amplitude and annihilation of colliding wavefronts, were observed.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Mayo Clinic; Harvard University			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				BACKX PH, 1989, J GEN PHYSIOL, V93, P963, DOI 10.1085/jgp.93.5.963; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1989, PROC R SOC SER B-BIO, V238, P235, DOI 10.1098/rspb.1989.0079; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CHEEK TR, 1989, J CELL SCI, V93, P211; DASCAL N, 1990, FEBS LETT, V267, P22, DOI 10.1016/0014-5793(90)80278-Q; DELISLE S, 1990, J BIOL CHEM, V265, P11726; FOERSTER P, 1989, P NATL ACAD SCI USA, V86, P6831, DOI 10.1073/pnas.86.18.6831; FOERSTER P, 1988, SCIENCE, V241, P685, DOI 10.1126/science.241.4866.685; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HARKINS A B, 1991, Biophysical Journal, V59, p240A; KEENER JP, 1986, PHYSICA D, V21, P307, DOI 10.1016/0167-2789(86)90007-2; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, IN PRESS NATURE; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAYLOR CW, 1989, BIOCHEM J, V259, P645, DOI 10.1042/bj2590645; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; Winfree AT, 1987, TIME BREAKS; WINFREE AT, 1990, ANN NY ACAD SCI, V591, P190; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	32	610	624	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1991	252	5002					123	126		10.1126/science.2011747	http://dx.doi.org/10.1126/science.2011747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011747				2022-12-24	WOS:A1991FE95200049
J	JOHNSEN, R; BERNERSEN, B; STRAUME, B; FORDE, OH; BOSTAD, L; BURHOL, PG				JOHNSEN, R; BERNERSEN, B; STRAUME, B; FORDE, OH; BOSTAD, L; BURHOL, PG			PREVALENCES OF ENDOSCOPIC AND HISTOLOGICAL-FINDINGS IN SUBJECTS WITH AND WITHOUT DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							PEPTIC-ULCER DISEASE; CHRONIC GASTRITIS; DUODENAL-ULCER; BIOPSY SPECIMENS; WORKING PARTY; DIAGNOSIS; SYMPTOMS; GASTRODUODENITIS; VOLUNTEERS; MANAGEMENT	Objective-To examine the association between dyspeptic symptoms and endoscopic and histological diagnoses. Design-Cross sectional study of people with dyspepsia and controls matched for age and sex identified by questionnaire survey of all inhabitants aged 20 to 69. Endoscopy and histological examination was performed with the examiner blind to whether or not the patient had dyspepsia. Setting-Population based survey in Sorreisa, Norway. Subjects-All people with dyspepsia and age and sex matched people without dyspepsia were offered endoscopy. A total of 309 people with dyspepsia and 310 without dyspepsia underwent endoscopy, giving 273 matched pairs. Main outcome measures-Prevalences of endoscopic and histological diagnoses made according to internationally accepted standards. Results-In all, 1802 of 2027 (88.9%) people returned the questionnaire. Of the 163 subjects who refused endoscopy, 114 were controls. Of five endoscopic and four histological diagnoses only peptic ulcer disease, endoscopic duodenitis, and active chronic gastritis were diagnosed significantly more often in people with dyspepsia. In all, 30% to 50% of the diagnoses of mucosal inflammation and peptic ulcer disease were made among subjects without dyspepsia, and only 10% of both those with and those without dyspepsia had normal endoscopic findings. Conclusions-The diagnostic findings, with possible exceptions of peptic ulcer disease and endoscopic duodenitis, showed no association of clinical value with dyspeptic symptoms. The small number of "normal" endoscopic findings in both those with and those without dyspepsia challenge well accepted endoscopic and histological diagnostic criteria with relation to the upper gastrointestinal tract.			JOHNSEN, R (corresponding author), UNIV TROMSO,GEN PRACTICE,N-9000 TROMSO,NORWAY.							AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; BARBARA L, 1989, DIGEST DIS SCI, V34, P1272, DOI 10.1007/BF01537277; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; CHELI R, 1982, SCAND J GASTROENTERO, V17, P84; CHELI R, 1986, ENDOSCOPY, V18, P125, DOI 10.1055/s-2007-1018350; CHELI R, 1983, HEPATO-GASTROENTEROL, V30, P21; COLINJONES DG, 1988, LANCET, V1, P576; DANIELSSON A, 1980, ANN CLIN RES, V12, P4; DELUCA VA, 1981, J CLIN GASTROENTEROL, V3, P17; EARLAM RJ, 1985, GUT, V26, P95, DOI 10.1136/gut.26.1.95; GREENLAW R, 1980, DIGEST DIS SCI, V25, P660, DOI 10.1007/BF01308325; GUSLANDI M, 1986, Digestive Diseases, V4, P231, DOI 10.1159/000171153; JOFFE SN, 1982, SCAND J GASTROENTERO, V17, P62; JOFFE SN, 1982, SCAND J GASTROENTERO, V17, P88; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; JORDE R, 1986, LANCET, V1, P119; KREUNING J, 1978, J CLIN PATHOL, V31, P69, DOI 10.1136/jcp.31.1.69; MACKINNON M, 1982, DIGEST DIS SCI, V27, P217, DOI 10.1007/BF01296918; MYREN J, 1974, SCAND J GASTROENTERO, V9, P457; NIE NH, 1975, STATISTICAL PACKAGE; OWEN DA, 1979, PATHOL ANNU, V1, P247; SAVARY M, 1977, LEHRBUCH ENDOSKOPISC; SIRCUS W, 1985, Q J MED, V56, P593; Siurala M, 1980, Front Gastrointest Res, V6, P148; Snedecor G. W., 1967, STATISTICAL METHODS, P432; SPIRO HM, 1974, NEW ENGL J MED, V291, P567, DOI 10.1056/NEJM197409122911107; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; THOMSON WO, 1977, LANCET, V1, P1197; TOUKAN AU, 1985, DIGEST DIS SCI, V30, P313, DOI 10.1007/BF01403839; VENABLES CW, 1985, SCAND J GASTROENTERO, V20, P91, DOI 10.3109/00365528509103941; VILLAKO K, 1984, ANN CLIN RES, V16, P192; VILLAKO K, 1976, SCAND J GASTROENTERO, V2, P817; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701; 1985, LANCET, V2, P1222	35	200	204	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					749	752		10.1136/bmj.302.6779.749	http://dx.doi.org/10.1136/bmj.302.6779.749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021764	Bronze, Green Published			2022-12-24	WOS:A1991FF22900019
J	BARRY, M				BARRY, M			THE INFLUENCE OF THE UNITED-STATES TOBACCO INDUSTRY ON THE HEALTH, ECONOMY, AND ENVIRONMENT OF DEVELOPING-COUNTRIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SMOKING				BARRY, M (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06504, USA.							CHANDLER WU, 1986, 68 WORLDW I WORLDW P, P20; COCKBURN A, 1989, NATION          1030, P482; CONNOLLY G, 1989, 1989 TOB US AM C HOU, P49; CORTI EC, 1931, HIST SMOKING, P1; COYLE P, 1990, NEW HAVEN REGIS 0625, P5; COYLE P, 1990, NEW HAVEN REGIS 0625, P1; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P993; FORBES WF, 1985, STRATEGIES SMOKE FRE, P21; JACOBSON B, 1983, BRIT MED J, V287, P483, DOI 10.1136/bmj.287.6390.483; JONES D, 1989, TOBACCO REPORTER JAN, P32; LEWIN T, 1990, NY TIMES        0524, pB10; Lewin Tamar, 1990, N Y Times Web, pA15; MAKHYOUN NA, 1974, BRIT J CANCER, V30, P577, DOI 10.1038/bjc.1974.238; NATH UR, 1986, WORLD HLTH       JUN, P6; NATH UR, 1986, SMOKING 3RD WORLD AL, P192; PETO R, 1987, LANCET, V2, P211; SAYCEL K, 1987, ENCY ZIMBABWE, P380; STEBBINS KR, 1990, SOC SCI MED, V30, P227, DOI 10.1016/0277-9536(90)90084-6; Taylor SA, 1989, BUSINESS CONT WO WIN, V55, P55; WARNER KE, 1990, AM J PUBLIC HEALTH, V80, P529, DOI 10.2105/AJPH.80.5.529; WHELAN E, 1984, SMOKING GUN TOBACCO, P167; WILLCOX PA, 1982, THORAX, V37, P598, DOI 10.1136/thx.37.8.598; YACH D, 1986, INT J HEALTH SERV, V16, P279, DOI 10.2190/Q27T-A7ER-0PYK-9LED; 1983, WHO TECH REP SER, V695; 1989, FT889 DEP AGR REP; 1990, JAMA-J AM MED ASSOC, V263, P3312; 1988, ADVERTISING AGE 1121, P37; 1990, MMWR, V39, P1; 1988, ACTIVITIES P MORRIS; 1990, MMWR, V39, P261	31	36	37	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					917	920		10.1056/NEJM199103283241311	http://dx.doi.org/10.1056/NEJM199103283241311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000116				2022-12-24	WOS:A1991FD11100011
J	KATO, H; HORIKOSHI, M; ROEDER, RG				KATO, H; HORIKOSHI, M; ROEDER, RG			REPRESSION OF HIV-1 TRANSCRIPTION BY A CELLULAR PROTEIN	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PREINITIATION COMPLEX; GENE-EXPRESSION; T-ANTIGEN; BINDING; PROMOTER; TATA; REGION	A cellular DNA binding protein, LBP-1, sequentially interacts in a concentration-dependent manner with two sites that surround the transcriptional initiation site of the human immunodeficiency virus type 1 (HIV-1) promoter. Although sequences in the downstream site (site I) were found to enhance transcription, purified LBP-1 specifically repressed transcription in vitro by binding to the upstream site (site II), which overlaps the TATA element. The binding of human TATA binding factor (TFIID) to the promoter before LBP-1 blocked repression, suggesting that repression resulted from an inhibition of TFIID binding to the TATA element. Furthermore, mutations that eliminated binding to site II both prevented repression in vitro and increased HIV-1 transcription in stably transformed cells. These findings suggest that a cellular factor regulates HIV-1 transcription in a manner that is characteristic of bacterial repressors and that this factor could be important in HIV-1 latency.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; Horikoshi M., UNPUB; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KATO H, UNPUB; KLIEWER S, 1989, J VIROL, V63, P4616, DOI 10.1128/JVI.63.11.4616-4625.1989; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PAVLAKIS GN, 1990, BIOLOGIST, V2, P20; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	38	142	145	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1476	1479		10.1126/science.2006421	http://dx.doi.org/10.1126/science.2006421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006421				2022-12-24	WOS:A1991FC85300045
J	SALOMAA, VV; STRANDBERG, TE; VANHANEN, H; NAUKKARINEN, V; SARNA, S; MIETTINEN, TA				SALOMAA, VV; STRANDBERG, TE; VANHANEN, H; NAUKKARINEN, V; SARNA, S; MIETTINEN, TA			GLUCOSE-TOLERANCE AND BLOOD-PRESSURE - LONG-TERM FOLLOW-UP IN MIDDLE-AGED MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESSENTIAL-HYPERTENSION; INSULIN RESISTANCE; HYPERINSULINEMIA	Objective - To investigate the role of glucose tolerance in the development of hypertension. Design - Retrospective analysis of the results of a health check up in a group of clinically healthy middle aged men in the late 1960s (median year 1968). The subjects were invited to enter into a primary prevention trial for cardiovascular disease in 1974, when they underwent clinical examination for risk factors. The trial was completed in 1979, when the men were re-examined. Follow up was in 1986. Setting - Institute of Occupational Health, Helsinki, Finland and second department of medicine, University of Helsinki. Subjects - In all, 3490 men born during 1919-34 participated in a health check up in the late 1960s. In 1974, 1815 of these men who were clinically healthy were entered into a primary prevention trial for cardiovascular disease. On clinical examination 1222 of the men were considered at high risk of cardiovascular disease. Of these, 612 received an intervention and were excluded from the study. A total of 593 men were without risk factors. The study comprised all of the men who did not have an intervention (n = 1203). In 1979, 1120 men were re-examined, and in 1986 945 men attended follow up. There were two groups for analysis: one comprising all subjects and the other comprising only men who were normotensive in 1968 and for whom complete information was available. Interventions - By 1979, 103 men were taking antihypertensive drugs, and by 1986, 131 were taking antihypertensive drugs and 12 were taking drugs for hyperglycaemia. Main outcome measures - Blood glucose concentration one hour after a glucose load, blood pressure, and body weight were measured in 1968, 1974, and 1979. In 1986 blood pressure and body weight were recorded. Results - Men who were hypertensive in 1986 had significantly higher blood pressures (p < 0.0001) and (after adjustment for body mass index and alcohol intake) significantly higher blood glucose concentrations one hour after a glucose load at all examinations than those who were normotensive in 1986. Regression analysis showed that the higher the blood glucose concentration after a glucose load in 1968 the higher the blood pressure during the following years. Those men between the second and third tertiles of blood glucose concentration in 1968 had a significantly higher risk of developing hypertension (odds ratio 1.71, 95% confidence interval 1.05 to 2.77) compared with those below the first tertile. Conclusion - In this study men who developed hypertension tended to have shown an increased intolerance to glucose up to 18 years before the clinical manifestation of their disorder. Blood glucose concentration one hour after a glucose load was an independent predictor of future hypertension.	UNIV HELSINKI, DEPT MED 2, SF-00100 HELSINKI 10, FINLAND; JORVI DIST HOSP, DEPT MED, ESPOO, FINLAND; UNIV HELSINKI, DEPT PUBL HLTH SCI, SF-00100 HELSINKI 10, FINLAND	University of Helsinki; University of Helsinki	SALOMAA, VV (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL, SF-00510 HELSINKI, FINLAND.			Sarna, Seppo/0000-0003-3458-1627; strandberg, timo/0000-0001-6299-925X				DIXON WJ, 1985, BMDP STATISTICAL SOF; DUVFLOREY C, 1976, BRIT MED J, V1, P1368, DOI 10.1136/bmj.1.6022.1368; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FOSTER DW, 1989, NEW ENGL J MED, V320, P733, DOI 10.1056/NEJM198903163201111; FOURNIER AM, 1986, AM J MED, V80, P861, DOI 10.1016/0002-9343(86)90629-7; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HULTMAN E, 1959, NATURE, V183, P108, DOI 10.1038/183108a0; JARRETT RJ, 1978, INT J EPIDEMIOL, V7, P15, DOI 10.1093/ije/7.1.15; Kessler G., 1966, AUTOMATION ANALYTICA, P341; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTILA S, 1980, THESIS U HELSINKI FI; MBANYA JCN, 1988, LANCET, V1, P733; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NAUKKARINEN VA, 1989, ANN MED, V21, P441, DOI 10.3109/07853898909149236; PORTA M, 1988, NEW ENGL J MED, V318, P383; REAVEN PD, 1990, DIABETES CARE, V13, P119, DOI 10.2337/diacare.13.2.119; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105; 1985, WHO TECH REP SER, V727	20	65	69	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 2	1991	302	6775					493	496		10.1136/bmj.302.6775.493	http://dx.doi.org/10.1136/bmj.302.6775.493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB055	2012844	Bronze, Green Published			2022-12-24	WOS:A1991FB05500016
J	GUO, XD; JOHNSON, JJ; KRAMER, JM				GUO, XD; JOHNSON, JJ; KRAMER, JM			EMBRYONIC LETHALITY CAUSED BY MUTATIONS IN BASEMENT-MEMBRANE COLLAGEN OF C-ELEGANS	NATURE			English	Article							CAENORHABDITIS-ELEGANS; IV COLLAGEN; DNA; SEQUENCE; REGION; DOMAIN; GENES; CHAIN	BASEMENT membranes are specialized forms of extracellular matrix with important functions in development 1-3. A major structural component of basement membranes is type IV collagen, a heterotrimer of two alpha-1(IV) and one alpha-2(IV) chains, which forms a complex, polygonal network associated with other basement membrane components 4,5. Here we report that the alpha-1(IV) collagen chain of Caenorhabditis elegans is encoded by the genetic locus emb-9. Mutations in emb-9 cause temperature-sensitive lethality during late embryogenesis. We have identified single nucleotide alterations that substitute glutamic acid for glycine in the triple-helical Gly-X-Y repeat region of the alpha-1(IV) collagen in three emb-9 mutant strains. These results are direct evidence that defects in basement membranes can disrupt embryonic development and form a basis for the genetic analysis of basement membrane function.	UNIV ILLINOIS,DEPT BIOL SCI,MOLEC BIOL LAB,POB 4348,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; CASADA R, 1981, DEV BIOL, V84, P193; CHEAH KSE, 1985, BIOCHEM J, V229, P287, DOI 10.1042/bj2290287; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GLANVILLE RW, 1985, EUR J BIOCHEM, V152, P213, DOI 10.1111/j.1432-1033.1985.tb09186.x; GREENWALD I, 1987, NUCLEIC ACIDS RES, V15, P2295, DOI 10.1093/nar/15.5.2295; GUO XD, 1989, J BIOL CHEM, V264, P17574; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; ISNENGHI E, 1983, DEV BIOL, V98, P465, DOI 10.1016/0012-1606(83)90376-7; KRAMER JM, 1988, CELL, V55, P555, DOI 10.1016/0092-8674(88)90214-0; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MIWA J, 1980, DEV BIOL, V76, P160, DOI 10.1016/0012-1606(80)90369-3; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SOININEN R, 1987, FEBS LETT, V225, P188; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	27	90	95	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					707	709		10.1038/349707a0	http://dx.doi.org/10.1038/349707a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1996137				2022-12-24	WOS:A1991EY62700051
J	COMPANY, M; ARENAS, J; ABELSON, J				COMPANY, M; ARENAS, J; ABELSON, J			REQUIREMENT OF THE RNA HELICASE-LIKE PROTEIN PRP22 FOR RELEASE OF MESSENGER-RNA FROM SPLICEOSOMES	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; NUCLEOTIDE-SEQUENCE; RIBOSOMAL PROTEIN-S1; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNIT; PUTATIVE HELICASES; YEAST; GENE; CLONING; ATP	The product of the yeast PRP22 gene acts late in the splicing of yeast pre-messenger RNA, mediating the release of the spliced mRNA from the spliceosome. The predicted PRP22 protein sequence shares extensive homology with that of PRP2 and PRP16 proteins, which are also involved in nuclear pre-mRNA splicing. The homologous region contains sequence elements characteristic of several demonstrated or putative ATP-dependent RNA helicases. A putative RNA-binding motif originally identified in bacterial ribosomal protein S1 and Escherichia coli polynucleotide phosph orylase has also been found in PRP22.			COMPANY, M (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BJORN SP, 1989, MOL CELL BIOL, V9, P3698, DOI 10.1128/MCB.9.9.3698; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.bi.55.070186.003123; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHANG TH, 1990, P NATL ACAD SCI USA, V87, P1571, DOI 10.1073/pnas.87.4.1571; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; ERNST H, 1987, J BIOL CHEM, V262, P1206; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAIN S, 1989, GENE, V82, P357, DOI 10.1016/0378-1119(89)90063-2; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LAIN S, 1989, VIRUS RES, V13, P157, DOI 10.1016/0168-1702(89)90013-0; LAIN S, 1991, J VIROL, V65, P1, DOI 10.1016/0042-6822(91)90641-N; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LANE D, 1988, NATURE, V334, P478, DOI 10.1038/334478a0; LIN RJ, 1987, GENE DEV, V1, P7, DOI 10.1101/gad.1.1.7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; MACKOW E, 1987, VIROLOGY, V159, P217, DOI 10.1016/0042-6822(87)90458-2; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RAY BK, 1985, J BIOL CHEM, V260, P7651; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1991, TRENDS GENET, V7, P79; SANDS JF, 1987, NUCLEIC ACIDS RES, V15, P5157, DOI 10.1093/nar/15.13.5157; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHNIER J, 1988, NUCLEIC ACIDS RES, V16, P3075, DOI 10.1093/nar/16.7.3075; SCHNIER J, 1982, P NATL ACAD SCI-BIOL, V79, P1008, DOI 10.1073/pnas.79.4.1008; SCHNIER J, 1985, MOL GEN GENET, V200, P476, DOI 10.1007/BF00425734; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIJBENMULLER G, 1986, NUCLEIC ACIDS RES, V14, P1029, DOI 10.1093/nar/14.2.1029; SIKORSKI RS, 1989, GENETICS, V122, P19; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1985, ESSAYS BIOCHEM, V21, P45; UMESONO K, 1984, NUCLEIC ACIDS RES, V12, P9551, DOI 10.1093/nar/12.24.9551; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; VIJAYRAGHAVAN U, 1989, NUCLEIC ACIDS MOL BI, V3, P197; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	67	303	307	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 7	1991	349	6309					487	493		10.1038/349487a0	http://dx.doi.org/10.1038/349487a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1992352				2022-12-24	WOS:A1991EW57100055
J	KEMP, JS; THACH, BT				KEMP, JS; THACH, BT			SUDDEN-DEATH IN INFANTS SLEEPING ON POLYSTYRENE-FILLED CUSHIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COT DEATH; HONG-KONG; AROUSAL; RESPONSES; MECHANISM; POSITION; SIDS	Background. Infants are at risk for both the sudden infant death syndrome (SIDS) and accidental suffocation. On postmortem examination, however, it is difficult to distinguish one from the other without information from the scene of death. Healthy infants are assumed to be able to turn their heads and, if not otherwise restrained, to obtain fresh air. We assessed this assumption in an investigation of infant deaths that occurred during sleep on cushions filled with polystyrene beads. Methods. We obtained data on 25 deaths from the U.S. Consumer Product Safety Commission. We also used mechanical and animal models to study physiologic aspects of ventilation relevant to these results, by simulating the effects on an infant of breathing into a cushion. We measured the effects of softness, malleability (molding of the cushion about an infant's head), airflow resistance, and rebreathing of expired gases. Results. All 25 study infants were prone when found dead, and at least 88 percent were face down with nose and mouth obstructed by the cushion. SIDS was the diagnosis in 19 of the 23 infants who underwent autopsy. Our findings show, however, that the cushion would have limited movement of the infant's head to obtain fresh air, and the amount of rebreathing we estimated to have occurred in the infants was lethal in a rabbit model. Conclusions. Accidental suffocation by rebreathing was the most likely cause of death in most of the 25 infants studied. Consequently, there is a need to reassess the cause of death in the 28 to 52 percent of the victims of SIDS who are found with their faces straight down. Safety regulations setting standards for softness, malleability, and the potential for rebreathing are needed for infant bedding.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, DIV PULM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, DIV NEWBORN MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NICHD NIH HHS [HD-10993] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD010993, R01HD010993] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADELSON L, 1956, PEDIATRICS, V17, P663; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; Batchelor G.K., 1967, INTRO FLUID DYNAMICS, P233; BECKWITH JB, 1988, ANN NY ACAD SCI, V533, P37, DOI 10.1111/j.1749-6632.1988.tb37232.x; BECKWITH JB, 1967, HOSP PRACT, V2, P44; BECKWITH JB, 1988, SUDDEN INFANT DEATH, P48; BOWDEN K, 1950, Med J Aust, V1, P65; CAMPS FE, 1970, SUDDEN UNEXPECTED DE, P1; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; EMERY JL, 1970, SUDDEN UNEXPECTED DE, P124; FEWELL JE, 1989, J DEV PHYSIOL, V11, P77; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GESELL A, 1934, INFANT BEHAV, P61; GOLIN M, 1959, JAMA-J AM MED ASSOC, V169, P2021; GORDON I, 1982, FORENSIC MED GUIDE P, P31; GUGGER M, 1989, AM REV RESPIR DIS, V140, P1301, DOI 10.1164/ajrccm/140.5.1301; GUNTHEROTH WG, 1989, CRIB DEATH SUDDEN IN, P21; HATCH DJ, 1982, ARCH DIS CHILD, V57, P443, DOI 10.1136/adc.57.6.443; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HUNT CE, 1981, J APPL PHYSIOL, V50, P1313, DOI 10.1152/jappl.1981.50.6.1313; ILLINGWORTH RS, 1980, DEV INFANT YOUNG CHI, P117; Jones A M, 1976, J Forensic Sci, V21, P833; KEMP J, 1990, PEDIATR RES, V27, pA358; KRAUS JF, 1985, PUBLIC HEALTH REP, V100, P231; KROUS HF, 1988, SUDDEN INFANT DEATH, P18; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MCGLASHAN ND, 1988, LANCET, V2, P106; MOUNTCASTLE VB, 1980, MED PHYSL, P1369; NELSON EAS, 1989, AUST PAEDIATR J, V25, P202; PETERSON DR, 1988, ANN NY ACAD SCI, V533, P6, DOI 10.1111/j.1749-6632.1988.tb37229.x; PHILLIPSON EA, 1978, AM REV RESPIR DIS, V118, P807; POLSON CJ, 1985, ESSENTIALS FORENSIC, P583; SMIALEK J E, 1988, Pediatrician, V15, P191; Sturner W Q, 1976, J Forensic Sci, V21, P483; STURNER WQ, 1977, FORENSIC MED, V2, P1015; SULLIVAN CE, 1979, J APPL PHYSIOL, V47, P1304, DOI 10.1152/jappl.1979.47.6.1304; TAN S, 1989, PEDIATR RES, V25, pA328; THACH BT, 1988, ANN NY ACAD SCI, V533, P314, DOI 10.1111/j.1749-6632.1988.tb37261.x; VALDESDAPENA MA, 1967, PEDIATRICS, V39, P123; WINN K, 1986, Pediatric Pathology, V5, P325; WOOLLEY PV, 1945, J PEDIATR-US, V26, P572, DOI 10.1016/S0022-3476(45)80085-9; 1990, FED REGISTER, V55, P42202; 1970, BS4578 BRIT STAND I	44	132	137	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1991	324	26					1858	1864		10.1056/NEJM199106273242605	http://dx.doi.org/10.1056/NEJM199106273242605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT580	2041551				2022-12-24	WOS:A1991FT58000005
J	MCGEE, S				MCGEE, S			RESTLESS LEGS SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DOUBLE-BLIND; PERIODIC MOVEMENTS; SLEEP				MCGEE, S (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195, USA.							AKPINAR S, 1987, CLIN NEUROPHARMACOL, V10, P69; BRODEUR C, 1988, NEUROLOGY, V38, P1845, DOI 10.1212/WNL.38.12.1845; CLOUGH C, 1987, BRIT MED J, V294, P262, DOI 10.1136/bmj.294.6567.262; EKBOM KA, 1970, HDB CLIN NEUROLOGY, V8, P311; GIBB WRG, 1986, POSTGRAD MED J, V62, P329, DOI 10.1136/pgmj.62.727.329; KRUEGER BR, 1990, MAYO CLIN PROC, V65, P999, DOI 10.1016/S0025-6196(12)65163-5; MONTAGNA P, 1984, ACTA NEUROL SCAND, V69, P428, DOI 10.1111/j.1600-0404.1984.tb07826.x; TELSTAD W, 1984, BRIT MED J, V288, P444, DOI 10.1136/bmj.288.6415.444; VONSCHEELE C, 1986, LANCET, V2, P426; WALTERS AS, 1988, ANN NEUROL, V24, P455, DOI 10.1002/ana.410240318	10	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1991	265	22					3014	3014		10.1001/jama.265.22.3014	http://dx.doi.org/10.1001/jama.265.22.3014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP635	2033777				2022-12-24	WOS:A1991FP63500044
J	DAVANZO, J; PARNELL, AM; FOEGE, WH				DAVANZO, J; PARNELL, AM; FOEGE, WH			HEALTH CONSEQUENCES OF CONTRACEPTIVE USE AND REPRODUCTIVE PATTERNS - SUMMARY OF A REPORT FROM THE UNITED-STATES NATIONAL-RESEARCH-COUNCIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY		RAND CORP,SANTA MONICA,CA 90406; DUKE UNIV,DEPT SOCIOL,DURHAM,NC 27706; EMORY UNIV,CARTER CTR,ATLANTA,GA 30322; NATL RES COUNCIL,COMM POPULAT,WASHINGTON,DC 20418	RAND Corporation; Duke University; Emory University; National Academies of Sciences, Engineering & Medicine								HAAGA J, 1989, CONTRACEPTION REPROD, V2; HOBCRAFT J, 1987, OCT INT C BETT HLTH; KRAMER MS, 1987, PEDIATRICS, V80, P502; KWAST BE, 1986, STUD FAMILY PLANN, V17, P288, DOI 10.2307/1966906; SCRIMSHAW SCM, 1978, POPUL DEV REV, V4, P383, DOI 10.2307/1972856; 1989, CONTRACEPTION REPROD	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2692	2696						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL989	2023350				2022-12-24	WOS:A1991FL98900034
J	KESTLER, HW; RINGLER, DJ; MORI, K; PANICALI, DL; SEHGAL, PK; DANIEL, MD; DESROSIERS, RC				KESTLER, HW; RINGLER, DJ; MORI, K; PANICALI, DL; SEHGAL, PK; DANIEL, MD; DESROSIERS, RC			IMPORTANCE OF THE NEF GENE FOR MAINTENANCE OF HIGH VIRUS LOADS AND FOR DEVELOPMENT OF AIDS	CELL			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; OPEN READING FRAME; RHESUS-MONKEYS; PERSISTENT INFECTION; MUTATIONAL ANALYSIS; MACAQUE MONKEYS; HTLV-III; SOR GENE; TYPE-1; PROTEIN	When rhesus monkeys were infected with a form of cloned SIVmac239 having a premature stop signal at the 93rd codon of nef, revertants with a coding codon at this position quickly and universally came to predominate in the infected animals. This suggests that there are strong selective forces for open functional forms of nef in vivo. Although deletion of nef sequences had no detectable effect on virus replication in cultured cells, deletion of nef sequences dramatically altered the properties of virus in infected rhesus monkeys. Our results indicate that nef is required for maintaining high virus loads during the course of persistent infection in vivo and for full pathologic potential. Thus, nef should become a target for antiviral drug development. Furthermore, the properties of virus with a deletion in nef suggest a means for making live-attenuated strains of virus for experimental vaccine testing.	APPLIED BIOTECHNOL,CAMBRIDGE,MA 02142		KESTLER, HW (corresponding author), HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772, USA.			Mori, Kazuyasu/0000-0002-1841-6376	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI25328] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ARMSTRONG JA, 1984, LANCET, V2, P370; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; COHEN EA, 1988, NATURE, V334, P532, DOI 10.1038/334532a0; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; CULLEN BR, 1990, VIROLOGY, V178, P1, DOI 10.1016/0042-6822(90)90373-Y; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1988, J VIROL, V62, P4123, DOI 10.1128/JVI.62.11.4123-4128.1988; DESROSIERS RC, 1981, J GEN VIROL, V56, P119, DOI 10.1099/0022-1317-56-1-119; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; GUYADER M, 1989, EMBO J, V8, P1169, DOI 10.1002/j.1460-2075.1989.tb03488.x; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAMINCHIK J, 1990, J VIROL, V64, P3447, DOI 10.1128/JVI.64.7.3447-3454.1990; KAMINCHIK J, 1991, J VIROL, V65, P583, DOI 10.1128/JVI.65.2.583-588.1991; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1988, NATURE, V331, P619, DOI 10.1038/331619a0; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; MALIM MH, 1989, P NATL ACAD SCI USA, V86, P8222, DOI 10.1073/pnas.86.21.8222; MILMAN G, 1981, SOMAT CELL GENET, V7, P161; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P8219, DOI 10.1093/nar/13.22.8219; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; RINGLER DJ, 1989, AM J PATHOL, V134, P373; SAKAI H, 1990, J VIROL, V64, P2202, DOI 10.1128/JVI.64.5.2202-2207.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; VIGLIANTI GA, 1990, J VIROL, V64, P4207, DOI 10.1128/JVI.64.9.4207-4216.1990; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329; ZWEIG M, 1990, VIROLOGY, V179, P504, DOI 10.1016/0042-6822(90)90325-L	49	1496	1524	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					651	662		10.1016/0092-8674(91)90097-I	http://dx.doi.org/10.1016/0092-8674(91)90097-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032289				2022-12-24	WOS:A1991FM03700015
J	PHILPOTT, A; LENO, GH; LASKEY, RA				PHILPOTT, A; LENO, GH; LASKEY, RA			SPERM DECONDENSATION IN XENOPUS EGG CYTOPLASM IS MEDIATED BY NUCLEOPLASMIN	CELL			English	Article							NUCLEOSOME ASSEMBLY INVITRO; HEN ERYTHROCYTE NUCLEI; CELL-FREE PREPARATIONS; PRONUCLEAR FORMATION; RABBIT SPERMATOZOA; HISTONE COMPLEXES; DNA-REPLICATION; LAEVIS OOCYTES; ACIDIC PROTEIN; SOMATIC CELLS	At fertilization, sperm chromatin decondenses in two stages, which can be mimicked in extracts of Xenopus eggs. Rapid, limited decondensation is followed by slower, membrane-dependent decondensation and swelling. Nucleoplasmin, an acidic nuclear protein, occurs at high concentration in Xenopus eggs and has a histone-binding role in nucleosome assembly. Immunodepleting nucleoplasmin from egg extracts inhibits the initial rapid stage of sperm decondensation, and also the decondensation of myeloma nuclei, relative to controls of mock depletion and TFIIIA depletion. Readdition of purified nucleoplasmin recues depleted extracts. A physiological concentration of purified nucleoplasmin alone decondenses both sperm and myeloma nuclei. We conclude that nucleoplasmin is both necessary and sufficient for the first stage of sperm decondensation in Xenopus eggs.	UNIV CAMBRIDGE, DEPT ZOOL, CANC RES CAMPAIGN, MOLEC EMBRYOL GRP, CAMBRIDGE CB2 3EJ, ENGLAND	CRUK Cambridge Institute; University of Cambridge				Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRY JM, 1972, EXP CELL RES, V71, P90, DOI 10.1016/0014-4827(72)90267-4; BEDFORD JM, 1974, J EXP ZOOL, V188, P137, DOI 10.1002/jez.1401880203; BERRIOS M, 1990, EXP CELL RES, V191, P64, DOI 10.1016/0014-4827(90)90036-A; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Calvin H. I, 1971, Journal Reprod Fertil, VNo. 13, P65; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GLEDHILL BL, 1972, EXP CELL RES, V73, P33, DOI 10.1016/0014-4827(72)90098-5; GRAHAM CF, 1966, DEV BIOL, V14, P349, DOI 10.1016/0012-1606(66)90020-0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1968, J EMBRYOL EXP MORPH, V20, P401; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNTER RHF, 1967, J EXP ZOOL, V165, P451, DOI 10.1002/jez.1401650313; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; JOHNSON RT, 1970, J CELL PHYSIOL, V76, P151, DOI 10.1002/jcp.1040760204; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LAMBERT SF, 1986, EUR J BIOCHEM, V160, P191, DOI 10.1111/j.1432-1033.1986.tb09957.x; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1983, PHILOS T ROY SOC B, V302, P143, DOI 10.1098/rstb.1983.0047; LEAKE RE, 1972, EXP CELL RES, V71, P17, DOI 10.1016/0014-4827(72)90257-1; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; Longo F.J., 1978, Current Topics in Developmental Biology, V12, P149, DOI 10.1016/S0070-2153(08)60596-7; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; SAWICKI W, 1971, EXP CELL RES, V66, P145, DOI 10.1016/S0014-4827(71)80022-8; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; THANDANI VM, 1979, J EXP ZOOL, V210, P161; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULITZUR N, 1989, FEBS LETT, V259, P113, DOI 10.1016/0014-5793(89)81507-8; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P767, DOI 10.1093/nar/17.2.767; ZELENIN AV, 1974, CELL DIFFER DEV, V3, P95, DOI 10.1016/0045-6039(74)90031-1	43	248	256	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					569	578		10.1016/0092-8674(91)90089-H	http://dx.doi.org/10.1016/0092-8674(91)90089-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032284				2022-12-24	WOS:A1991FM03700007
J	STEENLAND, K; STAYNER, L; GREIFE, A; HALPERIN, W; HAYES, R; HORNUNG, R; NOWLIN, S				STEENLAND, K; STAYNER, L; GREIFE, A; HALPERIN, W; HAYES, R; HORNUNG, R; NOWLIN, S			MORTALITY AMONG WORKERS EXPOSED TO ETHYLENE-OXIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SISTER-CHROMATID EXCHANGES; COHORT; CANCER	Background. Ethylene oxide is a sterilant gas that causes leukemia and other cancers in animals. Studies in Sweden have shown an excess of leukemia and stomach cancer in humans exposed to ethylene oxide, but other studies have generally failed to confirm these findings. Methods. We conducted a study of mortality in 18,254 U.S. workers exposed to ethylene oxide at 14 plants producing sterilized medical supplies and spices. The subjects averaged 4.9 years of exposure to the gas and 16 years of follow-up. The exposure levels in recent years averaged 4.3 ppm (eight-hour time-weighted adjusted exposure) for sterilizer operators and 2.0 ppm for other workers. The levels in earlier years are likely to have been several times higher. Mortality in this cohort was compared with that in the general U.S. population. Results. Overall there was no significant increase in mortality from any cause in the study cohort. The standardized mortality ratios (SMRs) were 0.97 for leukemia (95 percent confidence interval, 0.52 to 1.67; 13 deaths observed), 1.06 for all hematopoietic cancers (95 percent confidence interval, 0.75 to 1.47; 36 deaths), and 0.94 for stomach cancer (95 percent confidence interval, 0.45 to 1.70; 11 deaths). Analyses according to job category and according to the duration of exposure showed no excess in cancers, as compared with the rate in the general population, but there was a significant trend toward increased mortality with increasing lengths of time since the first exposure for all hematopoietic cancers. The rate of death from hematopoietic cancer (especially non-Hodgkin's lymphoma) was significantly increased among men (SMR, 1.55; 27 deaths). Mortality from leukemia in recent years (1985 through 1987) was significantly increased among men (SMR, 3.45; 5 deaths). Conclusions. For the entire cohort, there was no increase in mortality from hematopoietic cancer. There was a slight but significant increase among men, however. Among men and women combined, there was a trend toward an increased risk of death from hematopoietic cancer with increasing lengths of time since the first exposure to ethylene oxide.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	STEENLAND, K (corresponding author), NIOSH,R-13,4676 COLUMBIA PKWY,CINCINNATI,OH 45226, USA.							AXELSON O, 1988, AM J IND MED, V13, P105, DOI 10.1002/ajim.4700130107; BRESLOW NE, 1983, J AM STAT ASSOC, V78, P1, DOI 10.2307/2287093; CHECKOWAY H, 1990, ARCH ENVIRON HEALTH, V45, P95, DOI 10.1080/00039896.1990.9935932; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GALLOWAY SM, 1986, MUTAT RES, V170, P55, DOI 10.1016/0165-1218(86)90082-0; GARDNER MJ, 1989, BRIT J IND MED, V46, P860; GARRY VF, 1979, ENVIRON MUTAGEN, V1, P375, DOI 10.1002/em.2860010410; GREENBERG HL, 1990, BRIT J IND MED, V47, P221; HOGSTEDT C, 1986, JAMA-J AM MED ASSOC, V255, P1575, DOI 10.1001/jama.255.12.1575; HOGSTEDT C, 1979, JAMA-J AM MED ASSOC, V241, P1132, DOI 10.1001/jama.241.11.1132; HOGSTEDT C, 1979, BRIT J IND MED, V36, P276; HOGSTEDT C, 1988, INT AGENCY RES CANCE, V89, P265; KIESSELBACH N, 1990, BRIT J IND MED, V47, P182; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; LAURENT C, 1984, INT ARCH OCC ENV HEA, V54, P33, DOI 10.1007/BF00378726; LYNCH DW, 1984, TOXICOL APPL PHARM, V76, P69, DOI 10.1016/0041-008X(84)90030-9; MORGAN RW, 1981, J OCCUP ENVIRON MED, V23, P767, DOI 10.1097/00043764-198111000-00011; PATTERSON BH, 1986, J NATL CANCER I, V77, P877; RICHMOND GW, 1985, ARCH ENVIRON HEALTH, V40, P20, DOI 10.1080/00039896.1985.10545884; ROTHMAN KJ, 1979, NIH791649 PUBL; SARTO F, 1984, MUTAT RES, V138, P185, DOI 10.1016/0165-1218(84)90043-0; SNELLINGS WM, 1984, TOXICOL APPL PHARM, V75, P105, DOI 10.1016/0041-008X(84)90081-4; STEENLAND K, 1990, J OCCUP ENVIRON MED, V32, P1091, DOI 10.1097/00043764-199011000-00008; STEENLAND K, 1987, AM J IND MED, V12, P419, DOI 10.1002/ajim.4700120407; STOLLEY PD, 1984, MUTAT RES, V129, P89, DOI 10.1016/0027-5107(84)90127-1; THIESS A, 1982, OCCUPATIONAL SAFETY, V46, P249; YAGER JW, 1983, SCIENCE, V219, P1221, DOI 10.1126/science.6828851; 1985, NIH TECHNICAL REPORT, V275; 1987, NIH882582 NAT TOX PR; 1985, IARC MONOGRAPHS S7, V1; 1988, ETHYLENE OXIDE; 1990, DHHS NIOSH89102 NAT	32	94	95	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1402	1407		10.1056/NEJM199105163242004	http://dx.doi.org/10.1056/NEJM199105163242004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020295				2022-12-24	WOS:A1991FL12500004
J	GRISSO, JA; KELSEY, JL; STROM, BL; CHIU, GY; MAISLIN, G; OBRIEN, LA; HOFFMAN, S; KAPLAN, F				GRISSO, JA; KELSEY, JL; STROM, BL; CHIU, GY; MAISLIN, G; OBRIEN, LA; HOFFMAN, S; KAPLAN, F			RISK-FACTORS FOR FALLS AS A CAUSE OF HIP FRACTURE IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POST-MENOPAUSAL WOMEN; ELDERLY WOMEN; NHANES-I; OSTEOPOROSIS; WEIGHT; FEMUR; ESTROGENS	Background. Although even in the elderly most falls are not associated with fractures, over 90 percent of hip fractures are the result of a fall. Few studies have assessed whether the risk factors for falls are also important risk factors for hip fracture. Methods. To examine the importance of risk factors for falls in the epidemiology of hip fracture, we performed a case-control study of 174 women (median age, 80 years) admitted with a first hip fracture to 1 of 30 hospitals in New York and Philadelphia. Controls, matched to the case patients according to age and hospital, were selected from general surgical and orthopedic surgical hospital services. Information was obtained by direct interview. Results. As measured by the odds ratio, increased risks for hip fracture were associated with lower-limb dysfunction (odds ratio = 1.7; 95 percent confidence interval, 1.1 to 2.8), visual impairment (odds ratio = 5.1; 95 percent confidence interval, 1.9 to 13.9), previous stroke (odds ratio = 2.0; 95 percent confidence interval, 1.0 to 4.0), Parkinson's disease (odds ratio = 9.4; 95 percent confidence interval, 1.2 to 76.1), and use of long-acting barbiturates (odds ratio = 5.2; 95 percent confidence interval, 0.6 to 45.0). Of the controls, 44 (25 percent) had had a recent fall. The case patients were more likely than these controls to have fallen from a standing height or higher (odds ratio = 2.4; 95 percent confidence interval, 1.0 to 5.7). Of those with hip fracture the younger patients (< 75 years old) were more likely than the older ones (greater-than-or-equal-to 75 years old) to have fallen on a hard surface (odds ratio = 1.9; 95 percent confidence interval, 1.04 to 3.7). Conclusions. A number of factors that have been identified as risk factors for falls are also associated with hip fracture, including lower-limb dysfunction, neurologic conditions, barbiturate use, and visual impairment. Given the prevalence of these problems among the elderly, who are at highest risk, programs to prevent hip fracture should include measures to prevent falls in addition to measures to slow bone loss.	COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY 10027; HOSP UNIV PENN,DEPT ORTHOPED,PHILADELPHIA,PA 19104	Columbia University; University of Pennsylvania; Pennsylvania Medicine	GRISSO, JA (corresponding author), UNIV PENN,SCH MED,CLIN EPIDEMIOL UNIT,GEN INTERNAL MED SECT,317R NURSING EDUC BLDG,420 SERV DR,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035409] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR35409] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALFFRAM PER-AXEL, 1964, ACTA ORTHOPAED SCAND SUPPL, V65, P1; BASTOW MD, 1983, LANCET, V1, P143; BRESLOW NE, 1980, IARC SCI PUBL, V32, P373; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; CLARK ANG, 1968, GERONTOL CLIN, V10, P257, DOI 10.1159/000245191; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; FLOREY CDV, 1970, J CHRON DIS, V23, P93; HERZOG AR, 1988, J GERONTOL, V43, pS200, DOI 10.1093/geronj/43.6.S200; HUTCHINSON TA, 1979, LANCET, V2, P705; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAYE JM, 1990, GERONTOLOGIST, V30, P100, DOI 10.1093/geront/30.1.100; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOLLER WC, 1989, CLIN NEUROPHARMACOL, V12, P98; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LOTZ JC, 1990, J BONE JOINT SURG AM, V72A, P689, DOI 10.2106/00004623-199072050-00008; MELTON LJ, 1987, OSTEOPOROTIC SYNDROM, P45; MICOZZI MS, 1986, AM J CLIN NUTR, V44, P725, DOI 10.1093/ajcn/44.6.725; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Schlesselman JJ, 1982, CASE CONTROL STUDIES; TAGGART HM, 1988, J AM GERIATR SOC, V36, P1006, DOI 10.1111/j.1532-5415.1988.tb04367.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; WALLACE RB, 1987, PHS881214 DEP HLTH H, P423; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; WOOTTON R, 1979, CLIN SCI, V57, P93, DOI 10.1042/cs0570093; Wootton R, 1982, Age Ageing, V11, P160, DOI 10.1093/ageing/11.3.160; WYSHAK G, 1981, J GERONTOL, V36, P424, DOI 10.1093/geronj/36.4.424; [No title captured]	41	644	665	1	42	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1326	1331		10.1056/NEJM199105093241905	http://dx.doi.org/10.1056/NEJM199105093241905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK186	2017229				2022-12-24	WOS:A1991FK18600005
J	CLARKE, R; DALY, L; ROBINSON, K; NAUGHTEN, E; CAHALANE, S; FOWLER, B; GRAHAM, I				CLARKE, R; DALY, L; ROBINSON, K; NAUGHTEN, E; CAHALANE, S; FOWLER, B; GRAHAM, I			HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYSTATHIONINE BETA-SYNTHASE; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; ENDOTHELIAL-CELL INJURY; LOW-DENSITY LIPOPROTEIN; CONTAINING AMINO-ACIDS; MYOCARDIAL-INFARCTION; PLASMA HOMOCYSTEINE; FAMILY HISTORY; FOLIC-ACID	Background. Hyperhomocysteinemia arising from impaired methionine metabolism, probably usually due to a deficiency of cystathionine beta-synthase, is associated with premature cerebral, peripheral, and possibly coronary vascular disease. Both the strength of this association and its independence of other risk factors for cardiovascular disease are uncertain. We studied the extent to which the association could be explained by heterozygous cystathionine beta-synthase deficiency. Methods. We first established a diagnostic criterion for hyperhomocysteinemia by comparing peak serum levels of homocysteine after a standard methionine-loading test in 25 obligate heterozygotes with respect to cystathionine beta-synthase deficiency (whose children were known to be homozygous for homocystinuria due to this enzyme defect) with the levels in 27 unrelated age- and sex-matched normal subjects. A level of 24.0-mu-mol per liter or more was 92 percent sensitive and 100 percent specific in distinguishing the two groups. The peak serum homocysteine levels in these normal subjects were then compared with those in 123 patients whose vascular disease had been diagnosed before they were 55 years of age. Results. Hyperhomocysteinemia was detected in 16 of 38 patients with cerebrovascular disease (42 percent), 7 of 25 with peripheral vascular disease (28 percent), and 18 of 60 with coronary vascular disease (30 percent), but in none of the 27 normal subjects. After adjustment for the effects of conventional risk factors, the lower 95 percent confidence limit for the odds ratio for vascular disease among the patients with hyperhomocysteinemia, as compared with the normal subjects, was 3.2. The geometric-mean peak serum homocysteine level was 1.33 times higher in the patients with vascular disease than in the normal subjects (P = 0.002). The presence of cystathionine beta-synthase deficiency was confirmed in 18 of 23 patients with vascular disease who had hyperhomocysteinemia. Conclusions. Hyperhomocysteinemia is an independent risk factor for vascular disease, including coronary disease, and in most instances is probably due to cystathionine beta-synthase deficiency.	ADELAIDE HOSP,DEPT CARDIOL,PETER ST,DUBLIN 8,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT MED,DUBLIN 2,IRELAND; CHILDRENS HOSP,NATL SCREENING CTR METAB DIS,DUBLIN,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT COMMUNITY MED & EPIDEMIOL,DUBLIN 4,IRELAND; ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 1HA,LANCS,ENGLAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; University College Dublin; Royal Manchester Children's Hospital								USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; BARRETTCONNOR E, 1984, CIRCULATION, V69, P1065, DOI 10.1161/01.CIR.69.6.1065; BERG K, 1989, ARTERIOSCLEROSIS S, V9, P50; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; BRATTSTROM LE, 1985, METABOLISM, V34, P1073, DOI 10.1016/0026-0495(85)90082-4; BRESLOW NE, 1980, IARC SCI PUBL, V32, P124; CAREY MC, 1968, AM J MED, V45, P26, DOI 10.1016/0002-9343(68)90004-1; FOWLER B, 1978, J CLIN INVEST, V61, P645, DOI 10.1172/JCI108976; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; FRIMPTER GW, 1961, J BIOL CHEM, V236, pPC51; GOLDBOURT U, 1986, ARTERIOSCLEROSIS, V6, P357, DOI 10.1161/01.ATV.6.4.357; GRAEBER JE, 1982, PEDIATR RES, V16, P490, DOI 10.1203/00006450-198206000-00018; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KANNEL WB, 1977, HYPERTENSION PHYSIOP, P880; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P2047, DOI 10.1073/pnas.83.7.2047; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MCCULLY KS, 1987, RES COMMUN CHEM PATH, V56, P349; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1989, METABOLIC BASIS INHE, V1, P693; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; MYERS RH, 1989, 2ND P INT C PREV CAR, pA376; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; OLSZEWSKI AJ, 1988, ATHEROSCLEROSIS, V69, P109, DOI 10.1016/0021-9150(88)90003-2; PANGANAMALA RV, 1986, PROSTAG LEUKOTR ESS, V22, P349, DOI 10.1016/0262-1746(86)90145-9; PARTHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337, DOI 10.1016/0005-2760(87)90139-1; ROBINSON K, 1990, CDNA12834ENC OFF OFF; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROSENMAN RH, 1976, AM J CARDIOL, V37, P903, DOI 10.1016/0002-9149(76)90117-X; SKOVBY F, 1984, HUM GENET, V65, P291, DOI 10.1007/BF00286520; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WILCKEN DEL, 1983, METABOLISM, V32, P363, DOI 10.1016/0026-0495(83)90045-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; 1981, NIH822035 DEP HLTH H	49	1867	1956	3	54	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1149	1155		10.1056/NEJM199104253241701	http://dx.doi.org/10.1056/NEJM199104253241701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011158				2022-12-24	WOS:A1991FH57200001
J	STREISSGUTH, AP; AASE, JM; CLARREN, SK; RANDELS, SP; LADUE, RA; SMITH, DF				STREISSGUTH, AP; AASE, JM; CLARREN, SK; RANDELS, SP; LADUE, RA; SMITH, DF			FETAL ALCOHOL SYNDROME IN ADOLESCENTS AND ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL ALCOHOL; FOLLOW-UP; EXPOSURE; INFANCY	Fetal alcohol syndrome is a specific recognizable pattern of malformation. Manifestations in 61 adolescents and adults suffering from alcohol teratogenesis are presented. After puberty, the faces of patients with fetal alcohol syndrome or fetal alcohol effects were not as distinctive. Patients tended to remain short and microcephalic, although their weight was somewhat closer to the mean. The average IQ was 68, but the range of IQ scores widely varied. Average academic functioning was at the second- to fourth-grade levels, with arithmetic deficits most characteristic. Maladaptive behaviors such as poor judgment, distractibility, and difficulty perceiving social cues were common. Family environments were remarkably unstable. Fetal alcohol syndrome is not just a childhood disorder; there is a predictable long-term progression of the disorder into adulthood, in which maladaptive behaviors present the greatest challenge to management.	UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, CTR CHILD DEV MENTAL RETARDAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, INST ALCOHOLISM & DRUG ABUSE, SEATTLE, WA 98195 USA; UNIV VANCOUVER, DEPT PEDIAT, VANCOUVER, BC, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	STREISSGUTH, AP (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PSYCHIAT & BEHAV SCI, GG-20, 2707 NE BLAKELEY, SEATTLE, WA 98195 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA001455, R01AA001455] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA01455] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aase JM, 1990, DIAGNOSTIC DYSMORPHO; ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; CLARREN SK, 1990, ALCOHOL CLIN EXP RES, V14, P674, DOI 10.1111/j.1530-0277.1990.tb01226.x; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; DEHAENE P, 1977, REV ALCOOL, V23, P145; Dorris Michael, 1989, BROKEN CORD; DRISCOLL CD, 1990, NEUROTOXICOL TERATOL, V12, P231, DOI 10.1016/0892-0362(90)90094-S; GRAY J K, 1990, Alcoholism Clinical and Experimental Research, V14, P294; Grossman H. J., 1983, CLASSIFICATION MENTA; HALL JG, 1989, HDB NORMAL PHYSICAL; HANSON JW, 1978, J PEDIATR-US, V92, P457, DOI 10.1016/S0022-3476(78)80449-1; HARRIS JC, 1988, YOUNG PERSON DOWN SY, P35; IOSUB S, 1981, ALCOHOL CLIN EXP RES, V5, P523; JASTAK S, 1984, MANUAL WIDE RANGE AC; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; LANDESMANDWYER S, 1981, NEUROBEH TOXICOL TER, V3, P187; Lemoine P., 1968, OUEST MED THER DRUG, P476; LITTLE BB, 1990, AM J DIS CHILD, V144, P1142, DOI 10.1001/archpedi.1990.02150340088030; MAJEWSKI F, 1988, INT CONGR SER, V805, P837; MAY PA, 1983, SOC BIOL, V30, P374; RILEY EP, 1990, ALCOHOL CLIN EXP RES, V14, P670, DOI 10.1111/j.1530-0277.1990.tb01225.x; ROBINSON GC, 1987, CAN MED ASSOC J, V137, P203; SAMPSON PD, 1989, NEUROTOXICOL TERATOL, V11, P477, DOI 10.1016/0892-0362(89)90025-1; SAVAGE DD, 1989, ALCOHOL CLIN EXP RES, V13, P588, DOI 10.1111/j.1530-0277.1989.tb00382.x; Smith, 1982, RECOGNIZABLE PATTERN; SPARROW SS, 1984, MANUAL VINELAND; SPOHR HL, 1987, NEUROPEDIATRICS, V18, P13, DOI 10.1055/s-2008-1052428; STEINHAUSEN HC, 1984, J AM ACAD CHILD PSY, V23, P465, DOI 10.1016/S0002-7138(09)60326-5; STREISSGUTH AP, 1989, NEUROTOXICOL TERATOL, V11, P493, DOI 10.1016/0892-0362(89)90026-3; STREISSGUTH AP, 1985, LANCET, V2, P85; STREISSGUTH AP, 1978, ALCOHOL CLIN EXP RES, V2, P165, DOI 10.1111/j.1530-0277.1978.tb04717.x; STREISSGUTH AP, 1990, ALCOHOL CLIN EXP RES, V14, P662, DOI 10.1111/j.1530-0277.1990.tb01224.x; STREISSGUTH AP, 1989, ANN NY ACAD SCI, V562, P145, DOI 10.1111/j.1749-6632.1989.tb21013.x; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; Wechsler D, 1974, WECHSLER ADULT INTEL; WEST JR, 1986, ALCOHOL BRAIN DEV; 1976, MONTHLY VITAL STATIS, V25; 1981, FDA DRUG B, V2, P10	39	574	577	2	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1961	1967		10.1001/jama.265.15.1961	http://dx.doi.org/10.1001/jama.265.15.1961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008025				2022-12-24	WOS:A1991FF76800021
J	HENNIGAN, TW; FRANKS, PJ; HOCKEN, DB; ALLENMERSH, TG				HENNIGAN, TW; FRANKS, PJ; HOCKEN, DB; ALLENMERSH, TG			INFLUENCE OF UNDERGRADUATE TEACHING ON MEDICAL-STUDENTS ATTITUDES TO RECTAL EXAMINATION	BRITISH MEDICAL JOURNAL			English	Article											HENNIGAN, TW (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Franks, Peter J/G-3592-2013	Franks, Peter J/0000-0002-9782-0181				HENNIGAN TW, 1990, BRIT MED J, V301, P478, DOI 10.1136/bmj.301.6750.478; [No title captured]	2	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					829	829		10.1136/bmj.302.6780.829	http://dx.doi.org/10.1136/bmj.302.6780.829			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF377	2025707	Bronze, Green Published			2022-12-24	WOS:A1991FF37700027
J	NEWMAN, A; NORMAN, C				NEWMAN, A; NORMAN, C			MUTATIONS IN YEAST U5 SNRNA ALTER THE SPECIFICITY OF 5' SPLICE-SITE CLEAVAGE	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER RNA; U1 SNRNA; HOST STRAINS; TACTAAC BOX; PROTEIN; DNA; IDENTIFICATION; REQUIREMENTS; RECOGNITION	Recognition of 5' splice sites in pre-mRNA splicing is achieved in part by base pairing with U1 snRNA. We have used interactive suppression in the yeast Saccharomyces cerevisiae to look for other factors involved in 5' splice-site recognition. This approach identified an extragenic suppressor that activates a cryptic 5' splice site. The suppressor is a gene for U5 snRNA (snR7) with a single base mutation in a strictly conserved 9 base sequence. This suggests that U5 snRNA can play a part in determining the position of 5' splice-site cleavage. Consistent with this, we have been able to isolate other mutations in the 9 base element in U5 snRNA that specifically activate a second cryptic 5' splice site nearby.			NEWMAN, A (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; Green MR, 1989, CURR OPIN CELL BIOL, V1, P519, DOI 10.1016/0955-0674(89)90014-8; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUTENBERGER JA, 1987, GENE ANAL TECH, V4, P87, DOI 10.1016/0735-0651(87)90001-X; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; Miller J.H., 1972, EXPT MOL GENETICS; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PERELMAN D, 1990, MOL CELL BIOL, V10, P3284, DOI 10.1128/MCB.10.6.3284; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; VIJAYRAGHAVAN U, 1989, NUCLEIC ACIDS MOL BI, V3, P197; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WINKELMANN G, 1989, EMBO J, V8, P3105, DOI 10.1002/j.1460-2075.1989.tb08462.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	47	188	208	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					115	123		10.1016/0092-8674(91)90413-S	http://dx.doi.org/10.1016/0092-8674(91)90413-S			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013092	Bronze			2022-12-24	WOS:A1991FF77300014
J	BURKE, GL; SPRAFKA, JM; FOLSOM, AR; HAHN, LP; LUEPKER, RV; BLACKBURN, H				BURKE, GL; SPRAFKA, JM; FOLSOM, AR; HAHN, LP; LUEPKER, RV; BLACKBURN, H			TRENDS IN SERUM-CHOLESTEROL LEVELS FROM 1980 TO 1987 - THE MINNESOTA HEART SURVEY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE RISK-FACTORS; 2 NATIONAL SURVEYS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; DEATH; PERSPECTIVE; PREVALENCE; MORTALITY	Background and Methods. We assessed community trends in the awareness, treatment, and control of hypercholesterolemia (defined as a serum cholesterol level greater-than-or-equal-to 6.21 mmol per liter [240 mg per deciliter]) during the 1980s in the Minneapolis-St. Paul (Twin Cities) metropolitan area. Twin Cities residents 25 to 74 years old participated in independent, cross-sectional, population-based surveys of risk factors for cardiovascular disease in 1980-1982 (n = 3365) and 1985-1987 (n = 4545). Results. Mean serum total cholesterol levels, as adjusted for age, decreased significantly (P < 0.01) from 1980-1982 to 1985-1987 in men (from 5.30 mmol per liter [205 mg per deciliter] to 5.16 mmol per liter [200 mg per deciliter]) and women (from 5.19 mmol per liter [201 mg per deciliter] to 5.04 mmol per liter [195 mg per deciliter]). The prevalence of hypercholesterolemia as adjusted for age decreased significantly (P < 0.05) in men (17.8 to 15.1 percent) and women (17.1 to 13.6 percent). The ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was unchanged during this period, because of a concurrent decline in the level of HDL cholesterol. Participants with hypercholesterolemia in the 1985-1987 survey were more likely than those in the 1980-1982 survey to be aware of their condition (32.6 vs. 25.4 percent), to be treated with lipid-lowering agents (4.3 vs. 1.9 percent), and to have their condition controlled (1.9 vs. 0.3 percent). Among those who reported treatment by a physician for hyperlipidemia, changes were observed in the type of treatment recommended. A significant increase (P < 0.05) was noted from 1980-1982 to 1985-1987 in the percentage of men being treated for hyperlipidemia with lipid-lowering medication (5.2 vs. 11.6 percent) and with exercise programs (10.3 vs. 20.1 percent). In women being treated for hyperlipidemia, a nonsignificant increase was noted in the use of lipid-lowering medication (8.2 vs. 13.9 percent), and a significant increase (P < 0.05) was observed in the number of exercise prescriptions (4.1 vs. 12.0 percent). Conclusions. We found a substantial decline in the prevalence of hypercholesterolemia in the Twin Cities between 1980-1982 and 1985-1987 that may be attributed to changes in lifestyle, such as diet and exercise, and to a lesser extent to more aggressive intervention with lipid-lowering drugs by physicians.	UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	BURKE, GL (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.				PHS HHS [R01-23727] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; GILLUM RF, 1984, AM J MED, V76, P1055, DOI 10.1016/0002-9343(84)90857-X; GRAVES KL, 1990, CIRCULATION, V82, P347; GRUNDY SM, 1985, ARTERIOSCLEROSIS, V72, pA1135; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P2087, DOI 10.1001/jama.253.14.2087; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KEYS A, 1970, CIRCULATION S1, V41, P162; LUEPKER RV, 1988, J CLIN EPIDEMIOL, V41, P825, DOI 10.1016/0895-4356(88)90098-4; LUEPKER RV, 1985, J CHRON DIS, V38, P671, DOI 10.1016/0021-9681(85)90021-9; MARTIN MJ, 1986, LANCET, V2, P933; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TIKKANEN MJ, 1987, CIRCULATION, V76, P529, DOI 10.1161/01.CIR.76.3.529; TYROLER HA, 1971, ARCH INTERN MED, V128, P907, DOI 10.1001/archinte.128.6.907; 1979, J CHRON DIS, V32, P609; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V148, P36; 1985, SAS USERS GUIDE BASI; 1984, JAMA-J AM MED ASSOC, V251, P365; 1987, JAMA-J AM MED ASSOC, V257, P937; 1974, DHEW NIH75628 NAT HE; 1979, PREV MED, V8, P612	29	66	66	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					941	946		10.1056/NEJM199104043241402	http://dx.doi.org/10.1056/NEJM199104043241402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	2002818				2022-12-24	WOS:A1991FE37600002
J	OPPENHEIM, RW; PREVETTE, D; YIN, QW; COLLINS, F; MACDONALD, J				OPPENHEIM, RW; PREVETTE, D; YIN, QW; COLLINS, F; MACDONALD, J			CONTROL OF EMBRYONIC MOTONEURON SURVIVAL INVIVO BY CILIARY NEUROTROPHIC FACTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NORMAL-CELL-DEATH; CHICK-EMBRYO; SPINAL-CORD; NEURONAL DEATH; NEURONOTROPHIC FACTOR; PURIFICATION; REDUCTION; GANGLION; BRAIN	During development of the nervous system, neurons in many regions are overproduced by proliferation, after which the excess cells are eliminated by cell death. The survival of only a proportion of neurons during normal development is thought to be regulated by the limited availability of neurotrophic agents. One such putative trophic agent is ciliary neurotrophic factor (CNTF), a polypeptide that promotes the survival of ciliary, sensory, and sympathetic neurons in vitro. In contrast to the results of in vitro studies, however, the daily treatment of chick embryos in vivo with purified human recombinant CNTF failed to rescue any of these cell populations from cell death, whereas CNTF did promote the in vivo survival of spinal motoneurons. Thus, CNTF may not act as a neurotrophic agent in vivo for those embryonic neurons (especially ciliary neurons) on which it acts in vitro. Rather, CNTF may be required for in vivo survival of motoneurons.	SYNERGEN INC,BOULDER,CO 80301; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27103, USA.				NINDS NIH HHS [NS 20402] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020402] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], [No title captured]; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1988, TRENDS NEUROSCI, V11, P343, DOI 10.1016/0166-2236(88)90055-0; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Bhattacharyya A., UNPUB; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; CLARKE PGH, 1985, TRENDS NEUROSCI, V8, P345, DOI 10.1016/0166-2236(85)90120-1; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVIES AM, 1988, TRENDS NEUROSCI, V11, P243, DOI 10.1016/0166-2236(88)90099-9; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; ERNBERGER U, 1989, NEURON, V2, P1275; FURBER S, 1987, J NEUROSCI, V7, P1816; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOFFMANN HD, 1988, J NEUROCHEM, V51, P109; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HUGHES S, 1988, NATURE, V355, P70; LANDMESSER L, 1974, J PHYSIOL-LONDON, V241, P715, DOI 10.1113/jphysiol.1974.sp010680; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN LFH, 1990, J BIOL CHEM, V265, P8942; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1986, BRAIN RES, V367, P282, DOI 10.1016/0006-8993(86)91603-3; MCMANAMAN JL, 1990, NEURON, V4, P891, DOI 10.1016/0896-6273(90)90142-3; MERINEY SD, 1985, SCIENCE, V228, P1451, DOI 10.1126/science.2990029; OPPENHEIM RC, UNPUB; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; PITTMAN RH, 1978, NATURE, V271, P364, DOI 10.1038/271364a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P7537; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.neuro.12.1.103; WATTERS D, 1985, BIOCHEM INT, V11, P245; WATTERS DJ, 1987, J NEUROCHEM, V49, P705	50	418	439	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1616	1618		10.1126/science.2011743	http://dx.doi.org/10.1126/science.2011743			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011743				2022-12-24	WOS:A1991FD89000040
J	PACHOLCZYK, T; BLAKELY, RD; AMARA, SG				PACHOLCZYK, T; BLAKELY, RD; AMARA, SG			EXPRESSION CLONING OF A COCAINE-SENSITIVE AND ANTIDEPRESSANT-SENSITIVE HUMAN NORADRENALINE TRANSPORTER	NATURE			English	Article							SK-N-SH; NOREPINEPHRINE UPTAKE; TRANSIENT-EXPRESSION; DNA TRANSFECTION; ACTIVE UPTAKE; CELL-LINE; DOPAMINE; RECEPTOR; STORAGE; INHIBITION	AT most synapses, chemical signalling is terminated by a rapid reaccumulation of neurotransmitter into presynaptic terminals 1-5. Uptake systems for the biogenic amines are the initial site of action for therapeutic antidepressants and drugs such as cocaine and the amphetamines. We have isolated a complementary DNA clone encoding a human noradrenaline transporter. The cDNA sequence predicts a protein of 617 amino acids, with 12-13 highly hydrophobic regions compatible with membrane-spanning domains. Expression of the cDNA clone in transfected HeLa cells indicates that noradrenaline transport activity is sodium-dependent and sensitive to selective noradrenaline transport inhibitors. Transporter RNA is localized to the brainstem and the adrenal gland. The predicted protein sequence demonstrates significant amino-acid identity with the Na+/gamma-aminobutyric acid transporter, thus identifying a new gene family for neurotransmitter transporter proteins. Analysis of its structure and function may lead to structure-based drug design for the treatment of human depression and could help determine whether transporter abnormalities underlie affective disorders.	YALE UNIV,PROGRAM NEUROSCI,NEW HAVEN,CT 06510	Yale University	PACHOLCZYK, T (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,MOLEC NEUROBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Amara, Susan/0000-0001-8914-1106				ANDERSEN PH, 1989, EUR J PHARMACOL, V166, P493, DOI 10.1016/0014-2999(89)90363-4; BIEDLER JL, 1973, CANCER RES, V33, P2643; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BUCK J, 1985, CANCER RES, V45, P6366; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO AK, 1990, SCIENCE, V249, P631, DOI 10.1126/science.249.4969.631; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Iversen L., 1967, UPTAKE STORAGE NORAD; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIMELBERG HK, 1983, J NEUROCHEM, V40, P1265, DOI 10.1111/j.1471-4159.1983.tb13565.x; KOSTRZEWA RM, 1974, PHARMACOL REV, V26, P199; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHAR MJ, 1990, EUR NEUROL, V30, P15; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; RICHARDS ML, 1986, BRAIN RES, V384, P132, DOI 10.1016/0006-8993(86)91228-X; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROSS SB, 1976, J PHARM PHARMACOL, V28, P458, DOI 10.1111/j.2042-7158.1976.tb04659.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMETS LA, 1989, CANCER RES, V49, P2941; SNYDER S H, 1970, Biological Psychiatry, V2, P367; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0	37	804	850	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					350	354		10.1038/350350a0	http://dx.doi.org/10.1038/350350a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD838	2008212				2022-12-24	WOS:A1991FD83800096
J	URQUHART, JD; BLACK, RJ; MUIRHEAD, MJ; SHARP, L; MAXWELL, M; EDEN, OB; JONES, DA				URQUHART, JD; BLACK, RJ; MUIRHEAD, MJ; SHARP, L; MAXWELL, M; EDEN, OB; JONES, DA			CASE-CONTROL STUDY OF LEUKEMIA AND NON-HODGKINS-LYMPHOMA IN CHILDREN IN CAITHNESS NEAR THE DOUNREAY NUCLEAR INSTALLATION	BRITISH MEDICAL JOURNAL			English	Article							MAGNETIC-FIELDS; LEUKEMIA; EXPOSURE; CANCER	Objective-To examine whether the observed excess of childhood leukaemia and non-Hodgkin's lymphoma in the area around the Dounreay nuclear installation is associated with established risk factors, or with factors related to the plant, or with parental occupation in the nuclear industry. Design-Case-control study. Setting-Caithness local government district. Subjects-14 cases of leukaemia and non-Hodgkin's lymphoma occurring in children aged under 15 years diagnosed in the area between 1970 and 1986 and 55 controls matched for sex, date of birth, and area of residence within Caithness at time of birth. Main outcome measures-Antenatal abdominal x ray examination; drugs taken and viral infections during pregnancy; father's occupation; father's employment at Dounreay and radiation dose; distance of usual residence from the path of microwave beams, preconceptional exposure to non-ionising radiation in the father; and other lifestyle factors. Results-No raised relative risks were found for prenatal exposure to x rays, social class of parents, employment at Dounreay before conception or diagnosis, father's dose of ionising radiation before conception, or child's residence within 50 m of the path of microwave transmission beams. Results also proved negative for all lifestyle factors except an apparent association with use of beaches within 25 km of Dounreay. However, this result was based on small numbers, arose in the context of multiple hypothesis testing, and is certainly vulnerable to possible systematic bias. Conclusion-The raised incidence of childhood leukaemia and non-Hodgkin's lymphoma around Dounreay cannot be explained by paternal occupation at Dounreay or by paternal exposure to external ionising radiation before conception. The observation of an apparent association between the use of beaches around Dounreay and the development of childhood leukaemia and non-Hodgkin's lymphoma might be an artefact of multiple testing and influenced by recall bias.	ROYAL HOSP SICK CHILDREN,DEPT PAEDIAT HAEMATOL,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND		URQUHART, JD (corresponding author), SCOTTISH HLTH SERV,COMMON SERV AGCY,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BLACK D, 1984, INVESTIGATION POSSIB; Breslow N, 1980, STATISTICAL METHODS, V32; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN M A, 1987, Health Bulletin (Edinburgh), V45, P147; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; MCWHIRTER WR, 1982, BRIT J CANCER, V46, P640, DOI 10.1038/bjc.1982.249; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SEVERSON RK, 1988, AM J EPIDEMIOL, V128, P10, DOI 10.1093/oxfordjournals.aje.a114932; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; 1988, 2ND COMM MED ASP RAD; 1989, EGRET	13	102	102	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					687	692		10.1136/bmj.302.6778.687	http://dx.doi.org/10.1136/bmj.302.6778.687			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021742	Green Published, Bronze			2022-12-24	WOS:A1991FE33300021
J	PETERSON, CL; KRUGER, W; HERSKOWITZ, I				PETERSON, CL; KRUGER, W; HERSKOWITZ, I			A FUNCTIONAL INTERACTION BETWEEN THE C-TERMINAL DOMAIN OF RNA POLYMERASE-II AND THE NEGATIVE REGULATOR SIN1	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; HO GENE; ESCHERICHIA-COLI; REPEAT DOMAIN; YEAST; EXPRESSION; PROTEIN; BINDING	The C-terminal domain (CTD) of the largest subunit of yeast RNA polymerase II contains 26-27 tandem copies of a conserved heptapeptide of unknown function. Yeast strains whose CTD contains ten heptamers are viable but defective for transcription of the INO1 gene and cold sensitive for growth. Deletion of the SIN1 gene, which codes for a DNA-binding protein that negatively regulates HO transcription, restores INO1 transcription and reduces the cold sensitivity of such strains. A SIN1 deletion suppresses the lethality of a CTD with nine heptamer repeats but not with seven repeats. These observations indicate a functional relationship between SIN1 and the CTD: the CTD might remove SIN1 from DNA, or removal of SIN1 may be a prerequisite for function of the CTD. The SWI1, SWI2, and SWI3 genes, whose products activate HO transcription by antagonizing SIN1, are also required for INO1 transcription and may assist the CTD. In addition, an intact CTD binds nonspecifically to DNA in vitro.			PETERSON, CL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROEDER GS, 1985, MOL CELL BIOL, V5, P1543, DOI 10.1128/MCB.5.7.1543; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCHROTER H, 1982, EUR J BIOCHEM, V127, P429, DOI 10.1111/j.1432-1033.1982.tb06890.x; SILVERMAN SJ, 1984, MOL CELL BIOL, V4, P1246, DOI 10.1128/MCB.4.7.1246; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	39	163	163	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1135	1143		10.1016/0092-8674(91)90268-4	http://dx.doi.org/10.1016/0092-8674(91)90268-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004420				2022-12-24	WOS:A1991FD55800011
J	SUN, H; TRECO, D; SZOSTAK, JW				SUN, H; TRECO, D; SZOSTAK, JW			EXTENSIVE 3'-OVERHANGING, SINGLE-STRANDED-DNA ASSOCIATED WITH THE MEIOSIS-SPECIFIC DOUBLE-STRAND BREAKS AT THE ARG4 RECOMBINATION INITIATION SITE	CELL			English	Article							MEIOTIC GENE CONVERSION; SACCHAROMYCES-CEREVISIAE; YEAST; CHROMOSOME; SYNAPSIS; EXCHANGE	Meiosis-specific double-strand breaks occur at the initiation site for meiotic gene conversion in the yeast ARG4 gene. Here we show that the break fragments end in extensive 3'-overhanging, single-stranded tails. The single-stranded tails vary in length, generating a gradient of single-strandedness that parallels the gradient of gene conversion frequencies in ARG4. In strains carrying a rad50S mutation, which blocks meiotic recombination, the extensive single-stranded tails do not form, suggesting that their generation is an obligatory step in meiotic recombination. Using the rad50S mutant, we have mapped the site of the ARG4 break to a small region within the genetically defined recombination initiation site. These results strongly support the double-strand break model of meiotic recombination.			SUN, H (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORTS RH, 1986, GENETICS, V113, P551; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; FOGEL S, 1981, MOL BIOL YEAST SACCH, V1, P289; GAME JC, 1980, GENETICS, V94, P51; GAME JC, 1989, GENETICS, V123, P695; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLAPHOLZ S, 1985, GENETICS, V110, P187; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LICHTEN MJ, 1983, NUCLEIC ACIDS RES, V11, P3959, DOI 10.1093/nar/11.12.3959; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; Maniatis T., 1982, MOL CLONING; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; Whitehouse H. L. K., 1982, GENETIC RECOMBINATIO; WILLIAMSON MS, 1985, GENETICS, V110, P609	32	461	467	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1155	1161		10.1016/0092-8674(91)90270-9	http://dx.doi.org/10.1016/0092-8674(91)90270-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004421				2022-12-24	WOS:A1991FD55800013
J	MEADOR, CK				MEADOR, CK			A LAMENT FOR INVALIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Pickering GW., 1974, CREATIVE MALADY ILLN; WHEELER EO, 1950, JAMA-J AM MED ASSOC, V142, P878, DOI 10.1001/jama.1950.02910300016005	2	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1374	1375		10.1001/jama.265.11.1374	http://dx.doi.org/10.1001/jama.265.11.1374			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999875				2022-12-24	WOS:A1991FB55000008
J	VANDONSELAAR, CA; GEERTS, AT; SCHIMSHEIMER, RJ				VANDONSELAAR, CA; GEERTS, AT; SCHIMSHEIMER, RJ			IDIOPATHIC 1ST SEIZURE IN ADULT LIFE - WHO SHOULD BE TREATED	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNPROVOKED SEIZURE; EPILEPSY; PROGNOSIS; CARBAMAZEPINE; RECURRENCE; PHENYTOIN; CHILDHOOD; VALPROATE; PATIENT	Objective-To assess the accuracy of the diagnosis, recurrence rate, and fate after the first recurrence in adult patients with an untreated idiopathic first seizure. Design-Hospital based follow up study. Setting-One university hospital and three general hospitals in The Netherlands. Patients-165 patients aged 15 years or more with a clinically presumed idiopathic seizure; diagnosis was based on a description of the episode according to prespecified diagnostic criteria. Main outcome measures-Results of additional investigations and follow up regarding the accuracy of the diagnosis; first recurrence; and response to treatment after the first recurrence. Results-Computed tomography showed major abnormalities in 5.5% of the patients and follow up led to doubts about the initial clinical diagnosis in another 6%. Cumulative risk of recurrence was 40% at two years. The cumulative risk of recurrence at two years was 81% (95% confidence interval 66% to 97%) in patients with epileptic discharges on a standard or partial sleep deprivation electroencephalogram, 39% (27% to 51%) in patients with other electroencephalographic abnormalities, and 12% (3% to 21%) in patients with normal electroencephalograms. Treatment was initiated in most patients who had one or more recurrences; 40 (70%) patients were completely controlled, eight (14%) had sporadic seizures, and nine (16%) did not become free of seizures within one year despite treatment. Conclusions-The decision to initiate or delay treatment should be based on electroencephalographic findings.	ERASMUS UNIV, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam	VANDONSELAAR, CA (corresponding author), ERASMUS UNIV, HOSP DIJKZIGT, DEPT NEUROL, 3015 GD ROTTERDAM, NETHERLANDS.							ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1981, Epilepsia, V22, P489; BODENSTEINER JB, 1988, EPILEPSIA, V29, P123, DOI 10.1111/j.1528-1157.1988.tb04407.x; CALLAGHAN N, 1985, J NEUROL NEUROSUR PS, V48, P639, DOI 10.1136/jnnp.48.7.639; CAMFIELD P, 1989, NEUROLOGY, V39, P851, DOI 10.1212/WNL.39.6.851; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; ELWES RDC, 1988, LANCET, V2, P36; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; ELWES RDC, 1985, LANCET, V2, P752; ELWES RDC, 1988, BMJ-BRIT MED J, V47, P620; HACHINSKI V, 1986, ARCH NEUROL-CHICAGO, V43, P1290, DOI 10.1001/archneur.1986.00520120066019; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P1289, DOI 10.1001/archneur.1986.00520120065018; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HAUSER WA, 1986, ARCH NEUROL-CHICAGO, V43, P1287, DOI 10.1001/archneur.1986.00520120063017; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HOLMES GL, 1988, POSTGRAD MED, V83, P199, DOI 10.1080/00325481.1988.11700149; HOPKINS A, 1988, LANCET, V1, P721; JOHNSON LC, 1972, ARCH NEUROL-CHICAGO, V27, P193, DOI 10.1001/archneur.1972.00490150001001; LUHDORF K, 1986, ACTA NEUROL SCAND, V74, P409; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; RAMSAY RE, 1983, NEUROLOGY, V33, P904, DOI 10.1212/WNL.33.7.904; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; REYNOLDS EH, 1983, LANCET, V2, P952; SAUNDERS M, 1975, EPILEPSIA, V16, P731, DOI 10.1111/j.1528-1157.1975.tb04757.x; SCHOTT GD, 1977, BRIT MED J, V1, P1454, DOI 10.1136/bmj.1.6074.1454; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; SHORVON SD, 1982, BMJ-BRIT MED J, V285, P1699, DOI 10.1136/bmj.285.6356.1699; THOMAS MH, 1959, JAMA-J AM MED ASSOC, V169, P457, DOI 10.1001/jama.1959.03000220037008; TURNBULL DM, 1985, BRIT MED J, V290, P815, DOI 10.1136/bmj.290.6471.815; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267; VANDONSELAAR CA, 1990, EPILEPSIA, V31, P529; 1981, STATISTICAL SOFTWARE	33	50	51	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	1991	302	6777					620	623		10.1136/bmj.302.6777.620	http://dx.doi.org/10.1136/bmj.302.6777.620			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012874	Green Published, Bronze			2022-12-24	WOS:A1991FC07100019
J	BELL, MV; HIRST, MC; NAKAHORI, Y; MACKINNON, RN; ROCHE, A; FLINT, TJ; JACOBS, PA; TOMMERUP, N; TRANEBJAERG, L; FROSTERISKENIUS, U; KERR, B; TURNER, G; LINDENBAUM, RH; WINTER, R; PEMBREY, M; THIBODEAU, S; DAVIES, KE				BELL, MV; HIRST, MC; NAKAHORI, Y; MACKINNON, RN; ROCHE, A; FLINT, TJ; JACOBS, PA; TOMMERUP, N; TRANEBJAERG, L; FROSTERISKENIUS, U; KERR, B; TURNER, G; LINDENBAUM, RH; WINTER, R; PEMBREY, M; THIBODEAU, S; DAVIES, KE			PHYSICAL MAPPING ACROSS THE FRAGILE-X - HYPERMETHYLATION AND CLINICAL EXPRESSION OF THE FRAGILE-X SYNDROME	CELL			English	Article							LINKED MENTAL-RETARDATION; CHROMOSOME; DNA; SITE; METHYLATION; LINKAGE; LOCUS; FREQUENCY; REGION; FAMILY	The most common genetic cause of mental retardation after Down's syndrome, the fragile X syndrome, is associated with the occurrence of a fragile site at Xq27.3. This X-linked disease is intriguing because transmission can occur through phenotypically normal males. Theories to explain this unusual phenomenon include genomic rearrangements and methylation changes associated with a local block of reactivation of the X chromosome. Using microdissected markers close to the fragile site, we have been able to test these hypotheses. We present evidence for the association of methylation with the expression of the disease. However, there is no simple relationship between the degree of methylation and either the level of expression of the fragile site or the severity of the clinical phenotype.	GEN HOSP, WESSEX REG GENET LAB, SALISBURY SP2 7SX, WILTS, ENGLAND; ULLEVAL HOSP, DEPT MED GENET, N-0315 OSLO 3, NORWAY; UNIV TROMSO, N-9001 TROMSO, NORWAY; REG HOSP CORK, POLAR INST MED GENET, N-9012 TROMSO, NORWAY; LUBECK MED UNIV, DEPT GYNAECOL & OBSTET, W-2400 LUBECK, GERMANY; PRINCE WALES HOSP, DEPT MED GENET, RANDWICK, NSW 2031, AUSTRALIA; CHURCHILL HOSP, DEPT MED GENET, OXFORD OX3 7LJ, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, CLIN RES INST, NW THAMES REG GENET SERV, HARROW HA1 3UJ, MIDDX, ENGLAND; UNIV LONDON, INST CHILD HLTH, MOTHERCARE UNIT, LONDON WC1, ENGLAND; MAYO CLIN & MAYO FDN, DEPT LAB MED, ROCHESTER, MN 55905 USA	Salisbury District Hospital; University of Oslo; UiT The Arctic University of Tromso; University of Oxford; Imperial College London; University of London; Mayo Clinic	BELL, MV (corresponding author), JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC GENET GRP, OXFORD OX3 9DU, ENGLAND.		Tommerup, Niels/T-8776-2017; MacKinnon, Ruth/E-6202-2011	Tommerup, Niels/0000-0003-2304-0112; MacKinnon, Ruth/0000-0003-0294-5051				BARLOW D P, 1990, Technique (Philadelphia), V2, P79; DAHL N, 1989, AM J HUM GENET, V45, P304; DAVIES KE, 1985, HUM GENET, V70, P249; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRYNS JP, 1989, FRAGILE X SYNDROME, P1; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HARRISON CJ, 1983, J MED GENET, V20, P280, DOI 10.1136/jmg.20.4.280; HIRST MC, 1991, IN PRESS GENOMICS; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KENWRICK S, 1987, CELL, V48, P351, DOI 10.1016/0092-8674(87)90438-7; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LUBS HA, 1969, AM J HUM GENET, V21, P231; MACKINNON RN, 1990, AM J HUM GENET, V47, P181; Martin JP, 1943, J NEUROL PSYCHIATRY, V6, P154, DOI 10.1136/jnnp.6.3-4.154; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; PATTERSON M, 1988, AM J HUM GENET, V43, P684; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; SUTHERS GK, 1989, SCIENCE, V246, P1298, DOI 10.1126/science.2573953; TOMMERUP N, 1987, 3RD INT WORKSH FRAG; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; TURKER MS, 1989, J BIOL CHEM, V264, P11632; TURNER G, 1980, J PEDIATR-US, V96, P837, DOI 10.1016/S0022-3476(80)80552-X; VINCENT A, 1991, IN PRESS NATURE; VOELCKEL MA, 1989, HUM GENET, V81, P353, DOI 10.1007/BF00283690; WEBB TP, 1986, J MED GENET, V23, P396, DOI 10.1136/jmg.23.5.396; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759	34	307	313	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 22	1991	64	4					861	866		10.1016/0092-8674(91)90514-Y	http://dx.doi.org/10.1016/0092-8674(91)90514-Y			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1997211				2022-12-24	WOS:A1991EZ47800020
